<SEC-DOCUMENT>0001493152-24-013400.txt : 20240408
<SEC-HEADER>0001493152-24-013400.hdr.sgml : 20240408
<ACCEPTANCE-DATETIME>20240405215924
ACCESSION NUMBER:		0001493152-24-013400
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240408
DATE AS OF CHANGE:		20240405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Qualigen Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001460702
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				263474527
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37428
		FILM NUMBER:		24827976

	BUSINESS ADDRESS:	
		STREET 1:		2042 CORTE DEL NOGAL
		STREET 2:		CARLSBAD
		CITY:			CALIFORNIA
		STATE:			CA
		ZIP:			92011
		BUSINESS PHONE:		(760) 918-9165

	MAIL ADDRESS:	
		STREET 1:		2042 CORTE DEL NOGAL
		STREET 2:		CARLSBAD
		CITY:			CALIFORNIA
		STATE:			CA
		ZIP:			92011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RITTER PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20090402
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:QLGN="http://qualigendiagnostics.com/20231231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_QLGN_qualigendiagnostics.com_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001460702 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Sqft_0_utr%2D%2Dsqft -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000004" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000006" name="dei:EntityCentralIndexKey">0001460702</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0062" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl0068" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0072" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0074" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:WarrantLiabilitiesRelatedParty" contextRef="AsOf2023-12-31" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0101" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0107" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0113" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0114" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-12-31" id="xdx2ixbrl0144" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2023-12-31" id="xdx2ixbrl0153" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0187" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0190" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0193" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0196" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:DeconsolidationOfDiscontinuedOperations" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:DeconsolidationOfDiscontinuedOperations" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:DeconsolidationOfDiscontinuedOperations" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0441" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:LossOnVoluntaryConversionOfConvertibleDebt" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0504" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:AccretionOfDiscountOnConvertibleDebt" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ProceedsFromIssuanceOfConvertibleDebt" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FractionalSharePaymentsRelatedToReverseStockSplit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0575" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="xdx2ixbrl0584" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0593" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0594" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:TransfersOfInventoryFromEquipmentHeldForLease" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0603" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0605" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:RedemptionOfConvertibleDebtIntoCommonStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0609" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:VoluntaryConversionOfConvertibleDebtIntoCommonStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0612" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0614" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantModificationsForBusinessAcquisition" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0617" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ReceivableInvestmentSale" contextRef="AsOf2023-12-31" id="xdx2ixbrl0709" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ReceivableInvestmentSale" contextRef="AsOf2022-12-31" id="xdx2ixbrl0710" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:PreapaidResearchAndDevelopmentExpenses" contextRef="AsOf2022-12-31" id="xdx2ixbrl0713" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" contextRef="From2022-01-012022-12-31_srt_ParentCompanyMember" id="xdx2ixbrl0766" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" contextRef="From2022-01-012022-12-31_custom_NanosynexMember" id="xdx2ixbrl0767" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0768" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedSalesAndMarketing" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="xdx2ixbrl0845" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="xdx2ixbrl0852" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="xdx2ixbrl0854" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="xdx2ixbrl0861" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc." contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="xdx2ixbrl0870" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="xdx2ixbrl0952" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015" id="xdx2ixbrl0959" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="xdx2ixbrl0973" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1080" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1082" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1134" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="xdx2ixbrl1136" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1162" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1164" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1170" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1172" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1174" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1176" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnToEquity" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1178" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnToEquity" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1180" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1186" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1188" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ChangeInFairValueOfWarrantLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1194" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ChangeInFairValueOfWarrantLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1196" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1202" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1204" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="QLGN:DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1359" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1360" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="xdx2ixbrl1491" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="xdx2ixbrl1493" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="xdx2ixbrl1495" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="xdx2ixbrl1497" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1714" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1716" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1718" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1720" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1728" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1730" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1752" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1754" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:RangeOfExercisePriceNonexercisableNonvested" contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1756" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1768" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1770" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1772" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1774" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1776" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1778" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1780" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1782" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1804" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1806" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:RangeOfExercisePriceNonexercisableNonvested" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1808" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants" contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203" id="xdx2ixbrl1898" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203" id="xdx2ixbrl1900" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203" id="xdx2ixbrl1908" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203" id="xdx2ixbrl1910" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203" id="xdx2ixbrl1918" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203" id="xdx2ixbrl1920" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1934" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1936" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1948" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1950" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1970" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1972" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1996" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1998" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl2031" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl2032" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl2081" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2023-12-31" id="xdx2ixbrl2115" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2022-12-31" id="xdx2ixbrl2116" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="xdx2ixbrl2124" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2023-12-31" id="xdx2ixbrl2130" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="AsOf2023-12-31" id="xdx2ixbrl2133" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-12-31" id="xdx2ixbrl2136" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl2145" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl2146" unitRef="USD" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="qlgn-20231231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-242022-05-26_custom_NanoSynexLtdMember_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-24</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-242022-05-26_custom_NanoSynexLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-24</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_custom_PrefundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-242022-05-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-24</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-242022-05-26_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-24</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-24</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_custom_NanoSynexLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NanosynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_ParentCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_NanosynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_srt_ParentCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NanosynexMember983343">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_ParentCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NanosynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_custom_ChembioDiagnosticsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:ChembioDiagnosticsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-30_custom_AmendmentAndSettlementAgreementMember_custom_NanoSynexLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:AmendmentAndSettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_AmendmentAndSettlementAgreementMember_custom_NanoSynexLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:AmendmentAndSettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-202023-07-20_custom_AmendmentAndSettlementAgreementMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:AmendmentAndSettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-20</xbrli:startDate>
        <xbrli:endDate>2023-07-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MaximumMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MinimumMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-202023-07-20_custom_AmendmentAndSettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:AmendmentAndSettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-20</xbrli:startDate>
        <xbrli:endDate>2023-07-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_NanosynexMember983937">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NanosynexMember984015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesCWarrantsMember985078">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-25_srt_MaximumMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-25_srt_MinimumMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-232022-04-25_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-23</xbrli:startDate>
        <xbrli:endDate>2022-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_srt_MaximumMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_srt_MinimumMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-232022-05-26_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-23</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-232022-05-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-23</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_srt_MaximumMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_srt_MinimumMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-222022-12-22_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-22</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-222022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-22</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-05</xbrli:startDate>
        <xbrli:endDate>2023-12-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-05</xbrli:startDate>
        <xbrli:endDate>2023-12-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_WeightedAverageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_WeightedAverageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-22</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-22</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-30_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-012023-09-01_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AlphaCapitalOtherThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalOtherThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AlphaCapitalOtherThirdPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalOtherThirdPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-092023-01-12_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-09</xbrli:startDate>
        <xbrli:endDate>2023-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-12_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-31_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-012023-12-31_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-032023-10-03_custom_OctoberPaymentMember_us-gaap_CommonStockMember_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:OctoberPaymentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-03</xbrli:startDate>
        <xbrli:endDate>2023-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-082023-12-08_custom_OctoberPaymentMember_us-gaap_CommonStockMember_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:OctoberPaymentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-08</xbrli:startDate>
        <xbrli:endDate>2023-12-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-05</xbrli:startDate>
        <xbrli:endDate>2023-12-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeniorSecuredConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorSecuredConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorSecuredConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-052022-04-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-05</xbrli:startDate>
        <xbrli:endDate>2022-04-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_custom_UpfrontPaymentMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:UpfrontPaymentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-07-31_custom_MasterLaboratoryServicesAgreementMember_custom_MLMMedicalLabsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:MasterLaboratoryServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:MLMMedicalLabsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicensedProductSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-31_srt_MinimumMember_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-31_srt_MaximumMember_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SponsoredResearchAgreementsAndLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementsAndLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SponsoredResearchAgreementsAndLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementsAndLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012022-04-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012022-04-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012022-04-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012022-04-30_custom_PhaseOneClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012022-04-30_custom_PhaseTwoClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012022-04-30_custom_PhaseThreeClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012022-04-30_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicensedProductSalesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012022-04-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2022-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SponsoredResearchAgreementAndLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-012020-06-30_srt_MinimumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-012020-11-30_srt_MinimumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-01</xbrli:startDate>
        <xbrli:endDate>2020-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CompensatoryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CompensatoryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_CompensatoryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-25_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-252022-04-25_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-25</xbrli:startDate>
        <xbrli:endDate>2022-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-252022-04-25_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-25</xbrli:startDate>
        <xbrli:endDate>2022-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-25_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-25_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-242022-05-26_us-gaap_AdditionalPaidInCapitalMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-24</xbrli:startDate>
        <xbrli:endDate>2022-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-222022-12-22_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-22</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-05_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-05_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-05_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-052023-12-05_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-05</xbrli:startDate>
        <xbrli:endDate>2023-12-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-292021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-29</xbrli:startDate>
        <xbrli:endDate>2021-11-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-25_custom_NanosynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-252022-04-25_custom_NanosynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-25</xbrli:startDate>
        <xbrli:endDate>2022-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-26_custom_NanosynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-262023-05-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-26</xbrli:startDate>
        <xbrli:endDate>2023-05-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_custom_NanosynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-222022-12-22_custom_NanosynexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-22</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ConversionOfConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:ConversionOfConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember990578">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-22_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-292022-04-29_custom_NanoSynexLtdMember_custom_SeriesAOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-29</xbrli:startDate>
        <xbrli:endDate>2022-04-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-292022-04-29_custom_NanoSynexLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-29</xbrli:startDate>
        <xbrli:endDate>2022-04-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-29_custom_PrefundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureAndWarrantMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">QLGN:TwentyTwentyFourDebentureAndWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-26</xbrli:startDate>
        <xbrli:endDate>2024-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:TwentyTwentyFourDebentureMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:TwentyTwentyFourDebentureMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-26</xbrli:startDate>
        <xbrli:endDate>2024-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourWarrantMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:TwentyTwentyFourWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourWarrantMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:TwentyTwentyFourWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-26</xbrli:startDate>
        <xbrli:endDate>2024-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; color: Black"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; color: Black"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: Black"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; color: Black"><b>FORM
<span id="xdx_901_edei--DocumentType_c20230101__20231231_zWjj70tcCbRb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000013" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_900_edei--DocumentAnnualReport_c20230101__20231231_zQ5DzLeCERXl"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>For
the fiscal year ended <span id="xdx_905_edei--DocumentPeriodEndDate_c20230101__20231231_z5sSCEyz4nJd"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate"><span id="xdx_909_edei--CurrentFiscalYearEndDate_c20230101__20231231_zJVgDaFKduBk"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayen" id="Fact000016" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_909_edei--DocumentFiscalYearFocus_c20230101__20231231_zVUsHRrKCun4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000017" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>or</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90A_edei--DocumentTransitionReport_c20230101__20231231_zJsHSDHlOl39"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000018" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Commission
File Number <span id="xdx_903_edei--EntityFileNumber_c20230101__20231231_zXGuJoEg8cRh"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000019" name="dei:EntityFileNumber">001-37428</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><img src="logo_001.jpg" alt="" style="height: 100px; width: 100px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt; color: Black"><b><span id="xdx_906_edei--EntityRegistrantName_c20230101__20231231_z8lCaGh20Bt"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000020" name="dei:EntityRegistrantName">Qualigen
Therapeutics, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20230101__20231231_zpabwB2mquM3"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" id="Fact000021" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20230101__20231231_zRAQwemyaXY4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000022" name="dei:EntityTaxIdentificationNumber">26-3474527</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(State
                                            or other jurisdiction of </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>incorporation
    or organization)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(I.R.S.
                                            Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20230101__20231231_zMhElLqvRS7e"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000023" name="dei:EntityAddressAddressLine1">5857
Owens Avenue</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressAddressLine2_c20230101__20231231_zQoXfC1c8EYl"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000024" name="dei:EntityAddressAddressLine2">Suite 300</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressCityOrTown_c20230101__20231231_zVBrmXfgrlCe"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000025" name="dei:EntityAddressCityOrTown">Carlsbad</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20230101__20231231_zoLz3a01cdBk"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" id="Fact000026" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_904_edei--EntityAddressPostalZipCode_c20230101__20231231_zYWAOTOrb1n5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000027" name="dei:EntityAddressPostalZipCode">92008</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>(Address
of principal executive offices) (Zip Code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_904_edei--CityAreaCode_c20230101__20231231_ztDdzDX03Kni"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000028" name="dei:CityAreaCode">(760)</ix:nonNumeric></span>
<span id="xdx_906_edei--LocalPhoneNumber_c20230101__20231231_zegnuqN3Uou6"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000029" name="dei:LocalPhoneNumber">452-8111</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Registrant&#8217;s
telephone number, including area code</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; color: Black; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Name
    of Exchange on Which Registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_905_edei--Security12bTitle_c20230101__20231231_zEp8BzaZYxfc"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000030" name="dei:Security12bTitle">Common
    Stock, par value $0.001 per share</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_90C_edei--TradingSymbol_c20230101__20231231_zoCs1qaDQSnb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000031" name="dei:TradingSymbol">QLGN</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>The
    <span id="xdx_90B_edei--SecurityExchangeName_c20230101__20231231_zR7nGpgoWjJ8"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:exchnameen" id="Fact000032" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Securities
registered pursuant to Section 12(g) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_909_edei--EntityWellKnownSeasonedIssuer_c20230101__20231231_zFQo7PUR3oHh"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000033" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_904_edei--EntityVoluntaryFilers_c20230101__20231231_zBkeSpGloOCi"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000034" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_907_edei--EntityCurrentReportingStatus_c20230101__20231231_z6hwypSvCSY3"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000035" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_90F_edei--EntityInteractiveDataCurrent_c20230101__20231231_zM8zAD6SKJOd"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000036" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See definitions of &#8220;large accelerated filer, &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 27%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 42%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_901_edei--EntityFilerCategory_c20230101__20231231_zHt6bWtF9MVg"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000037" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90C_edei--EntitySmallBusiness_c20230101__20231231_zMiwYJWgZI5d"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000038" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20230101__20231231_zlgz670fwx51"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000039" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_907_edei--IcfrAuditorAttestationFlag_c20230101__20231231_zfjj1pNUfKe2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000040" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_907_edei--DocumentFinStmtErrorCorrectionFlag_c20230101__20231231_z4XwPMSIdMya"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000041" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; No <span id="xdx_90E_edei--EntityShellCompany_dbF_c20230101__20231231_zmJz6jdNwrtl"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000042" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of June 30, 2023, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates was approximately $<span id="xdx_90A_edei--EntityPublicFloat_iI_c20230630_zlIqGqxfasCb"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-06-30" id="Fact000043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,570,535</ix:nonFraction></span>
based on the closing price for the common stock of $0.91 on that date. Shares of common stock held by the registrant&#8217;s executive
officers and directors have been excluded from this calculation, as such persons may be deemed to be affiliates of the registrant. This
determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of March 25, 2024, there were <span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_c20240325_zxqhkxC4QIWi"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-03-25" id="Fact000044" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,307,371</ix:nonFraction></span> shares of the registrant&#8217;s common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>DOCUMENTS
INCORPORATED BY REFERENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span id="xdx_905_edei--DocumentsIncorporatedByReferenceTextBlock_c20230101__20231231_zO8dmIQP9ZB4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000045" name="dei:DocumentsIncorporatedByReferenceTextBlock">None.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; color: Black; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Page
    Number</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><a href="#na_001">Part I</a></b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    1</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#na_002">Business</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    1A</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#na_003">Risk Factors</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    1B</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#na_004">Unresolved Staff Comments</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    1C</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><span style="text-decoration: underline"><a href="#na_005">Cybersecurity</a></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#na_006">Properties</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#na_007">Legal Proceedings</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    4</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#na_008">Mine Safety Disclosures</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><a href="#na_010">Part II</a></b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    5</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#na_009">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    6</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#na_011">[Reserved]</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    7</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#na_012">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    7A</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#mm_001">Quantitative and Qualitative Disclosure About Market Risk</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">31</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    8</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#mm_002">Financial Statements and Supplementary Data</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    9</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#Su_002">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    9A</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#Su_003">Controls and Procedures</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    9B</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#Su_004">Other Information</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    9C</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#Su_005">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><a href="#Su_006">Part III</a></b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    10</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#Su_007">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">64</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    11</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#Su_008">Executive Compensation</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">66</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    12</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#Su_009">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    13</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#Su_010">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">74</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    14</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#Su_011">Principal Accounting Fees and Services</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">76</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><a href="#Su_012">Part IV</a></b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    15</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#Su_013">Exhibits and Financial Statement Schedules</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">77</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    16</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#Su_014">Form 10-K Summary</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">81</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="#Su_015">Signatures</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center">82</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">This
Annual Report on Form 10-K (&#8220;Annual Report&#8221;) contains forward-looking statements by Qualigen Therapeutics, Inc. that involve
risks and uncertainties and reflect our judgment as of the date of this Report. These statements generally relate to future events or
our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words
such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221;
&#8220;could,&#8221; &#8220;intends,&#8221; &#8220;target,&#8221; or &#8220;continue&#8221; or the negative of these words or other similar
terms or expressions that concern our expectations, strategy, plans or intentions. Such forward-looking statements may relate to, among
other things, potential future development, testing and launch of products and product candidates. Actual events or results may differ
from our expectations due to a number of factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">These
forward-looking statements include, but are not limited to, statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to procure sufficient working capital to continue and complete the development, testing and launch of our prospective drug
    products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to successfully develop any drugs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to progress our drug candidates through preclinical and clinical development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to obtain the requisite regulatory approvals for our clinical trials and to begin and complete such trials according to any
    projected timeline;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to complete enrollment in our clinical trials as contemplated by any projected timeline;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    likelihood that future clinical trial data will be favorable or that such trials will confirm any improvements over other products
    or lack negative impacts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to successfully commercialize any drugs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    likelihood that patents will issue on our in-licensed patent applications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to protect our intellectual property; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to compete.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">By
their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare,
regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur
on longer or shorter timelines than anticipated. <span style="background-color: white">In light of the significant uncertainties in these
forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. </span>Although we believe
that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that forward-looking
statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and
the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Annual
Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which
we operate, are consistent in some future periods with the forward-looking statements contained in this Annual Report, they may not be
predictive of results or developments in other future periods. Any forward-looking statement that we make in this Annual Report speaks
only as of the date of this Annual Report, and we disclaim any intent or obligation to update these forward-looking statements beyond
the date of this Annual Report, except as required by law. This caution is made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Future
filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;), future press releases and future oral or written statements
made by us or with our approval, which are not statements of historical fact, may also contain forward-looking statements. Because such
statements include risks and uncertainties, many of which are beyond our control, actual results may differ materially from those expressed
or implied by such forward-looking statements. The forward-looking statements speak only as of the date on which they are made, and we
undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they
are made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="na_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>As
used in this Annual Report, unless the context suggests otherwise, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221;or &#8220;the
Company&#8221; refer to Qualigen Therapeutics, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="na_002"></span>Item
1. Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
are an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Our business now consists
of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Our
lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding
affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Such binding could, by stabilizing the G4s against DNA
&#8220;unwinding,&#8221; help inhibit cancer cell proliferation. QN-302 is currently undergoing a Phase 1a clinical trial at START
Midwest in Grand Rapids, Michigan, and HonorHealth in Scottsdale, Arizona. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Our
Pan-RAS program, which is currently at the preclinical stage, consists of a family of RAS oncogene protein-protein interaction inhibitor
small molecules believed to inhibit or block mutated RAS genes&#8217; proteins from binding to their effector proteins </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">thereby
leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment
of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers<span style="background-color: white">.
</span>The investigational compounds within our Pan-RAS portfolio are designed to suppress the interaction of endogenous RAS with c-RAF,
upstream of the KRAS, HRAS and NRAS effector pathways.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">On
May 22, 2020, we completed a &#8220;reverse recapitalization&#8221; transaction with Qualigen, Inc. (not to be confused with the Company);
pursuant to which our merger subsidiary merged with and into Qualigen, Inc. with Qualigen, Inc. surviving as a wholly owned subsidiary
of the Company. The Company, which had previously been known as Ritter Pharmaceuticals, Inc., was renamed Qualigen Therapeutics, Inc.,
and the former stockholders of Qualigen, Inc. acquired, via the recapitalization, a substantial majority of the shares of the Company.
Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital Market under the ticker symbol &#8220;RTTR,&#8221;
commenced trading on Nasdaq, on a post-reverse-stock-split adjusted basis, under the ticker symbol &#8220;QLGN&#8221; on May 26, 2020.
We are no longer pursuing the gastrointestinal disease treatment business on which Ritter Pharmaceuticals, Inc. had focused before the
reverse recapitalization transaction. O</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">n
July 20, 2023, we sold our Qualigen, Inc. subsidiary, which contained our former FastPack<sup>&#174;</sup> diagnostics business to Chembio
Diagnostics, Inc., an American subsidiary of French diagnostics provider Biosynex, S.A. Accordingly, our former FastPack<sup>&#174;</sup>
diagnostics business is reported as Discontinued Operations in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
aggregate net purchase price for Qualigen, Inc. was $5.4 million in cash, of which $450,000 is being held in escrow to satisfy certain
Company indemnification obligations. Any amounts remaining in the escrow that have not been offset or reserved for claims will be released
to us within five business days following January 20, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
own a minority interest in NanoSynex, Ltd. (&#8220;NanoSynex&#8221;), a privately-held microbiologics diagnostic company domiciled in
Israel. NanoSynex&#8217;s technology is for Antimicrobial Susceptibility Testing that aims to enable better targeting of antibiotics
for their most suitable uses to ultimately result in faster and more efficacious treatment, hence reducing hospitals&#8217; mortality
and morbidity rates. On May 26, 2022, we acquired a 52.8% interest in NanoSynex from our related party Alpha Capital Anstalt (&#8220;Alpha&#8221;)
and NanoSynex, and entered into a Master Agreement for the Operational and Technological Funding of NanoSynex with NanoSynex (the &#8220;NanoSynex
Funding Agreement&#8221;). On July 20, 2023, we entered into an Amendment and Settlement Agreement with NanoSynex (the &#8220;NanoSynex
Amendment&#8221;), pursuant to which we agreed to, in exchange for eliminating all future Funding Agreement obligations for us to invest
further cash in NanoSynex (except for obligations to lend NanoSynex $560,000 on or before November 30, 2023, and $670,000 on or before
March 31, 2024), surrender 281,000 Series B Preferred Shares of NanoSynex held by us, resulting in our ownership in NanoSynex being reduced
from approximately 52.8% to approximately 49.97% of the voting equity of NanoSynex; in addition, we agreed to surrender approximately
$3.0 million of promissory notes which NanoSynex had issued to us under the Funding Agreement. On November 22, 2023 we further agreed
to eliminate our obligations to lend NanoSynex $560,000 on or before November 30, 2023, and $670,000 on or before March 31, 2024, by
instead surrendering shares of Series A-1 Preferred Stock of NanoSynex in an amount that reduced our ownership in NanoSynex voting equity
from approximately 49.97% to 39.90%. NanoSynex was deconsolidated from our financial statements as of July 20, 2023, and is reported
as Discontinued Operations in this Annual Report. Our investment in NanoSynex will be accounted for in the future as an equity method
investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b></b></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>QN-302</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
exclusively in-licensed the global rights to the G-Quadruplex (&#8220;G4&#8221;) selective transcription inhibitor platform from University
College London (&#8220;UCL&#8221;) in January 2022. The licensed technology comprises lead compound QN-302 (formerly known as SOP1812)
and back-up compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways.
Developed by Dr. Stephen Neidle and his group at UCL, the G4 binding concept is derived from nucleic acid research conducted over more
than over 30 years, including research on G4s, which are higher order DNA and RNA structures formed by sequences containing guanine-rich
repeats. G4s are overrepresented in telomeres (a region of repetitive DNA sequences at the end of a chromosome) as well as promoter sequences
and untranslated regions of many oncogenes. Their prevalence is therefore significantly greater in cancer cells compared to normal human
cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">G4-selective
small molecules such as QN-302 and backup compounds target the regulatory regions of cancer genes, which have a high prevalence of enriched
G4s. Stable G4-QN-302 complexes can be impediments to replication, transcription or translation of those cancer genes containing G4s,
and the drugs&#8217; binding to G4s are believed to stabilize the G4s against possible &#8220;unwinding.&#8221; G4 binders like QN-302
could be efficacious in a variety of cancer types with a high prevalence of G4s.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
believe that QN-302 has the potential to demonstrate superior efficacy and activity against pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;),
which represents 98% of pancreatic cancers. Pancreatic cancer is the tenth most common cancer in men and the seventh most common in women,
but it is the fourth leading cause of cancer deaths in men and the third leading cause in women; it accounts for about 3% of all cancers
in the United States but is responsible for about 8% of all cancer-related deaths. It has one of the lowest rates of survival of all
cancer types.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>In-vitro
</i>and <i>in-vivo</i> studies have shown that G4 stabilization by QN-302 resulted in inhibition of target gene expression and cessation
of cell growth in various cancers, including PDAC. In <i>in-vitro</i> studies, QN-302 was potent in inhibiting the growth of several
PDAC cell lines at low nanomolar concentrations. Similarly, in <i>in-vivo</i> studies, QN-302 showed a longer survival duration in a
KPC genetic mouse model for pancreatic cancer than gemcitabine (the current standard of care for PDAC) has historically shown. Additional
preclinical <i>in-vivo</i> studies suggest activity in gemcitabine-resistant PDAC. Data further demonstrated that QN-302 had significant
anti-tumor activity in three patient-derived PDAC xenograft models. Early safety indicators in pancreatic cancer mouse <i>in-vivo </i>models
suggest no significant adverse toxic effects at proposed therapeutic doses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
January 9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted Orphan Drug Designation (&#8220;ODD&#8221;) to QN-302
for the indication of pancreatic cancer. ODD provides advantages to pharmaceutical companies that are developing investigational drugs
or biological products that show promise in treating rare diseases or conditions that affect fewer than 200,000 people in the United
States, including seven-year marketing exclusivity and eligibility to receive regulatory support and guidance from the FDA in the design
of an overall drug development plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">There
are also economic advantages to receiving ODD, including a 25% federal tax credit for expenses incurred in conducting clinical research
on the orphan designated product within the United States. Tax credits may be applied to the prior year or applied to up to 20 years
of future taxes. ODD recipients may also have their Prescription Drug User Fee Act (PDUFA) application fees waived, a potential savings
of around $3.2 million (as of fiscal year 2023) for applications requiring covered clinical data, and may qualify to compete for research
grants from the Office of Orphan Products Development that support clinical studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
August 1, 2023 we announced that the FDA had cleared our investigational new drug (&#8220;IND&#8221;) application for QN-302, and on
November 1, 2023 the first patient in our Phase 1a clinical trial for QN-302 was dosed at START Midwest in Grand Rapids, Michigan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
will require additional cash resources to be able to continue and complete this Phase 1a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Pan-RAS
<span style="background-color: white">(formerly referred to as RAS or RAS-F)</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
July 2020 we entered into an exclusive worldwide in-license agreement with the University of Louisville&#8217;s Research Foundation (&#8220;UofL&#8221;
or &#8220;ULRF&#8221;) for the intellectual property covering the &#8220;RAS&#8221; family of pan-RAS inhibitor small molecule drug candidates,
which are believed to work by blocking RAS mutations directly, thereby inhibiting tumor formation (especially in pancreatic, colorectal
and lung cancers). Pursuant to the license agreement, we will seek to identify and develop a lead drug candidate from the compound family
and, upon commercialization, will pay UofL royalties in the low-to-mid-single-digit percentages on net sales of Pan-RAS inhibitor licensed
products. The license agreement with UofL for Pan-RAS was amended in March 2021 and June 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">RAS
is the most common oncogene in human cancer. Activating mutations in one of the three human RAS gene isoforms (KRAS, HRAS or NRAS) are
present in about one-fourth to one-third of all cancers. For example, mutant KRAS is found in 98% of pancreatic ductal adenocarcinomas,
52% of colon cancers, and 32% of lung adenocarcinomas. For these three cancer types, cancers with mutant KRAS are diagnosed in more than
170,000 people each year in the United States and cause more than 120,000 deaths. Drugs that target signaling downstream of RAS are available;
however, such drugs have shown disappointing clinical durability because RAS is a &#8220;hub&#8221; that activates multiple effectors,
so drugs that block a single pathway downstream may not account for the many other activated pathways.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
also had a sponsored research agreement with UofL for Pan-RAS research; that agreement expired in December 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
currently do not have the resources to advance our Pan-RAS program, and so we are seeking to out-license it.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
February 15, 2024, we entered into a License and Sublicense Agreement with Pan-RAS Holdings, Inc., a New York corporation (&#8220;Pan-RAS
Holdings&#8221;), which contemplated an exclusive out-license of our Pan-RAS drug development program, including our rights under the
ULRF license agreement, Pan-RAS Holdings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Although
the License and Sublicense Agreement called for a closing by March 16, 2024, the License and Sublicense Agreement was in essence structured
as a 30-day option in favor of Pan-RAS Holdings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">At
the contemplated closing, Pan-RAS Holdings would have paid us an upfront fee of $1,000,000 in cash. In addition, Pan-RAS Holdings would
have become responsible to pay on our behalf our in-license royalty obligations to ULRF, as and when required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Finally,
if the contemplated closing had occurred, Pan-RAS Holdings would have required to pay to us for our own account, on a semiannual basis,
royalties equal to 1.0% of net sales of any RAS products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
would have owed certain amounts to ULRF under our in-license agreement from them, if, as and when we received any Non-Royalty Sublicensing
Income from Pan-RAS Holdings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Pan-RAS
Holdings did not effectuate the closing by March 16, 2024, and we and they voluntarily terminated the License and Sublicense Agreement
effective as of March 16, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Previous
Programs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have discontinued all of our efforts the following programs, and we do not plan to resume them:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>1.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>QN-247(formerly
    referred to as ALAN or AS1411-GNP) </i></b>&#8211; an oligonucleotide aptamer-based, nucleolin-inhibiting anticancer drug candidate,
    consisting of QN-165 conjugated with gold nanoparticles.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>2.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>QN-165
    (formerly referred to as AS1411)</i></b> &#8211; an oligonucleotide aptamer-based drug candidate for the potential broad-spectrum
    treatment of infectious diseases such as COVID-19.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>3.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Selective
    Target Antigen Removal System (STARS) </i></b>&#8211; a therapeutic blood-filtering device product concept, which would be designed
    to remove circulating tumor cells, viruses, inflammation factors and immune checkpoints.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">For
research and development of our drug candidates, we have historically leveraged the scientific and technical resources and laboratory
facilities of UofL and UCL, through technology licensing, sponsored research, and other consulting agreements. We have engaged contract
research organizations (&#8220;CROs&#8221;) and clinical sites for the Phase 1a clinical trial of QN-302. We intend to focus our internal
research and development on oversight of these CROs. We currently have no internal research and development facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Regulatory
Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have obtained FDA clearance/approval for our QN-302 Phase 1a clinical trial. We have not obtained FDA or other regulatory approval for
any other drug candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>United
States&#8212;FDA Drug Approval Process</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
research, development, testing, and manufacture of product candidates are extensively regulated by governmental authorities in the United
States and other countries. In the United States, the FDA regulates drugs under the Food, Drug and Cosmetics Act and its implementing
regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
steps required to be completed before a drug may be marketed in the United States include, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">preclinical
    laboratory tests, animal studies, and formulation studies, all performed in accordance with the FDA&#8217;s Good Laboratory Practice
    (&#8220;GLP&#8221;) regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">submission
    to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin and
    for which progress reports must be submitted annually to the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">approval
    by an independent institutional review board (&#8220;IRB&#8221;) or Ethics Committee (&#8220;EC&#8221;) at each clinical trial site
    before each trial may be initiated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">adequate
    and well-controlled human clinical trials, conducted in accordance with applicable IND regulations, Good Clinical Practices (&#8220;GCP&#8221;),
    and other clinical trial related regulations, to establish the safety and efficacy of the drug for each proposed indication to the
    FDA&#8217;s satisfaction;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">submission
    to the FDA of a New Drug Application (&#8220;NDA&#8221;) and payment of user fees for FDA review of the NDA (unless a fee waiver
    applies);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">satisfactory
    completion of an FDA pre-approval inspection of one or more clinical trial site(s) at which the drug was studied in a clinical trial(s)
    and/or of us as a clinical trial sponsor to assess compliance with GCP regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">satisfactory
    completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the drug is produced to assess
    compliance with current GMPs regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">agreement
    with the FDA on the final labeling for the product and the design and implementation of any required Risk Evaluation and Mitigation
    Strategy; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">FDA
    review and approval of the NDA, including satisfactory completion of an FDA advisory committee review, if applicable, based on a
    determination that the drug is safe and effective for the proposed indication(s).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Preclinical
tests include laboratory evaluation of product chemistry, toxicity, and formulation, as well as animal studies. The conduct of the preclinical
tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations.
The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of
an IND application, which must become effective before human clinical trials may begin. An IND application will automatically become
effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about issues such as the conduct
of the trials as outlined in the IND application, and places the clinical trial(s) on a clinical hold. In such a case, the IND application
sponsor and the FDA must resolve any outstanding FDA concerns or questions before clinical trials can proceed. We cannot be certain that
submission of an IND application will result in the FDA allowing clinical trials to begin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Clinical
trials necessary for product approval are typically conducted in three sequential phases, but the phases may overlap or be combined.
The study protocol and informed consent information for study subjects in clinical trials must also be approved by an IRB for each institution
where the trials will be conducted, and each IRB must monitor the study until completion. Study subjects must provide informed consent
and sign an informed consent form before participating in a clinical trial. Clinical testing also must satisfy the extensive GCP regulations
for, among other things, informed consent and privacy of individually identifiable information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Phase
    1&#8212;Phase 1 clinical trials involve initial introduction of the study drug in a limited population of healthy human volunteers
    or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption,
    metabolism and distribution of the study drug in humans, evaluate the side effects associated with increasing doses, and, if possible,
    to gain early evidence of effectiveness.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Phase
    2&#8212;Phase 2 clinical trials typically involve administration of the study drug to a limited patient population with a specified
    disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side
    effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more
    expensive Phase 3 clinical trials.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Phase
    3&#8212;Phase 3 clinical trials typically involve administration of the study drug to an expanded patient population to further evaluate
    dosage, to provide substantial evidence of clinical efficacy and to further test for safety, generally at multiple geographically
    dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the study drug
    and to provide an adequate basis for product approval. Generally, adequate and well-controlled Phase 3 clinical trials are required
    by the FDA for approval of an NDA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Post-approval
trials, sometimes referred to as Phase 4 clinical trials, may be conducted after receiving initial marketing approval. These trials are
used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to
generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance
of Phase 4 clinical trials as a condition of approval of an NDA or, in certain circumstances, post-approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
FDA has various programs, including fast track designation, breakthrough therapy designation, priority review and accelerated approval,
which are intended to expedite or simplify the process for the development, and the FDA&#8217;s review of drugs (<i>e.g.,</i> approving
an NDA on the basis of surrogate endpoints subject to post-approval trials). Generally, drugs that may be eligible for one or more of
these programs are those intended to treat serious or life-threatening diseases or conditions, those with the potential to address unmet
medical needs for those disease or conditions, and/or those that provide a meaningful benefit over existing treatments. For example,
a sponsor may be granted FDA designation of a drug candidate as a &#8220;breakthrough therapy&#8221; if the drug candidate is intended,
alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical
evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints, such as substantial treatment effects observed early in clinical development. If a drug is designated as breakthrough therapy,
the FDA will take actions to help expedite the development and review of such drug. Moreover, if a sponsor submits an NDA for a product
intended to treat certain rare pediatric or tropical diseases or for use as a medical countermeasure for a material threat, and that
meets other eligibility criteria, upon approval such sponsor may be granted a priority review voucher that can be used for a subsequent
NDA. From time to time, we anticipate applying for such programs where we believe we meet the applicable FDA criteria. A company cannot
be sure that any of its drugs will qualify for any of these programs, or even if a drug does qualify, that the review time will be reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
results of the preclinical studies and of the clinical studies, together with other detailed information, including information on the
manufacture and composition of the drug, are submitted to the FDA in the form of an NDA requesting approval to market the product for
one or more proposed indications. The testing and approval process requires substantial time, effort and financial resources. Unless
the applicant qualifies for an exemption, the filing of an NDA typically must be accompanied by a substantial &#8220;user fee&#8221;
payment to the FDA. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety
and efficacy of the product in the proposed patient population to the satisfaction of the FDA. After an NDA is accepted for filing, the
FDA substantively reviews the application and may deem it to be inadequate, and companies cannot be sure that any approval will be granted
on a timely basis, if at all. The FDA may also refer the application to an appropriate advisory committee, typically a panel of clinicians,
for review, evaluation and a recommendation as to whether the application should be approved, but is not bound by the recommendations
of the advisory committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Before
approving an NDA, the FDA usually will inspect the facility or the facilities at which the drug is manufactured and determine whether
the manufacturing and production and testing facilities are in compliance with cGMP regulations. The FDA also may audit the clinical
trial sponsor and one or more sites at which clinical trials have been conducted to determine compliance with GCPs and data integrity.
If the NDA and the manufacturing facilities are deemed acceptable by the FDA, it may issue an approval letter, and, if not, the Agency
may issue a Complete Response Letter (&#8220;CRL&#8221;). An approval letter authorizes commercial marketing of the drug with specific
prescribing information for a specific indication(s). A CRL indicates that the review cycle of the application is complete and the application
is not ready for approval. A CRL may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or
other significant, expensive and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Even if
such additional information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The
FDA could also require, as a condition of NDA approval, post-marketing testing and surveillance to monitor the drug&#8217;s safety or
efficacy or impose other conditions, or a <span style="text-decoration: underline">Risk Evaluation and Mitigation Strategy</span> that may include both special labeling and controls,
known as Elements to Assure Safe Use, on the distribution, prescribing, dispensing and use of a drug product. Once issued, the FDA may
withdraw product approval if, among other things, ongoing regulatory requirements are not met, certain defects exist in the NDA, or safety
or efficacy problems occur after the product reaches the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Information
regarding our (in-licensed) issued patents and pending patent applications, as of December 31, 2023, is as follows (excluding patents
and pending patent applications which pertain to programs which we have discontinued). As of that date we did not have any directly-owned
issued patents and pending patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; background-color: white">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Subject
    Matter</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Issued</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Pending</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Geographic
    Scope</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; width: 16%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Patent
    Term</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; background-color: #CFF0FC">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>In-Licensed
    Patents</i></b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">University
    College London (UCL)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">QN-302</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">3</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">10</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">U.S.,
    Europe, Australia, Canada, China, Hong Kong, India, Japan, Korea, Russia</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2030-2040</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">University
    of Louisville (ULRF)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Pan-RAS</span></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">0</span></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">12</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">U.S.,
    Europe, Australia, Canada, China, Hong Kong, India, Israel, Japan, Korea, Mexico, Russia, South Africa</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2039*</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>TOTAL</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>3</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>22</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">*<i>Anticipated
patent term</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Human
Capital Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of <span style="background-color: white">March 25, 2024, </span>we had 4 employees, all of whom were full-time. None of our employees
is represented by a labor union or covered by a collective bargaining agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Diversity
&amp; Inclusion</i>. With respect to our employees overall, fifty percent (50%) are women and 0% are people of color.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b>Additional
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Ritter
Pharmaceuticals, Inc. (our predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the name Ritter Natural
Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals, Inc. On May
22, 2020, upon completing the &#8220;reverse recapitalization&#8221; transaction with Qualigen, Inc., Ritter Pharmaceuticals, Inc. was
renamed Qualigen Therapeutics, Inc. and Qualigen, Inc. became a wholly-owned subsidiary of the Company. On July 20, 2023 we sold Qualigen
Inc. to ChemBio Diagnostics, Inc., an American subsidiary of French diagnostics provider Biosynex S.A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
website address is <i>www.qlgntx.com</i>. We post links to our website to the following filings as soon as reasonably practicable after
they are electronically filed with or furnished to the SEC: annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports
on Form 8-K, proxy statements, information statements, beneficial ownership reports and any amendments to those reports or statements
filed or furnished pursuant to Sections 13(a), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).
All such filings are available through our website free of charge. However, the information contained on or accessed through our website
does not constitute part of this Annual Report, and references to our website address in this Annual Report are inactive textual references
only. <span style="background-color: white">All such reports are also available free of charge via EDGAR through the SEC website at <i>www.sec.gov</i>.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="na_003"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>An
investment in our common stock involves risks. You should carefully consider the risks described below, together with all of the other
information included in this Annual Report, as well as in our other filings with the SEC, in evaluating our business. If any of the following
risks actually occur, our business, financial condition, operating results and future prospects could be materially and adversely affected.
In that case, the trading price of our common stock may decline and you might lose all or part of your investment. The risks described
below, which are the risks we judge (rightly or wrongly) to be the most significant to investors, are not the only ones we face. Additional
risks that we currently do not judge to be among the &#8220;most significant&#8221; may also impair our business, financial condition,
operating results and prospects.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Certain
statements below are forward-looking statements. For additional information, see the section of this Annual Report under the caption
&#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b>Risks
Related to Our Business Generally</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>Our
business strategy is high-risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
are focusing our resources and efforts on development of drug product candidates, which requires extensive cash needs for research and
development activities. This is a high-risk strategy because there is no assurance that that our cash resources will be adequate to develop
our product candidates, that our product candidates will ever be proven to be safe and effective or that any products will ever become
commercially viable. This makes our stock an unsuitable investment for many investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>We
do not currently have enough working capital to execute our strategic plan</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have suffered recurring losses from operations, and we are now essentially a non-revenue company. We will need capital to maintain our
operations and to support our intended development of our therapeutics business. Future financings will be necessary in order for us
to survive as a going concern and to properly execute our strategic plan. However, there can be no assurance that such future financings
will be available to us (or, if they are, that they can be consummated on desirable terms).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
may, in the short and long-term, seek to raise capital through the issuance of equity securities or through other financing sources.
To the extent that we seek to raise additional funds by issuing equity or equity-linked securities, our stockholders may (as has already
occurred several times) experience significant dilution. Any debt financing, if available, may include financial and other covenants
that could restrict our use of the proceeds from such financing or impose other business and financial restrictions on us. In addition,
we may consider alternative approaches such as licensing, joint venture, or partnership arrangements to provide short term or long term
capital. Additional funding may not be available to us on acceptable terms, or at all. In addition, any future financing (depending on
the terms and conditions) may be subject to the approval of Alpha, a related party and the holder of our 8% Senior Convertible Debenture
and of our 8% Convertible Debenture (together, the &#8220;Debentures&#8221;), and/or trigger certain adjustments to the conversion prices
of the Debentures or to the exercise prices of warrants held by Alpha and/or by other persons. See Part II, Item 7 &#8220;<i>Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221; for additional details regarding the Debentures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Servicing
our debt will require a significant amount of cash, and we do not expect to have sufficient cash flow from our business to pay this debt.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
ability to <span style="background-color: white">make payments to Alpha of principal or interest on the Debentures or to make any potential
prepayments for the Debentures, to the extent applicable, depends on our future performance, which is subject to economic, financial,
competitive and other factors beyond our control. Our cash resources currently on hand, plus any anticipated near-term cash flow from
operations or dispositions, would not be sufficient to service our indebtedness and/or to make necessary expenditures.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
December 2022, we entered into a Securities Purchase Agreement with Alpha and in exchange for $3,000,000 in cash (less $50,000 for expense
reimbursement) issued to Alpha our 8% Senior Convertible Debenture with an original face amount of $3,300,000 due on December 22, 2025
(the &#8220;2022 Debenture&#8221;), plus 2,500,000 common stock warrants exercisable (from June 22, 2023 through June 22, 2028) at $1.65
per share. <span style="background-color: white">Commencing June 1, 2023 and continuing on the first day of each month thereafter until
the earlier of (i) December 22, 2025 and (ii) the full redemption of the 2022 Debenture (each such date, a &#8220;Monthly Redemption
Date&#8221;), we must redeem $110,000 plus accrued but unpaid interest, liquidated damages and any amounts then owing under the 2022
Debenture (the &#8220;Monthly Redemption Amount&#8221;). The Monthly Redemption Amount must be paid in cash; provided that after the
first two monthly redemptions, we may (if the Equity Conditions, as defined in the 2022 Debenture, are then satisfied or have been waived)
elect to pay all or a portion of a Monthly Redemption Amount in shares of our common stock, based on a conversion price equal to the
lesser of (i) the then applicable conversion price of the 2022 Debenture and (ii) 85% of the average of the VWAPs (as defined in the
2022 Debenture) for the five consecutive trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption
Date. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The
2022 Debenture accrues interest at the rate of 8% per annum, which began accruing on December 1, 2023, and will be payable on a quarterly
basis. Interest may be paid in cash or shares of common stock or a combination thereof at our option; provided that the Equity Conditions
have been satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Alpha
has waived the Equity Conditions for certain Monthly Redemption Amounts, but Alpha is not required to continue such waivers beyond May
2024. For the foreseeable future, we do not expect to be able to satisfy the Equity Conditions; as a result, where there is no waiver
of the Equity Conditions we would not have the opportunity to make 2022 Debenture payments in the form of stock rather than in the form
of cash, even for types of payments for which payment in the form of stock would have been allowed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The
2022 Debenture is convertible into our common stock at any time at the holder&#8217;s option; the conversion price was originally $1.32
but pursuant to a Securities Purchase Agreement amendment in December 2023 it was reduced to $0.73 and then in February 2024 it was adjusted
downward to $0.26 per share by virtue of the operation of a &#8220;ratchet&#8221; antidilution provision. (The exercise price of the
warrants issued with the 2022 Debenture was originally $1.65 but pursuant to a Securities Purchase Agreement amendment in December 2023
it was reduced to $0.73 and then in February 2024 it was adjusted downward to $0.26 per share by virtue of the operation of a &#8220;ratchet&#8221;
antidilution provision.)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Other
than the Monthly Redemption Amounts, the 2022 Debenture does not call for scheduled payments of principal before the scheduled maturity
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Both
the 2022 Debenture and the accompanying warrants provide for &#8220;ratchet&#8221; antidilution adjustments to their conversion price
and exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Both
the 2022 Debenture and the accompanying warrants include a beneficial ownership blocker of 9.99%, which may only be waived by Alpha upon
61 days&#8217; notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
granted Alpha resale registration rights for the common shares underlying the 2022 Debenture and the accompanying warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
December 2023 amendment of the 2022 Debenture conversion price (and the accompanying warrants&#8217; exercise price) to be $0.73 per
share resulted in the 2022 Debenture&#8217;s then current $1,528,922 principal amount thereof becoming convertible into 2,094,414 shares
of Company common stock (as opposed to the 1,158,274 shares into which such outstanding principal amount was convertible pre-adjustment).
Also, the December 2023 amendment triggered a &#8220;ratchet&#8221; antidilution adjustment in the Company&#8217;s outstanding &#8220;exploding&#8221;
&#8220;Series C Warrants,&#8221; resulting in such Series C Warrants becoming exercisable for 455,623 common shares (at an exercise price
of $0.73 per share), as opposed to the 251,971 common shares into which such outstanding Series C Warrants would have been exercisable
(at $1.32 per share) pre-adjustment. Finally, the $0.73 price triggered a &#8220;ratchet&#8221; antidilution adjustment in the exercise
price of other outstanding Company common stock warrants, including 7,048 warrants held by Alpha and 67,620 warrants held by other persons,
which were previously exercisable at $1.32 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
February 2024, we entered into a Securities Purchase Agreement with Alpha and in exchange for $500,000 in cash (less $25,000 for expense
reimbursement) issued to Alpha an 8% Convertible Debenture with a face amount of $550,000 due on December 31, 2024 (the &#8220;2024 Debenture&#8221;),
plus 900,016 5-year common stock warrants exercisable at $0.26 per share. In addition, per this Securities Purchase Agreement Alpha obtained
an option to purchase additional 8% Convertible Debentures, of like tenor, with face amounts of up to an aggregate of $1,100,000 (and
with a proportional number of accompanying common stock warrants of like tenor, up to a total of 1,800,032 additional warrants), which
would (if and when Alpha exercises such option) provide us up to an additional $1.0 million in cash proceeds (less expense reimbursement, and not including any possible cash proceeds from any future exercise of the additional warrants).
This option is valid through July 1, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
2024 Debenture has a maturity date of December 31, 2024 and is convertible, at any time, and from time to time, at Alpha&#8217;s option,
into shares of our common stock, at $0.6111 per share. <span style="background-color: white">The 2024 Debenture does not call for scheduled
payments of principal or interest before the scheduled maturity date. </span>Interest on the 2024 Debenture accrues on its outstanding
principal balance at the rate of 8% per annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Both
the 2024 Debenture and the accompanying warrants provide for &#8220;ratchet&#8221; antidilution adjustments to the Conversion Price and
Exercise Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Both
the 2024 Debenture and the accompanying warrants include a beneficial ownership blocker of 9.99%, which may only be waived by Alpha upon
61 days&#8217; notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
granted Alpha &#8220;piggyback&#8221; registration rights for the common shares underlying the 2024 Debenture and the accompanying warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
$0.26 exercise price of the warrants issued with the 2024 Debenture triggered a &#8220;ratchet&#8221; antidilution adjustment in the
2022 Debenture, resulting in the then current $1,198,922 principal amount thereof becoming convertible into 4,611,238 shares of Company
common stock (as opposed to the 1,642,359 shares into which such outstanding principal amount were convertible pre-adjustment). Also,
the $0.26 exercise price of the warrants issued with the 2024 Debenture triggered a &#8220;ratchet&#8221; antidilution adjustment in
the Company&#8217;s outstanding &#8220;exploding&#8221; &#8220;Series C Warrants,&#8221; resulting in such Series C Warrants becoming
exercisable for 1,279,261 common shares (at an exercise price of $0.26 per share), as opposed to the 455,623 common shares into which
such outstanding Series C Warrants would have been exercisable (at $0.73 per share) pre-adjustment. Finally, the $0.26 exercise price
of the Warrant would trigger a &#8220;ratchet&#8221; antidilution adjustment in the exercise price of other outstanding Company common
stock warrants, including 2,507,048 warrants held by Alpha and 67,620 warrants held by other persons, all of which were previously exercisable
at $0.73 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">If
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">we continue to lack cash resources sufficient
to service our indebtedness, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or issuing
additional equity, equity-linked or debt instruments on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness
will depend on the capital markets and our financial condition at such time. If we are unable to engage in any of these activities or
engage in these activities on desirable terms, we may be unable to meet our debt obligations, which would materially and adversely impact
our business, financial condition and operating results or even put us out of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b>Risks
Related to Our Product Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>Our
product candidates are still in the early stages of development. Although we have begun Phase 1a clinical trials for QN-302, we might
be unable to obtain further regulatory approval for QN-302 or any other drug candidate. We may never obtain marketing approval for any
of our drug candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
are still early in our Pan-RAS development efforts and have not yet sought approval for, or begun enrollment, in any clinical trials
evaluating Pan-RAS. There can be no assurance that any of our drug product candidates will achieve success in their clinical trials or
obtain regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Our
ability to generate revenues from our drug product candidates will depend on the successful development and eventual commercialization
of such drug candidates. The success of these products will depend on several factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">successful
    completion of preclinical studies and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">acceptance
    of an IND application by the FDA or other clinical trial or similar applications from foreign regulatory authorities for our future
    clinical trials for our pipeline;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">timely
    and successful enrollment of patients in, and completion of, clinical trials with favorable results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">demonstration
    of safety, efficacy and acceptable risk-benefit profiles of our products to the satisfaction of the FDA and foreign regulatory agencies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">receipt
    and related terms of marketing approvals from applicable regulatory authorities, including the completion of any required post-marketing
    studies or trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">obtaining
    and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">developing
    and implementing marketing and reimbursement strategies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">establishing
    sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone
    or in collaboration with others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">acceptance
    of our drugs, if and when approved, by patients, the medical community and third-party payors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">effectively
    competing with other therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">obtaining
    and maintaining third-party payor coverage and adequate reimbursement; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">maintaining
    a continued acceptable safety profile of the products following approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Many
of these factors are beyond our control, and it is possible that none of our drug candidates will ever obtain regulatory approval even
if we expend substantial time and resources seeking such approval. If we do not achieve one or more of these factors in a timely manner
or at all, we could experience significant delays or an inability to successfully commercialize our drug candidates. For example, our
business could be harmed if results of the clinical trials of QN-302, Pan-RAS or any other drug candidates vary adversely from our expectations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>Drug
development involves a lengthy and expensive process. We may incur additional costs or experience delays in completing, or ultimately
be unable to complete, the development and commercialization of our drug product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Most
drug candidates fail, and taking a drug candidate from concept through clinical trials and regulatory approval is not easy or guaranteed.
We are unable to predict when or if our drug candidates, will prove effective or safe in humans or will obtain marketing approval. Before
obtaining marketing approval from regulatory authorities for the sale of these products, we must complete preclinical development and
then conduct extensive clinical trials to demonstrate the safety and efficacy of these products for humans. Clinical testing is expensive,
difficult to design and implement, can take many years to complete and is uncertain as to the outcome. A failure of one or more clinical
trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success
of later clinical trials, and interim or preliminary results of a clinical trial do not necessarily predict final results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
may experience numerous unforeseen events that could delay or prevent our ability to obtain marketing approval or commercialize our drug
candidates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">we
    may not be able to obtain enough capital to begin clinical trials ort to complete any already-begun clinical trials, or to complete
    any necessary preclinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">regulators
    or IRBs or ECs may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective
    trial site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">we
    may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols
    with prospective trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">clinical
    trials for our drug candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to
    conduct additional clinical trials, delay clinical trials or abandon product development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    number of patients required for clinical trials for our drug candidates may be larger than we anticipate, enrollment in these clinical
    trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or
    the duration of these clinical trials may be longer than we anticipate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">competition
    for clinical trial participants from investigational and approved therapies may make it more difficult to enroll patients in our
    clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    third-party contractors may fail to meet their contractual obligations to us in a timely manner, or at all, or may fail to comply
    with regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">we
    may have to suspend or terminate clinical trials for our drug candidates for various reasons, including a finding that the participants
    are being exposed to unacceptable health risks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    drug candidates may have undesirable or unexpected side effects or other unexpected characteristics, causing us or our investigators,
    regulators or IRBs/ECs to suspend or terminate the trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    cost of clinical trials for our drug candidates may be greater than we anticipate; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    supply or quality of our drug candidates, or other materials necessary to conduct clinical trials may be insufficient or inadequate
    and result in delays or suspension of our clinical trials.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -12.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Our
product development costs will increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals.
We do not know whether any of our planned preclinical studies or clinical trials will begin on a timely basis or at all, will need to
be restructured or will be completed on schedule, or at all. For example, the FDA may place a partial or full clinical hold on any of
our clinical trials for a variety of reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Significant
preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our
drug candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize
our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>Any
delays in the commencement or completion, or termination or suspension, of our current clinical trial or our future clinical trials,
if any, could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Before
we can initiate clinical trials of a drug candidate, we must submit the results of preclinical studies to the FDA along with other information
as part of an IND application or similar regulatory filing, and the FDA (or corresponding foreign regulatory body) must approve the application.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Before
obtaining marketing approval from the FDA for the sale of QN-302, Pan-RAS or any other future drug candidate, we must conduct extensive
clinical studies to demonstrate safety and efficacy. Clinical testing is expensive, time consuming and uncertain as to outcome. The FDA
may require us to conduct additional preclinical studies for any drug candidate before it allows us to initiate clinical trials under
any IND application, which may lead to additional delays and increase the costs of our preclinical development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Any
delays in the commencement or completion of our ongoing, planned or future clinical trials could significantly increase our costs, slow
down our development and approval process and jeopardize our ability to commence product sales and generate revenues. We do not know
whether our planned trials will begin on time or at all, or be completed on schedule, if at all. The commencement and completion of clinical
trials can be delayed for a number of reasons, including delays related to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    ability to pay for the costs and expenses for the clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    FDA disagreeing as to the design or implementation of our clinical trials or with our recommended dose for any of our pipeline programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">obtaining
    FDA authorization to commence a trial or reaching a consensus with the FDA on trial design;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">obtaining
    approval from one or more IRBs/ECs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">IRBs/ECs
    refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects,
    or withdrawing their approval of the trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">changes
    to clinical trial protocol;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">clinical
    sites deviating from trial protocol or dropping out of a trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">failing
    to manufacture or obtain sufficient quantities of drug candidate, or, if applicable, combination therapies for use in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">patients
    failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment follow-up;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">patients
    choosing an alternative treatment, or participating in competing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">lack
    of adequate funding to continue the clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">patients
    experiencing severe or unexpected drug-related adverse effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">occurrence
    of serious adverse events in trials of the same class of agents conducted by other companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">selecting
    or being required to use clinical end points that require prolonged periods of clinical observation or analysis of the resulting
    data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">a
    facility manufacturing our drug candidates, or any of their components, including without limitation, our own facilities being ordered
    by the FDA to temporarily or permanently shut down due to violations of cGMP, regulations or other applicable requirements, or infections
    or cross-contaminations in the manufacturing process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">lack
    of stability of our clinical trial material or any quality issues that arise with the clinical trial material;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">any
    changes to our manufacturing process that may be necessary or desired;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our,
    or our third-party contractors, not performing data collection or analysis in a timely or accurate manner or improperly disclosing
    data prematurely or otherwise in violation of a clinical trial protocol; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">any
    third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities
    for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use
    some or all of the data produced by such contractors in support of our marketing applications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs/ECs of the institutions in which such trials
are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or
termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or
our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical
hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using the product under investigation,
changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition,
changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes.
Amendments may require us to resubmit our clinical trial protocols to IRBs/ECs for reexamination, which may impact the costs, timing
or successful completion of a clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>If
we experience delays or difficulties enrolling patients in our ongoing or planned clinical trials, our receipt of necessary regulatory
approval could be delayed or prevented.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
may not be able to initiate or continue our ongoing or planned clinical trials for our products if we are unable to identify and enroll
a sufficient number of eligible patients to participate in these trials as required by the FDA. In addition, some of our competitors
may have ongoing clinical trials for products that would treat the same patients as QN-302 or Pan-RAS, and patients who would otherwise
be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; products. In addition, introduction
of new drugs or devices to the marketplace may have an effect on the number of patients available or timing of the availability of the
patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Our
inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon
one or more clinical trials altogether.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>Adverse
side effects or other safety risks associated with our drug product candidates could delay or preclude approval, cause us to suspend
or discontinue any clinical trials or abandon further development, limit the commercial profile of an approved label, or result in significant
negative consequences following regulatory approval, if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Results
of our current and planned clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected
characteristics. Undesirable side effects caused by our products could result in the delay, suspension or termination of clinical trials
by us or the FDA for a number of reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Moreover,
if our products are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect
to abandon or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics
are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for our
products, if approved. We may also be required to modify our study plans based on findings in our clinical trials. Many drug candidates
that initially showed promise in early stage testing have later been found to cause side effects that prevented further development.
In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">It
is possible that as we test our drug candidates in larger, longer and more extensive clinical trials, including with different dosing
regimens, or as the use of our drug candidates becomes more widespread following any regulatory approval, illnesses, injuries, discomforts
and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous
trials, will be reported by patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>The
development and commercialization of pharmaceutical and device products are subject to extensive regulation, and we may not obtain regulatory
approvals for any product candidates, on a timely basis or at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The
clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing,
distribution, adverse event reporting, including the submission of safety and other post-marketing information and reports, and other
possible activities relating to drug product candidates such as ours are subject to extensive regulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>We
rely, and intend to continue to rely, on third parties to conduct our preclinical studies and clinical trials and perform some of our
research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties, fail to comply with
applicable regulatory requirements or do not meet expected deadlines, our development programs may be delayed or subject to increased
costs or we may be unable to obtain regulatory approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
are dependent on third parties to conduct our planned preclinical studies and clinical trials of our drug product candidates. The timing
of the initiation and completion of these trials will therefore be partially controlled by such third parties and may result in delays
to our development programs. We have relied heavily on UofL for preclinical studies related to Pan-RAS, and we expect to rely heavily
on CROs and sponsored academic researchers for any further preclinical studies. As to any clinical trials, we expect to rely on CROs,
sponsored academic researchers, clinical investigators and/or consultants to play a significant role in the conduct of these trials and
the subsequent collection and analysis of data. However, we will not be able to control all aspects of their activities. Nevertheless,
we are responsible for ensuring that each clinical trial is conducted in accordance with the applicable protocol and legal, regulatory
and scientific standards, including GCP, requirements, and our reliance on the CROs and other third parties does not relieve us of our
regulatory responsibilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">There
is no guarantee that any such CROs, clinical trial investigators and/or other third parties on which we rely will devote adequate time
and resources to our development activities or perform as contractually required. If any of these third parties fail to meet expected
deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise perform in a substandard manner, or terminate
their engagements with us, the timelines for our development programs may be extended or delayed or our development activities may be
suspended or terminated. If one of our clinical trial site terminates for any reason, we may experience the loss of follow-up information
on subjects enrolled in such clinical trial unless we are able to transfer those subjects to another qualified clinical trial site, which
may be difficult or impossible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">If
these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct clinical trials in accordance
with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, regulatory approvals
for our drug product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>Manufacturing
pharmaceutical products is complex and subject to product loss for a variety of reasons. We contract with third parties for the manufacture
of our product candidates for preclinical testing and clinical trials and expect to continue to do so for commercialization. This reliance
on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable
cost or quality, which could delay, prevent or impair our development or commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
rely, and expect to continue to rely, on third parties for the manufacture of our products for preclinical and any clinical testing,
as well as for future commercial manufacture if any of our product candidates obtain regulatory approval. This reliance on third parties
increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost or
quality, which could delay, prevent or impair our development or commercialization efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
may be unable to establish any agreements with third-party manufacturers or to do so on favorable terms. Even if we are able to establish
agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">reliance
    on the third-party for regulatory, compliance and quality assurance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">operations
    of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including
    the bankruptcy of the manufacturer or supplier or the issuance of an FDA Form 483 notice or warning letter;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    possible breach of the manufacturing agreement by the third-party; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">the
    possible termination or nonrenewal of the agreement by the third-party at a time that is costly or inconvenient for us.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -12.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
do not have manufacturing agreements in place for any of our current drug candidates. We acquire many key materials on a purchase order
basis. As a result, we do not have long-term committed arrangements with respect to our product candidates and other materials. If we
obtain regulatory approval for any of our product candidates, we will need to establish an agreement for commercial manufacture with
a third-party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Any
performance failure on the part of our existing or future manufacturers could delay clinical development or regulatory approval. We do
not currently have arrangements in place for redundant supply or a second source for bulk drug substance for QN-302 or Pan-RAS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>We
will need to seek and enter into out-licenses or collaborations with third parties for the development and commercialization of our products,
resulting in a limitation of our upside potential.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
expect that we will need third-party out-licensees or collaborators for the development and commercialization of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Our
likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical
companies and biotechnology companies. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive
agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise,
the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">If
we do enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources
that such collaborators dedicate to the development or commercialization of our products. Our ability to generate revenues from these
arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in
these arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Any
out-license or collaboration will necessarily result in a sharing of economics with the out licensee or collaborator, which might otherwise
have been captured by us directly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b>Risks
Related to our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>If
we are unable to obtain and maintain sufficient patent protection for our therapeutic product candidates, or if the scope of the patent
protection is not sufficiently broad, third parties, including our competitors, could develop and commercialize products similar or identical
to ours, and our ability to commercialize our product candidates successfully may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Our
commercial success depends significantly on our ability to protect our proprietary (and exclusively in-licensed) product candidates or
technologies that we believe are important to our business, including pursuing, obtaining and maintaining patent protection in the United
States and other countries intended to cover the composition of matter of our product candidates, the methods of use, related technologies,
and other inventions that are important to our business. In addition to patent protection, we also rely on trade secrets to protect aspects
of our business that are not amenable to, or that we do not consider appropriate for, patent protection. If we do not adequately pursue,
obtain, maintain, protect or enforce our intellectual property, third parties, including our competitors and/or collaborators, may be
able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Moreover,
depending on the terms of any license agreements to which we may become a party, we may not have the right to control the preparation,
filing, and prosecution of patent applications, or to maintain or defend the patents, covering technology licensed from third parties.
Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of
our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
cannot offer any assurances about which, if any, patents will issue, the breadth of any such patents, whether any issued patents will
be found invalid and unenforceable or will be threatened by third parties or whether any issued patents will effectively prevent others
from commercializing competing technologies and product candidates. Our licensors have not filed patent applications in every jurisdiction,
and some filings are only pending in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Moreover,
because the issuance of a patent, although presumptive, is not conclusive as to its inventorship, scope, validity or enforceability,
our licensors&#8217; patents or pending patent applications may be challenged in the courts or patent offices in the United States and
abroad. Such challenges may result in loss of exclusivity or in the patent claims being narrowed, invalidated or held unenforceable,
in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical products and technologies
or limit the duration of the patent protection of our products and technologies. Such challenges also may result in substantial cost
and require significant time from our scientists and management, even if the eventual outcome is favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Our
licensors&#8217; pending and future patent applications may not result in patents being issued that protect our product candidates and
technologies, in whole or in part, or that effectively prevent others from commercializing competitive products and technologies. Even
if the patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent
competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors and
other third parties may be able to circumvent our licensors&#8217; patents by developing similar or alternative products or technologies
in a non-infringing manner. Our competitors and other third parties may also seek approval to market their own products and technologies
similar to or otherwise competitive with our products and technologies. Alternatively, our competitors or other third parties may seek
to market generic versions of any approved products by submitting abbreviated NDAs to the FDA during which process they may claim that
patents owned by us are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our licensors&#8217;
patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency
with jurisdiction may find our licensors&#8217; patents invalid or unenforceable, or that our competitors are competing in a non-infringing
manner. Thus, even if we have in-licensed valid and enforceable patents, these patents still may not provide protection against competing
products or processes sufficient to achieve our business objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>The
term of our in-licensed patents may be inadequate to protect our competitive position on our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Given
the amount of time required for the development, testing and regulatory review of drug candidates, our in-licensed patents protecting
such candidates might expire before or shortly after such candidates are commercialized. In such an event (and if we are unable to obtain
patent term extension or the term of any such extension is less than we request), our competitors and other third parties may be able
to obtain approval of competing products following patent expiration and take advantage of our investment in development and clinical
trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. Generic competition
usually results in serious price erosion for the original drug brand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b>Risks
Related to Employee Matters, Potential Dilution, Stock Price Variability and Other Risks Related to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>Our
future success depends on our ability to retain key employees and to attract, retain and motivate qualified personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
are highly dependent on Michael Poirier, our Chief Executive Officer and Chairman, and Christopher Lotz, our Vice President and Chief
Financial Officer. In addition, the rest of our team has been sharply reduced due to rightsizing, voluntary departures and the disposition
of our Qualigen, Inc. diagnostics-products subsidiary &#8211; we currently have only two other employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Our
ability to compete depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific,
clinical, regulatory, manufacturing and management skills and experience. We may not be able to attract or retain qualified personnel
in the future. Many of the companies against which we compete have greater financial and other resources, different risk profiles and
a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better
opportunities for career advancement. Any or all of these competing factors (as well as our own limited resources) may limit our ability
to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize our
product candidates and to grow our business and operations as currently contemplated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>We
will need to rebuild our development and regulatory teams.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Due
to rightsizing, voluntary departures and the disposition of Qualigen, Inc. and our former FastPack&#174;products business, we currently
have only four </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">employees<span style="background-color: white">.
Although we outsource many drug development functions and may choose to continue to do so in the future, we expect that (resources allowing)
to recruit and retain more employees in all areas, and particularly in the areas of clinical development, clinical operations, and regulatory
affairs (and maybe, longer-term, in areas such as manufacturing, sales, marketing and distribution). We will also need to implement and
improve our managerial, operational and financial systems, and obtain stage-appropriate facilities. We do not currently have the cash
resources needed for any of the above.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
currently rely, and for the foreseeable future will continue to rely, in substantial part, on certain third-party contract research organizations
and consultants to provide certain services, including assuming substantial responsibilities for the conduct of our clinical trials.
We cannot assure that the services of such third-party contract research organizations and consultants will continue to be available
to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage
our outsourced activities or if the quality or accuracy of the services provided by our vendors or consultants is compromised for any
reason, our clinical trials may be extended, delayed or terminated. We cannot assure that we will be able to properly manage our existing
vendors or consultants or find other competent outside vendors and consultants on economically reasonable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>We
may engage in strategic transactions that could impact liquidity, increase expenses and present significant distractions to management.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">From
time to time, we may consider strategic transactions, such as acquisitions of companies, businesses or assets and out-licensing or in-licensing
of products, drug candidates or technologies. Potential transactions that we may consider include a variety of different business arrangements,
including spin-offs, in-licensing, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments.
Any such transaction may require us to incur non-recurring or other charges, may increase near term or long-term expenditures and may
pose significant integration challenges or disrupt management or business, which could adversely affect our operations and financial
results</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">. These transactions may entail
numerous operational and financial risks, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">exposure
    to unknown liabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">disruption
    of business and diversion of management&#8217;s time and attention in order to develop acquired products, drug candidates or technologies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">incurrence
    of substantial debt or dilutive issuances of equity securities to pay for acquisitions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">higher
    than expected acquisition and integration costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">write-downs
    of assets or impairment charges;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">increased
    amortization expenses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">difficulty
    and cost in combining the operations, systems and personnel of any acquired businesses with our operations, systems and personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">impairment
    of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">inability
    to retain key employees of any acquired businesses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Our
minority-interest investment in NanoSynex is illiquid and has many risks associated with it.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
investment in NanoSynex has been reduced to a 39% equity interest and has a number of risks associated with it, including, among others,
the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">a
    history of operating losses, with no assurance of future revenues or operating profits;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">uncertainty
    as to the availability to NanoSynex of the cash resources it needs to execute its plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">technological
    risk;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">our
    inability, now that we are no longer a majority shareholder of NanoSynex, to control or veto NanoSynex&#8217;s decisions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">risks
    associated with the development of medical devices and NanoSynex&#8217;s ability to obtain the necessary regulatory approvals for
    the development and commercialization of its antimicrobial susceptibility test platform;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">very
    limited manufacturing, marketing, distribution and sales capabilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">competition
    from both public and private companies and academic collaborators, many of which have significantly greater experience and financial
    resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">acceptance
    by life sciences research and diagnostic communities is not assured;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">commercial
    development of its antimicrobial susceptibility test platform is not assured;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">an
    inability to manufacture, market or sell its proposed products if it is unsuccessful in entering into strategic alliances or joint
    ventures with third parties; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">risks
    related to the political, economic and military conditions in Israel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
addition, NanoSynex is a privately-held company and its shares are illiquid, which means that we could not readily obtain cash in exchange
for some or all of our equity interest. We no longer hold any NanoSynex debt instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>Our
reported financial condition may fluctuate significantly from quarter to quarter and year to year, which makes them difficult to predict
or understand.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
expect our financial condition and results of operations to fluctuate from quarter to quarter and year to year due to a variety of factors,
many of which are beyond our control. Accordingly, you should not blindly rely upon the results of any quarterly or annual periods as
indications of future financial status or operating performance. Other investors may, however, attach undue significance to reported
results which are heavily influenced by such distortions and variability, which in turn could cause our stock price to rise or fall despite
there being no corresponding change in our prospects or position as a practical matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>We
have a substantial amount of derivative securities outstanding.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of December 31, 2023 there were 398,924 stock options outstanding under our equity incentive plans, 3,081,717 outstanding warrants, and
1,943,729 shares issuable upon voluntary conversion of principal amount of the 2022 Debenture issued to Alpha. (At December 31, 2023,
such principal amount was $1,418,922) Due to antidilution adjustments occurring as a result of the 2024 Debenture transaction in February
2024, the outstanding principal balance of the 2022 Debenture (which at March 25, 2024 was $1,088,922) is now convertible upon voluntary
conversions into 4,188,162 shares; and in addition the 2024 Debenture&#8217;s principal amount is convertible upon voluntary conversions
into 900,016 shares, and the warrants issued with the 2024 Debenture are exercisable for 900,016 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The
2022 and 2024 Debentures issued to Alpha are convertible, at any time, and from time to time, at Alpha&#8217;s option, into shares of
our common stock, subject to the terms and conditions described in the Debentures. Currently the conversion price for such optional conversions
is $0.26 per share for the 2022 Debenture and $0.6111 per share for the 2024 Debenture. Furthermore, subject to certain terms and conditions
described in the 2022 Debenture, we may elect to pay all or a portion of the Monthly Redemption Amount and/or interest required by the
2022 Debenture in shares of our common stock. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
issuance of shares upon the exercise or conversion of outstanding stock options, warrants and the Debentures (or our election to pay
amounts owed under the Debentures in shares of our common stock) could result in significant dilution to the holders of our existing
outstanding common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>We
rely significantly upon information technology, and any failure, inadequacy, interruption or security lapse of that technology, including
any cyber security incidents, could harm our ability to operate our business effectively and result in a material disruption of our product
development programs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
utilize information technology systems to transmit and store information, including sensitive personal information and proprietary or
confidential information, and otherwise to support our business and process. In the future, our systems may prove inadequate to our business
needs and necessary upgrades may not operate as designed, which could result in excessive costs or disruptions in portions of our business.
In particular, any disruptions, delays or deficiencies from our enterprise resource planning systems could adversely affect our ability
to, among other matters, process orders, procure supplies, manufacture and ship products, send invoices and track payments, fulfill contractual
obligations or otherwise operate our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
could also be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss
of information maintained in the information systems and networks of our company. Outside parties may attempt to penetrate our systems
or those of our partners or fraudulently induce our employees or employees of our partners to disclose sensitive information to gain
access to our data. Like other companies, we may experience threats to our data and systems, including malicious codes and computer viruses,
cyber-attacks or other system failures. Furthermore, a security breach could be facilitated by ineffective protection measures, employee
errors or omissions, and malfeasance. Despite our efforts to protect against cyber-attacks and security breaches, hackers and other cyber
criminals are using increasingly sophisticated and constantly evolving techniques, and we may need to expend substantial additional resources
to continue to protect against potential security breaches or to remediate problems caused by such attacks or any breach of our safeguards.
Any system failure, accident or security breach that causes interruptions in our operations, for us or our partners, could result in
a material disruption of our product development programs and business operations, in addition to possibly requiring substantial expenditures
of resources to remedy. For example, the loss of clinical trial data from completed clinical trials could result in delays in our regulatory
approval efforts and we could incur significant increases in costs to recover or reproduce the data. The risk o<span style="background-color: white">f
cyber incidents </span>could also be increased by cyberwarfare in connection with the ongoing war in Ukraine, including potential proliferation
of malware from the conflict into systems unrelated to the conflict. To the extent that any disruption or security breach results in
a loss of, or damage to, our data or applications, or inappropriate public disclosure of confidential or proprietary information, we
may incur liabilities and the further development of our product candidates may be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>We
or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery
plans may not adequately protect us from a serious disaster.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">We
are located in southern California and are subject to risks posed by natural disasters, including wildfires, earthquakes and severe weather
that may interfere with our operations. Extreme weather events and other natural disasters could severely disrupt our operations, and
have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power
outage or other event occurred that damaged critical infrastructure, such as the facilities of our third-party clinical sites or contract
manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business
for a substantial period of time. Any disaster recovery and business continuity plans we have in place may prove inadequate in the event
of a serious disaster or similar event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Any
failure to develop or maintain effective internal controls over financial reporting or difficulties encountered in implementing or improving
our internal controls over financial reporting could harm our operating results and prevent us from meeting our reporting obligations.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Effective
internal controls, particularly those related to financial reporting, are necessary for us to produce reliable financial reports. If
we cannot provide reliable financial reports, our business and operating results could be harmed, investors could lose confidence in
our reported financial information, and the trading price of our common stock could drop significantly. In addition, investors relying
upon this misinformation could make an uninformed investment decision, and we could be subject to sanctions or investigations by the
SEC or other regulatory authorities or to stockholder class action securities litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
previously described in our annual report on Form 10-K for the year ended December 31, 2021, in connection with the audit of our financial
statements as of and for the year ended December 31, 2021 (the &#8220;2021 audit&#8221;), our management identified a material weakness in our internal control over financial reporting related to the lack of accounting department
resources and/or policies and procedures to ensure recording and disclosure of items in compliance with U.S. GAAP. This material weakness
resulted in adjustments to our warrant valuations in connection with the 2021 audit. In response to the material weakness, we took a
number of remediation steps to enhance our internal controls, including implementing additional procedures and utilizing external consulting
resources with experience and expertise in U.S. GAAP and public company accounting and reporting requirements to assist management with
its accounting and reporting of complex and/or non-recurring transactions and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">In connection with the audit of our financial statements as of and for the year ended December 31, 2022 (the &#8220;2022 audit&#8221;),
our management determined that the material weakness identified in connection with the 2021 audit had not been fully remediated
and resulted in adjustments to the accounting treatment related to convertible debt, the business combination and goodwill impairment
during the 2022 audit, which resulted in the late filing of the 2022 Annual Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
connection with the audit of our financial statements as of and for the year ended December 31, 2023, our management identified material weaknesses in our internal control over financial reporting related to limited accounting
personnel and resources resulting in lack of segregation of duties, and to the fact that we have not designed and implemented effective Information Technology General Controls related
to access controls to financing accounting systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
intend to continue to take steps to enhance our internal controls, including implementing additional internal procedures and utilizing
well-established external consulting resources with experience and expertise in U.S. GAAP and public company accounting and reporting
requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
we are unable to remediate the material weaknesses and achieve and maintain effective internal control over financial reporting and effective
disclosure controls, our business could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Our
right to use our &#8220;shelf&#8221; Form S-3 registration statement is sharply limited.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
filed a Form S-3 &#8220;shelf&#8221; registration statement with the SEC for the issuance of up to $150,000,000 of securities, and the
SEC declared the registration statement effective on August 5, 2022. However, due to the &#8220;baby shelf&#8221; rules adopted by the
SEC, the maximum amount of securities we can sell under this registration is now limited to one-third of our public float. Because our
public float is very modest (e.g., $2.9 million at December 31, 2023), the maximum amount we could sell using this registration statement
was under $1.0 million at that time. Therefore, the registration statement no longer constitutes an important tool for accessing the
public markets to satisfy our needs for capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Our
failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
we fail to satisfy the continued listing requirements of Nasdaq, Nasdaq may take steps to delist our common stock. Such a delisting would
likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when
you wish to do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
April 20, 2023, we received a notification letter from the Listing Qualifications Department of Nasdaq indicating that, as a result of
our delay in filing the 2022 Annual Report, we were not in compliance with the timely filing requirements for continued listing under
Nasdaq Listing Rule 5250(c)(1). The notification letter had no immediate effect on the listing or trading of our common stock on the
Nasdaq Capital Market. On May 2, 2023, the Company filed the Form 10-K with the SEC and was subsequently notified by Nasdaq on May 4,
2023 that it had regained compliance with Nasdaq&#8217;s listing rule 5250(c)(1) as a result thereof and that the matter was closed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
November 20, 2023, we received a letter (the &#8220;Bid Price Deficiency Notice&#8221;) from The Nasdaq Stock Market (&#8220;Nasdaq&#8221;)
notifying the Company that, because the closing bid price for its common stock has been below $1.00 per share for 30 consecutive business
days, it no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing
Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the &#8220;Minimum Bid Price Requirement&#8221;),
and Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for
a period of 30 consecutive business days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Bid Price Deficiency Notice has no immediate effect on the listing of the Company&#8217;s common stock on The Nasdaq Capital Market.
Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or
until May 20, 2024 to regain compliance with the Minimum Bid Price Requirement. During the compliance period, the Company&#8217;s shares
of common stock will continue to be listed and traded on The Nasdaq Capital Market. To regain compliance, the closing bid price of the
Company&#8217;s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days during the 180 calendar
day grace period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
the event the Company is not in compliance with the Minimum Bid Price Requirement by May 20, 2024, the Company may be afforded a second
180 calendar day grace period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company intends to actively monitor the bid price for its common stock between now and May 20, 2024 and will consider available options
to regain compliance with the Minimum Bid Price Requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
November 21, 2023, the Company also received a letter (the &#8220;Equity Deficiency Letter&#8221;) from Nasdaq notifying the Company
that, based on the Company&#8217;s stockholders&#8217; deficit of ($1,640,552) as of September 30, 2023, as reported in the Company&#8217;s
Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, it is no longer in compliance with the minimum stockholders&#8217;
equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), which requires listed companies
to maintain stockholders&#8217; equity of at least $2.5 million (the &#8220;Minimum Stockholders&#8217; Equity Requirement&#8221;), or
the alternative criteria of $35 million market value of listed securities or $500,000 in net income from continuing operations in the
most recent fiscal year or two or the last three fiscal years&#8212;which alternatives, as noted in the Equity Deficiency Letter, the
Company does not meet. The Company was given until January 5, 2024 to provide Nasdaq with a specific plan (the &#8220;Compliance Plan&#8221;)
to achieve and sustain compliance with the Minimum Stockholders&#8217; Equity Requirement or its alternatives. If the Company&#8217;s
Compliance Plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Equity Deficiency Letter for
the Company to evidence compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
Company submitted a Compliance Plan to Nasdaq on January 5, 2024 to regain compliance with the Nasdaq Listing Rules. The Compliance Plan
was accepted by Nasdaq and <span style="background-color: white">the Company was granted an extension of up to 180 calendar days from
the date of the Equity Deficiency Letter (i.e., until May 20, 2024) for the Company to evidence compliance. If</span> the Company does
not regain compliance within the requisite time period, or if the Company fails to satisfy another Nasdaq requirement for continued listing,
Nasdaq could provide notice that the Company&#8217;s securities will become subject to delisting, which delisting determination the Company
has the right to appeal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">If
we are unable to maintain compliance with Nasdaq&#8217;s continued listing requirements, and in the event of a delisting, we would take
action to restore our compliance with Nasdaq&#8217;s listing requirements, but we can provide no assurance that any such action taken
by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent
our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#8217;s other
listing requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Losing
our Nasdaq other listing would seriously harm us, by undermining our ability to raise capital and decreasing our attractiveness to possible
merger partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><span id="na_004"></span>Item
1B. Unresolved Staff Comments.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="na_005"></span>Item
1C. Cybersecurity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
processes for assessing, identifying, and managing material risks from cybersecurity threats are not advanced. None of our personnel
are trained specialists in cybersecurity; we rely on off-the-shelf&#8221; security software. We have not conducted employee training
regarding cybersecurity or conducted internal tests or simulations. Nonetheless, we believe that, due to the nature and status of our
business, our cybersecurity position is currently satisfactory for our situation. We do not believe that cybersecurity risks have materially
affected (or are reasonably likely to materially affect) us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have only four employees and so disclosure of cybersecurity events to management would occur organically, or would in the first instance
be observed by management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">For
information of ours which resides on our CROs&#8217; computer systems, we rely on the CROs&#8217; own cybersecurity processes and systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="na_006"></span>Item
2. Properties.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">None.
The lease for our previous operating facilities at 2042 Corte Del Nogal, Carlsbad, California had been in the name of our subsidiary
Qualigen, Inc. We sold Qualigen, Inc. in 2023 and the Company has no responsibility for the lease going forward. The Company had also
utilized such facility (in addition to Qualigen, Inc.&#8217;s use), but now has removed from it. The Company is currently essentially
&#8220;virtual.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="na_007"></span>Item
3. Legal Proceedings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="na_008"></span>Item
4. Mine Safety Disclosures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="na_010"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="na_009"></span>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -69.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
common stock has been listed and traded on the Nasdaq Capital Market under the symbol &#8220;QLGN&#8221; since May 26, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Holders</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
of March 25, 2024, there were 287 registered holders of record of our common stock. This figure does not reflect the beneficial ownership
of shares held in nominee name.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Securities
Authorized for Issuance Under Equity Compensation Plans</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">See
Part III, Item 12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; for information
relating to our equity compensation plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Recent
Sales of Unregistered Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">No
further disclosure is required in response to this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Purchases
of Equity Securities by the Issuer and Affiliated Purchasers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="na_011"></span>Item
6. [Reserved]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="na_012"></span>Item
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>You
should read the following discussion and analysis of our financial condition and results of operations together with the consolidated
financial statements and related notes that are included elsewhere in this Annual Report. This discussion contains forward-looking statements
based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated
in these forward-looking statements as a result of various factors, including those set forth under &#8220;Risk Factors&#8221; or in
other parts of this Annual Report. See &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; for additional information.
Unless otherwise indicated, all information in this Annual Report on Form 10-K gives effect to a 1-for-10 reverse stock split of our
common stock that became effective on November 23, 2022, and all references to shares of common stock outstanding and per share amounts
give effect to the reverse stock split.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
are an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Our business now consists
of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Our
lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding
affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Such binding could, by stabilizing the G4s against DNA
&#8220;unwinding,&#8221; help inhibit cancer cell proliferation. QN-302 is currently undergoing a Phase 1a clinical trial at START
Midwest in Grand Rapids, Michigan, and HonorHealth in Scottsdale, Arizona. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Our
Pan-RAS program, which is currently at the preclinical stage, consists of a family of RAS oncogene protein-protein interaction inhibitor
small molecules believed to inhibit or block mutated RAS genes&#8217; proteins from binding to their effector proteins </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">thereby
leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment
of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers<span style="background-color: white">.
</span>The investigational compounds within our Pan-RAS portfolio are designed to suppress the interaction of endogenous RAS with c-RAF,
upstream of the KRAS, HRAS and NRAS effector pathways.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
November 23, 2022, we effected a 1-for-10, reverse stock split of our outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;).
The Reverse Stock Split reduced our shares of outstanding common stock, stock options, and warrants to purchase shares of our common
stock. Fractional shares of common stock that would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest
whole share and cash in lieu of fractional shares was paid to stockholders. All share and per share data for all periods presented in
this Annual Report on Form 10-K have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares
of common stock and the par value per share remains unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
do not expect to be profitable before products from our therapeutics pipeline are commercialized. To experience losses while therapeutic
products are still under development is, of course, typical for biotechnology companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Phase
1 Clinical Trial of QN-302</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
August 1, 2023, we announced that the FDA has cleared our IND application for QN-302. Based on this clearance, we chose Translational Drug Development, LLC (&#8220;TD2&#8221;) to serve
as our contract research organization to conduct a Phase 1 clinical trial in patients with advanced or metastatic solid tumors. The
Phase 1 trial (NCT06086522) is designed as a multicenter, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamic
study with dose expansion to evaluate safety, tolerability, and antitumor activity of QN-302 in patients with advanced solid tumors
that have not responded to or that have recurred following treatment with available therapies. On November 7, 2023, we announced
that the first patient had been enrolled and dosed in the dose escalation (Phase 1a) portion of the study. Subject to available
funding (which is, however, not all currently in hand), we anticipate that Phase 1a of the trial can be completed by the end of
2024. The exact number of patients to be enrolled in the trial will depend on the observed safety profile, which will
determine the number of patients per dose level, as well as the number of dose escalations required to meet the Maximum Tolerated
Dose (&#8220;MTD&#8221;). Once the MTD has been established in dose escalation, dose expansion will begin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Sale
of Diagnostics Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
July 20, 2023, we sold all of the issued and outstanding shares of common stock of Qualigen, Inc., a wholly-owned subsidiary and the
legal entity operating our FastPack&#8482; diagnostic business, to Chembio Diagnostics, Inc. (&#8220;Chembio&#8221;), a subsidiary of
Biosynex, S.A. As consideration for the shares of Qualigen, Inc., we received  cash payments of approximately $4.9 million, which payment
is subject to post-closing adjustments. An additional $450,000 was delivered by Chembio to an escrow account to satisfy our indemnification
obligations. Any amounts remaining in the escrow account that have not been offset or reserved for claims will be released to us within
five business days following January 20, 2025. Following the consummation of the transaction, Qualigen, Inc. became a wholly-owned subsidiary
of Chembio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Amendment
and Settlement Agreement with NanoSynex Ltd.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
July 20, 2023, we entered into and effectuated the NanoSynex Amendment, by which we agreed to, among other things, forfeit 281,000 Series
B Preferred Shares of NanoSynex held by us, resulting in our ownership in NanoSynex being reduced from approximately 52.8% to approximately
49.97% of the voting equity of NanoSynex. In addition, we agreed to cancel approximately $3.0 million of promissory notes which NanoSynex
had issued to us under the NanoSynex Funding Agreement, relieving NanoSynex of any repayment obligations to us with respect to such notes.
The NanoSynex Amendment superseded any NanoSynex Funding Agreement obligations to provide funding to NanoSynex, except we agreed to provide
future loans as follows: (i) $560,000 on or before November 30, 2023, and (ii) $670,000 on or before March 31, 2024. However, on November
22, 2023, in full settlement of any additional funding obligations to NanoSynex, we forfeited certain of our shares of Series A-1 Preferred
Stock of NanoSynex in an amount that reduced our ownership in NanoSynex from approximately 49.97% to 39.90%. Accordingly, NanoSynex was
deconsolidated from our financial statements as of July 20, 2023, and is reported as Discontinued Operations in this Annual Report. Our
investment in NanoSynex will be accounted for in the future as an equity method investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
consolidated financial statements historically have not separated our diagnostics-related activities from our therapeutics-related
activities. All of our historically reported revenue was diagnostics-related. Before the third quarter of 2023, our reported
expenses represented the total of our diagnostics-related and therapeutics-related expenses. In this Annual Report, all
diagnostics-related revenues and expenses have been reclassified to discontinued operations (See Note 5 - Discontinued
Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">This
discussion and analysis is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The
preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of
assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements.
On an ongoing basis, we evaluate our estimates and judgments, including those related to impairment of goodwill and other intangible
assets, fair value of warrant liabilities, and stock-based compensation. We base our estimates on historical experience, known trends
and events and various other factors we believe to be reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ
from these estimates under different assumptions or conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">While
our significant accounting policies are more fully described in Note 1 to our consolidated financial statements appearing in &#8220;Item
8. Financial Statements and Supplementary Data,&#8221; we believe that the following accounting policies are the most critical to aid
you in fully understanding and evaluating our financial condition and results of operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; color: Black; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Research
    and development</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Discontinued
    operations</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Impairment
    of long-lived assets</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Business
    combinations</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Derivative
    financial instruments and warrant liabilities</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Stock-based
    compensation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; color: Black; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; color: Black; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Income
    taxes</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white"><b><i>Warrant
Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">In
2004, Qualigen, Inc. issued Series C preferred stock warrants to investors and brokers in connection with a private placement. These
warrants were subsequently extended and survived the May 2020 Ritter reverse recapitalization transaction and are now exercisable
for Qualigen Therapeutics common stock. These warrants contain a provision that if the Company issues shares (except in certain
defined scenarios) at a price below the warrants&#8217; exercise price, the exercise price will be re-set to such new price and the
number of shares underlying the warrants will be increased in the same proportion as the exercise price decrease. For accounting
purposes, such warrants give rise to warrant liabilities. Accounting principles gene</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">rally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) require us to recognize the fair value of these warrants as
warrant liabilities on our Consolidated Balance Sheets and to reflect period-to-period changes in the fair value of the warrant
liabilities on our Consolidated Statements of Operations. The estimated fair value of these warrant liabilities was approximately
$0.1 million and $3.6 million at December 31, 2023 and 2022, respectively. There were 455,623 of these warrants outstanding at
December 31, 2023 and 1,349,571 of these warrants outstanding at December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Because
the fair value of the above liability classified warrants will <span style="background-color: white">be determined each quarter on a
&#8220;mark-to-market&#8221; basis , significant variability in our future quarterly and annual Consolidated Statement of Operations
and Consolidated Balance Sheets could occur based on changes in our public market common stock price. Pursuant to U.S. GAAP, a quarter-to-quarter
increase in our stock price would result in an increase in the fair value of the warrant liabilities and a quarter-to-quarter decrease
in our stock price would result in a decrease in the fair value of the warrant liabilities. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
December 22, 2022, as part of the 2022 Debenture financing, we issued to Alpha a common stock warrant (exercisable from June 22, 2023
through June 22, 2028) to purchase 2,500,000 shares of our common stock. The exercise price of the warrant was modified from $1.65 to
$0.73 on December 5, 2023, and was further modified to $0.26 on February 27, 2024. The warrant may be exercised by Alpha, in whole or
in part before June 22, 2028. The warrant was originally liability classified, but was modified on December 5, 2023 to allow for equity
classification. The estimated fair value of this warrant upon reclassification from warrant liabilities to equity was approximately $1.6
million and the estimated fair value of this warrant which was included in warrant liabilities-related party on December 31, 2022 was
approximately $2.8 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Comparison
of the Years Ended December 31, 2023 and 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; color: Black; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>For the Years Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>December 31,</b></span></p></td><td style="padding-bottom: 1.5pt; color: Black">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="color: Black">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td><td style="color: Black; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; color: Black; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; color: Black; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold">EXPENSES</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; color: Black; text-align: left; padding-left: 10pt">General and administrative</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">$</td><td style="width: 16%; color: Black; text-align: right">6,095,607</td><td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 2%; color: Black">&#160;</td>
    <td style="width: 1%; color: Black; text-align: left">&#160;</td><td style="width: 16%; color: Black; text-align: right">10,274,600</td><td style="width: 1%; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">5,209,250</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">4,486,120</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total expenses</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">11,304,857</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">14,760,720</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold; text-align: left">LOSS FROM OPERATIONS</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(11,304,857</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(14,760,720</td><td style="color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold; text-align: left">OTHER EXPENSE (INCOME), NET</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-left: 10pt">Gain on change in fair value of warrant liabilities</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(2,035,469</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(907,203</td><td style="color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-left: 10pt">Interest expense, net</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">1,524,722</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">34,397</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-left: 10pt">Loss on voluntary conversion of convertible debt</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">1,077,287</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-left: 10pt">Loss on debt extinguishment</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">625,653</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#8212;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Loss on fixed asset disposal</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right">21,747</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><p style="margin: 0">Other income, net</p></td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(38,994</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total other expense (income), net</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">1,174,946</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(872,806</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold; text-align: left">LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(12,479,803</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(13,887,914</td><td style="color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold; text-align: left; padding-bottom: 1.5pt">(BENEFIT) PROVISION FOR INCOME TAXES</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(4,793</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">6,548</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold; text-align: left">NET LOSS FROM CONTINUING OPERATIONS</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(12,475,010</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(13,894,462</td><td style="color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold; text-align: left">DISCONTINUED OPERATIONS</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-left: 10pt">Loss from discontinued operations, net of tax</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(683,008</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(7,140,181</td><td style="color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Loss on disposal of discontinued operations, net of tax</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(602,232</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold; text-align: left; padding-bottom: 1.5pt">LOSS FROM DISCONTINUED OPERATIONS</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(1,285,240</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(7,140,181</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold; text-align: left">NET LOSS</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(13,760,250</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(21,034,643</td><td style="color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Net loss attributable to non-controlling interest from discontinued operations</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(343,038</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(2,394,100</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to Qualigen Therapeutics, Inc.</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">(13,417,212</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">(18,640,543</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss per common share, basic and diluted - continuing operations</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">(2.46</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">(3.62</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss per common share, basic and diluted - discontinued operations</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">(0.19</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">(1.24</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 2.5pt">Weighted&#8212;average number of shares outstanding, basic and diluted</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">5,072,709</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">3,840,340</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; font-weight: bold; text-align: left">Other comprehensive loss, net of tax</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">&#160;</td><td style="color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Net loss</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">(13,760,250</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">$</td><td style="color: Black; text-align: right">(21,034,643</td><td style="color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Foreign currency translation adjustment from discontinued operations</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">119,473</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">50,721</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; text-align: left">Other comprehensive loss</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(13,640,777</td><td style="color: Black; text-align: left">)</td><td style="color: Black">&#160;</td>
    <td style="color: Black; text-align: left">&#160;</td><td style="color: Black; text-align: right">(20,983,922</td><td style="color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="color: Black; text-align: left; padding-bottom: 1.5pt">Comprehensive loss attributable to noncontrolling interest from discontinued operations</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(304,735</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; color: Black; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; color: Black; text-align: right">(2,394,100</td><td style="padding-bottom: 1.5pt; color: Black; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: Black; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Comprehensive loss attributable to Qualigen Therapeutics, Inc.</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">(13,336,042</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">)</td><td style="color: Black; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; color: Black; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; color: Black; text-align: right">(18,589,822</td><td style="padding-bottom: 2.5pt; color: Black; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">General
and administrative expenses decreased from $10.3 million for the year ended December 31, 2022 to $6.1 million for the year ended
December 31, 2023. This decrease was due to a $3.8 million decrease in stock-based compensation expense, a $0.4 million decrease in
payroll related expenses, a $0.3 million decrease in insurance expenses, and a $0.2 million decrease in license fees, offset by an
increase of $0.5 million in professional fees. (The foregoing comparison, and all other comparisons presented in this Item, exclude
Qualigen, Inc. and NanoSynex, Ltd. results for both years.)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Research
and Development Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Research
and development expenses increased from $4.5 million for the year ended December 31, 2022 to approximately $5.2 million for year ended December
31, 2023. This increase in research and development expenses for the year ended December 31, 2023 compared to for the year ended December
31, 2022 was primarily due to a $2.1 million increase in pre-clinical and clinical research costs for QN-302, offset by a $1.0 million
decrease in pre-clinical research costs for QN-247 a $0.3 million decrease in preclinical research costs for Pan-RAS, and a $0.1 million decrease in preclinical research costs for QN-165.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Other
Expense (Income)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Change
in Fair Value of Warrant Liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended December 31, 2023 we experienced a $2.0 million gain in other income because of the change in fair value of the
warrant liabilities arising from our liability classified warrants described above. The estimated fair value of these warrant
liabilities decreased to $0.1 million as of December 31, 2023 from $3.6 million as of December 31, 2022 due to a reduction in fair
value of the warrant liabilities resulting from an associated decrease in the market price of our common stock, and the
reclassification at fair value of a liability classified warrant to equity of $1.6 million. For the year ended December 31, 2022,
the gain on change in fair value of warrant liabilities was $0.9 million due to an associated decrease in the market price of our
common stock. Typically, a decline in our stock price would result in a decline in the fair value of our warrant liabilities,
generating a gain, while an increase in our stock price would result in an increase in the fair value of our warrant liabilities,
generating a loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
remaining liability classified warrants expire on June 26, 2024. Because the fair value of the warrant liabilities will be determined
each quarter on a &#8220;mark-to-market&#8221; basis, this item is likely to, until then, continue to result in variability in our future
quarterly Consolidated Statements of Operations based on unpredictable changes in our public market common stock price and the number
of warrants outstanding at the end of each quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Interest
(Income) Expense, Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">There
was $1.5 million in net interest expense during the year ended December 31, 2023 compared to net interest income of $34,000 during the
year ended December 31, 2022. The increase was due to the interest on the 2022 Debenture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Loss
on Voluntary Conversion of Convertible Debt</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended December 31, 2023 we issued 841,726 shares of common stock upon Alpha&#8217;s partial voluntary conversion of the
2022 Debenture at $1.32 per share for a total of $1,111,078 principal converted. Upon conversion, we recognized a loss on voluntary
conversion of convertible debt of approximately $1.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Loss
on Debt Extinguishment</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">During
the year ended December 31, 2023, we issued 309,665 shares of common stock in lieu of cash for the October and December 2023 monthly
redemptions, for a total of $220,000 principal redeemed, pursuant to the terms of the 2022 Debenture at a weighted average share
price of $0.71. Upon redemption in shares, we recognized a loss on partial debt extinguishment of $34,315. The modification of the 2022 Debenture during the year ended December 31, 2023 met the criteria to be accounted for
as a debt extinguishment in the amount of $591,338. Accordingly, we recognized an additional loss on partial debt extinguishment of that
amount.</p>
<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Loss
on Fixed Asset Disposal</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended December 31, 2023, we incurred a $21,747 loss on fixed asset disposal due to disposal of research and development equipment
previously used for QN-165.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Liquidity
and Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
financial position is weak. As of December 31, 2023, we had approximately $0.4 million in cash and net accounts payable of over $2.2
million. We are in arrears on accounts payable to important partners. We have incurred recurring losses from operations and have an accumulated
deficit of $116.8 million at December 31, 2023. We expect to continue to incur losses subsequent to the consolidated balance sheet date
of December 31, 2023. For the years ended December 31, 2023 and 2022, we used cash of $10.3 million and $13.2 million, respectively, in
operations. We sold our Qualigen, Inc. FastPack&#174; diagnostics products business in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
February 26, 2024, we entered into a Securities Purchase Agreement (&#8220;Agreement&#8221;) with Alpha. The transactions contemplated
by the Agreement closed on February 27, 2024, at which time we delivered to Alpha a new Debenture and warrant, as described in this paragraph,
and Alpha paid the Company a cash purchase price of $500,000 (less expenses). Pursuant to the Agreement, we issued to Alpha an 8% Convertible
Debenture (the &#8220;2024 Debenture&#8221;) in the principal amount of $550,000. The 2024 Debenture has a maturity date of December
31, 2024 and is convertible, at any time, and from time to time, at Alpha&#8217;s option, into shares of common stock of the Company,
at $0.6111 per share, subject to adjustment as described in the 2024 Debenture. The 2024 Debenture accrues interest on its outstanding
principal balance at the rate of 8% per annum, payable at maturity. Pursuant to the terms of the Agreement, we also issued to Alpha a
5-year common stock purchase warrant to purchase (at $0.26 per share) 900,016 shares of common stock of the Company. We also granted
to Alpha an option, exercisable until July 1, 2024, to purchase from us additional 8% Convertible Debentures, of like tenor, with face
amounts of up to an aggregate of $1,100,000 (and with a proportional number of accompanying common stock warrants of like tenor, up to
a total of 1,800,032 additional warrants), which would (if and when Alpha exercises such option) provide us up to an additional $1.0
million in cash proceeds (less expense reimbursement, and not including any possible cash proceeds from any future exercise of the additional warrants).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
currently expect our cash balances to fund operations only into the second quarter of 2024. We expect to continue to have net losses and negative cash flow from operations, which will challenge our liquidity.
These factors raise substantial doubt regarding our ability to continue as a going concern for the one-year period following the date
that the financial statements in this Annual Report were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">There
is no assurance that we will ever achieve profitable operations, or, if achieved, could be sustained on a continuing basis. In order
to fully execute our business plan, we will require significant additional financing for planned research and development activities,
capital expenditures, QN-302 clinical trials, and preclinical development of Pan-RAS, as well as commercialization activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Historically,
our principal sources of cash have, in addition to revenue from FastPack product sales and license revenues (see Note 5 - Discontinued
Operations), included proceeds from the issuance of common and preferred equity and proceeds from the issuance of debt. In December 2022
and February 2024 we raised approximately $3.0 million and $0.5 million, respectively from the sale of convertible debentures to Alpha. There can be
no assurance that further financing can be obtained on favorable terms, or at all. If we are unable to obtain funding, we could be required
to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, and
we could be unable to continue operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">To
the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our
common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect
the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise
additional funds through third-party funding, commercialization, marketing and distribution arrangements or other collaborations, strategic
alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue
streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. In addition, any future
financing (depending on the terms and conditions) may be subject to the approval of Alpha under the terms of the Debentures and/or trigger
certain adjustments to the Debentures or warrants held by Alpha.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements
do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be
required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ
from those reflected in the accompanying financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Our
current liabilities at December 31, 2023 include $2.2 million of accounts payable, $0.6 million of accrued expenses and other current
liabilities, $0.1 million in warrant liabilities, and $1.3 million of convertible debt to a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Contractual
Obligations and Commitments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have no material contractual obligations that are not fully recorded on our consolidated balance sheets or fully disclosed in the notes
to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>License
and Sponsored Research Agreements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have obligations under various license and sponsored research agreements to make future payments to third parties that become due and
payable on the achievement of certain development, regulatory and commercial milestones (such as the start of a clinical trial, filing
for product approval with the FDA or other regulatory agencies, product approval by the FDA or other regulatory agencies, product launch
or product sales) or on the sublicense of our rights to another party. We have not included these commitments on our balance sheet because
the achievement and timing of these events is not determinable. Certain milestones are in advance of receipt of revenue from the sale
of products and, therefore, we may require additional debt or equity capital to make such payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
have multiple license and sponsored research agreements with ULRF. Under these agreements, we have taken over development, regulatory
approval and commercialization of various drug compounds from ULRF and are responsible for maintenance of the related intellectual property
portfolio. We agreed to reimburse ULRF for sponsored research expenses of up to $2.7 million and prior patent costs of up to $112,000
for Pan-RAS. As of December 31, 2023, there were no remaining un-expensed amounts under this sponsored research agreement for Pan-RAS.
Under the terms of these agreements, we are required to make patent maintenance payments and payments based upon development, regulatory
and commercial milestones for any products covered by the in-licensed intellectual property. The maximum aggregate milestone payments
we may be obligated to make per product are $5 million. We will also be required to pay a royalty on net sales of products covered by
the in-licensed intellectual property in the low single digits. The royalty is subject to reduction for any third-party payments required
to be made, with a minimum floor in the low single digits. We have the right to sublicense our rights under these agreements, but we
will be required to pay ULRF a percentage of any sublicense income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
previously had sponsored research agreements with ULRF for QN-247 and QN-165. As of December 31, 2023, there were no remaining un-expensed
amounts under these sponsored research agreements and the agreements were terminated effective August 31, 2022, and November 30, 2021
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
January 13, 2022, we entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a
genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College
London, including lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization
company for University College London.) We are further developing the program&#8217;s lead compound under the name QN-302. The
License Agreement requires (if and when applicable) tiered royalty payments in the low to mid-single digits,
clinical/regulatory/sales milestone payments, and sharing of a percentage of any non-royalty sublicensing consideration paid to the
Company. In November 2023, we became obligated to pay $100,000 to UCL Business Limited upon the first patient dosing of QN-302,
which is included in accounts payable in our consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Alpha
Convertible Debt</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
December 22, 2022, pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022 (the &#8220;Alpha Purchase Agreement&#8221;),
we issued to Alpha, in exchange for $3,000,000 in cash (less $50,000 for expense reimbursement), the 2022 Debenture with an original
face amount of $3,300,000 due on December 22, 2025, plus 2,500,000 common stock warrants exercisable (from June 22, 2023 through June
22, 2028) at $1.65 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption
of the 2022 Debenture, we must redeem $110,000 plus accrued but unpaid interest, liquidated damages and any amounts then owing under
the 2022 Debenture. The Monthly Redemption Amount must be paid in cash; provided that after the first two monthly redemptions, we may
(if the Equity Conditions, as defined in the 2022 Debenture, are then satisfied or have been waived) elect to pay all or a portion of
a Monthly Redemption Amount in shares of our common stock, based on a conversion price equal to the lesser of (i) the then applicable
conversion price of the 2022 Debenture and (ii) 85% of the average of the VWAPs (as defined in the 2022 Debenture) for the five consecutive
trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The
2022 Debenture accrues interest at the rate of 8% per annum, which began accruing on December 1, 2023, and will be payable on a quarterly
basis. Interest may be paid in cash or shares of common stock or a combination thereof at our option; provided that the Equity Conditions
have been satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">Alpha
has waived the Equity Conditions for certain Monthly Redemption Amounts, but Alpha is not required to continue such waivers beyond May
2024. For the foreseeable future, we do not expect to be able to satisfy the Equity Conditions; as a result, where there is no waiver
of the Equity Conditions we would not have the opportunity to make 2022 Debenture payments in the form of stock rather than in the form
of cash, even for types of payments for which payment in the form of stock would have been allowed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black; background-color: white">The
2022 Debenture is convertible into our common stock at any time at the holder&#8217;s option; the conversion price was originally $1.32
but pursuant to a Securities Purchase Agreement amendment it was reduced to $0.73 on December 5, 2023 and then on February 27, 2024 it
was adjusted downward to $0.26 per share by virtue of the operation of a &#8220;ratchet&#8221; antidilution provision. (The exercise
price of the warrants issued with the 2022 Debenture was originally $1.65 but pursuant to the Securities Purchase Agreement amendment
it was reduced to $0.73 on December 5, 2023 and then on February 27, 2024 it was adjusted downward to $0.26 per share by virtue of the
operation of a &#8220;ratchet&#8221; antidilution provision.)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Both
the 2022 Debenture and the accompanying warrants provide for &#8220;ratchet&#8221; antidilution adjustments to their conversion price
and exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Both
the 2022 Debenture and the accompanying warrants include a beneficial ownership blocker of 9.99%, which may only be waived by Alpha upon
61 days&#8217; notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
granted Alpha resale registration rights for the common shares underlying the 2022 Debenture and the accompanying warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
December 5, 2023, we entered into an Amendment No. 1 with regard to Securities Purchase Agreement, with Alpha, which, among other things,
revised certain provisions of the 2,500,000 warrants to clarify the intention that such 2,500,000 warrants would not be liability-classified
for GAAP purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended December 31, 2023, we recognized an extinguishment loss on voluntary conversion of convertible debt of approximately
$1.1 million, an extinguishment loss of $0.6 million upon October and December 2023 share redemptions and the modification of the
2022 Debenture in December 2023, and recorded accrued interest of approximately $1.5 million, in other expenses in the consolidated
statements of operations. During the year ended December 31, 2023 we paid Monthly Redemption Amounts of $550,000 in cash and
$220,000 in common stock, and as of December 31, 2023 the remaining 2022 Debenture principal balance was approximately $1.4 million,
the remaining discount was approximately $0.1 million, and the fair value of the suite of bifurcated embedded derivative features
was $0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Reference
is also made to the 2024 Debenture, which was issued to Alpha after the end of the 2023 fiscal year and is described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>NanoSynex
Funding Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">As
a condition to our acquisition of a majority voting equity interest in NanoSynex from Alpha and NanoSynex, we entered into a Master Agreement
for the Operational and Technological Funding of NanoSynex (the &#8220;Funding Agreement&#8221;), on May 26, 2022, pursuant to which
we agreed to fund NanoSynex up to an aggregate of approximately $10.4 million, subject to NanoSynex&#8217;s achievement of certain performance
milestones specified in the Funding Agreement and the satisfaction of other terms and conditions described in the Funding Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During
the year ended December 31, 2022, we funded a total of approximately $2.4 million and in February 2023 we funded an additional $0.5 million
to NanoSynex under the Funding Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On
July 20, 2023, we entered into the NanoSynex Amendment, which amended the Funding Agreement, pursuant to which the Company agreed to,
among other things, forfeit 281,000 Series B Preferred Shares of NanoSynex held by the Company, resulting in our ownership in NanoSynex
being reduced from approximately 52.8% to approximately 49.97% of the voting equity of NanoSynex. In addition, we agreed to cancel approximately
$3.0 million of promissory notes which NanoSynex had issued to us under the NanoSynex Funding Agreement, relieving NanoSynex of any repayment
obligations to us with respect to such notes. The surrender of shares reducing our interest in NanoSynex from approximately 52.8% to
approximately 49.97% occurred on July 20, 2023. Accordingly, NanoSynex was deconsolidated from our financial statements as of July 20,
2023, and is reported as Discontinued Operations in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The
NanoSynex Amendment superseded any payment obligations contemplated by the original Funding Agreement and amended our obligations to
provide funding to NanoSynex, except we agreed to provide future funding as follows: (i) $560,000 on or before November 30, 2023,
and (ii) $670,000 on or before March 31, 2024, in each case issued in the form of a promissory note to the Company with a face value
in the amount of such funding. However, on November 22, 2023, in full settlement of any additional funding obligations to NanoSynex,
we forfeited certain of our shares of Series A-1 Preferred Stock of NanoSynex in an amount that reduced our ownership in NanoSynex
from approximately 49.97% to 39.90%. Our investment in NanoSynex will be accounted as an equity method investment</span>
prospectively from the July 20, 2023 deconsolidation date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i>Other
Service Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
enter into contracts in the normal course of business, including with clinical sites, contract research organizations, and other professional
service providers for the conduct of clinical trials, contract manufacturers for the production of our product candidates, contract research
service providers for preclinical research studies, professional consultants for expert advice and vendors for the sourcing of clinical
and laboratory supplies and materials. These contracts generally provide for termination on notice, and therefore are cancelable contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the significant sources and uses of cash for the periods set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Twelve Months Ended</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash (used in) provided by:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,304,263</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,247,541</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,215,943</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(183,763</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(550,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,910,515</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of exchange rate on cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,639</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    decrease in cash and restricted cash</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,638,320</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,498,150</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Cash Used in Operating Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, operating activities used $10.3 million of cash, primarily resulting from a loss from continuing
operations of $12.5 million. Cash flows from operating activities for the year ended December 31, 2023 were positively impacted by
adjustments for a $1.1 million non cash loss on voluntary conversion of convertible debt, a $0.6 million non cash loss on
convertible debt extinguishment, accretion of discount of $1.5 million on convertible debt, a $1.6 million increase in accounts
payable, and $1.1 million in non cash stock-based compensation expense. Cash flows from operating activities for the year ended December 31, 2023 were negatively impacted by adjustments for a
$2.0 million decrease in fair value of warrant liabilities, a $0.3 million increase in prepaid expenses and other assets, a $0.2
million decrease in accrued expenses and other current liabilities, and cash used in discontinued operations of $1.2 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, operating activities used $13.2 million of cash, primarily resulting from a loss from continuing
operations of $13.9 million. Cash flows from operating activities for the year ended December 31, 2022 were positively impacted by
an adjustment for $4.8 million in non cash stock-based compensation expense. Cash
flows from operating activities for the year ended December 31, 2022 were negatively impacted by cash used in discontinued
operations of $2.6 million, a $0.9 million decrease in fair value of warrant liabilities, a $0.5 million decrease in accrued
expenses and other current liabilities, and a $0.1 million increase in prepaid expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Cash Provided By Investing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, net cash provided by investing activities was approximately $4.2 million resulting from discontinued
operations due to $4.9 million in proceeds received from the sale of Qualigen, Inc., offset by $0.5 million advanced to NanoSynex, and
$0.2 million in purchases of property and equipment prior to deconsolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">During the year ended December 31, 2022, net cash used in investing activities
was approximately $0.2 million, due to capital expenditures offset by cash acquired in the NanoSynex acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Cash Provided by Financing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities for the year ended December 31, 2023, was approximately $0.6 million, due to monthly redemption
payments which we made in the form of stock (rather than in the form of cash) on the 2022 Debenture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">Net cash provided by financing activities for the year ended December 31,
2022, was approximately $2.9 million, due to the issuance of convertible debt to Alpha.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="mm_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
7A. Quantitative and Qualitative Disclosures about Market Risk.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise
required under this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span id="mm_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8. Consolidated Financial Statements and Supplementary Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mm_003">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID: <span id="xdx_90F_edei--AuditorFirmId_c20230101__20231231_zXZpoa6boWXe"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000046" name="dei:AuditorFirmId">23</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mm_004">Consolidated Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mm_005">Consolidated Statements of Operations and Comprehensive Loss</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mm_006">Consolidated Statements of Stockholders&#8217; Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mm_007">Consolidated Statements of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mm_008">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span id="mm_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders of Qualigen Therapeutics, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Qualigen Therapeutics, Inc. (the &#8220;Company&#8221;) as of December
31, 2023 and December 31, 2022, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity
(deficit) and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively
referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present
fairly, in all material respects, the financial position of the Company as of December 31, 2023 and December 31, 2022, and the
results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with
accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern Uncertainty</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 2 to the consolidated financial statements, the Company&#8217;s current liquidity position and projected cash needs raise substantial
doubt about its ability to continue as a going concern. Management&#8217;s plans regarding these matters are also described in Note 2.
The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion
on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<p style="margin: 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.5pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting
for Financial Instruments &#8211; </b></span><b>Modification of Convertible Debt with Warrants</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Critical
Audit Matter Description</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white">As described in Note 8 to the consolidated financial
statements, during the year ended December 31, 2023, the Company modified the conversion price and strike price of its convertible debenture
and common stock purchase warrants, respectively. Further, the Company modified certain terms of its stock warrant agreements that were
originally classified as liabilities enabling them to be classified as equity.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white">We identified the accounting for the modification
of this complex financial instrument as a critical audit matter. This includes both the evaluation of the various features as potential
embedded derivatives and the determination of the respective fair value of the instruments and the embedded features, as well as the determination
of the appropriate classification of warrants between equity and liabilities. The application of the accounting guidance applicable to
issuing and modifying a complex financial instrument requires significant judgment.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white">Determination of appropriate classification of warrants
requires management&#8217;s judgments relating to the interpretations of relevant accounting guidance based on specific provisions of
the warrant agreement. Accounting for the convertible notes and embedded conversion features requires management&#8217;s judgments related
to initial and subsequent recognition of the debt and related features, use of a valuation model, and key inputs used in the selected
valuation model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; background-color: white"><i>How We Addressed the Matter in Our Audit</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary procedures we performed to address this critical audit matter included:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-indent: -24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-indent: -24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inspecting the agreements associated with the transactions and evaluating management&#8217;s technical accounting analysis, including
the application of the relevant accounting literature.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Utilizing an auditor&#8217;s specialist to assist in assessing management&#8217;s analysis of the transaction, including (i) evaluating
the contracts to identify relevant terms that affect the recognition of the financial instruments, (ii) assessing the appropriateness
of conclusions reached by management, and (iii) reviewing the valuation model for derivatives, performing independent calculations, and
examining the significant assumptions utilized in the valuation model.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-indent: -24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
<span id="xdx_906_edei--AuditorName_c20230101__20231231_zuWzEFy5B7d2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000047" name="dei:AuditorName">Baker Tilly US, LLP</ix:nonNumeric></span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--AuditorLocation_c20230101__20231231_zJb2mmajir47"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000048" name="dei:AuditorLocation">San
Diego, California</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
5, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span id="mm_004"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_111_zejQ9bOY2Vka" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zsv0BNnaplk2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20221231_zhgbVIUPCLUa" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AssetsAbstract_iB_z7IRunPjqSab" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrentAbstract_i01B_ze0IDyzOYlwa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Cash_i02I_maCzI2M_z6fKhhyxQ1Z9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,803</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,165,985</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzI2M_zVhZwOJMKAc5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">764,964</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,366,704</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzI2M_zhJsjLerwW08" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Current assets of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0062">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,287,849</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrent_i02TI_mtCzI2M_maCzo3N_zhGiwbH8uYXd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,166,767</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,820,538</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzo3N_zAUKPKzod0zb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0068">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,242</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_i01I_maCzo3N_zm62lZs0RC01" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">866,481</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0072">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_i01I_maCzo3N_z3T5jfdeDkOd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Non-current assets of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0074">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="AsOf2022-12-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,236,711</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Assets_i01TI_mtCzo3N_z04sMYi5dpBb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total Assets</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,033,248</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,083,491</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zDZjJ36JdBBk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrentAbstract_i01B_z2ot8SqXGnJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableCurrent_i02I_maCzCJ5_z3AnwqS1F433" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,222,983</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">619,568</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_maCzCJ5_zN7VMYljwvC5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">560,006</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2022-12-31" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">864,559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--HedgingLiabilitiesCurrent_i02I_maCzCJ5_zpIKQu3RMDQf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:HedgingLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:HedgingLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">788,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WarrantLiabilitiesRelatedParty_i02I_maCzCJ5_zFpBAGdrQxt1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Warrant liabilities - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:WarrantLiabilitiesRelatedParty" contextRef="AsOf2022-12-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,834,547</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ConvertibleDebt_i02I_maCzCJ5_zmtJUvznQ7Ue" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible debt - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2023-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,299,216</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2022-12-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,197</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzCJ5_zsP1F46WDv5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0101">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,441,198</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrent_i02TI_mtCzCJ5_maCzIDe_zmKVTyJmqpp7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,136,805</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,608,169</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_iI_maCzIDe_zX2Fj7cGXqf8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Non-current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0107">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" contextRef="AsOf2022-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,708,732</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Liabilities_i01TI_mtCzIDe_maCz6nH_maLASEzl1h_zTVtZyyyMM18" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,136,805</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,316,901</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CommitmentsAndContingencies_i01I_maCz6nH_maLASEzl1h_zMgckhV6NCJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and Contingencies (Note 10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0113">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0114">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_i01B_zyQPPKcORtD5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; equity (deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquityAbstract_i01B_zNh3p24G6gld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Qualigen Therapeutics, Inc. stockholders&#8217; equity (deficit):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CommonStockValue_i02I_maCzGFE_ztj3H5p8dCA2" style="vertical-align: bottom; background-color: White">
    <td>Common stock, $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zJX4tcvNMd34" title="Common stock, par value"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zLPw12dmigI2" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zPOW5wwzqGld" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zRY8esSyKHBg" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">225,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zsuI1MCUv7Qj" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zosewuUBDSOl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,362,128</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_ziPNNlcQiKpc" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_z4lQLlfA0zp8" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,210,737</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,262</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,110</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_i02I_maCzGFE_zxfrK2YXHux" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,655,565</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,528,050</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maCzGFE_zzlJ9vmH6sV" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0144">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzGFE_zRmFYagle1tj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">116,802,384</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">103,385,172</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquity_i02TI_mtCzGFE_maSEIPAzgg9_zWBLEq90NBW4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total Qualigen Therapeutics, Inc. stockholders&#8217; equity (deficit)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,103,557</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,235,709</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--MinorityInterest_i02I_maSEIPAzgg9_zmBdOBAlJOji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Noncontrolling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0153">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2022-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,530,881</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_mtSEIPAzgg9_maLASEzl1h_zARJGSxzLr56" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total Stockholders&#8217; Equity (deficit)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000156" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,103,557</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,766,590</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzl1h_zvJhgtlWVek3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt; font-weight: bold; text-align: left">Total Liabilities &amp; Stockholders&#8217; Equity (Deficit)</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,033,248</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,083,491</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span id="mm_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_113_zUZfsSsMx1La" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zbGYgTLeyd8l" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="display: none; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20220101__20221231_zrRd53ojWGX" style="border-bottom: Black 1.5pt solid; display: none; font-weight: bold; text-align: center">2022</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingCostsAndExpensesAbstract_iB_zCZ0GrXvvHyi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzbrJ_zaBsmR7yaXGl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,095,607</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,274,600</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzbrJ_zrZlF2T4OBgg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,209,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact000169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,486,120</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpenses_i01T_mtCzbrJ_msCzGIs_z1q863Ycmpx8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,304,857</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-12-31" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,760,720</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_iT_mtCzGIs_maCzlgb_z1FkjKxTXiKh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LOSS FROM OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,304,857</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000175" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,760,720</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z5YNwvL4kPy3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">OTHER EXPENSE (INCOME), NET</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeGainLossOnDerivativeNet_i01N_di_maCzLqV_zWvDDhxFTKaa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-01to2023-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,035,469</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">907,203</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestIncomeExpenseNet_i01N_di_maCzLqV_zfOxXnFL8LEb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-01to2023-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,524,722</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-01-012022-12-31" id="Fact000184" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">34,397</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InducedConversionOfConvertibleDebtExpense_i01_msCzLqV_zH64MsLt46x5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss on voluntary conversion of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,077,287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0187">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01N_di_maCzLqV_zrw0xQZ7Syc3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on debt extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">625,653</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0190">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GainLossOnSaleOfOtherAssets_i01N_di_maCzLqV_zlbuFjXhurKe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss on fixed asset disposal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2023-01-01to2023-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,747</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0193">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherNonoperatingIncomeExpense_i01N_di_maCzLqV_z8Ahc5SWlidl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,994</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0196">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_i01NT_di_mtCzLqV_maCzlgb_zl0uCfhTzKab" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total other expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,174,946</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">872,806</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzlgb_maCzaVI_zAsgqKyzPZph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,479,803</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,887,914</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_msCzaVI_zdIusCOWLQU6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">(BENEFIT) PROVISION FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,793</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,548</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_mtCzaVI_maCzhiC_zBQQd26tDyE9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NET LOSS FROM CONTINUING OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,475,010</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,894,462</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_iB_zBqUHVGraX02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">DISCONTINUED OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_maCzBjD_zFFWERel9Djb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss from discontinued operations, net of tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" contextRef="From2023-01-01to2023-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">683,008</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" contextRef="From2022-01-012022-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,140,181</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_iN_di_msCzBjD_zkCN9Q6ZDU59" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Loss on disposal of discontinued operations, net of tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" contextRef="From2023-01-01to2023-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">602,232</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0217">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_mtCzBjD_maCzhiC_zcmj3GM46b98" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">LOSS FROM DISCONTINUED OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2023-01-01to2023-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,285,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2022-01-012022-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,140,181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProfitLoss_iT_mtCzhiC_maCzape_maCz9kQ_z5kbi3C2zrzd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NET LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,760,250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,034,643</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_msCzape_zf5B4nGQNTH9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Net loss attributable to non-controlling interest from discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">343,038</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,394,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_mtCzape_zRH9tPkrjLdk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Net loss attributable to Qualigen Therapeutics, Inc.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,417,212</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,640,543</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Net loss per common share, basic and diluted - continuing operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_c20230101__20231231_zfkJTElYo9ef" title="Net loss per common share, basic - continuing operations" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_c20230101__20231231_zwnCuhkC8Ps6" title="Net loss per common share, diluted - continuing operations" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2023-01-01to2023-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="From2023-01-01to2023-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.46</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_c20220101__20221231_zfS68OR3juXi" title="Net loss per common share, basic - continuing operations" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_902_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_c20220101__20221231_zoJ3aZf8BkGl" title="Net loss per common share, diluted - continuing operations" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2022-01-012022-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="From2022-01-012022-12-31" id="Fact000237" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.62</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Net loss per common share, basic and diluted - discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_c20230101__20231231_zrWJJizrInx6" title="Net loss per common share, basic - discontinued operations" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_904_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_c20230101__20231231_zEhORoYNCTAg" title="Net loss per common share, diluted - discontinued operations" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" contextRef="From2023-01-01to2023-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" contextRef="From2023-01-01to2023-12-31" id="Fact000241" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.19</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_c20220101__20221231_zFsNtLSgzsS4" title="Net loss per common share, basic - discontinued operations" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_904_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_c20220101__20221231_zZCPm6JjE9g7" title="Net loss per common share, diluted - discontinued operations" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" contextRef="From2022-01-012022-12-31" id="Fact000243" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" contextRef="From2022-01-012022-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.24</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Weighted-average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zEhNwVpkEEOa" title="Weighted-average number of shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zkqjHXHMfgL8" title="Weighted-average number of shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,072,709</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_z4LLiL5Sped6" title="Weighted-average number of shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zfIXDLxic4Kc" title="Weighted-average number of shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" id="Fact000253" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,840,340</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_iB_zK4iRf4PWKYg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other comprehensive loss, net of tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProfitLoss_iT_mtCzhiC_maCzape_maCz9kQ_zyLPpnutEUv8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,760,250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31" id="Fact000259" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,034,643</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01_maCz9kQ_znw5lJTjrych" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Foreign currency translation adjustment from discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-01to2023-12-31" id="Fact000261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,473</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31" id="Fact000262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_i01T_mtCz9kQ_maCzCWE_zmvCiR0XkT9k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,640,777</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000265" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,983,922</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_i01_msCzCWE_zwYroLWzi7nf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Comprehensive loss attributable to noncontrolling interest from discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" id="Fact000267" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">304,735</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000268" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,394,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_mtCzCWE_zYE5sI6B62Hi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Comprehensive loss attributable to Qualigen Therapeutics, Inc.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-01to2023-12-31" id="Fact000270" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,336,042</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-12-31" id="Fact000271" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,589,822</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span id="mm_006"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_114_zlY18WI7o0ej" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; display: none; vertical-align: bottom; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Shares</span></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zsQJrI7bu6w7" style="border-bottom: Black 1.5pt solid; display: none; vertical-align: bottom; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Amount</span></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z48AZ6uCmEMl" style="border-bottom: Black 1.5pt solid; display: none; vertical-align: bottom; font-weight: bold; text-align: center"><p style="display: none; margin-top: 0; margin-bottom: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Paid-In</span></p>
                                                                                                                            <p style="display: none; margin-top: 0; margin-bottom: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Capital</span></p></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zulYI77O7n73" style="border-bottom: Black 1.5pt solid; display: none; vertical-align: bottom; font-weight: bold; text-align: center"><p style="display: none; margin-top: 0; margin-bottom: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Comprehensive</span></p>
                                                                                <p style="display: none; margin-top: 0; margin-bottom: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Income</span></p></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z9itPU78ynJ7" style="border-bottom: Black 1.5pt solid; display: none; vertical-align: bottom; font-weight: bold; text-align: center"><p style="display: none; margin-top: 0; margin-bottom: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Accumulated</span></p>
                                                                                <p style="display: none; margin-top: 0; margin-bottom: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Deficit</span></p></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--ParentMember_zrDeBiGXpVZ6" style="border-bottom: Black 1.5pt solid; display: none; vertical-align: bottom; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Equity
    (Deficit)</span></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_z5FkiOwXzGrl" style="border-bottom: Black 1.5pt solid; display: none; vertical-align: bottom; font-weight: bold; text-align: center"><p style="display: none; margin-top: 0; margin-bottom: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Noncontrolling</span></p>
                                                                                <p style="display: none; margin-top: 0; margin-bottom: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Interest</span></p></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BC_zc368Ep0LM4j" style="border-bottom: Black 1.5pt solid; display: none; vertical-align: bottom; font-weight: bold; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Equity
    (Deficit)</span></td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Common
    Stock</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Additional</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Accumulated</span></p>
                                                                                                                 <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Other Comprehensive</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"/><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Total</span></p>
                                                                                                                 <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Qualigen</span></p>
                                                                                                                 <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Therapeutics,
                                            Inc.</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stockholders&#8217;</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"/><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Total</span></p>
                                                                                                                 <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stockholders&#8217;</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Shares</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Amount</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Paid-In</span></p>
                                                                                                                            <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Capital</span></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Income (Deficit)</span></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Accumulated</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Deficit</span></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Equity
    (Deficit)</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Noncontrolling</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Interest</span></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Equity
    (Deficit)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_43F_c20230101__20231231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zjzvgUpnVJyl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance at December 31, 2022</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPH34ibRboGj" title="Balance, shares" style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000281" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,210,737</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,110</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,528,050</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000276" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">103,385,172</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,235,709</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,530,881</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" id="Fact000279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,766,590</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_z6XkLHYIdXHf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Voluntary conversion of convertible
    debt into common stock</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwKD98Iq8Hc4" title="Voluntary conversion of convertible debt into common stock, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">841,726</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">842</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,111,740</ix:nonFraction></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0285">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,112,582</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-01to2023-12-31" id="Fact000289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,112,582</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock_zhPvZ7xh02Q7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Redemptions of convertible
    debt into common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td title="Voluntary conversion of convertible debt into common stock, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p id="xdx_984_ecustom--StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7tRWpRfdJt1" title="Redemptions of convertible debt into common stock, shares" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000301" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">309,665</ix:nonFraction></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">310</ix:nonFraction></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">254,006</ix:nonFraction></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">254,316</ix:nonFraction></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" contextRef="From2023-01-01to2023-12-31" id="Fact000299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">254,316</ix:nonFraction></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zg0ocXlW6SX4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Fair value of warrant modification
    for professional services</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,945</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,945</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-01to2023-12-31" id="Fact000309" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,945</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--FairValueOfWarrantReclassifiedFromLiabilitiesToEquity_zzRSoY1HRoud" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Fair value of warrant reclassified
    from liabilities to equity</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,626,694</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000315" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,626,694</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" contextRef="From2023-01-01to2023-12-31" id="Fact000317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,626,694</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zhJNI7d9dV0f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,098,533</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0321">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000323" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,098,533</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000324" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,297</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-01to2023-12-31" id="Fact000325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,107,830</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_zF9ctZRw3EVf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Foreign currency translation
    adjustment</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,597</ix:nonFraction></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,170</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000331" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,767</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,303</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" id="Fact000333" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,070</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--DeconsolidationOfDiscontinuedOperations_zx4CAkiKC9ka" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Deconsolidation of discontinued
    operations</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="QLGN:DeconsolidationOfDiscontinuedOperations" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000337" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">131,891</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="QLGN:DeconsolidationOfDiscontinuedOperations" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000339" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">131,891</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="QLGN:DeconsolidationOfDiscontinuedOperations" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000340" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,235,443</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="QLGN:DeconsolidationOfDiscontinuedOperations" contextRef="From2023-01-01to2023-12-31" id="Fact000341" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,367,334</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--ProfitLoss_zCj3gFNTaVf4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000346" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,417,212</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000347" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,417,212</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000348" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">343,038</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000349" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,760,250</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_434_c20230101__20231231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zSdHscyg22d8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance at December 31,
    2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDBzh6qnROTa" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000359" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,362,128</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000351" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,262</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000352" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,655,565</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000354" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">116,802,384</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31_us-gaap_ParentMember" id="Fact000355" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,103,557</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"></span><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2023-12-31" id="Fact000357" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,103,557</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Common
    Stock</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Additional</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Accumulated</span></p>
                                                                                                                 <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Other</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"/><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Total</span></p>
                                                                                                                 <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Qualigen</span></p>
                                                                                                                 <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Therapeutics,
                                            Inc.</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"/><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Total</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Shares</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Amount</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Paid-In</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Capital</span></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Comprehensive</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Income</span></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Accumulated</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Deficit</span></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stockholders&#8217;</span></p>
                                                                                                                            <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Equity</span></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Noncontrolling</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Interest</span></p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stockholders&#8217;</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Equity</span></p></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_438_c20220101__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zgCD1I9OwLL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance at December 31, 2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJQWrKYNNcU6" title="Balance, shares" style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000369" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,529,018</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,290</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,274,073</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000364" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,744,629</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_ParentMember" id="Fact000365" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,564,734</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" id="Fact000367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,564,734</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_439_c20220101__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zdOgf059x9Kf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zENmXjmaTar" title="Balance, shares" style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000379" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,529,018</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,290</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,274,073</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000374" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,744,629</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31_us-gaap_ParentMember" id="Fact000375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,564,734</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#8212;</span></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2021-12-31" id="Fact000377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,564,734</ix:nonFraction></span></td><td style="display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_zFQgUWBCzGzf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stock issued upon exercise
    of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z39G3GW3vTKi" title="Stock issued upon exercise of warrants, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000389" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">332,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000381" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,320</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000382" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,711</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,031</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31" id="Fact000387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,031</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zhFuwcMRuYx1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,484,044</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,484,044</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31" id="Fact000397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,484,044</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_zKRULjfwg6S9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Common stock and prefunded
    warrants issued for business acquisition</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAGdGQiGGNt9" title="Common stock and prefunded warrants issued for business acquisition, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000407" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000399" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,740,417</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000403" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,743,917</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,882,225</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" contextRef="From2022-01-012022-12-31" id="Fact000405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,626,142</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_z7AebQVdD1O4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;Noncontrolling interest
    adjustments relating to Stock-based compensation and other</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000410" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,756</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000413" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,756</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,756</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zWGPKZYQBLsk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Foreign currency translation
    adjustment</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000419" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000421" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zeWDlmAd4MGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Fair value of warrant modification
    for professional services</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31" id="Fact000431" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--FairValueOfWarrantModificationForBusinessAcquisition_zHtlFIyZ2AZg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Fair value of warrant modification
    for business acquisition</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0433">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000434" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0435">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationForBusinessAcquisition" contextRef="From2022-01-012022-12-31" id="Fact000439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValuesReverseStockSplits_zDJE6GmTGtE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance of rounded shares
    as a result of the reverse stock split</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8ruOAr3CQfh" title="Issuance of rounded shares as a result of the reverse stock split, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000449" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">281</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0441">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000442" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0443">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0444">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000445" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8212;</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="QLGN:StockIssuedDuringPeriodValuesReverseStockSplits" contextRef="From2022-01-012022-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--ProfitLoss_z76xsUsVFsS6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0453">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000454" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,640,543</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000455" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,640,543</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000456" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,394,100</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31" id="Fact000457" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,034,643</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td></tr>
  <tr id="xdx_43C_c20220101__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zwt0N4qydYX1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance at December 31,
    2022</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXvC1SQjxn5g" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000467" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,210,737</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,110</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,528,050</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000462" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">103,385,172</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,235,709</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,530,881</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" id="Fact000465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,766,590</ix:nonFraction></span><span style="font-family: Times New Roman, Times, Serif"></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_435_c20220101__20221231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_zTIYqQnY2XP9" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance </span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaydxsj4cn0a" title="Balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000477" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,210,737</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,110</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000470" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,528,050</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,721</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000472" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">103,385,172</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">)</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,235,709</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,530,881</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2022-12-31" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,766,590</ix:nonFraction></span><span style="display: none; font-family: Times New Roman, Times, Serif"></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span id="mm_007"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_112_zUvvPLV7k8D1" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="display: none; padding-bottom: 1.5pt">&#160;</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zN04i7JaYNU8" style="border-bottom: Black 1.5pt solid; display: none; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231_zCXrREykqxNb" style="border-bottom: Black 1.5pt solid; display: none; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="display: none; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zXp6Tns51kmj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProfitLoss_i01_mtNLOP_zBhiYCbqMMCd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000482" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,760,250</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31" id="Fact000483" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,034,643</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_i01_maNLOP_z6r9Gl9hwZId" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Loss from discontinued operations, net of tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="From2023-01-01to2023-12-31" id="Fact000485" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,285,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="From2022-01-012022-12-31" id="Fact000486" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,140,181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_i01T_maCzlEL_maNLOP_zxyrrq3b1HWa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" id="Fact000488" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,475,010</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,894,462</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zfL6eIrUXoWe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile loss from continuing operations to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DepreciationDepletionAndAmortization_i02_maCzlEL_z0TFsbkBcYY6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-01to2023-12-31" id="Fact000494" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,495</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-012022-12-31" id="Fact000495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,165</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_i02_maCzlEL_znRV83Vzu8c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-12-31" id="Fact000497" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,098,533</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,765,276</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FairValueAdjustmentOfWarrants_i02_maCzlEL_zRnbr7avCP5a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-01to2023-12-31" id="Fact000500" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,035,469</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">906,345</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--LossOnVoluntaryConversionOfConvertibleDebt_i02N_di_msCzlEL_zZ55soWbsKw6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss on voluntary conversion of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:LossOnVoluntaryConversionOfConvertibleDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000503" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,077,287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0504">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--AccretionOfDiscountOnConvertibleDebt_i02N_di_msCzlEL_z6O18Mr0j648" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accretion of discount on convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccretionOfDiscountOnConvertibleDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000506" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,469,640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0507">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msCzlEL_zZA7Bb04pQBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss on debt extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000509" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">625,653</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GainLossOnDispositionOfAssets1_i02N_di_msCzlEL_zkoK0CnnGur1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on disposal of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2023-01-01to2023-12-31" id="Fact000512" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,747</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--FairValueOfWarrantModificationForProfessionalServices_i02_maCzlEL_z6k0xuAyjUul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Fair value of warrant modification for professional services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationForProfessionalServices" contextRef="From2023-01-01to2023-12-31" id="Fact000515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,945</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationForProfessionalServices" contextRef="From2022-01-012022-12-31" id="Fact000516" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zJxf07akfAi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzlEL_zImYVMjKQK3e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-01to2023-12-31" id="Fact000521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,741</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,985</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maCzlEL_z9Qgt3qNGSnh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-01to2023-12-31" id="Fact000524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,603,422</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-012022-12-31" id="Fact000525" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,440</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_maCzlEL_zQIzbHRchNU6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">227,101</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-12-31" id="Fact000528" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">472,441</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_i01T_mtCzlEL_maCzzda_zoG0p3Zd7wea" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net cash used in operating activities - continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="From2023-01-01to2023-12-31" id="Fact000530" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,093,599</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="From2022-01-012022-12-31" id="Fact000531" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,598,862</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_i01_maCzzda_zqqceGuY86B5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Net cash provided by (used in) operating activities - discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="From2023-01-01to2023-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,210,664</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="From2022-01-012022-12-31" id="Fact000534" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,648,679</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzzda_maCCERCzwVY_zXtzjcKhXFM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,304,263</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,247,541</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zpWuPaN1DLmk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_i01_maCzKTE_zspWanoI8dE2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Net cash provided by (used in) investing activities -
    discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="From2023-01-01to2023-12-31" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,215,943</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="From2022-01-012022-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">183,763</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzKTE_maCCERCzwVY_z7MHOMjhzpq4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000545" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,215,943</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">183,763</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zTxfIU6fp3Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromWarrantExercises_i01_maCzk0X_zgETeogzTEeb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net proceeds from warrant exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-012022-12-31" id="Fact000552" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,173</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ProceedsFromIssuanceOfConvertibleDebt_i01_maCzk0X_zvNqZ2iC5wh6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:ProceedsFromIssuanceOfConvertibleDebt" contextRef="From2022-01-012022-12-31" id="Fact000555" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,903,847</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RepaymentsOfNotesPayable_i01N_di_msCzk0X_z0YVBzKUTzxc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payments on convertible notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-01-01to2023-12-31" id="Fact000557" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--FractionalSharePaymentsRelatedToReverseStockSplit_i01N_di_msCzk0X_zjcQDHMRLpf6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Fractional share payments related to the reverse stock split</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="QLGN:FractionalSharePaymentsRelatedToReverseStockSplit" contextRef="From2022-01-012022-12-31" id="Fact000561" format="ixt:numdotdecimal" decimals="0" unitRef="USD">505</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_i01T_mtCzk0X_maCzAIl_z0DbiO3EKyjg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net cash (used in)/provided by financing activities - continuing operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="From2023-01-01to2023-12-31" id="Fact000563" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">550,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="From2022-01-012022-12-31" id="Fact000564" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,910,515</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_i01_maCzAIl_z95kuRtbtOl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Net cash used in financing activities - discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzAIl_maCCERCzwVY_zSHseGVhvPL6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Net cash (used in) provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000569" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">550,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" id="Fact000570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,910,515</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCCERCzwVY_zM2kYLyda0wc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net change in cash and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-01-01to2023-12-31" id="Fact000572" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,638,320</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" id="Fact000573" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,520,789</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_zii6PdoJdeGi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Effect of exchange rate changes on cash and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0575">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2022-01-012022-12-31" id="Fact000576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,639</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zx2DkSgsCjSa" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Cash and restricted cash from continuing operations -
    beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" id="Fact000578" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,165,985</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-12-31" id="Fact000579" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,174,383</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zMmXLlETKXZh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Cash and restricted cash from discontinued operations - beginning of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000581" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,874,138</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"/><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" id="Fact000582" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,363,890</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iNE_di_z0fzShsy7pxg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold">Less: cash and restricted cash from discontinued operations - end of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0584">&#8212;</span></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,874,138</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zsY9X9O7rZz" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold">Cash from continuing operations - end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000587" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,803</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,165,985</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zhYZHAVuw6n6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash paid during the year for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestPaidNet_i01_zcnoloCmCKPk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0593">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0594">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxesPaidNet_i01_zKlQEy247dni" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">Taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-01to2023-12-31" id="Fact000596" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,571</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-012022-12-31" id="Fact000597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,571</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_z4OghGx0Egvc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NONCASH FINANCING AND INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--TransfersOfInventoryFromEquipmentHeldForLease_i01_zheZorPGtgM" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Net transfers to equipment held for lease from inventory</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:TransfersOfInventoryFromEquipmentHeldForLease" contextRef="From2023-01-01to2023-12-31" id="Fact000602" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,281</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0603">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_i01_z9tJOi0HtlNf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of warrant liabilities on date of exercise</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0605">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise" contextRef="From2022-01-012022-12-31" id="Fact000606" format="ixt:numdotdecimal" decimals="0" unitRef="USD">858</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--RedemptionOfConvertibleDebtIntoCommonStock_i01_zB5rpjXUV54i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Redemption of convertible debt into common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:RedemptionOfConvertibleDebtIntoCommonStock" contextRef="From2023-01-01to2023-12-31" id="Fact000608" format="ixt:numdotdecimal" decimals="0" unitRef="USD">254,316</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0609">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--VoluntaryConversionOfConvertibleDebtIntoCommonStock_i01_zrpjZoJoeej2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Voluntary conversion of convertible debt into common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:VoluntaryConversionOfConvertibleDebtIntoCommonStock" contextRef="From2023-01-01to2023-12-31" id="Fact000611" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,112,582</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0612">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement_i01_zFbTPKRUGYvl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Fair value of warrant modifications pursuant to Securities Purchase
    Agreement</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0614">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement" contextRef="From2022-01-012022-12-31" id="Fact000615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,439</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--FairValueOfWarrantModificationsForBusinessAcquisition_i01_zQKuZ7P4qtll" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Fair value of warrant modifications for business acquisition</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0617">&#8212;</span></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0"><ix:nonFraction name="QLGN:FairValueOfWarrantModificationsForBusinessAcquisition" contextRef="From2022-01-012022-12-31" id="Fact000618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,543</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span id="mm_008"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000620" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zOnsX2Pu4gA7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8212; <span id="xdx_825_zet8NYo4nIGd">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000622" name="QLGN:OrganizationPolicyTextBlock"><p id="xdx_84C_ecustom--OrganizationPolicyTextBlock_zoELRG00RZqb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zEHGaHZAHxR7">Organization</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ritter
Pharmaceuticals, Inc. (the Company&#8217;s predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the
name Ritter Natural Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals,
Inc. On May 22, 2020, upon completing a &#8220;reverse recapitalization&#8221; transaction with Qualigen, Inc., Ritter Pharmaceuticals,
Inc. was renamed Qualigen Therapeutics, Inc. (the &#8220;Company&#8221;). Qualisys Diagnostics, Inc. was formed as a Minnesota corporation
in 1996, reincorporated to become a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc.
was a wholly-owned subsidiary of the Company. On July 20, 2023, the Company sold all of the issued and outstanding shares of common stock
of Qualigen, Inc. to Chembio Diagnostics, Inc. (&#8220;Chembio&#8221;), a wholly-owned subsidiary of Biosynex, S.A. (&#8220;Biosynex&#8221;).
Following the consummation of this transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio (see Note 5 &#8211; Discontinued
Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 26, 2022, the Company acquired <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zAZ4kjiHJfug" title="Stock issued during period shares acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_custom_SeriesAOnePreferredStockMember" id="Fact000624" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,232,861</ix:nonFraction></span> shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (&#8220;NanoSynex&#8221;) from Alpha
Capital Anstalt (&#8220;Alpha&#8221;), a related party, in exchange for <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zm10E5bR0Vk9" title="Stock issued during period shares acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember" id="Fact000626" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> reverse split adjusted shares of the Company&#8217;s
common stock and a prefunded warrant to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zgOebxpv9q2h" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-05-26_custom_PrefundedWarrantMember" id="Fact000628" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction></span> reverse split adjusted shares of the Company&#8217;s common stock at an exercise
price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_znQiAcdJ9vQk" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_custom_PrefundedWarrantMember" id="Fact000630" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share. <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20220524__20220526_zZLCTUTXqaVa" title="Reverse stock split"><ix:nonNumeric contextRef="From2022-05-242022-05-26" id="Fact000632" name="us-gaap:StockholdersEquityReverseStockSplit">These warrants were subsequently exercised on September 13, 2022.</ix:nonNumeric></span> Concurrently with this transaction, the
Company also entered into a Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022,
with NanoSynex (the &#8220;NanoSynex Funding Agreement&#8221;), to, among other things, provide for the further funding of NanoSynex,
and purchased <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBH1w32dlfCa" title="Stock issued during period shares acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-05-242022-05-26_us-gaap_SeriesBPreferredStockMember" id="Fact000634" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">381,786</ix:nonFraction></span> shares of Series B preferred stock from NanoSynex for a total purchase price of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zP9BLEKsOO75" title="Stock issued during period, value, acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember" id="Fact000636" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">600,000</ix:nonFraction></span>. The transactions resulted
in the Company acquiring a <span id="xdx_905_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zmyx8kufwR2e" title="Voting interests acquired"><ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="AsOf2022-05-26_custom_NanoSynexLtdMember" id="Fact000638" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">52.8</ix:nonFraction></span>% interest in NanoSynex (the &#8220;NanoSynex Acquisition&#8221;). NanoSynex is a nanotechnology diagnostics
company domiciled in Israel. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex (the &#8220;NanoSynex
Amendment&#8221;), which amended the NanoSynex Funding Agreement, to, among other things, eliminate most of the Company obligation for
the further funding of NanoSynex. Pursuant to the terms of the NanoSynex Amendment, the Company lost its controlling interest in NanoSynex
(see Note 5 -Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000640" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNRMCvRcDep" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zONvBnmWnJ7c">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#8220;U.S. GAAP&#8221;), Regulation S-X and rules and regulations of the Securities and Exchange Commission
(&#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000642" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zf9hM2AKGiw7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zzRYl9MVKxT2">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the accounts of the Company and its former wholly-owned and majority owned subsidiaries.
All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance
is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional
currency of the Company and its subsidiaries is the U.S. dollar. For NanoSynex, the functional currency was the local currency, New Israeli
Shekels (NIS). As such, assets and liabilities for NanoSynex were translated into U.S. dollars with the effects of foreign currency translation
adjustments reflected as a component of accumulated other comprehensive loss within the Company&#8217;s consolidated statements of
changes in stockholders&#8217; equity (deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 20, 2023, NanoSynex was deconsolidated from these financial statements as the transactions contemplated by the NanoSynex Amendment
resulted in a loss of control of a subsidiary that constitutes a business under ASC 810. The retained investment in NanoSynex is accounted
for prospectively as an equity method investment. See Note 5 &#8211; Discontinued Operations for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000644" name="us-gaap:DiscontinuedOperationsPolicyTextBlock"><p id="xdx_84F_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zjBN6sDUY1X" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z6285TUmPecj">Discontinued
Operations</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, the Company completed the sale of Qualigen, Inc. to Chembio Diagnostics, Inc. The sale of Qualigen Inc. constituted a
significant disposition and as such, the Company concluded that the disposition of ownership in Qualigen, Inc. represented a strategic
shift that had a major effect on its operations and financial results. Therefore, Qualigen, Inc. is classified as discontinued operations
for all periods presented herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, the Company entered into the NanoSynex Amendment, which amended the Master Funding Agreement
for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the &#8220;NanoSynex
Funding Agreement&#8221;), a former majority owned subsidiary of the Company, to, among other things, forfeit 281,000 Series B Preferred
Shares of NanoSynex held by the Company, resulting in the deconsolidation of NanoSynex. The disposition represents a strategic shift
that will have a material effect on the Company&#8217;s operations and financial results. Accordingly, the business of NanoSynex is classified
as discontinued operations for all periods presented herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 5 - Discontinued Operations for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000646" name="us-gaap:EquityMethodInvestmentsPolicy"><p id="xdx_846_eus-gaap--EquityMethodInvestmentsPolicy_z0yVc3zgdCml" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zXqLYuXa0E2e">Equity
Method Investments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
deconsolidation of NanoSynex on July 20, 2023, the Company accounts for its retained investment under the equity method of accounting
as it retained the ability to exercise significant influence over the operating and financial policies of the investee. Under the equity
method, the Company recognizes its proportionate share earnings or losses each reporting period with an adjustment to the carrying value
of the investment. As of December 31, 2023, the carrying value of the retained investment was zero, and therefore the Company has suspended
application of the equity method as the Company is not liable for the obligations of the investee nor otherwise committed to provide
financial support. Future equity method earnings, if any, will not be recognized until the amount exceeds the unrecognized net losses
in prior periods. See Note 5 &#8211; Discontinued Operations for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000648" name="us-gaap:UseOfEstimates"><p id="xdx_846_eus-gaap--UseOfEstimates_z4xRxysj5w3b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zxiaUaiQGjf3">Accounting
Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant
liabilities, and stock-based compensation. Actual results could vary from the estimates that were used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000650" name="QLGN:ReverseStockSplitPolicyTextBlock"><p id="xdx_844_ecustom--ReverseStockSplitPolicyTextBlock_zPyRls5G3Qw8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z8rDi0S5KRI1">Reverse
Stock Split</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 23, 2022, the Company effected a 1-for-10 reverse stock split of its outstanding shares of common stock (the &#8220;Reverse
Stock Split&#8221;). The Reverse Stock Split reduced the Company&#8217;s shares of outstanding common stock, stock options, and warrants
to purchase shares of common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse Stock Split
were rounded down to the nearest whole share and cash in lieu of fractional shares was paid to stockholders. All share and per share
data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively
to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000652" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zptILlwsNoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zj906zf4TUrh">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains the majority of its cash in government money market mutual funds and in accounts at banking institutions in the U.S.
that are of high quality. Cash held in these accounts often exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits.
If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations.
In March 2023, Silicon Valley Bank and Signature Bank, and more recently in May 2023, First Republic Bank, were closed due to liquidity
concerns and taken over by the FDIC. While the Company did not have an account at any of these banks, in the event of failure of any
of the financial institutions where the Company maintains its cash and cash equivalents, there can be no assurance that the Company would
be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely
affect the Company&#8217;s business and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000654" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zES8EVAkVpFc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zzGtVIkWEHvd">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the years ended December 31, 2023 and 2022, <span id="xdx_908_eus-gaap--AssetImpairmentCharges_do_c20230101__20231231_zGFJtvprpUYc" title="Impairment losses on construction-in-progress"><span id="xdx_90E_eus-gaap--AssetImpairmentCharges_do_c20220101__20221231_zqrYIsRX9XLe" title="Impairment losses on construction-in-progress"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2023-01-01to2023-12-31" id="Fact000656" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2022-01-012022-12-31" id="Fact000658" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> such impairment
losses have been recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000660" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zFy6sd4R3J5d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z83nPQFph3kk">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company
has viewed its operations and managed its business as one segment operating primarily within the United States (and in Israel prior to
the NanoSynex deconsolidation).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000662" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zyju2okuavG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zVTC3o3ff6sc">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for acquired in process research and development (IPR&amp;D), the Company expenses research and development costs as incurred including
therapeutics license costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000664" name="QLGN:PatentCostsPolicyTextBlock"><p id="xdx_840_ecustom--PatentCostsPolicyTextBlock_zdZxPitk3Mlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zjug10Hktfve">Patent
Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000666" name="us-gaap:BusinessCombinationsPolicy"><p id="xdx_841_eus-gaap--BusinessCombinationsPolicy_z8WGLPtyAmeg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zsBOFrfYlQH3">Business
Combinations</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for business combinations using the acquisition method pursuant to Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;)
ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company&#8217;s
financial results beginning on the respective acquisition date, and that assets acquired and liabilities assumed are recognized at fair
value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted
cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of
capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value of
the intangible asset. Any excess of the fair value of consideration transferred (the &#8220;purchase price&#8221;) over the fair values
of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may
be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition
date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000668" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_847_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zOLyA9Skf2T" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zaNulaXka052">Goodwill</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired,
when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized but is reviewed
for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.
In testing for impairment, the fair value of the reporting unit is compared to the carrying value. If the net assets assigned to the
reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the difference is recorded. As a result of the
annual goodwill impairment analysis, the Company recognized a $<span id="xdx_905_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zn8hkA3dRh52" title="Goodwill impairment charges"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-012022-12-31" id="Fact000670" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,239,000</ix:nonFraction></span> non-cash goodwill and fixed asset impairment charge in the valuation
of its business acquisition of NanoSynex for the year ended December 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000672" name="QLGN:DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock"><p id="xdx_841_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_zpO2iZ5rIuMh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zUTkdHfTIgE7">Derivative
Financial Instruments and Warrant Liabilities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument,
the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception
and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as
liabilities or as equity, is re-assessed at the end of each reporting period (See Note 7-Warrant Liabilities and Note 8- Convertible
Debt - Related Party).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000674" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zl9QOmVDa5hl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zQXgBNLNIxY7">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability
    to access at the measurement date;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-align: justify; text-indent: -24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs
    in markets that are not considered to be active; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 - Inputs that are unobservable.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-align: justify; text-indent: -24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000676" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zcOOuCmQgig9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zElovFA8AgRk">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates
fair value due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000678" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zw3foD3WaGE1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zTi9ooXhuPug">Comprehensive
Loss</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss consists of net income and foreign currency translation adjustments related to the discontinued operations of NanoSynex. Comprehensive
gains (losses) have been reflected in the statements of operations and comprehensive loss and as a separate component in the statements
of stockholders&#8217; equity (deficit) for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000680" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_842_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z9jJfqsCkC8g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zlDItihaHpx6">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company&#8217;s
stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000682" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zm8AiE3fJ4p2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zsEuTaq4sI06">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years. For more information, refer to Note 14 - Income Taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update 2023-09, Improvements to Income Tax Disclosures, which requires more detailed
income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation
as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis,
with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early
adoption permitted. The Company is evaluating the disclosure requirements related to the new standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000684" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z1ONaR6BlLXl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zq5GXQbmj1Ka">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency for the Company is the U.S. dollar. The functional currency for the discontinued operations of NanoSynex was the
New Israeli Shekel (NIS). The financial statements of NanoSynex were translated into U.S. dollars using exchange rates in effect at each
period end for assets and liabilities; using exchange rates in effect during the period for results of operations; and using historical
exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of NanoSynex was reflected
as a separate component of other comprehensive income (loss) (see Note 5 - Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000686" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8LlnmXoZKt1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zpa55FKXxkR3">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected
to have a significant impact to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000688" name="QLGN:GlobalEconomicConditionsPolicyTextBlock"><p id="xdx_84A_ecustom--GlobalEconomicConditionsPolicyTextBlock_zRY1aEAurJui" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zgjKyfRNhO2a">Global
Economic Conditions</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ongoing
Wars in Ukraine and Israel</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor
any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the
conflict on the Company&#8217;s business and financial results remains uncertain and will depend on the severity and duration of the
conflict and its impact on regional and global economic conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, Hamas conducted terrorist attacks in Israel resulting in ongoing war. There continue to be hostilities between Israel and
Hezbollah in Lebanon and Hamas in the Gaza Strip, both of which have resulted in rockets being fired into Israel, causing casualties
and disruption of economic activities. In early 2023, there were a number of changes proposed to the political system in Israel by the
current government which, if implemented as planned, could lead to large-scale protests and additional uncertainty, negatively impacting
the operating environment in Israel. Popular uprisings in various countries in the Middle East over the last few years have also affected
the political stability of those countries and have led to a decline in the regional security situation. Such instability may also lead
to deterioration in the political and trade relationships that exist between Israel and these countries. Any armed conflicts, terrorist
activities or political instability involving Israel or other countries in the region could adversely affect the Company&#8217;s minority
interest in NanoSynex, its results of operations, financial condition, cash flows and prospects (see Note 5 &#8211; Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
and Global Economic Conditions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary
pressures attributable to government stimulus and recovery programs, government deficit spending and supply chain issues. The Company
cannot provide assurance that it will be successful in fully offsetting increased costs resulting from inflationary pressure. In addition,
the global economy suffers from slowing growth and rising interest rates, and some economists believe that there may be a global recession
in the near future. If the global economy slows, the Company&#8217;s business may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000690" name="QLGN:ImpactOfCovid19PandemicPolicyTextBlock"><p id="xdx_845_ecustom--ImpactOfCovid19PandemicPolicyTextBlock_zO8s7ZYnbAN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zNp25EDTxFY1">Impact
of COVID-19 Pandemic</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company&#8217;s business as well. During the height of
the pandemic, sales of diagnostic products decreased significantly and the Company&#8217;s net loss increased significantly, as clinics
and small hospitals&#8217; demand for Qualigen, Inc.&#8217;s FastPack&#8482; diagnostic test kits was reduced sharply, largely due to
deferral of patients&#8217; non-emergency visits to physician offices. In July 2023 the Company sold Qualigen, Inc., its wholly-owned
subsidiary, to Chembio (see Note 5 - Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#8217;s
consolidated financial statements.</span></p>

</ix:nonNumeric><p id="xdx_85D_z5DxZVh5ii58" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000692" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zMMAGQLjfmwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; <span><span id="xdx_82B_zwlfTzVoH959">LIQUIDITY AND GOING CONCERN</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&#160;31, 2023, the Company had approximately $<span id="xdx_909_eus-gaap--Cash_iI_pn5n6_c20231231_zpZpvhGTITN7"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000693" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in cash and an accumulated deficit of $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20231231_zvkb6ozWL58j"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000694" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">116.8</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. For the years ended December&#160;31,
2023 and 2022, the Company used cash of $<span id="xdx_90F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20231231_zw5hB5OETJle"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000695" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">10.3</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20221231_zA6QNfYcaBV9"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" id="Fact000696" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">13.2</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively, in operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s cash balances as of the date that these financial statements were issued along with the proceeds from the above sale
to Chembio, without additional financing, are expected to fund operations only into the second quarter of 2024. The Company expects to
continue to have net losses and negative cash flow from operations, which will challenge its liquidity. These factors raise substantial
doubt about the Company&#8217;s ability to continue as a going concern for the one-year period following the date that these financial
statements were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that profitable operations will ever be achieved, or, if achieved, could be sustained on a continuing basis. In order
to fully execute its business plan, the Company will require significant additional financing for planned research and development activities,
capital expenditures, clinical testing for QN-302 and preclinical development of Pan-RAS, as well as commercialization activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company&#8217;s principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds from
the issuance of debt. In December 2022 the Company raised $<span id="xdx_900_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20221201__20221231_z4aqTijq0Q68"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-12-012022-12-31" id="Fact000697" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million from the sale of an 8% Senior Convertible
Debenture (the &#8220;Debenture&#8221;) to  Alpha (see Note 8 - Convertible Debt - Related Party). There can be no assurance that further
financing can be obtained on favorable terms, or at all. If the Company is unable to obtain funding, the Company could be required to
delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which
could adversely affect the Company&#8217;s business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements
do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be
required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ
from those reflected in the accompanying financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000699" name="us-gaap:OtherAssetsDisclosureTextBlock"><p id="xdx_800_eus-gaap--OtherAssetsDisclosureTextBlock_zARgnBgCCkp3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8212; <span><span id="xdx_82F_zyOZAHr3dore">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000701" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p id="xdx_89C_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zFL6RiaYR2Ij" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following at December 31, 2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="display: none"><span id="xdx_8B3_zaBxxvAYKOaj">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zyipDHfi1Ki6" style="vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zz8Puu6B85T1" style="vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzdSM_zDgnhzRorW98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-12-31" id="Fact000703" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">566,011</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-12-31" id="Fact000704" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,329,034</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzdSM_zkttQ2OFjpO5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000706" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,053</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2022-12-31" id="Fact000707" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,670</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ReceivableInvestmentSale_iI_pp0p0_maPEAOAzdSM_zxVQHhn3sGF6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Receivable from sale of Qualigen, Inc.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0709">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PreapaidResearchAndDevelopmentExpenses_iI_pp0p0_maPEAOAzdSM_zlWYao4idRH2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Prepaid research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:PreapaidResearchAndDevelopmentExpenses" contextRef="AsOf2023-12-31" id="Fact000712" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">173,900</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0713">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzdSM_zXh1u3ZJH5Y8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and
    other current assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000715" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">764,964</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000716" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,366,704</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_z6jr4cMUTI11" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses attributable to Qualigen, Inc. and NanoSynex were deemed disposed of as discontinued operations (see Note 5 - Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000718" name="us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock"><p id="xdx_809_eus-gaap--InvestmentsAndOtherNoncurrentAssetsTextBlock_zug4PAji38r6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8212; <span id="xdx_82A_zcYjvQ5vXOzg">OTHER NON-CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000720" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfOtherAssetsNoncurrentTextBlock_zMaDE9peYpFc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
non-current assets consisted of the following at December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8BF_z89w6uHf1Bx7" style="display: none">SCHEDULE
OF OTHER NON CURRENT ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zaZrvYydfiJd" style="vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EscrowDeposit_iI_maOAzAWm_zzszp4MmBlLa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Funds held in escrow</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2023-12-31" id="Fact000722" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--LongtermResearchAndDevelopmentDeposits_iI_maOAzAWm_zi3qvIX2HLSi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Long-term research and development deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:LongtermResearchAndDevelopmentDeposits" contextRef="AsOf2023-12-31" id="Fact000724" format="ixt:numdotdecimal" decimals="0" unitRef="USD">416,481</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAssets_iI_mtOAzAWm_zgiA0JZTUTSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Other non-current assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2023-12-31" id="Fact000726" format="ixt:numdotdecimal" decimals="0" unitRef="USD">866,481</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_za5c34Gu05ef" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000728" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"><p id="xdx_804_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zGj9beVj43T" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8212; <span id="xdx_82C_zn99i7KT0Hc2">DISCONTINUED OPERATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000730" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_z5Dt0YsaFggi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of assets and liabilities classified in discontinued operations as of December 31, 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BE_zM2GFwfBcb99" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zodx01DSNDs4" style="border-bottom: Black 1.5pt solid; text-align: center">Qualigen, Inc.</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zkWbORC60jCl" style="border-bottom: Black 1.5pt solid; text-align: center">NanoSynex</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_z50z0zVBbJah" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzI2M_maTAODOzy7K_zXkOI4AdQZJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 46%; text-align: left">Current assets of discontinued operations</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31_srt_ParentCompanyMember" id="Fact000732" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,448,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember" id="Fact000733" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,838,850</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31" id="Fact000734" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,287,849</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_i01I_maCzo3N_maTAODOzy7K_z4TkzckFeGD8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Non-current assets of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="AsOf2022-12-31_srt_ParentCompanyMember" id="Fact000736" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,876,270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember" id="Fact000737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,360,441</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="AsOf2022-12-31" id="Fact000738" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,236,711</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--TotalAssetsOfDiscontinuedOperations_iI_zaOJz7puWoR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets of discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:TotalAssetsOfDiscontinuedOperations" contextRef="AsOf2022-12-31_srt_ParentCompanyMember" id="Fact000740" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,325,269</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:TotalAssetsOfDiscontinuedOperations" contextRef="AsOf2022-12-31_custom_NanosynexMember" id="Fact000741" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,199,291</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:TotalAssetsOfDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000742" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,524,560</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzCJ5_maTLOOzkOU_zEbnWh5YAST6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31_srt_ParentCompanyMember" id="Fact000744" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,299,948</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember" id="Fact000745" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,141,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31" id="Fact000746" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,441,198</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_i02I_maCzIDe_maTLOOzkOU_zwwt8URcENPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Non-current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" contextRef="AsOf2022-12-31_srt_ParentCompanyMember" id="Fact000748" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,350,975</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember" id="Fact000749" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,757</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" contextRef="AsOf2022-12-31" id="Fact000750" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,708,732</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--TotalLiabilitiesOfdiscontinuedOperations_iI_zCPvA2wOO6bh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities of discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:TotalLiabilitiesOfdiscontinuedOperations" contextRef="AsOf2022-12-31_srt_ParentCompanyMember" id="Fact000752" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,650,923</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:TotalLiabilitiesOfdiscontinuedOperations" contextRef="AsOf2022-12-31_custom_NanosynexMember" id="Fact000753" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,499,007</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:TotalLiabilitiesOfdiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,149,930</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of gain (loss) from discontinued operations, net of tax, as of December 31, 2023 and 2022 are as follows:<b>&#160;</b></span></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zgyRHLYRdNHk" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zYirOfUwnfHi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zZOHikC3k2A7" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_z7KOK0KzexEg" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zriQLS8NBlK6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zBmCU5FMeNv5" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Qualigen, Inc.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NanoSynex</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Qualigen, Inc.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NanoSynex</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_maCzBjD_zXK0Entbw48b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left">(Loss) from discontinued operations</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" contextRef="From2023-01-012023-12-31_srt_ParentCompanyMember" id="Fact000756" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">171,701</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" contextRef="From2023-01-012023-12-31_custom_NanosynexMember983343" id="Fact000757" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">511,307</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" contextRef="From2023-01-01to2023-12-31" id="Fact000758" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">683,008</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" contextRef="From2022-01-012022-12-31_srt_ParentCompanyMember" id="Fact000759" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,142,763</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" contextRef="From2022-01-012022-12-31_custom_NanosynexMember" id="Fact000760" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,997,418</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" contextRef="From2022-01-012022-12-31" id="Fact000761" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,140,181</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_iN_di_msCzBjD_zEyxLvK7bhpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Gain (loss) on disposal of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" contextRef="From2023-01-012023-12-31_srt_ParentCompanyMember" id="Fact000763" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,876,778</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" contextRef="From2023-01-012023-12-31_custom_NanosynexMember983343" id="Fact000764" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,479,010</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" contextRef="From2023-01-01to2023-12-31" id="Fact000765" format="ixt:numdotdecimal" decimals="0" unitRef="USD">602,232</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0767">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_mtCzBjD_maCzhiC_zjo8O9g2rzk2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total gain (loss) from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2023-01-012023-12-31_srt_ParentCompanyMember" id="Fact000770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,705,077</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2023-01-012023-12-31_custom_NanosynexMember983343" id="Fact000771" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,990,317</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2023-01-01to2023-12-31" id="Fact000772" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,285,240</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2022-01-012022-12-31_srt_ParentCompanyMember" id="Fact000773" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,142,763</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2022-01-012022-12-31_custom_NanosynexMember" id="Fact000774" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,997,418</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2022-01-012022-12-31" id="Fact000775" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,140,181</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A1_zHZhx5d7gqAe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sale
of Qualigen, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, the Company completed the sale of Qualigen, Inc., its formerly wholly-owned subsidiary, to Chembio Diagnostics, Inc.
for net cash consideration of $<span id="xdx_909_eus-gaap--Cash_iI_pn5n6_c20230720__dei--LegalEntityAxis__custom--ChembioDiagnosticsMember_zvbvfYJRY5d7" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-07-20_custom_ChembioDiagnosticsMember" id="Fact000777" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.4</ix:nonFraction></span> million, of which $<span id="xdx_90A_ecustom--PurchasePrice_iI_pn5n6_c20230720_zQ1JqRdHxet8" title="Purchase price"><ix:nonFraction name="QLGN:PurchasePrice" contextRef="AsOf2023-07-20" id="Fact000779" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.9</ix:nonFraction></span> million was received during the year ended December 31, 2023, and $<span id="xdx_906_eus-gaap--EscrowDeposit_iI_c20230720_z6ScgJ9i1cO6" title="Escrow deposit"><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2023-07-20" id="Fact000781" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></span>
is being held in escrow until January 20, 2025 to satisfy certain Company indemnification obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" escape="true" id="Fact000783" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zRICwWBIIOpg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets and liabilities classified in discontinued operations for Qualigen, Inc. as of December 31, 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span id="xdx_8BB_z8eP3ft272Ub" style="display: none">ASSETS
AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zOY75KWN9c0f" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_zGKYfYaxTuP6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000785" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,246,482</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_zHdqUvOvAWj4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000787" format="ixt:numdotdecimal" decimals="0" unitRef="USD">512,088</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_iI_zHtJnaXnk68d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inventory, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000789" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,586,297</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_zUgM1ml5g8S6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000791" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,132</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zIEHIrtrpUWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current assets of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000793" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,448,999</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets_iI_zHU6IGWDB8Y3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000795" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,422,538</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_iI_zKbRdheWsea" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000797" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,696</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_iI_zIDSZ58seAhc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000799" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,702</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_iI_zMkyyWT4oEha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000801" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,334</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_iI_zjRDEs67Ztx3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Total non-current assets of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000803" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,876,270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--TotalAssetsOfDiscontinuedOperations_zEMDVnMkIPPd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total assets of discontinued operations of Qualigen, Inc.</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="QLGN:TotalAssetsOfDiscontinuedOperations" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000805" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,325,269</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_zHmjfZc3mAO" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000807" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,470</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedVacation_iI_zFUrYTtBMubd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationAccruedVacation" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000809" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,906</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_iI_z9mMXvu4yod" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000811" format="ixt:numdotdecimal" decimals="0" unitRef="USD">518,766</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_iI_zCPQARiRXiq9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred revenue, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000813" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,161</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_iI_z4V9woU1rXdh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Operating lease liability, current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000815" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,645</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_z3PO2u2XYjzb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Total current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000817" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,299,948</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_iI_zQQ6Ddu84EN4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000819" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,301,919</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_iI_zonhoHs0imS" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Deferred revenue, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000821" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,056</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_iI_zhBTeigkBoW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total non-current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000823" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,350,975</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--TotalLiabilitiesOfdiscontinuedOperations_zPfVDec32Sy2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total liabilities of discontinued operations of Qualigen, Inc.</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="QLGN:TotalLiabilitiesOfdiscontinuedOperations" contextRef="AsOf2022-12-31_us-gaap_ParentMember" id="Fact000825" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,650,923</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reclassified the following statement of operations items to discontinued operations for the years ended December 31, 2023 and
2022, respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zHVOVMBBvRg2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zZgIAXsbIcn3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Years Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">REVENUES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedOperationNetProductSales_z80f30iqchab" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; width: 60%; text-align: left">Net product sales</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationNetProductSales" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000827" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,661,121</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationNetProductSales" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,983,556</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_z5vtcVatxqJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Total revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,661,121</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,983,556</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_zO8Rbrocq78c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cost of product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,551,114</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,302,755</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_z70FNxYXKUU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000836" format="ixt:numdotdecimal" decimals="0" unitRef="USD">610,559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000837" format="ixt:numdotdecimal" decimals="0" unitRef="USD">561,047</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_zvOj8wb280n3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000839" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206,819</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,245,973</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment_zRBHa9jfx3Yf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000842" format="ixt:numdotdecimal" decimals="0" unitRef="USD">405,626</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000843" format="ixt:numdotdecimal" decimals="0" unitRef="USD">950,420</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedSalesAndMarketing_z4yk1rxelthj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Goodwill and fixed asset impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedSalesAndMarketing" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000846" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedTotalExpenses_zFXxpOret2x8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedTotalExpenses" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000848" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,774,118</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedTotalExpenses" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000849" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,135,195</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">OTHER EXPENSE (INCOME), NET</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease_zMxym9pZFS8c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on disposal of equipment held for lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000851" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,302</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_ztT4uefCVgFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest (income) expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000855" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,751</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_znvkUZyg6kO" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000857" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,898</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000858" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,125</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal_zCYNcNK7eRr8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Loss on fixed asset disposal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_z5ZI3qdus78" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total other expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,704</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000864" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,876</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_zoGT3t7RNRC8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000866" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">171,701</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000867" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,142,763</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc._zjz18nM1MRD1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Gain on sale of Qualigen, Inc., net of tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc." contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000869" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,876,778</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_zUCJBATU4V7f" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">INCOME (LOSS) FROM DISCONTINUED OPERATIONS OF QUALIGEN, INC.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_ParentMember" id="Fact000872" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,705,077</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="QLGN:DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_ParentMember" id="Fact000873" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,142,763</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company recorded a gain on the sale of Qualigen, Inc. in its consolidated financial statements
for the years ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gain on sale of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Qualigen, Inc.</p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Fair value of consideration received</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived_c20230101__20231231_zopQLsek6o52" title="Fair value of consideration received" style="width: 16%; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived" contextRef="From2023-01-01to2023-12-31" id="Fact000875" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,489,337</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Working capital adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment_c20230101__20231231_zgKCXMukPacc" title="Working capital adjustment" style="text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment" contextRef="From2023-01-01to2023-12-31" id="Fact000877" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,402</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total Assets of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalAssets_iI_c20231231_z7F0kPUQmzjf" title="Total Assets of discontinued operations" style="text-align: right">(<ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationTotalAssets" contextRef="AsOf2023-12-31" id="Fact000879" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,225,562</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total Liabilities of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_iI_c20231231_zZB0sSvCh5Le" title="Total Liabilities of discontinued operations" style="text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationTotalLiabilities" contextRef="AsOf2023-12-31" id="Fact000881" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,005,407</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Transaction expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationTransactionExpenses_c20230101__20231231_zoV99ipBQx9j" title="Transaction expenses" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationTransactionExpenses" contextRef="From2023-01-01to2023-12-31" id="Fact000883" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">627,806</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Gain on sale of Qualigen, Inc.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_c20230101__20231231_zQ7H97dMMNFh" title="Gain on sale of Qualigen, Inc." style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2023-01-01to2023-12-31" id="Fact000885" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,876,778</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z7H3xYCom9q5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the fourth quarter of 2023, the gain was adjusted upward by $<span id="xdx_908_ecustom--DisposalGroupIncludingDiscontinuedOperationGainLoss_c20231001__20231231_zVbCg4GPOMM6" title="Gain upward upon final payment of transaction cost"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationGainLoss" contextRef="From2023-10-012023-12-31" id="Fact000887" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></span> upon final payment of transaction costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment
and Settlement Agreement with NanoSynex Ltd.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, the Company entered into and effectuated the NanoSynex Amendment, pursuant to which the Company agreed to, in exchange
for eliminating all future NanoSynex Funding Agreement obligations for the Company to invest further cash in NanoSynex (except for obligations
to lend NanoSynex $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20231130__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__dei--LegalEntityAxis__custom--NanoSynexLtdMember_zR58KpzlTHml" title="Aggregrate amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-11-30_custom_AmendmentAndSettlementAgreementMember_custom_NanoSynexLtdMember" id="Fact000889" format="ixt:numdotdecimal" decimals="0" unitRef="USD">560,000</ix:nonFraction></span> on or before November 30, 2023, and $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__dei--LegalEntityAxis__custom--NanoSynexLtdMember_zE6Utrvvdq8h" title="Aggregrate amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_AmendmentAndSettlementAgreementMember_custom_NanoSynexLtdMember" id="Fact000891" format="ixt:numdotdecimal" decimals="0" unitRef="USD">670,000</ix:nonFraction></span> on or before March 31, 2024), surrender <span id="xdx_90C_ecustom--StockIssuedDuringPeriodShareSurrender_c20230720__20230720__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjEXXTMviuec" title="Number of shares surrender"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodShareSurrender" contextRef="From2023-07-202023-07-20_custom_AmendmentAndSettlementAgreementMember_us-gaap_SeriesBPreferredStockMember" id="Fact000893" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">281,000</ix:nonFraction></span> Series B Preferred
Shares of NanoSynex held by the Company, resulting in the Company&#8217;s ownership in NanoSynex being reduced from approximately <span id="xdx_907_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20230720__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgZu0riom0j" title="Business acquisition, percentage of voting interests acquired"><ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MaximumMember_us-gaap_SeriesBPreferredStockMember" id="Fact000895" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">52.8</ix:nonFraction></span>%
to approximately <span id="xdx_900_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20230720__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGGlAYpWLnSa" title="Business acquisition, percentage of voting interests acquired"><ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MinimumMember_us-gaap_SeriesBPreferredStockMember" id="Fact000897" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">49.97</ix:nonFraction></span>% of the voting equity of NanoSynex; in addition, the Company agreed to surrender approximately $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_pn5n6_c20230720__20230720__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember_z9l1kPmz4bug" title="Aggregrate amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="From2023-07-202023-07-20_custom_AmendmentAndSettlementAgreementMember" id="Fact000899" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.0</ix:nonFraction></span> million of
promissory notes which NanoSynex had issued to the Company under the NanoSynex Funding Agreement. On November 22, 2023, the Company further
agreed to eliminate the Company&#8217;s obligations to lend NanoSynex $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20231130__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__dei--LegalEntityAxis__custom--NanoSynexLtdMember_zkqlYQSrKB5e" title="Aggregrate amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-11-30_custom_AmendmentAndSettlementAgreementMember_custom_NanoSynexLtdMember" id="Fact000901" format="ixt:numdotdecimal" decimals="0" unitRef="USD">560,000</ix:nonFraction></span> on or before November 30, 2023, and $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__dei--LegalEntityAxis__custom--NanoSynexLtdMember_zvbePe7rFk7i" title="Aggregrate amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_AmendmentAndSettlementAgreementMember_custom_NanoSynexLtdMember" id="Fact000903" format="ixt:numdotdecimal" decimals="0" unitRef="USD">670,000</ix:nonFraction></span> on or before
March 31, 2024, by instead surrendering shares of Series A-1 Preferred Stock of NanoSynex in an amount that reduced the Company&#8217;s
ownership in NanoSynex voting equity from approximately <span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20230720__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__srt--RangeAxis__srt--MaximumMember_zSRQbpI7ma94" title="Business acquisition, percentage of voting interests acquired"><ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MaximumMember" id="Fact000905" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">49.97</ix:nonFraction></span>% to <span id="xdx_907_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20230720__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__srt--RangeAxis__srt--MinimumMember_zcmgvLImb9o" title="Business acquisition, percentage of voting interests acquired"><ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MinimumMember" id="Fact000907" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39.90</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
surrender of Series B Preferred Shares of NanoSynex was accounted for as a loss of control of a subsidiary that constitutes a business
under ASC 810. As a result, on July 20, 2023, the Company deconsolidated NanoSynex&#8217;s related assets, liabilities, accumulated other
comprehensive income, and the noncontrolling interest. Subsequently, the retained investment in NanoSynex is accounted for as an equity
method investment. On the date of deconsolidation, the Company recognized its retained investment at fair value, which during the preparation
of these financial statements was determined to be de minimis based on various economic, industry, and other factors. As a result, the
Company has discontinued recognition of its proportionate share of equity method losses following the date of initial recognition. Future
equity method earnings, if any, will not be recognized until the amount exceeds the unrecognized net losses in prior periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the magnitude of the disposition and because the Company is exiting certain research and development operations, the disposition
represents a strategic shift that will have a material effect on the Company&#8217;s operations and financial results. Accordingly, the
business of NanoSynex is classified as discontinued operations for all periods presented herein.<br/>
<br/></span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_NanosynexMember" escape="true" id="Fact000909" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hdei--LegalEntityAxis__custom--NanosynexMember_zql7Ocd1YQD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets and liabilities classified in discontinued operations for NanoSynex as of December 31, 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8B8_zVjw2CrpUSug" style="display: none">ASSETS
AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231__dei--LegalEntityAxis__custom--NanosynexMember_ziAxeurFgqSb" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_hdei--LegalEntityAxis__custom--NanosynexMember_znAT1VGu4Enl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,621,967</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zN3N2jA1Xg8e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000913" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,499</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zS3OziL2bL64" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000915" format="ixt:numdotdecimal" decimals="0" unitRef="USD">190,384</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zudjy6jAUFJ8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total current assets of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000917" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,838,850</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash_iI_hdei--LegalEntityAxis__custom--NanosynexMember_z8jgHUgNV9f3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000919" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,690</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zURxSXiS75G4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000921" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,149</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zatJLqdJ3iFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000923" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,700,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zbN6DIJrYwDf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000925" format="ixt:numdotdecimal" decimals="0" unitRef="USD">625,602</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zeCqfvJF6T0h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total non-current assets of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000927" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,360,441</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalAssets_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zjeoubzzdNKb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total assets of discontinued operations of NanoSynex</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationTotalAssets" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,199,291</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zkJ2bH9V1TVi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000931" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,273</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zxpaYWoF1jK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000933" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,002</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zlEFbYuQa6tg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000935" format="ixt:numdotdecimal" decimals="0" unitRef="USD">293,571</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zsDzep8kKing" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D grant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000937" format="ixt:numdotdecimal" decimals="0" unitRef="USD">780,682</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zedLNhd2fXGc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Short term debt-related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000939" format="ixt:numdotdecimal" decimals="0" unitRef="USD">950,722</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_z7XSBcqOkN72" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000941" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,141,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zTYaf7L5SBr7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Deferred tax liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000943" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,757</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zTSesd573E2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total non-current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,757</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zRjpF4OyIlf9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total liabilities of discontinued operations of NanoSynex</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationTotalLiabilities" contextRef="AsOf2022-12-31_custom_NanosynexMember983937" id="Fact000947" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,499,007</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reclassified the following statement of operations items to discontinued operations for the years ended December 31, 2023 and
2022, respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zOTptJ3CuNPb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zx9oSOWhGWM3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_hdei--LegalEntityAxis__custom--NanosynexMember_zgccjshpdKPc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="Fact000949" format="ixt:numdotdecimal" decimals="0" unitRef="USD">869,064</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015" id="Fact000950" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,105,040</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment_hdei--LegalEntityAxis__custom--NanosynexMember_zZERACgexWla" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Goodwill and fixed asset impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment" contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015" id="Fact000953" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,164,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedTotalExpenses_hdei--LegalEntityAxis__custom--NanosynexMember_zmH5vnSWE61" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedTotalExpenses" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="Fact000955" format="ixt:numdotdecimal" decimals="0" unitRef="USD">869,064</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedTotalExpenses" contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015" id="Fact000956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,269,040</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zAk6YmXlslPj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on disposal of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="Fact000958" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,479,010</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0959">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_hdei--LegalEntityAxis__custom--NanosynexMember_zMk686AGWUY8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">(BENEFIT) PROVISION FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="Fact000961" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">357,757</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015" id="Fact000962" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">271,622</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zEcbOD2Rc3z4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">LOSS FROM DISCONTINUED OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="Fact000964" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,990,317</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015" id="Fact000965" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,997,418</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_hdei--LegalEntityAxis__custom--NanosynexMember_zZ5uISHWCvCh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Loss attributable to noncontrolling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="Fact000967" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">343,038</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015" id="Fact000968" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,394,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zbH1l6INY484" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">NET LOSS ATTRIBUTABLE TO STOCKHOLDERS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="QLGN:DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="Fact000970" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,647,279</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="QLGN:DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015" id="Fact000971" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,603,318</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company recorded a loss on deconsolidation of NanoSynex in its consolidated financial statements
for the years ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Loss on deconsolidation of NanoSynex</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value of NanoSynex interest retained</td><td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98E_ecustom--DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_z5EXg1W5lC7f" title="Fair value of Nan-Synex interest retained" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0973">&#8212;</span></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Net assets deconsolidated</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zipg4Uspz2kf" title="Net assets deconsolidated" style="width: 16%; text-align: right">(<ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="Fact000975" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,768,403</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Non-controlling interest share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zycwxuIdu0u" title="Non-controlling interest share" style="text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="Fact000977" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,235,443</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated other comprehensive income attributable to NanoSynex</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_z3pfPwc5XUqe" title="Accumulated OCI attributable to NanoSynex" style="text-align: right"><ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="Fact000979" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,891</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forgiveness of debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zairUjzSigPa" title="Forgiveness of debt" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="Fact000981" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,077,941</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss from deconsolidation of NanoSynex</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zW9JtpnpW2f8" title="Loss from deconsolidation of NanoSynex" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="QLGN:DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation" contextRef="From2023-01-012023-12-31_custom_NanosynexMember" id="Fact000983" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,479,010</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zKybyRV7sKGb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000985" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z0ZCmVmVIgna" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8212; <span id="xdx_82B_zCP3sYxSfsya">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000987" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zFErq1PZDlN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consisted of the following at December 31, 2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8BA_zjGznIpol2O9" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zHHxTMsGUIh" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231_zQSJfkKD45Cc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedCompensation_iI_pp0p0_maALCzkYM_zpGjW49FxaAe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Board compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="QLGN:AccruedCompensation" contextRef="AsOf2023-12-31" id="Fact000989" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">129,499</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="QLGN:AccruedCompensation" contextRef="AsOf2022-12-31" id="Fact000990" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestPayableCurrent_iI_pp0p0_maALCzkYM_zDHR8SsSsiFg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest (Convertible debt)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000992" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-31" id="Fact000993" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,829</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzkYM_zcthN6R2i8Tc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">License fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedLicenseFees" contextRef="AsOf2023-12-31" id="Fact000995" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedLicenseFees" contextRef="AsOf2022-12-31" id="Fact000996" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,130</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCzkYM_z7Xgssvzn5lg" style="vertical-align: bottom; background-color: White">
    <td>Payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2023-12-31" id="Fact000998" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2022-12-31" id="Fact000999" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,247</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzkYM_zpF47Vp9U8U1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" id="Fact001001" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">121,775</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2022-12-31" id="Fact001002" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">136,203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCzkYM_zDTbB2YyfHzf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedResearchAndDevelopmentCurrent" contextRef="AsOf2023-12-31" id="Fact001004" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">104,402</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedResearchAndDevelopmentCurrent" contextRef="AsOf2022-12-31" id="Fact001005" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">329,412</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maALCzkYM_zxhaJd2lGG5g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2023-12-31" id="Fact001007" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">151,286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2022-12-31" id="Fact001008" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,040</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzkYM_zXgg7XyiUQh5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001010" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,850</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact001011" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,698</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzkYM_zw6s9z17hSI1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and
    other current liabilities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001013" format="ixt:numdotdecimal" decimals="0" unitRef="USD">560,006</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact001014" format="ixt:numdotdecimal" decimals="0" unitRef="USD">864,559</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zoBao6Ime7Vh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
accrued liabilities attributable to Qualigen Inc, and NanoSynex were deemed disposed of as discontinued operations (see Note 5 &#8211; Discontinued
Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001016" name="QLGN:WarrantLiabilitiesTextBlock"><p id="xdx_807_ecustom--WarrantLiabilitiesTextBlock_ziSawuytXNPd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; <span id="xdx_82D_zqOuPtOArNda">WARRANT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a
private placement (the &#8220;Series C Warrants&#8221;). The Series C Warrants were subsequently extended and, upon closing of the
reverse recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, at $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zjLBgv89eAh2" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember" id="Fact001018" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.195</ix:nonFraction></span>
per share, subject to adjustment. As of December 31, 2023, the Series C Warrants had a remaining term of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zzetds2CH1A1" title="Warrants and rights outstanding term"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember985078" format="ixt-sec:duryear" id="Fact001020" name="us-gaap:WarrantsAndRightsOutstandingTerm">0.49</ix:nonNumeric></span>
years. The Series C Warrants were determined to be liability-classified pursuant to the guidance in ASC 480 and ASC 815-40, based on
the inclusion of a leveraged ratchet provision for subsequent dilutive issuances. On April 25, 2022, the Series C warrants were
repriced from $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zzmD55EmAmi7" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-25_srt_MaximumMember_custom_SeriesCWarrantsMember" id="Fact001022" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.195</ix:nonFraction></span>
per share exercise price to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zZNvUdCZ1Ea2" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-25_srt_MinimumMember_custom_SeriesCWarrantsMember" id="Fact001024" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span>
per share exercise price with <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220423__20220425__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zbihTPaibQx6" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-04-232022-04-25_custom_SeriesCWarrantsMember" id="Fact001026" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,318</ix:nonFraction></span>
additional ratchet Warrants issued. On May 26, 2022, the Series C warrants were repriced from $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z3uFW8slN005" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_srt_MaximumMember_custom_SeriesCWarrantsMember" id="Fact001028" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span>
per share exercise price to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zwgMKMWUJg3k" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_srt_MinimumMember_custom_SeriesCWarrantsMember" id="Fact001030" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.136</ix:nonFraction></span>
per share exercise price with <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220523__20220526__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zq1owi3Gtaf4" title="Warrants issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-05-232022-05-26_custom_SeriesCWarrantsMember" id="Fact001032" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,952</ix:nonFraction></span>
additional ratchet Warrants issued. As a result of these repricings, <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20220523__20220526_zQyGBjCzz1Oj" title="Warrants forfeited"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2022-05-232022-05-26" id="Fact001034" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">247,625</ix:nonFraction></span>
warrants were forfeited and <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesTreasuryStockReissued_pid_c20220523__20220526_zOiUsRZom3nk" title="Warrants reissued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" contextRef="From2022-05-232022-05-26" id="Fact001036" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">346,896</ix:nonFraction></span>
warrants were reissued. On December 22, 2022, the Series C Warrants were repriced again from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zLcK3W8ZBp14" title="Warrants repriced"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_srt_MaximumMember_custom_SeriesCWarrantsMember" id="Fact001038" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.136</ix:nonFraction></span>
per share exercise price to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zrE1noWegDQg" title="Warrants repriced"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_srt_MinimumMember_custom_SeriesCWarrantsMember" id="Fact001040" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>
per share exercise price with <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221222__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zePqKIF8pos5" title="Warrants issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-12-222022-12-22_custom_SeriesCWarrantsMember" id="Fact001042" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,002,717</ix:nonFraction></span>
additional ratchet Warrants issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
on December 22, 2022, in conjunction with the issuance of the Debenture to Alpha (see Note 8 &#8211; Convertible Debt &#8211; Related
Party), the Company issued to Alpha a warrant to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zwDokrBI7CQ7" title="Warrant to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" id="Fact001044" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;Alpha Warrant&#8221;).
The exercise price of the Alpha Warrant was $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zE6EfD32PX0i" title="Exercise price of warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" id="Fact001046" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></span> (equal to <span id="xdx_90C_ecustom--ConversionPricePercentage_pid_dp_uPure_c20221222__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zT7a2w0nD7Of" title="Conversion price percentage"><ix:nonFraction name="QLGN:ConversionPricePercentage" contextRef="From2022-12-222022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" id="Fact001048" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">125</ix:nonFraction></span>% of the conversion price of the Debenture on the closing date). The Alpha
Warrant may be exercised by Alpha, in whole or in part, at any time before June 22, 2028, subject to certain terms and conditions described
in the Alpha Warrant. The fair value of this warrant was included in Warrant liabilities-related party on the Company&#8217;s consolidated
balance sheet as of December 31, 2022. On December 5, 2023, the Company entered into an Amendment No. 1 with regard to Securities Purchase
Agreement, with Alpha. This Amendment amended two instruments which the Company issued under the Securities Purchase Agreement dated
December 21, 2022: (a) the 8% Senior Convertible Debenture dated December 22, 2022 in favor of Alpha, and (b) the Common Stock Purchase
Warrant dated December 22, 2022 in favor of Alpha. The Amendment reduced the conversion price of the Debenture from $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_ztFYgmnKLve4" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPriceDecrease" contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember" id="Fact001050" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span> per share to
$<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_z9LmP1Jf1Cs8" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPriceDecrease" contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember" id="Fact001052" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span> per share (subject to possible future adjustment pursuant to the terms of the Debenture) and reduced the exercise price of the
Warrant from $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zA5AbY3sRk7i" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember" id="Fact001054" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></span> per share to $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_zhPI9NpFr8qg" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember" id="Fact001056" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span> per share (subject to possible future adjustment pursuant to the terms of the Warrant). The Amendment
also eliminated certain adjustment provisions of the Warrant. The Company determined the event resulted in equity classification for
the Warrant and, accordingly, the Company remeasured the warrant liabilities to fair value, and reclassified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Alpha Warrant repricing, on December 5, 2023 the Series C Warrants were repriced again from $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zltPM2dK32xe" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPriceDecrease" contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember" id="Fact001058" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span> per share exercise
price to $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_zFsev7ElZnXd" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPriceDecrease" contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember" id="Fact001060" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span> per share exercise price with <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zTIxmVXtZvOb" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesCWarrantsMember" id="Fact001062" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">203,652</ix:nonFraction></span> additional ratchet Series C Warrants issued, resulting in <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z4cZ7Z5huAV6" title="Warrants outstanding"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zz1hCFPExOz2" title="Warrants exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesCWarrantsMember" id="Fact001064" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2023-12-31_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesCWarrantsMember" id="Fact001066" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">455,623</ix:nonFraction></ix:nonFraction></span></span> of these Series
C Warrants outstanding and exercisable as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001068" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z18l24KyS6ta" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity in liability classified warrants for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8BC_zJNRDQGyMj46" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLGBKDH5jCM8" title="Number of Shares, Warrants Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001070" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,849,571</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvoji3It3bBh" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001072" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.53</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">$<span id="xdx_902_ecustom--RangeOfExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_z7jM54PAtM0l" title="Range of Exercise Price, Beginning"><ix:nonFraction name="QLGN:RangeOfExercisePrice" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MinimumMember" id="Fact001074" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span> - $<span id="xdx_90D_ecustom--RangeOfExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zDCVhsWUI7j2" title="Range of Exercise Price, Beginning"><ix:nonFraction name="QLGN:RangeOfExercisePrice" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MaximumMember" id="Fact001076" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zt8ioksd4Nj2" title="Weighted - Average Remaining Life (Years) Outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" id="Fact001078" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">3.9</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfoQPq9CTgsi" title="Number of Shares, Warrants Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1080">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zV5xLhqe6H7g" title="Weighted Average Exercise Price Per Share Warrants Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1082">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z2rOK24p9BB4" title="Number of Shares, Warrants Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001084" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,751,976</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAAPPHoSgwma" title="Weighted Average Exercise Price Per Share Warrants Forfeited" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001086" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.53</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAXKcmhEslUf" title="Number of Shares, Warrants Expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001088" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,097,595</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbpd7h2BKfgh" title="Weighted Average Exercise Price Per Share Warrants Expired" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001090" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--RangeOfExercisePriceExpired_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSEHJRBUfAQd" title="Range of Exercise Price, Expired"><ix:nonFraction name="QLGN:RangeOfExercisePriceExpired" contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001092" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVpJAcv8Ar4l" title="Number of Shares, Warrants Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001094" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">455,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1Z7EYrTSynd" title="Weighted Average Exercise Price Per Share Warrants Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001096" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePriceGranted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSiMilgKv4Il" title="Range of Exercise Price, Granted"><ix:nonFraction name="QLGN:RangeOfExercisePriceGranted" contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001098" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zUL1lFj2TI7d" title="Weighted-Average Remaining Life (Years) Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" id="Fact001100" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1">0.49</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zKnMToyCwnDb" title="Number of Shares, Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001102" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">455,623</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zIOYWv2qwJol" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001104" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1XzwHeUAWF8" title="Range of Exercise Ending"><ix:nonFraction name="QLGN:RangeOfExercisePrice" contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001106" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zorsiQiwHZs1" title="Weighted-Average Remaining Life (Years) Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" id="Fact001108" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">0.49</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7TWvyYNgRKj" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001110" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">455,623</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRkqheAxivS3" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001112" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iE_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSfXDRtCkEga" title="Range of Exercise Price, Exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001114" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zzbe4oYcHff1" title="Weighted-Average Remaining Life (Years) Exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" id="Fact001116" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1">0.49</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity in the Common Stock Warrants received in exchange for the Series C Warrants for the year ended
December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Weighted&#8211;
Average</b></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Exercise</b></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Price</b></p></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Range
of</b></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Exercise</b></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Price</b></p></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Weighted&#8211;Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Life (Years)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Total outstanding &#8211;December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbVsTqAi6BIl" title="Number of Shares, Warrants Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001118" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">248,162</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcm9ENx2x3Jj" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001120" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAEfVtKR2M2a" title="Range of Exercise Price, Beginning"><ix:nonFraction name="QLGN:RangeOfExercisePrice" contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001122" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zm0YDjme8jk3" title="Weighted-Average Remaining Life (Years) Outstanding"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" id="Fact001124" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">2.00</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z3h5SS635N6i" title="Number of Shares, Warrants Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">536</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvPJJa7NcJge" title="Weighted Average Exercise Price Per Share Warrants Exercised" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zERGmqx8Uiga" title="Number of Shares, Warrants Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001130" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">247,625</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zITd2jiWwCv8" title="Weighted Average Exercise Price Per Share Warrants Forfeited" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001132" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZHXjaE4aeB2" title="Number of Shares, Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1134">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zv3z6B66dCfe" title="Weighted Average Exercise Price Per Share Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1136">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zb1pcj7U3ZZ9" title="Number of Shares, Warrants Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001138" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,849,570</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwDH4H3gphs4" title="Weighted Average Exercise Price Per Share Warrants Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001140" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.53</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgaSi0tLfGad" title="Number of Shares, Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001142" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,849,571</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zUB0yjZJU51a" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001144" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.53</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--RangeOfExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zCidTcXmjyz1" title="Range of Exercise Ending"><ix:nonFraction name="QLGN:RangeOfExercisePrice" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MinimumMember" id="Fact001146" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span> - <span id="xdx_901_ecustom--RangeOfExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zosRg7CkBXB9" title="Range of Exercise Ending"><ix:nonFraction name="QLGN:RangeOfExercisePrice" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MaximumMember" id="Fact001148" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z058uCfQcjNg" title="Weighted-Average Remaining Life (Years) Outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" id="Fact001150" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">3.9</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRMnQL7QMLje" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001152" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,349,571</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfqXh6Hdo6Ia" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001154" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5pCfLasIRn4" title="Range of Exercise Price, Exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" id="Fact001156" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbFX0nxgMxMb" title="Weighted-Average Remaining Life (Years) Exercisable"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember" format="ixt-sec:duryear" id="Fact001158" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1">1.00</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A1_zVLM4UbzjEPl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001160" name="QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock"><p id="xdx_894_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_zaRegjGYHHA5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s fair value hierarchy for its Common Stock Warrant liabilities measured at fair value on
a recurring basis as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span id="xdx_8B1_zf8I8IX64Hpe" style="display: none">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Quoted</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Market</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Significant</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Prices for</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Other</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Significant</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Identical</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Observable</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unobservable</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Assets</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Inputs</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Inputs</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Stock Warrant liabilities</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Balance as of December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zk2S50r1wUo9" title="Fair value for warrant liabilities" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwF17oo6oJ0b" title="Fair value for warrant liabilities" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1164">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3YSTwRWIp9f" title="Fair value for warrant liabilities" style="width: 12%; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001166" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,622,647</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231_zUZVCfHgsG3d" title="Fair value for warrant liabilities" style="width: 12%; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2022-12-31" id="Fact001168" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,622,647</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQy3t8j7Pkc5" title="Common Stock Warrant liabilities, Exercises" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1170">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbGSQkPGKFtl" title="Common Stock Warrant liabilities, Exercises" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1172">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmr2VS7RgnY3" title="Common Stock Warrant liabilities, Exercises" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1174">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231_zjrQMRAP23P6" title="Common Stock Warrant liabilities, Exercises" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1176">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value of warrant reclassified from liabilities to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3WJcEyKG0Gf" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1178">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zOjcm6ivjhDg" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1180">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zBfZXoBC0lmd" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity" style="text-align: right">(<ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnToEquity" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001182" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,626,694</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231_zYtjNdEmpwHk" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity" style="text-align: right">(<ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesOnToEquity" contextRef="From2023-01-01to2023-12-31" id="Fact001184" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,626,694</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on debt extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLxxDu42GPxj" title="Common Stock Warrant liabilities, Loss on debt extinguishment" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1186">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdVYXEMqMZ2h" title="Common Stock Warrant liabilities, Loss on debt extinguishment" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1188">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGifwwzAL4Hk" title="Common Stock Warrant liabilities, Loss on debt extinguishment" style="text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001190" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231_zMx7CBzLSDK" title="Common Stock Warrant liabilities, Loss on debt extinguishment" style="text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" contextRef="From2023-01-01to2023-12-31" id="Fact001192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,116</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Gain on change in fair value of warrant liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6PA4TroVkH4" title="Change in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1194">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEfdE8kUk6y" title="Change in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1196">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuqXgmjIP9R6" title="Change in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="QLGN:ChangeInFairValueOfWarrantLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001198" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,035,469</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231_z8TZTLxXZBJg" title="Change in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="QLGN:ChangeInFairValueOfWarrantLiabilities" contextRef="From2023-01-01to2023-12-31" id="Fact001200" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,035,469</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zA2x9DGqSMv5" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1202">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zR9Pz6ubn7Ll" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1204">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjCqS6yr3EFg" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231_zABKNkMvGdd7" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="AsOf2023-12-31" id="Fact001208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z1qpV7OyD7vc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers of financial assets or liabilities between category levels for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo
simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the
fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a
public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common
stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and
does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher
or lower fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001210" name="QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_z931rg3adps8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the assumptions used in, and the weighted average and the range of assumptions used in estimating the fair value of warrant
liabilities (weighted average calculated based on the number of outstanding warrants on each issuance) as of December 31, 2023 and December
31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8B9_z96BAMXS0VHi" style="display: none">SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Actual</td><td>&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Range</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 48%">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJCfIiEqdgMe" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001212" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.13</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zxlMDbpDQmzg" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001214" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.906</ix:nonFraction></span>% &#8212; <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_za3tnsv0nytg" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001216" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.628</ix:nonFraction></span>%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_z0l4hoNa3Vl5" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_WeightedAverageMember" id="Fact001218" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.15</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (peer group)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zb3YVa1Xbt5i" title="Expected volatility"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001220" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">68.9</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zcvwFxKOAXf5" title="Expected volatility"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001222" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">88</ix:nonFraction></span>% &#8212; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z7fyT5FHPUg" title="Expected volatility"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001224" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">103</ix:nonFraction></span>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxuFn49vKpAe" title="Expected volatility"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001226" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">98</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term of warrants (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zehqffzt9hZe" title="Term of warrants (in years)"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact001228" name="us-gaap:WarrantsAndRightsOutstandingTerm">0.49</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuG1mYphnsXg" title="Term of warrants (in years)"><ix:nonNumeric contextRef="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact001230" name="us-gaap:WarrantsAndRightsOutstandingTerm">.90</ix:nonNumeric></span> &#8212; <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zbVrTNrWKuk8" title="Term of warrants (in years)"><ix:nonNumeric contextRef="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact001232" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.48</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6bowoNviRDa" title="Fair value assumptions, measurement input, term"><ix:nonNumeric contextRef="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" id="Fact001234" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.9</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zUID2ZCOsYb1" title="Expected dividend yield"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001236" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJ5NamsSDabb" title="Expected dividend yield"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001238" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zoGx3mIIsM7h" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_WeightedAverageMember" id="Fact001240" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A6_zwqn3b2J6boc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001242" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_zXPNpobi84E2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8212; <span id="xdx_826_zU0mCH8rZLB8">CONVERTIBLE DEBT- RELATED PARTY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2022, the Company issued to Alpha an <span id="xdx_908_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z8roDX7mhdwa" title="Senior convertible debenture rate"><ix:nonFraction name="us-gaap:ShortTermDebtInterestRateIncrease" contextRef="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" id="Fact001244" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%
Senior Convertible Debenture in the aggregate principal amount of $<span id="xdx_909_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zJjwuj3Wkfmi" title="Principal amount"><ix:nonFraction name="us-gaap:SecuredDebt" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" id="Fact001246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,300,000</ix:nonFraction></span>
for a purchase price of $<span id="xdx_90A_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zZxNtAGjOgdf" title="Purchase Price"><ix:nonFraction name="QLGN:PurchasePrice" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" id="Fact001248" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>
(less expenses) pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture has a maturity date
of <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zXINtaF809T" title="Maturity date"><ix:nonNumeric contextRef="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" format="ixt:datemonthdayyearen" id="Fact001250" name="us-gaap:DebtInstrumentMaturityDate">December
22, 2025</ix:nonNumeric></span> and was initially convertible, at any time, and from time to time, until the Debenture is no longer outstanding, at
Alpha&#8217;s option, into shares of common stock of the Company (the &#8220;Conversion Shares&#8221;), at a price equal to $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zEVFFvK7NUzb" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" id="Fact001252" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>
per share, subject to adjustment as described in the Debenture (the &#8220;Conversion Price&#8221;) and other terms and conditions
described in the Debenture, including the necessary stockholder approvals, which the Company obtained at its 2023 annual meeting of
stockholders on July 13, 2023. As a part of the same transaction, on December 22, 2022, the Company issued to Alpha a
liability classified warrant (the &#8220;Alpha Warrant&#8221;) to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zUn6rDXZB204" title="Warrant to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" id="Fact001254" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock (see Note 7 - Warrant Liabilities). The exercise price of the Alpha Warrant was initially
$<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zaAHAlERsS7" title="Exercise price of warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" id="Fact001256" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></span>
(equal to <span id="xdx_902_ecustom--ConversionPricePercentage_pid_dp_uPure_c20221222__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zNe8JeCy6HU8" title="Conversion price percentage"><ix:nonFraction name="QLGN:ConversionPricePercentage" contextRef="From2022-12-222022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" id="Fact001258" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">125</ix:nonFraction></span>%
of the Conversion Price of the Debenture on the closing date) subject to adjustment as described in the Alpha Warrant. The Alpha
Warrant may be exercised by Alpha, in whole or in part, at any time before June 22, 2028, subject to certain terms and
conditions described in the Alpha Warrant, including the necessary stockholder approvals, which the Company obtained at its 2023
annual meeting of stockholders on July 13, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds from the transaction were used to advance the Company&#8217;s QN-302 Investigative New Drug candidate towards clinical trials
and other working capital purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption
of the Debenture (each such date, a &#8220;Monthly Redemption Date&#8221;), the Company must redeem $<span id="xdx_90B_eus-gaap--RepaymentsOfLongTermDebtAndCapitalSecurities_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z7kI6s7A3oL8" title="Redeemable debt"><ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember" id="Fact001260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,000</ix:nonFraction></span> plus accrued but unpaid
interest, liquidated damages and any amounts then owing under the Debenture (the &#8220;Monthly Redemption Amount&#8221;). The Monthly
Redemption Amount must be paid in cash; provided that after the first two monthly redemptions, the Company may elect to pay all or a
portion of a Monthly Redemption Amount in shares of common stock of the Company, based on a Conversion Price equal to the lesser of (i)
the then Conversion Price of the Debenture and (ii) <span id="xdx_902_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zYYn5O6h1BS1" title="Conversion rate"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember" id="Fact001262" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85</ix:nonFraction></span>% of the average of the VWAPs (as defined in the Debenture) for the five consecutive
trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. The Company may also redeem
some or all of the then outstanding principal amount of the Debenture at any time for cash in an amount equal to <span id="xdx_901_ecustom--PrincipalAmountPercentage_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zVJpjKZNZtP9" title="Principal amount percentage"><ix:nonFraction name="QLGN:PrincipalAmountPercentage" contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember" id="Fact001264" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105</ix:nonFraction></span>% of the then outstanding
principal amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under
the Debenture. The Company&#8217;s election to pay monthly redemptions in Conversion Shares or to effect an optional redemption is subject
to the satisfaction (or waiver) of the Equity Conditions (as defined in the Debenture), including the necessary stockholder approvals,
which the Company obtained at its 2023 annual meeting of stockholders on July 13, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Debenture accrues interest at the rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221222_zhA0tJv13IH4" title="Debenture accrues interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-12-22" id="Fact001266" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum, which did not begin accruing until December 1, 2023. Interest may be paid in
cash or shares of common stock of the Company or a combination thereof at the option of the Company; provided that interest may only
be paid in shares if the Equity Conditions have been satisfied (or waived).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the Debenture and the Alpha Warrant provide for adjustments to the Conversion Price and exercise price, respectively, in connection with
stock dividends and splits, subsequent equity sales and rights offerings, pro rata distributions, and certain fundamental transactions.
Both the Debenture and the Alpha Warrant include a beneficial ownership blocker of <span id="xdx_907_ecustom--DebentureBeneficialOwnershipBlockerPercentage_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zFs5ai4mfo8c" title="Debenture beneficial ownership blocker percentage"><ix:nonFraction name="QLGN:DebentureBeneficialOwnershipBlockerPercentage" contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember" id="Fact001268" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>%, which may only be waived by Alpha upon
61 days&#8217; notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to resale registration rights granted by the Company to Alpha in such Securities Purchase Agreement, the Company filed a
resale registration statement on Form S-3 (File Number 333-269088) on December 30, 2022 registering the resale by Alpha of
up to <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_pid_c20221230__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlphaCapitalMember_zh0M8xs4Zapb" title="Shares of Common stock, issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-30_custom_AlphaCapitalMember" id="Fact001270" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,157,087</ix:nonFraction></span>
shares of common stock of the Company which could be issued to Alpha pursuant to the Debenture and the Alpha Warrant, which
registration statement was declared effective by the SEC on January 5, 2023 (the &#8220;Original Registration Statement&#8221;). The
Company later became ineligible to update the Original Registration Statement via incorporation by reference of its future SEC
periodic and current reports as a result of its failure to timely file its annual report on Form 10-K for the fiscal year ended
December 31, 2022. Therefore, the Company filed a Post-Effective Amendment No. 1 to Form S-3 on Form S-1 (No. 333-269088)(the
&#8220;Post-Effective Amendment No. 1&#8221;) on September 1, 2023 in order to maintain the registration of the resale by Alpha of up to <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230901__20230901__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlphaCapitalMember_zoC4W55AW0md" title="Resale of common stock shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-09-012023-09-01_custom_AlphaCapitalMember" id="Fact001272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,958,537</ix:nonFraction></span>
shares of common stock of the Company issuable under the Debenture and the Alpha Warrant., which Post-Effective Amendment No. 1 was
declared effective by the SEC on September 7, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the Debenture and the Alpha Warrant and determined that the Alpha Warrant is a freestanding financial instrument. Initially,
the Alpha Warrant is not considered indexed to the Company&#8217;s own stock, because the settlement amount would not equal the difference
between the fair value of a fixed number of the Company&#8217;s equity shares and a fixed strike price and all of the adjustment features
in Section 3(b) of the Alpha Warrant are not down round provisions, as defined in ASU 2017-11. Accordingly, the Alpha Warrant was classified
as a liability and recognized at fair value, with subsequent changes in fair value recognized in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds from the Debenture were allocated to the initial fair value of the Alpha Warrant, with the residual balance allocated to the
initial carrying value of the Debenture. The Company has not elected the fair value option for the Debenture. The Debenture was recognized
as proceeds received after allocating the proceeds to the Alpha Warrant, and then allocating remaining proceeds to a suite of bifurcated
embedded derivative features (conversion option, contingent acceleration upon an Event of Default, and contingent interest upon an Event
of Default), with the resulting difference, if any, allocated to the loan host instrument. The suite of derivative features was measured
and determined to have no fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
original issue discount of $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zEgEQc4q7Zr2" title="Debt discount"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-01-012023-12-31_custom_AlphaCapitalOtherThirdPartiesMember" id="Fact001274" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span> million, the initial fair value of the Alpha Warrant of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zTnCdbaQyKk7" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_custom_AlphaCapitalOtherThirdPartiesMember" id="Fact001276" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span> million, the initial fair value of the suite
of bifurcated embedded derivative features of $<span id="xdx_90F_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_iI_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_z98HP0how0Ea" title="Fair value of embedded derivative features"><ix:nonFraction name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" contextRef="AsOf2023-12-31_custom_AlphaCapitalOtherThirdPartiesMember" id="Fact001278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, and the fees and costs paid to Alpha and other third parties of $<span id="xdx_905_eus-gaap--PaymentsForFees_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zrMTqvxAkYxj" title="Fees and costs paid"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2023-01-012023-12-31_custom_AlphaCapitalOtherThirdPartiesMember" id="Fact001280" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million
comprised the debt discount upon issuance. The debt discount is amortized to interest expense over the expected term of the Debenture
using the effective interest method, in accordance with ASC 835-30. The debt host instrument of the Debenture will subsequently be measured
at amortized cost using the effective interest method to accrete interest over its term to bring the Debenture&#8217;s initial carrying
value to the principal balance at maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
January 9 and 12, 2023, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230109__20230112__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zpKLUlhKdc6j" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-092023-01-12_custom_AlphaCapitalMember" id="Fact001282" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">841,726</ix:nonFraction></span>
shares of common stock upon Alpha&#8217;s partial conversion of the Debenture at $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230112__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z6LXJUp5nUg6" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-01-12_custom_AlphaCapitalMember" id="Fact001284" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>
per share for a total of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20230112__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zPqlWAgmu3gd" title="Debenture voluntarily converted"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-01-12_custom_AlphaCapitalMember" id="Fact001286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,111,078</ix:nonFraction></span>
principal. Upon conversion, the Company recognized a loss on conversion of convertible debt of approximately $<span id="xdx_90E_eus-gaap--ConvertibleDebtCurrent_iI_pn5n6_c20230112__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zqYlqHFJOLgd" title="Debt conversion of convertible debt"><ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2023-01-12_custom_AlphaCapitalMember" id="Fact001288" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span>
million, recorded to other expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October and December 2023, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231031__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zfO8ezg0jt32" title="Number of shares issued"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231201__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zwZJmES49Kl5" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-012023-10-31_custom_AlphaCapitalMember" id="Fact001290" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-12-012023-12-31_custom_AlphaCapitalMember" id="Fact001292" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">309,665</ix:nonFraction></ix:nonFraction></span></span>
shares of common stock to Alpha in lieu of cash for monthly redemption payments on the Debenture at a weighted average price
of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20231031__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_znzRejM6O6m8" title="Weighted price per share"><span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zbVsq0thiYN6" title="Weighted price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-10-31_custom_AlphaCapitalMember" id="Fact001294" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-12-31_custom_AlphaCapitalMember" id="Fact001296" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.71</ix:nonFraction></ix:nonFraction></span></span>
per share. Upon redemption for shares, the Company recognized a loss on partial debt extinguishment of $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20231001__20231031__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zxaPPvA0wwcj" title="Losses on debt extinguishment"><span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20231201__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_znbCtZ507maa" title="Losses on debt extinguishment"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-10-012023-10-31_custom_AlphaCapitalMember" id="Fact001298" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-12-012023-12-31_custom_AlphaCapitalMember" id="Fact001300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,315</ix:nonFraction></ix:nonFraction></span></span>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2023, the Company entered into a consent and waiver (the &#8220;Waiver&#8221;) with Alpha. Pursuant to the Waiver,
Alpha consented to the Company&#8217;s election to pay all of the Monthly Redemption Amount for October 2023 in Conversion Shares
(the &#8220;October Payment&#8221;) and waived the requirement of satisfaction of the Equity Conditions in relation to the October and
December Payment. On October 3, 2023 the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20231003__20231003__us-gaap--TypeOfArrangementAxis__custom--OctoberPaymentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlphaCapitalMember_zh1tCKtDFNv4" title="October payment in shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-10-032023-10-03_custom_OctoberPaymentMember_us-gaap_CommonStockMember_custom_AlphaCapitalMember" id="Fact001302" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">128,595</ix:nonFraction></span> shares of common stock to Alpha in satisfaction of the October
Payment. On December 8, 2023 the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20231208__20231208__us-gaap--TypeOfArrangementAxis__custom--OctoberPaymentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlphaCapitalMember_z02IwALocw64" title="October payment in shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-12-082023-12-08_custom_OctoberPaymentMember_us-gaap_CommonStockMember_custom_AlphaCapitalMember" id="Fact001304" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">181,070</ix:nonFraction></span> shares of common stock to Alpha in satisfaction of the December Payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2023, the Company and Alpha executed Amendment No. 1 with regard to Securities Purchase Agreement (the &#8220;SPA
Amendment&#8221;), pursuant to which the Company and Alpha agreed to, among other things, reduce the Conversion Price of the
Debenture from $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zErmCRdhg94b" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember" id="Fact001306" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>
per share to $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_z71owejzYxXf" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember" id="Fact001308" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span>
per share and reduce the exercise price of the Alpha Warrant from $<span id="xdx_909_eus-gaap--WarrantExercisePriceIncrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zNQPdd9gHgLd" title="Conversion price"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001310" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></span>
per share to $<span id="xdx_907_eus-gaap--WarrantExercisePriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5h5hVHuscji" title="Conversion price"><ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001312" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span>
per share, in each case subject to certain adjustments. In addition, the SPA Amendment revised certain provisions of the Alpha
Warrant to (i) limit the circumstances which would trigger a potential adjustment to the exercise price of the Alpha Warrant and
(ii) clarify the treatment of the Alpha Warrant upon a Fundamental Transaction. The purpose of these revisions was to remove the
terms that caused the Alpha Warrant to be liability-classified under U.S. GAAP. The Company performed an assessment and concluded
that all remaining adjustment features in the revised language meet the FASB&#8217;s definition of a down-round feature. In
addition, the Alpha Warrant was determined to meet all of the additional requirements for equity classification. Accordingly, as of
December 5, 2023, the Company remeasured the Alpha Warrant to its fair value immediately prior to the modification and recognized
the change in fair value in earnings. The incremental fair value impact from the Alpha Warrant modification of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_pn4n6_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zsHzOVlBYjfk" title="Fair value of warrant liability"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001314" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.09</ix:nonFraction></span>
million was included in the Company&#8217;s evaluation of the Debenture modification under ASC 470, discussed further below. The
Company then reclassified the Alpha Warrant liability to equity at its post-modification fair value of $<span id="xdx_903_eus-gaap--WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_pn5n6_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z28OGtBcetVc" title="Warrant liability to equity"><ix:nonFraction name="us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001316" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 470-50, the Company determined that the modified terms of the Debenture were substantially different when
compared to the original terms that existed prior to the SPA Amendment, and thus the event was required to be accounted for as a
debt extinguishment. Accordingly, the Company derecognized the net carrying value of the original Debenture, and recorded the new
debt instrument at its fair value of $<span id="xdx_909_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmEovKpEQWoc" title="Debt instrument fair value"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001318" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span>
million, and recorded a $<span id="xdx_90A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zrGXj6XAxCP1" title="Loss on extinguishment"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember" id="Fact001320" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span>
million loss on debt extinguishment. The difference between the remaining Debenture principal and its fair value on December 5, 2023
was recorded as a debt discount and will be amortized to interest expense over the expected term of the Debenture using the
effective interest method, in accordance with ASC 835-30.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recognized a loss on voluntary conversion of convertible debt of
approximately $<span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20230101__20231231_zlBLnd30p5Md" title="Debt conversion of convertible debt"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2023-01-01to2023-12-31" id="Fact001322" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span>
million, recognized an extinguishment loss of $<span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20230101__20231231__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ConvertibleDebtMember_z4AhbSkaLfd6" title="Extinguishment loss"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtMember" id="Fact001324" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span>
million upon October and December 2023 share redemptions and December 2023 modification of the Debenture, and recorded
accrued interest of approximately $<span id="xdx_903_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20230101__20231231_zPBNjTr9bLu7" title="Accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2023-01-01to2023-12-31" id="Fact001326" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.5</ix:nonFraction></span>
million, in other expenses in the consolidated statements of operations. During the year ended December 31, 2023 the Company paid
Monthly Redemption Amounts of $<span id="xdx_904_ecustom--DebtRedemptionAmountInCash_c20230101__20231231_z2HOt3us9Rel" title="Redemption amount in cash"><ix:nonFraction name="QLGN:DebtRedemptionAmountInCash" contextRef="From2023-01-01to2023-12-31" id="Fact001328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,000</ix:nonFraction></span>
in cash and $<span id="xdx_907_ecustom--DebtRedemptionAmountInCommonStock_c20230101__20231231_zBrNhLXO6z77" title="Redemption amounts in common stock"><ix:nonFraction name="QLGN:DebtRedemptionAmountInCommonStock" contextRef="From2023-01-01to2023-12-31" id="Fact001330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">220,000</ix:nonFraction></span>
in common stock, and as of December 31, 2023 the remaining Debenture principal balance was approximately $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20231231_zGKiB1S3yAn5" title="Debenture principal balance"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-31" id="Fact001332" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span>
million, the remaining discount was approximately $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20231231_zQyEIsVwkAgf" title="Debt discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2023-12-31" id="Fact001334" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million, and the fair value of the suite of bifurcated embedded derivative features was $<span id="xdx_90E_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20231231_zPo5ocEwE4Bj" title="Derivative fair value of warrants"><ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeNet" contextRef="AsOf2023-12-31" id="Fact001336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001338" name="us-gaap:ConvertibleDebtTableTextBlock"><p id="xdx_893_eus-gaap--ConvertibleDebtTableTextBlock_zOeh0D24vQXj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
senior convertible debt comprises the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span id="xdx_8B8_zH4MDVn648ug" style="display: none">SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zB5SrNpsgSZ5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zJufdsid8uN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SecuredDebt_iI_zL6i72Wp3Pah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Senior convertible debenture</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SecuredDebt" contextRef="AsOf2023-12-31_custom_SeniorSecuredConvertibleDebtMember" id="Fact001340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,418,922</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SecuredDebt" contextRef="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember" id="Fact001341" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,300,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_znbJgSde29C9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Discount on convertible debenture</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2023-12-31_custom_SeniorSecuredConvertibleDebtMember" id="Fact001343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember" id="Fact001344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,239,803</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_zQZXTcRUnVne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total convertible debt-related party</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2023-12-31_custom_SeniorSecuredConvertibleDebtMember" id="Fact001346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,299,216</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember" id="Fact001347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,197</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zWRyG2Pv5sQk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, there were no unwaived events of default or violation of any covenants under the Company&#8217;s financing obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001349" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zJPsDjOau3O6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8212; <span id="xdx_827_zPGQQYysyT1e">EARNINGS (LOSS) PER SHARE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share (&#8220;EPS&#8221;) is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted
EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during
the period. Potentially dilutive common shares consist of shares issuable from convertible debt, stock options and warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001351" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z3OXkzOiCRvi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potentially dilutive securities have been excluded from diluted net loss per share as of December 31, 2023 and 2022 because
their effect would be anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span id="xdx_8B7_zlzE769K8vK4" style="display: none">SCHEDULE
OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zSIovIChNxfh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zQLGPWwKm7yg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Years Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zJiUFN0xyJHh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; width: 60%; text-align: left">Net loss used for basic earnings per share</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-12-31" id="Fact001353" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,417,212</ix:nonFraction></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31" id="Fact001354" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,640,543</ix:nonFraction></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zIibE0Bcgfv9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Basic weighted-average common shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-12-31" id="Fact001356" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,072,709</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" id="Fact001357" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,840,340</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_zE5ERx10oJ9a" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Dilutive potential shares issuable from convertible debt, stock options and warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1359">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1360">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zhTDRiIz5Ita" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Diluted weighted-average common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" id="Fact001362" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,072,709</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" id="Fact001363" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,840,340</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zMzxpJE7OSu" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001365" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3eveFH7U4Je" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8212; <span id="xdx_82E_zK0KLzZoSfxb">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation
and Other Legal Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2021, the Company was named as a defendant in an action brought by Mediant Communications Inc. (&#8220;Mediant&#8221;) in
the U.S. District Court for the Southern District of New York. The complaint alleged that Qualigen entered into an implied contract with
Mediant, whereby Qualigen retained Mediant to distribute proxy materials and subsequently conduct shareholder vote tabulations. The Company
filed a Motion to Dismiss with the District Court and on March 14, 2022 a hearing was held during which the presiding judge ruled in
favor of the Motion to Dismiss. The Company and Mediant settled the litigation on April 5, 2022 in the amount of $<span id="xdx_90E_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pdp0_c20220405__20220405_zzjcwTUTcAV" title="Litigation paid"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2022-04-052022-04-05" id="Fact001367" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">96,558</ix:nonFraction></span>, at which time
the amount was paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001369" name="QLGN:ResearchAndLicenseAgreementsTextBlock"><p id="xdx_80A_ecustom--ResearchAndLicenseAgreementsTextBlock_z5Spl7nwPGt5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8212; <span id="xdx_82E_zKvwRiE4sicb">RESEARCH AND LICENSE AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>UCL
Business Limited</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, the Company entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a
genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London,
including lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for
University College London.) The program&#8217;s lead compound is now being developed at the Company under the name QN-302 as a candidate
for treatment for pancreatic ductal adenocarcinoma, which represents the vast majority of pancreatic cancers. The License Agreement required
a $<span id="xdx_900_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--AwardTypeAxis__custom--UpfrontPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zPhiPwBij0sa" title="Reimbursement of patent"><ix:nonFraction name="QLGN:ReimbursementOfPatent" contextRef="From2022-01-012022-01-31_custom_UpfrontPaymentMember_custom_LicenseAgreementMember" id="Fact001371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> upfront payment, reimbursement of past patent prosecution expenses (approximately $<span id="xdx_900_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z6J1jIG6szR2" title="Reimbursement of patent"><ix:nonFraction name="QLGN:ReimbursementOfPatent" contextRef="From2022-01-012022-01-31_custom_LicenseAgreementMember" id="Fact001373" format="ixt:numdotdecimal" decimals="0" unitRef="USD">160,000</ix:nonFraction></span>), and (if and when applicable)
tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments and a percentage of any non-royalty
sublicensing consideration paid to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022 there were license costs of approximately $<span id="xdx_90B_ecustom--LicenseCost_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zSJnVgnPmzR4" title="License cost"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2023-01-012023-12-31_custom_LicenseAgreementMember" id="Fact001375" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">128,000</ix:nonFraction></span> and $<span id="xdx_900_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zhJsnrAaVqSi" title="License cost"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2022-01-012022-12-31_custom_LicenseAgreementMember" id="Fact001377" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">338,000</ix:nonFraction></span>, respectively, related to
this agreement which are included in research and development expenses in the consolidated statements of operations and other comprehensive
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>QN-302
Phase 1 Study</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Company entered into a Master Clinical Research Services Agreement with Translational Drug Development, LLC (&#8220;TD2&#8221;)
whereby TD2 agreed to perform certain clinical research and development services for the Company including but not limited to trial management,
side identification and selection, site monitoring/management, medical monitoring, project management, data collection, statistical programming
or analysis, quality assurance auditing, scientific and medical communications, regulatory affairs consulting and submissions, strategic
consulting, and/or other related services. From time to time, the Company intends to enter into statements of work with TD2 for the performance
of specific services under this Master Clinical Research Services Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Company entered into a Master Laboratory Services Agreement with MLM Medical Labs, LLC (&#8220;MLM&#8221;) whereby MLM
agreed to perform certain clinical research and development services for the Company including but not limited to laboratory, supply,
testing, validation, data management, and storage services. From time to time, the Company intends to enter into work orders with MLM
for the performance of specific services under this Master Laboratory Services Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Company entered into a Master Services Agreement with Clinigen Clinical Supplies Management, Inc. (&#8220;Clinigen&#8221;)
whereby Clinigen agreed to provide certain pharmaceutical products and/or services. From time to time, the Company intends to enter into
statements of work with Clinigen for the performance of specific services under this Master Services Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, pursuant to the above agreements, the Company entered into work orders and statements of work for clinical trial services
for the conduct of the QN-302 Phase 1 study. The project timeline started in July 2023 and is expected to continue until approximately
July 2026. The total amount to be paid under these work orders and statements of work is currently expected to be approximately $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20230701__20230731__us-gaap--TypeOfArrangementAxis__custom--MasterLaboratoryServicesAgreementMember__dei--LegalEntityAxis__custom--MLMMedicalLabsMember_z72LbVTys471" title="Research and Development Expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-07-31_custom_MasterLaboratoryServicesAgreementMember_custom_MLMMedicalLabsMember" id="Fact001379" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.6</ix:nonFraction></span>
million over the term of the QN-302 Phase 1 study, subject to available funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>University
of Louisville Research Foundation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with University of Louisville
Research Foundation, Inc. (&#8220;ULRF&#8221;) for development of several small-molecule RAS interaction inhibitor drug candidates. Under
the terms of this agreement, the Company agreed to reimburse ULRF for sponsored research expenses of initially up to $<span id="xdx_90A_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z9ihjn2cNfO4"><ix:nonFraction name="QLGN:ReimbursementOfResearchExpenses" contextRef="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001380" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">693,000</ix:nonFraction></span> for this
program. This agreement was amended in February 2021, March 2022 and August 2023, with the current term of this agreement set to expire
in December 2023 and the aggregate amount that the Company would reimburse ULRF for sponsored research expenses increased to approximately
$<span id="xdx_904_ecustom--ReimbursementOfResearchExpenses_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zxzcpDsU38Oj" title="Research expenses"><ix:nonFraction name="QLGN:ReimbursementOfResearchExpenses" contextRef="From2023-01-012023-12-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001382" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.9</ix:nonFraction></span> million. <span id="xdx_901_ecustom--AgreementTermPaymentDescription_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zmY422FEK0rl" title="Agreement term payment, description"><ix:nonNumeric contextRef="From2020-07-012020-07-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001384" name="QLGN:AgreementTermPaymentDescription">In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates.
Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is
responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront
license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered
net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative
$250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30%
to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement,
40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth
year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution
and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $<span id="xdx_908_ecustom--MilestonePayment_pp0p0_c20200701__20200731__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z1QYrpKnNfFl" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2020-07-012020-07-31_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001386" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span> to $<span id="xdx_906_ecustom--MilestonePayment_pp0p0_c20200701__20200731__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z6v8GZqfH8Ih" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2020-07-012020-07-31_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001388" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> upon the achievement
of certain regulatory and commercial milestones.</ix:nonNumeric></span> Milestone payments for the first therapeutic indication would be $<span id="xdx_901_ecustom--MilestonePayment_pp0p0_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_zu95KF0L3qSc" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2020-07-012020-07-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember" id="Fact001390" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span> for first dosing
in a Phase 1 clinical trial, $<span id="xdx_90C_ecustom--MilestonePayment_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zki8k56pknbj"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2020-07-012020-07-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember" id="Fact001391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> for first dosing in a Phase 2 clinical trial, $<span id="xdx_900_ecustom--MilestonePayment_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zM5uSQcQwsEl" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2020-07-012020-07-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember" id="Fact001393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> for first dosing in a Phase 3 clinical trial,
$<span id="xdx_905_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zGFYrI2V68Z8" title="Marketing approval expenses"><ix:nonFraction name="QLGN:RegulatoryMarketingApprovalExpenses" contextRef="From2020-07-012020-07-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001395" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></span> for regulatory marketing approval and $<span id="xdx_90A_ecustom--CumulativeSales_pp0p0_c20200701__20200731__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zKSMxhSwBF5a" title="Cumulative sales"><ix:nonFraction name="QLGN:CumulativeSales" contextRef="From2020-07-012020-07-31_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001397" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> upon achieving a cumulative $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zQVumjShMKX4" title="Revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2020-07-012020-07-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001399" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000,000</ix:nonFraction></span> of Licensed Product sales. The Company
also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income
for any year is less than the applicable annual minimum (ranging from $<span id="xdx_90A_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200731__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zbWgwfbBkx0j" title="Upfront license fee"><ix:nonFraction name="QLGN:UpfrontLicenseFee" contextRef="AsOf2020-07-31_srt_MinimumMember_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001401" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction></span> to $<span id="xdx_90D_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200731__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zY838exDZYJi" title="Upfront license fee"><ix:nonFraction name="QLGN:UpfrontLicenseFee" contextRef="AsOf2020-07-31_srt_MaximumMember_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001403" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span>) for such year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsored
research expenses related to these RAS agreements for the years ended December 31, 2023 and December 31, 2022 were approximately $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember_zYYDVW9x8cz9" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_SponsoredResearchAgreementsAndLicenseMember" id="Fact001405" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">743,000</ix:nonFraction></span>
and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember_zsIRTn6j87hh" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementsAndLicenseMember" id="Fact001407" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">758,000</ix:nonFraction></span>, respectively, and are recorded in research and development expenses in the Consolidated Statements of Operations. License
costs related to these agreements for the years ended December 31, 2023 and December 31, 2022 were approximately $<span id="xdx_901_ecustom--LicenseCost_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember_zeOno0P3mY36" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2023-01-012023-12-31_custom_SponsoredResearchAgreementsAndLicenseMember" id="Fact001409" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">133,000</ix:nonFraction></span> and $<span id="xdx_90E_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember_zAeEG0xHV4If" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementsAndLicenseMember" id="Fact001411" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,000</ix:nonFraction></span>,
respectively, and are included in research and development expenses in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
June 2018 and April 2022, the Company entered into license and sponsored research agreements with ULRF for QN-247, a novel aptamer-based
compound that has shown promise as an anticancer drug. Under the agreements, the Company took over development, regulatory approval and
commercialization of the compound from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return,
ULRF received a $<span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_ziXZGPOYq6L4" title="Proceeds from convertible debt"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2018-06-012022-04-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001413" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span> convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#8217;s
common stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to approximately $<span id="xdx_900_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zWsGO7qjqMdc" title="Reimbursement of research expenses"><ix:nonFraction name="QLGN:ReimbursementOfResearchExpenses" contextRef="From2018-06-012022-04-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001415" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">805,000</ix:nonFraction></span> and prior patent
costs of up to $<span id="xdx_90D_ecustom--PatentCosts_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zR5SyuN5SDIl" title="Patent costs"><ix:nonFraction name="QLGN:PatentCosts" contextRef="From2018-06-012022-04-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001417" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span>. <span id="xdx_90C_ecustom--AgreementTermPaymentDescription_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z02gdTuCaJe9" title="Agreement term payment, description"><ix:nonNumeric contextRef="From2018-06-012022-04-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001419" name="QLGN:AgreementTermPaymentDescription">In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization
of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative
$250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income
received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third
or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter),
(iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred
prior to June 2018, and (iv) payments ranging from $<span id="xdx_903_ecustom--MilestonePayment_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zPdeQJply0Q1" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012022-04-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001421" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> to $<span id="xdx_90B_ecustom--MilestonePayment_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zoqDS22p7z97" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012022-04-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001423" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> upon the achievement of certain regulatory and commercial milestones.</ix:nonNumeric></span>
Milestone payments for the first therapeutic indication would be $<span id="xdx_90A_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z3pIMe0TMwJ3" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012022-04-30_custom_PhaseOneClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001425" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> for first dosing in a Phase 1 clinical trial, $<span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zUZtPwpffupa" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012022-04-30_custom_PhaseTwoClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001427" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></span> for
first dosing in a Phase 2 clinical trial, $<span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zMaz19EJUYxg" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012022-04-30_custom_PhaseThreeClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001429" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">350,000</ix:nonFraction></span> for first dosing in a Phase 3 clinical trial, $<span id="xdx_900_ecustom--RegulatoryMarketingApprovalExpenses_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zfN7wuwOKwrd" title="Marketing approval expenses"><ix:nonFraction name="QLGN:RegulatoryMarketingApprovalExpenses" contextRef="From2018-06-012022-04-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001431" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> for regulatory marketing approval
and $<span id="xdx_90F_ecustom--CumulativeSales_pp0p0_c20180601__20220430__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zxlmofmtKRPk" title="Cumulative sales"><ix:nonFraction name="QLGN:CumulativeSales" contextRef="From2018-06-012022-04-30_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001433" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> upon achieving a cumulative $<span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z3hlTwNjuUsb" title="Revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2018-06-012022-04-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001435" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000,000</ix:nonFraction></span> of Licensed Product sales. The Company also agreed to pay another $<span id="xdx_900_ecustom--RegulatoryMarketingApprovalExpensesOne_pp0p0_c20180601__20220430__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zmVCw5mhYaJc" title="Regulatory marketing approval, expenses"><ix:nonFraction name="QLGN:RegulatoryMarketingApprovalExpensesOne" contextRef="From2018-06-012022-04-30_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001437" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span> milestone
payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The Company must
also pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for
any year is less than the applicable annual minimum (ranging from $<span id="xdx_908_ecustom--ShortfallPayments_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zOISJkAzMvy1" title="Shortfall payments"><ix:nonFraction name="QLGN:ShortfallPayments" contextRef="From2018-06-012022-04-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001439" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></span> to $<span id="xdx_905_ecustom--ShortfallPayments_c20180601__20220430__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zkaSrkWUhRE7" title="Shortfall payments"><ix:nonFraction name="QLGN:ShortfallPayments" contextRef="From2018-06-012022-04-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>) for such year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sponsored research agreement for QN-247 expired in August 2022. The sponsored research expenses related to these QN-247 agreements for
the years ended December 31, 2023 and December 31, 2022 were $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_z4lt68itSEqi"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_SponsoredResearchAgreementAndLicenseMember" id="Fact001442" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and approximately $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zaeeugH71kw"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember" id="Fact001443" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">164,000</ix:nonFraction></span>, respectively, and these amounts are recorded
in research and development expenses in the consolidated statements of operations and other comprehensive loss. License costs related
to these agreements were approximately $<span id="xdx_907_ecustom--LicenseCost_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zzGECV6B2eeg"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2023-01-012023-12-31_custom_SponsoredResearchAgreementAndLicenseMember" id="Fact001444" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,000</ix:nonFraction></span> and $<span id="xdx_904_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zLULny5Wi9qa"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember" id="Fact001445" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">94,000</ix:nonFraction></span> for the years ended December 31, 2023 and December 31, 2022, respectively,
and are included in research and development expenses in the consolidated statements of operations and other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
In June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as
a treatment for COVID-19. Under the agreement, the Company took over development, regulatory approval and commercialization of the compound
(for such use) from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received
approximately $<span id="xdx_904_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zs6wIUOQmRSa" title="Upfront license fee"><ix:nonFraction name="QLGN:UpfrontLicenseFee" contextRef="AsOf2020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001447" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,000</ix:nonFraction></span> for an upfront license fee and reimbursement of prior patent costs. In addition, the Company was required to enter
into a separate sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) for at least $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200601__20200630__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zwcC8dBKeIhh" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-06-012020-06-30_srt_MinimumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001449" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span>. In November 2020,
the Company executed a sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) supporting up to approximately
$<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20201101__20201130__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zfrwx4kHwiF4" title="Research and development expense"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-11-012020-11-30_srt_MinimumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" id="Fact001451" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">430,000</ix:nonFraction></span> in research which satisfied this requirement. This sponsored research agreement expired in November 2021 and the exclusive license
agreement was terminated on October 31, 2022. There were no sponsored research expenses or license costs related to these QN-165 agreements
for the years ended December 31, 2023 and 2022.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001453" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z3CfDa6rNHjg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 &#8212; <span id="xdx_82B_zJQMTosbNfn2">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, and 2022 the Company had two classes of capital stock: common stock and preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject
to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive
dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, any
remaining assets will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of any
preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive,
subscription or conversion rights and there are no redemption or sinking fund provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company has reserved <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231_zwCKHUUeVtdj" title="Common stock reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31" id="Fact001455" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,781,161</ix:nonFraction></span> shares of authorized but unissued common stock for possible future issuance as
follows:</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001457" name="QLGN:ScheduleOfReservedSharesTableTextBlock"><p id="xdx_89A_ecustom--ScheduleOfReservedSharesTableTextBlock_zwTy7UYVbLH4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_z6DIgiLX7U56" style="display: none">SCHEDULE
OF RESERVED SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20231231_zHoQ9JF85b0f" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5WBLsQhG06k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Exercise of issued and future grants of stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31_us-gaap_StockOptionMember" id="Fact001459" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">755,715</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__custom--ConversionOfConvertibleDebtMember_zNUiJ3e0hid5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Conversion of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31_custom_ConversionOfConvertibleDebtMember" id="Fact001461" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,943,729</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zr39N6ecJFsc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercise of stock warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31_us-gaap_WarrantMember990578" id="Fact001463" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,081,717</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zjAWdC7CbToj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31" id="Fact001465" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,781,161</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zMTDeIMRyP9d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and December 31, 2022, there were <span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_zQHj2ADN0JKc" title="Preferred stock, shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zU3ojb1dnOL9" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact001467" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact001469" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares of preferred stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options and Equity Classified Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes all compensatory stock-based payments as compensation expense over the service period, which is generally the vesting
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which provides for the grant of incentive
or non-statutory common stock options, restricted stock, stock bonus awards, stock appreciation rights, restricted stock units and performance
awards to qualified employees, officers, directors, consultants and other service providers. At December 31, 2023 and December 31, 2022
there were <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z2PHP0fjlCIa" title="Options outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact001471" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">398,924</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z9WFEV0vLDZ7" title="Options outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact001473" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">608,012</ix:nonFraction></span> outstanding stock options, respectively, under the 2020 Plan and there were <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zuHsQg5DiD0j" title="Plan shares available"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact001475" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">356,778</ix:nonFraction></span> and <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zpNtBMtkpoHb" title="Plan shares available"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact001477" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,690</ix:nonFraction></span> Plan shares
available, respectively, for future grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001479" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zs8yiFww238k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December
31, 2023, and changes during the twelve months then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zFOnad0Z0GNb" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted&#8211;Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted&#8211;Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Total outstanding &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkIsHDFTE0Oi" title="Number of shares, options outstanding, beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001481" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">608,012</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ziTkSGk7A1vf" title="Weighted Average Exercise Price, Outstanding, Beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001483" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.02</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z1A2GvKClF0g" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" id="Fact001485" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span> - $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_z09sF6T2A68f" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" id="Fact001487" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">51.30</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zsPcTXYTQkFk" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" id="Fact001489" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.09</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zYz3AeE2OExk" title="Number of shares, options granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1491">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zIRryovNL914" title="Weighted average exercise price, options granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1493">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zZU1qmiE3F8" title="Number of shares, options expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1495">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ziujHsfwWzMa" title="Weighted average exercise price, options expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1497">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zzTGWHF4F2Tk" title="Number of shares, options forfeited" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001499" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">209,088</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zpmO8ELPhGq9" title="Weighted average exercise price, options forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001501" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">34.71</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zbWJhn9PPoIj" title="Range of Exercise price, Options Forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" id="Fact001503" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span> - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zEkZKn9nbud6" title="Range of Exercise price, Options Forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" id="Fact001505" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">51.30</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zN2jD7JuHcYa" title="Number of Shares, Options Outstanding at Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001507" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">398,924</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBrjiTdDhbO2" title="Weighted Average Exercise Price, Outstanding at Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001509" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.21</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zvj28x2nVpl" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" id="Fact001511" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span> &#8212; $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zvf5zIhj1efd" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" id="Fact001513" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">51.30</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkBJbEz2epD5" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" id="Fact001515" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.06</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Exercisable (vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zpG7XaKkSemc" title="Number of shares, options exercisable (vested)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001517" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">320,918</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zaeMd4Xni5We" title="Range of exercise price, options exercisable (vested)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001519" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">41.97</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zpVEguyqgJAa" title="Range of exercise price, options exercisable (vested)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" id="Fact001521" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span> &#8212; $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zkGjM8ZYcPug" title="Range of exercise price, options exercisable (vested)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" id="Fact001523" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">51.30</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zKKIJUisZMfh" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" id="Fact001525" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">6.77</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Non-Exercisable (non-vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjNvfdbF1y98" title="Number of shares, options non-exercisable (non-vested)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001527" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,006</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zG2CA3CSl6v8" title="Weighted average exercise price, options non-exercisable (non-vested)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001529" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.36</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z91mmxAdBLH3" title="Range of exercise price, options non-exercisable (non-vested)"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" id="Fact001531" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span> - $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zIpg0XstkxAf" title="Range of exercise price, options non-exercisable (non-vested)"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" id="Fact001533" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">32.90</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zJwkYBBjO96" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" id="Fact001535" name="QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested">8.36</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that were outstanding at December 31, 2022, and changes during the twelve months then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
of</b></span></p>
                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p>
                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zWIRkBiiTiEg" title="Number of shares, options outstanding, beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001537" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">484,186</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zlVZE02OJEza" title="Weighted Average Exercise Price, Outstanding, Beginning" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001539" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.70</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">$<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zGiHtX3PY4j3" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" id="Fact001541" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.40</ix:nonFraction></span> &#8212; $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zVqt1XV08gM6" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" id="Fact001543" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14,657.50</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkE37PmUN0sh" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" id="Fact001545" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.52</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zP3cmn02hWCb" title="Number of shares, options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001547" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">134,469</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zrek5FW0Qc76" title="Weighted average exercise price, options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001549" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zm71m9uYtMf7" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" id="Fact001551" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span> &#8212; <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zlYsjj8aE7xc" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" id="Fact001553" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zza9MJn3zL58" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" id="Fact001555" name="QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">5.99</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBjp6n0FxRok" title="Number of shares, options expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001557" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,379</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zM2Q23Z80GFc" title="Weighted average exercise price, options expired" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001559" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">932.75</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zCChvyUDs58k" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" id="Fact001561" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">57.50</ix:nonFraction></span> - <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zbVQ4jXmBnl1" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" id="Fact001563" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14,657.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zxMo7qCM7wNc" title="Number of shares, options forfeited" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001565" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zVJyXMhMu384" title="Weighted average exercise price, options forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001567" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.64</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zIDOyHLqNdt1" title="Range of Exercise price, Options Forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" id="Fact001569" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_z7zVE50RAY8h" title="Range of Exercise price, Options Forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" id="Fact001571" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">49.70</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z3yGc3Sl9Gqc" title="Number of Shares, Options Outstanding at Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001573" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">608,012</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zqrDsAW48I64" title="Weighted Average Exercise Price, Outstanding at Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001575" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">35.02</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z2xuq1t7WRTg" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" id="Fact001577" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span> &#8212; $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zqHOPdJQSIl3" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" id="Fact001579" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">51.30</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zARB0aqcuL8c" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" id="Fact001581" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.09</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Exercisable (vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zXrgdO5t8oe4" title="Number of shares, options exercisable (vested)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001583" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">288,704</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zprySz4oLgx" title="Range of exercise price, options exercisable (vested)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001585" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">46.32</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zmcvWVbJnsJh" title="Range of exercise price, options exercisable (vested)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" id="Fact001587" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.40</ix:nonFraction></span> &#8212; $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zD2GTW2aYwh2" title="Range of exercise price, options exercisable (vested)"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" id="Fact001589" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">51.30</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zn9slRtEYqG1" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" id="Fact001591" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">7.59</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Non-Exercisable (non-vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z1apKxQ2FgBb" title="Number of shares, options non-exercisable (non-vested)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001593" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">319,308</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zLrGcJzs1uV" title="Weighted average exercise price, options non-exercisable (non-vested)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" id="Fact001595" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zLKKejEF9B8l" title="Range of exercise price, options non-exercisable (non-vested)"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" id="Fact001597" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span> &#8212; $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zKV52WE0uOo5" title="Range of exercise price, options non-exercisable (non-vested)"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" id="Fact001599" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zbXPeuyw7Ib1" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" id="Fact001601" name="QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested">8.59</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AE_zfzureZsPRAf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was approximately $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zooOWNiHFMH" title="Compensation cost"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001603" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGTD59yVg9Bl" title="Compensation cost"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001605" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.4</ix:nonFraction></span> million of compensation costs related to outstanding options for the year ended December 31, 2023
and December 31, 2022, respectively. This cost is expected to be recognized over a weighted average period of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zEFcpGopUTX6" title="Cost is expected to be recognized over a weighted average period"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" id="Fact001607" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.09</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7Q7cPFBqe6b" title="Stock options granted"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAH04MYGtoi" title="Stock options granted"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZ5iV4mgRYCe" title="Stock options exercised"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zu7XI7ZF6ic3" title="Stock options exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" id="Fact001609" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember" id="Fact001611" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" id="Fact001613" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember" id="Fact001615" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span>
stock options were granted or exercised during the year ended December 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z5VbRTNexEaa" title="Stock options description"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember" id="Fact001617" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.</ix:nonNumeric></span> The options awarded under the 2020 Plan will vest as determined by the Board of Directors but will not exceed a 10-year
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9mA0gyIhvwk" title="Stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" id="Fact001619" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> options granted during the year ended December 31, 2023. The weighted average grant date fair value per share of the shares underlying
options granted during the year ended December 31, 2022 was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZz9Cag701Cl" title="Stock option granted exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember" id="Fact001621" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.96</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Equity Awards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes the Black-Scholes option pricing model to value awards under the 2020 Plan, and for equity classified compensatory warrants.
Key valuation assumptions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    dividend yield.</i> The expected dividend is assumed to be zero, as the Company has never paid dividends and has no current plans
    to pay any dividends on the Company&#8217;s common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    stock-price volatility.</i> The Company&#8217;s expected volatility is derived from the average historical volatilities of publicly
    traded companies within the Company&#8217;s industry that the Company considers to be comparable to the Company&#8217;s business
    over a period approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-free
    interest rate.</i> The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon
    U.S. Treasury notes with maturities approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    term.</i> The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&#8217;s
    historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of
    a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the SEC.
    The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001623" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zGHR15bCdKc4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zAEDyLzxwr3i" style="display: none">SCHEDULE
OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Years Ended December 31,</b></span></p>

</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Expected dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zQSr5rVaOadd" title="Expected dividend yield" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31" id="Fact001625" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected stock-price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zcPUuOZ6PVR1" title="Expected stock-price volatility" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31" id="Fact001627" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">103</ix:nonFraction>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zCM8i4TCTp58" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2022-01-012022-12-31_srt_MinimumMember" id="Fact001629" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.58</ix:nonFraction></span>% &#8212; <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_ztgDn7Z1c4V1" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2022-01-012022-12-31_srt_MaximumMember" id="Fact001631" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.77</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected average term of options (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zLv60PDr8SAl" title="Expected average term of options (in years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt-sec:duryear" id="Fact001633" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.99</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MinimumMember_z41UFMKa2Jvk" title="Stock price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_srt_MinimumMember" id="Fact001635" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.14</ix:nonFraction></span> - <span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MaximumMember_zQmQktOllcn9" title="Stock price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_srt_MaximumMember" id="Fact001637" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.50</ix:nonFraction></span></td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8AC_zsnSQFGnqo1h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001639" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_z4fcGluRwcLf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense and classified it in the Consolidated Statements of Operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zCQVTkRPAy18" style="display: none">SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zWeGmRQVC7Vf" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_zHKS76KQYz95" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zzLhM2YRzOl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001641" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,228</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,649,649</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrifLxBJYHPe" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001644" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,305</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001645" format="ixt:numdotdecimal" decimals="0" unitRef="USD">834,395</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zpHZ3aJEeIDd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-01to2023-12-31" id="Fact001647" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,098,533</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31" id="Fact001648" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,484,044</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zdZbf09O8MU9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
Classified Compensatory Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zVMGPmt8I3ig" title="Issuance or sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantsMember" id="Fact001650" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction></span> million equity capital raise as part of the May 2020 reverse recapitalization transaction, the Company issued
common stock warrants to an advisor and its designees for the purchase of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zleuOGXOvu4k" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-12-31_custom_CompensatoryWarrantsMember" id="Fact001652" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">81,143</ix:nonFraction></span> reverse split adjusted shares of the Company&#8217;s
common stock at a reverse split adjusted exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zJ8Dch6Fh1c6" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_CompensatoryWarrantsMember" id="Fact001654" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></span> per share. The issuance cost of these warrants was charged to additional
paid-in capital, and did not result in expense in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier (originally exercisable to
purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock) for the purchase of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20171231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zFhqKb3CUDy8" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2017-12-31_custom_CompensatoryWarrantsMember" id="Fact001656" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,802</ix:nonFraction></span> reverse
split adjusted shares of Company common stock at a weighted average exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20171231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_ze31QcTqJ2p2" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2017-12-31_custom_CompensatoryWarrantsMember" id="Fact001658" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.40</ix:nonFraction></span> per share. These are to be differentiated
from the Series C Warrants described in Note 7- Warrant Liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2022, <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyOAFc5gq2g2" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-04-25_us-gaap_WarrantMember" id="Fact001660" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></span>
warrants were repriced from $<span id="xdx_906_ecustom--StockholdersEquityReverseStockSplitPricePerShare_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZHAB7WEFjef" title="Reverse stock split, price per share"><ix:nonFraction name="QLGN:StockholdersEquityReverseStockSplitPricePerShare" contextRef="AsOf2022-04-25_us-gaap_WarrantMember" id="Fact001662" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.20</ix:nonFraction></span>
per share exercise price to a reverse split adjusted exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zy2ncQaMYXuf" title="Class of warrant or right, exercise"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-25_us-gaap_WarrantMember" id="Fact001664" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span>
per share exercise price and extended from <span id="xdx_905_ecustom--WarrantsExtendedDateDescription_c20220425__20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ4P2TtwzZMk" title="Warrants extended date description"><ix:nonNumeric contextRef="From2022-04-252022-04-25_us-gaap_WarrantMember" id="Fact001666" name="QLGN:WarrantsExtendedDateDescription">June
3, 2023 to September 14, 2023</ix:nonNumeric></span>. The increase in fair value of $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20220425__20220425__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLO5vzQCCQ0g" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-04-252022-04-25_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_WarrantMember" id="Fact001668" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></span>
for the modification of these warrants was charged to general and administrative expenses in the Company&#8217;s consolidated
statements of operations and comprehensive loss. These warrants expired on <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsGUBQ9bxlH5" title="Warrants expired date"><ix:nonNumeric contextRef="AsOf2022-04-25_us-gaap_WarrantMember" format="ixt:datemonthdayyearen" id="Fact001670" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">September 14, 2023</ix:nonNumeric></span>. On April 25, 2022 and May 26, 2022 an
additional <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrPmMJgYvLL7" title="Purchase of warrants"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z88LO3jDDlcl" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-04-25_us-gaap_WarrantMember" id="Fact001672" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-05-26_us-gaap_WarrantMember" id="Fact001674" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,620</ix:nonFraction></ix:nonFraction></span></span>
reverse split adjusted warrants were repriced from reverse split adjusted $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zNhQJ7inRFig" title="Exercise price"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z7d2IK97cXQ6" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001676" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-25_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001678" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></ix:nonFraction></span></span>
per share exercise price to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zjSVTpw5APqc" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5CupuhJkOU5" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001680" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-25_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001682" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.136</ix:nonFraction></ix:nonFraction></span></span>
per share exercise price. The increase in fair value of $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20220424__20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zUgUb2bQVW01" title="Fiar value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-04-242022-05-26_us-gaap_AdditionalPaidInCapitalMember_us-gaap_WarrantMember" id="Fact001684" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,010</ix:nonFraction></span>
for the modification of these warrants was charged to additional paid-in capital and did not result in expense on the
Company&#8217;s consolidated statements of operations and comprehensive loss. On December 22, 2022 <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaquUJUAi2E2" title="Warrants purchased"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-12-22_us-gaap_WarrantMember" id="Fact001686" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,620</ix:nonFraction></span>
warrants were repriced from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_ziu87vorlQ16" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001688" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.136</ix:nonFraction></span>
per share exercise price to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYcyNViqXhdh" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001690" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>
per share exercise price. The increase in fair value of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20221222__20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9xfLHm4udul" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-12-222022-12-22_us-gaap_WarrantMember" id="Fact001692" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,548</ix:nonFraction></span>
for the modification of these warrants was charged to additional paid-in capital and did not result in expense on the
Company&#8217;s consolidated statements of operations and comprehensive loss. On December 5, 2023, <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231205__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSqSvUUOWNgk" title="Warrants purchased"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-12-05_us-gaap_WarrantMember" id="Fact001694" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67,620</ix:nonFraction></span>
warrants were repriced from $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zBCUPRV7uDCk" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-05_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001696" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>
per share exercise price to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zxzprKaDj7el" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-05_us-gaap_WarrantMember_srt_MaximumMember" id="Fact001698" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span>
per share exercise price. The increase in fair value of $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20231205__20231205__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6qC580aP7oa" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-12-052023-12-05_us-gaap_WarrantMember" id="Fact001700" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,945</ix:nonFraction></span>
for the modification of these warrants was charged to general and administrative expenses in the Company&#8217;s consolidated
statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
new compensatory warrants were issued during the year ended December 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember" escape="true" id="Fact001702" name="QLGN:SummaryOfWarrantActivityTableTextBlock"><p id="xdx_898_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6GUf15Mz9we" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zVoQ4hpIQza" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
                                                                                             <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Common Stock</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zblP58bGJTgk" title="Number of Shares, Warrants Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001704" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,046</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zAphciBbsr2g" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001706" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.12</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zVWAipJ9nxTk" title="Range of exercise price - beginning"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" id="Fact001708" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span> &#8212; $<span id="xdx_90A_ecustom--RangeOfExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zcrVGzRoA0U" title="Range of exercise price - beginning"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" id="Fact001710" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.40</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zATa9y3tLSWk" title="Weighted Average Remaining Life (Years) - outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" id="Fact001712" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1">1.73</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Granted to advisor and its designees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zABUY8DGxu79" title="Number of shares, warrants granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1714">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zaV5yahtMok5" title="Weighted average exercise price per share warrants granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1716">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_za5wV3NENpWk" title="Number of Shares, Warrants Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1718">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zyHYwqNDa7xl" title="Weighted average exercise price per share warrants exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1720">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsy6bu1YZI31" title="Number of Shares, Warrants Expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001722" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z07igXGcGk5d" title="Weighted average exercise price per share warrants expired" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001724" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_ecustom--RangeOfExercisePriceExpired_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zh3G3jVWMf69" title="Range of exercise price, expired"><ix:nonFraction name="QLGN:RangeOfExercisePriceExpired" contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001726" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1XLk7Se0jXc" title="Number of Shares, Warrants Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1728">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zoiiH9doHS5g" title="Weighted average exercise price per share warrants forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1730">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztLDDtjzLI24" title="Number of Shares, Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001732" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,046</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zvcMxxZlzkYc" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001734" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.69</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_909_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z65Y5bhD4Bb4" title="Range of exercise price - ending"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" id="Fact001736" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span> &#8212; $<span id="xdx_90B_ecustom--RangeOfExercisePriceOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zl74jsOcklha" title="Range of exercise price - ending"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" id="Fact001738" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.40</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfjVOPoa6mBi" title="Weighted Average Remaining Life (Years) - outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" id="Fact001740" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1">1.25</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziITM2nIy0Bc" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001742" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">119,046</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9I7XEbBX41" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001744" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.69</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zGpi0HjkqS9e" title="Range of exercise price, exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" id="Fact001746" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span> &#8212; $<span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z68Cyzk7jgb" title="Range of exercise price, exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" id="Fact001748" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.40</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zxMf8XuvRAxg" title="Weighted Average Remaining Life (Years) Exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" id="Fact001750" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">1.25</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zUyd0KSTciX2" title="Number of shares, warrants non-exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1752">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfeqZe9NdTp5" title="Weighted Average Exercise Price Per Share Non-Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1754">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zNklYsKDniK7" title="Range of Exercise Price, Non-Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1756">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -10pt; width: 36%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zhT8uY9khi6g" title="Number of Shares, Warrants Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001758" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,046</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3EkFTjq7eo4" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001760" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.20</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90A_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zM8mOXJfgBG7" title="Range of exercise price - beginning"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" id="Fact001762" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></span> &#8212; $<span id="xdx_90D_ecustom--RangeOfExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zqDFez1h6oFb" title="Range of exercise price - beginning"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" id="Fact001764" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.40</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zncdrQjLZiHj" title="Weighted Average Remaining Life (Years) - outstanding"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" id="Fact001766" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1">2.64</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Granted to advisor and its designees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4mYEWAlcD9d" title="Number of shares, warrants granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1768">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zn7zpQy6lX8c" title="Weighted average exercise price per share warrants granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1770">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGk8OwJR8lgk" title="Number of Shares, Warrants Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1772">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7Cl3FRLOAx3" title="Weighted average exercise price per share warrants exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1774">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zOHYQClIytwc" title="Number of Shares, Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1776">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGp4H3CPLHmb" title="Weighted average exercise price per share warrants expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1778">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zQFsnR4DvQ05" title="Number of Shares, Warrants Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1780">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zVGeXTuAvgMa" title="Weighted average exercise price per share warrants forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1782">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdmXJDFfiAc5" title="Number of Shares, Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001784" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,046</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zk2SAluuWPo2" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001786" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z21SEWJvbacf" title="Range of exercise price - ending"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" id="Fact001788" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span> &#8212; $<span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zi4vL1vjSsel" title="Range of exercise price - ending"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" id="Fact001790" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.40</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zS1GFYyy2eTk" title="Weighted Average Remaining Life (Years) - outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" id="Fact001792" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1">1.73</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7kgmnZyJDL3" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001794" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">179,046</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zzbLVt5DRJgf" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001796" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z66oet1uEKP5" title="Range of exercise price, exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" id="Fact001798" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>- $<span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zLYXiXmkFyui" title="Range of exercise price, exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" id="Fact001800" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.40</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zavWyHEIYK5l" title="Weighted Average Remaining Life (Years) Exercisable"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" id="Fact001802" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">1.73</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zO9vfILQfrI2" title="Number of shares, warrants non-exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMbWmp31gAJ8" title="Weighted Average Exercise Price Per Share Non-Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1806">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1kvtOKXwtP4" title="Range of Exercise Price, Non-Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1808">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A7_zo38110xVQ08" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">There
was $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zrX8NulCZstd" title="Compensation cost"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,945</ix:nonFraction></span> in compensation costs related to outstanding warrants for the year ended December 31, 2023 and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqB81TWujB54" title="Compensation cost"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember" id="Fact001812" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,370</ix:nonFraction></span> for the year
ended December 31, 2022. As of December 31, 2023 and December 31, 2022, there was <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlf1IIJEmkXj" title="Unrecognized compensation cost related to nonvested"><span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHmeMbRvRsYj" title="Unrecognized compensation cost related to nonvested"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact001814" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact001816" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> unrecognized compensation cost related to nonvested
warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Noncompensatory
Equity Classified Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to Alpha (a related party) for the
purchase of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zzQVYo7vfJJ9" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" id="Fact001818" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,048</ix:nonFraction></span> reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zu4Tmmpb8Id5" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" id="Fact001820" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></span> per share
(of which warrants for <span id="xdx_903_ecustom--WarrantsExercised_pid_c20201201__20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zpbYVDRcGhId" title="Warrants exercised"><ix:nonFraction name="QLGN:WarrantsExercised" contextRef="From2020-12-012020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" id="Fact001822" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> shares were subsequently exercised in December 2020). In July 2020 the Company issued noncompensatory equity
classified warrants to Alpha for the purchase of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z2XOLcPgyFki" title="Warrants purchased"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember" id="Fact001824" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,019</ix:nonFraction></span> reverse split adjusted shares of Company common stock at a reverse split
adjusted exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z5rA4ikxSTo" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember" id="Fact001826" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share (which were subsequently exercised in July 2020), and <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_ztz2ydT8N9rh" title="Class of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" id="Fact001828" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">192,068</ix:nonFraction></span> reverse split adjusted shares
of Company common stock at a reverse split adjusted exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zmUy60jbvmdg" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" id="Fact001830" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">52.50</ix:nonFraction></span> per share. In August 2020, the Company issued noncompensatory
equity classified warrants to Alpha for the purchase of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200831__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmpm4YzLcY01" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember_us-gaap_WarrantMember" id="Fact001832" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">128,783</ix:nonFraction></span> reverse split adjusted shares of Company common stock at a reverse
split adjusted exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200831__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZi8fPyl1nxh" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember_us-gaap_WarrantMember" id="Fact001834" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">60.00</ix:nonFraction></span> per share. In December 2020, the Company issued noncompensatory equity classified warrants to
Alpha for the purchase of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zd8zgoN5ezU3" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember" id="Fact001836" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> reverse split adjusted shares of Company common stock at a reverse split adjusted exercise
price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zrCioPMb5uF9" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember" id="Fact001838" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></span> per share (which were exercised in February 2021) and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20201231_zI2VMyaMLim1" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-12-31" id="Fact001840" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">219,101</ix:nonFraction></span> reverse split adjusted shares of Company common stock at
a reverse split adjusted exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20201231_zuwzuPLSE4d3" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31" id="Fact001842" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">40.70</ix:nonFraction></span> per share. In May 2022, the Company issued noncompensatory equity classified warrants
to Alpha for the purchase of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zBrDNpvbQL8d" title="Purchase of shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" id="Fact001844" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction></span> reverse split adjusted shares of Company common stock at a reverse split adjusted exercise
price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zQEuAIMh7A1f" title="Class of warrant or right, exercise"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" id="Fact001846" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 29, 2021, with the exception of the warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zvX0rMY85Rdk" title="Number of securities called by Each warrant or right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember" id="Fact001848" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,048</ix:nonFraction></span> reverse split adjusted shares of the Company&#8217;s common
stock at a reverse split adjusted exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhiB8i3YySk" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_WarrantMember" id="Fact001850" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></span> per share, the exercise prices of all outstanding warrants to purchase a total
of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zDKAPdIKLncb" title="Number of outstanding warrants to purchase, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember" id="Fact001852" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">539,951</ix:nonFraction></span> reverse split adjusted shares of the Company&#8217;s common stock were modified to a reverse split adjusted exercise price
of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z419J8Rk6vNj" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember" id="Fact001854" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span> per share and each of their remaining terms extended by six months. The fair value of the modification cost of these warrant
modifications of approximately $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20211129__20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zmOqfUomSUl9" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-11-292021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember" id="Fact001856" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.3</ix:nonFraction></span> million was charged to additional paid-in capital and did not result in expense on the Company&#8217;s
consolidated statements of operations and comprehensive loss. In May 2022, pre-funded warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zd5iP2ijhVWf" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" id="Fact001858" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction></span> reverse split adjusted
shares of the Company&#8217;s common stock at a reverse split adjusted exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zV8JVjwigXoj" title=" Exercise price of warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" id="Fact001860" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share with no expiration date were
issued to Alpha. These warrants were subsequently exercised in 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the NanoSynex Acquisition, on April 25, 2022 the exercise price of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zt6anm1UdZ34" title="Purchase of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-04-25_custom_NanosynexMember" id="Fact001862" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,048</ix:nonFraction></span>
reverse split adjusted outstanding warrants at $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_z1i8COC4aik7" title="Exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-25_custom_NanosynexMember" id="Fact001864" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></span>
was modified to a reverse split adjusted exercise price of $<span id="xdx_90C_ecustom--ModifiedToExercisePrice_iI_pid_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zByuF8VeXI44" title="Modified to exercise price"><ix:nonFraction name="QLGN:ModifiedToExercisePrice" contextRef="AsOf2022-04-25_custom_NanosynexMember" id="Fact001866" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span>.
The increase in fair value of $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20220425__20220425__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zP376pEeUFSl" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-04-252022-04-25_custom_NanosynexMember" id="Fact001868" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,533</ix:nonFraction></span>,
using a Monte Carlo pricing model for the modification of these warrants, was charged to additional paid-in capital and did not
result in expense on the Company&#8217;s consolidated statements of operations and comprehensive loss. On May 26, 2022, the reverse
split adjusted exercise price of these warrants was modified again to $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zq5hDeNKiAE5" title="Class of warrant or right, exercise"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-05-26_custom_NanosynexMember" id="Fact001870" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.136</ix:nonFraction></span>,
and the increase in fair value of $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20230526__20230526_zreq5GUJ0oLf" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-05-262023-05-26" id="Fact001872" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696</ix:nonFraction></span>,
using a Monte Carlo pricing model for the modification of these warrants, was included in consideration transferred in the NanoSynex
Acquisition. On December 22, 2022 the exercise price of these warrants was modified again to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zNQhfNL33gFi" title="Class of warrant or right, exercise"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_custom_NanosynexMember" id="Fact001874" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span>.
The increase in fair value of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20221222__20221222__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_z3Co7zbBG5gj" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-12-222022-12-22_custom_NanosynexMember" id="Fact001876" format="ixt:numdotdecimal" decimals="0" unitRef="USD">891</ix:nonFraction></span>,
using a Monte Carlo pricing model for the modification of those warrants, was charged to additional paid-in capital and did not
result in expense on the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2023, the Company entered into an Amendment No. 1 with regard to Securities Purchase Agreement, with Alpha. This
Amendment amended two instruments which the Company issued under the Securities Purchase Agreement dated December 21, 2022: (a) the 8%
Senior Convertible Debenture dated December 22, 2022 in favor of Alpha, and (b) the Common Stock Purchase Warrant dated December
22, 2022 in favor of Alpha. The Amendment reduced the Conversion Price of the Debenture from $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zNQCYDt9tMC" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPriceDecrease" contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember" id="Fact001878" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span> per share to $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_zB5dR6kulR44" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPriceDecrease" contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember" id="Fact001880" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span>
per share (subject to possible future adjustment pursuant to the terms of the Debenture) and reduced the Exercise Price of the Alpha
Warrant from $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zB0NfVcoZzr1" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember" id="Fact001882" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></span> per share to $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_zkui0DYHTHO5" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember" id="Fact001884" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span> per share (subject to possible future adjustment pursuant to the terms of the Alpha Warrant). The
Amendment revised certain provisions of the Warrant which resulted in reclassification of the Warrant from liabilities to equity. For
more details see Note 7 - Warrant Liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember" escape="true" id="Fact001886" name="QLGN:SummaryOfWarrantActivityTableTextBlock"><p id="xdx_893_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zBR5N0UoTtm" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zWaJcYtP6cid" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zBrhwrtA08f5" title="Number of shares, warrants outstanding beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001888" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">547,003</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z16lgZwUetj" title="Weighted Average exercise price, warrants outstanding beginning" style="width: 12%; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001890" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.76</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6GP6w0701Se" title="Range of exercise price"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember" id="Fact001892" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span> - $<span id="xdx_90C_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zrjLOhUdlhJ1" title="Range of exercise price"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember" id="Fact001894" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6gEOFOhuxa1" title="Weighted average remaining life (Years) exercisable"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt-sec:duryear" id="Fact001896" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1">0.33</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Legacy Ritter warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z753JNxyM1al" title="Number of shares legal ritter warrants" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1898">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSJEhpZPXz7k" title="Weighted Average exercise price, legal ritter warrants" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1900">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Reclassification of Alpha Warrant from warrant liabilities to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zXLV6IWbAiWf" title="Number of shares, warrants reclassification of Alpha warrant from warrant liabilities to equity" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203" id="Fact001902" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zcoxUHSQUkW1" title="Weighted Average exercise price, reclassification of Alpha warrant from warrant liabilities to equity" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203" id="Fact001904" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6JkInoHrxci" title="Range of exercise price, reclassification of Alpha warrant from warrant liabilities to equity"><ix:nonFraction name="QLGN:RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001906" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zXc9CV8ffE54" title="Number of Shares, Warrants Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1908">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfE1qxUbr91" title="Weighted average exercise price, warrants exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1910">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zyu7TMkrjFw" title="Number of Shares, Warrants Expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203" id="Fact001912" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">539,953</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSctCIyTwZT9" title="Weighted average exercise price, warrants expired" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203" id="Fact001914" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMLIYRkHsNGk" title="Range of exercise price, expired"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001916" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z255AwZBtLR" title="Number of Shares, Warrants Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1918">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zc54vnC1hR5b" title="Weighted average exercise price, warrants forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1920">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zNDjU6eYyCmc" title="Number of shares, warrants outstanding ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001922" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,507,050</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwuIMebw57Nf" title="Weighted Average exercise price, warrants outstanding ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001924" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zn3TozeyExo7" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001926" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,507,050</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zphXwBoGbAQa" title="Weighted average exercise price, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001928" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zQg5veEAr0a1" title="Range of exercise price, exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001930" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z0XUjsjeZ0H3" title="Weighted average remaining life (Years) exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203" format="ixt-sec:duryear" id="Fact001932" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">4.47</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGEjBufrUuo3" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1934">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuZLFbaOM9a6" title="Weighted average exercise price, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1936">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211; Average Exercise
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zO7Cg7lGZ0T9" title="Number of shares, warrants outstanding beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001938" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">554,914</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zg0hga9tUFDj" title="Weighted average exercise price, warrants outstanding beginning" style="width: 12%; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001940" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUg4iabg9xKe" title="Range of exercise price"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2021-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember" id="Fact001942" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.10</ix:nonFraction></span>&#8212; <span id="xdx_90E_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zT1SmbA6nB61" title="Range of exercise price"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2021-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember" id="Fact001944" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.78</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zoksFYh7JX2g" title="Weighted average remaining life (Years) exercisable"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt-sec:duryear" id="Fact001946" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1">1.32</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Legacy Ritter warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z3DaDuZucKPb" title="Number of shares legal ritter warrants" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1948">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zO6BRIKiu9Yi" title="Weighted average exercise price, legal ritter warrants" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1950">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJHb6Nismj6g" title="Number of shares, warrants granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001952" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zLMahoHMM1Ag" title="Weighted average exercise price, warrants granted" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001954" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--RangeOfExercisePriceExercisableGranted_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZn1SgKiH9h8" title="Range of exercise price, granted"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableGranted" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001956" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgFA4ipoXUD2" title="Number of Shares, Warrants Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001958" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zjS2TWnu8HI3" title="Weighted average exercise price, warrants exercised" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001960" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePriceExercised_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfUq2hkkhWSh" title="Range of exercise price, exercised"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercised" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001962" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTUse044gCFk" title="Number of Shares, Warrants Expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001964" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,911</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zpLxlMN7pXK6" title="Weighted average exercise price, warrants expired" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001966" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePriceExercisableExpired_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSPSLF3Ce2dg" title="Range of exercise price, expired"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableExpired" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001968" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.78</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJXpTgZPuKHk" title="Number of Shares, Warrants Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1970">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zh0txminHaOl" title="Weighted average exercise price, warrants forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1972">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_ecustom--RangeOfExercisePriceForfeited_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z8tIuIDKsdY8" title="Range of exercise price, forfeited"><ix:nonFraction name="QLGN:RangeOfExercisePriceForfeited" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001974" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdXwh1vfSNjd" title="Number of shares, warrants outstanding ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001976" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">547,003</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgxS2qW5u3X5" title="Weighted average exercise price, warrants outstanding ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001978" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.76</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zbnws0F622Z" title="Range of exercise price"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember" id="Fact001980" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span> - <span id="xdx_906_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJe2u5fV8yJ6" title="Range of exercise price"><ix:nonFraction name="QLGN:RangeOfExercisePriceOutstanding" contextRef="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember" id="Fact001982" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zL8m6zhtMyU9" title="Weighted average remaining life (Years) exercisable"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt-sec:duryear" id="Fact001984" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1">0.33</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuBf0CI8zkRj" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001986" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">547,003</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwGx9fu8t437" title="Weighted average exercise price, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember" id="Fact001988" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.76</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zrfdrjj9x2b" title="Range of exercise price, exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember" id="Fact001990" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.32</ix:nonFraction></span> - <span id="xdx_908_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zHgslEXoYM7h" title="Range of exercise price - Exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember" id="Fact001992" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.00</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZvOqXPsGhT7" title="Weighted average remaining life (Years) exercisable"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt-sec:duryear" id="Fact001994" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">0.33</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxV5nkyftnZi" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1996">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zPfNZv7sMpv3" title="Weighted average exercise price, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1998">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zkPWLd4VQhp3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact002000" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zsCa2udMVYug" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8212; <span id="xdx_823_zxb0Y46TjKI6">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Debt</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 8 &#8211; Convertible Debt &#8211; Related Party for additional information concerning convertible debt &#8211; related party
transactions. On December 22, 2022, the Company issued to Alpha, an <span id="xdx_900_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zHrR5fn6Fovb" title="Senior convertible debenture rate"><ix:nonFraction name="us-gaap:ShortTermDebtInterestRateIncrease" contextRef="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" id="Fact002002" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%
Senior Convertible Debenture in the aggregate principal amount of $<span id="xdx_905_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_znva6CQlRlx4" title="Principal amount"><ix:nonFraction name="us-gaap:SecuredDebt" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" id="Fact002004" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,300,000</ix:nonFraction></span>
for a purchase price of $<span id="xdx_900_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zPMhZnl4aWr2" title="Purchase Price"><ix:nonFraction name="QLGN:PurchasePrice" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" id="Fact002006" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>
pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. As of December 31, 2023 the Debenture had a
remaining principal balance of $<span id="xdx_90B_eus-gaap--SecuredDebt_iI_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zcwEnj3Z8fC9" title="Principal amount"><ix:nonFraction name="us-gaap:SecuredDebt" contextRef="AsOf2023-12-31_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" id="Fact002008" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,418,922</ix:nonFraction></span>,
and was convertible, at any time, and from time to time, at Alpha&#8217;s option, into shares of common stock of the Company, at a
price equal to $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zdyXAhxZRHe8" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-12-31_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember" id="Fact002010" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span>
per share, subject to adjustment as described in the Debenture and other terms and conditions described in the Debenture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
on December 22, 2022, in conjunction with the issuance of the Debenture to Alpha, the Company issued to Alpha the Alpha
Warrant to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z8sfarcko6C3" title="Warrant to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember" id="Fact002012" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></span> shares of the Company&#8217;s common stock (the &#8220;Alpha Warrant&#8221;). As of December 31, 2023,
the exercise price of the Alpha Warrant was $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_znlmZKGazR41" title="Exercise price of warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-12-22_custom_AlphaCapitalMember" id="Fact002014" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.73</ix:nonFraction></span>. The Alpha Warrant may be exercised by Alpha, in whole or in part, at any time
before June 22, 2028, subject to certain terms and conditions described in the Alpha Warrant. The Alpha Warrant is included in equity
on the Company&#8217;s consolidated balance sheets (see Note 12 &#8211; Stockholders&#8217; Equity).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NanoSynex</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a Share Purchase Agreement dated April 29, 2022, the Company acquired <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220429__20220429__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z40TJa9X7eSj" title="Number of common stock acquired shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-04-292022-04-29_custom_NanoSynexLtdMember_custom_SeriesAOnePreferredStockMember" id="Fact002016" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,232,861</ix:nonFraction></span> shares of NanoSynex Series A-1 Preferred Stock from
Alpha in exchange for <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220429__20220429__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zPCdWz5fKSea" title="Number of common stock acquired shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2022-04-292022-04-29_custom_NanoSynexLtdMember" id="Fact002018" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> reverse split adjusted shares of the Company&#8217;s common stock and a prefunded warrant to purchase
<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220429__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zw0gIIuu5k42" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-04-29_custom_PrefundedWarrantMember" id="Fact002020" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,464</ix:nonFraction></span> reverse split adjusted shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220429__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zBxwYZBeQzrc" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-04-29_custom_PrefundedWarrantMember" id="Fact002022" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact002024" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zbT1rnyeVcif" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14 &#8212; <span id="xdx_82A_z8mcgtwwCItb">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact002026" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_znNnnEo4tKLd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents domestic and foreign components of consolidated loss before income taxes from continuing operations for the
periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8BC_zLVxJoxV0zt9" style="display: none">SCHEDULE
OF DOMESTIC AND FOREIGN COMPONENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zroRJrFub7S4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zTWpwWAqnQoi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zi07Z33bFCFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2023-01-01to2023-12-31" id="Fact002028" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,479,803</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2022-01-012022-12-31" id="Fact002029" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,887,914</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zLt9DRSh7xpk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2031">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2032">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zQ14WvxvlJa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss before provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" id="Fact002034" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,479,803</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact002035" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,887,914</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z918ZCezRllb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact002037" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zCwKsoCY7LYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory income tax rates and the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zJSrkVjWc5O4" style="display: none">SCHEDULE
OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_z8vka4fOhIJg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_z3Q4fMFAj0x6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zuGzWVPbb409" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Statutory federal income tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" id="Fact002039" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" id="Fact002040" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.00</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_zfIwNUKyYcia" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-01to2023-12-31" id="Fact002042" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.76</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31" id="Fact002043" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.50</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_maABC_zePFyfdYh9qb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" contextRef="From2023-01-01to2023-12-31" id="Fact002045" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.64</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" contextRef="From2022-01-012022-12-31" id="Fact002046" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.09</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_maABC_zvOKfgEE5Ia7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NOL expiration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" contextRef="From2023-01-01to2023-12-31" id="Fact002048" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">5.26</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" contextRef="From2022-01-012022-12-31" id="Fact002049" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">19.88</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_zbjEnCHJzTn4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2023-01-01to2023-12-31" id="Fact002051" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.92</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="From2022-01-012022-12-31" id="Fact002052" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3.71</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_maABC_z1D7Vrub6YEc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" contextRef="From2023-01-01to2023-12-31" id="Fact002054" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" contextRef="From2022-01-012022-12-31" id="Fact002055" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maABC_zWBv6eerD4l5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-01-01to2023-12-31" id="Fact002057" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-01-012022-12-31" id="Fact002058" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_pid_dp_uPure_maABC_zhe4RJi20f5e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" contextRef="From2023-01-01to2023-12-31" id="Fact002060" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.35</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" contextRef="From2022-01-012022-12-31" id="Fact002061" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_pid_dp_uPure_maABC_z3jsT0z4L993" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax impact of convertible debenture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" contextRef="From2023-01-01to2023-12-31" id="Fact002063" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">5.46</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" contextRef="From2022-01-012022-12-31" id="Fact002064" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.37</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_pid_dp_uPure_maABC_zKHOwMPbHVz3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax impact of divestiture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" contextRef="From2023-01-01to2023-12-31" id="Fact002066" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">229.26</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" contextRef="From2022-01-012022-12-31" id="Fact002067" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.01</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationTrueUp_pid_dp_uPure_maABC_z7WhUdWrI7Sa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>True-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationTrueUp" contextRef="From2023-01-01to2023-12-31" id="Fact002069" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">10.65</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:EffectiveIncomeTaxRateReconciliationTrueUp" contextRef="From2022-01-012022-12-31" id="Fact002070" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.24</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_zCt7BzuD2EFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-01to2023-12-31" id="Fact002072" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">222.28</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" id="Fact002073" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">17.91</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_mtABC_z59jjaWlBCb2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income taxes provision (benefit)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-01to2023-12-31" id="Fact002075" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.04</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-12-31" id="Fact002076" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.05</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zlhfMWSfWB73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact002078" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zHUvtkkhZDhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense for the year ended December 31, 2023 and 2022 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zZUShjraxBOk" style="display: none">SCHEDULE
OF PROVISION FOR INCOME TAXES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zVKL8yGFKLvd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_zuiJFykVdqQe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBz1MC_zmZ4dcINcYNd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">U.S. Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact002080" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2081">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBz1MC_zV7QvzcEmUPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">U.S. State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact002083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact002084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBz1MC_zE9wn5sLbkSg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total current provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact002086" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact002087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzCKf_zz2EpiDIeaM3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">U.S. Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact002089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,128,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact002090" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">236,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzCKf_zDJeFJdwOUX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">U.S. State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact002092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,697,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact002093" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,252,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzCKf_maITEBzWbu_z1ABCzTJbD76" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total deferred benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact002095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,825,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact002096" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,488,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzWbu_zU5dkRo9vuZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in valuation allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-01-01to2023-12-31" id="Fact002098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,825,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-01-012022-12-31" id="Fact002099" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,488,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3d_mtITEBzWbu_zPlvv7UdRbOc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total provision (benefit) for income taxes</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact002101" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact002102" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">7,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A2_z51p20xX4ET4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact002104" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zU271WlknDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of deferred tax assets and liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zRjLOzKUlSAh" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zo0eKliPjx44" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_zUhsCaslYAy2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTATDzYdX_zXgzvBZDbCC2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact002106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,644,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" id="Fact002107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,587,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTATDzYdX_zhEvn7CTUbf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact002109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,970,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-12-31" id="Fact002110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,857,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DefferdTaxAssetsAccruedExpenses_iI_maDTATDzYdX_zbl8ZIJmlpmi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DefferdTaxAssetsAccruedExpenses" contextRef="AsOf2023-12-31" id="Fact002112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DefferdTaxAssetsAccruedExpenses" contextRef="AsOf2022-12-31" id="Fact002113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,020,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTATDzYdX_zz9WMcVBhkIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Patent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2115">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2116">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTATDzYdX_zLOm9WndY0v1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact002118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,004,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" id="Fact002119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,069,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentExpenses_iI_maDTATDzYdX_zR0akY1zAry" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DeferredTaxAssetsResearchAndDevelopmentExpenses" contextRef="AsOf2023-12-31" id="Fact002121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,102,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:DeferredTaxAssetsResearchAndDevelopmentExpenses" contextRef="AsOf2022-12-31" id="Fact002122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,196,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTATDzYdX_zSinl3k6I6s6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2124">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="Fact002125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iTI_mtDTATDzYdX_maDTAGzJfc_z9gjg4N7CKhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total deferred income tax assets</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="AsOf2023-12-31" id="Fact002127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,788,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="AsOf2022-12-31" id="Fact002128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,009,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzOxa_zGB9JwhXUJRk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2130">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2022-12-31" id="Fact002131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_maDITLzOxa_zuj0yBDZZ4yh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Right-of-use asset</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2133">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="AsOf2022-12-31" id="Fact002134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">382,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzOxa_msDTAGzJfc_zonkDxVfkkZ4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total deferred income tax liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2136">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-12-31" id="Fact002137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">395,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJfc_maDTALNzbeu_zxiB9qCTVw0e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net deferred income tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact002139" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,788,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" id="Fact002140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,614,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzbeu_zeGtvy75BvAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact002142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,788,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" id="Fact002143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,614,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNTI_di_mtDTALNzbeu_zdG5p2mx3xAe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax asset, net of allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2145">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2146">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zhMBM80kDSg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the available objective evidence, including the Company&#8217;s history of cumulative losses, management believes it is likely that
the Company&#8217;s U.S. federal and state net deferred tax assets will not be realizable. Accordingly, the Company provided for a full
valuation allowance against its U.S. federal and state net deferred tax assets at December 31, 2023 and December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the full valuation allowance already in place on the Company&#8217;s U.S. federal and state net deferred tax assets, the Company does
not anticipate significant changes in the Company&#8217;s effective tax rate. However, there is no valuation allowance recorded against
the Company&#8217;s foreign net operating loss deferred tax assets, as the Company&#8217;s foreign IPR&amp;D deferred tax liabilities
and foreign net operating loss deferred tax assets are both indefinite-lived and thus they may be netted to arrive at a net foreign deferred
tax liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act resulted in significant changes to the treatment of research or experimental (&#8220;R&amp;E&#8221;) expenditures
under Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&amp;E expenditures
that are paid or incurred in connection with their trade or business which represent costs in the experimental or laboratory sense. Specifically,
costs for U.S. based R&amp;E activities must be amortized over five years and costs for foreign R&amp;E activities must be amortized
over 15 years; both using a midyear convention. The Company has incorporated the impact of this new tax legislation into its 2023 and
2022 consolidated financial statements, noting that the impact on the Company&#8217;s consolidated financial statements was immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company has U.S. federal and state net operating loss carryforwards of approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20231231_zY2Mbl5CiQo3" title="U.S. federal operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2023-12-31" id="Fact002148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,942,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20231231_zapUZGzk1bki" title="State operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2023-12-31" id="Fact002150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,693,000</ix:nonFraction></span>,
respectively, which are available to offset future taxable income. U.S. federal and state net operating loss carryovers began to expire
in 2020. As a result of the May 2020 reverse recapitalization, an ownership change has occurred. The Company has not completed an Internal
Revenue Code Section 382 analysis. As a result, there could be substantial limitations on the Company&#8217;s ability to utilize its
pre-ownership change net operating loss and tax credit carryforwards. These substantial limitations may result in both a permanent loss
of certain tax benefits related to net operating loss carryforwards and federal research and development credits, and an annual utilization
limitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has research and development credit carryforwards for federal and state tax purposes of approximately $<span id="xdx_902_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zIebNCmZ8608" title="Research and development credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact002152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,560,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zrpFbfYHE9I1" title="Research and development credit carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact002154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,410,000</ix:nonFraction></span>,
respectively. <span id="xdx_902_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_c20230101__20231231_zQhT2ePyxmil" title="Tax credit carryforward, limitations on use"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact002156" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse">The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite
life for state tax purposes</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
income tax has not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries
that is indefinitely reinvested outside the United States. This amount becomes taxable upon a repatriation of assets from the subsidiary
or a sale or liquidation of the subsidiary. Determination of the amount of any unrecognized deferred income tax liability on this temporary
difference is not practicable because of the complexities of the hypothetical calculation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files income tax returns in the U.S. federal jurisdiction and in various states. The Company&#8217;s U.S. federal income tax
returns remain subject to examination by the Internal Revenue Service. The Company&#8217;s California income tax returns remain subject
to examination by the California Franchise Tax Board. Due to net operating losses, research and development credits and other tax credit
carryforwards that may be utilized in future years, all U.S. federal and state tax years are open to examination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally
accepted accounting principles clarify the accounting for uncertainty in income taxes recognized in the Company&#8217;s financial statements
and prescribe thresholds for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax
return, and also provide guidance on de-recognition and measurement of a tax position taken or expected to be taken in a tax return.
The Company adopted these provisions effective April 1, 2009.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did <span id="xdx_909_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20231231_zBEjxnZLFxwd" title="Unrecognized tax benefits"><span id="xdx_900_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20221231_zR5qIRXeS3n6" title="Unrecognized tax benefits"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2023-12-31" id="Fact002158" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2022-12-31" id="Fact002160" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t have any unrecognized tax benefits as of December 31, 2023 and December 31, 2022 and does not expect this to change significantly
over the next 12 months. In accordance with generally accepted accounting principles, the Company will recognize interest and penalties
accrued on any unrecognized tax benefits as a component of income tax expense. As of December 31, 2023, the Company has not accrued any
interest or penalties related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact002162" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zlao3mNfPhG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 &#8212; <span id="xdx_826_zrMWVJ9CLbw6">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2024, the Company entered into a Securities Purchase Agreement (&#8220;Agreement&#8221;) with Alpha. The transactions
contemplated by the Agreement closed on February 27, 2024, at which time the Company delivered to Alpha the 2024 Debenture and the
2024 Warrant, as described below, and Alpha paid the Company a cash purchase price of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourDebentureAndWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJ6vRphEqjz3" title="Cash purchase price"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureAndWarrantMember_us-gaap_SubsequentEventMember" id="Fact002164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span>
(less $<span id="xdx_903_ecustom--ReimbursementExpenses_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourDebentureAndWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNea2Tid9vP2" title="Reimbursement expenses"><ix:nonFraction name="QLGN:ReimbursementExpenses" contextRef="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureAndWarrantMember_us-gaap_SubsequentEventMember" id="Fact002166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span>
for expense reimbursement). Pursuant to the Agreement, the Company issued to Alpha an 8% Convertible Debenture (the &#8220;2024
Debenture&#8221;) in the principal amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSGjOK5oxFO4" title="Principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember" id="Fact002168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,000</ix:nonFraction></span>.
The Debenture has a maturity date of <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrj2kxG5AzJk" title="Maturity date"><ix:nonNumeric contextRef="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember" format="ixt:datemonthdayyearen" id="Fact002170" name="us-gaap:DebtInstrumentMaturityDate">December
31, 2024</ix:nonNumeric></span> and is convertible, at any time, and from time to time, at Alpha&#8217;s option, into shares of common stock of the
Company, at $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zt0mDH2hYBt6" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember" id="Fact002172" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.6111</ix:nonFraction></span>
per share, subject to adjustment as described in the 2024 Debenture (the &#8220;Conversion Price&#8221;). The Debenture accrues
interest on its outstanding principal balance at the rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHp0piqUBawd" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember" id="Fact002174" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%
per annum. The 2024 Debenture does not call for scheduled payments of principal or interest before the scheduled maturity date of
December 31, 2024. Pursuant to the terms of the Agreement, the Company also issued to Alpha a 5-year common stock purchase warrant
(the &#8220;2024 Warrant&#8221;) to purchase (at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyFourWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvG5H1y2PZlb" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourWarrantMember_us-gaap_SubsequentEventMember" id="Fact002176" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.26</ix:nonFraction></span>
per share) <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyFourWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGkwqWb9Q8S6" title="Purchase of warrants for shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourWarrantMember_us-gaap_SubsequentEventMember" id="Fact002178" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">900,016</ix:nonFraction></span>
shares of common stock of the Company. Under the Agreement, Alpha also has an option, exercisable until July 1, 2024, to
purchase from the Company up to an additional $<span id="xdx_901_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmGym4aSzN7j" title="Principal amount increase decrease"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" contextRef="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember" id="Fact002180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,100,000</ix:nonFraction></span>
in principal amount of 2024 Debentures of like tenor, together with up to an additional <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyFourWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxOHAZj8cS3i" title="Purchase of shares increase decrease"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" contextRef="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourWarrantMember_us-gaap_SubsequentEventMember" id="Fact002182" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,800,032</ix:nonFraction></span>
2024 Warrants of like tenor, which would (if and when Alpha exercises such option) provide us up to an additional $<span id="xdx_903_ecustom--AdditionalProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourDebentureAndWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z45OZjJ06Td8" title="Additional cash proceeds"><ix:nonFraction name="QLGN:AdditionalProceedsFromIssuanceOrSaleOfEquity" contextRef="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureAndWarrantMember_us-gaap_SubsequentEventMember" id="Fact002184" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span>
million in cash proceeds (less expense reimbursement, and not including any possible cash proceeds from any future exercise of the
additional 2024 Warrants). We granted Alpha &#8220;piggyback&#8221; registration rights for the common shares underlying the
2024 Debenture and the 2024 Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_815_zH3REeQQZqYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_002"></span>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_003"></span>Item
9A. Controls and Procedures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of
our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2023,
the end of the year covered by this Annual Report. Based on this evaluation, our principal executive officer and principal financial
officer concluded that, as of December 31, 2023, our disclosure controls and procedures were effective. We believe that a disclosure
controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the disclosure controls
system are met, and no evaluation of disclosure controls can provide absolute assurance that all disclosure control issues, if any, within
a company have been detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Report on Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f)
and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with
the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes
in accordance with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, our management assessed the effectiveness of our internal control over financial reporting using the criteria set
forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework. Based on the
continuing material weakness described below, our management concluded that as of December 31, 2023, our internal control over financial
reporting was not effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
of Material Weaknesses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">In connection
with the audit of our financial statements as of and for the year ended December 31, 2023, we identified material weaknesses related to a lack of sufficient number of personnel within our accounting function
to adequately segregate duties, and we have not designed and implemented effective Information Technology General Controls (&#8220;ITGC&#8221;)
related to access controls to financial accounting systems.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We lack the resources to employ
additional personnel to help mitigate these material weaknesses and we foresee that these material weaknesses will not be remediated until we
receive additional funding to support our accounting department.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remediation
of Material Weakness</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We cannot assure you that these
or other measures will fully remediate the material weakness in a timely manner. Notwithstanding the identified material weakness, our
management believes that the consolidated financial statements included in this report fairly represent in all material respects our financial
condition, results of operations and cash flows at and for the periods presented in accordance with U.S. GAAP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described above, there were no changes in our internal control over financial reporting identified in management&#8217;s evaluation
pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the year ended December 31, 2023 that materially affected, or are
reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitation
on Effectiveness of Controls</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
designing and evaluating our controls and procedures, management recognized that any controls and procedures, no matter how well designed
and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. No evaluation of internal
control can provide absolute assurance that all internal control issues and instances of fraud, if any, within a company are detected.
In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit
relationship of possible controls and procedures. There are inherent limitations to the effectiveness of any system of disclosure controls
and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. In addition,
the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be
no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may
become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because
of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_004"></span>Item
9B. Other Information.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_005"></span>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.5pt; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_006"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_007"></span>Item
10. Directors, Executive Officers and Corporate Governance.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors currently consists of six members, each of whose current term of office as a director expires at the 2024 annual meeting
of stockholders. Biographical information with respect to our directors is provided below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors hold office for one year or until their respective successors have been duly elected or until their death, resignation or removal.
Our amended and restated bylaws provide that the authorized number of directors comprising our board of directors will be fixed, from
time to time, by a majority of the total number of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our directors or executive officers. There is no arrangement or understanding between any director
and any other person pursuant to which the director was selected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Position with the Company</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Age</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Director Since</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 29%; text-align: left">Michael Poirier</td><td style="width: 2%">&#160;</td>
    <td style="width: 30%; text-align: left">Chairman and Chief Executive Officer</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">68</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2020</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Richard David</td><td>&#160;</td>
    <td>Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2020</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sidney Emery, Jr.</td><td>&#160;</td>
    <td>Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2020</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Matthew Korenberg</td><td>&#160;</td>
    <td>Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2020</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Kurt Kruger</td><td>&#160;</td>
    <td>Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2020</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ira Ritter</td><td>&#160;</td>
    <td>Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2008</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Michael
S. Poirier</b>. Mr. Poirier founded the Qualigen business in 1996 and is its Chairman and Chief Executive Officer. Before founding Qualigen,
Mr. Poirier had relevant operating, marketing and sales positions with Ashirus Technologies, Inc., EnSys, Inc., Sanofi Pasteur and Abbott
Laboratories, Inc. Before working at Abbott, Mr. Poirier served as an officer in the United States Navy, assigned to the US Atlantic
Fleet. Mr. Poirier holds a B.A. from Providence College and attended the University of Z&#252;rich, Switzerland, School of Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Poirier&#8217;s commitment to our strategic goals, his long experience leading our company and his deep knowledge of its technologies
and business contributed to our board of directors&#8217; conclusion that he should serve as a director of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Richard
A. David, MD FACS</b>. Dr. David serves as Chief Medical Officer for the Los Angeles Division of Genesis Healthcare Partners, the largest
urology group in Southern California. He also serves as medical director for Genesis&#8217; Advanced Prostate Cancer Center of Excellence.
In addition, Dr. David serves as Clinical Professor of Urology for the David Geffen School of Medicine at UCLA. Dr. David obtained his
undergraduate education at Stanford University and his medical degree at Thomas Jefferson University in Philadelphia. He also holds a
Master&#8217;s degree in Medical Management (MMM) from the Marshall School of Business at the University of Southern California. He trained
in general surgery and completed his urology residency at UCLA Medical Center in Los Angeles. Dr. David is a fellow of the American College
of Surgeons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
David&#8217;s experience as an executive of a large healthcare organization, including his background as a medical doctor, contributed
to our board of directors&#8217; conclusion that he should serve as a director of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sidney
W. Emery, Jr.</b> Mr. Emery is a seasoned executive in manufacturing, distribution and supply chain management. He served as Chairman
and Chief Executive Officer of MTS Systems Corporation (Nasdaq-GS: MTSC), a leading global supplier of mechanical testing systems and
high-performance industrial position sensors. Mr. Emery served on the Board of Directors of Allete, Inc. (NYSE: ALE), a Minnesota-based
utilities and energy company, from 2006 to 2018. Mr. Emery chairs the University of St. Thomas College of Engineering Board of Governors.
Mr. Emery holds a PhD in Industrial Engineering from Stanford University and a B.S. in Engineering from the US Naval Academy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Emery&#8217;s extensive board service with and executive leadership of major companies contributed to our board of directors&#8217; conclusion
that he should serve as a director of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Matthew
E. Korenberg</b>. Mr. Korenberg has served as President and Chief Operating Officer of Ligand Pharmaceuticals Incorporated (Nasdaq: LGND),
a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines,
since November 2022, and before that as Executive Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated
since August 2015. Before joining Ligand, commencing in September 2013, Mr. Korenberg was the founder, Chief Executive Officer and a
director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial
focus on Down syndrome. Before founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare
investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg
was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and
San Francisco. Before Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read &amp; Co. Inc. where he spent two
years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds
a B.B.A. in Finance and Accounting from the University of Michigan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Korenberg&#8217;s financial and accounting expertise, his experience as chief financial officer of a large public biopharmaceutical company
and his investment banking background contributed to our board of directors&#8217; conclusion that he should serve as a director of our
company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Kurt
H. Kruger</b>. Mr. Kruger has enjoyed a 30-year career in medical technology. His deep involvement in the field has ranged from product
design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an
equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the
first-ever implantable defibrillator. As a securities analyst he led Hambrecht &amp; Quist&#8217;s efforts in providing venture funds
for, and then taking public, Ventritex, which was later acquired by St. Jude Medical/Abbott. After H&amp;Q, Mr. Kruger worked as an analyst
for Montgomery Securities and Bank of America. Across 20 years of research work, Mr. Kruger has overseen the IPOs of over 30 medical
products companies. Later he headed up the Life Sciences banking effort for WR Hambrecht &amp; Co. Mr. Kruger received a Sc.B. degree
in Biomedical Engineering from Brown University; a Master&#8217;s degree in Bioengineering from the University of Michigan; and a business
degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate
program at Columbia University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Kruger&#8217;s long experience in investment banking and securities analysis with a life sciences focus contributed to our board of directors&#8217;
conclusion that he should serve as a director of our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ira
E. Ritter.</b> Mr. Ritter served as Co-Founder, Chief Strategic Officer and Executive Chairman of the Company during its Ritter Pharmaceuticals,
Inc. phase, from its inception in 2004 through the formation of the Ritter Pharmaceuticals, Inc. corporate entity in 2008 and served
in those positions with Ritter Pharmaceuticals, Inc. from 2008 until the May 22, 2020 reverse recapitalization transaction (the &#8220;Reverse
Recapitalization Transaction&#8221;) in which Ritter Pharmaceuticals, Inc. changed its name to Qualigen Therapeutics, Inc. Mr. Ritter
has extensive experience creating and building diverse business enterprises and since 1987 through Andela Corporation, of which he is
the CEO, has provided corporate management, strategic planning and financial consulting for a wide range of market segments including;
health product related national distribution and private label production, television and publishing. He assisted taking Ritter Pharmaceuticals,
Inc. public on Nasdaq and Martin Lawrence Art Galleries public on the New York Stock Exchange. Since 2010, Mr. Ritter has also acted
as a managing partner of Stonehenge Partners, LLC. Mr. Ritter has a long history of public service that includes appointments by three
Governors to several State of California Commissions including eight years as Commissioner on the California Prison Industry Authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Ritter&#8217;s experience as an entrepreneur and chairman of a publicly traded development-phase therapeutics company contributed to
our board of directors&#8217; conclusion that he should serve as a director of our company. Mr. Ritter continued his service on our board
of directors, by agreement in connection with the Reverse Recapitalization Transaction, as the designated legacy member from the pre-Reverse
Recapitalization Transaction public-company board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of the Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee.
Each committee operates under a charter. Copies of each committee&#8217;s charter are posted on the Investor Relations section of our
website, which is located at <i>www.qlgntx.com</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b>. The current members of our Audit Committee are Mr. Kruger (Chair), Mr. Emery, and Mr. Korenberg, each of whom was
determined by our board of directors to be independent under Rule 10A-3 under the Exchange Act and the continued listing requirements
of Nasdaq, and to satisfy the other continued listing requirements of Nasdaq for audit committee membership. The Company has identified
Matthew Korenberg as an &#8220;audit committee financial expert&#8221; as such term is defined in Item 407(d)(5) of SEC Regulation S-K,
and has determined that he has the requisite level of financial sophistication required by the continued listing requirements of Nasdaq;
this identification does not constitute a determination that other members of the Audit Committee would not also be able to qualify as
an &#8220;audit committee financial expert.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXECUTIVE
<span style="text-transform: uppercase">OFFICERS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information about our current executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Age</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Position with the Company</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left">Michael Poirier</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 8%; text-align: center">68</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 66%; text-align: left">Chairman and Chief Executive Officer</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Christopher Lotz</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Chief Financial Officer, Vice President of Finance</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Officers
serve at the discretion of the board of directors. There are no family relationships among any of our directors or executive officers.
There is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was
selected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the biography of Mr. Poirier, please see &#8220;Board of Directors&#8221; above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Christopher
L. Lotz</b> | Chief Financial Officer, Vice President of Finance. Mr. Lotz joined Qualigen, Inc. as Director of Finance in 2002 and was
promoted to his current role of Chief Financial Officer, Vice President of Finance in 2003. He became an officer of the Company at the
time of the Reverse Recapitalization Transaction in 2020. Before joining Qualigen, Inc. Mr. Lotz spent the previous 15 years serving
in financial leadership positions with Bexcom, an Asian-based software developer, California Furniture Collections, Inc., a custom furniture
manufacturer, and Group Publishing, Inc., an educational media publisher. Mr. Lotz holds a B.S. in Business Administration from Colorado
State University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delinquent
Section 16(a) Reports</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires the Company&#8217;s officers and directors, and persons who own more than 10% of our common stock,
to file reports of securities ownership and changes in such ownership with the SEC. Officers, directors, and greater than 10% stockholders
also are required by SEC rules to furnish the Company with copies of all Section 16(a) forms they file.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
solely on the Company&#8217;s review of Forms 3, 4 and 5 filed by such persons and information provided by the Company&#8217;s directors
and officers, the Company believes that during the year ended December 31, 2023, all Section 16(a) filing requirements applicable to
such persons were met in a timely manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_008"></span>Item
11. Executive Compensation.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 58.5pt; text-align: justify; text-indent: -58.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table (2023 and 2022)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the compensation paid to or earned by our named executive officers for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Name and Principal Position</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">&#8220;Year&#8221;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Salary <br/>($)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Bonus <br/>($)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option Awards<sup>(1)</sup></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($)</span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All Other Compensation<sup>(2)</sup></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($)</span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total <br/>($)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left">Michael Poirier, Chairman and Chief Executive Officer</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 7%; text-align: center">2023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">512,635</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">118,174</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,889</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">632,698</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">575,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,180</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">728,454</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tariq Arshad, Former Chief
    Medical Officer and Senior Vice President <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">356,615</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,231</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">463,172</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,512</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">138</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">439,650</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="margin: 0">Amy Broidrick, Former President, Chief Strategy and Operating Officer<sup>(4)</sup></p></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">194,017</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">371,454</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">565,470</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,359</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,642</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">508,001</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            amounts reported in this column reflect the aggregate grant date fair value of the option
                                            awards granted during  2022, computed in accordance with Financial Accounting Standards
                                            Board Accounting Standards Codification Topic 718 for stock-based compensation transactions
                                            (&#8220;ASC 718&#8221;). Such grant date fair values do not take into account any estimated
                                            forfeitures related to service-based vesting conditions. Assumptions used in the calculation
                                            of these amounts are included in the notes to our consolidated financial statements included
                                            in this Annual Report. These amounts do not reflect the actual economic value that may be
                                            realized by the executive officers upon the exercise of the stock options or the sale of
                                            the common stock underlying such stock options. There were no option awards granted during 2023.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amounts reported in this column represent
                                            401(k) matching contributions and life insurance premiums paid by us for Mr. Poirier and Dr. Arshad, and $1,316 in 401(k) matching contributions and life insurance premiums paid by us for Ms. Broidrick,
and $370,138 in severance compensation for Ms. Broidrick.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
                                            Arshad resigned from his role as Chief Medical Officer and Senior Vice President effective
                                            February 25, 2024.</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">(4)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Ms. Broidrick resigned from her role as President, Chief
                                                                                                                             Strategy and Operating Officer and as a Director effective June 16, 2023. The 2023 &#8220;Salary&#8221; for Ms. Broidrick includes
                                                                                                                             amounts we paid through June 16, 2023. The 2023 &#8220;All Other Compensation&#8221; for Ms. Broidrick includes $370,138 of severance compensation.</td></tr>
                                                                               </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Employment Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Michael Poirier</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Poirier is party to an Executive Employment Agreement dated February 1, 2017, as amended January 9, 2018 (the &#8220;Poirier
Employment Agreement&#8221;). The Poirier Employment Agreement had an initial three-year term and is now automatically renewed for successive
one-year periods unless either party gives notice of nonrenewal at least 90 days before the end of such a one-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Poirier Employment Agreement, Mr. Poirier is entitled to an annual base salary of at least $315,000, is eligible to
participate in the Company&#8217;s bonus plans, benefit programs and medical benefits, is eligible for certain event-based bonuses (including
for &#8220;Liquidity Event&#8221; acquisition transactions), and is entitled to four weeks of vacation per year. If Mr. Poirier&#8217;s
employment is terminated without Cause or he resigns for Good Reason (as such terms are defined in the Poirier Employment Agreement),
and he provides a general release to the Company, he will be entitled to one year of salary continuation plus the cost of COBRA coverage
continuation for such one year period. In May 2021, our board of directors and its compensation committee increased Mr. Poirier&#8217;s
annual base salary to $575,000. On January 13, 2023, the Company&#8217;s board of directors, as part of certain cost-cutting measures,
approved a temporary 20% reduction to the base salaries of all executive officers of the Company. Accordingly, on January 16, 2023, Mr.
Poirier&#8217;s base salary was reduced to $460,000; it was subsequently restored in August 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Christopher Lotz</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Lotz is party to an Executive Employment Agreement dated February 1, 2017, as amended January 9, 2018 (the &#8220;Lotz
Employment Agreement&#8221;). The Lotz Employment Agreement had an initial three-year term and is now automatically renewed for successive
one-year periods unless either party gives notice of nonrenewal at least 90 days before the end of such a one-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Lotz Employment Agreement, Mr. Lotz is entitled to an annual base salary of at least $225,000, is eligible to participate
in the Company&#8217;s bonus plans, benefit programs and medical benefits, is eligible for certain event-based bonuses (including for
&#8220;Liquidity Event&#8221; acquisition transactions), and is entitled to four weeks of vacation per year. If Mr. Lotz&#8217;s employment
is terminated without Cause or he resigns for Good Reason (as such terms are defined in the Lotz Employment Agreement), and he provides
a general release to the Company, he will be entitled to 180 days of salary continuation plus the cost of COBRA coverage continuation
for such 180 day period. In May 2021, our board of directors and its compensation committee increased Mr. Lotz&#8217;s annual base salary
to $300,000. On January 13, 2023, the Company&#8217;s board of directors, as part of certain cost-cutting measures, approved a temporary
20% reduction to the base salaries of all executive officers of the Company. Accordingly, on January 16, 2023, Mr. Lotz&#8217;s base
salary was reduced to $240,000; it was subsequently restored in August 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Offer
Letter with Tariq Arshad</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of his hire offer letter with the Company, dated May 17, 2021, Dr. Arshad was entitled to an annual base salary of at
least $400,000. He received a cash signing bonus of $25,000 when he joined the Company, was eligible to receive annual cash bonuses
equal to an amount up to 40% of his annualized base salary, and is entitled to four weeks of vacation per year. Under the terms of
his hire offer letter, if Dr. Arshad&#8217;s employment is terminated without Cause or he resigns for Good Reason, and he provides a
general release to the Company, he will be entitled to 180 days of salary continuation plus the cost of COBRA coverage continuation
for such 180 day period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 25, 2024, Dr. Arshad resigned from his position as the Company&#8217;s Chief Medical Officer and Senior Vice President. He
did not assert that the resignation was for Good Reason and he did not provide a general release to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employment Agreement with Amy Broidrick</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Ms. Broidrick was party to an Executive
Employment Agreement with Qualigen, Inc., a former wholly-owned subsidiary of the Company, dated December 10, 2021. On May 16, 2023,
Ms. Broidrick resigned from all officer and director positions with the Company and its subsidiaries, which became effective June
16, 2023 (the &#8220;Separation Date&#8221;). Ms. Broidrick&#8217;s departure was not related to any disagreement with the Company
on any matter relating to the Company&#8217;s operations, policies, or practices. In connection with her termination of employment,
on June 20, 2023, Qualigen, Inc, entered into a separation agreement and general release with Ms. Broidrick, which became effective
after a 7 day revocation period following Ms. Broidrick&#8217;s signing of it, on June 24, 2023. Under the terms of the Separation
Agreement, Qualigen, Inc. was obligated to provide Ms. Broidrick severance in the form of continued salary pay at the rate then in
effect on the Separation Date ($360,000 per annum) for a period of 12 months following the Separation Date, subject to applicable
withholding, and payment or reimbursement for the cost of COBRA continuation medical and dental insurance coverage for 12 months
following the Separation Date, less any required taxes or withholdings. Upon the July 20, 2023 closing of our sale of Qualigen,
Inc., Chembio (as the new parent company of Qualigen, Inc.) undertook the remaining severance liability to Ms. Broidrick.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock
Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material terms of our 2020 Stock Equity Incentive Plan (as amended, the &#8220;2020 Plan&#8221;) are outlined below. This summary is
qualified in its entirety by reference to the complete text of the 2020 Plan, which is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Authorized
Shares</i>. We have reserved an aggregate of 755,702 shares of our common stock for issuance under the 2020 Plan. The number of shares
is subject to adjustment in the event of any recapitalization, stock split, reclassification, stock dividend or other change in our capitalization.
In addition, the following shares of our common stock will be available for grant and issuance under the 2020 Plan:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            subject to stock options or stock appreciation rights (&#8220;SARs&#8221;), granted under
                                            the 2020 Plan that cease to be subject to the stock option or SAR for any reason other than
                                            exercise of the stock option or SAR;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            subject to awards granted under the 2020 Plan that are subsequently forfeited or repurchased
                                            by us at the original issue price;</span></td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            subject to awards granted under the 2020 Plan that otherwise terminate without shares being
                                            issued;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            surrendered, canceled, or exchanged for cash or a different award (or combination thereof);
                                            and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            subject to awards under the 2020 Plan that are used to pay the exercise price of an award
                                            or withheld to satisfy the tax withholding obligations related to any award.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Plan
Administration</i>. The 2020 Plan will be administered by our Compensation Committee or by our board of directors acting in place of
our Compensation Committee. Our Compensation Committee will have the authority to construe and interpret the 2020 Plan, grant awards
and make all other determinations necessary or advisable for the administration of the 2020 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Awards
and Eligible Participants</i>. The 2020 Plan authorizes the award of stock options, stock appreciation rights, restricted stock unit,
performance awards and stock bonuses. The 2020 Plan provides for the grant of awards to our employees, directors, consultants and independent
contractor service providers, subject to certain exceptions. No non-employee director may be granted awards under the 2020 Plan in any
calendar year that, taken together with any cash fees paid by us to such non-employee director during such calendar year, exceed $5,000,000
(calculating the value of any award based on the grant date fair value determined in accordance with GAAP). No more than 98,000,000 shares
of our common stock will be issued under the 2020 Plan pursuant to the exercise of incentive stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i>. The 2020 Plan permits us to grant incentive stock options and non-qualified stock options. The exercise price of stock options
will be determined by our Compensation Committee, and may not be less than 100% of the fair market value of our common stock on the date
of grant. Our Compensation Committee has the authority to reprice any outstanding stock option (by reducing the exercise price, or canceling
the stock option in exchange for cash or another equity award) under the 2020 Plan without the approval of our stockholders. Stock options
may vest based on the passage of time or the achievement of performance conditions in the discretion of our compensation committee. Our
Compensation Committee may provide for stock options to be exercised only as they vest or to be immediately exercisable with any shares
issued on exercise being subject to our right of repurchase that lapses as the shares vest. The maximum term of stock options granted
under the 2020 Plan is 10 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Appreciation Rights</i>. SARs provide for a payment to the holder, in cash or shares of our common stock, based upon the difference between
the fair market value of our common stock on the date of exercise and the stated exercise price on the date of grant, up to a maximum
amount of cash or number of shares. SARs may vest based on the passage of time or the achievement of performance conditions in the discretion
of our Compensation Committee. Our Compensation Committee has the authority to reprice any outstanding SAR (by reducing the exercise
price, or canceling the SAR in exchange for cash or another equity award) under the 2020 Plan without the approval of our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Awards</i>. A restricted stock award represents the issuance to the holder of shares of our common stock, subject to the forfeiture
of those shares in the event of failure to achieve certain performance conditions or termination of employment. The purchase price, if
any, for the shares will be determined by our Compensation Committee. Unless otherwise determined by the administrator at the time of
award, vesting will cease on the date the holder no longer provides services to us and unvested shares will be forfeited to us or can
be repurchased by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Units</i>. Restricted stock units (&#8220;RSUs&#8221;) represent the right on the part of the holder to receive shares of our common
stock at a specified date in the future, subject to forfeiture of that right in the event of failure to achieve certain performance conditions
or termination of employment. If a RSU has not been forfeited, then, on the specified date, we will deliver to the holder of the RSU
shares of our common stock, cash or a combination of cash and shares of our common stock, as previously determined by the Compensation
Committee at the time of the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Awards</i>. Performance awards cover a number of shares of our common stock that may be settled upon achievement of performance conditions
as provided in the 2020 Plan in cash or by issuance of the underlying common stock. These awards are subject to forfeiture before settlement
in the event of failure to achieve certain performance conditions or termination of employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Bonuses</i>. Stock bonuses may be granted as additional compensation for past or future service or performance and, therefore, no payment
will be required from a participant for any shares awarded under a stock bonus. Unless otherwise determined by our Compensation Committee
at the time of award, vesting will cease on the date the holder no longer provides services to us and unvested shares will be forfeited
to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Change-in-Control</i>.
If we are party to a merger or consolidation, sale of all or substantially all our assets or similar change-in-control transaction, outstanding
awards, including any vesting provisions, may be assumed or substituted by the successor company. In the alternative, the successor company
may issue, in place of outstanding shares held by a 2020 Plan participant, substantially similar shares or other property subject to
repurchase obligations no less favorable to the participant. Outstanding awards that are not assumed, substituted or cashed out will
accelerate in full and expire immediately before the transaction, and awards will be exercisable for a period of time determined by the
administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendment;
Termination</i>. The 2020 Plan will terminate 10 years from April 8, 2020, unless it is terminated earlier by our board of directors.
Our board of directors may amend, suspend or terminate the 2020 Plan at any time, subject to compliance with applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Federal
Income Tax Summary</i>. The following is a brief summary of the principal federal income tax consequences to us and to an eligible person
(who is a citizen or resident of the United States for U.S. federal income tax purposes) (a &#8220;Participant&#8221;) of awards that
may be granted under the 2020 Plan. The summary is not intended to be exhaustive and, among other things, does not describe state, local
or foreign tax consequences. The federal income tax consequences of an eligible person&#8217;s award under the 2020 Plan are complex,
are subject to change and differ from person to person. Each person should consult with his or her own tax adviser as to his or her own
particular situation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion is based on the Code, Treasury Regulations promulgated under the Code, Internal Revenue Service rulings, judicial decisions
and administrative rulings as of the date of this proxy statement, all of which are subject to change or differing interpretations, including
changes and interpretations with retroactive effect. No assurance can be given that the tax treatment described herein will remain unchanged
at the time that awards under the 2020 Plan are made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Participant will not recognize income upon the grant of an option or at any time prior to the exercise of the option. At the time the
participant exercises a non-qualified option, he or she will recognize compensation taxable as ordinary income in an amount equal to
the excess of the fair market value of the common stock on the date the option is exercised over the price paid for the common stock,
and we will then be entitled to a corresponding deduction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Participant who exercises an incentive stock option will not be taxed at the time he or she exercises his or her options or a portion
thereof. Instead, he or she will be taxed at the time he or she sells the common stock purchased pursuant to the option. The Participant
will be taxed on the excess of the amount for which he or she sells the stock over the price he or she had paid for the stock. If the
Participant does not sell the stock prior to two years from the date of grant of the option and one year from the date the stock is transferred
to him or her upon exercise, the gain will be capital gain and we will not get a corresponding deduction. If the Participant sells the
stock at a gain prior to that time, the difference between the amount the Participant paid for the stock and the lesser of the fair market
value on the date of the exercise or the amount for which the stock is sold, will be taxed as ordinary income and we will be entitled
to a corresponding deduction. If the Participant sells the stock for less than the amount he or she paid for the stock prior to the one
or two year periods indicated, no amount will be taxed as ordinary income and the loss will be taxed as a capital loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Participant generally will not recognize income upon the grant of a stock appreciation right or a restricted stock unit. At the time
a Participant receives shares or cash payment under any such award, he or she generally will recognize compensation taxable as ordinary
income in an amount equal to the cash or the fair market value of the common stock received, less any amount paid for the stock, and
we will then be entitled to a corresponding deduction. Upon a subsequent sale of the shares received under the stock appreciation right
or restricted stock unit, if any, the difference between the amount realized on the sale and the Participant&#8217;s tax basis (the amount
previously included in income) is generally taxable as a capital gain or loss, which will be short-term or long-term depending on the
Participant&#8217;s holding time of such shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
taxation of restricted stock is dependent on the actions taken by the Participant. Generally, absent an election to be taxed currently
under Section 83(b) of the Code, or an 83(b) election, there will be no federal income tax consequences to the Participant upon the grant
of a restricted stock award. At the lapse of the restrictions or satisfaction of the conditions on the restricted stock, the Participant
will recognize ordinary income equal to the fair market value of our common stock at that time. If the Participant makes an 83(b) election
within 30 days of the date of grant, he or she will recognize ordinary income equal to the fair market value of our common stock at the
time of grant, determined without regard to the applicable restrictions. If an 83(b) election is made, no additional income will be recognized
by the Participant upon the lapse of the restrictions or satisfaction of the conditions on the restricted stock award. We generally should
be entitled to a deduction equal to the amount of ordinary income recognized by the Participant, at the same time as the ordinary income
is recognized by the Participant. Upon a subsequent sale of the formerly restricted stock, the difference between the amount realized
on the sale and the Participant&#8217;s tax basis (the amount previously included in income) is generally taxable as a capital gain or
loss, which will be short-term or long-term depending on the Participant&#8217;s holding time of such shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax consequences to Participants who receive performance-based awards depend on the particular type of award issued. Our ability to take
a deduction for such awards similarly depends on the terms of the awards and the limitations of Section 162(m) of the Code, if applicable.
Section 162(m) of the Code currently imposes a $1 million limit on the amount that a public company may deduct for compensation paid
to an employee who is chief executive officer, chief financial officer, or another &#8220;covered employee&#8221; (as defined by Section
162(m)), or was such an employee beginning in any year after 2017. The Compensation Committee retains the discretion to establish the
compensation paid or intended to be paid or awarded to the executive officers as the Compensation Committee may determine is in the best
interest of us and our stockholders, and without regard to any limitation provided in Section 162(m). This discretion is an important
feature of the Compensation Committee&#8217;s compensation practices because it provides the Compensation Committee with sufficient flexibility
to respond to specific circumstances facing us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at December 31, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the outstanding stock options and compensatory warrants held by each of the named executive officers as of December
31, 2023. There were no direct stock awards, restricted stock units or stock appreciation rights outstanding at December 31, 2023. All
pre-2020 &#8220;option&#8221; awards shown were initially issued as Qualigen, Inc. Series C Warrants, and became warrants exercisable
instead for our common stock (at an adjusted exercise price) upon the Reverse Recapitalization Transaction. The share numbers and exercise
prices in the table below reflect the reverse stock split, which was effected by the Company on November 23, 2022 (the &#8220;Reverse
Stock Split&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="15" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity Awards</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p></td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unexercised</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(#)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercisable</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underlying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unexercised</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(#)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unexercisable</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 21%; text-align: left">Michael Poirier</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: right">7/11/2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">12,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">25,000</td><td style="width: 1%; text-align: left">(1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">5.14</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: right">7/11/2032</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/5/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/5/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">9/22/2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">9/22/2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/3/2015</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/2/2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/2/2014</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,984</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/2/2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/31/2014</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/31/2024</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tariq Arshad</td><td>&#160;</td>
    <td style="text-align: right">7/11/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,800</span></td><td style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">7/11/2032</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/8/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/17/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/17/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,333</td><td style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/17/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amy Broidrick</td><td>&#160;</td>
    <td style="text-align: right">7/11/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,000</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">7/11/2032</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/8/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/8/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/7/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/7/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/27/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/27/2030</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            underlying the stock option vest over three years in three equal annual installments from
                                            the date of grant.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            underlying the stock option vest over three years in three equal annual installments from
                                            the vesting commencement date of May 17, 2021.</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
                                                                                                           <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">(3)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> Following Ms. Broidrick&#8217;s termination of employment on June 16, 2023, she did not exercise any vested stock options, and all of her
equity awards were subsequently forfeited.</td></tr>
                                                                                                           </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pay
Versus Performance (PVP)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the SEC&#8217;s disclosure requirements regarding pay versus performance, or PVP, this section presents the
SEC-defined &#8220;Compensation Actually Paid,&#8221; or CAP of our principal executive officer (&#8220;PEO&#8221;) and named
executive officers (&#8220;NEOs&#8221;) for each of the fiscal years ended December 31, 2023, 2022, and 2021, and our financial
performance. Also as required by the SEC, this section compares CAP to various measures used to gauge performance at the Company for
each such fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pay
versus Performance Table - Compensation Definitions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary,
Bonus, Stock Awards, and All Other Compensation are each calculated in the same manner for purposes of both CAP and Summary Compensation
Table, or SCT values. The primary difference between the calculation of CAP and SCT total compensation is the calculation of the value
of &#8220;Stock Awards,&#8221; with the table below describing the differences in how these awards are valued for purposes of SCT total
and CAP:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SCT
    Total</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 51%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAP</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Awards</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    date fair value of stock awards granted during the year</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value of stock awards that are unvested as of the end of the year, or vested during the year</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pay
Versus Performance Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the SEC&#8217;s new PVP rules, the following table sets forth information concerning the compensation of our NEOs for
each of the fiscal years ended December 31, 2023, 2022, and 2021, and our financial performance for each such fiscal year:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Summary Compensation Table Total for PEO</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Compensation Actually Paid to PEO</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average Summary Compensation Table Total for non-PEO Named Executive Officers</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average Compensation Actually Paid to non-PEO Named Executive Officers</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value of Initial Fixed $100 Investment Based On Total Shareholder Return</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Loss Attributable to Qualigen Therapeutics, Inc. (millions)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; text-align: right">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">632,698</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">612,865</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">514,321</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">488,856</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.83</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(13.4</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">728,454</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262,274</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">473,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,235</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18.6</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">742,279</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(753,431</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">811,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">609,691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17.9</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The principal executive officer (&#8220;PEO&#8221;) in 2023, 2022, and 2021
was Michael Poirier, our Chairman and Chief Executive Officer. The Non-PEO NEOs in 2023, 2022, and 2021 were Amy Broidrick, who was our
President, Chief Strategy and Operating Officer, and Tariq Arshad, who was our Chief Medical Officer and Senior Vice President. The CAP
was calculated beginning with the NEOs SCT total. The following amounts were deducted from and added to the applicable SCT total compensation:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">SCT Total</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stock awards deducted from SCT</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Increase for fair value of awards granted during the year that remain unvested as of year end</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Decrease in fair value from prior year-end to current year-end for awards granted in prior years and unvested as of year end</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Decrease in fair value from prior year-end to current year vesting date for awards granted in prior years</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total CAP</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(A)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(B)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(C )</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(D)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(E )</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">A-B+C+D+E</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic">PEO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 22%; text-align: right">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">632,698</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(13,650</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(6,183</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">612,865</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">728,454</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(145,274</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,387</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(218,695</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(133,598</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">262,274</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">742,279</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,236,534</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(259,176</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(753,431</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic">Average Non-PEO NEO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">514,321</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(23,708</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,757</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">488,856</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">473,826</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(44,936</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,709</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(218,541</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(98,823</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">811,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(363,370</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314,858</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(48,997</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">609,691</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of stock options reported for CAP purposes in columns (B), (C), (D) and (E) above was estimated using a Black-Scholes option
pricing model for the purposes of this PVP calculation in accordance with SEC rules. This model uses both historical data and current
market data to estimate the fair value of options and requires several assumptions. The assumptions used in estimating fair value for
awards granted during 2022 were as follows: volatility 102%, expected life 5.99 years, expected dividend yield 0%, risk-free rate 3.04%.
The assumptions used in estimating fair value for awards granted during 2021 and prior were as follows: volatility 102%, expected life
5.99 years, expected dividend yield 0%, risk-free rate 0.42% - 1.43%. There were no awards granted in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Analysis
of Information Presented in the Pay versus Performance Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Our executive compensation program
reflects a variable pay-for-performance philosophy. While we utilize several performance measures to align executive compensation with
Company performance, all of those Company measures are not presented in the Pay versus Performance table. Moreover, we generally seek
to incentivize long-term performance, and therefore we do not specifically align our performance measures with compensation that is actually
paid (as computed in accordance with SEC rules) for a particular year. Further, we do not have the right to (without the executive&#8217;s
consent) reduce an executive&#8217;s salary for a particular year to an amount lower than is provided for in any employment agreement
with the executive which covers such year.&#160; In accordance with SEC rules, we provide the following narrative disclosure:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Compensation
Actually Paid and Cumulative Total Stockholder Return</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Compensation actually paid to our PEO increased from ($753,431) in 2021
to $262,274 in 2022, and further increased to $612,865 in 2023. Average compensation actually paid to our named executive officers other
than our PEO decreased from $609,691 in 2021 to $121,235 in 2022, and increased to $488,856 in 2023. Over the same period, the value of
an investment of $100 in our common stock on the last trading day of 2020 decreased by $61.79 to $38.21 during 2021, further decreased
by $33.92 to $4.29 during 2022, and further decreased by $2.46 during 2023, for a total decrease over 2021, 2022, and 2023 of $98.17.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Compensation
Actually Paid and Net Loss</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Compensation actually paid to our PEO increased from ($753,431) in 2021
to $262,274 in 2022, and further increased to $612,865 in 2023. Average compensation actually paid to our named executive officers other
than our PEO decreased from $609,691 in 2021 to $121,235 in 2022, and increased to $488,856 in 2023. Over the same period, our net loss
increased by $0.7 million during 2022 (from a net loss in 2021 of $17.9 million to a net loss in 2022 of $18.6 million), and decreased
by $5.2 million during 2023 (from a net loss in 2022 of $18.6 million to a net loss in 2023 of $13.4 million).</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
2023<span style="text-transform: uppercase">, </span>our non-employee directors were eligible to receive $35,000 in annual cash compensation.
The Audit Committee chair was eligible to receive additional annual cash compensation of $15,000 and the other Board committee chairs
were eligible to receive additional annual cash compensation of $10,000. Each non-chair member of each Board committee was eligible to
receive additional annual cash compensation of $7,500 (Audit Committee) and $5,000 (other Committees). On January 13, 2023, the Company&#8217;s
board of directors, as part of certain cost-cutting measures, approved a temporary 20% reduction to the compensation of all directors
of the Company effective January 1, 2023. On August 1, 2023 the Company&#8217;s board of directors approved the reinstatement of the
compensation of all directors of the Company to the above amounts effective August 1, 2023. Non-employee directors did not receive stock
option grants during 2023. The amounts in the table below represent fees actually paid in cash during 2023 and include some fees earned in 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
paid to Mr. Poirier and Ms. Broidrick is presented as part of the &#8220;Summary Compensation Table&#8221; above, rather than here.
Our employee directors do not receive compensation for their service as directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Name of Director</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Fees Paid in</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Cash ($)</p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Option <br/>Awards <br/>($)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">All other compensation <br/>($)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total <br/>($)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Richard David</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">40,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">40,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Sidney Emery, Jr.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Matthew Korenberg</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kurt Kruger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ira Ritter</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,333</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, all non-employee directors had been paid for compensation earned through July 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hedging
or Offsetting Against Compensatory Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a policy that our employees (including officers) and directors shall not purchase securities or other financial instruments,
or otherwise engage in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of equity
securities granted as compensation to, or held directly or indirectly by, those persons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a formal claw-back policy for the recovery of incentive-based
executive compensation erroneously awarded to executive officers based on misstated financial reporting measures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_009"></span>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -58.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information regarding the beneficial ownership of our common stock as of March 25, 2024 by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 1.5in">&#160;</td>
  <td style="text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our named executive officers;</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our directors;</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all of our current directors and executive officers as a group;
and</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: justify">&#160;</td>
  <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each stockholder known by us to own beneficially more than
5% of our common stock.</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.
Shares of common stock that may be acquired by an individual or group within 60 days after March 25, 2024, pursuant to the exercise of
options or warrants, are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group,
but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. The
percentage of beneficial ownership of our common stock is calculated based on an aggregate of 6,307,371 shares outstanding as of March
25, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as indicated in the footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power
with respect to all shares of common stock shown to be beneficially owned by them, based on information provided to us by such stockholders.
Unless otherwise indicated, the address for each director and executive officer listed is: c/o Qualigen Therapeutics, Inc., 5857 Owens
Avenue, Suite 300, Carlsbad, California 92008 USA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares <br/> Beneficially Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Percentage of <br/> Common Stock <br/> Beneficially Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Five Percent Stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alpha Capital Anstalt <sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">700,041</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">9.99</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left">Executive Officers, Directors and Director Nominees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Poirier <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">142,376</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Lotz <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,353</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard David <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sidney Emery, Jr. <sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,302</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew Korenberg <sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kurt Kruger <sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ira Ritter <sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,738</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All current executive officers and directors as a group (7 persons)<sup>(9)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">252,341</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.9</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Represents beneficial ownership of less than 1% of the shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            shares of common stock issuable upon the exercise of warrants or conversion of its convertible
                                            debentures; Alpha Capital Anstalt would not be permitted to convert or exercise all or any
                                            portion of its warrants or debentures to the extent that such conversion or exercise would
                                            result in Alpha Capital Anstalt (and its affiliates) beneficially owning more than 9.99%
                                            of the number of shares of Company common stock outstanding immediately after giving effect
                                            to the issuance of shares of common stock issuable upon conversion/exercise. Konrad Ackermann
                                            has voting and investment power over the shares held by Alpha Capital Anstalt.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            112,500 shares of common stock exercisable within 60 days under outstanding stock options
                                            and 8,855 shares of common stock exercisable within 60 days under outstanding warrants.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            63,333 shares of common stock exercisable within 60 days under outstanding stock options
                                            and 7,766 shares of common stock exercisable within 60 days under outstanding warrants.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Includes 6,334 shares of common stock exercisable within 60 days under
outstanding stock options and 885 shares of common stock exercisable within 60 days under outstanding warrants.</p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Includes 6,334 shares of common stock exercisable within 60 days under
outstanding stock options.</p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            6,334 shares of common stock exercisable within 60 days under outstanding stock options.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Includes 6,334 shares of common stock exercisable within 60 days under
outstanding stock options and 885 shares of common stock exercisable within 60 days under outstanding warrants.</p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Includes 6,334 shares of common stock exercisable within 60 days under
outstanding stock options. Also includes shares of common stock held in a retirement plan trust of which Ira Ritter and his spouse are
trustees; and also includes shares beneficially owned by Stonehenge Partners. As a managing partner of Stonehenge Partners, Ira Ritter
may be deemed the beneficial owner of these shares.</p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Includes 207,503 shares of common stock exercisable within 60 days under
outstanding stock options and 18,391 shares of common stock exercisable within 60 days under outstanding warrants.</p></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information regarding securities authorized for issuance under equity compensation plans as of December 31,
2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Plan Category</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>to be Issued upon</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options, Warrants and Rights</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price of Outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options, Warrants and Rights</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining Available</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>for Future Issuance</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Under Equity</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation Plans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(excluding securities</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>reflected in</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>column (a))</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(a)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(b)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(c)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Equity compensation plans approved by stockholders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">398,924</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">35.21</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">356,791</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity compensation plans not approved by stockholders (1)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,046</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10.35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">517,970</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">29.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,791</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
                                            of shares of common stock issuable upon the exercise of compensatory warrants granted to
                                            service providers.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_010"></span>Item
13. Certain Relationships and Related Transactions, and Director Independence.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -58.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Relationships and Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee is responsible for reviewing, approving and overseeing any transaction between the Company and its directors, director
nominees, executive officers, greater than 5% beneficial owners, and each of their respective immediate family members, where the amount
involved exceeds the lesser of (i) $120,000 and (ii) 1% of the average of our total assets at year-end for the prior two fiscal years.
Since January 1, 2021, there have been no such transactions except as described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 26, 2022, the Company acquired 2,232,861 shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (&#8220;NanoSynex&#8221;) from Alpha a related party, in exchange for 350,000 reverse split adjusted shares of the Company&#8217;s
common stock and a prefunded warrant to purchase 331,464 reverse split adjusted shares of the Company&#8217;s common stock at an exercise
price of $0.001 per share. These warrants were subsequently exercised on September 13, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21 and 22, 2022, we entered into a Securities Purchase Agreement with Alpha and in exchange for $3,000,000 in cash (less $50,000
for expense reimbursement) issued to Alpha the 2022 Debenture, plus 2,500,000 common stock warrants exercisable (from June 22, 2023 through
June 22, 2028) at $1.65 per share. Commencing June 1, 2023 and continuing on the first day of each month thereafter until the earlier
of (i) December 22, 2025 and (ii) the full redemption of the 2022 Debenture (each such date, a &#8220;Monthly Redemption Date&#8221;),
we must redeem $110,000 plus accrued but unpaid interest, liquidated damages and any amounts then owing under the 2022 Debenture (the
&#8220;Monthly Redemption Amount&#8221;). The Monthly Redemption Amount must be paid in cash; provided that after the first two monthly
redemptions, we may (if the Equity Conditions, as defined in the 2022 Debenture, are then satisfied or have been waived) elect to pay
all or a portion of a Monthly Redemption Amount in shares of our common stock, based on a conversion price equal to the lesser of (i)
the then applicable conversion price of the 2022 Debenture and (ii) 85% of the average of the VWAPs (as defined in the 2022 Debenture)
for the five consecutive trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 Debenture accrues interest at the rate of 8% per annum, which began accruing on December 1, 2023, and will be payable on a quarterly
basis. Interest may be paid in cash or shares of common stock or a combination thereof at our option; provided that the Equity Conditions
have been satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 Debenture is convertible into our common stock at any time at the holder&#8217;s option; the conversion price was originally $1.32.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than the Monthly Redemption Amounts, the 2022 Debenture does not call for scheduled payments of principal before the scheduled maturity
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the 2022 Debenture and the accompanying warrants provide for &#8220;ratchet&#8221; antidilution adjustments to their conversion price
and exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the 2022 Debenture and the accompanying warrants include a beneficial ownership blocker of 9.99%, which may only be waived by Alpha upon
61 days&#8217; notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2023, we and Alpha entered into an Amendment No. 1 with regard to Securities Purchase Agreement, under which the conversion
price of the 2022 Debenture and the exercise price of the associated warrants were reduced to $0.73 per share, in exchange for Alpha
permitting us to make certain Monthly Redemption Amount payments in the form of our stock rather than in cash even though the Equity
Conditions were not satisfied (which would otherwise have prevented payment in the form of stock). In addition, such Amendment revised
certain provisions of the 2,500,000 common stock warrants to (i) limit the circumstances which would trigger a potential adjustment to
the exercise price of the 2,500,000 common stock warrants and (ii) clarify the treatment of the 2,500,000 common stock warrants upon
a &#8220;Fundamental Transaction.&#8221; (The purpose of these revisions was to remove the terms that caused the 2,500,000 common stock
warrants to be liability-classified under U.S. GAAP).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
new $0.73 per share conversion/exercise price triggered a &#8220;ratchet&#8221; antidilution adjustment in the Company&#8217;s outstanding
&#8220;exploding&#8221; &#8220;Series C Warrants,&#8221; resulting in such Series C Warrants becoming exercisable for 455,623 common
shares (at an exercise price of $0.73 per share), as opposed to the 251,971 common shares into which such outstanding Series C Warrants
would have been exercisable (at $1.32 per share) pre-adjustment. Finally, the $0.73 per share price triggered a &#8220;ratchet&#8221;
antidilution adjustment in the exercise price of other outstanding Company common stock warrants, including 7,084 warrants held by Alpha
and 67,620 warrants held by other persons, all of which were previously exercisable at $1.32 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 26 and 27, 2024, we entered into a Securities Purchase Agreement with Alpha and in exchange for $500,000 in cash (less $25,000
for expense reimbursement) issued to Alpha an 8% Convertible Debenture with a face amount of $550,000 due on December 31, 2024 (the &#8220;2024
Debenture&#8221;), plus 900,016 5-year common stock warrants exercisable at $0.26 per share. In addition, per this Securities Purchase
Agreement Alpha obtained an option to purchase additional 8% Convertible Debentures, of like tenor, with face amounts of up to an aggregate
of $1,100,000 (and with a proportional number of accompanying common stock warrants of like tenor, up to a total of 1,800,032 additional
warrants), which would (if and when Alpha exercises such option) provide us up to an additional $1.0 million in cash proceeds (less expense
reimbursement, and not including any possible cash proceeds from any future exercise of the additional warrants). This option is valid through July 1, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 Debenture has a maturity date of December 31, 2024 and is convertible, at any time, and from time to time, at Alpha&#8217;s option,
into shares of our common stock, at $0.6111 per share. The 2024 Debenture does not call for scheduled payments of principal or interest
before the scheduled maturity date. Interest on the 2024 Debenture accrues on its outstanding principal balance at the rate of 8% per
annum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the 2024 Debenture and the accompanying warrants provide for &#8220;ratchet&#8221; antidilution adjustments to their conversion price/exercise
price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the 2024 Debenture and the accompanying warrants include a beneficial ownership blocker of 9.99%, which may only be waived by Alpha upon
61 days&#8217; notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
granted Alpha &#8220;piggyback&#8221; registration rights for the common shares underlying the 2024 Debenture and the accompanying warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
$0.26 exercise price of the warrants issued with the 2024 Debenture triggered a &#8220;ratchet&#8221; antidilution adjustment in the
2022 Debenture, resulting in the then current $1,198,922 principal amount thereof becoming convertible into 4,611,238 shares of Company
common stock (as opposed to the 1,642,359 shares into which such outstanding principal amount were convertible pre-adjustment). Also,
the $0.26 exercise price of the warrants issued with the 2024 Debenture triggered a &#8220;ratchet&#8221; antidilution adjustment in
the Company&#8217;s outstanding &#8220;exploding&#8221; &#8220;Series C Warrants,&#8221; resulting in such Series C Warrants becoming
exercisable for 1,279,261 common shares (at an exercise price of $0.26 per share), as opposed to the 455,623 common shares into which
such outstanding Series C Warrants would have been exercisable (at $0.73 per share) pre-adjustment. Finally, the $0.26 exercise price
of the warrant triggered a &#8220;ratchet&#8221; antidilution adjustment in the exercise price of other outstanding Company common stock
warrants, including 2,507,048 warrants held by Alpha and 67,620 warrants held by other persons, all of which were previously exercisable
at $0.73 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with her termination of employment, on June 20, 2023, Qualigen, Inc., a former wholly-owned subsidiary of the Company,
signed a separation agreement and general release (the &#8220;Separation Agreement&#8221;) with Amy Broidrick, which became
effective on June 24, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the Separation Agreement, Qualigen, Inc. provided Ms. Broidrick with (i) $16,637 in cash compensation, less applicable withholdings
for federal and state income and employment taxes, which represented Ms. Broidrick&#8217;s accrued but unpaid salary and vacation pay
through the Separation Date, and reimbursement of certain expenses incurred by Ms. Broidrick, (ii) severance in the form of continued
salary pay to Ms. Broidrick at the rate then in effect on the Separation Date ($360,000 per annum) for a period of 12 months following
the Separation Date, subject to applicable withholding, and (iii) payment or reimbursement for the cost of COBRA continuation medical
and dental insurance coverage for 12 months following the Separation Date, less any required taxes or withholdings. In addition, Ms.
Broidrick is entitled to any rights or benefits under Qualigen Inc.&#8217;s employee benefit plans, to the extent earned and vested,
and had three months from the Separation Date to exercise any vested stock options. Ms. Broidrick did not exercise any vested stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Nasdaq&#8217;s continued listing requirements, a majority of a listed company&#8217;s board of directors must be comprised of independent
directors, subject to certain exceptions. In addition, Nasdaq&#8217;s continued listing requirements require that, subject to certain
exceptions, each member of a listed company&#8217;s audit, compensation and governance and nominating committees must be independent.
Audit Committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Exchange Act. Under Nasdaq&#8217;s
continued listing requirements, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s
board of directors, such person does not have a relationship that would interfere with the exercise of independent judgment in carrying
out the responsibilities of a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon information requested from and provided by each director concerning their background, employment and affiliations, including family
relationships, our board of directors determined that each of Messrs. David, Emery, Korenberg, Kruger and Ritter are independent under
the applicable rules and regulations of Nasdaq. In making such determinations, the board of directors considered the relationships that
each such non-employee director has with our company and all other facts and circumstances the board of directors deemed relevant in
determining their independence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_011"></span>Item
14. Principal Accounting Fees and Services.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -58.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Baker
Tilly US, LLP (&#8220;Baker Tilly&#8221;) serves as the Company&#8217;s independent registered public accounting firm and has served
in that capacity since June 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee considered the independence of Baker Tilly and whether the audit services Baker Tilly provided to the Company are compatible
with maintaining that independence. The Audit Committee has adopted procedures by which the Audit Committee must approve in advance all
services provided by and fees paid to the Company&#8217;s independent registered public accounting firm. The advance approval requirement
was not waived in any instance during 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees
and Services of Baker Tilly US, LLP</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the aggregate fees billed to the Company by Baker Tilly for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Audit Fees(1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">495,955</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">411,362</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audit-Related Fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax Fees (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,789</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,050</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">All Other Fees</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">514,744</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">446,412</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
                                            fees consisted of fees for audit work performed in the audit of financial statements, as
                                            well as fees for quarterly reviews and registration statements.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
                                            fees were incurred for professional services rendered in connection with tax compliance,
                                            tax advice, and tax planning. These services included income tax compliance and related tax
                                            services.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee has adopted a formal policy on auditor independence requiring the advance approval by the Audit Committee of all audit
and non-audit services provided by our independent registered public accounting firm. In determining whether to approve any services
by our independent registered public accounting firm, the Audit Committee reviews the services and the estimated fees, and considers
whether approval of the proposed services will have a detrimental impact on the auditor&#8217;s independence. On an annual basis, our
management reports to the Audit Committee all audit services performed during the previous 12 months and all fees billed by our independent
registered public accounting firm for such services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, all audit services and the corresponding fees were approved by our Audit Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_012"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_013"></span>Item
15. Exhibits and Financial Statement Schedules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The following documents are filed as part of this Annual Report:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <i>Financial
Statements.</i> The following documents are included in Part II, Item 8 of this Annual Report and are incorporated by reference
herein:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mm_003">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID 23)</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements:</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="#mm_004">Consolidated Balance Sheets as of December 31, 2023 and December 31, 2022</a></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="#mm_005">Consolidated Statements of Operations and Comprehensive Loss for the Year Ended December 31, 2023 and Year Ended December 31, 2022</a></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="#mm_006">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) for the Year Ended December 31, 2023 and Year Ended December 31, 2022</a></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="#mm_007">Consolidated Statements of Cash Flows for the Year Ended December 31, 2023 and Year Ended December 31, 2022</a></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CFF0FC">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="#mm_008">Notes to Consolidated Financial Statements</a></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<i>Financial Statement Schedules.</i> Financial statement schedules have been omitted because they are not required or are not applicable,
or the required information is shown in the consolidated financial statements or notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<i>Exhibits. </i>See EXHIBIT INDEX</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    No.</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing
    Date</b></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315223025606/ex2-1.htm" style="-sec-extract: exhibit">Stock Purchase Agreement dated July 20, 2023 with Chembio Diagnostics, Inc., Biosynex, S.A. and Qualigen, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/26/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000157104915005411/t1501532_ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation of Ritter Pharmaceuticals, Inc.</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/1/2015</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315217011241/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Certificate of Incorporation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/15/2017</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315218003738/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Certificate of Incorporation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/22/2018</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of Series Alpha Preferred Stock of the Company, filed with the Delaware Secretary of State on May 29, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex3-2.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 [reverse stock split]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex3-3.htm" style="-sec-extract: exhibit">Certificate of Merger, filed with the Delaware Secretary of State on May 22, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex3-4.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221019709/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws of the Company, as of August 10, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/13/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222033252/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Certificate of Incorporation, filed with the Delaware Secretary of State on November 21, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/22/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex10-13.htm" style="-sec-extract: exhibit">Warrant, issued by the Company in favor of Alpha Capital Anstalt, dated May 22, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex10-10.htm" style="-sec-extract: exhibit">Form of Warrant, issued by the Company in favor of GreenBlock Capital LLC and its designees, dated May 22, 2020 [post-Merger]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220013097/ex10-2.htm" style="-sec-extract: exhibit">Common Stock Purchase Warrant in favor of Alpha Capital Anstalt, dated July 10, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/10/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220014596/ex10-3.htm" style="-sec-extract: exhibit">Common Stock Purchase Warrant in favor of Alpha Capital Anstalt, dated August 4, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/4/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220023916/ex10-3.htm" style="-sec-extract: exhibit">&#8220;Two-Year&#8221; Common Stock Purchase Warrant for 1,348,314 shares in favor of Alpha Capital Anstalt, dated December 18, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/18/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220023916/ex10-4.htm" style="-sec-extract: exhibit">&#8220;Deferred&#8221; Common Stock Purchase Warrant in favor of Alpha Capital Anstalt, dated December 18, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/18/2020</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221007476/ex4-13.htm" style="-sec-extract: exhibit">Form of liability classified Warrant to Purchase Common Stock</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221007476/ex4-14.htm" style="-sec-extract: exhibit">Form of &#8220;service provider&#8221; compensatory equity classified Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315223024027/ex4-9.htm" style="-sec-extract: exhibit">Description of Common Stock</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/7/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222013149/ex4-15.htm" style="-sec-extract: exhibit">Amended and Restated Common Stock Purchase Warrant to GreenBlock Capital LLC, dated April 25, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222013149/ex4-16.htm" style="-sec-extract: exhibit">Amended and Restated Common Stock Purchase Warrant to Christopher Nelson, dated April 25, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/ex4-1.htm" style="-sec-extract: exhibit">Common Stock Purchase Warrant for 2,500,000 shares in favor of Alpha Capital Anstalt, dated December 22, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/22/2022</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex10-1.htm" style="-sec-extract: exhibit">Executive Employment Agreement, by and between Qualigen, Inc. and Michael Poirier, dated as of February 1, 2017 and as amended on January 9, 2018</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex10-2.htm" style="-sec-extract: exhibit">Executive Employment Agreement, by and between Qualigen, Inc. and Christopher Lotz, dated as of February 1, 2017 and as amended on January 9, 2018</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex10-20.htm" style="-sec-extract: exhibit">2020 Stock Equity Incentive Plan</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010979/ex10-1.htm" style="-sec-extract: exhibit">Standard template of Stock Option Agreement for use under 2020 Stock Incentive Plan</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/11/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220014596/ex10-4.htm" style="-sec-extract: exhibit">Exclusive License Agreement (RAS) between the Company and University of Louisville Research Foundation, Inc., dated as of July 17, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/4/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315223015184/ex10-11.htm" style="-sec-extract: exhibit">Amendment 1 to the Exclusive License Agreement (RAS), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc., dated March 16, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">10.11</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/2/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221011439/ex10-1.htm" style="-sec-extract: exhibit">Novation Agreement (RAS) among the Company, Qualigen, Inc. and University of Louisville Research Foundation, Inc. dated January 30, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/14/2021</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315221020170/ex10-1.htm" style="-sec-extract: exhibit">Hire offer letter from the Company to Tariq Arshad, dated April 22, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/16/2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222008431/ex10-55.htm" style="-sec-extract: exhibit">License Agreement with UCL Business Limited dated January 12, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315223015184/ex10-21.htm" style="-sec-extract: exhibit">First Deed of Variation to License Agreement with UCL Business Limited dated March 30, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/2/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222013149/ex10-1.htm" style="-sec-extract: exhibit">Series B Preferred Share Purchase Agreement between the Company and NanoSynex Ltd. dated April 29, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222013149/ex10-2.htm" style="-sec-extract: exhibit">Share Purchase Agreement between the Company and Alpha Capital Anstalt dated April 29, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/13/2022</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222015663/ex10-1.htm" style="-sec-extract: exhibit">Master Agreement for the Operational and Technological Funding of NanoSynex between Qualigen Therapeutics, Inc. and NanoSynex Ltd., dated May 26, 2022</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/2/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222032189/ex10-1.htm" style="-sec-extract: exhibit">Qualigen Therapeutics, Inc. 2022 Employee Stock Purchase Plan</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/14/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222033252/ex10-1.htm" style="-sec-extract: exhibit">Amendment No. 2 to the 2020 Stock Incentive Plan of Qualigen Therapeutics, Inc.</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/22/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222033252/ex10-2.htm" style="-sec-extract: exhibit">Amendment No. 1 to the 2022 Employee Stock Purchase Plan of Qualigen Therapeutics, Inc.</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/22/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/ex10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated December 21, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/22/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/ex10-2.htm" style="-sec-extract: exhibit">8% Senior Convertible Debenture Due December 22, 2025 in favor of Alpha Capital Anstalt</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/22/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/ex10-3.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated December 22, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/22/2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315223015184/ex10-31.htm" style="-sec-extract: exhibit">Letter to Michael  Poirier, dated January 13, 2023, regarding compensatory changes</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin: 0">10-K</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin: 0">001-37428</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin: 0">10.31</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/2/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315223015184/ex10-32.htm" style="-sec-extract: exhibit">Letter to Amy Broidrick, dated January 13, 2023, regarding compensatory changes</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/2/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315223015184/ex10-33.htm" style="-sec-extract: exhibit">Letter to Tariq Arshad, dated January 13, 2023, regarding compensatory changes</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin: 0">001-37428</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/2/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315223044019/ex10-1.htm" style="-sec-extract: exhibit">Amendment No. 1 with regard to Securities Purchase Agreement dated December 5, 2023 with Alpha Capital Anstalt</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/7/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315223025606/ex10-1.htm" style="-sec-extract: exhibit">Amendment and Settlement Agreement dated July 19, 2023 with NanoSynex, Ltd.</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/26/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315223028465/ex10-1.htm" style="-sec-extract: exhibit">Separation Agreement and General Release dated June 20, 2023 with Amy Broidrick</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/14/2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex14-1.htm" style="-sec-extract: exhibit">Code of Business Conduct and Ethics</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21-1.htm">Subsidiaries of the Registrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="ex23-1.htm">Consent of Baker Tilly US, LLP, independent registered public accounting firm</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Su_001">Power of Attorney (included on signature page)</a></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="ex31-1.htm">Certificate of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="ex31-2.htm">Certificate of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="ex32-1.htm">Certificate of principal executive officer and principal financial officer pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">97.1*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex97-1.htm">Clawback Policy</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed or furnished herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedules will be furnished to the SEC
upon request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+
Indicates management contract or compensatory plan or arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
XBRL (Extensible Business Reporting Language) information is furnished and not filed herewith, is not a part of a registration statement
or Prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the
Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_014"></span>Item
16. Form 10-K Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_015"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report
to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen
    Therapeutics, Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael S. Poirier</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 5, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Christopher L. Lotz</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    L. Lotz</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President of Finance, Chief Financial Officer (Principal Financial Officer and Chief Accounting Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 5, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Su_001"></span>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Michael S. Poirier and
Christopher L. Lotz, and each of them individually, his true and lawful attorneys-in-fact and agents, with full power of substitution
and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual
Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every
act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do
in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or his substitute or substitutes,
may lawfully do or cause to be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf
of the Registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 43%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael S. Poirier</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board, Chief Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 5, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Christopher L. Lotz</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President of Finance, Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 5, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    L. Lotz</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Richard A. David</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 5, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    A. David</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Sidney W. Emery, Jr.</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 5, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sidney
    W. Emery, Jr.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Matthew E. Korenberg</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 5, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthew
    E. Korenberg</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Kurt H. Kruger</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 5, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kurt
    H. Kruger</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ira E. Ritter</i></span></td>
    <td style="border-bottom: white 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 5, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ira
    E. Ritter</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 82; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></p>



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZi7ajLuxOi4pYRYqI28FGGWwnJTP+HclbGlvE8CAJ732JUj21pIWtkOE4K3LYY91UJiAUeEZGd0JJZKt1CtILvFgf2LjQrj8wI2FQmHFfayNGG71bj2UK8XCgRSMZ0uEEphsVff2M3NmW6II1FRhXwo6pYYvB8Ku7sDdPclS/2lcHZG/JpZD0485+g44TDVu6mwfx1UOeZyrqtRWpJdOtkdT8GdB9SZhXWMs739F/RR//QEqA -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSIDIARIES
OF THE REGISTRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONSENT
OF BAKER TILLY US, LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements on Form S-3 (File No. 333-265691, 333-266430, and 333-269088)
and Form S-8 (File No. 333-249280, 333-249281 and 333-262090) of Qualigen Therapeutics, Inc. of our
report dated April 5, 2024, relating to the consolidated financial statements, which includes an explanatory paragraph relating to the
Company&rsquo;s ability to continue as a going concern and appears on page 33 of this annual report on Form 10-K for the year ended December
31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Baker Tilly US, LLP</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San
Diego, CA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
5, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C<B>ERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Michael S. Poirier, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Annual Report on Form 10-K of Qualigen Therapeutics, Inc., a Delaware
                                            corporation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the condensed consolidated financial statements, and other financial information
                                            included in this report, fairly present in all material respects the financial condition,
                                            results of operations and cash flows of the registrant as of, and for, the periods presented
                                            in this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
                                            disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
                                            and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
                                            and 15d-15(f)) for the registrant and have:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant is made known to us by others within those entities, particularly during the period
                                            in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such control over financial reporting, or caused such internal control over financial reporting
                                            to be designed under our supervision, to provide reasonable assurance regarding the reliability
                                            of financial reporting and the preparation of condensed consolidated financial statements
                                            for external purposes with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal control over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
                                            and the audit committee of the registrant&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    5, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael S. Poirier</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Christopher L. Lotz, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Annual report on Form 10-K of Qualigen Therapeutics, Inc., a Delaware
                                            corporation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the condensed consolidated financial statements, and other financial information
                                            included in this report, fairly present in all material respects the financial condition,
                                            results of operations and cash flows of the registrant as of, and for, the periods presented
                                            in this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining
                                            disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
                                            and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
                                            and 15d-15(f)) for the registrant and have:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant is made known to us by others within those entities, particularly during the period
                                            in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such control over financial reporting, or caused such internal control over financial reporting
                                            to be designed under our supervision, to provide reasonable assurance regarding the reliability
                                            of financial reporting and the preparation of condensed consolidated financial statements
                                            for external purposes with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal control over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
                                            and the audit committee of the registrant&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    5, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christopher L. Lotz</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    L. Lotz</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the undersigned, Michael S. Poirier, Chief Executive Officer of Qualigen Therapeutics, Inc., a Delaware corporation (the &ldquo;Company&rdquo;),
and Christopher L. Lotz, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge (1) the Annual Report on Form 10-K of the Company for the year
ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
5, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael S. Poirier</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
5, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christopher L. Lotz</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    L. Lotz</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>These
certifications accompanying and being &ldquo;furnished&rdquo; with this Report, shall not be deemed &ldquo;filed&rdquo; by the Company
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and
shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation
language contained in such filing.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>7
<FILENAME>ex97-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
97.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CLAWBACK
POLICY</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>QUALIGEN
THERAPEUTICS, INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Purpose</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen
Therapeutics, Inc. (the &ldquo;Company&rdquo;) is establishing this policy to align the interests of executive officers of the Company
with those of shareholders, to create and maintain a culture that emphasizes integrity and accountability and to enforce the Company&rsquo;s
pay-for-performance compensation philosophy. This policy provides for the recoupment of certain executive compensation in the event of
an accounting restatement resulting from material noncompliance with financial reporting requirements under the federal securities laws
(the &ldquo;<B>Policy</B>&rdquo;). This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934 (the &ldquo;<B>Exchange
Act</B>&rdquo;), Rule 10D-1 promulgated under the Exchange Act (&ldquo;<B>Rule 10D-1</B>&rdquo;), and Nasdaq Listing Rule 5608 (the &ldquo;<B>Listing
Standards</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Administration</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be administered by the Board of Directors (the &ldquo;<B>Board</B>&rdquo;) of the Company or, if so designated by the Board,
a committee thereof including the Compensation Committee, in which case references herein to the Board shall be deemed references to
such committee. The Board is authorized to interpret and construe this Policy and to make all determinations and rules as it deems to
be necessary or advisable for its administration. It is intended that this Policy be interpreted in a manner that is consistent with
the requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted by the Securities and Exchange Commission
or The Nasdaq Stock Market (&ldquo;<B>Nasdaq</B>&rdquo;). Any determinations made by the Board shall be final and binding on all affected
individuals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Covered
Executives</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to the Company&rsquo;s current and former executive officers, as determined by the Board in accordance with Section 10D
of the Exchange Act, the definition of executive officer set forth in Rule 10D-1 and the Listing Standards (&ldquo;<B>Covered Executives</B>&rdquo;),
and such other employees who may from time to time be deemed subject to the Policy by the Board. For this purpose, an &ldquo;executive
officer&rdquo; includes the Company&rsquo;s president, principal financial officer, principal accounting officer (or controller), any
vice president in charge of a principal business unit, division or function or any other officer or person who performs a &ldquo;policy-making&rdquo;
function for the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Recoupment;
Accounting Restatement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that the Company is required to prepare an Accounting Restatement, as defined herein, the Board will promptly require reimbursement
or forfeiture of any Excess Incentive Compensation, as defined herein, received by any Covered Executive during the three completed fiscal
years immediately preceding the date on which the Company is required to prepare an Accounting Restatement, and including any transition
period (that results from a change in the Company&rsquo;s fiscal year) within or immediately following those three completed fiscal years,
except that a transition period comprising a period of at least nine months shall count as a full fiscal year. The Policy applies to
all Incentive-Based Compensation received by a Covered Executive (i) after beginning service as an executive officer; (ii) who served
as an executive officer at any time during the performance period for that Incentive-Based Compensation; and (iii) while the Company
has a listed class of securities. Recovery of amounts under this Policy with respect to a Covered Executive shall not require the finding
of any misconduct by such Covered Executive or that such Covered Executive is responsible for any error associated with an Accounting
Restatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Policy, an &ldquo;<B>Accounting Restatement</B>&rdquo; means an accounting restatement of the Company&rsquo;s financial
statements due to the Company&rsquo;s material noncompliance with any financial reporting requirement under the securities laws, including
any required accounting restatement to correct an error in previously issued financial statements that is material to the previously
issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left
uncorrected in the current period. Also for purposes of this Policy, the date on which the Company is required to prepare an accounting
restatement is the earlier of (i) the date the Board concludes, or reasonably should have concluded, that the Company is required to
prepare an Accounting Restatement; or (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare
an Accounting Restatement, in each case regardless of whether or when the restated financial statements are filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Excess
Incentive Compensation: Amount Subject to Recovery</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount subject to recovery (the &ldquo;<B>Excess Incentive Compensation</B>&rdquo;) is the excess of the Incentive-Based Compensation
paid to the Covered Executive based on the erroneous data over the Incentive-Based Compensation that would have been paid to the Covered
Executive had it been based on the restated results. Excess Incentive Compensation shall be determined by the Board without regard to
any taxes paid by the Covered Executive with respect to the Excess Incentive Compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
Incentive-Based Compensation based on stock price or total shareholder return: (i) the Board shall determine the amount of the Excess
Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder
return upon which the Incentive-Based Compensation was received; and (ii) the Company shall maintain documentation of the determination
of that reasonable estimate and provide such documentation to Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Incentive-Based
Compensation</B>&rdquo; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial
Reporting Measure. Incentive-Based Compensation is received for purposes of this Policy in the Company&rsquo;s fiscal period during which
the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of the
Incentive-Based Compensation occurs after the end of that period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
&ldquo;<B>Financial Reporting Measure</B>&rdquo; means any measure that is determined and presented in accordance with the accounting
principles used in preparing the Company&rsquo;s financial statements, and any measure that is derived in whole or in part from such
measure. For purposes of this Policy, Financial Reporting Measures include, but are not limited to, the following, and any measures derived
from the following: revenues; earnings before interest, taxes, depreciation and amortization; net income; Company stock price; and total
shareholder return. A Financial Reporting Measure need not be presented within the Company&rsquo;s financial statements or included in
a filing with the Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Method
of Recoupment</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board shall determine, in its sole discretion, the timing and method for promptly recouping Excess Incentive Compensation, which may
include without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
seeking reimbursement of all or part of any cash or equity Incentive-Based Compensation previously paid,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based
awards,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
cancelling prior cash or equity-based awards, whether vested or unvested or paid or unpaid,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
cancelling or offsetting against any planned future cash or equity-based awards,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
forfeiture of deferred compensation, subject to compliance with Section 409A of the Internal Revenue Code (the &ldquo;<B>Code</B>&rdquo;)
and the regulations promulgated thereunder, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
any other method authorized by applicable law or contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to compliance with any applicable law, the Board may recover amounts under this Policy from any amount otherwise payable to the Covered
Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized and directed pursuant to this Policy to recoup Excess Incentive Compensation in compliance with this Policy unless
the Compensation Committee of the Board has determined that recovery would be impracticable solely for the following limited reasons,
and subject to the following procedural and disclosure requirements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            direct expense paid to a third party to assist in enforcing the Policy would exceed the amount
                                            to be recovered; provided that prior to concluding that it would be impracticable to recover
                                            any amount of Excess Incentive Compensation based on expense of enforcement, the Board must
                                            make a reasonable attempt to recover such erroneously awarded compensation, document such
                                            reasonable attempt(s) to recover and provide that documentation to Nasdaq; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recovery
                                            would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly
                                            available to employees of the Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13)
                                            or 26 U.S.C. 411(a) and regulations thereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>No
Indemnification of Covered Executives</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall not indemnify any Covered Executives against the loss of any incorrectly awarded Excess Incentive Compensation. The Company
is prohibited from paying or reimbursing a Covered Executive for purchasing insurance to cover any such loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Board
Indemnification</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
members of the Board or its delegates shall not be personally liable for any action, determination or interpretation made with respect
to this Policy and shall be fully indemnified by the Company to the fullest extent under applicable law and Company organizational documents
and policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights
to indemnification of the members of the Board or its delegates under applicable law or Company organizational documents and policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Effective
Date</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be effective as of the effective date of the Listing Standards (the &ldquo;<B>Effective Date</B>&rdquo;). The terms of this
Policy shall apply to any Incentive-Based Compensation that is received by Covered Executives on or after the Effective Date and during
the applicable clawback period described herein, even if such Incentive-Based Compensation was approved, awarded, granted or paid to
Covered Executives prior to the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Amendment
and Termination</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary to reflect final regulations
adopted by the Securities and Exchange Commission under Section 10D of the Exchange Act, to comply with any rules or standards adopted
by Nasdaq, and to comply with (or maintain an exemption from the application of) Section 409A of the Code. The Board may terminate this
Policy at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Other
Recoupment Rights</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board intends that this Policy will be applied to the fullest extent of the law. The Board may require that any employment agreement,
equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit
thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in
addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms
of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available
to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Severability</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions in this Policy are intended to be applied to the fullest extent of the law. To the extent that any provision of this Policy
is found to be unenforceable or invalid under any applicable law, such provision shall be applied to the maximum extent permitted, and
shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations
required under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Governing
Law</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy and all rights and obligations hereunder are governed by and construed in accordance with the internal laws of the State of Delaware,
excluding any choice of law rules or principles that may direct the application of the laws of another jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Successors</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other
legal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
Filing Requirement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of this Policy and any amendments thereto shall be posted on the Company&rsquo;s website and filed as an exhibit to the Company&rsquo;s
annual report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[FOR
SIGNATURE BY THE COMPANY&rsquo;S COVERED EXECUTIVES]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clawback
Policy Acknowledgment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
the undersigned, agree and acknowledge that I am fully bound by, and subject to, all of the terms and conditions of the Clawback Policy
(as may be amended, restated, supplemented or otherwise modified from time to time, the &ldquo;Policy&rdquo;). In the event of any inconsistency
between the Policy and the terms of any employment agreement to which I am a party, or the terms of any compensation plan, program or
agreement under which any compensation has been granted, awarded, earned or paid, the terms of the Policy shall govern. In the event
it is determined by the Board, or such committee thereof that is charged with administration of the Policy, that any amounts granted,
awarded, earned or paid to me must be forfeited or reimbursed to the Company, I will promptly take any action necessary to effectuate
such forfeiture and/or reimbursement. Any capitalized terms used in this Acknowledgment without definition shall have the meaning set
forth in the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Name]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Title]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>logo_001.jpg
<TEXT>
begin 644 logo_001.jpg
M_]C_X  02D9)1@ ! 0$!( $@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %< 5P# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS@1Z;J4S<D]!#(?7LK?@>U>1B,+:\Z?W'T6$QSDU3J_)GV'1117EGN!1110
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M5)>_/[C\G-4\!^)])4M>>'=5MU_O/9R8'XXQ7+RO\S*>&7@J>HK]B659%*L
MRGJ",@UP_C;X(^!_B%;M'K7AVSGD(P+B*,13)[AUP0:2S"_Q1*EE%O@G]Y^4
MDKU3D;-?67QF_87U;P]!<:IX'NI-;LT!=M,N"!<H/]ANC_0X/UKY*O89;.>6
MWN(G@GB8I)%(I5D8=00>0:[858U%>+/.J4*E%VFBO-)6EX;O3'=&'<5)^=&!
MP0P]/\]JQI'IMG=?9[Z"0'[KC/T[U2E9W)<>:+1^I'[+/QF;XG^"_L&IS;_$
M&DA8KAF/,\?1)?KQ@^X]Z]MK\SO@;\0)/AG\2-)U@.4LV<6]XO9H7(#9^G#?
M45^E\<BRQJZ$,C#(8="*\;&4?8U+K9GT&6XEXBE:7Q1'4445PGK!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5\2_ME^*&U;XD6FD*^8-+M1E?223YF_\=V5]M5^;_QRU1M6^+OBNX8Y(OGA
M_P"^/D'_ *#7J9='FJM]D?/YU4<<.HKJSA6-9VLZM!H]C)<SGY5X51U8]@/>
MKS-BN6\*VZ_$CXS>%-!8DV%QJL%KC/!!<;C^E>]5J>SC<^4PM!UIJ/0^_OV1
M?@_%X#\%VGB?74B7Q3K\:RJ)",VT##<D*9[D89L<G/M7T17'>,/A7HGC;6/#
M6I7_ -ICG\/W'VFT6VF,:;@,891U' K@?"O[0&L^(/V@M7^'TWA6:UTRS1RF
MI'=N^500[<;=K9P,5\15Q#]I>K]IV7]=#]9PN6^TH/ZKK[.+E):*R3MIKKW[
MGM]%<QX=\7OX@\3>(]-6V"6^DRQP>=NY=V7<PQ[<5PO@/3=:U#XZ>.M7D\27
MESH-L(K&+2)/]5'+M#$KVX_/FKES1:LK_H<-&I0JIMU+;VT?O-/5*R]7=Z:'
ML-%?/]O=?$V\_:HN[6#58F\#V5M')/:Y&Q4=3M&,9\S<,Y]*MR?M5::GQ\7X
M:?V'=%S/]D_M+S!CSMI;_5XSMX^]FN?ZQ&/\1..ME?J>S'*ZU?7"R56T.>7*
M[\J6Z>VJZH]UKYR_:D_97L?BUI=QKWA^".R\86Z;AM 5+X ?<?\ VO1OP/M]
M&4M=L9N#YHGA5*<:L>62/Q+U"VGTZ\GM+J%[>Z@=HI89!AD8'!4CL0:SY&YK
M[#_X*%?".#P]XBTSQUIT(B@U9C;7ZH,+]H495_JRY_%2:^/+>,W5Y!".3(ZK
M^9KVX3]I%21\S4INC-Q?0]:@RT*$\$@']*_2+]G?Q4WB[X/^'KN5]]S##]DE
M).3NC.T$^Y !_&OSDCCK[4_8AU)IO >MV!;(M[_S%'H'0?\ Q-:YA"]%2['+
ME%3EQ+CW1]'T445\X?:!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5^9?Q2RGQ*\6!N"-5NO_1K5^FE?G)^T
M1I3:)\9/%$!&!)<_:%]Q(H?^M>OEK_>27D?-YW%NE!]F>3>*-1.G:+=3*<.5
MV+]3Q7,_!/7(O"_Q>\&:O<-MM[/5K>61C_=#@'^=6_B%,?[/MX@?O2Y/X UQ
M,:D8*DJPY!'8^M>A7]Z7*>5@_<AS>9^XGWA[5GZW8W%UI.H)I\BVFHS6[QPW
M)7)1RIVD_0XKR#]DGXW6WQ>^&5G#<3K_ ,)%I$:VM_"3\S #"2CU# #GU!KW
M"OF9Q<6XL^XIU%)*<3YM^!>@>*?V>O!_C/7OBCKB2V+3"ZW+*;AR0,,^<9RQ
MQ@5V?[,_BK3/&_@O4M<T^X$\M[JMQ+<!AAXR6^56'J%Q7HWB_P (Z7XZ\.WV
MA:U;"[TV\C\N:(D@D>H(Y!'K7&6OP7M/ WPIUGPIX E;P_>744A@OG=G=9F'
MWV;K[<=*XH0J4+0AK!+KO<]W$5,'F3>)Q'N8AR5K)*FHM)-M+6^G0D^$O_$V
MU7QEK^=R7NJ-!"Q_YYQ )C\\U1\#Z%INO?%WQGXG>PMWN[.6+3(+EH@778F7
M*M[YP?I47[/_ ,.?%OPP^%DNC:[J=OJ6N>;/- P=I(XRW*@N0"PW<GCO5_X!
M^%_%7A?P;<P^,?L9UNYU">YD>S;<K*S9!)_SQ6\:GM+<T&FU]W_!/%EE\L(W
M&E7C*,)--IM<][ZI=8][^6YYE\#;#XAZ?\6?'FN>*?%/VOPA9RSP,)K@F+>I
M#*R*>$5%R#7OWA/QKH?CK33J&@:I;:M9!S&9K9]P##J#Z&J"_#71O^$1U?PX
MZRRZ?JAF-SN?YV,I);YOQX^E>?Z3\/8_V7_A?J<?@+0K_P 6WLETL[VDTX\V
M4G"YR% PJ@< 5@HO#NT=8:MMZL]IUHYI3Y\1:.(?+%**486VNW?1[:_TL7]N
M_38;[]G'6Y90"UG<6]Q'GLV_;_)S7YK^!M.-]K0F89CMQO/ID\ ?Y]*^^/\
M@H#XX:S^"NBZ"T1@U;Q!>1,;/(9D1%W.#CT9D&?8U\?>%]#&BZ:D1P9W^>5O
M]KT_"OI\!!RC?H?GF;5%3DX];6-=%KZ\_895AI'BMC]TSP8_[Y>OD=17VK^Q
M7I+6GPXU*^=<&[U!@I]55%&?S+5V8]VH->AY.4IRQ:?9,^A:***^8/O0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGOIE[OCA ?11Q^9[UZ/117RDY.<G*6[/T2G3C2@H06B"BBBH- HHHH ****
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MF!\UU&B_L+Z7 ZOJGB>[N1_%%;0+&/\ OHDG]*T^N4(_:.=9;BI/X/Q1\AJ
MO7BO2?AO\!O%WQ*FC>RT]K+3B?FU"]4I$!_L]V/L*^R_!W[.O@+P4Z2VFB1W
M=TO2XU ^>_Z\?I7I*QK&JJH"JHP !@ 5R5<RZ4E]YZ%#)-;UY?)?YGFGPC^
M?A[X3VXFMT_M'6F7$FHW"C=[A!_ /IS7IM%%>-.<JCYI.[/IJ=*%&*A35D%%
M%%0:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3_USM_\ T77HG_!,F^>W^,?B2V4_)<:.-P_W901_.O._VZ/^3G/%/_7.W_\
M1=7%6JLB4G*@KGI?_!,7_DK'BO\ [!*?^C:_2>OS8_X)B_\ )6/%?_8)3_T;
M7Z3USUOC9U8?^&CG_B%_R(/B7_L&7/\ Z*:OPR;[[_[Q_G7[F_$+_D0?$O\
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MC\UN(X_917ZK?L;_ +,>@?#7X=Z3XAU72X+WQ=JL"W4US=1AVME<96*//W<
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M@G_@I/X^\.Z+#8ZUHVF^(YX4"+?2,T,KX[OMR"?< 45:3D[H*%:,(\LC[O\
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M1EI H(D0#U*$XIU'RU(MA2BY4I)'YJ?L_P"M6OAOXY> ]3O9!%:6VL0/(YZ
M$[<_F17[75^"7/NI!^A!_H:^F/AO^WW\4O!>E:?H;R:7K]M$8X(YM5@=IE3(
M &Y'7=@=VR:*M-SLT*A65--2/HO_ (*>?\DI\,?]A;_VF:_/KP#_ ,C]X7_[
M"UG_ .CTK[\_X*3W3WOP6\&7$@ >;4$D8+TR8LG%? ?@'_D?O"__ &%K/_T>
ME.C_  Q5_P"*?H/_ ,%-/!4^L_"_P]XC@0NNBZ@R3[1TCF4+N/L"H_.OSO\
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M)>>$]=M1*]CJ:61GME!&"LO!"YR:U]C'VBBTTOZ\O\S!8F?L744DWI\K_/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>qlgn-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCMWbP9z5Z8mekhvWB8bQm6rywusOpZdCI+ubYWkf0A -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:QLGN="http://qualigendiagnostics.com/20231231" elementFormDefault="qualified" targetNamespace="http://qualigendiagnostics.com/20231231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" id="OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates">
          <link:definition>00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/LiquidityAndGoingConcern" id="LiquidityAndGoingConcern">
          <link:definition>00000008 - Disclosure - LIQUIDITY AND GOING CONCERN</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
          <link:definition>00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/OtherNon-currentAssets" id="OtherNon-currentAssets">
          <link:definition>00000010 - Disclosure - OTHER NON-CURRENT ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/DiscontinuedOperations" id="DiscontinuedOperations">
          <link:definition>00000011 - Disclosure - DISCONTINUED OPERATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
          <link:definition>00000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/WarrantLiabilities" id="WarrantLiabilities">
          <link:definition>00000013 - Disclosure - WARRANT LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedParty" id="ConvertibleDebt-RelatedParty">
          <link:definition>00000014 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/EarningsLossPerShare" id="EarningsLossPerShare">
          <link:definition>00000015 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreements" id="ResearchAndLicenseAgreements">
          <link:definition>00000017 - Disclosure - RESEARCH AND LICENSE AGREEMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>00000018 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000019 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000020 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000021 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies">
          <link:definition>00000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
          <link:definition>00000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/OtherNon-currentAssetsTables" id="OtherNon-currentAssetsTables">
          <link:definition>00000024 - Disclosure - OTHER NON-CURRENT ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/DiscontinuedOperationsTables" id="DiscontinuedOperationsTables">
          <link:definition>00000025 - Disclosure - DISCONTINUED OPERATIONS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
          <link:definition>00000026 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/WarrantLiabilitiesTables" id="WarrantLiabilitiesTables">
          <link:definition>00000027 - Disclosure - WARRANT LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyTables" id="ConvertibleDebt-RelatedPartyTables">
          <link:definition>00000028 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/EarningsLossPerShareTables" id="EarningsLossPerShareTables">
          <link:definition>00000029 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>00000030 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000031 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative">
          <link:definition>00000032 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/LiquidityAndGoingConcernDetailsNarrative" id="LiquidityAndGoingConcernDetailsNarrative">
          <link:definition>00000033 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:definition>00000034 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails" id="ScheduleOfOtherNonCurrentAssetsDetails">
          <link:definition>00000035 - Disclosure - SCHEDULE OF OTHER NON CURRENT ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails" id="ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails">
          <link:definition>00000036 - Disclosure - SCHEDULE OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails" id="AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails">
          <link:definition>00000037 - Disclosure - ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative" id="DiscontinuedOperationsDetailsNarrative">
          <link:definition>00000038 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:definition>00000039 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails" id="ScheduleOfWarrantsActivityDetails">
          <link:definition>00000040 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" id="ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails">
          <link:definition>00000041 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" id="ScheduleOfAssumptionsOfWarrantLiabilitiesDetails">
          <link:definition>00000042 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative" id="WarrantLiabilitiesDetailsNarrative">
          <link:definition>00000043 - Disclosure - WARRANT LIABILITIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" id="ScheduleOfSeniorSecuredConvertibleDebtDetails">
          <link:definition>00000044 - Disclosure - SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" id="ConvertibleDebt-RelatedPartyDetailsNarrative">
          <link:definition>00000045 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" id="ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails">
          <link:definition>00000046 - Disclosure - SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative" id="ResearchAndLicenseAgreementsDetailsNarrative">
          <link:definition>00000048 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails" id="ScheduleOfReservedSharesDetails">
          <link:definition>00000049 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>00000050 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" id="ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails">
          <link:definition>00000051 - Disclosure - SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails" id="ScheduleOfShare-basedCompensationExpenseDetails">
          <link:definition>00000052 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
          <link:definition>00000053 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>00000054 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000055 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfDomesticAndForeignComponentsDetails" id="ScheduleOfDomesticAndForeignComponentsDetails">
          <link:definition>00000056 - Disclosure - SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" id="ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails">
          <link:definition>00000057 - Disclosure - SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails" id="ScheduleOfProvisionForIncomeTaxesDetails">
          <link:definition>00000058 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>00000059 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000060 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000061 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="QLGN_NanoSynexLtdMember" name="NanoSynexLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeriesAOnePreferredStockMember" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PrefundedWarrantMember" name="PrefundedWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NanosynexMember" name="NanosynexMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ChembioDiagnosticsMember" name="ChembioDiagnosticsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AmendmentAndSettlementAgreementMember" name="AmendmentAndSettlementAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeriesCWarrantsMember" name="SeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AlphaCapitalMember" name="AlphaCapitalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeniorConvertibleDebentureMember" name="SeniorConvertibleDebentureMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AlphaCapitalOtherThirdPartiesMember" name="AlphaCapitalOtherThirdPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_OctoberPaymentMember" name="OctoberPaymentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeniorSecuredConvertibleDebtMember" name="SeniorSecuredConvertibleDebtMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_UpfrontPaymentMember" name="UpfrontPaymentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_MasterLaboratoryServicesAgreementMember" name="MasterLaboratoryServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_MLMMedicalLabsMember" name="MLMMedicalLabsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SponsoredResearchAgreementAndLicenseMember" name="SponsoredResearchAgreementAndLicenseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_UniversityOfLouisvilleResearchFoundationMember" name="UniversityOfLouisvilleResearchFoundationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicenseAndSponsoredResearchAgreementsMember" name="LicenseAndSponsoredResearchAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PhaseOneClinicalTrialMember" name="PhaseOneClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PhaseTwoClinicalTrialMember" name="PhaseTwoClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PhaseThreeClinicalTrialMember" name="PhaseThreeClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicensedProductSalesMember" name="LicensedProductSalesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SponsoredResearchAgreementsAndLicenseMember" name="SponsoredResearchAgreementsAndLicenseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TwoThousandTwentyStockIncentivePlanMember" name="TwoThousandTwentyStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CompensatoryWarrantsMember" name="CompensatoryWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CompensatoryWarrantActivityMember" name="CompensatoryWarrantActivityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NoncompensatoryEquityClassifiedWarrantsMember" name="NoncompensatoryEquityClassifiedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NonCompensatoryWarrantActivityMember" name="NonCompensatoryWarrantActivityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ConversionOfConvertibleDebtMember" name="ConversionOfConvertibleDebtMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EmployeesAndNonemployeeServiceProviderMember" name="EmployeesAndNonemployeeServiceProviderMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TwentyTwentyFourDebentureAndWarrantMember" name="TwentyTwentyFourDebentureAndWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TwentyTwentyFourDebentureMember" name="TwentyTwentyFourDebentureMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TwentyTwentyFourWarrantMember" name="TwentyTwentyFourWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantLiabilitiesRelatedParty" name="WarrantLiabilitiesRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" name="StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock" name="StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" name="FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DeconsolidationOfDiscontinuedOperations" name="DeconsolidationOfDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" name="StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" name="StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" name="NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantModificationForBusinessAcquisition" name="FairValueOfWarrantModificationForBusinessAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" name="StockIssuedDuringPeriodValuesReverseStockSplits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LossOnVoluntaryConversionOfConvertibleDebt" name="LossOnVoluntaryConversionOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccretionOfDiscountOnConvertibleDebt" name="AccretionOfDiscountOnConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantModificationForProfessionalServices" name="FairValueOfWarrantModificationForProfessionalServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ProceedsFromIssuanceOfConvertibleDebt" name="ProceedsFromIssuanceOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" name="FractionalSharePaymentsRelatedToReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TransfersOfInventoryFromEquipmentHeldForLease" name="TransfersOfInventoryFromEquipmentHeldForLease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" name="FairValueOfWarrantLiabilitiesOnDateOfExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RedemptionOfConvertibleDebtIntoCommonStock" name="RedemptionOfConvertibleDebtIntoCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock" name="VoluntaryConversionOfConvertibleDebtIntoCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement" name="FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition" name="FairValueOfWarrantModificationsForBusinessAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisclosureWarrantLiabilitiesAbstract" name="DisclosureWarrantLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantLiabilitiesTextBlock" name="WarrantLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisclosureResearchAndLicenseAgreementsAbstract" name="DisclosureResearchAndLicenseAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ResearchAndLicenseAgreementsTextBlock" name="ResearchAndLicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_OrganizationPolicyTextBlock" name="OrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" name="DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_GlobalEconomicConditionsPolicyTextBlock" name="GlobalEconomicConditionsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ImpactOfCovid19PandemicPolicyTextBlock" name="ImpactOfCovid19PandemicPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" name="ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" name="ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfReservedSharesTableTextBlock" name="ScheduleOfReservedSharesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SummaryOfWarrantActivityTableTextBlock" name="SummaryOfWarrantActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PreapaidResearchAndDevelopmentExpenses" name="PreapaidResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LongtermResearchAndDevelopmentDeposits" name="LongtermResearchAndDevelopmentDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TotalAssetsOfDiscontinuedOperations" name="TotalAssetsOfDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TotalLiabilitiesOfdiscontinuedOperations" name="TotalLiabilitiesOfdiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets" name="DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation" name="DisposalGroupIncludingDiscontinuedOperationAccruedVacation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales" name="DisposalGroupIncludingDiscontinuedOperationNetProductSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment" name="DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing" name="DisposalGroupIncludingDiscontinuedSalesAndMarketing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses" name="DisposalGroupIncludingDiscontinuedTotalExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease" name="DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" name="DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal" name="DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc." name="DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc." nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" name="DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived" name="DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment" name="DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets" name="DisposalGroupIncludingDiscontinuedOperationTotalAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities" name="DisposalGroupIncludingDiscontinuedOperationTotalLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses" name="DisposalGroupIncludingDiscontinuedOperationTransactionExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash" name="AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty" name="DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment" name="DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained" name="DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated" name="DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare" name="DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable" name="DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt" name="DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation" name="DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PurchasePrice" name="PurchasePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss" name="DisposalGroupIncludingDiscontinuedOperationGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedDuringPeriodShareSurrender" name="StockIssuedDuringPeriodShareSurrender" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedCompensation" name="AccruedCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedLicenseFees" name="AccruedLicenseFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedResearchAndDevelopmentCurrent" name="AccruedResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePrice" name="RangeOfExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceExpired" name="RangeOfExercisePriceExpired" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceGranted" name="RangeOfExercisePriceGranted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceExercisableVested" name="RangeOfExercisePriceExercisableVested" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueAdjustmentOfWarrant" name="FairValueAdjustmentOfWarrant" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantLiabilitiesOnToEquity" name="FairValueOfWarrantLiabilitiesOnToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" name="FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ChangeInFairValueOfWarrantLiabilities" name="ChangeInFairValueOfWarrantLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ConversionPricePercentage" name="ConversionPricePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PrincipalAmountPercentage" name="PrincipalAmountPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DebentureBeneficialOwnershipBlockerPercentage" name="DebentureBeneficialOwnershipBlockerPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DebtRedemptionAmountInCash" name="DebtRedemptionAmountInCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DebtRedemptionAmountInCommonStock" name="DebtRedemptionAmountInCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" name="DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ReimbursementOfPatent" name="ReimbursementOfPatent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicenseCost" name="LicenseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ReimbursementOfResearchExpenses" name="ReimbursementOfResearchExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AgreementTermPaymentDescription" name="AgreementTermPaymentDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_MilestonePayment" name="MilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RegulatoryMarketingApprovalExpenses" name="RegulatoryMarketingApprovalExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CumulativeSales" name="CumulativeSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_UpfrontLicenseFee" name="UpfrontLicenseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PatentCosts" name="PatentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RegulatoryMarketingApprovalExpensesOne" name="RegulatoryMarketingApprovalExpensesOne" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShortfallPayments" name="ShortfallPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" name="WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceOutstanding" name="RangeOfExercisePriceOutstanding" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceNonexercisableNonvested" name="RangeOfExercisePriceNonexercisableNonvested" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" name="RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceExercisableGranted" name="RangeOfExercisePriceExercisableGranted" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceExercised" name="RangeOfExercisePriceExercised" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceExercisableExpired" name="RangeOfExercisePriceExercisableExpired" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceForfeited" name="RangeOfExercisePriceForfeited" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockholdersEquityReverseStockSplitPricePerShare" name="StockholdersEquityReverseStockSplitPricePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantsExtendedDateDescription" name="WarrantsExtendedDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantsExercised" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ModifiedToExercisePrice" name="ModifiedToExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" name="EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" name="EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" name="EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" name="EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EffectiveIncomeTaxRateReconciliationTrueUp" name="EffectiveIncomeTaxRateReconciliationTrueUp" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DefferdTaxAssetsAccruedExpenses" name="DefferdTaxAssetsAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" name="DeferredTaxAssetsResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ReimbursementExpenses" name="ReimbursementExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity" name="AdditionalProceedsFromIssuanceOrSaleOfEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantModifcationsPursuantToSecuritiesPurchaseAgreeement" name="FairValueOfWarrantModifcationsPursuantToSecuritiesPurchaseAgreeement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>qlgn-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/Cover" xlink:href="qlgn-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/BalanceSheets" xlink:href="qlgn-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/BalanceSheetsParenthetical" xlink:href="qlgn-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="qlgn-20231231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="qlgn-20231231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StatementsOfCashFlows" xlink:href="qlgn-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:href="qlgn-20231231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/LiquidityAndGoingConcern" xlink:href="qlgn-20231231.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="qlgn-20231231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OtherNon-currentAssets" xlink:href="qlgn-20231231.xsd#OtherNon-currentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/DiscontinuedOperations" xlink:href="qlgn-20231231.xsd#DiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="qlgn-20231231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/WarrantLiabilities" xlink:href="qlgn-20231231.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedParty" xlink:href="qlgn-20231231.xsd#ConvertibleDebt-RelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/EarningsLossPerShare" xlink:href="qlgn-20231231.xsd#EarningsLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/CommitmentsAndContingencies" xlink:href="qlgn-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreements" xlink:href="qlgn-20231231.xsd#ResearchAndLicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StockholdersEquity" xlink:href="qlgn-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/RelatedPartyTransactions" xlink:href="qlgn-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/IncomeTaxes" xlink:href="qlgn-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/SubsequentEvents" xlink:href="qlgn-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:href="qlgn-20231231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="qlgn-20231231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OtherNon-currentAssetsTables" xlink:href="qlgn-20231231.xsd#OtherNon-currentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/DiscontinuedOperationsTables" xlink:href="qlgn-20231231.xsd#DiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="qlgn-20231231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/WarrantLiabilitiesTables" xlink:href="qlgn-20231231.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyTables" xlink:href="qlgn-20231231.xsd#ConvertibleDebt-RelatedPartyTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/EarningsLossPerShareTables" xlink:href="qlgn-20231231.xsd#EarningsLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StockholdersEquityTables" xlink:href="qlgn-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/IncomeTaxesTables" xlink:href="qlgn-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:href="qlgn-20231231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="qlgn-20231231.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfOtherNonCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails" xlink:href="qlgn-20231231.xsd#AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative" xlink:href="qlgn-20231231.xsd#DiscontinuedOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="qlgn-20231231.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:href="qlgn-20231231.xsd#ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="qlgn-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:href="qlgn-20231231.xsd#ResearchAndLicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfReservedSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfShare-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative" xlink:href="qlgn-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="qlgn-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfDomesticAndForeignComponentsDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfDomesticAndForeignComponentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative" xlink:href="qlgn-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative" xlink:href="qlgn-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingLiabilitiesCurrent" xlink:label="loc_us-gaapHedgingLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapHedgingLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WarrantLiabilitiesRelatedParty" xlink:label="loc_QLGNWarrantLiabilitiesRelatedParty" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_QLGNWarrantLiabilitiesRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaapInducedConversionOfConvertibleDebtExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInducedConversionOfConvertibleDebtExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LossOnVoluntaryConversionOfConvertibleDebt" xlink:label="loc_QLGNLossOnVoluntaryConversionOfConvertibleDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_QLGNLossOnVoluntaryConversionOfConvertibleDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AccretionOfDiscountOnConvertibleDebt" xlink:label="loc_QLGNAccretionOfDiscountOnConvertibleDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_QLGNAccretionOfDiscountOnConvertibleDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantModificationForProfessionalServices" xlink:label="loc_QLGNFairValueOfWarrantModificationForProfessionalServices" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_QLGNFairValueOfWarrantModificationForProfessionalServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ProceedsFromIssuanceOfConvertibleDebt" xlink:label="loc_QLGNProceedsFromIssuanceOfConvertibleDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_QLGNProceedsFromIssuanceOfConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" xlink:label="loc_QLGNFractionalSharePaymentsRelatedToReverseStockSplit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_QLGNFractionalSharePaymentsRelatedToReverseStockSplit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapCashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/LiquidityAndGoingConcern" xlink:title="00000008 - Disclosure - LIQUIDITY AND GOING CONCERN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OtherNon-currentAssets" xlink:title="00000010 - Disclosure - OTHER NON-CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/DiscontinuedOperations" xlink:title="00000011 - Disclosure - DISCONTINUED OPERATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/WarrantLiabilities" xlink:title="00000013 - Disclosure - WARRANT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedParty" xlink:title="00000014 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/EarningsLossPerShare" xlink:title="00000015 - Disclosure - EARNINGS (LOSS) PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreements" xlink:title="00000017 - Disclosure - RESEARCH AND LICENSE AGREEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/RelatedPartyTransactions" xlink:title="00000019 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/IncomeTaxes" xlink:title="00000020 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:title="00000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OtherNon-currentAssetsTables" xlink:title="00000024 - Disclosure - OTHER NON-CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/DiscontinuedOperationsTables" xlink:title="00000025 - Disclosure - DISCONTINUED OPERATIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000026 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/WarrantLiabilitiesTables" xlink:title="00000027 - Disclosure - WARRANT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyTables" xlink:title="00000028 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/EarningsLossPerShareTables" xlink:title="00000029 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:title="00000032 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="00000033 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableInvestmentSale" xlink:label="loc_us-gaapReceivableInvestmentSale" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapReceivableInvestmentSale" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PreapaidResearchAndDevelopmentExpenses" xlink:label="loc_QLGNPreapaidResearchAndDevelopmentExpenses" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_QLGNPreapaidResearchAndDevelopmentExpenses" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF OTHER NON CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LongtermResearchAndDevelopmentDeposits" xlink:label="loc_QLGNLongtermResearchAndDevelopmentDeposits" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_QLGNLongtermResearchAndDevelopmentDeposits" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails" xlink:title="00000037 - Disclosure - ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative" xlink:title="00000038 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AccruedCompensation" xlink:label="loc_QLGNAccruedCompensation" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_QLGNAccruedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AccruedLicenseFees" xlink:label="loc_QLGNAccruedLicenseFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_QLGNAccruedLicenseFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_QLGNAccruedResearchAndDevelopmentCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_QLGNAccruedResearchAndDevelopmentCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000043 - Disclosure - WARRANT LIABILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:title="00000045 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:title="00000048 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000053 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000054 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000055 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfDomesticAndForeignComponentsDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" xlink:label="loc_QLGNEffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_QLGNEffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" xlink:label="loc_QLGNEffectiveIncomeTaxRateReconciliationFairValueOfWarrant" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_QLGNEffectiveIncomeTaxRateReconciliationFairValueOfWarrant" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" xlink:label="loc_QLGNEffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_QLGNEffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" xlink:label="loc_QLGNEffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_QLGNEffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationTrueUp" xlink:label="loc_QLGNEffectiveIncomeTaxRateReconciliationTrueUp" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_QLGNEffectiveIncomeTaxRateReconciliationTrueUp" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DefferdTaxAssetsAccruedExpenses" xlink:label="loc_QLGNDefferdTaxAssetsAccruedExpenses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_QLGNDefferdTaxAssetsAccruedExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:label="loc_QLGNDeferredTaxAssetsResearchAndDevelopmentExpenses" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_QLGNDeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000060 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000061 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>qlgn-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/Cover" xlink:href="qlgn-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/BalanceSheets" xlink:href="qlgn-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/BalanceSheetsParenthetical" xlink:href="qlgn-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="qlgn-20231231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="qlgn-20231231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StatementsOfCashFlows" xlink:href="qlgn-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:href="qlgn-20231231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/LiquidityAndGoingConcern" xlink:href="qlgn-20231231.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="qlgn-20231231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OtherNon-currentAssets" xlink:href="qlgn-20231231.xsd#OtherNon-currentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/DiscontinuedOperations" xlink:href="qlgn-20231231.xsd#DiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="qlgn-20231231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/WarrantLiabilities" xlink:href="qlgn-20231231.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedParty" xlink:href="qlgn-20231231.xsd#ConvertibleDebt-RelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/EarningsLossPerShare" xlink:href="qlgn-20231231.xsd#EarningsLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/CommitmentsAndContingencies" xlink:href="qlgn-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreements" xlink:href="qlgn-20231231.xsd#ResearchAndLicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StockholdersEquity" xlink:href="qlgn-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/RelatedPartyTransactions" xlink:href="qlgn-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/IncomeTaxes" xlink:href="qlgn-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/SubsequentEvents" xlink:href="qlgn-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:href="qlgn-20231231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="qlgn-20231231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OtherNon-currentAssetsTables" xlink:href="qlgn-20231231.xsd#OtherNon-currentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/DiscontinuedOperationsTables" xlink:href="qlgn-20231231.xsd#DiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="qlgn-20231231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/WarrantLiabilitiesTables" xlink:href="qlgn-20231231.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyTables" xlink:href="qlgn-20231231.xsd#ConvertibleDebt-RelatedPartyTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/EarningsLossPerShareTables" xlink:href="qlgn-20231231.xsd#EarningsLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StockholdersEquityTables" xlink:href="qlgn-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/IncomeTaxesTables" xlink:href="qlgn-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:href="qlgn-20231231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="qlgn-20231231.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfOtherNonCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails" xlink:href="qlgn-20231231.xsd#AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative" xlink:href="qlgn-20231231.xsd#DiscontinuedOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="qlgn-20231231.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:href="qlgn-20231231.xsd#ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="qlgn-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:href="qlgn-20231231.xsd#ResearchAndLicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfReservedSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfShare-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative" xlink:href="qlgn-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="qlgn-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfDomesticAndForeignComponentsDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfDomesticAndForeignComponentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative" xlink:href="qlgn-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative" xlink:href="qlgn-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" xlink:label="loc_QLGNStockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock" xlink:label="loc_QLGNStockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" xlink:label="loc_QLGNFairValueOfWarrantReclassifiedFromLiabilitiesToEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNFairValueOfWarrantReclassifiedFromLiabilitiesToEquity_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DeconsolidationOfDiscontinuedOperations" xlink:label="loc_QLGNDeconsolidationOfDiscontinuedOperations_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDeconsolidationOfDiscontinuedOperations_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_80" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" xlink:label="loc_QLGNStockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_80" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" xlink:label="loc_QLGNStockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_80" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" xlink:label="loc_QLGNNoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNNoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_80" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_80" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantModificationForBusinessAcquisition" xlink:label="loc_QLGNFairValueOfWarrantModificationForBusinessAcquisition_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNFairValueOfWarrantModificationForBusinessAcquisition_80" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:label="loc_QLGNStockIssuedDuringPeriodValuesReverseStockSplits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValuesReverseStockSplits_80" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_80" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/LiquidityAndGoingConcern" xlink:title="00000008 - Disclosure - LIQUIDITY AND GOING CONCERN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OtherNon-currentAssets" xlink:title="00000010 - Disclosure - OTHER NON-CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/DiscontinuedOperations" xlink:title="00000011 - Disclosure - DISCONTINUED OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/WarrantLiabilities" xlink:title="00000013 - Disclosure - WARRANT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedParty" xlink:title="00000014 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/EarningsLossPerShare" xlink:title="00000015 - Disclosure - EARNINGS (LOSS) PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreements" xlink:title="00000017 - Disclosure - RESEARCH AND LICENSE AGREEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/RelatedPartyTransactions" xlink:title="00000019 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/IncomeTaxes" xlink:title="00000020 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:title="00000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OtherNon-currentAssetsTables" xlink:title="00000024 - Disclosure - OTHER NON-CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/DiscontinuedOperationsTables" xlink:title="00000025 - Disclosure - DISCONTINUED OPERATIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanosynexMember" xlink:label="loc_QLGNNanosynexMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNNanosynexMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000026 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/WarrantLiabilitiesTables" xlink:title="00000027 - Disclosure - WARRANT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyTables" xlink:title="00000028 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/EarningsLossPerShareTables" xlink:title="00000029 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="loc_QLGNNonCompensatoryWarrantActivityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNNonCompensatoryWarrantActivityMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:label="loc_QLGNScheduleOfReservedSharesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNScheduleOfReservedSharesTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:label="loc_QLGNSummaryOfWarrantActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNSummaryOfWarrantActivityTableTextBlock_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:title="00000032 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesAOnePreferredStockMember" xlink:label="loc_QLGNSeriesAOnePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAOnePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PrefundedWarrantMember" xlink:label="loc_QLGNPrefundedWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNPrefundedWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss_100" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="00000033 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF OTHER NON CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="loc_srtParentCompanyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_srtParentCompanyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanosynexMember" xlink:label="loc_QLGNNanosynexMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_QLGNNanosynexMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TotalAssetsOfDiscontinuedOperations" xlink:label="loc_QLGNTotalAssetsOfDiscontinuedOperations_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNTotalAssetsOfDiscontinuedOperations_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TotalLiabilitiesOfdiscontinuedOperations" xlink:label="loc_QLGNTotalLiabilitiesOfdiscontinuedOperations_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNTotalLiabilitiesOfdiscontinuedOperations_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax_100" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails" xlink:title="00000037 - Disclosure - ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanosynexMember" xlink:label="loc_QLGNNanosynexMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNNanosynexMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationInventoryCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationInventoryCurrent_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TotalAssetsOfDiscontinuedOperations" xlink:label="loc_QLGNTotalAssetsOfDiscontinuedOperations_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNTotalAssetsOfDiscontinuedOperations_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationAccruedVacation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationAccruedVacation_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_90" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_90" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TotalLiabilitiesOfdiscontinuedOperations" xlink:label="loc_QLGNTotalLiabilitiesOfdiscontinuedOperations_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNTotalLiabilitiesOfdiscontinuedOperations_90" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationNetProductSales_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationNetProductSales_90" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue_90" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_90" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_90" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_90" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment_90" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedSalesAndMarketing_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedSalesAndMarketing_90" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedTotalExpenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedTotalExpenses_90" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease_90" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_90" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_90" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal_90" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_90" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_90" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc." xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc._90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc._90" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_QLGNDiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_90" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived_90" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment_90" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationTotalAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationTotalAssets_90" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationTotalLiabilities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationTotalLiabilities_90" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationTransactionExpenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationTransactionExpenses_90" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments_90" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash" xlink:label="loc_QLGNAssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNAssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash_90" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_90" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_90" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability_90" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty_90" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment_90" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_90" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_90" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax_90" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_90" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained_90" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated_90" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare_90" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable_90" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt_90" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation_90" xlink:type="arc" order="58" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative" xlink:title="00000038 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ChembioDiagnosticsMember" xlink:label="loc_QLGNChembioDiagnosticsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNChembioDiagnosticsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNNanoSynexLtdMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AmendmentAndSettlementAgreementMember" xlink:label="loc_QLGNAmendmentAndSettlementAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNAmendmentAndSettlementAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PurchasePrice" xlink:label="loc_QLGNPurchasePrice_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNPurchasePrice_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEscrowDeposit_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationGainLoss_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationGainLoss_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodShareSurrender" xlink:label="loc_QLGNStockIssuedDuringPeriodShareSurrender_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodShareSurrender_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited_120" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CommonStockWarrantsMember" xlink:label="loc_QLGNCommonStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCommonStockWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePrice" xlink:label="loc_QLGNRangeOfExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePrice_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExpired" xlink:label="loc_QLGNRangeOfExercisePriceExpired_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExpired_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceGranted" xlink:label="loc_QLGNRangeOfExercisePriceGranted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePriceGranted_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_90" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested_90" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_90" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueAdjustmentOfWarrant" xlink:label="loc_QLGNFairValueAdjustmentOfWarrant_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_QLGNFairValueAdjustmentOfWarrant_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:label="loc_QLGNFairValueOfWarrantLiabilitiesOnDateOfExercise_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_QLGNFairValueOfWarrantLiabilitiesOnDateOfExercise_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantLiabilitiesOnToEquity" xlink:label="loc_QLGNFairValueOfWarrantLiabilitiesOnToEquity_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_QLGNFairValueOfWarrantLiabilitiesOnToEquity_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" xlink:label="loc_QLGNFairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_QLGNFairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_QLGNChangeInFairValueOfWarrantLiabilities_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_QLGNChangeInFairValueOfWarrantLiabilities_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="loc_srtWeightedAverageMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtWeightedAverageMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_160" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000043 - Disclosure - WARRANT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesTreasuryStockReissued_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesTreasuryStockReissued_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ConversionPricePercentage" xlink:label="loc_QLGNConversionPricePercentage_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNConversionPricePercentage_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPriceDecrease_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPriceDecrease_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_210" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeniorSecuredConvertibleDebtMember" xlink:label="loc_QLGNSeniorSecuredConvertibleDebtMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorSecuredConvertibleDebtMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSecuredDebt_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:title="00000045 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalOtherThirdPartiesMember" xlink:label="loc_QLGNAlphaCapitalOtherThirdPartiesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalOtherThirdPartiesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeniorConvertibleDebentureMember" xlink:label="loc_QLGNSeniorConvertibleDebentureMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorConvertibleDebentureMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_QLGNAlphaCapitalMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_OctoberPaymentMember" xlink:label="loc_QLGNOctoberPaymentMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNOctoberPaymentMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_QLGNAlphaCapitalMember_160" xlink:type="arc" order="163" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_180" xlink:type="arc" order="183" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_190" xlink:type="arc" order="193" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaapExtinguishmentOfDebtAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapExtinguishmentOfDebtAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaapExtinguishmentOfDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapExtinguishmentOfDebtAxis" xlink:to="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaapExtinguishmentOfDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapExtinguishmentOfDebtAxis" xlink:to="loc_us-gaapExtinguishmentOfDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="loc_us-gaapShortTermDebtInterestRateIncrease_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtInterestRateIncrease_260" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSecuredDebt_260" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PurchasePrice" xlink:label="loc_QLGNPurchasePrice_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNPurchasePrice_260" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_260" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_260" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_260" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_260" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ConversionPricePercentage" xlink:label="loc_QLGNConversionPricePercentage_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNConversionPricePercentage_260" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="loc_us-gaapRepaymentsOfLongTermDebtAndCapitalSecurities_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfLongTermDebtAndCapitalSecurities_260" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_260" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PrincipalAmountPercentage" xlink:label="loc_QLGNPrincipalAmountPercentage_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNPrincipalAmountPercentage_260" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_260" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DebentureBeneficialOwnershipBlockerPercentage" xlink:label="loc_QLGNDebentureBeneficialOwnershipBlockerPercentage_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNDebentureBeneficialOwnershipBlockerPercentage_260" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_260" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_260" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_260" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_260" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:label="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_260" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsForFees_260" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_260" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_260" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebtCurrent_260" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_260" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_260" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_260" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease_260" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease_260" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="loc_us-gaapWarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_260" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue_260" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1_260" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_260" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DebtRedemptionAmountInCash" xlink:label="loc_QLGNDebtRedemptionAmountInCash_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNDebtRedemptionAmountInCash_260" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DebtRedemptionAmountInCommonStock" xlink:label="loc_QLGNDebtRedemptionAmountInCommonStock_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNDebtRedemptionAmountInCommonStock_260" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_260" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet_260" xlink:type="arc" order="34" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:title="00000048 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_UpfrontPaymentMember" xlink:label="loc_QLGNUpfrontPaymentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNUpfrontPaymentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PhaseOneClinicalTrialMember" xlink:label="loc_QLGNPhaseOneClinicalTrialMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseOneClinicalTrialMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PhaseTwoClinicalTrialMember" xlink:label="loc_QLGNPhaseTwoClinicalTrialMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseTwoClinicalTrialMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PhaseThreeClinicalTrialMember" xlink:label="loc_QLGNPhaseThreeClinicalTrialMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseThreeClinicalTrialMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LicenseAgreementMember" xlink:label="loc_QLGNLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLicenseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_MasterLaboratoryServicesAgreementMember" xlink:label="loc_QLGNMasterLaboratoryServicesAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNMasterLaboratoryServicesAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:label="loc_QLGNSponsoredResearchAgreementAndLicenseMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSponsoredResearchAgreementAndLicenseMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:label="loc_QLGNLicenseAndSponsoredResearchAgreementsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLicenseAndSponsoredResearchAgreementsMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SponsoredResearchAgreementsAndLicenseMember" xlink:label="loc_QLGNSponsoredResearchAgreementsAndLicenseMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSponsoredResearchAgreementsAndLicenseMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_MLMMedicalLabsMember" xlink:label="loc_QLGNMLMMedicalLabsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNMLMMedicalLabsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:label="loc_QLGNUniversityOfLouisvilleResearchFoundationMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNUniversityOfLouisvilleResearchFoundationMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LicensedProductSalesMember" xlink:label="loc_QLGNLicensedProductSalesMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicensedProductSalesMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ReimbursementOfPatent" xlink:label="loc_QLGNReimbursementOfPatent_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNReimbursementOfPatent_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LicenseCost" xlink:label="loc_QLGNLicenseCost_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNLicenseCost_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ReimbursementOfResearchExpenses" xlink:label="loc_QLGNReimbursementOfResearchExpenses_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNReimbursementOfResearchExpenses_320" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AgreementTermPaymentDescription" xlink:label="loc_QLGNAgreementTermPaymentDescription_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNAgreementTermPaymentDescription_320" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_MilestonePayment" xlink:label="loc_QLGNMilestonePayment_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNMilestonePayment_320" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RegulatoryMarketingApprovalExpenses" xlink:label="loc_QLGNRegulatoryMarketingApprovalExpenses_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRegulatoryMarketingApprovalExpenses_320" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CumulativeSales" xlink:label="loc_QLGNCumulativeSales_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNCumulativeSales_320" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_320" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_UpfrontLicenseFee" xlink:label="loc_QLGNUpfrontLicenseFee_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNUpfrontLicenseFee_320" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_320" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PatentCosts" xlink:label="loc_QLGNPatentCosts_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNPatentCosts_320" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RegulatoryMarketingApprovalExpensesOne" xlink:label="loc_QLGNRegulatoryMarketingApprovalExpensesOne_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRegulatoryMarketingApprovalExpensesOne_320" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShortfallPayments" xlink:label="loc_QLGNShortfallPayments_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShortfallPayments_320" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ConversionOfConvertibleDebtMember" xlink:label="loc_QLGNConversionOfConvertibleDebtMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNConversionOfConvertibleDebtMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:label="loc_QLGNEmployeesAndNonemployeeServiceProviderMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNEmployeesAndNonemployeeServiceProviderMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_170" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_170" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_170" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_170" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_170" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:label="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_170" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_170" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_170" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_170" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000053 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="loc_QLGNNonCompensatoryWarrantActivityMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNNonCompensatoryWarrantActivityMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_230" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceOutstanding" xlink:label="loc_QLGNRangeOfExercisePriceOutstanding_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOutstanding_230" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_230" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_230" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_230" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_230" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_230" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_230" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_230" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExpired" xlink:label="loc_QLGNRangeOfExercisePriceExpired_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExpired_230" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_230" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_230" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_230" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_230" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested_230" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_230" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_230" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_230" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:label="loc_QLGNRangeOfExercisePriceNonexercisableNonvested_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceNonexercisableNonvested_230" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_230" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_230" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_230" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice_230" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" xlink:label="loc_QLGNRangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_230" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_230" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_230" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_230" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercisableGranted" xlink:label="loc_QLGNRangeOfExercisePriceExercisableGranted_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableGranted_230" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercised" xlink:label="loc_QLGNRangeOfExercisePriceExercised_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercised_230" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercisableExpired" xlink:label="loc_QLGNRangeOfExercisePriceExercisableExpired_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableExpired_230" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceForfeited" xlink:label="loc_QLGNRangeOfExercisePriceForfeited_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceForfeited_230" xlink:type="arc" order="35" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000054 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CompensatoryWarrantsMember" xlink:label="loc_QLGNCompensatoryWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNCompensatoryWarrantsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:label="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_QLGNTwoThousandTwentyStockIncentivePlanMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_QLGNTwoThousandTwentyStockIncentivePlanMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember_360" xlink:type="arc" order="362" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanosynexMember" xlink:label="loc_QLGNNanosynexMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanosynexMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember_510" xlink:type="arc" order="512" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_560" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_560" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_560" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation_560" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_560" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_560" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_560" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_560" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_560" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_560" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_560" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_560" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_560" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockholdersEquityReverseStockSplitPricePerShare" xlink:label="loc_QLGNStockholdersEquityReverseStockSplitPricePerShare_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNStockholdersEquityReverseStockSplitPricePerShare_560" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WarrantsExtendedDateDescription" xlink:label="loc_QLGNWarrantsExtendedDateDescription_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNWarrantsExtendedDateDescription_560" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_560" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_560" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_560" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_560" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WarrantsExercised" xlink:label="loc_QLGNWarrantsExercised_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNWarrantsExercised_560" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_560" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ModifiedToExercisePrice" xlink:label="loc_QLGNModifiedToExercisePrice_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNModifiedToExercisePrice_560" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPriceDecrease_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPriceDecrease_560" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000055 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeniorConvertibleDebentureMember" xlink:label="loc_QLGNSeniorConvertibleDebentureMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorConvertibleDebentureMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesAOnePreferredStockMember" xlink:label="loc_QLGNSeriesAOnePreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAOnePreferredStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PrefundedWarrantMember" xlink:label="loc_QLGNPrefundedWarrantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNPrefundedWarrantMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="loc_us-gaapShortTermDebtInterestRateIncrease_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermDebtInterestRateIncrease_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSecuredDebt_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PurchasePrice" xlink:label="loc_QLGNPurchasePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNPurchasePrice_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_90" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfDomesticAndForeignComponentsDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000060 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000061 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TwentyTwentyFourDebentureAndWarrantMember" xlink:label="loc_QLGNTwentyTwentyFourDebentureAndWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_QLGNTwentyTwentyFourDebentureAndWarrantMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TwentyTwentyFourDebentureMember" xlink:label="loc_QLGNTwentyTwentyFourDebentureMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNTwentyTwentyFourDebentureMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TwentyTwentyFourWarrantMember" xlink:label="loc_QLGNTwentyTwentyFourWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNTwentyTwentyFourWarrantMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ReimbursementExpenses" xlink:label="loc_QLGNReimbursementExpenses_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_QLGNReimbursementExpenses_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPeriodIncreaseDecrease_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPeriodIncreaseDecrease_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_QLGNAdditionalProceedsFromIssuanceOrSaleOfEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_QLGNAdditionalProceedsFromIssuanceOrSaleOfEquity_60" xlink:type="arc" order="10" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>qlgn-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanoSynexLtdMember" xlink:label="QLGN_NanoSynexLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NanoSynexLtdMember" xlink:to="QLGN_NanoSynexLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NanoSynexLtdMember_lbl" xml:lang="en-US">NanoSynex Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesAOnePreferredStockMember" xlink:label="QLGN_SeriesAOnePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesAOnePreferredStockMember" xlink:to="QLGN_SeriesAOnePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US">Series A-1 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PrefundedWarrantMember" xlink:label="QLGN_PrefundedWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrefundedWarrantMember" xlink:to="QLGN_PrefundedWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PrefundedWarrantMember_lbl" xml:lang="en-US">Pre-funded Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanosynexMember" xlink:label="QLGN_NanosynexMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NanosynexMember" xlink:to="QLGN_NanosynexMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NanosynexMember_lbl" xml:lang="en-US">NanoSynex [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ParentCompanyMember_lbl" xml:lang="en-US">Parent Company [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ChembioDiagnosticsMember" xlink:label="QLGN_ChembioDiagnosticsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ChembioDiagnosticsMember" xlink:to="QLGN_ChembioDiagnosticsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ChembioDiagnosticsMember_lbl" xml:lang="en-US">Chembio diagnostics [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AmendmentAndSettlementAgreementMember" xlink:label="QLGN_AmendmentAndSettlementAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AmendmentAndSettlementAgreementMember" xlink:to="QLGN_AmendmentAndSettlementAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AmendmentAndSettlementAgreementMember_lbl" xml:lang="en-US">Amendment and Settlement Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="QLGN_SeriesCWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesCWarrantsMember" xlink:to="QLGN_SeriesCWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeriesCWarrantsMember_lbl" xml:lang="en-US">Series C Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="QLGN_AlphaCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AlphaCapitalMember" xlink:to="QLGN_AlphaCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AlphaCapitalMember_lbl" xml:lang="en-US">Alpha Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="QLGN_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SecuritiesPurchaseAgreementMember" xlink:to="QLGN_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CommonStockWarrantsMember" xlink:label="QLGN_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommonStockWarrantsMember" xlink:to="QLGN_CommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US">Weighted Average [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeniorConvertibleDebentureMember" xlink:label="QLGN_SeniorConvertibleDebentureMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeniorConvertibleDebentureMember" xlink:to="QLGN_SeniorConvertibleDebentureMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeniorConvertibleDebentureMember_lbl" xml:lang="en-US">Senior Convertible Debenture [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalOtherThirdPartiesMember" xlink:label="QLGN_AlphaCapitalOtherThirdPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AlphaCapitalOtherThirdPartiesMember" xlink:to="QLGN_AlphaCapitalOtherThirdPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AlphaCapitalOtherThirdPartiesMember_lbl" xml:lang="en-US">Alpha Capital Other Third Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_OctoberPaymentMember" xlink:label="QLGN_OctoberPaymentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_OctoberPaymentMember" xlink:to="QLGN_OctoberPaymentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_OctoberPaymentMember_lbl" xml:lang="en-US">October Payment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_lbl" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">Convertible Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeniorSecuredConvertibleDebtMember" xlink:label="QLGN_SeniorSecuredConvertibleDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeniorSecuredConvertibleDebtMember" xlink:to="QLGN_SeniorSecuredConvertibleDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeniorSecuredConvertibleDebtMember_lbl" xml:lang="en-US">Senior Secured Convertible Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_UpfrontPaymentMember" xlink:label="QLGN_UpfrontPaymentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UpfrontPaymentMember" xlink:to="QLGN_UpfrontPaymentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_UpfrontPaymentMember_lbl" xml:lang="en-US">Upfront Payment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LicenseAgreementMember" xlink:label="QLGN_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseAgreementMember" xlink:to="QLGN_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_MasterLaboratoryServicesAgreementMember" xlink:label="QLGN_MasterLaboratoryServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MasterLaboratoryServicesAgreementMember" xlink:to="QLGN_MasterLaboratoryServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_MasterLaboratoryServicesAgreementMember_lbl" xml:lang="en-US">Master Laboratory Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_MLMMedicalLabsMember" xlink:label="QLGN_MLMMedicalLabsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MLMMedicalLabsMember" xlink:to="QLGN_MLMMedicalLabsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_MLMMedicalLabsMember_lbl" xml:lang="en-US">MLM Medical Labs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:label="QLGN_SponsoredResearchAgreementAndLicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:to="QLGN_SponsoredResearchAgreementAndLicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SponsoredResearchAgreementAndLicenseMember_lbl" xml:lang="en-US">Sponsored Research and License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:label="QLGN_UniversityOfLouisvilleResearchFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:to="QLGN_UniversityOfLouisvilleResearchFoundationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_UniversityOfLouisvilleResearchFoundationMember_lbl" xml:lang="en-US">University of Louisville Research Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:label="QLGN_LicenseAndSponsoredResearchAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:to="QLGN_LicenseAndSponsoredResearchAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicenseAndSponsoredResearchAgreementsMember_lbl" xml:lang="en-US">License and Sponsored Research Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PhaseOneClinicalTrialMember" xlink:label="QLGN_PhaseOneClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseOneClinicalTrialMember" xlink:to="QLGN_PhaseOneClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PhaseOneClinicalTrialMember_lbl" xml:lang="en-US">Phase 1 Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PhaseTwoClinicalTrialMember" xlink:label="QLGN_PhaseTwoClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseTwoClinicalTrialMember" xlink:to="QLGN_PhaseTwoClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US">Phase 2 Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PhaseThreeClinicalTrialMember" xlink:label="QLGN_PhaseThreeClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseThreeClinicalTrialMember" xlink:to="QLGN_PhaseThreeClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PhaseThreeClinicalTrialMember_lbl" xml:lang="en-US">Phase 3 Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LicensedProductSalesMember" xlink:label="QLGN_LicensedProductSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicensedProductSalesMember" xlink:to="QLGN_LicensedProductSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicensedProductSalesMember_lbl" xml:lang="en-US">Licensed Product Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SponsoredResearchAgreementsAndLicenseMember" xlink:label="QLGN_SponsoredResearchAgreementsAndLicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SponsoredResearchAgreementsAndLicenseMember" xlink:to="QLGN_SponsoredResearchAgreementsAndLicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SponsoredResearchAgreementsAndLicenseMember_lbl" xml:lang="en-US">Sponsored Research Agreements And License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:label="QLGN_TwoThousandTwentyStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:to="QLGN_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TwoThousandTwentyStockIncentivePlanMember_lbl" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CompensatoryWarrantsMember" xlink:label="QLGN_CompensatoryWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CompensatoryWarrantsMember" xlink:to="QLGN_CompensatoryWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CompensatoryWarrantsMember_lbl" xml:lang="en-US">Compensatory Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="QLGN_CompensatoryWarrantActivityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CompensatoryWarrantActivityMember" xlink:to="QLGN_CompensatoryWarrantActivityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CompensatoryWarrantActivityMember_lbl" xml:lang="en-US">Compensatory Warrant Activity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:label="QLGN_NoncompensatoryEquityClassifiedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:to="QLGN_NoncompensatoryEquityClassifiedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NoncompensatoryEquityClassifiedWarrantsMember_lbl" xml:lang="en-US">Noncompensatory Equity Classified Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="QLGN_NonCompensatoryWarrantActivityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NonCompensatoryWarrantActivityMember" xlink:to="QLGN_NonCompensatoryWarrantActivityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NonCompensatoryWarrantActivityMember_lbl" xml:lang="en-US">Non Compensatory Warrant Activity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ConversionOfConvertibleDebtMember" xlink:label="QLGN_ConversionOfConvertibleDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ConversionOfConvertibleDebtMember" xlink:to="QLGN_ConversionOfConvertibleDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ConversionOfConvertibleDebtMember_lbl" xml:lang="en-US">Conversion Of Convertible Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:label="QLGN_EmployeesAndNonemployeeServiceProviderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:to="QLGN_EmployeesAndNonemployeeServiceProviderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EmployeesAndNonemployeeServiceProviderMember_lbl" xml:lang="en-US">Employees and Non-employee Service Provider [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TwentyTwentyFourDebentureAndWarrantMember" xlink:label="QLGN_TwentyTwentyFourDebentureAndWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwentyTwentyFourDebentureAndWarrantMember" xlink:to="QLGN_TwentyTwentyFourDebentureAndWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TwentyTwentyFourDebentureAndWarrantMember_lbl" xml:lang="en-US">2024 Debenture And Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TwentyTwentyFourDebentureMember" xlink:label="QLGN_TwentyTwentyFourDebentureMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwentyTwentyFourDebentureMember" xlink:to="QLGN_TwentyTwentyFourDebentureMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TwentyTwentyFourDebentureMember_lbl" xml:lang="en-US">2024 Debenture [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TwentyTwentyFourWarrantMember" xlink:label="QLGN_TwentyTwentyFourWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwentyTwentyFourWarrantMember" xlink:to="QLGN_TwentyTwentyFourWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TwentyTwentyFourWarrantMember_lbl" xml:lang="en-US">2024 Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Current assets of discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xml:lang="en-US">Non-current assets of discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingLiabilitiesCurrent" xlink:label="us-gaap_HedgingLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingLiabilitiesCurrent" xlink:to="us-gaap_HedgingLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HedgingLiabilitiesCurrent_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WarrantLiabilitiesRelatedParty" xlink:label="QLGN_WarrantLiabilitiesRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantLiabilitiesRelatedParty" xlink:to="QLGN_WarrantLiabilitiesRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WarrantLiabilitiesRelatedParty_lbl" xml:lang="en-US">Warrant liabilities - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible debt - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Current liabilities of discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl" xml:lang="en-US">Non-current liabilities of discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Qualigen Therapeutics, Inc. stockholders&#8217; equity (deficit):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 225,000,000 shares authorized; 5,362,128 and 4,210,737 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Qualigen Therapeutics, Inc. stockholders&#8217; equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities &amp; Stockholders&#8217; Equity (Deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER EXPENSE (INCOME), NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Gain on change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="us-gaap_InducedConversionOfConvertibleDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense_lbl" xml:lang="en-US">Loss on voluntary conversion of convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xml:lang="en-US">Loss on fixed asset disposal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense (income), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">(BENEFIT) PROVISION FOR INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">NET LOSS FROM CONTINUING OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_lbl" xml:lang="en-US">DISCONTINUED OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_lbl" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_lbl" xml:lang="en-US">Loss on disposal of discontinued operations, net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">LOSS FROM DISCONTINUED OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss attributable to non-controlling interest from discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss attributable to Qualigen Therapeutics, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Net loss per common share, basic - continuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Net loss per common share, diluted - continuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Net loss per common share, basic - discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">Net loss per common share, diluted - discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average number of shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average number of shares outstanding, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive loss, net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment from discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest from discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss attributable to Qualigen Therapeutics, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Voluntary conversion of convertible debt into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Voluntary conversion of convertible debt into common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" xlink:label="QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" xlink:to="QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock_lbl" xml:lang="en-US">Redemptions of convertible debt into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock" xlink:label="QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock" xlink:to="QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock_lbl" xml:lang="en-US">Redemptions of convertible debt into common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Fair value of warrant modification for professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" xlink:label="QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" xlink:to="QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity_lbl" xml:lang="en-US">Fair value of warrant reclassified from liabilities to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DeconsolidationOfDiscontinuedOperations" xlink:label="QLGN_DeconsolidationOfDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DeconsolidationOfDiscontinuedOperations" xlink:to="QLGN_DeconsolidationOfDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DeconsolidationOfDiscontinuedOperations_lbl" xml:lang="en-US">Deconsolidation of discontinued operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Stock issued upon exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock issued upon exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" xlink:label="QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" xlink:to="QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_lbl" xml:lang="en-US">Common stock and prefunded warrants issued for business acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" xlink:label="QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" xlink:to="QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_lbl" xml:lang="en-US">Common stock and prefunded warrants issued for business acquisition, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" xlink:label="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" xlink:to="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_lbl" xml:lang="en-US">&#160;Noncontrolling interest adjustments relating to Stock-based compensation and other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantModificationForBusinessAcquisition" xlink:label="QLGN_FairValueOfWarrantModificationForBusinessAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationForBusinessAcquisition" xlink:to="QLGN_FairValueOfWarrantModificationForBusinessAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantModificationForBusinessAcquisition_lbl" xml:lang="en-US">Fair value of warrant modification for business acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:label="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:to="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits_lbl" xml:lang="en-US">Issuance of rounded shares as a result of the reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Issuance of rounded shares as a result of the reverse stock split, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_lbl" xml:lang="en-US">Loss from discontinued operations, net of tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Loss from continuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile loss from continuing operations to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LossOnVoluntaryConversionOfConvertibleDebt" xlink:label="QLGN_LossOnVoluntaryConversionOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LossOnVoluntaryConversionOfConvertibleDebt" xlink:to="QLGN_LossOnVoluntaryConversionOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="QLGN_LossOnVoluntaryConversionOfConvertibleDebt_lbl" xml:lang="en-US">Loss on voluntary conversion of convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AccretionOfDiscountOnConvertibleDebt" xlink:label="QLGN_AccretionOfDiscountOnConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccretionOfDiscountOnConvertibleDebt" xlink:to="QLGN_AccretionOfDiscountOnConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="QLGN_AccretionOfDiscountOnConvertibleDebt_lbl" xml:lang="en-US">Accretion of discount on convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantModificationForProfessionalServices" xlink:label="QLGN_FairValueOfWarrantModificationForProfessionalServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationForProfessionalServices" xlink:to="QLGN_FairValueOfWarrantModificationForProfessionalServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_FairValueOfWarrantModificationForProfessionalServices_lbl" xml:lang="en-US">Fair value of warrant modification for professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in operating activities - continuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities - discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities - discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Net proceeds from warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ProceedsFromIssuanceOfConvertibleDebt" xlink:label="QLGN_ProceedsFromIssuanceOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ProceedsFromIssuanceOfConvertibleDebt" xlink:to="QLGN_ProceedsFromIssuanceOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ProceedsFromIssuanceOfConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payments on convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" xlink:label="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" xlink:to="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit_lbl" xml:lang="en-US">Fractional share payments related to the reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash (used in)/provided by financing activities - continuing operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_lbl" xml:lang="en-US">Net cash used in financing activities - discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and restricted cash from continuing operations - beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and restricted cash from discontinued operations - beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Less: cash and restricted cash from discontinued operations - end of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash from continuing operations - end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">NONCASH FINANCING AND INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TransfersOfInventoryFromEquipmentHeldForLease" xlink:label="QLGN_TransfersOfInventoryFromEquipmentHeldForLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TransfersOfInventoryFromEquipmentHeldForLease" xlink:to="QLGN_TransfersOfInventoryFromEquipmentHeldForLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TransfersOfInventoryFromEquipmentHeldForLease_lbl" xml:lang="en-US">Net transfers to equipment held for lease from inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:label="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:to="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise_lbl" xml:lang="en-US">Fair value of warrant liabilities on date of exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RedemptionOfConvertibleDebtIntoCommonStock" xlink:label="QLGN_RedemptionOfConvertibleDebtIntoCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RedemptionOfConvertibleDebtIntoCommonStock" xlink:to="QLGN_RedemptionOfConvertibleDebtIntoCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RedemptionOfConvertibleDebtIntoCommonStock_lbl" xml:lang="en-US">Redemption of convertible debt into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock" xlink:label="QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock" xlink:to="QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock_lbl" xml:lang="en-US">Voluntary conversion of convertible debt into common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement" xlink:label="QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement" xlink:to="QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement_lbl" xml:lang="en-US">Fair value of warrant modifications pursuant to Securities Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantModificationsForBusinessAcquisition" xlink:label="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition" xlink:to="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition_lbl" xml:lang="en-US">Fair value of warrant modifications for business acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">LIQUIDITY AND GOING CONCERN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER NON-CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">DISCONTINUED OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="QLGN_DisclosureWarrantLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:to="QLGN_DisclosureWarrantLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisclosureWarrantLiabilitiesAbstract_lbl" xml:lang="en-US">Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WarrantLiabilitiesTextBlock" xlink:label="QLGN_WarrantLiabilitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantLiabilitiesTextBlock" xlink:to="QLGN_WarrantLiabilitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WarrantLiabilitiesTextBlock_lbl" xml:lang="en-US">WARRANT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE DEBT- RELATED PARTY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisclosureResearchAndLicenseAgreementsAbstract" xlink:label="QLGN_DisclosureResearchAndLicenseAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisclosureResearchAndLicenseAgreementsAbstract" xlink:to="QLGN_DisclosureResearchAndLicenseAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisclosureResearchAndLicenseAgreementsAbstract_lbl" xml:lang="en-US">Research And License Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ResearchAndLicenseAgreementsTextBlock" xlink:label="QLGN_ResearchAndLicenseAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ResearchAndLicenseAgreementsTextBlock" xlink:to="QLGN_ResearchAndLicenseAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ResearchAndLicenseAgreementsTextBlock_lbl" xml:lang="en-US">RESEARCH AND LICENSE AGREEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_OrganizationPolicyTextBlock" xlink:label="QLGN_OrganizationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_OrganizationPolicyTextBlock" xlink:to="QLGN_OrganizationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_OrganizationPolicyTextBlock_lbl" xml:lang="en-US">Organization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsPolicyTextBlock_lbl" xml:lang="en-US">Discontinued Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US">Equity Method Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ReverseStockSplitPolicyTextBlock" xlink:label="QLGN_ReverseStockSplitPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReverseStockSplitPolicyTextBlock" xlink:to="QLGN_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PatentCostsPolicyTextBlock" xlink:label="QLGN_PatentCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PatentCostsPolicyTextBlock" xlink:to="QLGN_PatentCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US">Patent Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US">Business Combinations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" xlink:label="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" xlink:to="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Financial Instruments and Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_GlobalEconomicConditionsPolicyTextBlock" xlink:label="QLGN_GlobalEconomicConditionsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_GlobalEconomicConditionsPolicyTextBlock" xlink:to="QLGN_GlobalEconomicConditionsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_GlobalEconomicConditionsPolicyTextBlock_lbl" xml:lang="en-US">Global Economic Conditions</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ImpactOfCovid19PandemicPolicyTextBlock" xlink:label="QLGN_ImpactOfCovid19PandemicPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ImpactOfCovid19PandemicPolicyTextBlock" xlink:to="QLGN_ImpactOfCovid19PandemicPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ImpactOfCovid19PandemicPolicyTextBlock_lbl" xml:lang="en-US">Impact of COVID-19 Pandemic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OTHER NON CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:label="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:label="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:label="QLGN_ScheduleOfReservedSharesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:to="QLGN_ScheduleOfReservedSharesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfReservedSharesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESERVED SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:label="QLGN_SummaryOfWarrantActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:to="QLGN_SummaryOfWarrantActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SummaryOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANT ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROVISION FOR INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Stock issued during period shares acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Stock issued during period, value, acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US">Voting interests acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment losses on construction-in-progress</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Goodwill impairment charges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableInvestmentSale" xlink:label="us-gaap_ReceivableInvestmentSale" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableInvestmentSale" xlink:to="us-gaap_ReceivableInvestmentSale_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableInvestmentSale_lbl" xml:lang="en-US">Receivable from sale of Qualigen, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PreapaidResearchAndDevelopmentExpenses" xlink:label="QLGN_PreapaidResearchAndDevelopmentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PreapaidResearchAndDevelopmentExpenses" xlink:to="QLGN_PreapaidResearchAndDevelopmentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PreapaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Prepaid research and development expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit" xlink:label="us-gaap_EscrowDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDeposit_lbl" xml:lang="en-US">Funds held in escrow</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LongtermResearchAndDevelopmentDeposits" xlink:label="QLGN_LongtermResearchAndDevelopmentDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LongtermResearchAndDevelopmentDeposits" xlink:to="QLGN_LongtermResearchAndDevelopmentDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LongtermResearchAndDevelopmentDeposits_lbl" xml:lang="en-US">Long-term research and development deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TotalAssetsOfDiscontinuedOperations" xlink:label="QLGN_TotalAssetsOfDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TotalAssetsOfDiscontinuedOperations" xlink:to="QLGN_TotalAssetsOfDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TotalAssetsOfDiscontinuedOperations_lbl" xml:lang="en-US">Total assets of discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TotalLiabilitiesOfdiscontinuedOperations" xlink:label="QLGN_TotalLiabilitiesOfdiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TotalLiabilitiesOfdiscontinuedOperations" xlink:to="QLGN_TotalLiabilitiesOfdiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TotalLiabilitiesOfdiscontinuedOperations_lbl" xml:lang="en-US">Total liabilities of discontinued operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_2_lbl" xml:lang="en-US">(Loss) from discontinued operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_2_lbl" xml:lang="en-US">Gain (loss) on disposal of discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" xml:lang="en-US">Inventory, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2_lbl" xml:lang="en-US">Total current assets of discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_2_lbl" xml:lang="en-US">Total non-current assets of discontinued operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TotalAssetsOfDiscontinuedOperations" xlink:to="QLGN_TotalAssetsOfDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_TotalAssetsOfDiscontinuedOperations_2_lbl" xml:lang="en-US">Total assets of discontinued operations of Qualigen, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation_lbl" xml:lang="en-US">Accrued vacation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_lbl" xml:lang="en-US">Operating lease liability, current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2_lbl" xml:lang="en-US">Total current liabilities of discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Total non-current liabilities of discontinued operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_lbl" xml:lang="en-US">Deferred tax liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_2_lbl" xml:lang="en-US">Total non-current liabilities of discontinued operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TotalLiabilitiesOfdiscontinuedOperations" xlink:to="QLGN_TotalLiabilitiesOfdiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_TotalLiabilitiesOfdiscontinuedOperations_2_lbl" xml:lang="en-US">Total liabilities of discontinued operations of Qualigen, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales_lbl" xml:lang="en-US">Net product sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Cost of product sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment_lbl" xml:lang="en-US">Sales and marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing_lbl" xml:lang="en-US">Goodwill and fixed asset impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses_lbl" xml:lang="en-US">Total expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease_lbl" xml:lang="en-US">Loss on disposal of equipment held for lease</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_lbl" xml:lang="en-US">Interest (income) expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_lbl" xml:lang="en-US">Other expense (income), net</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal_lbl" xml:lang="en-US">Loss on fixed asset disposal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_lbl" xml:lang="en-US">Total other expense (income), net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_3_lbl" xml:lang="en-US">INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc." xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc." />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc." xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc._lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc._lbl" xml:lang="en-US">Gain on sale of Qualigen, Inc., net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO STOCKHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived_lbl" xml:lang="en-US">Fair value of consideration received</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment_lbl" xml:lang="en-US">Working capital adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets_lbl" xml:lang="en-US">Total assets of discontinued operations of NanoSynex</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_lbl" xml:lang="en-US">Total liabilities of discontinued operations of NanoSynex</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses_lbl" xml:lang="en-US">Transaction expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfInvestments_lbl" xml:lang="en-US">Gain on sale of Qualigen, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash" xlink:label="QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash" xlink:to="QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued vacation</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability_lbl" xml:lang="en-US">R&amp;D grant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty_lbl" xml:lang="en-US">Short term debt-related party</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment_lbl" xml:lang="en-US">Goodwill and fixed asset impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_lbl" xml:lang="en-US">Loss on disposal of discontinued operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_3_lbl" xml:lang="en-US">(BENEFIT) PROVISION FOR INCOME TAXES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2_lbl" xml:lang="en-US">LOSS FROM DISCONTINUED OPERATIONS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Loss attributable to noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained_lbl" xml:lang="en-US">Fair value of Nan-Synex interest retained</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated_lbl" xml:lang="en-US">Net assets deconsolidated</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare_lbl" xml:lang="en-US">Non-controlling interest share</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable_lbl" xml:lang="en-US">Accumulated OCI attributable to NanoSynex</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt_lbl" xml:lang="en-US">Forgiveness of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation_lbl" xml:lang="en-US">Loss from deconsolidation of NanoSynex</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PurchasePrice" xlink:label="QLGN_PurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PurchasePrice" xlink:to="QLGN_PurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PurchasePrice_lbl" xml:lang="en-US">Purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EscrowDeposit_2_lbl" xml:lang="en-US">Escrow deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss_lbl" xml:lang="en-US">Gain upward upon final payment of transaction cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Aggregrate amount</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodShareSurrender" xlink:label="QLGN_StockIssuedDuringPeriodShareSurrender" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodShareSurrender" xlink:to="QLGN_StockIssuedDuringPeriodShareSurrender_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedDuringPeriodShareSurrender_lbl" xml:lang="en-US">Number of shares surrender</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2_lbl" xml:lang="en-US">Business acquisition, percentage of voting interests acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_lbl" xml:lang="en-US">Aggregrate amount</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AccruedCompensation" xlink:label="QLGN_AccruedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedCompensation" xlink:to="QLGN_AccruedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccruedCompensation_lbl" xml:lang="en-US">Board compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest (Convertible debt)</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AccruedLicenseFees" xlink:label="QLGN_AccruedLicenseFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedLicenseFees" xlink:to="QLGN_AccruedLicenseFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccruedLicenseFees_lbl" xml:lang="en-US">License fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Payroll</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AccruedResearchAndDevelopmentCurrent" xlink:label="QLGN_AccruedResearchAndDevelopmentCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedResearchAndDevelopmentCurrent" xlink:to="QLGN_AccruedResearchAndDevelopmentCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Vacation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePrice" xlink:label="QLGN_RangeOfExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePrice" xlink:to="QLGN_RangeOfExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="QLGN_RangeOfExercisePrice_lbl" xml:lang="en-US">Range of Exercise Price, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Remaining Life (Years) Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Shares, Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Number of Shares, Warrants Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of Shares, Warrants Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExpired" xlink:label="QLGN_RangeOfExercisePriceExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExpired" xlink:to="QLGN_RangeOfExercisePriceExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceExpired_lbl" xml:lang="en-US">Range of Exercise Price, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Shares, Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceGranted" xlink:label="QLGN_RangeOfExercisePriceGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceGranted" xlink:to="QLGN_RangeOfExercisePriceGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceGranted_lbl" xml:lang="en-US">Range of Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Remaining Life (Years) Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Outstanding Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePrice" xlink:to="QLGN_RangeOfExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_RangeOfExercisePrice_2_lbl" xml:lang="en-US">Range of Exercise Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Warrants Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="QLGN_RangeOfExercisePriceExercisableVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableVested" xlink:to="QLGN_RangeOfExercisePriceExercisableVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_RangeOfExercisePriceExercisableVested_lbl" xml:lang="en-US">Range of Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Remaining Life (Years) Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueAdjustmentOfWarrant" xlink:label="QLGN_FairValueAdjustmentOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueAdjustmentOfWarrant" xlink:to="QLGN_FairValueAdjustmentOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="QLGN_FairValueAdjustmentOfWarrant_lbl" xml:lang="en-US">Fair value for warrant liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:to="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise_2_lbl" xml:lang="en-US">Common Stock Warrant liabilities, Exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantLiabilitiesOnToEquity" xlink:label="QLGN_FairValueOfWarrantLiabilitiesOnToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantLiabilitiesOnToEquity" xlink:to="QLGN_FairValueOfWarrantLiabilitiesOnToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantLiabilitiesOnToEquity_lbl" xml:lang="en-US">Common Stock Warrant liabilities, Fair value of warrant liabilities to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" xlink:label="QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" xlink:to="QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_lbl" xml:lang="en-US">Common Stock Warrant liabilities, Loss on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ChangeInFairValueOfWarrantLiabilities" xlink:label="QLGN_ChangeInFairValueOfWarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ChangeInFairValueOfWarrantLiabilities" xlink:to="QLGN_ChangeInFairValueOfWarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ChangeInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueAdjustmentOfWarrant" xlink:to="QLGN_FairValueAdjustmentOfWarrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_FairValueAdjustmentOfWarrant_2_lbl" xml:lang="en-US">Fair value for warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Fair value assumptions, measurement input, percentages</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Fair value assumptions, measurement input, term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrants and rights outstanding term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Warrants forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_lbl" xml:lang="en-US">Warrants reissued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ConversionPricePercentage" xlink:label="QLGN_ConversionPricePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ConversionPricePercentage" xlink:to="QLGN_ConversionPricePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ConversionPricePercentage_lbl" xml:lang="en-US">Conversion price percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_2_lbl" xml:lang="en-US">Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebt_lbl" xml:lang="en-US">Senior convertible debenture</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Discount on convertible debenture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebt_2_lbl" xml:lang="en-US">Total convertible debt-related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtInterestRateIncrease" xlink:to="us-gaap_ShortTermDebtInterestRateIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease_lbl" xml:lang="en-US">Senior convertible debenture rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SecuredDebt_2_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PurchasePrice" xlink:to="QLGN_PurchasePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_PurchasePrice_2_lbl" xml:lang="en-US">Purchase Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrant to purchase shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Exercise price of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xml:lang="en-US">Redeemable debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US">Conversion rate</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PrincipalAmountPercentage" xlink:label="QLGN_PrincipalAmountPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrincipalAmountPercentage" xlink:to="QLGN_PrincipalAmountPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PrincipalAmountPercentage_lbl" xml:lang="en-US">Principal amount percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debenture accrues interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DebentureBeneficialOwnershipBlockerPercentage" xlink:label="QLGN_DebentureBeneficialOwnershipBlockerPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DebentureBeneficialOwnershipBlockerPercentage" xlink:to="QLGN_DebentureBeneficialOwnershipBlockerPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DebentureBeneficialOwnershipBlockerPercentage_lbl" xml:lang="en-US">Debenture beneficial ownership blocker percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Shares of Common stock, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Resale of common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Debt discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_lbl" xml:lang="en-US">Fair value of embedded derivative features</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Fees and costs paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Debenture principal balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Debt conversion of convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Weighted price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Extinguishment loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">October payment in shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_lbl" xml:lang="en-US">Warrant liability to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US">Debt instrument fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt conversion of convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DebtRedemptionAmountInCash" xlink:label="QLGN_DebtRedemptionAmountInCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DebtRedemptionAmountInCash" xlink:to="QLGN_DebtRedemptionAmountInCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DebtRedemptionAmountInCash_lbl" xml:lang="en-US">Redemption amount in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DebtRedemptionAmountInCommonStock" xlink:label="QLGN_DebtRedemptionAmountInCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DebtRedemptionAmountInCommonStock" xlink:to="QLGN_DebtRedemptionAmountInCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DebtRedemptionAmountInCommonStock_lbl" xml:lang="en-US">Redemption amounts in common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xml:lang="en-US">Derivative fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss used for basic earnings per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Basic weighted-average common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" xlink:label="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" xlink:to="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_lbl" xml:lang="en-US">Dilutive potential shares issuable from convertible debt, stock options and warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Diluted weighted-average common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xml:lang="en-US">Litigation paid</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ReimbursementOfPatent" xlink:label="QLGN_ReimbursementOfPatent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementOfPatent" xlink:to="QLGN_ReimbursementOfPatent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ReimbursementOfPatent_lbl" xml:lang="en-US">Reimbursement of patent</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LicenseCost" xlink:label="QLGN_LicenseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseCost" xlink:to="QLGN_LicenseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicenseCost_lbl" xml:lang="en-US">License costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ReimbursementOfResearchExpenses" xlink:label="QLGN_ReimbursementOfResearchExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementOfResearchExpenses" xlink:to="QLGN_ReimbursementOfResearchExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ReimbursementOfResearchExpenses_lbl" xml:lang="en-US">Reimbursement of research expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AgreementTermPaymentDescription" xlink:label="QLGN_AgreementTermPaymentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AgreementTermPaymentDescription" xlink:to="QLGN_AgreementTermPaymentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AgreementTermPaymentDescription_lbl" xml:lang="en-US">Agreement term payment, description</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_MilestonePayment" xlink:label="QLGN_MilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestonePayment" xlink:to="QLGN_MilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RegulatoryMarketingApprovalExpenses" xlink:label="QLGN_RegulatoryMarketingApprovalExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RegulatoryMarketingApprovalExpenses" xlink:to="QLGN_RegulatoryMarketingApprovalExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RegulatoryMarketingApprovalExpenses_lbl" xml:lang="en-US">Marketing approval expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CumulativeSales" xlink:label="QLGN_CumulativeSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CumulativeSales" xlink:to="QLGN_CumulativeSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CumulativeSales_lbl" xml:lang="en-US">Cumulative sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_UpfrontLicenseFee" xlink:label="QLGN_UpfrontLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UpfrontLicenseFee" xlink:to="QLGN_UpfrontLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_UpfrontLicenseFee_lbl" xml:lang="en-US">Upfront license fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xml:lang="en-US">Proceeds from convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PatentCosts" xlink:label="QLGN_PatentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PatentCosts" xlink:to="QLGN_PatentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PatentCosts_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RegulatoryMarketingApprovalExpensesOne" xlink:label="QLGN_RegulatoryMarketingApprovalExpensesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RegulatoryMarketingApprovalExpensesOne" xlink:to="QLGN_RegulatoryMarketingApprovalExpensesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RegulatoryMarketingApprovalExpensesOne_lbl" xml:lang="en-US">Regulatory marketing approval, expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShortfallPayments" xlink:label="QLGN_ShortfallPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShortfallPayments" xlink:to="QLGN_ShortfallPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShortfallPayments_lbl" xml:lang="en-US">Shortfall payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Range of Exercise price, Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares, options expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares, options forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Range of Exercise price, Options Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Options Outstanding at Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Range of Exercise price, Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Number of shares, options exercisable (vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Range of exercise price, options exercisable (vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of shares, options non-exercisable (non-vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options non-exercisable (non-vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Range of exercise price, options non-exercisable (non-vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:label="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:to="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Range of Exercise price, Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US">Range of Exercise price, Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected stock-price volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected average term of options (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceOutstanding" xlink:label="QLGN_RangeOfExercisePriceOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOutstanding" xlink:to="QLGN_RangeOfExercisePriceOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="QLGN_RangeOfExercisePriceOutstanding_lbl" xml:lang="en-US">Range of exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining life (Years) exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Number of shares, warrants granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, warrants granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Number of Shares, Warrants Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Number of Shares, Warrants Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, warrants expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExpired" xlink:to="QLGN_RangeOfExercisePriceExpired_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_RangeOfExercisePriceExpired_2_lbl" xml:lang="en-US">Range of exercise price, expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, warrants forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOutstanding" xlink:to="QLGN_RangeOfExercisePriceOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_RangeOfExercisePriceOutstanding_2_lbl" xml:lang="en-US">Range of exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xml:lang="en-US">Number of Shares, Warrants Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableVested" xlink:to="QLGN_RangeOfExercisePriceExercisableVested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceExercisableVested_2_lbl" xml:lang="en-US">Range of exercise price - Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_2_lbl" xml:lang="en-US">Weighted average remaining life (Years) exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_lbl" xml:lang="en-US">Number of shares, warrants non-exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Non-Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:label="QLGN_RangeOfExercisePriceNonexercisableNonvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:to="QLGN_RangeOfExercisePriceNonexercisableNonvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceNonexercisableNonvested_lbl" xml:lang="en-US">Range of Exercise Price, Non-Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_lbl" xml:lang="en-US">Number of shares legal ritter warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, legal ritter warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_lbl" xml:lang="en-US">Number of shares, warrants reclassification of Alpha warrant from warrant liabilities to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average exercise price, reclassification of Alpha warrant from warrant liabilities to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" xlink:label="QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" xlink:to="QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_lbl" xml:lang="en-US">Range of exercise price, reclassification of Alpha warrant from warrant liabilities to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_lbl" xml:lang="en-US">Range of exercise price, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Warrants Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercisableGranted" xlink:label="QLGN_RangeOfExercisePriceExercisableGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableGranted" xlink:to="QLGN_RangeOfExercisePriceExercisableGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceExercisableGranted_lbl" xml:lang="en-US">Range of exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercised" xlink:label="QLGN_RangeOfExercisePriceExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercised" xlink:to="QLGN_RangeOfExercisePriceExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceExercised_lbl" xml:lang="en-US">Range of exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercisableExpired" xlink:label="QLGN_RangeOfExercisePriceExercisableExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableExpired" xlink:to="QLGN_RangeOfExercisePriceExercisableExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_RangeOfExercisePriceExercisableExpired_lbl" xml:lang="en-US">Range of exercise price, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceForfeited" xlink:label="QLGN_RangeOfExercisePriceForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceForfeited" xlink:to="QLGN_RangeOfExercisePriceForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceForfeited_lbl" xml:lang="en-US">Range of exercise price, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xml:lang="en-US">Plan shares available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Compensation cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Cost is expected to be recognized over a weighted average period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Stock options description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Stock option granted exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Issuance or sale of equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xml:lang="en-US">Purchase of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Purchase of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockholdersEquityReverseStockSplitPricePerShare" xlink:label="QLGN_StockholdersEquityReverseStockSplitPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockholdersEquityReverseStockSplitPricePerShare" xlink:to="QLGN_StockholdersEquityReverseStockSplitPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockholdersEquityReverseStockSplitPricePerShare_lbl" xml:lang="en-US">Reverse stock split, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WarrantsExtendedDateDescription" xlink:label="QLGN_WarrantsExtendedDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantsExtendedDateDescription" xlink:to="QLGN_WarrantsExtendedDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WarrantsExtendedDateDescription_lbl" xml:lang="en-US">Warrants extended date description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair value adjustment of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrants expired date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost related to nonvested</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WarrantsExercised" xlink:label="QLGN_WarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantsExercised" xlink:to="QLGN_WarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WarrantsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of outstanding warrants to purchase, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ModifiedToExercisePrice" xlink:label="QLGN_ModifiedToExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ModifiedToExercisePrice" xlink:to="QLGN_ModifiedToExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ModifiedToExercisePrice_lbl" xml:lang="en-US">Modified to exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2_lbl" xml:lang="en-US">Number of common stock acquired shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory federal income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_lbl" xml:lang="en-US">Non-deductible expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_lbl" xml:lang="en-US">NOL expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl" xml:lang="en-US">Goodwill impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign rate differential</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_lbl" xml:lang="en-US">Tax impact of convertible debenture</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_lbl" xml:lang="en-US">Tax impact of divestiture</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationTrueUp" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationTrueUp" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationTrueUp" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationTrueUp_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationTrueUp_lbl" xml:lang="en-US">True-up</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income taxes provision (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Total provision (benefit) for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DefferdTaxAssetsAccruedExpenses" xlink:label="QLGN_DefferdTaxAssetsAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DefferdTaxAssetsAccruedExpenses" xlink:to="QLGN_DefferdTaxAssetsAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DefferdTaxAssetsAccruedExpenses_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Patent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:label="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:to="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_lbl" xml:lang="en-US">Total deferred income tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred income tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Net deferred income tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax asset, net of allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">U.S. federal operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xml:lang="en-US">Tax credit carryforward, limitations on use</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2_lbl" xml:lang="en-US">Cash purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ReimbursementExpenses" xlink:label="QLGN_ReimbursementExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementExpenses" xlink:to="QLGN_ReimbursementExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ReimbursementExpenses_lbl" xml:lang="en-US">Reimbursement expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_3_lbl" xml:lang="en-US">Principal amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US">Principal amount increase decrease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xml:lang="en-US">Purchase of shares increase decrease</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity" xlink:label="QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity" xlink:to="QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Additional cash proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NanoSynexLtdMember" xlink:to="QLGN_NanoSynexLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NanoSynexLtdMember_doc" xml:lang="en-US">Nano Synex Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesAOnePreferredStockMember" xlink:to="QLGN_SeriesAOnePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeriesAOnePreferredStockMember_doc" xml:lang="en-US">Series A-1 Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrefundedWarrantMember" xlink:to="QLGN_PrefundedWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PrefundedWarrantMember_doc" xml:lang="en-US">Pre-funded Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_OrganizationPolicyTextBlock" xlink:to="QLGN_OrganizationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_OrganizationPolicyTextBlock_doc" xml:lang="en-US">Organization Policy [TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReverseStockSplitPolicyTextBlock" xlink:to="QLGN_ReverseStockSplitPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ReverseStockSplitPolicyTextBlock_doc" xml:lang="en-US">Reverse Stock Split [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PatentCostsPolicyTextBlock" xlink:to="QLGN_PatentCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PatentCostsPolicyTextBlock_doc" xml:lang="en-US">Patent Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" xlink:to="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_doc" xml:lang="en-US">Derivative Financial Instruments and Warrant Liabilities [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_GlobalEconomicConditionsPolicyTextBlock" xlink:to="QLGN_GlobalEconomicConditionsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_GlobalEconomicConditionsPolicyTextBlock_doc" xml:lang="en-US">Global Economic Conditions [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PreapaidResearchAndDevelopmentExpenses" xlink:to="QLGN_PreapaidResearchAndDevelopmentExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PreapaidResearchAndDevelopmentExpenses_doc" xml:lang="en-US">Preapaid research and development expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LongtermResearchAndDevelopmentDeposits" xlink:to="QLGN_LongtermResearchAndDevelopmentDeposits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LongtermResearchAndDevelopmentDeposits_doc" xml:lang="en-US">Long-term research and development deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationForProfessionalServices" xlink:to="QLGN_FairValueOfWarrantModificationForProfessionalServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantModificationForProfessionalServices_doc" xml:lang="en-US">Fair value of warrant modification for professional services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PurchasePrice" xlink:to="QLGN_PurchasePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PurchasePrice_doc" xml:lang="en-US">Purchase price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets_doc" xml:lang="en-US">Disposal group including discontinued operation property right of use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TotalAssetsOfDiscontinuedOperations" xlink:to="QLGN_TotalAssetsOfDiscontinuedOperations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TotalAssetsOfDiscontinuedOperations_doc" xml:lang="en-US">Total assets of discontinued operations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation_doc" xml:lang="en-US">Disposal group including discontinued operation accrued vacation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DeconsolidationOfDiscontinuedOperations" xlink:to="QLGN_DeconsolidationOfDiscontinuedOperations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DeconsolidationOfDiscontinuedOperations_doc" xml:lang="en-US">Deconsolidation of discontinued operations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TotalLiabilitiesOfdiscontinuedOperations" xlink:to="QLGN_TotalLiabilitiesOfdiscontinuedOperations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TotalLiabilitiesOfdiscontinuedOperations_doc" xml:lang="en-US">Total liabilities of discontinued operations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales_doc" xml:lang="en-US">Disposal group including discontinued operation net product sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing_doc" xml:lang="en-US">Disposal group including discontinued sales and marketing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses_doc" xml:lang="en-US">Disposal group including discontinued total expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease_doc" xml:lang="en-US">Disposal group including discontinued loss on disposal of equipment held for lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_doc" xml:lang="en-US">Amount of other income expense attributable to disposal group, including, but not limited to, discontinued operation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal_doc" xml:lang="en-US">Disposal group including discontinued loss onfixed asset disposal.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" xlink:to="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther_doc" xml:lang="en-US">Noncontrolling interest adjustments relating to stockbased compensation and other.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationForBusinessAcquisition" xlink:to="QLGN_FairValueOfWarrantModificationForBusinessAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantModificationForBusinessAcquisition_doc" xml:lang="en-US">Fair value of warrant modification for business acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:to="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedDuringPeriodValuesReverseStockSplits_doc" xml:lang="en-US">Stock issued during period values reverse stock splits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AmendmentAndSettlementAgreementMember" xlink:to="QLGN_AmendmentAndSettlementAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AmendmentAndSettlementAgreementMember_doc" xml:lang="en-US">Amendment And Settlement Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NanosynexMember" xlink:to="QLGN_NanosynexMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NanosynexMember_doc" xml:lang="en-US">Nano Synex [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash" xlink:to="QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash_doc" xml:lang="en-US">Assets of disposal group including discontinued restricted cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantLiabilitiesRelatedParty" xlink:to="QLGN_WarrantLiabilitiesRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantLiabilitiesRelatedParty_doc" xml:lang="en-US">Warrant liabilities related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ChembioDiagnosticsMember" xlink:to="QLGN_ChembioDiagnosticsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ChembioDiagnosticsMember_doc" xml:lang="en-US">Chembio diagnostics [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc." xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc._doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc._doc" xml:lang="en-US">Disposal group including discontinued operation gain on sale of qualigenInc.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment_doc" xml:lang="en-US">Disposal group including discontinued goodwill and fixed asset impairment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_doc" xml:lang="en-US">Disposal group including discontinued operation interest income expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" xlink:to="QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity_doc" xml:lang="en-US">Fair value of warrant reclassified from liabilities to equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedCompensation" xlink:to="QLGN_AccruedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedCompensation_doc" xml:lang="en-US">Accrued compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedLicenseFees" xlink:to="QLGN_AccruedLicenseFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedLicenseFees_doc" xml:lang="en-US">Accrued license fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedResearchAndDevelopmentCurrent" xlink:to="QLGN_AccruedResearchAndDevelopmentCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedResearchAndDevelopmentCurrent_doc" xml:lang="en-US">Research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesCWarrantsMember" xlink:to="QLGN_SeriesCWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeriesCWarrantsMember_doc" xml:lang="en-US">Series C Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ProceedsFromIssuanceOfConvertibleDebt" xlink:to="QLGN_ProceedsFromIssuanceOfConvertibleDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ProceedsFromIssuanceOfConvertibleDebt_doc" xml:lang="en-US">Proceeds from issuance of convertible debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" xlink:to="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit_doc" xml:lang="en-US">Fractional share payments related to the reverse stock split.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AlphaCapitalMember" xlink:to="QLGN_AlphaCapitalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AlphaCapitalMember_doc" xml:lang="en-US">Alpha Capital [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ConversionPricePercentage" xlink:to="QLGN_ConversionPricePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ConversionPricePercentage_doc" xml:lang="en-US">Conversion price percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommonStockWarrantsMember" xlink:to="QLGN_CommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CommonStockWarrantsMember_doc" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price per share warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price per share warrants forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average common stock warrants reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_doc" xml:lang="en-US">Weighted average exercise price per share exercisable (vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePrice" xlink:to="QLGN_RangeOfExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePrice_doc" xml:lang="en-US">Range of exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableVested" xlink:to="QLGN_RangeOfExercisePriceExercisableVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceExercisableVested_doc" xml:lang="en-US">Range of exercise price, exercisable (vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_doc" xml:lang="en-US">Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule Of Fair Value Hierarchy For Warrant Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueAdjustmentOfWarrant" xlink:to="QLGN_FairValueAdjustmentOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueAdjustmentOfWarrant_doc" xml:lang="en-US">Amount of expense (income) related to adjustment to fair value of warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ChangeInFairValueOfWarrantLiabilities" xlink:to="QLGN_ChangeInFairValueOfWarrantLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ChangeInFairValueOfWarrantLiabilities_doc" xml:lang="en-US">Change in fair value of warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeniorConvertibleDebentureMember" xlink:to="QLGN_SeniorConvertibleDebentureMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeniorConvertibleDebentureMember_doc" xml:lang="en-US">Senior Convertible Debenture [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrincipalAmountPercentage" xlink:to="QLGN_PrincipalAmountPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PrincipalAmountPercentage_doc" xml:lang="en-US">Principal amount percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AlphaCapitalOtherThirdPartiesMember" xlink:to="QLGN_AlphaCapitalOtherThirdPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AlphaCapitalOtherThirdPartiesMember_doc" xml:lang="en-US">Alpha Capital Other Third Parties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_OctoberPaymentMember" xlink:to="QLGN_OctoberPaymentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_OctoberPaymentMember_doc" xml:lang="en-US">October Payment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:to="QLGN_ScheduleOfReservedSharesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfReservedSharesTableTextBlock_doc" xml:lang="en-US">Schedule Of Reserved Shares [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeniorSecuredConvertibleDebtMember" xlink:to="QLGN_SeniorSecuredConvertibleDebtMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeniorSecuredConvertibleDebtMember_doc" xml:lang="en-US">Senior Secured Convertible Debt [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" xlink:to="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_doc" xml:lang="en-US">Dilutive potential shares issuable from stock options and warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ResearchAndLicenseAgreementsTextBlock" xlink:to="QLGN_ResearchAndLicenseAgreementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ResearchAndLicenseAgreementsTextBlock_doc" xml:lang="en-US">Research And License Agreements [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementOfPatent" xlink:to="QLGN_ReimbursementOfPatent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ReimbursementOfPatent_doc" xml:lang="en-US">Reimbursement of patent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseAgreementMember" xlink:to="QLGN_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UpfrontPaymentMember" xlink:to="QLGN_UpfrontPaymentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_UpfrontPaymentMember_doc" xml:lang="en-US">Upfront Payment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseCost" xlink:to="QLGN_LicenseCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicenseCost_doc" xml:lang="en-US">License costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementOfResearchExpenses" xlink:to="QLGN_ReimbursementOfResearchExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ReimbursementOfResearchExpenses_doc" xml:lang="en-US">Reimbursement of research expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:to="QLGN_SponsoredResearchAgreementAndLicenseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SponsoredResearchAgreementAndLicenseMember_doc" xml:lang="en-US">Sponsored Research and License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:to="QLGN_UniversityOfLouisvilleResearchFoundationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_UniversityOfLouisvilleResearchFoundationMember_doc" xml:lang="en-US">University of Louisville Research Foundation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:to="QLGN_TwoThousandTwentyStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TwoThousandTwentyStockIncentivePlanMember_doc" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AgreementTermPaymentDescription" xlink:to="QLGN_AgreementTermPaymentDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AgreementTermPaymentDescription_doc" xml:lang="en-US">Agreement term payment, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestonePayment" xlink:to="QLGN_MilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_MilestonePayment_doc" xml:lang="en-US">Milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:to="QLGN_LicenseAndSponsoredResearchAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicenseAndSponsoredResearchAgreementsMember_doc" xml:lang="en-US">License and Sponsored Research Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseTwoClinicalTrialMember" xlink:to="QLGN_PhaseTwoClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PhaseTwoClinicalTrialMember_doc" xml:lang="en-US">Phase 2 Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RegulatoryMarketingApprovalExpenses" xlink:to="QLGN_RegulatoryMarketingApprovalExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RegulatoryMarketingApprovalExpenses_doc" xml:lang="en-US">Regulatory marketing approval, expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CumulativeSales" xlink:to="QLGN_CumulativeSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CumulativeSales_doc" xml:lang="en-US">Cumulative sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicensedProductSalesMember" xlink:to="QLGN_LicensedProductSalesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicensedProductSalesMember_doc" xml:lang="en-US">Licensed Product Sales [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UpfrontLicenseFee" xlink:to="QLGN_UpfrontLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_UpfrontLicenseFee_doc" xml:lang="en-US">Upfront license fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PatentCosts" xlink:to="QLGN_PatentCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PatentCosts_doc" xml:lang="en-US">Patent costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:to="QLGN_EmployeesAndNonemployeeServiceProviderMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EmployeesAndNonemployeeServiceProviderMember_doc" xml:lang="en-US">Employees and Non-employee Service Provider [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseOneClinicalTrialMember" xlink:to="QLGN_PhaseOneClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PhaseOneClinicalTrialMember_doc" xml:lang="en-US">Phase 1 Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseThreeClinicalTrialMember" xlink:to="QLGN_PhaseThreeClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PhaseThreeClinicalTrialMember_doc" xml:lang="en-US">Phase 3 Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RegulatoryMarketingApprovalExpensesOne" xlink:to="QLGN_RegulatoryMarketingApprovalExpensesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RegulatoryMarketingApprovalExpensesOne_doc" xml:lang="en-US">Regulatory marketing approval expenses one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price, options non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShortfallPayments" xlink:to="QLGN_ShortfallPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShortfallPayments_doc" xml:lang="en-US">Shortfall payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:to="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_doc" xml:lang="en-US">Weighted- average remaining contractual life (in years), options non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MasterLaboratoryServicesAgreementMember" xlink:to="QLGN_MasterLaboratoryServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_MasterLaboratoryServicesAgreementMember_doc" xml:lang="en-US">Master Laboratory Services Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MLMMedicalLabsMember" xlink:to="QLGN_MLMMedicalLabsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_MLMMedicalLabsMember_doc" xml:lang="en-US">MLM Medical Labs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award option granted weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award option expired weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Options Granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CompensatoryWarrantsMember" xlink:to="QLGN_CompensatoryWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CompensatoryWarrantsMember_doc" xml:lang="en-US">Compensatory Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockholdersEquityReverseStockSplitPricePerShare" xlink:to="QLGN_StockholdersEquityReverseStockSplitPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockholdersEquityReverseStockSplitPricePerShare_doc" xml:lang="en-US">Stockholders equity reverse stock split price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantsExtendedDateDescription" xlink:to="QLGN_WarrantsExtendedDateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantsExtendedDateDescription_doc" xml:lang="en-US">Warrants extended date, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantLiabilitiesTextBlock" xlink:to="QLGN_WarrantLiabilitiesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantLiabilitiesTextBlock_doc" xml:lang="en-US">Warrant Liabilities [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:to="QLGN_SummaryOfWarrantActivityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SummaryOfWarrantActivityTableTextBlock_doc" xml:lang="en-US">Summary Of Warrant Activity [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CompensatoryWarrantActivityMember" xlink:to="QLGN_CompensatoryWarrantActivityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CompensatoryWarrantActivityMember_doc" xml:lang="en-US">Compensatory Warrant Activity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_doc" xml:lang="en-US">Number of shares, warrants non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_doc" xml:lang="en-US">Weighted average exercise price per share non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOutstanding" xlink:to="QLGN_RangeOfExercisePriceOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceOutstanding_doc" xml:lang="en-US">Range Of Exercise Price Outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:to="QLGN_RangeOfExercisePriceNonexercisableNonvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceNonexercisableNonvested_doc" xml:lang="en-US">Range of exercise price, non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:to="QLGN_NoncompensatoryEquityClassifiedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NoncompensatoryEquityClassifiedWarrantsMember_doc" xml:lang="en-US">Noncompensatory Equity Classified Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantsExercised" xlink:to="QLGN_WarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantsExercised_doc" xml:lang="en-US">Warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ModifiedToExercisePrice" xlink:to="QLGN_ModifiedToExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ModifiedToExercisePrice_doc" xml:lang="en-US">Modified to exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NonCompensatoryWarrantActivityMember" xlink:to="QLGN_NonCompensatoryWarrantActivityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NonCompensatoryWarrantActivityMember_doc" xml:lang="en-US">Non Compensatory Warrant Activity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments legal ritter warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments legal ritter warrants weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableGranted" xlink:to="QLGN_RangeOfExercisePriceExercisableGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceExercisableGranted_doc" xml:lang="en-US">Range of exercise price exercisable granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceForfeited" xlink:to="QLGN_RangeOfExercisePriceForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceForfeited_doc" xml:lang="en-US">Range of exercise price forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LossOnVoluntaryConversionOfConvertibleDebt" xlink:to="QLGN_LossOnVoluntaryConversionOfConvertibleDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LossOnVoluntaryConversionOfConvertibleDebt_doc" xml:lang="en-US">Loss on voluntary conversion of convertible debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccretionOfDiscountOnConvertibleDebt" xlink:to="QLGN_AccretionOfDiscountOnConvertibleDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccretionOfDiscountOnConvertibleDebt_doc" xml:lang="en-US">Accretion of discount on convertible debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TransfersOfInventoryFromEquipmentHeldForLease" xlink:to="QLGN_TransfersOfInventoryFromEquipmentHeldForLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TransfersOfInventoryFromEquipmentHeldForLease_doc" xml:lang="en-US">Transfers of inventory from equipment held for lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:to="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise_doc" xml:lang="en-US">Fair value of warrant liabilities on date of exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock" xlink:to="QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock_doc" xml:lang="en-US">Voluntary conversion of convertible debt into common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceGranted" xlink:to="QLGN_RangeOfExercisePriceGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceGranted_doc" xml:lang="en-US">Range of exercise price granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExpired" xlink:to="QLGN_RangeOfExercisePriceExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceExpired_doc" xml:lang="en-US">Range of exercise price expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments granted weighted averag remaining contractual term1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantLiabilitiesOnToEquity" xlink:to="QLGN_FairValueOfWarrantLiabilitiesOnToEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantLiabilitiesOnToEquity_doc" xml:lang="en-US">Fair value of  warrant liabilities on to equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" xlink:to="QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_doc" xml:lang="en-US">Fair value of warrant liabilities loss on debt extinguishment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule Of Assumptions Of Warrant Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ConversionOfConvertibleDebtMember" xlink:to="QLGN_ConversionOfConvertibleDebtMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ConversionOfConvertibleDebtMember_doc" xml:lang="en-US">`Conversion Of Convertible Debt [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SecuritiesPurchaseAgreementMember" xlink:to="QLGN_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments reclassification of alpha warrant from warrant liabilities to equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments non exercisable number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments eeclassification of alpha warrant from warrant liabilities to equity weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average vested non exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" xlink:to="QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_doc" xml:lang="en-US">Range of exercise price reclassification of  alpha warrant from warrant liabilities to equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments expired in range of exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercised" xlink:to="QLGN_RangeOfExercisePriceExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceExercised_doc" xml:lang="en-US">Range of exercise price exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableExpired" xlink:to="QLGN_RangeOfExercisePriceExercisableExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceExercisableExpired_doc" xml:lang="en-US">Range of exercise price exercisable expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_doc" xml:lang="en-US">Effective income tax rate reconciliation non operating loss expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_doc" xml:lang="en-US">Effective income tax rate reconciliation fair value of warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_doc" xml:lang="en-US">Effective income tax rate reconciliation tax impact of convertible debenture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_doc" xml:lang="en-US">Effective income tax rate reconciliation tax impact of divestiture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DefferdTaxAssetsAccruedExpenses" xlink:to="QLGN_DefferdTaxAssetsAccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DefferdTaxAssetsAccruedExpenses_doc" xml:lang="en-US">Defferd tax assets accrued expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:to="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses_doc" xml:lang="en-US">Research and development expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwentyTwentyFourDebentureMember" xlink:to="QLGN_TwentyTwentyFourDebentureMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TwentyTwentyFourDebentureMember_doc" xml:lang="en-US">2024 Debenture [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementExpenses" xlink:to="QLGN_ReimbursementExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ReimbursementExpenses_doc" xml:lang="en-US">Reimbursement expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwentyTwentyFourWarrantMember" xlink:to="QLGN_TwentyTwentyFourWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TwentyTwentyFourWarrantMember_doc" xml:lang="en-US">2024 Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_doc" xml:lang="en-US">Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" xlink:to="QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition_doc" xml:lang="en-US">Stock issued during period value common stock and prefunded warrants issued for business acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" xlink:to="QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition_doc" xml:lang="en-US">Stock issued during period shares common stock and prefunded warrants issued for business acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability_doc" xml:lang="en-US">Disposal group including discontinued operation research and development grant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty_doc" xml:lang="en-US">Disposal group including discontinued operation short term debt related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_doc" xml:lang="en-US">Disposal group including discontinued operation research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment_doc" xml:lang="en-US">Disposal group including discontinued operation goodwill and fixed asset impairment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss_doc" xml:lang="en-US">Disposal group including discontinued operation gain loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived_doc" xml:lang="en-US">Disposal group including discontinued operation fair value of consideration received.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment_doc" xml:lang="en-US">Disposal group including discontinued operation working capital adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets_doc" xml:lang="en-US">Disposal group including discontinued operation total assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_doc" xml:lang="en-US">Disposal group including discontinued operation total liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses_doc" xml:lang="en-US">Disposal group including discontinued operation transaction expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained_doc" xml:lang="en-US">Disposal group including discontinued operation fair value of interest retained.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated_doc" xml:lang="en-US">Disposal group including discontinued operation net assets deconsolidated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare_doc" xml:lang="en-US">Disposal group including discontinued operation non controlling interest share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable_doc" xml:lang="en-US">Disposal group including discontinued operation accumulated oci attributable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt_doc" xml:lang="en-US">Disposal group including discontinued operation forgiveness of debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation_doc" xml:lang="en-US">Disposal group including discontinued operation loss from deconsolidation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ImpactOfCovid19PandemicPolicyTextBlock" xlink:to="QLGN_ImpactOfCovid19PandemicPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ImpactOfCovid19PandemicPolicyTextBlock_doc" xml:lang="en-US">Impact Of Covid19 Pandemic [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodShareSurrender" xlink:to="QLGN_StockIssuedDuringPeriodShareSurrender_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedDuringPeriodShareSurrender_doc" xml:lang="en-US">Stock issued during period share surrender.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DebentureBeneficialOwnershipBlockerPercentage" xlink:to="QLGN_DebentureBeneficialOwnershipBlockerPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DebentureBeneficialOwnershipBlockerPercentage_doc" xml:lang="en-US">Debenture beneficial ownership blocker percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DebtRedemptionAmountInCash" xlink:to="QLGN_DebtRedemptionAmountInCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DebtRedemptionAmountInCash_doc" xml:lang="en-US">Debt redemption amount in cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DebtRedemptionAmountInCommonStock" xlink:to="QLGN_DebtRedemptionAmountInCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DebtRedemptionAmountInCommonStock_doc" xml:lang="en-US">Debt redemption amount in common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SponsoredResearchAgreementsAndLicenseMember" xlink:to="QLGN_SponsoredResearchAgreementsAndLicenseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SponsoredResearchAgreementsAndLicenseMember_doc" xml:lang="en-US">Sponsored Research Agreements And License [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwentyTwentyFourDebentureAndWarrantMember" xlink:to="QLGN_TwentyTwentyFourDebentureAndWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TwentyTwentyFourDebentureAndWarrantMember_doc" xml:lang="en-US">2024 Debenture And Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity" xlink:to="QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity_doc" xml:lang="en-US">Additional proceeds from issuance or sale of equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectiveIncomeTaxRateReconciliationTrueUp" xlink:to="QLGN_EffectiveIncomeTaxRateReconciliationTrueUp_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EffectiveIncomeTaxRateReconciliationTrueUp_doc" xml:lang="en-US">Effective income tax rate true-up.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" xlink:to="QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock_doc" xml:lang="en-US">Redemptions of convertible debt into common stock, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock" xlink:to="QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock_doc" xml:lang="en-US">Redemptions of convertible debt into common stock, shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantModifcationsPursuantToSecuritiesPurchaseAgreeement" xlink:label="QLGN_FairValueOfWarrantModifcationsPursuantToSecuritiesPurchaseAgreeement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModifcationsPursuantToSecuritiesPurchaseAgreeement" xlink:to="QLGN_FairValueOfWarrantModifcationsPursuantToSecuritiesPurchaseAgreeement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantModifcationsPursuantToSecuritiesPurchaseAgreeement_doc" xml:lang="en-US">Fair value of warrant modifcations pursuant to Securities Purchase Agreeement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition" xlink:to="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantModificationsForBusinessAcquisition_doc" xml:lang="en-US">Fair value of warrant modifications for business acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_2_lbl" xml:lang="en-US">Interest Income (Expense), Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:to="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_4_lbl" xml:lang="en-US">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_2_lbl" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LossOnVoluntaryConversionOfConvertibleDebt" xlink:to="QLGN_LossOnVoluntaryConversionOfConvertibleDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LossOnVoluntaryConversionOfConvertibleDebt_3_lbl" xml:lang="en-US">LossOnVoluntaryConversionOfConvertibleDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccretionOfDiscountOnConvertibleDebt" xlink:to="QLGN_AccretionOfDiscountOnConvertibleDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccretionOfDiscountOnConvertibleDebt_3_lbl" xml:lang="en-US">AccretionOfDiscountOnConvertibleDebt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantModificationForProfessionalServices" xlink:to="QLGN_FairValueOfWarrantModificationForProfessionalServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantModificationForProfessionalServices_3_lbl" xml:lang="en-US">FairValueOfWarrantModificationForProfessionalServices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" xlink:to="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FractionalSharePaymentsRelatedToReverseStockSplit_3_lbl" xml:lang="en-US">FractionalSharePaymentsRelatedToReverseStockSplit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock" xlink:to="QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock_3_lbl" xml:lang="en-US">VoluntaryConversionOfConvertibleDebtIntoCommonStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_3_lbl" xml:lang="en-US">Disposal group including discontinued operation research and development</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment" xlink:to="QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment_3_lbl" xml:lang="en-US">Disposal group including discontinued operation goodwill and fixed asset impairment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_2_lbl" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedResearchAndDevelopmentCurrent" xlink:to="QLGN_AccruedResearchAndDevelopmentCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccruedResearchAndDevelopmentCurrent_3_lbl" xml:lang="en-US">AccruedResearchAndDevelopmentCurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePrice" xlink:to="QLGN_RangeOfExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePrice_4_lbl" xml:lang="en-US">RangeOfExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueAdjustmentOfWarrant" xlink:to="QLGN_FairValueAdjustmentOfWarrant_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueAdjustmentOfWarrant_4_lbl" xml:lang="en-US">FairValueAdjustmentOfWarrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ChangeInFairValueOfWarrantLiabilities" xlink:to="QLGN_ChangeInFairValueOfWarrantLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ChangeInFairValueOfWarrantLiabilities_3_lbl" xml:lang="en-US">ChangeInFairValueOfWarrantLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_3_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_2_lbl" xml:lang="en-US">Warrant, Exercise Price, Increase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_2_lbl" xml:lang="en-US">Warrant, Exercise Price, Decrease</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_2_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_3_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOutstanding" xlink:to="QLGN_RangeOfExercisePriceOutstanding_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceOutstanding_4_lbl" xml:lang="en-US">RangeOfExercisePriceOutstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableExpired" xlink:to="QLGN_RangeOfExercisePriceExercisableExpired_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceExercisableExpired_3_lbl" xml:lang="en-US">RangeOfExercisePriceExercisableExpired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpense_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>qlgn-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/Cover" xlink:href="qlgn-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/BalanceSheets" xlink:href="qlgn-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/BalanceSheetsParenthetical" xlink:href="qlgn-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="qlgn-20231231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="qlgn-20231231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StatementsOfCashFlows" xlink:href="qlgn-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:href="qlgn-20231231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/LiquidityAndGoingConcern" xlink:href="qlgn-20231231.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="qlgn-20231231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OtherNon-currentAssets" xlink:href="qlgn-20231231.xsd#OtherNon-currentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/DiscontinuedOperations" xlink:href="qlgn-20231231.xsd#DiscontinuedOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="qlgn-20231231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/WarrantLiabilities" xlink:href="qlgn-20231231.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedParty" xlink:href="qlgn-20231231.xsd#ConvertibleDebt-RelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/EarningsLossPerShare" xlink:href="qlgn-20231231.xsd#EarningsLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/CommitmentsAndContingencies" xlink:href="qlgn-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreements" xlink:href="qlgn-20231231.xsd#ResearchAndLicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StockholdersEquity" xlink:href="qlgn-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/RelatedPartyTransactions" xlink:href="qlgn-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/IncomeTaxes" xlink:href="qlgn-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/SubsequentEvents" xlink:href="qlgn-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:href="qlgn-20231231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="qlgn-20231231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OtherNon-currentAssetsTables" xlink:href="qlgn-20231231.xsd#OtherNon-currentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/DiscontinuedOperationsTables" xlink:href="qlgn-20231231.xsd#DiscontinuedOperationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="qlgn-20231231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/WarrantLiabilitiesTables" xlink:href="qlgn-20231231.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyTables" xlink:href="qlgn-20231231.xsd#ConvertibleDebt-RelatedPartyTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/EarningsLossPerShareTables" xlink:href="qlgn-20231231.xsd#EarningsLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StockholdersEquityTables" xlink:href="qlgn-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/IncomeTaxesTables" xlink:href="qlgn-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:href="qlgn-20231231.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="qlgn-20231231.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfOtherNonCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails" xlink:href="qlgn-20231231.xsd#AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative" xlink:href="qlgn-20231231.xsd#DiscontinuedOperationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="qlgn-20231231.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:href="qlgn-20231231.xsd#ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="qlgn-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:href="qlgn-20231231.xsd#ResearchAndLicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfReservedSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfShare-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative" xlink:href="qlgn-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="qlgn-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfDomesticAndForeignComponentsDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfDomesticAndForeignComponentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="qlgn-20231231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative" xlink:href="qlgn-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative" xlink:href="qlgn-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingLiabilitiesCurrent" xlink:label="loc_us-gaapHedgingLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapHedgingLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WarrantLiabilitiesRelatedParty" xlink:label="loc_QLGNWarrantLiabilitiesRelatedParty" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_QLGNWarrantLiabilitiesRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaapOperatingCostsAndExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaapInducedConversionOfConvertibleDebtExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInducedConversionOfConvertibleDebtExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsPerDilutedShare" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:label="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:label="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" xlink:label="loc_QLGNStockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock" xlink:label="loc_QLGNStockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity" xlink:label="loc_QLGNFairValueOfWarrantReclassifiedFromLiabilitiesToEquity" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNFairValueOfWarrantReclassifiedFromLiabilitiesToEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DeconsolidationOfDiscontinuedOperations" xlink:label="loc_QLGNDeconsolidationOfDiscontinuedOperations" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDeconsolidationOfDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" xlink:label="loc_QLGNStockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" xlink:label="loc_QLGNStockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" xlink:label="loc_QLGNNoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNNoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantModificationForBusinessAcquisition" xlink:label="loc_QLGNFairValueOfWarrantModificationForBusinessAcquisition" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNFairValueOfWarrantModificationForBusinessAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:label="loc_QLGNStockIssuedDuringPeriodValuesReverseStockSplits" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValuesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LossOnVoluntaryConversionOfConvertibleDebt" xlink:label="loc_QLGNLossOnVoluntaryConversionOfConvertibleDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_QLGNLossOnVoluntaryConversionOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AccretionOfDiscountOnConvertibleDebt" xlink:label="loc_QLGNAccretionOfDiscountOnConvertibleDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_QLGNAccretionOfDiscountOnConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantModificationForProfessionalServices" xlink:label="loc_QLGNFairValueOfWarrantModificationForProfessionalServices" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_QLGNFairValueOfWarrantModificationForProfessionalServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapCashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapCashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ProceedsFromIssuanceOfConvertibleDebt" xlink:label="loc_QLGNProceedsFromIssuanceOfConvertibleDebt" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_QLGNProceedsFromIssuanceOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FractionalSharePaymentsRelatedToReverseStockSplit" xlink:label="loc_QLGNFractionalSharePaymentsRelatedToReverseStockSplit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_QLGNFractionalSharePaymentsRelatedToReverseStockSplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaapCashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TransfersOfInventoryFromEquipmentHeldForLease" xlink:label="loc_QLGNTransfersOfInventoryFromEquipmentHeldForLease" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_QLGNTransfersOfInventoryFromEquipmentHeldForLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:label="loc_QLGNFairValueOfWarrantLiabilitiesOnDateOfExercise" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_QLGNFairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RedemptionOfConvertibleDebtIntoCommonStock" xlink:label="loc_QLGNRedemptionOfConvertibleDebtIntoCommonStock" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_QLGNRedemptionOfConvertibleDebtIntoCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock" xlink:label="loc_QLGNVoluntaryConversionOfConvertibleDebtIntoCommonStock" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_QLGNVoluntaryConversionOfConvertibleDebtIntoCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement" xlink:label="loc_QLGNFairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_QLGNFairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantModificationsForBusinessAcquisition" xlink:label="loc_QLGNFairValueOfWarrantModificationsForBusinessAcquisition" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_QLGNFairValueOfWarrantModificationsForBusinessAcquisition" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/LiquidityAndGoingConcern" xlink:title="00000008 - Disclosure - LIQUIDITY AND GOING CONCERN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OtherNon-currentAssets" xlink:title="00000010 - Disclosure - OTHER NON-CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:label="loc_us-gaapInvestmentsAndOtherNoncurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapInvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/DiscontinuedOperations" xlink:title="00000011 - Disclosure - DISCONTINUED OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/WarrantLiabilities" xlink:title="00000013 - Disclosure - WARRANT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WarrantLiabilitiesTextBlock" xlink:label="loc_QLGNWarrantLiabilitiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_QLGNWarrantLiabilitiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedParty" xlink:title="00000014 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/EarningsLossPerShare" xlink:title="00000015 - Disclosure - EARNINGS (LOSS) PER SHARE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreements" xlink:title="00000017 - Disclosure - RESEARCH AND LICENSE AGREEMENTS">
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisclosureResearchAndLicenseAgreementsAbstract" xlink:label="loc_QLGNDisclosureResearchAndLicenseAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ResearchAndLicenseAgreementsTextBlock" xlink:label="loc_QLGNResearchAndLicenseAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureResearchAndLicenseAgreementsAbstract" xlink:to="loc_QLGNResearchAndLicenseAgreementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/RelatedPartyTransactions" xlink:title="00000019 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/IncomeTaxes" xlink:title="00000020 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:title="00000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_OrganizationPolicyTextBlock" xlink:label="loc_QLGNOrganizationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNOrganizationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:label="loc_us-gaapDiscontinuedOperationsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapDiscontinuedOperationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaapEquityMethodInvestmentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ReverseStockSplitPolicyTextBlock" xlink:label="loc_QLGNReverseStockSplitPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNReverseStockSplitPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PatentCostsPolicyTextBlock" xlink:label="loc_QLGNPatentCostsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNPatentCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaapBusinessCombinationsPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBusinessCombinationsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" xlink:label="loc_QLGNDerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNDerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_GlobalEconomicConditionsPolicyTextBlock" xlink:label="loc_QLGNGlobalEconomicConditionsPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNGlobalEconomicConditionsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ImpactOfCovid19PandemicPolicyTextBlock" xlink:label="loc_QLGNImpactOfCovid19PandemicPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNImpactOfCovid19PandemicPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OtherNon-currentAssetsTables" xlink:title="00000024 - Disclosure - OTHER NON-CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="loc_us-gaapScheduleOfOtherAssetsNoncurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/DiscontinuedOperationsTables" xlink:title="00000025 - Disclosure - DISCONTINUED OPERATIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanosynexMember" xlink:label="loc_QLGNNanosynexMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNNanosynexMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000026 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/WarrantLiabilitiesTables" xlink:title="00000027 - Disclosure - WARRANT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:label="loc_QLGNScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_QLGNScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:label="loc_QLGNScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_QLGNScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyTables" xlink:title="00000028 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaapConvertibleDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/EarningsLossPerShareTables" xlink:title="00000029 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="loc_QLGNNonCompensatoryWarrantActivityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNNonCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:label="loc_QLGNScheduleOfReservedSharesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNScheduleOfReservedSharesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:label="loc_QLGNSummaryOfWarrantActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNSummaryOfWarrantActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/IncomeTaxesTables" xlink:title="00000031 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:title="00000032 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesAOnePreferredStockMember" xlink:label="loc_QLGNSeriesAOnePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PrefundedWarrantMember" xlink:label="loc_QLGNPrefundedWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNPrefundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="00000033 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableInvestmentSale" xlink:label="loc_us-gaapReceivableInvestmentSale" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapReceivableInvestmentSale" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PreapaidResearchAndDevelopmentExpenses" xlink:label="loc_QLGNPreapaidResearchAndDevelopmentExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_QLGNPreapaidResearchAndDevelopmentExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF OTHER NON CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LongtermResearchAndDevelopmentDeposits" xlink:label="loc_QLGNLongtermResearchAndDevelopmentDeposits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_QLGNLongtermResearchAndDevelopmentDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsAllOtherInvestmentsAbstract" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember" xlink:label="loc_srtParentCompanyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_srtParentCompanyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanosynexMember" xlink:label="loc_QLGNNanosynexMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_QLGNNanosynexMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TotalAssetsOfDiscontinuedOperations" xlink:label="loc_QLGNTotalAssetsOfDiscontinuedOperations" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNTotalAssetsOfDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TotalLiabilitiesOfdiscontinuedOperations" xlink:label="loc_QLGNTotalLiabilitiesOfdiscontinuedOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNTotalLiabilitiesOfdiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails" xlink:title="00000037 - Disclosure - ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanosynexMember" xlink:label="loc_QLGNNanosynexMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNNanosynexMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TotalAssetsOfDiscontinuedOperations" xlink:label="loc_QLGNTotalAssetsOfDiscontinuedOperations" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNTotalAssetsOfDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationAccruedVacation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationAccruedVacation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TotalLiabilitiesOfdiscontinuedOperations" xlink:label="loc_QLGNTotalLiabilitiesOfdiscontinuedOperations" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNTotalLiabilitiesOfdiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationNetProductSales" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationNetProductSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedSalesAndMarketing" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedSalesAndMarketing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedTotalExpenses" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedTotalExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc." xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc." />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc." xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_QLGNDiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationTotalAssets" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationTotalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationTotalLiabilities" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationTotalLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationTransactionExpenses" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationTransactionExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash" xlink:label="loc_QLGNAssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNAssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationGoodwillCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:label="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative" xlink:title="00000038 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ChembioDiagnosticsMember" xlink:label="loc_QLGNChembioDiagnosticsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNChembioDiagnosticsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNNanoSynexLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AmendmentAndSettlementAgreementMember" xlink:label="loc_QLGNAmendmentAndSettlementAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNAmendmentAndSettlementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PurchasePrice" xlink:label="loc_QLGNPurchasePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss" xlink:label="loc_QLGNDisposalGroupIncludingDiscontinuedOperationGainLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNDisposalGroupIncludingDiscontinuedOperationGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockIssuedDuringPeriodShareSurrender" xlink:label="loc_QLGNStockIssuedDuringPeriodShareSurrender" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodShareSurrender" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AccruedCompensation" xlink:label="loc_QLGNAccruedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_QLGNAccruedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AccruedLicenseFees" xlink:label="loc_QLGNAccruedLicenseFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_QLGNAccruedLicenseFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_QLGNAccruedResearchAndDevelopmentCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_QLGNAccruedResearchAndDevelopmentCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000040 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CommonStockWarrantsMember" xlink:label="loc_QLGNCommonStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePrice" xlink:label="loc_QLGNRangeOfExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExpired" xlink:label="loc_QLGNRangeOfExercisePriceExpired" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceGranted" xlink:label="loc_QLGNRangeOfExercisePriceGranted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePriceGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePrice" xlink:label="loc_QLGNRangeOfExercisePrice_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueAdjustmentOfWarrant" xlink:label="loc_QLGNFairValueAdjustmentOfWarrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_QLGNFairValueAdjustmentOfWarrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:label="loc_QLGNFairValueOfWarrantLiabilitiesOnDateOfExercise" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_QLGNFairValueOfWarrantLiabilitiesOnDateOfExercise" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantLiabilitiesOnToEquity" xlink:label="loc_QLGNFairValueOfWarrantLiabilitiesOnToEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_QLGNFairValueOfWarrantLiabilitiesOnToEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" xlink:label="loc_QLGNFairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_QLGNFairValueOfWarrantLiabilitiesLossOnDebtExtinguishment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_QLGNChangeInFairValueOfWarrantLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_QLGNChangeInFairValueOfWarrantLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_FairValueAdjustmentOfWarrant" xlink:label="loc_QLGNFairValueAdjustmentOfWarrant_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_QLGNFairValueAdjustmentOfWarrant_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember" xlink:label="loc_srtWeightedAverageMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtWeightedAverageMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000043 - Disclosure - WARRANT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesTreasuryStockReissued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ConversionPricePercentage" xlink:label="loc_QLGNConversionPricePercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNConversionPricePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPriceDecrease" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPriceDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails" xlink:title="00000044 - Disclosure - SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeniorSecuredConvertibleDebtMember" xlink:label="loc_QLGNSeniorSecuredConvertibleDebtMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorSecuredConvertibleDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSecuredDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative" xlink:title="00000045 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalOtherThirdPartiesMember" xlink:label="loc_QLGNAlphaCapitalOtherThirdPartiesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalOtherThirdPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeniorConvertibleDebentureMember" xlink:label="loc_QLGNSeniorConvertibleDebentureMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorConvertibleDebentureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_QLGNAlphaCapitalMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_OctoberPaymentMember" xlink:label="loc_QLGNOctoberPaymentMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNOctoberPaymentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember_3" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_QLGNAlphaCapitalMember_3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtRangeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaapExtinguishmentOfDebtAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapExtinguishmentOfDebtAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaapExtinguishmentOfDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtAxis" xlink:to="loc_us-gaapExtinguishmentOfDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapExtinguishmentOfDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="loc_us-gaapShortTermDebtInterestRateIncrease" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShortTermDebtInterestRateIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSecuredDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PurchasePrice" xlink:label="loc_QLGNPurchasePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNPurchasePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ConversionPricePercentage" xlink:label="loc_QLGNConversionPricePercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNConversionPricePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="loc_us-gaapRepaymentsOfLongTermDebtAndCapitalSecurities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapRepaymentsOfLongTermDebtAndCapitalSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PrincipalAmountPercentage" xlink:label="loc_QLGNPrincipalAmountPercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNPrincipalAmountPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DebentureBeneficialOwnershipBlockerPercentage" xlink:label="loc_QLGNDebentureBeneficialOwnershipBlockerPercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNDebentureBeneficialOwnershipBlockerPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:label="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:label="loc_us-gaapWarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DebtRedemptionAmountInCash" xlink:label="loc_QLGNDebtRedemptionAmountInCash" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNDebtRedemptionAmountInCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DebtRedemptionAmountInCommonStock" xlink:label="loc_QLGNDebtRedemptionAmountInCommonStock" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_QLGNDebtRedemptionAmountInCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants" xlink:label="loc_QLGNDilutivePotentialSharesIssuableFromStockOptionsAndWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_QLGNDilutivePotentialSharesIssuableFromStockOptionsAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:title="00000048 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DisclosureResearchAndLicenseAgreementsAbstract" xlink:label="loc_QLGNDisclosureResearchAndLicenseAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureResearchAndLicenseAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_UpfrontPaymentMember" xlink:label="loc_QLGNUpfrontPaymentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNUpfrontPaymentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PhaseOneClinicalTrialMember" xlink:label="loc_QLGNPhaseOneClinicalTrialMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseOneClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PhaseTwoClinicalTrialMember" xlink:label="loc_QLGNPhaseTwoClinicalTrialMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseTwoClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PhaseThreeClinicalTrialMember" xlink:label="loc_QLGNPhaseThreeClinicalTrialMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseThreeClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LicenseAgreementMember" xlink:label="loc_QLGNLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_MasterLaboratoryServicesAgreementMember" xlink:label="loc_QLGNMasterLaboratoryServicesAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNMasterLaboratoryServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:label="loc_QLGNSponsoredResearchAgreementAndLicenseMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSponsoredResearchAgreementAndLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:label="loc_QLGNLicenseAndSponsoredResearchAgreementsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLicenseAndSponsoredResearchAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SponsoredResearchAgreementsAndLicenseMember" xlink:label="loc_QLGNSponsoredResearchAgreementsAndLicenseMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSponsoredResearchAgreementsAndLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_MLMMedicalLabsMember" xlink:label="loc_QLGNMLMMedicalLabsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNMLMMedicalLabsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:label="loc_QLGNUniversityOfLouisvilleResearchFoundationMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNUniversityOfLouisvilleResearchFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LicensedProductSalesMember" xlink:label="loc_QLGNLicensedProductSalesMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicensedProductSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ReimbursementOfPatent" xlink:label="loc_QLGNReimbursementOfPatent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNReimbursementOfPatent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_LicenseCost" xlink:label="loc_QLGNLicenseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNLicenseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ReimbursementOfResearchExpenses" xlink:label="loc_QLGNReimbursementOfResearchExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNReimbursementOfResearchExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AgreementTermPaymentDescription" xlink:label="loc_QLGNAgreementTermPaymentDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNAgreementTermPaymentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_MilestonePayment" xlink:label="loc_QLGNMilestonePayment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RegulatoryMarketingApprovalExpenses" xlink:label="loc_QLGNRegulatoryMarketingApprovalExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRegulatoryMarketingApprovalExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CumulativeSales" xlink:label="loc_QLGNCumulativeSales" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNCumulativeSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_UpfrontLicenseFee" xlink:label="loc_QLGNUpfrontLicenseFee" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNUpfrontLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PatentCosts" xlink:label="loc_QLGNPatentCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNPatentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RegulatoryMarketingApprovalExpensesOne" xlink:label="loc_QLGNRegulatoryMarketingApprovalExpensesOne" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNRegulatoryMarketingApprovalExpensesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShortfallPayments" xlink:label="loc_QLGNShortfallPayments" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNShortfallPayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ConversionOfConvertibleDebtMember" xlink:label="loc_QLGNConversionOfConvertibleDebtMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNConversionOfConvertibleDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000050 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:label="loc_QLGNEmployeesAndNonemployeeServiceProviderMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNEmployeesAndNonemployeeServiceProviderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:label="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails" xlink:title="00000051 - Disclosure - SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000053 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="loc_QLGNNonCompensatoryWarrantActivityMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNNonCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceOutstanding" xlink:label="loc_QLGNRangeOfExercisePriceOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExpired" xlink:label="loc_QLGNRangeOfExercisePriceExpired" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExpired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceOutstanding" xlink:label="loc_QLGNRangeOfExercisePriceOutstanding_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:label="loc_QLGNRangeOfExercisePriceNonexercisableNonvested" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceNonexercisableNonvested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" xlink:label="loc_QLGNRangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercisableGranted" xlink:label="loc_QLGNRangeOfExercisePriceExercisableGranted" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercised" xlink:label="loc_QLGNRangeOfExercisePriceExercised" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceExercisableExpired" xlink:label="loc_QLGNRangeOfExercisePriceExercisableExpired" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableExpired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_RangeOfExercisePriceForfeited" xlink:label="loc_QLGNRangeOfExercisePriceForfeited" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceForfeited" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000054 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CompensatoryWarrantsMember" xlink:label="loc_QLGNCompensatoryWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNCompensatoryWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:label="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_QLGNTwoThousandTwentyStockIncentivePlanMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_QLGNTwoThousandTwentyStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanosynexMember" xlink:label="loc_QLGNNanosynexMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanosynexMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_StockholdersEquityReverseStockSplitPricePerShare" xlink:label="loc_QLGNStockholdersEquityReverseStockSplitPricePerShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNStockholdersEquityReverseStockSplitPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WarrantsExtendedDateDescription" xlink:label="loc_QLGNWarrantsExtendedDateDescription" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNWarrantsExtendedDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_WarrantsExercised" xlink:label="loc_QLGNWarrantsExercised" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ModifiedToExercisePrice" xlink:label="loc_QLGNModifiedToExercisePrice" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNModifiedToExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPriceDecrease" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPriceDecrease" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000055 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeniorConvertibleDebentureMember" xlink:label="loc_QLGNSeniorConvertibleDebentureMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNSeniorConvertibleDebentureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SeriesAOnePreferredStockMember" xlink:label="loc_QLGNSeriesAOnePreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_NanoSynexLtdMember" xlink:label="loc_QLGNNanoSynexLtdMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_QLGNNanoSynexLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PrefundedWarrantMember" xlink:label="loc_QLGNPrefundedWarrantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNPrefundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtInterestRateIncrease" xlink:label="loc_us-gaapShortTermDebtInterestRateIncrease" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermDebtInterestRateIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt" xlink:label="loc_us-gaapSecuredDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSecuredDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_PurchasePrice" xlink:label="loc_QLGNPurchasePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNPurchasePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfDomesticAndForeignComponentsDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails" xlink:title="00000057 - Disclosure - SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" xlink:label="loc_QLGNEffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_QLGNEffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant" xlink:label="loc_QLGNEffectiveIncomeTaxRateReconciliationFairValueOfWarrant" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_QLGNEffectiveIncomeTaxRateReconciliationFairValueOfWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" xlink:label="loc_QLGNEffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_QLGNEffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" xlink:label="loc_QLGNEffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_QLGNEffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_EffectiveIncomeTaxRateReconciliationTrueUp" xlink:label="loc_QLGNEffectiveIncomeTaxRateReconciliationTrueUp" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_QLGNEffectiveIncomeTaxRateReconciliationTrueUp" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DefferdTaxAssetsAccruedExpenses" xlink:label="loc_QLGNDefferdTaxAssetsAccruedExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_QLGNDefferdTaxAssetsAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:label="loc_QLGNDeferredTaxAssetsResearchAndDevelopmentExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_QLGNDeferredTaxAssetsResearchAndDevelopmentExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000060 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardLimitationsOnUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000061 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AlphaCapitalMember" xlink:label="loc_QLGNAlphaCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNAlphaCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TwentyTwentyFourDebentureAndWarrantMember" xlink:label="loc_QLGNTwentyTwentyFourDebentureAndWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_QLGNTwentyTwentyFourDebentureAndWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TwentyTwentyFourDebentureMember" xlink:label="loc_QLGNTwentyTwentyFourDebentureMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_QLGNTwentyTwentyFourDebentureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_TwentyTwentyFourWarrantMember" xlink:label="loc_QLGNTwentyTwentyFourWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNTwentyTwentyFourWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_ReimbursementExpenses" xlink:label="loc_QLGNReimbursementExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_QLGNReimbursementExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20231231.xsd#QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_QLGNAdditionalProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_QLGNAdditionalProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235498224992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 25, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Qualigen
Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001460702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3474527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5857
Owens Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">452-8111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">QLGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,570,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,307,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Baker Tilly US, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San
Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235413656896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 401,803<span></span>
</td>
<td class="nump">$ 3,165,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">764,964<span></span>
</td>
<td class="nump">1,366,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,287,849<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,166,767<span></span>
</td>
<td class="nump">10,820,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">26,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">866,481<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Non-current assets of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,236,711<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">2,033,248<span></span>
</td>
<td class="nump">19,083,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,222,983<span></span>
</td>
<td class="nump">619,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">560,006<span></span>
</td>
<td class="nump">864,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingLiabilitiesCurrent', window );">Warrant liabilities</a></td>
<td class="nump">54,600<span></span>
</td>
<td class="nump">788,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_WarrantLiabilitiesRelatedParty', window );">Warrant liabilities - related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,834,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt - related party</a></td>
<td class="nump">1,299,216<span></span>
</td>
<td class="nump">60,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,441,198<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,136,805<span></span>
</td>
<td class="nump">8,608,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Non-current liabilities of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,708,732<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,136,805<span></span>
</td>
<td class="nump">10,316,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Qualigen Therapeutics, Inc. stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 225,000,000 shares authorized; 5,362,128 and 4,210,737 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">43,262<span></span>
</td>
<td class="nump">42,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">114,655,565<span></span>
</td>
<td class="nump">110,528,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(116,802,384)<span></span>
</td>
<td class="num">(103,385,172)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Qualigen Therapeutics, Inc. stockholders&#8217; equity (deficit)</a></td>
<td class="num">(2,103,557)<span></span>
</td>
<td class="nump">7,235,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,530,881<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Stockholders&#8217; Equity (deficit)</a></td>
<td class="num">(2,103,557)<span></span>
</td>
<td class="nump">8,766,590<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities &amp; Stockholders&#8217; Equity (Deficit)</a></td>
<td class="nump">$ 2,033,248<span></span>
</td>
<td class="nump">$ 19,083,491<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WarrantLiabilitiesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WarrantLiabilitiesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the liability arising from a financial instrument or a contract used to mitigate a specified risk (hedge), and which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235498324768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000,000<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,362,128<span></span>
</td>
<td class="nump">4,210,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,362,128<span></span>
</td>
<td class="nump">4,210,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235523142496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 6,095,607<span></span>
</td>
<td class="nump">$ 10,274,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,209,250<span></span>
</td>
<td class="nump">4,486,120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total expenses</a></td>
<td class="nump">11,304,857<span></span>
</td>
<td class="nump">14,760,720<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(11,304,857)<span></span>
</td>
<td class="num">(14,760,720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER EXPENSE (INCOME), NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on change in fair value of warrant liabilities</a></td>
<td class="num">(2,035,469)<span></span>
</td>
<td class="num">(907,203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="nump">1,524,722<span></span>
</td>
<td class="nump">34,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Loss on voluntary conversion of convertible debt</a></td>
<td class="nump">1,077,287<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">625,653<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Loss on fixed asset disposal</a></td>
<td class="nump">21,747<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">(38,994)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense (income), net</a></td>
<td class="nump">1,174,946<span></span>
</td>
<td class="num">(872,806)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES</a></td>
<td class="num">(12,479,803)<span></span>
</td>
<td class="num">(13,887,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(BENEFIT) PROVISION FOR INCOME TAXES</a></td>
<td class="num">(4,793)<span></span>
</td>
<td class="nump">6,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">NET LOSS FROM CONTINUING OPERATIONS</a></td>
<td class="num">(12,475,010)<span></span>
</td>
<td class="num">(13,894,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract', window );"><strong>DISCONTINUED OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="num">(683,008)<span></span>
</td>
<td class="num">(7,140,181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Loss on disposal of discontinued operations, net of tax</a></td>
<td class="num">(602,232)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">LOSS FROM DISCONTINUED OPERATIONS</a></td>
<td class="num">(1,285,240)<span></span>
</td>
<td class="num">(7,140,181)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(13,760,250)<span></span>
</td>
<td class="num">(21,034,643)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest from discontinued operations</a></td>
<td class="num">(343,038)<span></span>
</td>
<td class="num">(2,394,100)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Qualigen Therapeutics, Inc.</a></td>
<td class="num">$ (13,417,212)<span></span>
</td>
<td class="num">$ (18,640,543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss per common share, basic - continuing operations</a></td>
<td class="num">$ (2.46)<span></span>
</td>
<td class="num">$ (3.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss per common share, diluted - continuing operations</a></td>
<td class="num">(2.46)<span></span>
</td>
<td class="num">(3.62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare', window );">Net loss per common share, basic - discontinued operations</a></td>
<td class="num">(0.19)<span></span>
</td>
<td class="num">(1.24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare', window );">Net loss per common share, diluted - discontinued operations</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (1.24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares outstanding, basic</a></td>
<td class="nump">5,072,709<span></span>
</td>
<td class="nump">3,840,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares outstanding, diluted</a></td>
<td class="nump">5,072,709<span></span>
</td>
<td class="nump">3,840,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment from discontinued operations</a></td>
<td class="nump">$ 119,473<span></span>
</td>
<td class="nump">$ 50,721<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive loss</a></td>
<td class="num">(13,640,777)<span></span>
</td>
<td class="num">(20,983,922)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interest from discontinued operations</a></td>
<td class="num">(304,735)<span></span>
</td>
<td class="num">(2,394,100)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Qualigen Therapeutics, Inc.</a></td>
<td class="num">$ (13,336,042)<span></span>
</td>
<td class="num">$ (18,589,822)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481194/470-20-40-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235413738320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Parent [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 35,290<span></span>
</td>
<td class="nump">$ 101,274,073<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (84,744,629)<span></span>
</td>
<td class="nump">$ 16,564,734<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16,564,734<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">3,529,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Fair value of warrant modification for professional services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">67,370<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">67,370<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">67,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,484,044<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,484,044<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,484,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,640,543)<span></span>
</td>
<td class="num">(18,640,543)<span></span>
</td>
<td class="num">(2,394,100)<span></span>
</td>
<td class="num">(21,034,643)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock issued upon exercise of warrants</a></td>
<td class="nump">$ 3,320<span></span>
</td>
<td class="nump">4,711<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,031<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock issued upon exercise of warrants, shares</a></td>
<td class="nump">332,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition', window );">Common stock and prefunded warrants issued for business acquisition</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">3,740,417<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,743,917<span></span>
</td>
<td class="nump">3,882,225<span></span>
</td>
<td class="nump">7,626,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition', window );">Common stock and prefunded warrants issued for business acquisition, shares</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther', window );">&#160;Noncontrolling interest adjustments relating to Stock-based compensation and other</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(42,756)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(42,756)<span></span>
</td>
<td class="nump">42,756<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,721<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,721<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationForBusinessAcquisition', window );">Fair value of warrant modification for business acquisition</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodValuesReverseStockSplits', window );">Issuance of rounded shares as a result of the reverse stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(505)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(505)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Issuance of rounded shares as a result of the reverse stock split, shares</a></td>
<td class="num">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 42,110<span></span>
</td>
<td class="nump">110,528,050<span></span>
</td>
<td class="nump">50,721<span></span>
</td>
<td class="num">(103,385,172)<span></span>
</td>
<td class="nump">7,235,709<span></span>
</td>
<td class="nump">1,530,881<span></span>
</td>
<td class="nump">8,766,590<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">4,210,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Voluntary conversion of convertible debt into common stock</a></td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">1,111,740<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,112,582<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,112,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Voluntary conversion of convertible debt into common stock, shares</a></td>
<td class="nump">841,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock', window );">Redemptions of convertible debt into common stock</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="nump">254,006<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">254,316<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">254,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock', window );">Redemptions of convertible debt into common stock, shares</a></td>
<td class="nump">309,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Fair value of warrant modification for professional services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,945<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,945<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity', window );">Fair value of warrant reclassified from liabilities to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,626,694<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,626,694<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,626,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,098,533<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,098,533<span></span>
</td>
<td class="nump">9,297<span></span>
</td>
<td class="nump">1,107,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">28,597<span></span>
</td>
<td class="nump">81,170<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">109,767<span></span>
</td>
<td class="nump">38,303<span></span>
</td>
<td class="nump">148,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DeconsolidationOfDiscontinuedOperations', window );">Deconsolidation of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(131,891)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(131,891)<span></span>
</td>
<td class="num">(1,235,443)<span></span>
</td>
<td class="num">(1,367,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,417,212)<span></span>
</td>
<td class="num">(13,417,212)<span></span>
</td>
<td class="num">(343,038)<span></span>
</td>
<td class="num">(13,760,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,473<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 43,262<span></span>
</td>
<td class="nump">$ 114,655,565<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (116,802,384)<span></span>
</td>
<td class="num">$ (2,103,557)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (2,103,557)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">5,362,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DeconsolidationOfDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DeconsolidationOfDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantModificationForBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant modification for business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantModificationForBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant reclassified from liabilities to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest adjustments relating to stockbased compensation and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common stock and prefunded warrants issued for business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemptions of convertible debt into common stock, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common stock and prefunded warrants issued for business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemptions of convertible debt into common stock, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedDuringPeriodValuesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period values reverse stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedDuringPeriodValuesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235497824016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (13,760,250)<span></span>
</td>
<td class="num">$ (21,034,643)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="num">(1,285,240)<span></span>
</td>
<td class="num">(7,140,181)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="num">(12,475,010)<span></span>
</td>
<td class="num">(13,894,462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile loss from continuing operations to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,495<span></span>
</td>
<td class="nump">12,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,098,533<span></span>
</td>
<td class="nump">4,765,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(2,035,469)<span></span>
</td>
<td class="num">(906,345)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_LossOnVoluntaryConversionOfConvertibleDebt', window );">Loss on voluntary conversion of convertible debt</a></td>
<td class="nump">1,077,287<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AccretionOfDiscountOnConvertibleDebt', window );">Accretion of discount on convertible debt</a></td>
<td class="nump">1,469,640<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">625,653<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">21,747<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationForProfessionalServices', window );">Fair value of warrant modification for professional services</a></td>
<td class="nump">7,945<span></span>
</td>
<td class="nump">67,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(264,741)<span></span>
</td>
<td class="num">(126,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,603,422<span></span>
</td>
<td class="num">(43,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(227,101)<span></span>
</td>
<td class="num">(472,441)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities - continuing operations</a></td>
<td class="num">(9,093,599)<span></span>
</td>
<td class="num">(10,598,862)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by (used in) operating activities - discontinued operations</a></td>
<td class="num">(1,210,664)<span></span>
</td>
<td class="num">(2,648,679)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,304,263)<span></span>
</td>
<td class="num">(13,247,541)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided by (used in) investing activities - discontinued operations</a></td>
<td class="nump">4,215,943<span></span>
</td>
<td class="num">(183,763)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">4,215,943<span></span>
</td>
<td class="num">(183,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from warrant exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ProceedsFromIssuanceOfConvertibleDebt', window );">Proceeds from issuance of convertible debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,903,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on convertible notes payable</a></td>
<td class="num">(550,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FractionalSharePaymentsRelatedToReverseStockSplit', window );">Fractional share payments related to the reverse stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(505)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash (used in)/provided by financing activities - continuing operations</a></td>
<td class="num">(550,000)<span></span>
</td>
<td class="nump">2,910,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash used in financing activities - discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(550,000)<span></span>
</td>
<td class="nump">2,910,515<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and restricted cash</a></td>
<td class="num">(6,638,320)<span></span>
</td>
<td class="num">(10,520,789)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and restricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">22,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash from continuing operations - beginning of period</a></td>
<td class="nump">3,165,985<span></span>
</td>
<td class="nump">9,174,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and restricted cash from discontinued operations - beginning of period</a></td>
<td class="nump">3,874,138<span></span>
</td>
<td class="nump">8,363,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Less: cash and restricted cash from discontinued operations - end of period</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,874,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash from continuing operations - end of period</a></td>
<td class="nump">401,803<span></span>
</td>
<td class="nump">3,165,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Taxes</a></td>
<td class="nump">5,571<span></span>
</td>
<td class="nump">5,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NONCASH FINANCING AND INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_TransfersOfInventoryFromEquipmentHeldForLease', window );">Net transfers to equipment held for lease from inventory</a></td>
<td class="nump">83,281<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise', window );">Fair value of warrant liabilities on date of exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RedemptionOfConvertibleDebtIntoCommonStock', window );">Redemption of convertible debt into common stock</a></td>
<td class="nump">254,316<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock', window );">Voluntary conversion of convertible debt into common stock</a></td>
<td class="nump">1,112,582<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement', window );">Fair value of warrant modifications pursuant to Securities Purchase Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantModificationsForBusinessAcquisition', window );">Fair value of warrant modifications for business acquisition</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 33,543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccretionOfDiscountOnConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of discount on convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccretionOfDiscountOnConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities on date of exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantModificationForProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant modification for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantModificationForProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantModificationsForBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant modifications for business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantModificationsForBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FractionalSharePaymentsRelatedToReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fractional share payments related to the reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FractionalSharePaymentsRelatedToReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_LossOnVoluntaryConversionOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on voluntary conversion of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_LossOnVoluntaryConversionOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ProceedsFromIssuanceOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ProceedsFromIssuanceOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RedemptionOfConvertibleDebtIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RedemptionOfConvertibleDebtIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_TransfersOfInventoryFromEquipmentHeldForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfers of inventory from equipment held for lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_TransfersOfInventoryFromEquipmentHeldForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Voluntary conversion of convertible debt into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235414995008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</a></td>
<td class="text"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zOnsX2Pu4gA7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8212; <span id="xdx_825_zet8NYo4nIGd">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--OrganizationPolicyTextBlock_zoELRG00RZqb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zEHGaHZAHxR7">Organization</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ritter
Pharmaceuticals, Inc. (the Company&#8217;s predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the
name Ritter Natural Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals,
Inc. On May 22, 2020, upon completing a &#8220;reverse recapitalization&#8221; transaction with Qualigen, Inc., Ritter Pharmaceuticals,
Inc. was renamed Qualigen Therapeutics, Inc. (the &#8220;Company&#8221;). Qualisys Diagnostics, Inc. was formed as a Minnesota corporation
in 1996, reincorporated to become a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc.
was a wholly-owned subsidiary of the Company. On July 20, 2023, the Company sold all of the issued and outstanding shares of common stock
of Qualigen, Inc. to Chembio Diagnostics, Inc. (&#8220;Chembio&#8221;), a wholly-owned subsidiary of Biosynex, S.A. (&#8220;Biosynex&#8221;).
Following the consummation of this transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio (see Note 5 &#8211; Discontinued
Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 26, 2022, the Company acquired <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zAZ4kjiHJfug" title="Stock issued during period shares acquisitions">2,232,861</span> shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (&#8220;NanoSynex&#8221;) from Alpha
Capital Anstalt (&#8220;Alpha&#8221;), a related party, in exchange for <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zm10E5bR0Vk9" title="Stock issued during period shares acquisitions">350,000</span> reverse split adjusted shares of the Company&#8217;s
common stock and a prefunded warrant to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zgOebxpv9q2h" title="Warrants to purchase common stock">331,464</span> reverse split adjusted shares of the Company&#8217;s common stock at an exercise
price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_znQiAcdJ9vQk" title="Warrants exercise price">0.001</span> per share. <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20220524__20220526_zZLCTUTXqaVa" title="Reverse stock split">These warrants were subsequently exercised on September 13, 2022.</span> Concurrently with this transaction, the
Company also entered into a Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022,
with NanoSynex (the &#8220;NanoSynex Funding Agreement&#8221;), to, among other things, provide for the further funding of NanoSynex,
and purchased <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBH1w32dlfCa" title="Stock issued during period shares acquisitions">381,786</span> shares of Series B preferred stock from NanoSynex for a total purchase price of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zP9BLEKsOO75" title="Stock issued during period, value, acquisitions">600,000</span>. The transactions resulted
in the Company acquiring a <span id="xdx_905_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zmyx8kufwR2e" title="Voting interests acquired">52.8</span>% interest in NanoSynex (the &#8220;NanoSynex Acquisition&#8221;). NanoSynex is a nanotechnology diagnostics
company domiciled in Israel. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex (the &#8220;NanoSynex
Amendment&#8221;), which amended the NanoSynex Funding Agreement, to, among other things, eliminate most of the Company obligation for
the further funding of NanoSynex. Pursuant to the terms of the NanoSynex Amendment, the Company lost its controlling interest in NanoSynex
(see Note 5 -Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNRMCvRcDep" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zONvBnmWnJ7c">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#8220;U.S. GAAP&#8221;), Regulation S-X and rules and regulations of the Securities and Exchange Commission
(&#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zf9hM2AKGiw7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zzRYl9MVKxT2">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the accounts of the Company and its former wholly-owned and majority owned subsidiaries.
All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance
is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional
currency of the Company and its subsidiaries is the U.S. dollar. For NanoSynex, the functional currency was the local currency, New Israeli
Shekels (NIS). As such, assets and liabilities for NanoSynex were translated into U.S. dollars with the effects of foreign currency translation
adjustments reflected as a component of accumulated other comprehensive loss within the Company&#8217;s consolidated statements of
changes in stockholders&#8217; equity (deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 20, 2023, NanoSynex was deconsolidated from these financial statements as the transactions contemplated by the NanoSynex Amendment
resulted in a loss of control of a subsidiary that constitutes a business under ASC 810. The retained investment in NanoSynex is accounted
for prospectively as an equity method investment. See Note 5 &#8211; Discontinued Operations for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zjBN6sDUY1X" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z6285TUmPecj">Discontinued
Operations</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, the Company completed the sale of Qualigen, Inc. to Chembio Diagnostics, Inc. The sale of Qualigen Inc. constituted a
significant disposition and as such, the Company concluded that the disposition of ownership in Qualigen, Inc. represented a strategic
shift that had a major effect on its operations and financial results. Therefore, Qualigen, Inc. is classified as discontinued operations
for all periods presented herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, the Company entered into the NanoSynex Amendment, which amended the Master Funding Agreement
for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the &#8220;NanoSynex
Funding Agreement&#8221;), a former majority owned subsidiary of the Company, to, among other things, forfeit 281,000 Series B Preferred
Shares of NanoSynex held by the Company, resulting in the deconsolidation of NanoSynex. The disposition represents a strategic shift
that will have a material effect on the Company&#8217;s operations and financial results. Accordingly, the business of NanoSynex is classified
as discontinued operations for all periods presented herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 5 - Discontinued Operations for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--EquityMethodInvestmentsPolicy_z0yVc3zgdCml" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zXqLYuXa0E2e">Equity
Method Investments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
deconsolidation of NanoSynex on July 20, 2023, the Company accounts for its retained investment under the equity method of accounting
as it retained the ability to exercise significant influence over the operating and financial policies of the investee. Under the equity
method, the Company recognizes its proportionate share earnings or losses each reporting period with an adjustment to the carrying value
of the investment. As of December 31, 2023, the carrying value of the retained investment was zero, and therefore the Company has suspended
application of the equity method as the Company is not liable for the obligations of the investee nor otherwise committed to provide
financial support. Future equity method earnings, if any, will not be recognized until the amount exceeds the unrecognized net losses
in prior periods. See Note 5 &#8211; Discontinued Operations for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--UseOfEstimates_z4xRxysj5w3b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zxiaUaiQGjf3">Accounting
Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant
liabilities, and stock-based compensation. Actual results could vary from the estimates that were used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_ecustom--ReverseStockSplitPolicyTextBlock_zPyRls5G3Qw8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z8rDi0S5KRI1">Reverse
Stock Split</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 23, 2022, the Company effected a 1-for-10 reverse stock split of its outstanding shares of common stock (the &#8220;Reverse
Stock Split&#8221;). The Reverse Stock Split reduced the Company&#8217;s shares of outstanding common stock, stock options, and warrants
to purchase shares of common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse Stock Split
were rounded down to the nearest whole share and cash in lieu of fractional shares was paid to stockholders. All share and per share
data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively
to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zptILlwsNoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zj906zf4TUrh">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains the majority of its cash in government money market mutual funds and in accounts at banking institutions in the U.S.
that are of high quality. Cash held in these accounts often exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits.
If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations.
In March 2023, Silicon Valley Bank and Signature Bank, and more recently in May 2023, First Republic Bank, were closed due to liquidity
concerns and taken over by the FDIC. While the Company did not have an account at any of these banks, in the event of failure of any
of the financial institutions where the Company maintains its cash and cash equivalents, there can be no assurance that the Company would
be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely
affect the Company&#8217;s business and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zES8EVAkVpFc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zzGtVIkWEHvd">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the years ended December 31, 2023 and 2022, <span id="xdx_908_eus-gaap--AssetImpairmentCharges_do_c20230101__20231231_zGFJtvprpUYc" title="Impairment losses on construction-in-progress"><span id="xdx_90E_eus-gaap--AssetImpairmentCharges_do_c20220101__20221231_zqrYIsRX9XLe" title="Impairment losses on construction-in-progress">no</span></span> such impairment
losses have been recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zFy6sd4R3J5d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z83nPQFph3kk">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company
has viewed its operations and managed its business as one segment operating primarily within the United States (and in Israel prior to
the NanoSynex deconsolidation).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zyju2okuavG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zVTC3o3ff6sc">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for acquired in process research and development (IPR&amp;D), the Company expenses research and development costs as incurred including
therapeutics license costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--PatentCostsPolicyTextBlock_zdZxPitk3Mlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zjug10Hktfve">Patent
Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--BusinessCombinationsPolicy_z8WGLPtyAmeg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zsBOFrfYlQH3">Business
Combinations</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for business combinations using the acquisition method pursuant to Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;)
ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company&#8217;s
financial results beginning on the respective acquisition date, and that assets acquired and liabilities assumed are recognized at fair
value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted
cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of
capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value of
the intangible asset. Any excess of the fair value of consideration transferred (the &#8220;purchase price&#8221;) over the fair values
of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may
be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition
date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_847_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zOLyA9Skf2T" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zaNulaXka052">Goodwill</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired,
when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized but is reviewed
for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.
In testing for impairment, the fair value of the reporting unit is compared to the carrying value. If the net assets assigned to the
reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the difference is recorded. As a result of the
annual goodwill impairment analysis, the Company recognized a $<span id="xdx_905_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zn8hkA3dRh52" title="Goodwill impairment charges">4,239,000</span> non-cash goodwill and fixed asset impairment charge in the valuation
of its business acquisition of NanoSynex for the year ended December 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_zpO2iZ5rIuMh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zUTkdHfTIgE7">Derivative
Financial Instruments and Warrant Liabilities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument,
the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception
and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as
liabilities or as equity, is re-assessed at the end of each reporting period (See Note 7-Warrant Liabilities and Note 8- Convertible
Debt - Related Party).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zl9QOmVDa5hl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zQXgBNLNIxY7">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability
    to access at the measurement date;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-align: justify; text-indent: -24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs
    in markets that are not considered to be active; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 - Inputs that are unobservable.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-align: justify; text-indent: -24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zcOOuCmQgig9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zElovFA8AgRk">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates
fair value due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zw3foD3WaGE1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zTi9ooXhuPug">Comprehensive
Loss</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss consists of net income and foreign currency translation adjustments related to the discontinued operations of NanoSynex. Comprehensive
gains (losses) have been reflected in the statements of operations and comprehensive loss and as a separate component in the statements
of stockholders&#8217; equity (deficit) for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_842_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z9jJfqsCkC8g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zlDItihaHpx6">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company&#8217;s
stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zm8AiE3fJ4p2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zsEuTaq4sI06">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years. For more information, refer to Note 14 - Income Taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update 2023-09, Improvements to Income Tax Disclosures, which requires more detailed
income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation
as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis,
with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early
adoption permitted. The Company is evaluating the disclosure requirements related to the new standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z1ONaR6BlLXl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zq5GXQbmj1Ka">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency for the Company is the U.S. dollar. The functional currency for the discontinued operations of NanoSynex was the
New Israeli Shekel (NIS). The financial statements of NanoSynex were translated into U.S. dollars using exchange rates in effect at each
period end for assets and liabilities; using exchange rates in effect during the period for results of operations; and using historical
exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of NanoSynex was reflected
as a separate component of other comprehensive income (loss) (see Note 5 - Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8LlnmXoZKt1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zpa55FKXxkR3">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected
to have a significant impact to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84A_ecustom--GlobalEconomicConditionsPolicyTextBlock_zRY1aEAurJui" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zgjKyfRNhO2a">Global
Economic Conditions</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ongoing
Wars in Ukraine and Israel</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor
any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the
conflict on the Company&#8217;s business and financial results remains uncertain and will depend on the severity and duration of the
conflict and its impact on regional and global economic conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, Hamas conducted terrorist attacks in Israel resulting in ongoing war. There continue to be hostilities between Israel and
Hezbollah in Lebanon and Hamas in the Gaza Strip, both of which have resulted in rockets being fired into Israel, causing casualties
and disruption of economic activities. In early 2023, there were a number of changes proposed to the political system in Israel by the
current government which, if implemented as planned, could lead to large-scale protests and additional uncertainty, negatively impacting
the operating environment in Israel. Popular uprisings in various countries in the Middle East over the last few years have also affected
the political stability of those countries and have led to a decline in the regional security situation. Such instability may also lead
to deterioration in the political and trade relationships that exist between Israel and these countries. Any armed conflicts, terrorist
activities or political instability involving Israel or other countries in the region could adversely affect the Company&#8217;s minority
interest in NanoSynex, its results of operations, financial condition, cash flows and prospects (see Note 5 &#8211; Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
and Global Economic Conditions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary
pressures attributable to government stimulus and recovery programs, government deficit spending and supply chain issues. The Company
cannot provide assurance that it will be successful in fully offsetting increased costs resulting from inflationary pressure. In addition,
the global economy suffers from slowing growth and rising interest rates, and some economists believe that there may be a global recession
in the near future. If the global economy slows, the Company&#8217;s business may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_ecustom--ImpactOfCovid19PandemicPolicyTextBlock_zO8s7ZYnbAN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zNp25EDTxFY1">Impact
of COVID-19 Pandemic</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company&#8217;s business as well. During the height of
the pandemic, sales of diagnostic products decreased significantly and the Company&#8217;s net loss increased significantly, as clinics
and small hospitals&#8217; demand for Qualigen, Inc.&#8217;s FastPack&#8482; diagnostic test kits was reduced sharply, largely due to
deferral of patients&#8217; non-emergency visits to physician offices. In July 2023 the Company sold Qualigen, Inc., its wholly-owned
subsidiary, to Chembio (see Note 5 - Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#8217;s
consolidated financial statements.</span></p>

<p id="xdx_85D_z5DxZVh5ii58" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235411351136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND GOING CONCERN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY AND GOING CONCERN</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zMMAGQLjfmwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8212; <span><span id="xdx_82B_zwlfTzVoH959">LIQUIDITY AND GOING CONCERN</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&#160;31, 2023, the Company had approximately $<span id="xdx_909_eus-gaap--Cash_iI_pn5n6_c20231231_zpZpvhGTITN7">0.4</span></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in cash and an accumulated deficit of $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20231231_zvkb6ozWL58j">116.8
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. For the years ended December&#160;31,
2023 and 2022, the Company used cash of $<span id="xdx_90F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20231231_zw5hB5OETJle">10.3</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20221231_zA6QNfYcaBV9">13.2
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively, in operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s cash balances as of the date that these financial statements were issued along with the proceeds from the above sale
to Chembio, without additional financing, are expected to fund operations only into the second quarter of 2024. The Company expects to
continue to have net losses and negative cash flow from operations, which will challenge its liquidity. These factors raise substantial
doubt about the Company&#8217;s ability to continue as a going concern for the one-year period following the date that these financial
statements were issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that profitable operations will ever be achieved, or, if achieved, could be sustained on a continuing basis. In order
to fully execute its business plan, the Company will require significant additional financing for planned research and development activities,
capital expenditures, clinical testing for QN-302 and preclinical development of Pan-RAS, as well as commercialization activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the Company&#8217;s principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds from
the issuance of debt. In December 2022 the Company raised $<span id="xdx_900_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20221201__20221231_z4aqTijq0Q68">3.0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million from the sale of an 8% Senior Convertible
Debenture (the &#8220;Debenture&#8221;) to  Alpha (see Note 8 - Convertible Debt - Related Party). There can be no assurance that further
financing can be obtained on favorable terms, or at all. If the Company is unable to obtain funding, the Company could be required to
delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which
could adversely affect the Company&#8217;s business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements
do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be
required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ
from those reflected in the accompanying financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235511710448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--OtherAssetsDisclosureTextBlock_zARgnBgCCkp3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8212; <span><span id="xdx_82F_zyOZAHr3dore">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zFL6RiaYR2Ij" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following at December 31, 2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="display: none"><span id="xdx_8B3_zaBxxvAYKOaj">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zyipDHfi1Ki6" style="vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zz8Puu6B85T1" style="vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzdSM_zDgnhzRorW98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">566,011</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,329,034</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzdSM_zkttQ2OFjpO5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,670</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ReceivableInvestmentSale_iI_pp0p0_maPEAOAzdSM_zxVQHhn3sGF6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Receivable from sale of Qualigen, Inc.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0709">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PreapaidResearchAndDevelopmentExpenses_iI_pp0p0_maPEAOAzdSM_zlWYao4idRH2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Prepaid research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">173,900</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0713">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzdSM_zXh1u3ZJH5Y8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and
    other current assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">764,964</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,366,704</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_z6jr4cMUTI11" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses attributable to Qualigen, Inc. and NanoSynex were deemed disposed of as discontinued operations (see Note 5 - Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235411253600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER NON-CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock', window );">OTHER NON-CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--InvestmentsAndOtherNoncurrentAssetsTextBlock_zug4PAji38r6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8212; <span id="xdx_82A_zcYjvQ5vXOzg">OTHER NON-CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfOtherAssetsNoncurrentTextBlock_zMaDE9peYpFc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
non-current assets consisted of the following at December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8BF_z89w6uHf1Bx7" style="display: none">SCHEDULE
OF OTHER NON CURRENT ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zaZrvYydfiJd" style="vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EscrowDeposit_iI_maOAzAWm_zzszp4MmBlLa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Funds held in escrow</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">450,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--LongtermResearchAndDevelopmentDeposits_iI_maOAzAWm_zi3qvIX2HLSi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Long-term research and development deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">416,481</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAssets_iI_mtOAzAWm_zgiA0JZTUTSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Other non-current assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">866,481</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_za5c34Gu05ef" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235414260800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISCONTINUED OPERATIONS</a></td>
<td class="text"><p id="xdx_804_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zGj9beVj43T" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8212; <span id="xdx_82C_zn99i7KT0Hc2">DISCONTINUED OPERATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p id="xdx_89D_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_z5Dt0YsaFggi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of assets and liabilities classified in discontinued operations as of December 31, 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BE_zM2GFwfBcb99" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zodx01DSNDs4" style="border-bottom: Black 1.5pt solid; text-align: center">Qualigen, Inc.</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zkWbORC60jCl" style="border-bottom: Black 1.5pt solid; text-align: center">NanoSynex</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_z50z0zVBbJah" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzI2M_maTAODOzy7K_zXkOI4AdQZJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 46%; text-align: left">Current assets of discontinued operations</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">4,448,999</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">1,838,850</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">6,287,849</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_i01I_maCzo3N_maTAODOzy7K_z4TkzckFeGD8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Non-current assets of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,876,270</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,360,441</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,236,711</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--TotalAssetsOfDiscontinuedOperations_iI_zaOJz7puWoR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets of discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,325,269</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,199,291</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,524,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzCJ5_maTLOOzkOU_zEbnWh5YAST6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,299,948</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,141,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,441,198</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_i02I_maCzIDe_maTLOOzkOU_zwwt8URcENPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Non-current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,350,975</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">357,757</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,708,732</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--TotalLiabilitiesOfdiscontinuedOperations_iI_zCPvA2wOO6bh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities of discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,650,923</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,499,007</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,149,930</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of gain (loss) from discontinued operations, net of tax, as of December 31, 2023 and 2022 are as follows:<b>&#160;</b></span></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zgyRHLYRdNHk" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zYirOfUwnfHi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zZOHikC3k2A7" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_z7KOK0KzexEg" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zriQLS8NBlK6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zBmCU5FMeNv5" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Qualigen, Inc.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NanoSynex</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Qualigen, Inc.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NanoSynex</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_maCzBjD_zXK0Entbw48b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left">(Loss) from discontinued operations</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(171,701</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(511,307</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(683,008</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(2,142,763</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(4,997,418</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(7,140,181</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_iN_di_msCzBjD_zEyxLvK7bhpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Gain (loss) on disposal of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,876,778</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,479,010</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(602,232</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0767">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_mtCzBjD_maCzhiC_zjo8O9g2rzk2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total gain (loss) from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,705,077</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,990,317</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,285,240</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,142,763</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,997,418</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,140,181</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>
<p id="xdx_8A1_zHZhx5d7gqAe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sale
of Qualigen, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, the Company completed the sale of Qualigen, Inc., its formerly wholly-owned subsidiary, to Chembio Diagnostics, Inc.
for net cash consideration of $<span id="xdx_909_eus-gaap--Cash_iI_pn5n6_c20230720__dei--LegalEntityAxis__custom--ChembioDiagnosticsMember_zvbvfYJRY5d7" title="Cash">5.4</span> million, of which $<span id="xdx_90A_ecustom--PurchasePrice_iI_pn5n6_c20230720_zQ1JqRdHxet8" title="Purchase price">4.9</span> million was received during the year ended December 31, 2023, and $<span id="xdx_906_eus-gaap--EscrowDeposit_iI_c20230720_z6ScgJ9i1cO6" title="Escrow deposit">450,000</span>
is being held in escrow until January 20, 2025 to satisfy certain Company indemnification obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zRICwWBIIOpg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets and liabilities classified in discontinued operations for Qualigen, Inc. as of December 31, 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span id="xdx_8BB_z8eP3ft272Ub" style="display: none">ASSETS
AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zOY75KWN9c0f" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_zGKYfYaxTuP6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,246,482</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_zHdqUvOvAWj4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">512,088</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_iI_zHtJnaXnk68d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inventory, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,586,297</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_zUgM1ml5g8S6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104,132</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zIEHIrtrpUWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current assets of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,448,999</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets_iI_zHU6IGWDB8Y3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,422,538</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_iI_zKbRdheWsea" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289,696</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_iI_zIDSZ58seAhc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,702</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_iI_zMkyyWT4oEha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,334</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_iI_zjRDEs67Ztx3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Total non-current assets of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,876,270</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--TotalAssetsOfDiscontinuedOperations_zEMDVnMkIPPd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total assets of discontinued operations of Qualigen, Inc.</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,325,269</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_zHmjfZc3mAO" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">236,470</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedVacation_iI_zFUrYTtBMubd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187,906</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_iI_z9mMXvu4yod" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">518,766</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_iI_zCPQARiRXiq9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred revenue, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,161</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_iI_z4V9woU1rXdh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Operating lease liability, current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">240,645</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_z3PO2u2XYjzb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Total current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,299,948</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_iI_zQQ6Ddu84EN4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,301,919</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_iI_zonhoHs0imS" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Deferred revenue, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49,056</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_iI_zhBTeigkBoW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total non-current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,350,975</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--TotalLiabilitiesOfdiscontinuedOperations_zPfVDec32Sy2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total liabilities of discontinued operations of Qualigen, Inc.</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,650,923</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reclassified the following statement of operations items to discontinued operations for the years ended December 31, 2023 and
2022, respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zHVOVMBBvRg2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zZgIAXsbIcn3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Years Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">REVENUES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedOperationNetProductSales_z80f30iqchab" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; width: 60%; text-align: left">Net product sales</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">3,661,121</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">4,983,556</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_z5vtcVatxqJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Total revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,661,121</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,983,556</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_zO8Rbrocq78c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cost of product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,551,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,302,755</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_z70FNxYXKUU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">610,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">561,047</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_zvOj8wb280n3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,245,973</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment_zRBHa9jfx3Yf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">405,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">950,420</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedSalesAndMarketing_z4yk1rxelthj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Goodwill and fixed asset impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedTotalExpenses_zFXxpOret2x8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,774,118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,135,195</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">OTHER EXPENSE (INCOME), NET</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease_zMxym9pZFS8c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on disposal of equipment held for lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,302</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_ztT4uefCVgFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest (income) expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,751</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_znvkUZyg6kO" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,898</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,125</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal_zCYNcNK7eRr8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Loss on fixed asset disposal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_z5ZI3qdus78" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total other expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,876</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_zoGT3t7RNRC8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(171,701</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,142,763</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc._zjz18nM1MRD1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Gain on sale of Qualigen, Inc., net of tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,876,778</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_zUCJBATU4V7f" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">INCOME (LOSS) FROM DISCONTINUED OPERATIONS OF QUALIGEN, INC.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,705,077</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,142,763</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company recorded a gain on the sale of Qualigen, Inc. in its consolidated financial statements
for the years ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gain on sale of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Qualigen, Inc.</p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Fair value of consideration received</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived_c20230101__20231231_zopQLsek6o52" style="width: 16%; text-align: right" title="Fair value of consideration received">5,489,337</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Working capital adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment_c20230101__20231231_zgKCXMukPacc" style="text-align: right" title="Working capital adjustment">235,402</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total Assets of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalAssets_iI_c20231231_z7F0kPUQmzjf" style="text-align: right" title="Total Assets of discontinued operations">(4,225,562</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total Liabilities of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_iI_c20231231_zZB0sSvCh5Le" style="text-align: right" title="Total Liabilities of discontinued operations">3,005,407</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Transaction expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationTransactionExpenses_c20230101__20231231_zoV99ipBQx9j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transaction expenses">(627,806</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Gain on sale of Qualigen, Inc.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_c20230101__20231231_zQ7H97dMMNFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Gain on sale of Qualigen, Inc.">3,876,778</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_z7H3xYCom9q5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the fourth quarter of 2023, the gain was adjusted upward by $<span id="xdx_908_ecustom--DisposalGroupIncludingDiscontinuedOperationGainLoss_c20231001__20231231_zVbCg4GPOMM6" title="Gain upward upon final payment of transaction cost">17,000</span> upon final payment of transaction costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment
and Settlement Agreement with NanoSynex Ltd.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, the Company entered into and effectuated the NanoSynex Amendment, pursuant to which the Company agreed to, in exchange
for eliminating all future NanoSynex Funding Agreement obligations for the Company to invest further cash in NanoSynex (except for obligations
to lend NanoSynex $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20231130__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__dei--LegalEntityAxis__custom--NanoSynexLtdMember_zR58KpzlTHml" title="Aggregrate amount">560,000</span> on or before November 30, 2023, and $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__dei--LegalEntityAxis__custom--NanoSynexLtdMember_zE6Utrvvdq8h" title="Aggregrate amount">670,000</span> on or before March 31, 2024), surrender <span id="xdx_90C_ecustom--StockIssuedDuringPeriodShareSurrender_c20230720__20230720__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjEXXTMviuec" title="Number of shares surrender">281,000</span> Series B Preferred
Shares of NanoSynex held by the Company, resulting in the Company&#8217;s ownership in NanoSynex being reduced from approximately <span id="xdx_907_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20230720__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgZu0riom0j" title="Business acquisition, percentage of voting interests acquired">52.8</span>%
to approximately <span id="xdx_900_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20230720__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGGlAYpWLnSa" title="Business acquisition, percentage of voting interests acquired">49.97</span>% of the voting equity of NanoSynex; in addition, the Company agreed to surrender approximately $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_pn5n6_c20230720__20230720__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember_z9l1kPmz4bug" title="Aggregrate amount">3.0</span> million of
promissory notes which NanoSynex had issued to the Company under the NanoSynex Funding Agreement. On November 22, 2023, the Company further
agreed to eliminate the Company&#8217;s obligations to lend NanoSynex $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20231130__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__dei--LegalEntityAxis__custom--NanoSynexLtdMember_zkqlYQSrKB5e" title="Aggregrate amount">560,000</span> on or before November 30, 2023, and $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__dei--LegalEntityAxis__custom--NanoSynexLtdMember_zvbePe7rFk7i" title="Aggregrate amount">670,000</span> on or before
March 31, 2024, by instead surrendering shares of Series A-1 Preferred Stock of NanoSynex in an amount that reduced the Company&#8217;s
ownership in NanoSynex voting equity from approximately <span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20230720__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__srt--RangeAxis__srt--MaximumMember_zSRQbpI7ma94" title="Business acquisition, percentage of voting interests acquired">49.97</span>% to <span id="xdx_907_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20230720__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__srt--RangeAxis__srt--MinimumMember_zcmgvLImb9o" title="Business acquisition, percentage of voting interests acquired">39.90</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
surrender of Series B Preferred Shares of NanoSynex was accounted for as a loss of control of a subsidiary that constitutes a business
under ASC 810. As a result, on July 20, 2023, the Company deconsolidated NanoSynex&#8217;s related assets, liabilities, accumulated other
comprehensive income, and the noncontrolling interest. Subsequently, the retained investment in NanoSynex is accounted for as an equity
method investment. On the date of deconsolidation, the Company recognized its retained investment at fair value, which during the preparation
of these financial statements was determined to be de minimis based on various economic, industry, and other factors. As a result, the
Company has discontinued recognition of its proportionate share of equity method losses following the date of initial recognition. Future
equity method earnings, if any, will not be recognized until the amount exceeds the unrecognized net losses in prior periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the magnitude of the disposition and because the Company is exiting certain research and development operations, the disposition
represents a strategic shift that will have a material effect on the Company&#8217;s operations and financial results. Accordingly, the
business of NanoSynex is classified as discontinued operations for all periods presented herein.<br/>
<br/></span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hdei--LegalEntityAxis__custom--NanosynexMember_zql7Ocd1YQD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets and liabilities classified in discontinued operations for NanoSynex as of December 31, 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8B8_zVjw2CrpUSug" style="display: none">ASSETS
AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231__dei--LegalEntityAxis__custom--NanosynexMember_ziAxeurFgqSb" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_hdei--LegalEntityAxis__custom--NanosynexMember_znAT1VGu4Enl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,621,967</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zN3N2jA1Xg8e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,499</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zS3OziL2bL64" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">190,384</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zudjy6jAUFJ8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total current assets of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,838,850</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash_iI_hdei--LegalEntityAxis__custom--NanosynexMember_z8jgHUgNV9f3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,690</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zURxSXiS75G4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,149</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zatJLqdJ3iFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,700,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zbN6DIJrYwDf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">625,602</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zeCqfvJF6T0h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total non-current assets of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,360,441</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalAssets_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zjeoubzzdNKb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total assets of discontinued operations of NanoSynex</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,199,291</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zkJ2bH9V1TVi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,273</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zxpaYWoF1jK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,002</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zlEFbYuQa6tg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">293,571</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zsDzep8kKing" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D grant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">780,682</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zedLNhd2fXGc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Short term debt-related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">950,722</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_z7XSBcqOkN72" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,141,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zTYaf7L5SBr7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Deferred tax liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">357,757</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zTSesd573E2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total non-current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">357,757</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zRjpF4OyIlf9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total liabilities of discontinued operations of NanoSynex</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,499,007</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reclassified the following statement of operations items to discontinued operations for the years ended December 31, 2023 and
2022, respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zOTptJ3CuNPb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zx9oSOWhGWM3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_hdei--LegalEntityAxis__custom--NanosynexMember_zgccjshpdKPc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">869,064</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,105,040</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment_hdei--LegalEntityAxis__custom--NanosynexMember_zZERACgexWla" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Goodwill and fixed asset impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,164,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedTotalExpenses_hdei--LegalEntityAxis__custom--NanosynexMember_zmH5vnSWE61" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">869,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,269,040</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zAk6YmXlslPj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on disposal of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,479,010</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0959">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_hdei--LegalEntityAxis__custom--NanosynexMember_zMk686AGWUY8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">(BENEFIT) PROVISION FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(357,757</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(271,622</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zEcbOD2Rc3z4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">LOSS FROM DISCONTINUED OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,990,317</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,997,418</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_hdei--LegalEntityAxis__custom--NanosynexMember_zZ5uISHWCvCh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Loss attributable to noncontrolling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(343,038</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,394,100</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zbH1l6INY484" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">NET LOSS ATTRIBUTABLE TO STOCKHOLDERS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,647,279</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,603,318</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company recorded a loss on deconsolidation of NanoSynex in its consolidated financial statements
for the years ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Loss on deconsolidation of NanoSynex</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value of NanoSynex interest retained</td><td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98E_ecustom--DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_z5EXg1W5lC7f" style="text-align: right" title="Fair value of Nan-Synex interest retained"><span style="-sec-ix-hidden: xdx2ixbrl0973">&#8212;</span></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Net assets deconsolidated</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zipg4Uspz2kf" style="width: 16%; text-align: right" title="Net assets deconsolidated">(2,768,403</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Non-controlling interest share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zycwxuIdu0u" style="text-align: right" title="Non-controlling interest share">1,235,443</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated other comprehensive income attributable to NanoSynex</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_z3pfPwc5XUqe" style="text-align: right" title="Accumulated OCI attributable to NanoSynex">131,891</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forgiveness of debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zairUjzSigPa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forgiveness of debt">(3,077,941</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss from deconsolidation of NanoSynex</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zW9JtpnpW2f8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Loss from deconsolidation of NanoSynex">(4,479,010</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A9_zKybyRV7sKGb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235411351136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z0ZCmVmVIgna" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8212; <span id="xdx_82B_zCP3sYxSfsya">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zFErq1PZDlN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consisted of the following at December 31, 2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8BA_zjGznIpol2O9" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zHHxTMsGUIh" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231_zQSJfkKD45Cc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedCompensation_iI_pp0p0_maALCzkYM_zpGjW49FxaAe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Board compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">129,499</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">70,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestPayableCurrent_iI_pp0p0_maALCzkYM_zDHR8SsSsiFg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest (Convertible debt)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,829</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzkYM_zcthN6R2i8Tc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">License fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,130</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCzkYM_z7Xgssvzn5lg" style="vertical-align: bottom; background-color: White">
    <td>Payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,247</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzkYM_zpF47Vp9U8U1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,775</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,203</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCzkYM_zDTbB2YyfHzf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,402</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329,412</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maALCzkYM_zxhaJd2lGG5g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,040</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzkYM_zXgg7XyiUQh5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,850</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,698</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzkYM_zw6s9z17hSI1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and
    other current liabilities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">560,006</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">864,559</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zoBao6Ime7Vh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
accrued liabilities attributable to Qualigen Inc, and NanoSynex were deemed disposed of as discontinued operations (see Note 5 &#8211; Discontinued
Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235414647744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisclosureWarrantLiabilitiesAbstract', window );"><strong>Warrant Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_WarrantLiabilitiesTextBlock', window );">WARRANT LIABILITIES</a></td>
<td class="text"><p id="xdx_807_ecustom--WarrantLiabilitiesTextBlock_ziSawuytXNPd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; <span id="xdx_82D_zqOuPtOArNda">WARRANT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a
private placement (the &#8220;Series C Warrants&#8221;). The Series C Warrants were subsequently extended and, upon closing of the
reverse recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, at $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zjLBgv89eAh2" title="Warrant exercise price">7.195</span>
per share, subject to adjustment. As of December 31, 2023, the Series C Warrants had a remaining term of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zzetds2CH1A1" title="Warrants and rights outstanding term">0.49</span>
years. The Series C Warrants were determined to be liability-classified pursuant to the guidance in ASC 480 and ASC 815-40, based on
the inclusion of a leveraged ratchet provision for subsequent dilutive issuances. On April 25, 2022, the Series C warrants were
repriced from $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zzmD55EmAmi7" title="Exercise price">7.195</span>
per share exercise price to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zZNvUdCZ1Ea2" title="Exercise price">6.00</span>
per share exercise price with <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220423__20220425__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zbihTPaibQx6" title="Issuance of shares">49,318</span>
additional ratchet Warrants issued. On May 26, 2022, the Series C warrants were repriced from $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z3uFW8slN005" title="Exercise price">6.00</span>
per share exercise price to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zwgMKMWUJg3k" title="Exercise price">5.136</span>
per share exercise price with <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220523__20220526__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zq1owi3Gtaf4" title="Warrants issued">49,952</span>
additional ratchet Warrants issued. As a result of these repricings, <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20220523__20220526_zQyGBjCzz1Oj" title="Warrants forfeited">247,625</span>
warrants were forfeited and <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesTreasuryStockReissued_pid_c20220523__20220526_zOiUsRZom3nk" title="Warrants reissued">346,896</span>
warrants were reissued. On December 22, 2022, the Series C Warrants were repriced again from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zLcK3W8ZBp14" title="Warrants repriced">5.136</span>
per share exercise price to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zrE1noWegDQg" title="Warrants repriced">1.32</span>
per share exercise price with <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221222__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zePqKIF8pos5" title="Warrants issued">1,002,717</span>
additional ratchet Warrants issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
on December 22, 2022, in conjunction with the issuance of the Debenture to Alpha (see Note 8 &#8211; Convertible Debt &#8211; Related
Party), the Company issued to Alpha a warrant to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zwDokrBI7CQ7" title="Warrant to purchase shares">2,500,000</span> shares of the Company&#8217;s common stock (the &#8220;Alpha Warrant&#8221;).
The exercise price of the Alpha Warrant was $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zE6EfD32PX0i" title="Exercise price of warrant">1.65</span> (equal to <span id="xdx_90C_ecustom--ConversionPricePercentage_pid_dp_uPure_c20221222__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zT7a2w0nD7Of" title="Conversion price percentage">125</span>% of the conversion price of the Debenture on the closing date). The Alpha
Warrant may be exercised by Alpha, in whole or in part, at any time before June 22, 2028, subject to certain terms and conditions described
in the Alpha Warrant. The fair value of this warrant was included in Warrant liabilities-related party on the Company&#8217;s consolidated
balance sheet as of December 31, 2022. On December 5, 2023, the Company entered into an Amendment No. 1 with regard to Securities Purchase
Agreement, with Alpha. This Amendment amended two instruments which the Company issued under the Securities Purchase Agreement dated
December 21, 2022: (a) the 8% Senior Convertible Debenture dated December 22, 2022 in favor of Alpha, and (b) the Common Stock Purchase
Warrant dated December 22, 2022 in favor of Alpha. The Amendment reduced the conversion price of the Debenture from $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_ztFYgmnKLve4" title="Conversion price">1.32</span> per share to
$<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_z9LmP1Jf1Cs8" title="Conversion price">0.73</span> per share (subject to possible future adjustment pursuant to the terms of the Debenture) and reduced the exercise price of the
Warrant from $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zA5AbY3sRk7i" title="Warrant exercise price">1.65</span> per share to $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_zhPI9NpFr8qg" title="Warrant exercise price">0.73</span> per share (subject to possible future adjustment pursuant to the terms of the Warrant). The Amendment
also eliminated certain adjustment provisions of the Warrant. The Company determined the event resulted in equity classification for
the Warrant and, accordingly, the Company remeasured the warrant liabilities to fair value, and reclassified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the Alpha Warrant repricing, on December 5, 2023 the Series C Warrants were repriced again from $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zltPM2dK32xe" title="Conversion price">1.32</span> per share exercise
price to $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_zFsev7ElZnXd" title="Conversion price">0.73</span> per share exercise price with <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zTIxmVXtZvOb" title="Warrants issued">203,652</span> additional ratchet Series C Warrants issued, resulting in <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z4cZ7Z5huAV6" title="Warrants outstanding"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zz1hCFPExOz2" title="Warrants exercisable">455,623</span></span> of these Series
C Warrants outstanding and exercisable as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z18l24KyS6ta" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity in liability classified warrants for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8BC_zJNRDQGyMj46" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLGBKDH5jCM8" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">3,849,571</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvoji3It3bBh" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">1.53</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">$<span id="xdx_902_ecustom--RangeOfExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_z7jM54PAtM0l" title="Range of Exercise Price, Beginning">1.32</span> - $<span id="xdx_90D_ecustom--RangeOfExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zDCVhsWUI7j2" title="Range of Exercise Price, Beginning">1.65</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zt8ioksd4Nj2" title="Weighted - Average Remaining Life (Years) Outstanding">3.9</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfoQPq9CTgsi" style="text-align: right" title="Number of Shares, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1080">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zV5xLhqe6H7g" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1082">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z2rOK24p9BB4" style="text-align: right" title="Number of Shares, Warrants Forfeited">(2,751,976</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAAPPHoSgwma" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited">1.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAXKcmhEslUf" style="text-align: right" title="Number of Shares, Warrants Expired">(1,097,595</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbpd7h2BKfgh" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired">1.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--RangeOfExercisePriceExpired_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSEHJRBUfAQd" title="Range of Exercise Price, Expired">1.32</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVpJAcv8Ar4l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted">455,623</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1Z7EYrTSynd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">0.73</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePriceGranted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSiMilgKv4Il" title="Range of Exercise Price, Granted">0.73</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zUL1lFj2TI7d" title="Weighted-Average Remaining Life (Years) Outstanding">0.49</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zKnMToyCwnDb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">455,623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zIOYWv2qwJol" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">0.73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1XzwHeUAWF8" title="Range of Exercise Ending">0.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zorsiQiwHZs1" title="Weighted-Average Remaining Life (Years) Outstanding">0.49</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7TWvyYNgRKj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">455,623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRkqheAxivS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">0.73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iE_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSfXDRtCkEga" title="Range of Exercise Price, Exercisable">0.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zzbe4oYcHff1" title="Weighted-Average Remaining Life (Years) Exercisable">0.49</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity in the Common Stock Warrants received in exchange for the Series C Warrants for the year ended
December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Weighted&#8211;
Average</b></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Exercise</b></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Price</b></p></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Range
of</b></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Exercise</b></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Price</b></p></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Weighted&#8211;Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Life (Years)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Total outstanding &#8211;December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbVsTqAi6BIl" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">248,162</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcm9ENx2x3Jj" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">7.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAEfVtKR2M2a" title="Range of Exercise Price, Beginning">7.20</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zm0YDjme8jk3" title="Weighted-Average Remaining Life (Years) Outstanding">2.00</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z3h5SS635N6i" style="text-align: right" title="Number of Shares, Warrants Exercised">(536</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvPJJa7NcJge" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">7.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zERGmqx8Uiga" style="text-align: right" title="Number of Shares, Warrants Forfeited">(247,625</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zITd2jiWwCv8" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited">7.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZHXjaE4aeB2" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1134">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zv3z6B66dCfe" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1136">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zb1pcj7U3ZZ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted">3,849,570</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwDH4H3gphs4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">1.53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgaSi0tLfGad" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">3,849,571</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zUB0yjZJU51a" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1.53</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--RangeOfExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zCidTcXmjyz1" title="Range of Exercise Ending">1.32</span> - <span id="xdx_901_ecustom--RangeOfExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zosRg7CkBXB9" title="Range of Exercise Ending">1.65</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z058uCfQcjNg" title="Weighted-Average Remaining Life (Years) Outstanding">3.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRMnQL7QMLje" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">1,349,571</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfqXh6Hdo6Ia" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">1.32</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5pCfLasIRn4" title="Range of Exercise Price, Exercisable">1.32</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbFX0nxgMxMb" title="Weighted-Average Remaining Life (Years) Exercisable">1.00</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A1_zVLM4UbzjEPl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p id="xdx_894_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_zaRegjGYHHA5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s fair value hierarchy for its Common Stock Warrant liabilities measured at fair value on
a recurring basis as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span id="xdx_8B1_zf8I8IX64Hpe" style="display: none">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Quoted</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Market</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Significant</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Prices for</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Other</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Significant</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Identical</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Observable</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unobservable</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Assets</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Inputs</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Inputs</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Stock Warrant liabilities</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Balance as of December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zk2S50r1wUo9" style="width: 12%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1162">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwF17oo6oJ0b" style="width: 12%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1164">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3YSTwRWIp9f" style="width: 12%; text-align: right" title="Fair value for warrant liabilities">3,622,647</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231_zUZVCfHgsG3d" style="width: 12%; text-align: right" title="Fair value for warrant liabilities">3,622,647</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQy3t8j7Pkc5" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1170">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbGSQkPGKFtl" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1172">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmr2VS7RgnY3" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1174">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231_zjrQMRAP23P6" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1176">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value of warrant reclassified from liabilities to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3WJcEyKG0Gf" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity"><span style="-sec-ix-hidden: xdx2ixbrl1178">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zOjcm6ivjhDg" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity"><span style="-sec-ix-hidden: xdx2ixbrl1180">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zBfZXoBC0lmd" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity">(1,626,694</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231_zYtjNdEmpwHk" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity">(1,626,694</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on debt extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLxxDu42GPxj" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment"><span style="-sec-ix-hidden: xdx2ixbrl1186">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdVYXEMqMZ2h" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment"><span style="-sec-ix-hidden: xdx2ixbrl1188">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGifwwzAL4Hk" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment">94,116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231_zMx7CBzLSDK" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment">94,116</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Gain on change in fair value of warrant liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6PA4TroVkH4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1194">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEfdE8kUk6y" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1196">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuqXgmjIP9R6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities">(2,035,469</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231_z8TZTLxXZBJg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities">(2,035,469</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zA2x9DGqSMv5" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1202">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zR9Pz6ubn7Ll" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1204">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjCqS6yr3EFg" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities">54,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231_zABKNkMvGdd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities">54,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z1qpV7OyD7vc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers of financial assets or liabilities between category levels for the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo
simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the
fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a
public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common
stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and
does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher
or lower fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_z931rg3adps8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the assumptions used in, and the weighted average and the range of assumptions used in estimating the fair value of warrant
liabilities (weighted average calculated based on the number of outstanding warrants on each issuance) as of December 31, 2023 and December
31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8B9_z96BAMXS0VHi" style="display: none">SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Actual</td><td>&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Range</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 48%">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJCfIiEqdgMe" title="Risk-free interest rate">5.13</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zxlMDbpDQmzg" title="Risk-free interest rate">3.906</span>% &#8212; <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_za3tnsv0nytg" title="Risk-free interest rate">4.628</span>%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_z0l4hoNa3Vl5" title="Fair value assumptions, measurement input, percentages">4.15</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (peer group)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zb3YVa1Xbt5i" title="Expected volatility">68.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zcvwFxKOAXf5" title="Expected volatility">88</span>% &#8212; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z7fyT5FHPUg" title="Expected volatility">103</span>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxuFn49vKpAe" title="Expected volatility">98</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term of warrants (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zehqffzt9hZe" title="Term of warrants (in years)">0.49</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuG1mYphnsXg" title="Term of warrants (in years)">.90</span> &#8212; <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zbVrTNrWKuk8" title="Term of warrants (in years)">5.48</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6bowoNviRDa" title="Fair value assumptions, measurement input, term">3.9</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zUID2ZCOsYb1" title="Expected dividend yield">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJ5NamsSDabb" title="Expected dividend yield">0.00</span>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zoGx3mIIsM7h" title="Fair value assumptions, measurement input, percentages">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>


<p id="xdx_8A6_zwqn3b2J6boc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosureWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosureWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WarrantLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WarrantLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235411349536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE DEBT- RELATED PARTY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE DEBT- RELATED PARTY</a></td>
<td class="text"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_zXPNpobi84E2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8212; <span id="xdx_826_zU0mCH8rZLB8">CONVERTIBLE DEBT- RELATED PARTY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2022, the Company issued to Alpha an <span id="xdx_908_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z8roDX7mhdwa" title="Senior convertible debenture rate">8</span>%
Senior Convertible Debenture in the aggregate principal amount of $<span id="xdx_909_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zJjwuj3Wkfmi" title="Principal amount">3,300,000</span>
for a purchase price of $<span id="xdx_90A_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zZxNtAGjOgdf" title="Purchase Price">3,000,000</span>
(less expenses) pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture has a maturity date
of <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zXINtaF809T" title="Maturity date">December
22, 2025</span> and was initially convertible, at any time, and from time to time, until the Debenture is no longer outstanding, at
Alpha&#8217;s option, into shares of common stock of the Company (the &#8220;Conversion Shares&#8221;), at a price equal to $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zEVFFvK7NUzb" title="Conversion price">1.32</span>
per share, subject to adjustment as described in the Debenture (the &#8220;Conversion Price&#8221;) and other terms and conditions
described in the Debenture, including the necessary stockholder approvals, which the Company obtained at its 2023 annual meeting of
stockholders on July 13, 2023. As a part of the same transaction, on December 22, 2022, the Company issued to Alpha a
liability classified warrant (the &#8220;Alpha Warrant&#8221;) to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zUn6rDXZB204" title="Warrant to purchase shares">2,500,000</span>
shares of the Company&#8217;s common stock (see Note 7 - Warrant Liabilities). The exercise price of the Alpha Warrant was initially
$<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zaAHAlERsS7" title="Exercise price of warrant">1.65</span>
(equal to <span id="xdx_902_ecustom--ConversionPricePercentage_pid_dp_uPure_c20221222__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zNe8JeCy6HU8" title="Conversion price percentage">125</span>%
of the Conversion Price of the Debenture on the closing date) subject to adjustment as described in the Alpha Warrant. The Alpha
Warrant may be exercised by Alpha, in whole or in part, at any time before June 22, 2028, subject to certain terms and
conditions described in the Alpha Warrant, including the necessary stockholder approvals, which the Company obtained at its 2023
annual meeting of stockholders on July 13, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds from the transaction were used to advance the Company&#8217;s QN-302 Investigative New Drug candidate towards clinical trials
and other working capital purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption
of the Debenture (each such date, a &#8220;Monthly Redemption Date&#8221;), the Company must redeem $<span id="xdx_90B_eus-gaap--RepaymentsOfLongTermDebtAndCapitalSecurities_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z7kI6s7A3oL8" title="Redeemable debt">110,000</span> plus accrued but unpaid
interest, liquidated damages and any amounts then owing under the Debenture (the &#8220;Monthly Redemption Amount&#8221;). The Monthly
Redemption Amount must be paid in cash; provided that after the first two monthly redemptions, the Company may elect to pay all or a
portion of a Monthly Redemption Amount in shares of common stock of the Company, based on a Conversion Price equal to the lesser of (i)
the then Conversion Price of the Debenture and (ii) <span id="xdx_902_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zYYn5O6h1BS1" title="Conversion rate">85</span>% of the average of the VWAPs (as defined in the Debenture) for the five consecutive
trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. The Company may also redeem
some or all of the then outstanding principal amount of the Debenture at any time for cash in an amount equal to <span id="xdx_901_ecustom--PrincipalAmountPercentage_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zVJpjKZNZtP9" title="Principal amount percentage">105</span>% of the then outstanding
principal amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under
the Debenture. The Company&#8217;s election to pay monthly redemptions in Conversion Shares or to effect an optional redemption is subject
to the satisfaction (or waiver) of the Equity Conditions (as defined in the Debenture), including the necessary stockholder approvals,
which the Company obtained at its 2023 annual meeting of stockholders on July 13, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Debenture accrues interest at the rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221222_zhA0tJv13IH4" title="Debenture accrues interest rate">8</span>% per annum, which did not begin accruing until December 1, 2023. Interest may be paid in
cash or shares of common stock of the Company or a combination thereof at the option of the Company; provided that interest may only
be paid in shares if the Equity Conditions have been satisfied (or waived).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
the Debenture and the Alpha Warrant provide for adjustments to the Conversion Price and exercise price, respectively, in connection with
stock dividends and splits, subsequent equity sales and rights offerings, pro rata distributions, and certain fundamental transactions.
Both the Debenture and the Alpha Warrant include a beneficial ownership blocker of <span id="xdx_907_ecustom--DebentureBeneficialOwnershipBlockerPercentage_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zFs5ai4mfo8c" title="Debenture beneficial ownership blocker percentage">9.99</span>%, which may only be waived by Alpha upon
61 days&#8217; notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to resale registration rights granted by the Company to Alpha in such Securities Purchase Agreement, the Company filed a
resale registration statement on Form S-3 (File Number 333-269088) on December 30, 2022 registering the resale by Alpha of
up to <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_pid_c20221230__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlphaCapitalMember_zh0M8xs4Zapb" title="Shares of Common stock, issued">5,157,087</span>
shares of common stock of the Company which could be issued to Alpha pursuant to the Debenture and the Alpha Warrant, which
registration statement was declared effective by the SEC on January 5, 2023 (the &#8220;Original Registration Statement&#8221;). The
Company later became ineligible to update the Original Registration Statement via incorporation by reference of its future SEC
periodic and current reports as a result of its failure to timely file its annual report on Form 10-K for the fiscal year ended
December 31, 2022. Therefore, the Company filed a Post-Effective Amendment No. 1 to Form S-3 on Form S-1 (No. 333-269088)(the
&#8220;Post-Effective Amendment No. 1&#8221;) on September 1, 2023 in order to maintain the registration of the resale by Alpha of up to <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230901__20230901__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlphaCapitalMember_zoC4W55AW0md" title="Resale of common stock shares">3,958,537</span>
shares of common stock of the Company issuable under the Debenture and the Alpha Warrant., which Post-Effective Amendment No. 1 was
declared effective by the SEC on September 7, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated the Debenture and the Alpha Warrant and determined that the Alpha Warrant is a freestanding financial instrument. Initially,
the Alpha Warrant is not considered indexed to the Company&#8217;s own stock, because the settlement amount would not equal the difference
between the fair value of a fixed number of the Company&#8217;s equity shares and a fixed strike price and all of the adjustment features
in Section 3(b) of the Alpha Warrant are not down round provisions, as defined in ASU 2017-11. Accordingly, the Alpha Warrant was classified
as a liability and recognized at fair value, with subsequent changes in fair value recognized in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proceeds from the Debenture were allocated to the initial fair value of the Alpha Warrant, with the residual balance allocated to the
initial carrying value of the Debenture. The Company has not elected the fair value option for the Debenture. The Debenture was recognized
as proceeds received after allocating the proceeds to the Alpha Warrant, and then allocating remaining proceeds to a suite of bifurcated
embedded derivative features (conversion option, contingent acceleration upon an Event of Default, and contingent interest upon an Event
of Default), with the resulting difference, if any, allocated to the loan host instrument. The suite of derivative features was measured
and determined to have no fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
original issue discount of $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zEgEQc4q7Zr2" title="Debt discount">0.3</span> million, the initial fair value of the Alpha Warrant of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zTnCdbaQyKk7" title="Fair value of warrants">2.8</span> million, the initial fair value of the suite
of bifurcated embedded derivative features of $<span id="xdx_90F_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_iI_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_z98HP0how0Ea" title="Fair value of embedded derivative features">0</span>, and the fees and costs paid to Alpha and other third parties of $<span id="xdx_905_eus-gaap--PaymentsForFees_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zrMTqvxAkYxj" title="Fees and costs paid">0.1</span> million
comprised the debt discount upon issuance. The debt discount is amortized to interest expense over the expected term of the Debenture
using the effective interest method, in accordance with ASC 835-30. The debt host instrument of the Debenture will subsequently be measured
at amortized cost using the effective interest method to accrete interest over its term to bring the Debenture&#8217;s initial carrying
value to the principal balance at maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
January 9 and 12, 2023, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230109__20230112__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zpKLUlhKdc6j" title="Number of shares issued">841,726</span>
shares of common stock upon Alpha&#8217;s partial conversion of the Debenture at $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230112__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z6LXJUp5nUg6" title="Conversion price">1.32</span>
per share for a total of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20230112__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zPqlWAgmu3gd" title="Debenture voluntarily converted">1,111,078</span>
principal. Upon conversion, the Company recognized a loss on conversion of convertible debt of approximately $<span id="xdx_90E_eus-gaap--ConvertibleDebtCurrent_iI_pn5n6_c20230112__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zqYlqHFJOLgd" title="Debt conversion of convertible debt">1.1</span>
million, recorded to other expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October and December 2023, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231031__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zfO8ezg0jt32" title="Number of shares issued"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231201__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zwZJmES49Kl5" title="Number of shares issued">309,665</span></span>
shares of common stock to Alpha in lieu of cash for monthly redemption payments on the Debenture at a weighted average price
of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20231031__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_znzRejM6O6m8" title="Weighted price per share"><span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zbVsq0thiYN6" title="Weighted price per share">0.71</span></span>
per share. Upon redemption for shares, the Company recognized a loss on partial debt extinguishment of $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20231001__20231031__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zxaPPvA0wwcj" title="Losses on debt extinguishment"><span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20231201__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_znbCtZ507maa" title="Losses on debt extinguishment">34,315</span></span>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2023, the Company entered into a consent and waiver (the &#8220;Waiver&#8221;) with Alpha. Pursuant to the Waiver,
Alpha consented to the Company&#8217;s election to pay all of the Monthly Redemption Amount for October 2023 in Conversion Shares
(the &#8220;October Payment&#8221;) and waived the requirement of satisfaction of the Equity Conditions in relation to the October and
December Payment. On October 3, 2023 the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20231003__20231003__us-gaap--TypeOfArrangementAxis__custom--OctoberPaymentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlphaCapitalMember_zh1tCKtDFNv4" title="October payment in shares">128,595</span> shares of common stock to Alpha in satisfaction of the October
Payment. On December 8, 2023 the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20231208__20231208__us-gaap--TypeOfArrangementAxis__custom--OctoberPaymentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlphaCapitalMember_z02IwALocw64" title="October payment in shares">181,070</span> shares of common stock to Alpha in satisfaction of the December Payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2023, the Company and Alpha executed Amendment No. 1 with regard to Securities Purchase Agreement (the &#8220;SPA
Amendment&#8221;), pursuant to which the Company and Alpha agreed to, among other things, reduce the Conversion Price of the
Debenture from $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zErmCRdhg94b" title="Conversion price">1.32</span>
per share to $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_z71owejzYxXf" title="Conversion price">0.73</span>
per share and reduce the exercise price of the Alpha Warrant from $<span id="xdx_909_eus-gaap--WarrantExercisePriceIncrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zNQPdd9gHgLd" title="Conversion price">1.65</span>
per share to $<span id="xdx_907_eus-gaap--WarrantExercisePriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5h5hVHuscji" title="Conversion price">0.73</span>
per share, in each case subject to certain adjustments. In addition, the SPA Amendment revised certain provisions of the Alpha
Warrant to (i) limit the circumstances which would trigger a potential adjustment to the exercise price of the Alpha Warrant and
(ii) clarify the treatment of the Alpha Warrant upon a Fundamental Transaction. The purpose of these revisions was to remove the
terms that caused the Alpha Warrant to be liability-classified under U.S. GAAP. The Company performed an assessment and concluded
that all remaining adjustment features in the revised language meet the FASB&#8217;s definition of a down-round feature. In
addition, the Alpha Warrant was determined to meet all of the additional requirements for equity classification. Accordingly, as of
December 5, 2023, the Company remeasured the Alpha Warrant to its fair value immediately prior to the modification and recognized
the change in fair value in earnings. The incremental fair value impact from the Alpha Warrant modification of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_pn4n6_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zsHzOVlBYjfk" title="Fair value of warrant liability">0.09</span>
million was included in the Company&#8217;s evaluation of the Debenture modification under ASC 470, discussed further below. The
Company then reclassified the Alpha Warrant liability to equity at its post-modification fair value of $<span id="xdx_903_eus-gaap--WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_pn5n6_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z28OGtBcetVc" title="Warrant liability to equity">1.6</span>
million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 470-50, the Company determined that the modified terms of the Debenture were substantially different when
compared to the original terms that existed prior to the SPA Amendment, and thus the event was required to be accounted for as a
debt extinguishment. Accordingly, the Company derecognized the net carrying value of the original Debenture, and recorded the new
debt instrument at its fair value of $<span id="xdx_909_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmEovKpEQWoc" title="Debt instrument fair value">1.4</span>
million, and recorded a $<span id="xdx_90A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zrGXj6XAxCP1" title="Loss on extinguishment">0.6</span>
million loss on debt extinguishment. The difference between the remaining Debenture principal and its fair value on December 5, 2023
was recorded as a debt discount and will be amortized to interest expense over the expected term of the Debenture using the
effective interest method, in accordance with ASC 835-30.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recognized a loss on voluntary conversion of convertible debt of
approximately $<span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20230101__20231231_zlBLnd30p5Md" title="Debt conversion of convertible debt">1.1</span>
million, recognized an extinguishment loss of $<span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20230101__20231231__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ConvertibleDebtMember_z4AhbSkaLfd6" title="Extinguishment loss">0.6</span>
million upon October and December 2023 share redemptions and December 2023 modification of the Debenture, and recorded
accrued interest of approximately $<span id="xdx_903_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20230101__20231231_zPBNjTr9bLu7" title="Accrued interest">1.5</span>
million, in other expenses in the consolidated statements of operations. During the year ended December 31, 2023 the Company paid
Monthly Redemption Amounts of $<span id="xdx_904_ecustom--DebtRedemptionAmountInCash_c20230101__20231231_z2HOt3us9Rel" title="Redemption amount in cash">550,000</span>
in cash and $<span id="xdx_907_ecustom--DebtRedemptionAmountInCommonStock_c20230101__20231231_zBrNhLXO6z77" title="Redemption amounts in common stock">220,000</span>
in common stock, and as of December 31, 2023 the remaining Debenture principal balance was approximately $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20231231_zGKiB1S3yAn5" title="Debenture principal balance">1.4</span>
million, the remaining discount was approximately $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20231231_zQyEIsVwkAgf" title="Debt discount">0.1</span>
million, and the fair value of the suite of bifurcated embedded derivative features was $<span id="xdx_90E_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20231231_zPo5ocEwE4Bj" title="Derivative fair value of warrants">0</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--ConvertibleDebtTableTextBlock_zOeh0D24vQXj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
senior convertible debt comprises the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span id="xdx_8B8_zH4MDVn648ug" style="display: none">SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zB5SrNpsgSZ5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zJufdsid8uN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SecuredDebt_iI_zL6i72Wp3Pah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Senior convertible debenture</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,418,922</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,300,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_znbJgSde29C9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Discount on convertible debenture</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(119,706</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,239,803</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_zQZXTcRUnVne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total convertible debt-related party</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,299,216</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">60,197</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zWRyG2Pv5sQk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, there were no unwaived events of default or violation of any covenants under the Company&#8217;s financing obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235414742848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text"><p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zJPsDjOau3O6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8212; <span id="xdx_827_zPGQQYysyT1e">EARNINGS (LOSS) PER SHARE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share (&#8220;EPS&#8221;) is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted
EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during
the period. Potentially dilutive common shares consist of shares issuable from convertible debt, stock options and warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z3OXkzOiCRvi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potentially dilutive securities have been excluded from diluted net loss per share as of December 31, 2023 and 2022 because
their effect would be anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span id="xdx_8B7_zlzE769K8vK4" style="display: none">SCHEDULE
OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zSIovIChNxfh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zQLGPWwKm7yg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Years Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zJiUFN0xyJHh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; width: 60%; text-align: left">Net loss used for basic earnings per share</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(13,417,212</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(18,640,543</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zIibE0Bcgfv9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Basic weighted-average common shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,072,709</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,840,340</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_zE5ERx10oJ9a" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Dilutive potential shares issuable from convertible debt, stock options and warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1359">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1360">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zhTDRiIz5Ita" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Diluted weighted-average common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,072,709</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,840,340</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zMzxpJE7OSu" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235497756176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3eveFH7U4Je" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8212; <span id="xdx_82E_zK0KLzZoSfxb">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation
and Other Legal Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2021, the Company was named as a defendant in an action brought by Mediant Communications Inc. (&#8220;Mediant&#8221;) in
the U.S. District Court for the Southern District of New York. The complaint alleged that Qualigen entered into an implied contract with
Mediant, whereby Qualigen retained Mediant to distribute proxy materials and subsequently conduct shareholder vote tabulations. The Company
filed a Motion to Dismiss with the District Court and on March 14, 2022 a hearing was held during which the presiding judge ruled in
favor of the Motion to Dismiss. The Company and Mediant settled the litigation on April 5, 2022 in the amount of $<span id="xdx_90E_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pdp0_c20220405__20220405_zzjcwTUTcAV" title="Litigation paid">96,558</span>, at which time
the amount was paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235509555104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisclosureResearchAndLicenseAgreementsAbstract', window );"><strong>Research And License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ResearchAndLicenseAgreementsTextBlock', window );">RESEARCH AND LICENSE AGREEMENTS</a></td>
<td class="text"><p id="xdx_80A_ecustom--ResearchAndLicenseAgreementsTextBlock_z5Spl7nwPGt5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8212; <span id="xdx_82E_zKvwRiE4sicb">RESEARCH AND LICENSE AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>UCL
Business Limited</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, the Company entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a
genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London,
including lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for
University College London.) The program&#8217;s lead compound is now being developed at the Company under the name QN-302 as a candidate
for treatment for pancreatic ductal adenocarcinoma, which represents the vast majority of pancreatic cancers. The License Agreement required
a $<span id="xdx_900_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--AwardTypeAxis__custom--UpfrontPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zPhiPwBij0sa" title="Reimbursement of patent">150,000</span> upfront payment, reimbursement of past patent prosecution expenses (approximately $<span id="xdx_900_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z6J1jIG6szR2" title="Reimbursement of patent">160,000</span>), and (if and when applicable)
tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments and a percentage of any non-royalty
sublicensing consideration paid to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022 there were license costs of approximately $<span id="xdx_90B_ecustom--LicenseCost_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zSJnVgnPmzR4" title="License cost">128,000</span> and $<span id="xdx_900_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zhJsnrAaVqSi" title="License cost">338,000</span>, respectively, related to
this agreement which are included in research and development expenses in the consolidated statements of operations and other comprehensive
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>QN-302
Phase 1 Study</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Company entered into a Master Clinical Research Services Agreement with Translational Drug Development, LLC (&#8220;TD2&#8221;)
whereby TD2 agreed to perform certain clinical research and development services for the Company including but not limited to trial management,
side identification and selection, site monitoring/management, medical monitoring, project management, data collection, statistical programming
or analysis, quality assurance auditing, scientific and medical communications, regulatory affairs consulting and submissions, strategic
consulting, and/or other related services. From time to time, the Company intends to enter into statements of work with TD2 for the performance
of specific services under this Master Clinical Research Services Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Company entered into a Master Laboratory Services Agreement with MLM Medical Labs, LLC (&#8220;MLM&#8221;) whereby MLM
agreed to perform certain clinical research and development services for the Company including but not limited to laboratory, supply,
testing, validation, data management, and storage services. From time to time, the Company intends to enter into work orders with MLM
for the performance of specific services under this Master Laboratory Services Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Company entered into a Master Services Agreement with Clinigen Clinical Supplies Management, Inc. (&#8220;Clinigen&#8221;)
whereby Clinigen agreed to provide certain pharmaceutical products and/or services. From time to time, the Company intends to enter into
statements of work with Clinigen for the performance of specific services under this Master Services Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2023, pursuant to the above agreements, the Company entered into work orders and statements of work for clinical trial services
for the conduct of the QN-302 Phase 1 study. The project timeline started in July 2023 and is expected to continue until approximately
July 2026. The total amount to be paid under these work orders and statements of work is currently expected to be approximately $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20230701__20230731__us-gaap--TypeOfArrangementAxis__custom--MasterLaboratoryServicesAgreementMember__dei--LegalEntityAxis__custom--MLMMedicalLabsMember_z72LbVTys471" title="Research and Development Expense">7.6</span>
million over the term of the QN-302 Phase 1 study, subject to available funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>University
of Louisville Research Foundation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with University of Louisville
Research Foundation, Inc. (&#8220;ULRF&#8221;) for development of several small-molecule RAS interaction inhibitor drug candidates. Under
the terms of this agreement, the Company agreed to reimburse ULRF for sponsored research expenses of initially up to $<span id="xdx_90A_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z9ihjn2cNfO4">693,000</span> for this
program. This agreement was amended in February 2021, March 2022 and August 2023, with the current term of this agreement set to expire
in December 2023 and the aggregate amount that the Company would reimburse ULRF for sponsored research expenses increased to approximately
$<span id="xdx_904_ecustom--ReimbursementOfResearchExpenses_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zxzcpDsU38Oj" title="Research expenses">2.9</span> million. <span id="xdx_901_ecustom--AgreementTermPaymentDescription_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zmY422FEK0rl" title="Agreement term payment, description">In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates.
Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is
responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront
license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered
net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative
$250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30%
to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement,
40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth
year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution
and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $<span id="xdx_908_ecustom--MilestonePayment_pp0p0_c20200701__20200731__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z1QYrpKnNfFl" title="Milestone payment">50,000</span> to $<span id="xdx_906_ecustom--MilestonePayment_pp0p0_c20200701__20200731__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z6v8GZqfH8Ih" title="Milestone payment">5,000,000</span> upon the achievement
of certain regulatory and commercial milestones.</span> Milestone payments for the first therapeutic indication would be $<span id="xdx_901_ecustom--MilestonePayment_pp0p0_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_zu95KF0L3qSc" title="Milestone payment">50,000</span> for first dosing
in a Phase 1 clinical trial, $<span id="xdx_90C_ecustom--MilestonePayment_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zki8k56pknbj">100,000</span> for first dosing in a Phase 2 clinical trial, $<span id="xdx_900_ecustom--MilestonePayment_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zM5uSQcQwsEl" title="Milestone payment">150,000</span> for first dosing in a Phase 3 clinical trial,
$<span id="xdx_905_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zGFYrI2V68Z8" title="Marketing approval expenses">300,000</span> for regulatory marketing approval and $<span id="xdx_90A_ecustom--CumulativeSales_pp0p0_c20200701__20200731__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zKSMxhSwBF5a" title="Cumulative sales">5,000,000</span> upon achieving a cumulative $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zQVumjShMKX4" title="Revenue">500,000,000</span> of Licensed Product sales. The Company
also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income
for any year is less than the applicable annual minimum (ranging from $<span id="xdx_90A_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200731__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zbWgwfbBkx0j" title="Upfront license fee">20,000</span> to $<span id="xdx_90D_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200731__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zY838exDZYJi" title="Upfront license fee">100,000</span>) for such year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsored
research expenses related to these RAS agreements for the years ended December 31, 2023 and December 31, 2022 were approximately $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember_zYYDVW9x8cz9" title="Research and development expenses">743,000</span>
and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember_zsIRTn6j87hh" title="Research and development expenses">758,000</span>, respectively, and are recorded in research and development expenses in the Consolidated Statements of Operations. License
costs related to these agreements for the years ended December 31, 2023 and December 31, 2022 were approximately $<span id="xdx_901_ecustom--LicenseCost_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember_zeOno0P3mY36" title="License costs">133,000</span> and $<span id="xdx_90E_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember_zAeEG0xHV4If" title="License costs">40,000</span>,
respectively, and are included in research and development expenses in the Consolidated Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
June 2018 and April 2022, the Company entered into license and sponsored research agreements with ULRF for QN-247, a novel aptamer-based
compound that has shown promise as an anticancer drug. Under the agreements, the Company took over development, regulatory approval and
commercialization of the compound from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return,
ULRF received a $<span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_ziXZGPOYq6L4" title="Proceeds from convertible debt">50,000</span> convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#8217;s
common stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to approximately $<span id="xdx_900_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zWsGO7qjqMdc" title="Reimbursement of research expenses">805,000</span> and prior patent
costs of up to $<span id="xdx_90D_ecustom--PatentCosts_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zR5SyuN5SDIl" title="Patent costs">200,000</span>. <span id="xdx_90C_ecustom--AgreementTermPaymentDescription_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z02gdTuCaJe9" title="Agreement term payment, description">In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization
of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative
$250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income
received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third
or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter),
(iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred
prior to June 2018, and (iv) payments ranging from $<span id="xdx_903_ecustom--MilestonePayment_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zPdeQJply0Q1" title="Milestone payment">100,000</span> to $<span id="xdx_90B_ecustom--MilestonePayment_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zoqDS22p7z97" title="Milestone payment">5,000,000</span> upon the achievement of certain regulatory and commercial milestones.</span>
Milestone payments for the first therapeutic indication would be $<span id="xdx_90A_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z3pIMe0TMwJ3" title="Milestone payment">100,000</span> for first dosing in a Phase 1 clinical trial, $<span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zUZtPwpffupa" title="Milestone payment">200,000</span> for
first dosing in a Phase 2 clinical trial, $<span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zMaz19EJUYxg" title="Milestone payment">350,000</span> for first dosing in a Phase 3 clinical trial, $<span id="xdx_900_ecustom--RegulatoryMarketingApprovalExpenses_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zfN7wuwOKwrd" title="Marketing approval expenses">500,000</span> for regulatory marketing approval
and $<span id="xdx_90F_ecustom--CumulativeSales_pp0p0_c20180601__20220430__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zxlmofmtKRPk" title="Cumulative sales">5,000,000</span> upon achieving a cumulative $<span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z3hlTwNjuUsb" title="Revenue">500,000,000</span> of Licensed Product sales. The Company also agreed to pay another $<span id="xdx_900_ecustom--RegulatoryMarketingApprovalExpensesOne_pp0p0_c20180601__20220430__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zmVCw5mhYaJc" title="Regulatory marketing approval, expenses">500,000</span> milestone
payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The Company must
also pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for
any year is less than the applicable annual minimum (ranging from $<span id="xdx_908_ecustom--ShortfallPayments_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zOISJkAzMvy1" title="Shortfall payments">10,000</span> to $<span id="xdx_905_ecustom--ShortfallPayments_c20180601__20220430__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zkaSrkWUhRE7" title="Shortfall payments">50,000</span>) for such year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sponsored research agreement for QN-247 expired in August 2022. The sponsored research expenses related to these QN-247 agreements for
the years ended December 31, 2023 and December 31, 2022 were $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_z4lt68itSEqi">0</span> and approximately $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zaeeugH71kw">164,000</span>, respectively, and these amounts are recorded
in research and development expenses in the consolidated statements of operations and other comprehensive loss. License costs related
to these agreements were approximately $<span id="xdx_907_ecustom--LicenseCost_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zzGECV6B2eeg">23,000</span> and $<span id="xdx_904_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zLULny5Wi9qa">94,000</span> for the years ended December 31, 2023 and December 31, 2022, respectively,
and are included in research and development expenses in the consolidated statements of operations and other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
In June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as
a treatment for COVID-19. Under the agreement, the Company took over development, regulatory approval and commercialization of the compound
(for such use) from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received
approximately $<span id="xdx_904_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zs6wIUOQmRSa" title="Upfront license fee">24,000</span> for an upfront license fee and reimbursement of prior patent costs. In addition, the Company was required to enter
into a separate sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) for at least $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200601__20200630__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zwcC8dBKeIhh" title="Research and development expense">250,000</span>. In November 2020,
the Company executed a sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) supporting up to approximately
$<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20201101__20201130__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zfrwx4kHwiF4" title="Research and development expense">430,000</span> in research which satisfied this requirement. This sponsored research agreement expired in November 2021 and the exclusive license
agreement was terminated on October 31, 2022. There were no sponsored research expenses or license costs related to these QN-165 agreements
for the years ended December 31, 2023 and 2022.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosureResearchAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosureResearchAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ResearchAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And License Agreements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ResearchAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235414690608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z3CfDa6rNHjg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12 &#8212; <span id="xdx_82B_zJQMTosbNfn2">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, and 2022 the Company had two classes of capital stock: common stock and preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject
to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive
dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, any
remaining assets will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of any
preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive,
subscription or conversion rights and there are no redemption or sinking fund provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company has reserved <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231_zwCKHUUeVtdj" title="Common stock reserved for future issuance">5,781,161</span> shares of authorized but unissued common stock for possible future issuance as
follows:</span></p>

<p id="xdx_89A_ecustom--ScheduleOfReservedSharesTableTextBlock_zwTy7UYVbLH4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_z6DIgiLX7U56" style="display: none">SCHEDULE
OF RESERVED SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20231231_zHoQ9JF85b0f" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5WBLsQhG06k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Exercise of issued and future grants of stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">755,715</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__custom--ConversionOfConvertibleDebtMember_zNUiJ3e0hid5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Conversion of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,943,729</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zr39N6ecJFsc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercise of stock warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,081,717</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zjAWdC7CbToj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,781,161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zMTDeIMRyP9d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023 and December 31, 2022, there were <span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_zQHj2ADN0JKc" title="Preferred stock, shares outstanding"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zU3ojb1dnOL9" title="Preferred stock, shares outstanding">no</span></span> shares of preferred stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options and Equity Classified Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes all compensatory stock-based payments as compensation expense over the service period, which is generally the vesting
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which provides for the grant of incentive
or non-statutory common stock options, restricted stock, stock bonus awards, stock appreciation rights, restricted stock units and performance
awards to qualified employees, officers, directors, consultants and other service providers. At December 31, 2023 and December 31, 2022
there were <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z2PHP0fjlCIa" title="Options outstanding">398,924</span> and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z9WFEV0vLDZ7" title="Options outstanding">608,012</span> outstanding stock options, respectively, under the 2020 Plan and there were <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zuHsQg5DiD0j" title="Plan shares available">356,778</span> and <span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zpNtBMtkpoHb" title="Plan shares available">147,690</span> Plan shares
available, respectively, for future grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zs8yiFww238k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December
31, 2023, and changes during the twelve months then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zFOnad0Z0GNb" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted&#8211;Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted&#8211;Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Total outstanding &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkIsHDFTE0Oi" style="width: 14%; text-align: right" title="Number of shares, options outstanding, beginning">608,012</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ziTkSGk7A1vf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning">35.02</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z1A2GvKClF0g" title="Range of Exercise price, Options Outstanding">5.14</span> - $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_z09sF6T2A68f" title="Range of Exercise price, Options Outstanding">51.30</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zsPcTXYTQkFk" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning">8.09</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zYz3AeE2OExk" style="text-align: right" title="Number of shares, options granted"><span style="-sec-ix-hidden: xdx2ixbrl1491">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zIRryovNL914" style="text-align: right" title="Weighted average exercise price, options granted"><span style="-sec-ix-hidden: xdx2ixbrl1493">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zZU1qmiE3F8" style="text-align: right" title="Number of shares, options expired"><span style="-sec-ix-hidden: xdx2ixbrl1495">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ziujHsfwWzMa" style="text-align: right" title="Weighted average exercise price, options expired"><span style="-sec-ix-hidden: xdx2ixbrl1497">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zzTGWHF4F2Tk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options forfeited">(209,088</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zpmO8ELPhGq9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited">34.71</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zbWJhn9PPoIj" title="Range of Exercise price, Options Forfeited">5.14</span> - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zEkZKn9nbud6" title="Range of Exercise price, Options Forfeited">51.30</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zN2jD7JuHcYa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options Outstanding at Ending">398,924</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBrjiTdDhbO2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending">35.21</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zvj28x2nVpl" title="Range of Exercise price, Options Outstanding">5.14</span> &#8212; $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zvf5zIhj1efd" title="Range of Exercise price, Options Outstanding">51.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkBJbEz2epD5" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending">7.06</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Exercisable (vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zpG7XaKkSemc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)">320,918</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zaeMd4Xni5We" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of exercise price, options exercisable (vested)">41.97</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zpVEguyqgJAa" title="Range of exercise price, options exercisable (vested)">5.14</span> &#8212; $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zkGjM8ZYcPug" title="Range of exercise price, options exercisable (vested)">51.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zKKIJUisZMfh" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)">6.77</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Non-Exercisable (non-vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjNvfdbF1y98" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)">78,006</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zG2CA3CSl6v8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)">7.36</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z91mmxAdBLH3" title="Range of exercise price, options non-exercisable (non-vested)">5.14</span> - $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zIpg0XstkxAf" title="Range of exercise price, options non-exercisable (non-vested)">32.90</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zJwkYBBjO96" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)">8.36</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that were outstanding at December 31, 2022, and changes during the twelve months then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
of</b></span></p>
                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p>
                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zWIRkBiiTiEg" style="width: 14%; text-align: right" title="Number of shares, options outstanding, beginning">484,186</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zlVZE02OJEza" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning">60.70</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">$<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zGiHtX3PY4j3" title="Range of Exercise price, Options Outstanding">12.40</span> &#8212; $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zVqt1XV08gM6" title="Range of Exercise price, Options Outstanding">14,657.50</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkE37PmUN0sh" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning">8.52</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zP3cmn02hWCb" style="text-align: right" title="Number of shares, options granted">134,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zrek5FW0Qc76" style="text-align: right" title="Weighted average exercise price, options granted">5.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zm71m9uYtMf7" title="Range of Exercise price, Options Outstanding">5.14</span> &#8212; <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zlYsjj8aE7xc" title="Range of Exercise price, Options Outstanding">10.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zza9MJn3zL58" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted">5.99</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBjp6n0FxRok" style="text-align: right" title="Number of shares, options expired">(9,379</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zM2Q23Z80GFc" style="text-align: right" title="Weighted average exercise price, options expired">932.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zCChvyUDs58k" title="Range of Exercise price, Options Outstanding">57.50</span> - <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zbVQ4jXmBnl1" title="Range of Exercise price, Options Outstanding">14,657.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zxMo7qCM7wNc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options forfeited">(1,264</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zVJyXMhMu384" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited">22.64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zIDOyHLqNdt1" title="Range of Exercise price, Options Forfeited">5.14</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_z7zVE50RAY8h" title="Range of Exercise price, Options Forfeited">49.70</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z3yGc3Sl9Gqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options Outstanding at Ending">608,012</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zqrDsAW48I64" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending">35.02</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z2xuq1t7WRTg" title="Range of Exercise price, Options Outstanding">5.14</span> &#8212; $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zqHOPdJQSIl3" title="Range of Exercise price, Options Outstanding">51.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zARB0aqcuL8c" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending">8.09</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Exercisable (vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zXrgdO5t8oe4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)">288,704</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zprySz4oLgx" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of exercise price, options exercisable (vested)">46.32</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zmcvWVbJnsJh" title="Range of exercise price, options exercisable (vested)">12.40</span> &#8212; $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zD2GTW2aYwh2" title="Range of exercise price, options exercisable (vested)">51.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zn9slRtEYqG1" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)">7.59</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Non-Exercisable (non-vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z1apKxQ2FgBb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)">319,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zLrGcJzs1uV" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)">24.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zLKKejEF9B8l" title="Range of exercise price, options non-exercisable (non-vested)">5.14</span> &#8212; $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zKV52WE0uOo5" title="Range of exercise price, options non-exercisable (non-vested)">10.50</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zbXPeuyw7Ib1" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)">8.59</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AE_zfzureZsPRAf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was approximately $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zooOWNiHFMH" title="Compensation cost">1.1</span> million and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGTD59yVg9Bl" title="Compensation cost">5.4</span> million of compensation costs related to outstanding options for the year ended December 31, 2023
and December 31, 2022, respectively. This cost is expected to be recognized over a weighted average period of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zEFcpGopUTX6" title="Cost is expected to be recognized over a weighted average period">1.09</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7Q7cPFBqe6b" title="Stock options granted"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAH04MYGtoi" title="Stock options granted"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZ5iV4mgRYCe" title="Stock options exercised"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zu7XI7ZF6ic3" title="Stock options exercised">No</span></span></span></span>
stock options were granted or exercised during the year ended December 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z5VbRTNexEaa" title="Stock options description">The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.</span> The options awarded under the 2020 Plan will vest as determined by the Board of Directors but will not exceed a 10-year
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9mA0gyIhvwk" title="Stock options granted">no</span> options granted during the year ended December 31, 2023. The weighted average grant date fair value per share of the shares underlying
options granted during the year ended December 31, 2022 was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZz9Cag701Cl" title="Stock option granted exercise price">3.96</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Equity Awards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes the Black-Scholes option pricing model to value awards under the 2020 Plan, and for equity classified compensatory warrants.
Key valuation assumptions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    dividend yield.</i> The expected dividend is assumed to be zero, as the Company has never paid dividends and has no current plans
    to pay any dividends on the Company&#8217;s common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    stock-price volatility.</i> The Company&#8217;s expected volatility is derived from the average historical volatilities of publicly
    traded companies within the Company&#8217;s industry that the Company considers to be comparable to the Company&#8217;s business
    over a period approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-free
    interest rate.</i> The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon
    U.S. Treasury notes with maturities approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected
    term.</i> The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&#8217;s
    historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of
    a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the SEC.
    The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zGHR15bCdKc4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zAEDyLzxwr3i" style="display: none">SCHEDULE
OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Years Ended December 31,</b></span></p>

</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Expected dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zQSr5rVaOadd" style="width: 16%; text-align: right" title="Expected dividend yield">0.00%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected stock-price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zcPUuOZ6PVR1" style="text-align: right" title="Expected stock-price volatility">103%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zCM8i4TCTp58" title="Risk-free interest rate, minimum">1.58</span>% &#8212; <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_ztgDn7Z1c4V1" title="Risk-free interest rate, minimum">3.77</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected average term of options (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zLv60PDr8SAl" title="Expected average term of options (in years)">5.99</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MinimumMember_z41UFMKa2Jvk" title="Stock price">5.14</span> - <span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MaximumMember_zQmQktOllcn9" title="Stock price">10.50</span></td></tr>
  </table>



<p id="xdx_8AC_zsnSQFGnqo1h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_z4fcGluRwcLf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense and classified it in the Consolidated Statements of Operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zCQVTkRPAy18" style="display: none">SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zWeGmRQVC7Vf" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_zHKS76KQYz95" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zzLhM2YRzOl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">939,228</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,649,649</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrifLxBJYHPe" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">159,305</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">834,395</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zpHZ3aJEeIDd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,098,533</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,484,044</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zdZbf09O8MU9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity
Classified Compensatory Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zVMGPmt8I3ig" title="Issuance or sale of equity">4.0</span> million equity capital raise as part of the May 2020 reverse recapitalization transaction, the Company issued
common stock warrants to an advisor and its designees for the purchase of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zleuOGXOvu4k" title="Warrants issued">81,143</span> reverse split adjusted shares of the Company&#8217;s
common stock at a reverse split adjusted exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zJ8Dch6Fh1c6" title="Exercise price">11.10</span> per share. The issuance cost of these warrants was charged to additional
paid-in capital, and did not result in expense in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier (originally exercisable to
purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock) for the purchase of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20171231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zFhqKb3CUDy8" title="Purchase of warrants">66,802</span> reverse
split adjusted shares of Company common stock at a weighted average exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20171231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_ze31QcTqJ2p2" title="Exercise price of warrants">23.40</span> per share. These are to be differentiated
from the Series C Warrants described in Note 7- Warrant Liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2022, <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyOAFc5gq2g2" title="Purchase of warrants">60,000</span>
warrants were repriced from $<span id="xdx_906_ecustom--StockholdersEquityReverseStockSplitPricePerShare_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZHAB7WEFjef" title="Reverse stock split, price per share">13.20</span>
per share exercise price to a reverse split adjusted exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zy2ncQaMYXuf" title="Class of warrant or right, exercise">6.00</span>
per share exercise price and extended from <span id="xdx_905_ecustom--WarrantsExtendedDateDescription_c20220425__20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ4P2TtwzZMk" title="Warrants extended date description">June
3, 2023 to September 14, 2023</span>. The increase in fair value of $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20220425__20220425__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLO5vzQCCQ0g" title="Fair value of warrants">67,370</span>
for the modification of these warrants was charged to general and administrative expenses in the Company&#8217;s consolidated
statements of operations and comprehensive loss. These warrants expired on <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsGUBQ9bxlH5" title="Warrants expired date">September 14, 2023</span>. On April 25, 2022 and May 26, 2022 an
additional <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrPmMJgYvLL7" title="Purchase of warrants"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z88LO3jDDlcl" title="Purchase of warrants">67,620</span></span>
reverse split adjusted warrants were repriced from reverse split adjusted $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zNhQJ7inRFig" title="Exercise price"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z7d2IK97cXQ6" title="Exercise price">11.10</span></span>
per share exercise price to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zjSVTpw5APqc" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5CupuhJkOU5" title="Exercise price">5.136</span></span>
per share exercise price. The increase in fair value of $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20220424__20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zUgUb2bQVW01" title="Fiar value of warrants">31,010</span>
for the modification of these warrants was charged to additional paid-in capital and did not result in expense on the
Company&#8217;s consolidated statements of operations and comprehensive loss. On December 22, 2022 <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaquUJUAi2E2" title="Warrants purchased">67,620</span>
warrants were repriced from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_ziu87vorlQ16" title="Exercise price">5.136</span>
per share exercise price to $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYcyNViqXhdh" title="Exercise price">1.32</span>
per share exercise price. The increase in fair value of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20221222__20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9xfLHm4udul" title="Fair value of warrants">8,548</span>
for the modification of these warrants was charged to additional paid-in capital and did not result in expense on the
Company&#8217;s consolidated statements of operations and comprehensive loss. On December 5, 2023, <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231205__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSqSvUUOWNgk" title="Warrants purchased">67,620</span>
warrants were repriced from $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zBCUPRV7uDCk" title="Exercise price">1.32</span>
per share exercise price to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zxzprKaDj7el" title="Exercise price">0.73</span>
per share exercise price. The increase in fair value of $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20231205__20231205__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6qC580aP7oa" title="Fair value of warrants">7,945</span>
for the modification of these warrants was charged to general and administrative expenses in the Company&#8217;s consolidated
statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
new compensatory warrants were issued during the year ended December 31, 2023 or 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6GUf15Mz9we" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zVoQ4hpIQza" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
                                                                                             <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Common Stock</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zblP58bGJTgk" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">179,046</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zAphciBbsr2g" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">9.12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zVWAipJ9nxTk" title="Range of exercise price - beginning">1.32</span> &#8212; $<span id="xdx_90A_ecustom--RangeOfExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zcrVGzRoA0U" title="Range of exercise price - beginning">25.40</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zATa9y3tLSWk" title="Weighted Average Remaining Life (Years) - outstanding">1.73</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Granted to advisor and its designees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zABUY8DGxu79" style="text-align: right" title="Number of shares, warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1714">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zaV5yahtMok5" style="text-align: right" title="Weighted average exercise price per share warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1716">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_za5wV3NENpWk" style="text-align: right" title="Number of Shares, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1718">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zyHYwqNDa7xl" style="text-align: right" title="Weighted average exercise price per share warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1720">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsy6bu1YZI31" style="text-align: right" title="Number of Shares, Warrants Expired">(60,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z07igXGcGk5d" style="text-align: right" title="Weighted average exercise price per share warrants expired">6.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_ecustom--RangeOfExercisePriceExpired_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zh3G3jVWMf69" title="Range of exercise price, expired">6.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1XLk7Se0jXc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1728">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zoiiH9doHS5g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1730">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztLDDtjzLI24" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">119,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zvcMxxZlzkYc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">10.69</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_909_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z65Y5bhD4Bb4" title="Range of exercise price - ending">0.73</span> &#8212; $<span id="xdx_90B_ecustom--RangeOfExercisePriceOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zl74jsOcklha" title="Range of exercise price - ending">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfjVOPoa6mBi" title="Weighted Average Remaining Life (Years) - outstanding">1.25</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziITM2nIy0Bc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">119,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9I7XEbBX41" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">10.69</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zGpi0HjkqS9e" title="Range of exercise price, exercisable">0.73</span> &#8212; $<span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z68Cyzk7jgb" title="Range of exercise price, exercisable">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zxMf8XuvRAxg" title="Weighted Average Remaining Life (Years) Exercisable">1.25</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zUyd0KSTciX2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1752">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfeqZe9NdTp5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1754">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zNklYsKDniK7" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1756">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -10pt; width: 36%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zhT8uY9khi6g" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">179,046</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3EkFTjq7eo4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">15.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90A_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zM8mOXJfgBG7" title="Range of exercise price - beginning">11.10</span> &#8212; $<span id="xdx_90D_ecustom--RangeOfExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zqDFez1h6oFb" title="Range of exercise price - beginning">25.40</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zncdrQjLZiHj" title="Weighted Average Remaining Life (Years) - outstanding">2.64</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Granted to advisor and its designees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4mYEWAlcD9d" style="text-align: right" title="Number of shares, warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1768">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zn7zpQy6lX8c" style="text-align: right" title="Weighted average exercise price per share warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1770">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGk8OwJR8lgk" style="text-align: right" title="Number of Shares, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1772">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7Cl3FRLOAx3" style="text-align: right" title="Weighted average exercise price per share warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1774">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zOHYQClIytwc" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1776">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGp4H3CPLHmb" style="text-align: right" title="Weighted average exercise price per share warrants expired"><span style="-sec-ix-hidden: xdx2ixbrl1778">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zQFsnR4DvQ05" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1780">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zVGeXTuAvgMa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1782">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdmXJDFfiAc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">179,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zk2SAluuWPo2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">9.12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z21SEWJvbacf" title="Range of exercise price - ending">1.32</span> &#8212; $<span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zi4vL1vjSsel" title="Range of exercise price - ending">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zS1GFYyy2eTk" title="Weighted Average Remaining Life (Years) - outstanding">1.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7kgmnZyJDL3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">179,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zzbLVt5DRJgf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">9.12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z66oet1uEKP5" title="Range of exercise price, exercisable">1.32</span>- $<span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zLYXiXmkFyui" title="Range of exercise price, exercisable">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zavWyHEIYK5l" title="Weighted Average Remaining Life (Years) Exercisable">1.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zO9vfILQfrI2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMbWmp31gAJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1806">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1kvtOKXwtP4" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1808">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A7_zo38110xVQ08" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">There
was $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zrX8NulCZstd" title="Compensation cost">7,945</span> in compensation costs related to outstanding warrants for the year ended December 31, 2023 and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqB81TWujB54" title="Compensation cost">67,370</span> for the year
ended December 31, 2022. As of December 31, 2023 and December 31, 2022, there was <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlf1IIJEmkXj" title="Unrecognized compensation cost related to nonvested"><span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHmeMbRvRsYj" title="Unrecognized compensation cost related to nonvested">no</span></span> unrecognized compensation cost related to nonvested
warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Noncompensatory
Equity Classified Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to Alpha (a related party) for the
purchase of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zzQVYo7vfJJ9" title="Purchase of warrants">27,048</span> reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zu4Tmmpb8Id5" title="Exercise price">11.10</span> per share
(of which warrants for <span id="xdx_903_ecustom--WarrantsExercised_pid_c20201201__20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zpbYVDRcGhId" title="Warrants exercised">20,000</span> shares were subsequently exercised in December 2020). In July 2020 the Company issued noncompensatory equity
classified warrants to Alpha for the purchase of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z2XOLcPgyFki" title="Warrants purchased">78,019</span> reverse split adjusted shares of Company common stock at a reverse split
adjusted exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z5rA4ikxSTo" title="Exercise price">0.01</span> per share (which were subsequently exercised in July 2020), and <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_ztz2ydT8N9rh" title="Class of warrants">192,068</span> reverse split adjusted shares
of Company common stock at a reverse split adjusted exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zmUy60jbvmdg" title="Exercise price">52.50</span> per share. In August 2020, the Company issued noncompensatory
equity classified warrants to Alpha for the purchase of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200831__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmpm4YzLcY01" title="Purchase of warrants">128,783</span> reverse split adjusted shares of Company common stock at a reverse
split adjusted exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200831__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZi8fPyl1nxh" title="Exercise price">60.00</span> per share. In December 2020, the Company issued noncompensatory equity classified warrants to
Alpha for the purchase of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zd8zgoN5ezU3" title="Purchase of warrants">100,000</span> reverse split adjusted shares of Company common stock at a reverse split adjusted exercise
price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zrCioPMb5uF9" title="Exercise price">0.10</span> per share (which were exercised in February 2021) and <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20201231_zI2VMyaMLim1" title="Purchase of warrants">219,101</span> reverse split adjusted shares of Company common stock at
a reverse split adjusted exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20201231_zuwzuPLSE4d3" title="Exercise price">40.70</span> per share. In May 2022, the Company issued noncompensatory equity classified warrants
to Alpha for the purchase of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zBrDNpvbQL8d" title="Purchase of shares">331,464</span> reverse split adjusted shares of Company common stock at a reverse split adjusted exercise
price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zQEuAIMh7A1f" title="Class of warrant or right, exercise">0.01</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 29, 2021, with the exception of the warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zvX0rMY85Rdk" title="Number of securities called by Each warrant or right">27,048</span> reverse split adjusted shares of the Company&#8217;s common
stock at a reverse split adjusted exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhiB8i3YySk" title="Exercise price of warrants">11.10</span> per share, the exercise prices of all outstanding warrants to purchase a total
of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zDKAPdIKLncb" title="Number of outstanding warrants to purchase, shares">539,951</span> reverse split adjusted shares of the Company&#8217;s common stock were modified to a reverse split adjusted exercise price
of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z419J8Rk6vNj" title="Exercise price of warrants">20.00</span> per share and each of their remaining terms extended by six months. The fair value of the modification cost of these warrant
modifications of approximately $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20211129__20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zmOqfUomSUl9" title="Fair value of warrants">2.3</span> million was charged to additional paid-in capital and did not result in expense on the Company&#8217;s
consolidated statements of operations and comprehensive loss. In May 2022, pre-funded warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zd5iP2ijhVWf" title="Purchase of warrants">331,464</span> reverse split adjusted
shares of the Company&#8217;s common stock at a reverse split adjusted exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zV8JVjwigXoj" title=" Exercise price of warrants or rights">0.01</span> per share with no expiration date were
issued to Alpha. These warrants were subsequently exercised in 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the NanoSynex Acquisition, on April 25, 2022 the exercise price of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zt6anm1UdZ34" title="Purchase of warrants">7,048</span>
reverse split adjusted outstanding warrants at $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_z1i8COC4aik7" title="Exercise price of warrants">11.10</span>
was modified to a reverse split adjusted exercise price of $<span id="xdx_90C_ecustom--ModifiedToExercisePrice_iI_pid_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zByuF8VeXI44" title="Modified to exercise price">6.00</span>.
The increase in fair value of $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20220425__20220425__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zP376pEeUFSl" title="Fair value of warrants">2,533</span>,
using a Monte Carlo pricing model for the modification of these warrants, was charged to additional paid-in capital and did not
result in expense on the Company&#8217;s consolidated statements of operations and comprehensive loss. On May 26, 2022, the reverse
split adjusted exercise price of these warrants was modified again to $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zq5hDeNKiAE5" title="Class of warrant or right, exercise">5.136</span>,
and the increase in fair value of $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20230526__20230526_zreq5GUJ0oLf" title="Fair value adjustment of warrants">696</span>,
using a Monte Carlo pricing model for the modification of these warrants, was included in consideration transferred in the NanoSynex
Acquisition. On December 22, 2022 the exercise price of these warrants was modified again to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zNQhfNL33gFi" title="Class of warrant or right, exercise">1.32</span>.
The increase in fair value of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20221222__20221222__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_z3Co7zbBG5gj" title="Fair value adjustment of warrants">891</span>,
using a Monte Carlo pricing model for the modification of those warrants, was charged to additional paid-in capital and did not
result in expense on the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2023, the Company entered into an Amendment No. 1 with regard to Securities Purchase Agreement, with Alpha. This
Amendment amended two instruments which the Company issued under the Securities Purchase Agreement dated December 21, 2022: (a) the 8%
Senior Convertible Debenture dated December 22, 2022 in favor of Alpha, and (b) the Common Stock Purchase Warrant dated December
22, 2022 in favor of Alpha. The Amendment reduced the Conversion Price of the Debenture from $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zNQCYDt9tMC" title="Conversion price">1.32</span> per share to $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_zB5dR6kulR44" title="Conversion price">0.73</span>
per share (subject to possible future adjustment pursuant to the terms of the Debenture) and reduced the Exercise Price of the Alpha
Warrant from $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zB0NfVcoZzr1" title="Warrant exercise price">1.65</span> per share to $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_zkui0DYHTHO5" title="Warrant exercise price">0.73</span> per share (subject to possible future adjustment pursuant to the terms of the Alpha Warrant). The
Amendment revised certain provisions of the Warrant which resulted in reclassification of the Warrant from liabilities to equity. For
more details see Note 7 - Warrant Liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zBR5N0UoTtm" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zWaJcYtP6cid" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zBrhwrtA08f5" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning">547,003</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z16lgZwUetj" style="width: 12%; text-align: right" title="Weighted Average exercise price, warrants outstanding beginning">19.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6GP6w0701Se" title="Range of exercise price">1.32</span> - $<span id="xdx_90C_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zrjLOhUdlhJ1" title="Range of exercise price">20.00</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6gEOFOhuxa1" title="Weighted average remaining life (Years) exercisable">0.33</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Legacy Ritter warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z753JNxyM1al" style="text-align: right" title="Number of shares legal ritter warrants"><span style="-sec-ix-hidden: xdx2ixbrl1898">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSJEhpZPXz7k" style="text-align: right" title="Weighted Average exercise price, legal ritter warrants"><span style="-sec-ix-hidden: xdx2ixbrl1900">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Reclassification of Alpha Warrant from warrant liabilities to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zXLV6IWbAiWf" style="text-align: right" title="Number of shares, warrants reclassification of Alpha warrant from warrant liabilities to equity">2,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zcoxUHSQUkW1" style="text-align: right" title="Weighted Average exercise price, reclassification of Alpha warrant from warrant liabilities to equity">0.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6JkInoHrxci" title="Range of exercise price, reclassification of Alpha warrant from warrant liabilities to equity">0.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zXc9CV8ffE54" style="text-align: right" title="Number of Shares, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1908">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfE1qxUbr91" style="text-align: right" title="Weighted average exercise price, warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1910">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zyu7TMkrjFw" style="text-align: right" title="Number of Shares, Warrants Expired">(539,953</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSctCIyTwZT9" style="text-align: right" title="Weighted average exercise price, warrants expired">20.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMLIYRkHsNGk" title="Range of exercise price, expired">20.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z255AwZBtLR" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1918">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zc54vnC1hR5b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1920">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zNDjU6eYyCmc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending">2,507,050</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwuIMebw57Nf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average exercise price, warrants outstanding ending balance">0.73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zn3TozeyExo7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">2,507,050</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zphXwBoGbAQa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">0.73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zQg5veEAr0a1" title="Range of exercise price, exercisable">0.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z0XUjsjeZ0H3" title="Weighted average remaining life (Years) exercisable">4.47</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGEjBufrUuo3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1934">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuZLFbaOM9a6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1936">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211; Average Exercise
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zO7Cg7lGZ0T9" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning">554,914</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zg0hga9tUFDj" style="width: 12%; text-align: right" title="Weighted average exercise price, warrants outstanding beginning">20.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUg4iabg9xKe" title="Range of exercise price">11.10</span>&#8212; <span id="xdx_90E_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zT1SmbA6nB61" title="Range of exercise price">37.78</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zoksFYh7JX2g" title="Weighted average remaining life (Years) exercisable">1.32</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Legacy Ritter warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z3DaDuZucKPb" style="text-align: right" title="Number of shares legal ritter warrants"><span style="-sec-ix-hidden: xdx2ixbrl1948">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zO6BRIKiu9Yi" style="text-align: right" title="Weighted average exercise price, legal ritter warrants"><span style="-sec-ix-hidden: xdx2ixbrl1950">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJHb6Nismj6g" style="text-align: right" title="Number of shares, warrants granted">331,464</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zLMahoHMM1Ag" style="text-align: right" title="Weighted average exercise price, warrants granted">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--RangeOfExercisePriceExercisableGranted_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZn1SgKiH9h8" title="Range of exercise price, granted">0.01</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgFA4ipoXUD2" style="text-align: right" title="Number of Shares, Warrants Exercised">(331,464</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zjS2TWnu8HI3" style="text-align: right" title="Weighted average exercise price, warrants exercised">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePriceExercised_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfUq2hkkhWSh" title="Range of exercise price, exercised">0.01</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTUse044gCFk" style="text-align: right" title="Number of Shares, Warrants Expired">(7,911</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zpLxlMN7pXK6" style="text-align: right" title="Weighted average exercise price, warrants expired">37.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePriceExercisableExpired_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSPSLF3Ce2dg" title="Range of exercise price, expired">37.78</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJXpTgZPuKHk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1970">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zh0txminHaOl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1972">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_ecustom--RangeOfExercisePriceForfeited_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z8tIuIDKsdY8" title="Range of exercise price, forfeited">0</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdXwh1vfSNjd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending">547,003</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgxS2qW5u3X5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants outstanding ending balance">19.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zbnws0F622Z" title="Range of exercise price">1.32</span> - <span id="xdx_906_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJe2u5fV8yJ6" title="Range of exercise price">20.00</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zL8m6zhtMyU9" title="Weighted average remaining life (Years) exercisable">0.33</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuBf0CI8zkRj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">547,003</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwGx9fu8t437" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">19.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zrfdrjj9x2b" title="Range of exercise price, exercisable">1.32</span> - <span id="xdx_908_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zHgslEXoYM7h" title="Range of exercise price - Exercisable">20.00</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZvOqXPsGhT7" title="Weighted average remaining life (Years) exercisable">0.33</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxV5nkyftnZi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1996">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zPfNZv7sMpv3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1998">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zkPWLd4VQhp3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235411491872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zsCa2udMVYug" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
13 &#8212; <span id="xdx_823_zxb0Y46TjKI6">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible
Debt</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 8 &#8211; Convertible Debt &#8211; Related Party for additional information concerning convertible debt &#8211; related party
transactions. On December 22, 2022, the Company issued to Alpha, an <span id="xdx_900_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zHrR5fn6Fovb" title="Senior convertible debenture rate">8</span>%
Senior Convertible Debenture in the aggregate principal amount of $<span id="xdx_905_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_znva6CQlRlx4" title="Principal amount">3,300,000</span>
for a purchase price of $<span id="xdx_900_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zPMhZnl4aWr2" title="Purchase Price">3,000,000</span>
pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. As of December 31, 2023 the Debenture had a
remaining principal balance of $<span id="xdx_90B_eus-gaap--SecuredDebt_iI_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zcwEnj3Z8fC9" title="Principal amount">1,418,922</span>,
and was convertible, at any time, and from time to time, at Alpha&#8217;s option, into shares of common stock of the Company, at a
price equal to $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zdyXAhxZRHe8" title="Conversion price">0.73</span>
per share, subject to adjustment as described in the Debenture and other terms and conditions described in the Debenture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
on December 22, 2022, in conjunction with the issuance of the Debenture to Alpha, the Company issued to Alpha the Alpha
Warrant to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z8sfarcko6C3" title="Warrant to purchase shares">2,500,000</span> shares of the Company&#8217;s common stock (the &#8220;Alpha Warrant&#8221;). As of December 31, 2023,
the exercise price of the Alpha Warrant was $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_znlmZKGazR41" title="Exercise price of warrant">0.73</span>. The Alpha Warrant may be exercised by Alpha, in whole or in part, at any time
before June 22, 2028, subject to certain terms and conditions described in the Alpha Warrant. The Alpha Warrant is included in equity
on the Company&#8217;s consolidated balance sheets (see Note 12 &#8211; Stockholders&#8217; Equity).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NanoSynex</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to a Share Purchase Agreement dated April 29, 2022, the Company acquired <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220429__20220429__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z40TJa9X7eSj" title="Number of common stock acquired shares">2,232,861</span> shares of NanoSynex Series A-1 Preferred Stock from
Alpha in exchange for <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220429__20220429__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zPCdWz5fKSea" title="Number of common stock acquired shares">350,000</span> reverse split adjusted shares of the Company&#8217;s common stock and a prefunded warrant to purchase
<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220429__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zw0gIIuu5k42" title="Warrants to purchase common stock">331,464</span> reverse split adjusted shares of the Company&#8217;s common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220429__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zBxwYZBeQzrc" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">0.001</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235497750480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zbT1rnyeVcif" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
14 &#8212; <span id="xdx_82A_z8mcgtwwCItb">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_znNnnEo4tKLd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents domestic and foreign components of consolidated loss before income taxes from continuing operations for the
periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8BC_zLVxJoxV0zt9" style="display: none">SCHEDULE
OF DOMESTIC AND FOREIGN COMPONENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zroRJrFub7S4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zTWpwWAqnQoi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zi07Z33bFCFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(12,479,803</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(13,887,914</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zLt9DRSh7xpk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2031">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2032">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zQ14WvxvlJa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss before provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,479,803</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,887,914</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A8_z918ZCezRllb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zCwKsoCY7LYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory income tax rates and the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zJSrkVjWc5O4" style="display: none">SCHEDULE
OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_z8vka4fOhIJg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_z3Q4fMFAj0x6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zuGzWVPbb409" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Statutory federal income tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_zfIwNUKyYcia" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.76</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.50</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_maABC_zePFyfdYh9qb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.64</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-2.09</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_maABC_zvOKfgEE5Ia7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NOL expiration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-5.26</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-19.88</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_zbjEnCHJzTn4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.92</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.71</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_maABC_z1D7Vrub6YEc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maABC_zWBv6eerD4l5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_pid_dp_uPure_maABC_zhe4RJi20f5e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.35</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_pid_dp_uPure_maABC_z3jsT0z4L993" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax impact of convertible debenture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-5.46</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.37</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_pid_dp_uPure_maABC_zKHOwMPbHVz3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax impact of divestiture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-229.26</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.01</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationTrueUp_pid_dp_uPure_maABC_z7WhUdWrI7Sa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>True-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-10.65</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.24</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_zCt7BzuD2EFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">222.28</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-17.91</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_mtABC_z59jjaWlBCb2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income taxes provision (benefit)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.04</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0.05</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8AB_zlhfMWSfWB73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zHUvtkkhZDhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense for the year ended December 31, 2023 and 2022 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zZUShjraxBOk" style="display: none">SCHEDULE
OF PROVISION FOR INCOME TAXES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zVKL8yGFKLvd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_zuiJFykVdqQe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBz1MC_zmZ4dcINcYNd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">U.S. Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(10,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2081">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBz1MC_zV7QvzcEmUPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">U.S. State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBz1MC_zE9wn5sLbkSg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total current provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzCKf_zz2EpiDIeaM3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">U.S. Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,128,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(236,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzCKf_zDJeFJdwOUX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">U.S. State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,697,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,252,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzCKf_maITEBzWbu_z1ABCzTJbD76" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total deferred benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,825,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,488,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzWbu_zU5dkRo9vuZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in valuation allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,825,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,488,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3d_mtITEBzWbu_zPlvv7UdRbOc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total provision (benefit) for income taxes</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,000</td><td style="text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A2_z51p20xX4ET4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zU271WlknDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of deferred tax assets and liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zRjLOzKUlSAh" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zo0eKliPjx44" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_zUhsCaslYAy2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTATDzYdX_zXgzvBZDbCC2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,644,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">32,587,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTATDzYdX_zhEvn7CTUbf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,970,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,857,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DefferdTaxAssetsAccruedExpenses_iI_maDTATDzYdX_zbl8ZIJmlpmi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,020,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTATDzYdX_zz9WMcVBhkIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Patent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2115">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2116">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTATDzYdX_zLOm9WndY0v1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,004,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,069,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentExpenses_iI_maDTATDzYdX_zR0akY1zAry" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,102,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,196,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTATDzYdX_zSinl3k6I6s6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2124">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">280,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iTI_mtDTATDzYdX_maDTAGzJfc_z9gjg4N7CKhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total deferred income tax assets</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,788,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,009,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzOxa_zGB9JwhXUJRk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2130">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_maDITLzOxa_zuj0yBDZZ4yh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Right-of-use asset</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2133">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(382,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzOxa_msDTAGzJfc_zonkDxVfkkZ4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total deferred income tax liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2136">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(395,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJfc_maDTALNzbeu_zxiB9qCTVw0e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net deferred income tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,788,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,614,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzbeu_zeGtvy75BvAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,788,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45,614,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNTI_di_mtDTALNzbeu_zdG5p2mx3xAe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax asset, net of allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2145">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2146">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zhMBM80kDSg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the available objective evidence, including the Company&#8217;s history of cumulative losses, management believes it is likely that
the Company&#8217;s U.S. federal and state net deferred tax assets will not be realizable. Accordingly, the Company provided for a full
valuation allowance against its U.S. federal and state net deferred tax assets at December 31, 2023 and December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the full valuation allowance already in place on the Company&#8217;s U.S. federal and state net deferred tax assets, the Company does
not anticipate significant changes in the Company&#8217;s effective tax rate. However, there is no valuation allowance recorded against
the Company&#8217;s foreign net operating loss deferred tax assets, as the Company&#8217;s foreign IPR&amp;D deferred tax liabilities
and foreign net operating loss deferred tax assets are both indefinite-lived and thus they may be netted to arrive at a net foreign deferred
tax liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act resulted in significant changes to the treatment of research or experimental (&#8220;R&amp;E&#8221;) expenditures
under Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&amp;E expenditures
that are paid or incurred in connection with their trade or business which represent costs in the experimental or laboratory sense. Specifically,
costs for U.S. based R&amp;E activities must be amortized over five years and costs for foreign R&amp;E activities must be amortized
over 15 years; both using a midyear convention. The Company has incorporated the impact of this new tax legislation into its 2023 and
2022 consolidated financial statements, noting that the impact on the Company&#8217;s consolidated financial statements was immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2023, the Company has U.S. federal and state net operating loss carryforwards of approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20231231_zY2Mbl5CiQo3" title="U.S. federal operating loss carryforwards">15,942,000</span> and $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20231231_zapUZGzk1bki" title="State operating loss carryforwards">78,693,000</span>,
respectively, which are available to offset future taxable income. U.S. federal and state net operating loss carryovers began to expire
in 2020. As a result of the May 2020 reverse recapitalization, an ownership change has occurred. The Company has not completed an Internal
Revenue Code Section 382 analysis. As a result, there could be substantial limitations on the Company&#8217;s ability to utilize its
pre-ownership change net operating loss and tax credit carryforwards. These substantial limitations may result in both a permanent loss
of certain tax benefits related to net operating loss carryforwards and federal research and development credits, and an annual utilization
limitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also has research and development credit carryforwards for federal and state tax purposes of approximately $<span id="xdx_902_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zIebNCmZ8608" title="Research and development credit carryforwards">3,560,000</span> and $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zrpFbfYHE9I1" title="Research and development credit carryforwards">1,410,000</span>,
respectively. <span id="xdx_902_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_c20230101__20231231_zQhT2ePyxmil" title="Tax credit carryforward, limitations on use">The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite
life for state tax purposes</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
income tax has not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries
that is indefinitely reinvested outside the United States. This amount becomes taxable upon a repatriation of assets from the subsidiary
or a sale or liquidation of the subsidiary. Determination of the amount of any unrecognized deferred income tax liability on this temporary
difference is not practicable because of the complexities of the hypothetical calculation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files income tax returns in the U.S. federal jurisdiction and in various states. The Company&#8217;s U.S. federal income tax
returns remain subject to examination by the Internal Revenue Service. The Company&#8217;s California income tax returns remain subject
to examination by the California Franchise Tax Board. Due to net operating losses, research and development credits and other tax credit
carryforwards that may be utilized in future years, all U.S. federal and state tax years are open to examination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally
accepted accounting principles clarify the accounting for uncertainty in income taxes recognized in the Company&#8217;s financial statements
and prescribe thresholds for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax
return, and also provide guidance on de-recognition and measurement of a tax position taken or expected to be taken in a tax return.
The Company adopted these provisions effective April 1, 2009.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did <span id="xdx_909_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20231231_zBEjxnZLFxwd" title="Unrecognized tax benefits"><span id="xdx_900_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20221231_zR5qIRXeS3n6" title="Unrecognized tax benefits">no</span></span>t have any unrecognized tax benefits as of December 31, 2023 and December 31, 2022 and does not expect this to change significantly
over the next 12 months. In accordance with generally accepted accounting principles, the Company will recognize interest and penalties
accrued on any unrecognized tax benefits as a component of income tax expense. As of December 31, 2023, the Company has not accrued any
interest or penalties related to uncertain tax positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235415020016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zlao3mNfPhG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
15 &#8212; <span id="xdx_826_zrMWVJ9CLbw6">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2024, the Company entered into a Securities Purchase Agreement (&#8220;Agreement&#8221;) with Alpha. The transactions
contemplated by the Agreement closed on February 27, 2024, at which time the Company delivered to Alpha the 2024 Debenture and the
2024 Warrant, as described below, and Alpha paid the Company a cash purchase price of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourDebentureAndWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJ6vRphEqjz3" title="Cash purchase price">500,000</span>
(less $<span id="xdx_903_ecustom--ReimbursementExpenses_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourDebentureAndWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNea2Tid9vP2" title="Reimbursement expenses">25,000</span>
for expense reimbursement). Pursuant to the Agreement, the Company issued to Alpha an 8% Convertible Debenture (the &#8220;2024
Debenture&#8221;) in the principal amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSGjOK5oxFO4" title="Principal amount">550,000</span>.
The Debenture has a maturity date of <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrj2kxG5AzJk" title="Maturity date">December
31, 2024</span> and is convertible, at any time, and from time to time, at Alpha&#8217;s option, into shares of common stock of the
Company, at $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zt0mDH2hYBt6" title="Conversion price">0.6111</span>
per share, subject to adjustment as described in the 2024 Debenture (the &#8220;Conversion Price&#8221;). The Debenture accrues
interest on its outstanding principal balance at the rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHp0piqUBawd" title="Interest rate">8</span>%
per annum. The 2024 Debenture does not call for scheduled payments of principal or interest before the scheduled maturity date of
December 31, 2024. Pursuant to the terms of the Agreement, the Company also issued to Alpha a 5-year common stock purchase warrant
(the &#8220;2024 Warrant&#8221;) to purchase (at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyFourWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvG5H1y2PZlb" title="Warrant exercise price">0.26</span>
per share) <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyFourWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGkwqWb9Q8S6" title="Purchase of warrants for shares">900,016</span>
shares of common stock of the Company. Under the Agreement, Alpha also has an option, exercisable until July 1, 2024, to
purchase from the Company up to an additional $<span id="xdx_901_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmGym4aSzN7j" title="Principal amount increase decrease">1,100,000</span>
in principal amount of 2024 Debentures of like tenor, together with up to an additional <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyFourWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxOHAZj8cS3i" title="Purchase of shares increase decrease">1,800,032</span>
2024 Warrants of like tenor, which would (if and when Alpha exercises such option) provide us up to an additional $<span id="xdx_903_ecustom--AdditionalProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourDebentureAndWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z45OZjJ06Td8" title="Additional cash proceeds">1.0</span>
million in cash proceeds (less expense reimbursement, and not including any possible cash proceeds from any future exercise of the
additional 2024 Warrants). We granted Alpha &#8220;piggyback&#8221; registration rights for the common shares underlying the
2024 Debenture and the 2024 Warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235497894896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><p id="xdx_84C_ecustom--OrganizationPolicyTextBlock_zoELRG00RZqb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zEHGaHZAHxR7">Organization</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ritter
Pharmaceuticals, Inc. (the Company&#8217;s predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the
name Ritter Natural Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals,
Inc. On May 22, 2020, upon completing a &#8220;reverse recapitalization&#8221; transaction with Qualigen, Inc., Ritter Pharmaceuticals,
Inc. was renamed Qualigen Therapeutics, Inc. (the &#8220;Company&#8221;). Qualisys Diagnostics, Inc. was formed as a Minnesota corporation
in 1996, reincorporated to become a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc.
was a wholly-owned subsidiary of the Company. On July 20, 2023, the Company sold all of the issued and outstanding shares of common stock
of Qualigen, Inc. to Chembio Diagnostics, Inc. (&#8220;Chembio&#8221;), a wholly-owned subsidiary of Biosynex, S.A. (&#8220;Biosynex&#8221;).
Following the consummation of this transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio (see Note 5 &#8211; Discontinued
Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 26, 2022, the Company acquired <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zAZ4kjiHJfug" title="Stock issued during period shares acquisitions">2,232,861</span> shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (&#8220;NanoSynex&#8221;) from Alpha
Capital Anstalt (&#8220;Alpha&#8221;), a related party, in exchange for <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zm10E5bR0Vk9" title="Stock issued during period shares acquisitions">350,000</span> reverse split adjusted shares of the Company&#8217;s
common stock and a prefunded warrant to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zgOebxpv9q2h" title="Warrants to purchase common stock">331,464</span> reverse split adjusted shares of the Company&#8217;s common stock at an exercise
price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_znQiAcdJ9vQk" title="Warrants exercise price">0.001</span> per share. <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20220524__20220526_zZLCTUTXqaVa" title="Reverse stock split">These warrants were subsequently exercised on September 13, 2022.</span> Concurrently with this transaction, the
Company also entered into a Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022,
with NanoSynex (the &#8220;NanoSynex Funding Agreement&#8221;), to, among other things, provide for the further funding of NanoSynex,
and purchased <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBH1w32dlfCa" title="Stock issued during period shares acquisitions">381,786</span> shares of Series B preferred stock from NanoSynex for a total purchase price of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zP9BLEKsOO75" title="Stock issued during period, value, acquisitions">600,000</span>. The transactions resulted
in the Company acquiring a <span id="xdx_905_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zmyx8kufwR2e" title="Voting interests acquired">52.8</span>% interest in NanoSynex (the &#8220;NanoSynex Acquisition&#8221;). NanoSynex is a nanotechnology diagnostics
company domiciled in Israel. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex (the &#8220;NanoSynex
Amendment&#8221;), which amended the NanoSynex Funding Agreement, to, among other things, eliminate most of the Company obligation for
the further funding of NanoSynex. Pursuant to the terms of the NanoSynex Amendment, the Company lost its controlling interest in NanoSynex
(see Note 5 -Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNRMCvRcDep" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zONvBnmWnJ7c">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#8220;U.S. GAAP&#8221;), Regulation S-X and rules and regulations of the Securities and Exchange Commission
(&#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zf9hM2AKGiw7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zzRYl9MVKxT2">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the accounts of the Company and its former wholly-owned and majority owned subsidiaries.
All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance
is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional
currency of the Company and its subsidiaries is the U.S. dollar. For NanoSynex, the functional currency was the local currency, New Israeli
Shekels (NIS). As such, assets and liabilities for NanoSynex were translated into U.S. dollars with the effects of foreign currency translation
adjustments reflected as a component of accumulated other comprehensive loss within the Company&#8217;s consolidated statements of
changes in stockholders&#8217; equity (deficit).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of July 20, 2023, NanoSynex was deconsolidated from these financial statements as the transactions contemplated by the NanoSynex Amendment
resulted in a loss of control of a subsidiary that constitutes a business under ASC 810. The retained investment in NanoSynex is accounted
for prospectively as an equity method investment. See Note 5 &#8211; Discontinued Operations for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zjBN6sDUY1X" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z6285TUmPecj">Discontinued
Operations</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, the Company completed the sale of Qualigen, Inc. to Chembio Diagnostics, Inc. The sale of Qualigen Inc. constituted a
significant disposition and as such, the Company concluded that the disposition of ownership in Qualigen, Inc. represented a strategic
shift that had a major effect on its operations and financial results. Therefore, Qualigen, Inc. is classified as discontinued operations
for all periods presented herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2023, the Company entered into the NanoSynex Amendment, which amended the Master Funding Agreement
for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the &#8220;NanoSynex
Funding Agreement&#8221;), a former majority owned subsidiary of the Company, to, among other things, forfeit 281,000 Series B Preferred
Shares of NanoSynex held by the Company, resulting in the deconsolidation of NanoSynex. The disposition represents a strategic shift
that will have a material effect on the Company&#8217;s operations and financial results. Accordingly, the business of NanoSynex is classified
as discontinued operations for all periods presented herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 5 - Discontinued Operations for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text"><p id="xdx_846_eus-gaap--EquityMethodInvestmentsPolicy_z0yVc3zgdCml" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zXqLYuXa0E2e">Equity
Method Investments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
deconsolidation of NanoSynex on July 20, 2023, the Company accounts for its retained investment under the equity method of accounting
as it retained the ability to exercise significant influence over the operating and financial policies of the investee. Under the equity
method, the Company recognizes its proportionate share earnings or losses each reporting period with an adjustment to the carrying value
of the investment. As of December 31, 2023, the carrying value of the retained investment was zero, and therefore the Company has suspended
application of the equity method as the Company is not liable for the obligations of the investee nor otherwise committed to provide
financial support. Future equity method earnings, if any, will not be recognized until the amount exceeds the unrecognized net losses
in prior periods. See Note 5 &#8211; Discontinued Operations for further information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p id="xdx_846_eus-gaap--UseOfEstimates_z4xRxysj5w3b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zxiaUaiQGjf3">Accounting
Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant
liabilities, and stock-based compensation. Actual results could vary from the estimates that were used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p id="xdx_844_ecustom--ReverseStockSplitPolicyTextBlock_zPyRls5G3Qw8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z8rDi0S5KRI1">Reverse
Stock Split</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 23, 2022, the Company effected a 1-for-10 reverse stock split of its outstanding shares of common stock (the &#8220;Reverse
Stock Split&#8221;). The Reverse Stock Split reduced the Company&#8217;s shares of outstanding common stock, stock options, and warrants
to purchase shares of common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse Stock Split
were rounded down to the nearest whole share and cash in lieu of fractional shares was paid to stockholders. All share and per share
data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively
to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zptILlwsNoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zj906zf4TUrh">Cash</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains the majority of its cash in government money market mutual funds and in accounts at banking institutions in the U.S.
that are of high quality. Cash held in these accounts often exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits.
If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations.
In March 2023, Silicon Valley Bank and Signature Bank, and more recently in May 2023, First Republic Bank, were closed due to liquidity
concerns and taken over by the FDIC. While the Company did not have an account at any of these banks, in the event of failure of any
of the financial institutions where the Company maintains its cash and cash equivalents, there can be no assurance that the Company would
be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely
affect the Company&#8217;s business and financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zES8EVAkVpFc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zzGtVIkWEHvd">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the years ended December 31, 2023 and 2022, <span id="xdx_908_eus-gaap--AssetImpairmentCharges_do_c20230101__20231231_zGFJtvprpUYc" title="Impairment losses on construction-in-progress"><span id="xdx_90E_eus-gaap--AssetImpairmentCharges_do_c20220101__20221231_zqrYIsRX9XLe" title="Impairment losses on construction-in-progress">no</span></span> such impairment
losses have been recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zFy6sd4R3J5d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_z83nPQFph3kk">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company
has viewed its operations and managed its business as one segment operating primarily within the United States (and in Israel prior to
the NanoSynex deconsolidation).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zyju2okuavG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zVTC3o3ff6sc">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for acquired in process research and development (IPR&amp;D), the Company expenses research and development costs as incurred including
therapeutics license costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p id="xdx_840_ecustom--PatentCostsPolicyTextBlock_zdZxPitk3Mlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zjug10Hktfve">Patent
Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><p id="xdx_841_eus-gaap--BusinessCombinationsPolicy_z8WGLPtyAmeg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zsBOFrfYlQH3">Business
Combinations</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for business combinations using the acquisition method pursuant to Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;)
ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company&#8217;s
financial results beginning on the respective acquisition date, and that assets acquired and liabilities assumed are recognized at fair
value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted
cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of
capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value of
the intangible asset. Any excess of the fair value of consideration transferred (the &#8220;purchase price&#8221;) over the fair values
of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may
be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition
date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><p id="xdx_847_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zOLyA9Skf2T" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zaNulaXka052">Goodwill</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired,
when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized but is reviewed
for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.
In testing for impairment, the fair value of the reporting unit is compared to the carrying value. If the net assets assigned to the
reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the difference is recorded. As a result of the
annual goodwill impairment analysis, the Company recognized a $<span id="xdx_905_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zn8hkA3dRh52" title="Goodwill impairment charges">4,239,000</span> non-cash goodwill and fixed asset impairment charge in the valuation
of its business acquisition of NanoSynex for the year ended December 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock', window );">Derivative Financial Instruments and Warrant Liabilities</a></td>
<td class="text"><p id="xdx_841_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_zpO2iZ5rIuMh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zUTkdHfTIgE7">Derivative
Financial Instruments and Warrant Liabilities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument,
the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception
and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as
liabilities or as equity, is re-assessed at the end of each reporting period (See Note 7-Warrant Liabilities and Note 8- Convertible
Debt - Related Party).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zl9QOmVDa5hl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zQXgBNLNIxY7">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability
    to access at the measurement date;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-align: justify; text-indent: -24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs
    in markets that are not considered to be active; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 - Inputs that are unobservable.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-align: justify; text-indent: -24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zcOOuCmQgig9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zElovFA8AgRk">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates
fair value due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zw3foD3WaGE1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zTi9ooXhuPug">Comprehensive
Loss</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss consists of net income and foreign currency translation adjustments related to the discontinued operations of NanoSynex. Comprehensive
gains (losses) have been reflected in the statements of operations and comprehensive loss and as a separate component in the statements
of stockholders&#8217; equity (deficit) for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_842_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z9jJfqsCkC8g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zlDItihaHpx6">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company&#8217;s
stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zm8AiE3fJ4p2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zsEuTaq4sI06">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years. For more information, refer to Note 14 - Income Taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued Accounting Standards Update 2023-09, Improvements to Income Tax Disclosures, which requires more detailed
income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation
as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis,
with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early
adoption permitted. The Company is evaluating the disclosure requirements related to the new standard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z1ONaR6BlLXl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zq5GXQbmj1Ka">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency for the Company is the U.S. dollar. The functional currency for the discontinued operations of NanoSynex was the
New Israeli Shekel (NIS). The financial statements of NanoSynex were translated into U.S. dollars using exchange rates in effect at each
period end for assets and liabilities; using exchange rates in effect during the period for results of operations; and using historical
exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of NanoSynex was reflected
as a separate component of other comprehensive income (loss) (see Note 5 - Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8LlnmXoZKt1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zpa55FKXxkR3">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected
to have a significant impact to the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_GlobalEconomicConditionsPolicyTextBlock', window );">Global Economic Conditions</a></td>
<td class="text"><p id="xdx_84A_ecustom--GlobalEconomicConditionsPolicyTextBlock_zRY1aEAurJui" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zgjKyfRNhO2a">Global
Economic Conditions</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ongoing
Wars in Ukraine and Israel</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor
any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the
conflict on the Company&#8217;s business and financial results remains uncertain and will depend on the severity and duration of the
conflict and its impact on regional and global economic conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, Hamas conducted terrorist attacks in Israel resulting in ongoing war. There continue to be hostilities between Israel and
Hezbollah in Lebanon and Hamas in the Gaza Strip, both of which have resulted in rockets being fired into Israel, causing casualties
and disruption of economic activities. In early 2023, there were a number of changes proposed to the political system in Israel by the
current government which, if implemented as planned, could lead to large-scale protests and additional uncertainty, negatively impacting
the operating environment in Israel. Popular uprisings in various countries in the Middle East over the last few years have also affected
the political stability of those countries and have led to a decline in the regional security situation. Such instability may also lead
to deterioration in the political and trade relationships that exist between Israel and these countries. Any armed conflicts, terrorist
activities or political instability involving Israel or other countries in the region could adversely affect the Company&#8217;s minority
interest in NanoSynex, its results of operations, financial condition, cash flows and prospects (see Note 5 &#8211; Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
and Global Economic Conditions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary
pressures attributable to government stimulus and recovery programs, government deficit spending and supply chain issues. The Company
cannot provide assurance that it will be successful in fully offsetting increased costs resulting from inflationary pressure. In addition,
the global economy suffers from slowing growth and rising interest rates, and some economists believe that there may be a global recession
in the near future. If the global economy slows, the Company&#8217;s business may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ImpactOfCovid19PandemicPolicyTextBlock', window );">Impact of COVID-19 Pandemic</a></td>
<td class="text"><p id="xdx_845_ecustom--ImpactOfCovid19PandemicPolicyTextBlock_zO8s7ZYnbAN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zNp25EDTxFY1">Impact
of COVID-19 Pandemic</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company&#8217;s business as well. During the height of
the pandemic, sales of diagnostic products decreased significantly and the Company&#8217;s net loss increased significantly, as clinics
and small hospitals&#8217; demand for Qualigen, Inc.&#8217;s FastPack&#8482; diagnostic test kits was reduced sharply, largely due to
deferral of patients&#8217; non-emergency visits to physician offices. In July 2023 the Company sold Qualigen, Inc., its wholly-owned
subsidiary, to Chembio (see Note 5 - Discontinued Operations).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#8217;s
consolidated financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Financial Instruments and Warrant Liabilities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_GlobalEconomicConditionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Global Economic Conditions [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_GlobalEconomicConditionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ImpactOfCovid19PandemicPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact Of Covid19 Pandemic [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ImpactOfCovid19PandemicPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization Policy [TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Stock Split [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235502412448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zFL6RiaYR2Ij" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets consisted of the following at December 31, 2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="display: none"><span id="xdx_8B3_zaBxxvAYKOaj">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zyipDHfi1Ki6" style="vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zz8Puu6B85T1" style="vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzdSM_zDgnhzRorW98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">566,011</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,329,034</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzdSM_zkttQ2OFjpO5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,670</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ReceivableInvestmentSale_iI_pp0p0_maPEAOAzdSM_zxVQHhn3sGF6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Receivable from sale of Qualigen, Inc.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0709">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PreapaidResearchAndDevelopmentExpenses_iI_pp0p0_maPEAOAzdSM_zlWYao4idRH2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Prepaid research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">173,900</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0713">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzdSM_zXh1u3ZJH5Y8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and
    other current assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">764,964</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,366,704</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235411469776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER NON-CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">SCHEDULE OF OTHER NON CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfOtherAssetsNoncurrentTextBlock_zMaDE9peYpFc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
non-current assets consisted of the following at December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8BF_z89w6uHf1Bx7" style="display: none">SCHEDULE
OF OTHER NON CURRENT ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zaZrvYydfiJd" style="vertical-align: bottom; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EscrowDeposit_iI_maOAzAWm_zzszp4MmBlLa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Funds held in escrow</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">450,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--LongtermResearchAndDevelopmentDeposits_iI_maOAzAWm_zi3qvIX2HLSi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Long-term research and development deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">416,481</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAssets_iI_mtOAzAWm_zgiA0JZTUTSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Other non-current assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">866,481</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235414709856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_z5Dt0YsaFggi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of assets and liabilities classified in discontinued operations as of December 31, 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BE_zM2GFwfBcb99" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zodx01DSNDs4" style="border-bottom: Black 1.5pt solid; text-align: center">Qualigen, Inc.</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zkWbORC60jCl" style="border-bottom: Black 1.5pt solid; text-align: center">NanoSynex</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231_z50z0zVBbJah" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzI2M_maTAODOzy7K_zXkOI4AdQZJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 46%; text-align: left">Current assets of discontinued operations</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">4,448,999</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">1,838,850</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">6,287,849</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_i01I_maCzo3N_maTAODOzy7K_z4TkzckFeGD8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Non-current assets of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,876,270</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,360,441</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,236,711</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--TotalAssetsOfDiscontinuedOperations_iI_zaOJz7puWoR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total assets of discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,325,269</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,199,291</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,524,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzCJ5_maTLOOzkOU_zEbnWh5YAST6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,299,948</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,141,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,441,198</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_i02I_maCzIDe_maTLOOzkOU_zwwt8URcENPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Non-current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,350,975</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">357,757</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,708,732</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--TotalLiabilitiesOfdiscontinuedOperations_iI_zCPvA2wOO6bh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities of discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,650,923</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,499,007</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,149,930</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of gain (loss) from discontinued operations, net of tax, as of December 31, 2023 and 2022 are as follows:<b>&#160;</b></span></p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zgyRHLYRdNHk" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zYirOfUwnfHi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zZOHikC3k2A7" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_z7KOK0KzexEg" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zriQLS8NBlK6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zBmCU5FMeNv5" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Qualigen, Inc.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NanoSynex</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Qualigen, Inc.</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">NanoSynex</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_maCzBjD_zXK0Entbw48b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left">(Loss) from discontinued operations</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(171,701</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(511,307</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(683,008</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(2,142,763</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(4,997,418</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(7,140,181</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_iN_di_msCzBjD_zEyxLvK7bhpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Gain (loss) on disposal of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,876,778</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,479,010</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(602,232</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0767">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_mtCzBjD_maCzhiC_zjo8O9g2rzk2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total gain (loss) from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,705,077</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,990,317</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,285,240</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,142,763</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,997,418</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(7,140,181</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_NanosynexMember', window );">NanoSynex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hdei--LegalEntityAxis__custom--NanosynexMember_zql7Ocd1YQD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets and liabilities classified in discontinued operations for NanoSynex as of December 31, 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8B8_zVjw2CrpUSug" style="display: none">ASSETS
AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231__dei--LegalEntityAxis__custom--NanosynexMember_ziAxeurFgqSb" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_hdei--LegalEntityAxis__custom--NanosynexMember_znAT1VGu4Enl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,621,967</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zN3N2jA1Xg8e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,499</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zS3OziL2bL64" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">190,384</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zudjy6jAUFJ8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total current assets of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,838,850</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash_iI_hdei--LegalEntityAxis__custom--NanosynexMember_z8jgHUgNV9f3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,690</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zURxSXiS75G4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,149</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zatJLqdJ3iFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,700,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zbN6DIJrYwDf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">625,602</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zeCqfvJF6T0h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total non-current assets of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,360,441</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalAssets_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zjeoubzzdNKb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total assets of discontinued operations of NanoSynex</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,199,291</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zkJ2bH9V1TVi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,273</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zxpaYWoF1jK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,002</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zlEFbYuQa6tg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">293,571</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zsDzep8kKing" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D grant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">780,682</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zedLNhd2fXGc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Short term debt-related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">950,722</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_z7XSBcqOkN72" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,141,250</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zTYaf7L5SBr7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Deferred tax liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">357,757</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zTSesd573E2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total non-current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">357,757</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zRjpF4OyIlf9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total liabilities of discontinued operations of NanoSynex</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,499,007</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reclassified the following statement of operations items to discontinued operations for the years ended December 31, 2023 and
2022, respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zOTptJ3CuNPb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20221231_zx9oSOWhGWM3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_hdei--LegalEntityAxis__custom--NanosynexMember_zgccjshpdKPc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">869,064</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,105,040</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment_hdei--LegalEntityAxis__custom--NanosynexMember_zZERACgexWla" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Goodwill and fixed asset impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,164,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedTotalExpenses_hdei--LegalEntityAxis__custom--NanosynexMember_zmH5vnSWE61" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">869,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,269,040</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zAk6YmXlslPj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on disposal of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,479,010</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0959">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_hdei--LegalEntityAxis__custom--NanosynexMember_zMk686AGWUY8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">(BENEFIT) PROVISION FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(357,757</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(271,622</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zEcbOD2Rc3z4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">LOSS FROM DISCONTINUED OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,990,317</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,997,418</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_hdei--LegalEntityAxis__custom--NanosynexMember_zZ5uISHWCvCh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Loss attributable to noncontrolling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(343,038</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,394,100</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zbH1l6INY484" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">NET LOSS ATTRIBUTABLE TO STOCKHOLDERS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,647,279</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,603,318</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company recorded a loss on deconsolidation of NanoSynex in its consolidated financial statements
for the years ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">Loss on deconsolidation of NanoSynex</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value of NanoSynex interest retained</td><td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98E_ecustom--DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_z5EXg1W5lC7f" style="text-align: right" title="Fair value of Nan-Synex interest retained"><span style="-sec-ix-hidden: xdx2ixbrl0973">&#8212;</span></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Net assets deconsolidated</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zipg4Uspz2kf" style="width: 16%; text-align: right" title="Net assets deconsolidated">(2,768,403</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Non-controlling interest share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zycwxuIdu0u" style="text-align: right" title="Non-controlling interest share">1,235,443</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated other comprehensive income attributable to NanoSynex</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_z3pfPwc5XUqe" style="text-align: right" title="Accumulated OCI attributable to NanoSynex">131,891</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forgiveness of debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zairUjzSigPa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forgiveness of debt">(3,077,941</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss from deconsolidation of NanoSynex</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zW9JtpnpW2f8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Loss from deconsolidation of NanoSynex">(4,479,010</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember', window );">Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zRICwWBIIOpg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets and liabilities classified in discontinued operations for Qualigen, Inc. as of December 31, 2022 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span id="xdx_8BB_z8eP3ft272Ub" style="display: none">ASSETS
AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zOY75KWN9c0f" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_zGKYfYaxTuP6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,246,482</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_zHdqUvOvAWj4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">512,088</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_iI_zHtJnaXnk68d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Inventory, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,586,297</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_zUgM1ml5g8S6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104,132</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zIEHIrtrpUWh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current assets of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,448,999</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets_iI_zHU6IGWDB8Y3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,422,538</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_iI_zKbRdheWsea" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289,696</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_iI_zIDSZ58seAhc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145,702</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_iI_zMkyyWT4oEha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,334</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_iI_zjRDEs67Ztx3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Total non-current assets of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,876,270</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--TotalAssetsOfDiscontinuedOperations_zEMDVnMkIPPd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total assets of discontinued operations of Qualigen, Inc.</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,325,269</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_zHmjfZc3mAO" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">236,470</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedVacation_iI_zFUrYTtBMubd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187,906</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_iI_z9mMXvu4yod" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">518,766</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_iI_zCPQARiRXiq9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred revenue, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,161</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_iI_z4V9woU1rXdh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Operating lease liability, current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">240,645</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_z3PO2u2XYjzb" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Total current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,299,948</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_iI_zQQ6Ddu84EN4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,301,919</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_iI_zonhoHs0imS" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Deferred revenue, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">49,056</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_iI_zhBTeigkBoW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total non-current liabilities of discontinued operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,350,975</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--TotalLiabilitiesOfdiscontinuedOperations_zPfVDec32Sy2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Total liabilities of discontinued operations of Qualigen, Inc.</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,650,923</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reclassified the following statement of operations items to discontinued operations for the years ended December 31, 2023 and
2022, respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zHVOVMBBvRg2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zZgIAXsbIcn3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Years Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">REVENUES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedOperationNetProductSales_z80f30iqchab" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; width: 60%; text-align: left">Net product sales</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">3,661,121</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">4,983,556</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_z5vtcVatxqJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Total revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,661,121</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,983,556</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_zO8Rbrocq78c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cost of product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,551,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,302,755</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_z70FNxYXKUU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">610,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">561,047</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_zvOj8wb280n3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,245,973</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment_zRBHa9jfx3Yf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Sales and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">405,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">950,420</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedSalesAndMarketing_z4yk1rxelthj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Goodwill and fixed asset impairment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedTotalExpenses_zFXxpOret2x8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,774,118</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,135,195</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">OTHER EXPENSE (INCOME), NET</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease_zMxym9pZFS8c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on disposal of equipment held for lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63,302</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_ztT4uefCVgFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest (income) expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,751</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_znvkUZyg6kO" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,898</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,125</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal_zCYNcNK7eRr8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Loss on fixed asset disposal</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_z5ZI3qdus78" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total other expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,704</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,876</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_zoGT3t7RNRC8" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(171,701</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,142,763</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc._zjz18nM1MRD1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Gain on sale of Qualigen, Inc., net of tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,876,778</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_zUCJBATU4V7f" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">INCOME (LOSS) FROM DISCONTINUED OPERATIONS OF QUALIGEN, INC.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,705,077</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,142,763</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company recorded a gain on the sale of Qualigen, Inc. in its consolidated financial statements
for the years ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Gain on sale of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Qualigen, Inc.</p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Fair value of consideration received</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived_c20230101__20231231_zopQLsek6o52" style="width: 16%; text-align: right" title="Fair value of consideration received">5,489,337</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Working capital adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment_c20230101__20231231_zgKCXMukPacc" style="text-align: right" title="Working capital adjustment">235,402</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total Assets of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalAssets_iI_c20231231_z7F0kPUQmzjf" style="text-align: right" title="Total Assets of discontinued operations">(4,225,562</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total Liabilities of discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_iI_c20231231_zZB0sSvCh5Le" style="text-align: right" title="Total Liabilities of discontinued operations">3,005,407</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Transaction expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationTransactionExpenses_c20230101__20231231_zoV99ipBQx9j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transaction expenses">(627,806</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Gain on sale of Qualigen, Inc.</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_c20230101__20231231_zQ7H97dMMNFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Gain on sale of Qualigen, Inc.">3,876,778</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_NanosynexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_NanosynexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235412430496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zFErq1PZDlN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses and other current liabilities consisted of the following at December 31, 2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8BA_zjGznIpol2O9" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zHHxTMsGUIh" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231_zQSJfkKD45Cc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_ecustom--AccruedCompensation_iI_pp0p0_maALCzkYM_zpGjW49FxaAe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Board compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">129,499</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">70,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestPayableCurrent_iI_pp0p0_maALCzkYM_zDHR8SsSsiFg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest (Convertible debt)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,829</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzkYM_zcthN6R2i8Tc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">License fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,130</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCzkYM_z7Xgssvzn5lg" style="vertical-align: bottom; background-color: White">
    <td>Payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,247</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzkYM_zpF47Vp9U8U1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,775</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">136,203</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCzkYM_zDTbB2YyfHzf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,402</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329,412</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maALCzkYM_zxhaJd2lGG5g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,040</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzkYM_zXgg7XyiUQh5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,850</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,698</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzkYM_zw6s9z17hSI1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and
    other current liabilities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">560,006</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">864,559</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235411407184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisclosureWarrantLiabilitiesAbstract', window );"><strong>Warrant Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF WARRANTS ACTIVITY</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z18l24KyS6ta" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity in liability classified warrants for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8BC_zJNRDQGyMj46" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLGBKDH5jCM8" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">3,849,571</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvoji3It3bBh" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">1.53</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">$<span id="xdx_902_ecustom--RangeOfExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_z7jM54PAtM0l" title="Range of Exercise Price, Beginning">1.32</span> - $<span id="xdx_90D_ecustom--RangeOfExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zDCVhsWUI7j2" title="Range of Exercise Price, Beginning">1.65</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zt8ioksd4Nj2" title="Weighted - Average Remaining Life (Years) Outstanding">3.9</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfoQPq9CTgsi" style="text-align: right" title="Number of Shares, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1080">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zV5xLhqe6H7g" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1082">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z2rOK24p9BB4" style="text-align: right" title="Number of Shares, Warrants Forfeited">(2,751,976</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAAPPHoSgwma" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited">1.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAXKcmhEslUf" style="text-align: right" title="Number of Shares, Warrants Expired">(1,097,595</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbpd7h2BKfgh" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired">1.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--RangeOfExercisePriceExpired_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSEHJRBUfAQd" title="Range of Exercise Price, Expired">1.32</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVpJAcv8Ar4l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted">455,623</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1Z7EYrTSynd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">0.73</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePriceGranted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSiMilgKv4Il" title="Range of Exercise Price, Granted">0.73</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zUL1lFj2TI7d" title="Weighted-Average Remaining Life (Years) Outstanding">0.49</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zKnMToyCwnDb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">455,623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zIOYWv2qwJol" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">0.73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1XzwHeUAWF8" title="Range of Exercise Ending">0.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zorsiQiwHZs1" title="Weighted-Average Remaining Life (Years) Outstanding">0.49</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7TWvyYNgRKj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">455,623</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRkqheAxivS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">0.73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iE_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSfXDRtCkEga" title="Range of Exercise Price, Exercisable">0.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zzbe4oYcHff1" title="Weighted-Average Remaining Life (Years) Exercisable">0.49</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity in the Common Stock Warrants received in exchange for the Series C Warrants for the year ended
December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Weighted&#8211;
Average</b></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Exercise</b></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Price</b></p></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Range
of</b></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Exercise</b></p>
                                                                                                         <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Price</b></p></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Weighted&#8211;Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Remaining</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Life (Years)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Total outstanding &#8211;December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbVsTqAi6BIl" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">248,162</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcm9ENx2x3Jj" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">7.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_90F_ecustom--RangeOfExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAEfVtKR2M2a" title="Range of Exercise Price, Beginning">7.20</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zm0YDjme8jk3" title="Weighted-Average Remaining Life (Years) Outstanding">2.00</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z3h5SS635N6i" style="text-align: right" title="Number of Shares, Warrants Exercised">(536</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvPJJa7NcJge" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">7.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zERGmqx8Uiga" style="text-align: right" title="Number of Shares, Warrants Forfeited">(247,625</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zITd2jiWwCv8" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited">7.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZHXjaE4aeB2" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1134">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zv3z6B66dCfe" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1136">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zb1pcj7U3ZZ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted">3,849,570</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwDH4H3gphs4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted">1.53</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgaSi0tLfGad" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">3,849,571</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zUB0yjZJU51a" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">1.53</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--RangeOfExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zCidTcXmjyz1" title="Range of Exercise Ending">1.32</span> - <span id="xdx_901_ecustom--RangeOfExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zosRg7CkBXB9" title="Range of Exercise Ending">1.65</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z058uCfQcjNg" title="Weighted-Average Remaining Life (Years) Outstanding">3.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRMnQL7QMLje" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">1,349,571</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfqXh6Hdo6Ia" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">1.32</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5pCfLasIRn4" title="Range of Exercise Price, Exercisable">1.32</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbFX0nxgMxMb" title="Weighted-Average Remaining Life (Years) Exercisable">1.00</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock', window );">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</a></td>
<td class="text"><p id="xdx_894_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_zaRegjGYHHA5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the Company&#8217;s fair value hierarchy for its Common Stock Warrant liabilities measured at fair value on
a recurring basis as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span id="xdx_8B1_zf8I8IX64Hpe" style="display: none">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Quoted</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Market</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Significant</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Prices for</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Other</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Significant</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Identical</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Observable</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Unobservable</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Assets</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Inputs</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">Inputs</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Stock Warrant liabilities</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Balance as of December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zk2S50r1wUo9" style="width: 12%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1162">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwF17oo6oJ0b" style="width: 12%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1164">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3YSTwRWIp9f" style="width: 12%; text-align: right" title="Fair value for warrant liabilities">3,622,647</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231_zUZVCfHgsG3d" style="width: 12%; text-align: right" title="Fair value for warrant liabilities">3,622,647</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQy3t8j7Pkc5" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1170">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbGSQkPGKFtl" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1172">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmr2VS7RgnY3" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1174">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231_zjrQMRAP23P6" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"><span style="-sec-ix-hidden: xdx2ixbrl1176">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair value of warrant reclassified from liabilities to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3WJcEyKG0Gf" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity"><span style="-sec-ix-hidden: xdx2ixbrl1178">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zOjcm6ivjhDg" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity"><span style="-sec-ix-hidden: xdx2ixbrl1180">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zBfZXoBC0lmd" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity">(1,626,694</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231_zYtjNdEmpwHk" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity">(1,626,694</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on debt extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLxxDu42GPxj" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment"><span style="-sec-ix-hidden: xdx2ixbrl1186">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdVYXEMqMZ2h" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment"><span style="-sec-ix-hidden: xdx2ixbrl1188">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGifwwzAL4Hk" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment">94,116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231_zMx7CBzLSDK" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment">94,116</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Gain on change in fair value of warrant liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6PA4TroVkH4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1194">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEfdE8kUk6y" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1196">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuqXgmjIP9R6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities">(2,035,469</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231_z8TZTLxXZBJg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities">(2,035,469</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zA2x9DGqSMv5" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1202">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zR9Pz6ubn7Ll" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1204">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjCqS6yr3EFg" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities">54,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231_zABKNkMvGdd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities">54,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock', window );">SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_z931rg3adps8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the assumptions used in, and the weighted average and the range of assumptions used in estimating the fair value of warrant
liabilities (weighted average calculated based on the number of outstanding warrants on each issuance) as of December 31, 2023 and December
31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8B9_z96BAMXS0VHi" style="display: none">SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Actual</td><td>&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Range</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 48%">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJCfIiEqdgMe" title="Risk-free interest rate">5.13</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 14%; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zxlMDbpDQmzg" title="Risk-free interest rate">3.906</span>% &#8212; <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_za3tnsv0nytg" title="Risk-free interest rate">4.628</span>%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_z0l4hoNa3Vl5" title="Fair value assumptions, measurement input, percentages">4.15</span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility (peer group)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zb3YVa1Xbt5i" title="Expected volatility">68.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zcvwFxKOAXf5" title="Expected volatility">88</span>% &#8212; <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z7fyT5FHPUg" title="Expected volatility">103</span>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxuFn49vKpAe" title="Expected volatility">98</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Term of warrants (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zehqffzt9hZe" title="Term of warrants (in years)">0.49</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuG1mYphnsXg" title="Term of warrants (in years)">.90</span> &#8212; <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zbVrTNrWKuk8" title="Term of warrants (in years)">5.48</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6bowoNviRDa" title="Fair value assumptions, measurement input, term">3.9</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zUID2ZCOsYb1" title="Expected dividend yield">0.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJ5NamsSDabb" title="Expected dividend yield">0.00</span>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zoGx3mIIsM7h" title="Fair value assumptions, measurement input, percentages">0.00</span></td><td style="text-align: left">%</td></tr>
  </table>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosureWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosureWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Assumptions Of Warrant Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Fair Value Hierarchy For Warrant Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235411476064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE DEBT- RELATED PARTY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ConvertibleDebtTableTextBlock_zOeh0D24vQXj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
senior convertible debt comprises the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span id="xdx_8B8_zH4MDVn648ug" style="display: none">SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zB5SrNpsgSZ5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zJufdsid8uN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SecuredDebt_iI_zL6i72Wp3Pah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Senior convertible debenture</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,418,922</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,300,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_znbJgSde29C9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Discount on convertible debenture</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(119,706</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,239,803</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_zQZXTcRUnVne" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total convertible debt-related party</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,299,216</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">60,197</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235509082352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z3OXkzOiCRvi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potentially dilutive securities have been excluded from diluted net loss per share as of December 31, 2023 and 2022 because
their effect would be anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span id="xdx_8B7_zlzE769K8vK4" style="display: none">SCHEDULE
OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zSIovIChNxfh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zQLGPWwKm7yg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Years Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zJiUFN0xyJHh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; width: 60%; text-align: left">Net loss used for basic earnings per share</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(13,417,212</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">(18,640,543</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zIibE0Bcgfv9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Basic weighted-average common shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,072,709</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,840,340</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_zE5ERx10oJ9a" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Dilutive potential shares issuable from convertible debt, stock options and warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1359">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1360">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zhTDRiIz5Ita" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Diluted weighted-average common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,072,709</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,840,340</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235414642448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ScheduleOfReservedSharesTableTextBlock', window );">SCHEDULE OF RESERVED SHARES</a></td>
<td class="text"><p id="xdx_89A_ecustom--ScheduleOfReservedSharesTableTextBlock_zwTy7UYVbLH4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_z6DIgiLX7U56" style="display: none">SCHEDULE
OF RESERVED SHARES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20231231_zHoQ9JF85b0f" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5WBLsQhG06k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Exercise of issued and future grants of stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">755,715</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__custom--ConversionOfConvertibleDebtMember_zNUiJ3e0hid5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Conversion of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,943,729</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zr39N6ecJFsc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercise of stock warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,081,717</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zjAWdC7CbToj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,781,161</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zs8yiFww238k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December
31, 2023, and changes during the twelve months then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zFOnad0Z0GNb" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted&#8211;Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted&#8211;Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Total outstanding &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkIsHDFTE0Oi" style="width: 14%; text-align: right" title="Number of shares, options outstanding, beginning">608,012</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ziTkSGk7A1vf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning">35.02</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z1A2GvKClF0g" title="Range of Exercise price, Options Outstanding">5.14</span> - $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_z09sF6T2A68f" title="Range of Exercise price, Options Outstanding">51.30</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zsPcTXYTQkFk" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning">8.09</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zYz3AeE2OExk" style="text-align: right" title="Number of shares, options granted"><span style="-sec-ix-hidden: xdx2ixbrl1491">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zIRryovNL914" style="text-align: right" title="Weighted average exercise price, options granted"><span style="-sec-ix-hidden: xdx2ixbrl1493">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zZU1qmiE3F8" style="text-align: right" title="Number of shares, options expired"><span style="-sec-ix-hidden: xdx2ixbrl1495">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ziujHsfwWzMa" style="text-align: right" title="Weighted average exercise price, options expired"><span style="-sec-ix-hidden: xdx2ixbrl1497">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zzTGWHF4F2Tk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options forfeited">(209,088</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zpmO8ELPhGq9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited">34.71</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zbWJhn9PPoIj" title="Range of Exercise price, Options Forfeited">5.14</span> - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zEkZKn9nbud6" title="Range of Exercise price, Options Forfeited">51.30</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zN2jD7JuHcYa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options Outstanding at Ending">398,924</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBrjiTdDhbO2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending">35.21</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zvj28x2nVpl" title="Range of Exercise price, Options Outstanding">5.14</span> &#8212; $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zvf5zIhj1efd" title="Range of Exercise price, Options Outstanding">51.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkBJbEz2epD5" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending">7.06</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Exercisable (vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zpG7XaKkSemc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)">320,918</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zaeMd4Xni5We" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of exercise price, options exercisable (vested)">41.97</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zpVEguyqgJAa" title="Range of exercise price, options exercisable (vested)">5.14</span> &#8212; $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zkGjM8ZYcPug" title="Range of exercise price, options exercisable (vested)">51.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zKKIJUisZMfh" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)">6.77</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Non-Exercisable (non-vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjNvfdbF1y98" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)">78,006</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zG2CA3CSl6v8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)">7.36</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z91mmxAdBLH3" title="Range of exercise price, options non-exercisable (non-vested)">5.14</span> - $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zIpg0XstkxAf" title="Range of exercise price, options non-exercisable (non-vested)">32.90</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zJwkYBBjO96" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)">8.36</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that were outstanding at December 31, 2022, and changes during the twelve months then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Range
of</b></span></p>
                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p>
                                               <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zWIRkBiiTiEg" style="width: 14%; text-align: right" title="Number of shares, options outstanding, beginning">484,186</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zlVZE02OJEza" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning">60.70</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">$<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zGiHtX3PY4j3" title="Range of Exercise price, Options Outstanding">12.40</span> &#8212; $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zVqt1XV08gM6" title="Range of Exercise price, Options Outstanding">14,657.50</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkE37PmUN0sh" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning">8.52</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zP3cmn02hWCb" style="text-align: right" title="Number of shares, options granted">134,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zrek5FW0Qc76" style="text-align: right" title="Weighted average exercise price, options granted">5.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zm71m9uYtMf7" title="Range of Exercise price, Options Outstanding">5.14</span> &#8212; <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zlYsjj8aE7xc" title="Range of Exercise price, Options Outstanding">10.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zza9MJn3zL58" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted">5.99</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBjp6n0FxRok" style="text-align: right" title="Number of shares, options expired">(9,379</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zM2Q23Z80GFc" style="text-align: right" title="Weighted average exercise price, options expired">932.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zCChvyUDs58k" title="Range of Exercise price, Options Outstanding">57.50</span> - <span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zbVQ4jXmBnl1" title="Range of Exercise price, Options Outstanding">14,657.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zxMo7qCM7wNc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options forfeited">(1,264</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zVJyXMhMu384" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited">22.64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zIDOyHLqNdt1" title="Range of Exercise price, Options Forfeited">5.14</span> - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_z7zVE50RAY8h" title="Range of Exercise price, Options Forfeited">49.70</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z3yGc3Sl9Gqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options Outstanding at Ending">608,012</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zqrDsAW48I64" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending">35.02</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z2xuq1t7WRTg" title="Range of Exercise price, Options Outstanding">5.14</span> &#8212; $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zqHOPdJQSIl3" title="Range of Exercise price, Options Outstanding">51.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zARB0aqcuL8c" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending">8.09</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Exercisable (vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zXrgdO5t8oe4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)">288,704</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zprySz4oLgx" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of exercise price, options exercisable (vested)">46.32</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zmcvWVbJnsJh" title="Range of exercise price, options exercisable (vested)">12.40</span> &#8212; $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zD2GTW2aYwh2" title="Range of exercise price, options exercisable (vested)">51.30</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zn9slRtEYqG1" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)">7.59</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Non-Exercisable (non-vested)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z1apKxQ2FgBb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)">319,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zLrGcJzs1uV" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)">24.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zLKKejEF9B8l" title="Range of exercise price, options non-exercisable (non-vested)">5.14</span> &#8212; $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zKV52WE0uOo5" title="Range of exercise price, options non-exercisable (non-vested)">10.50</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zbXPeuyw7Ib1" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)">8.59</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zGHR15bCdKc4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B5_zAEDyLzxwr3i" style="display: none">SCHEDULE
OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Years Ended December 31,</b></span></p>

</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Expected dividend yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zQSr5rVaOadd" style="width: 16%; text-align: right" title="Expected dividend yield">0.00%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected stock-price volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zcPUuOZ6PVR1" style="text-align: right" title="Expected stock-price volatility">103%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zCM8i4TCTp58" title="Risk-free interest rate, minimum">1.58</span>% &#8212; <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_ztgDn7Z1c4V1" title="Risk-free interest rate, minimum">3.77</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected average term of options (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zLv60PDr8SAl" title="Expected average term of options (in years)">5.99</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MinimumMember_z41UFMKa2Jvk" title="Stock price">5.14</span> - <span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MaximumMember_zQmQktOllcn9" title="Stock price">10.50</span></td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_z4fcGluRwcLf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded stock-based compensation expense and classified it in the Consolidated Statements of Operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zCQVTkRPAy18" style="display: none">SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_zWeGmRQVC7Vf" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20220101__20221231_zHKS76KQYz95" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zzLhM2YRzOl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">939,228</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,649,649</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrifLxBJYHPe" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">159,305</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">834,395</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zpHZ3aJEeIDd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,098,533</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,484,044</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_SummaryOfWarrantActivityTableTextBlock', window );">SCHEDULE OF WARRANT ACTIVITY</a></td>
<td class="text"><p id="xdx_898_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6GUf15Mz9we" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zVoQ4hpIQza" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
                                                                                             <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom">Common Stock</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zblP58bGJTgk" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">179,046</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zAphciBbsr2g" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">9.12</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zVWAipJ9nxTk" title="Range of exercise price - beginning">1.32</span> &#8212; $<span id="xdx_90A_ecustom--RangeOfExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zcrVGzRoA0U" title="Range of exercise price - beginning">25.40</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zATa9y3tLSWk" title="Weighted Average Remaining Life (Years) - outstanding">1.73</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Granted to advisor and its designees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zABUY8DGxu79" style="text-align: right" title="Number of shares, warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1714">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zaV5yahtMok5" style="text-align: right" title="Weighted average exercise price per share warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1716">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_za5wV3NENpWk" style="text-align: right" title="Number of Shares, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1718">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zyHYwqNDa7xl" style="text-align: right" title="Weighted average exercise price per share warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1720">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsy6bu1YZI31" style="text-align: right" title="Number of Shares, Warrants Expired">(60,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z07igXGcGk5d" style="text-align: right" title="Weighted average exercise price per share warrants expired">6.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_ecustom--RangeOfExercisePriceExpired_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zh3G3jVWMf69" title="Range of exercise price, expired">6.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1XLk7Se0jXc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1728">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zoiiH9doHS5g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1730">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztLDDtjzLI24" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">119,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zvcMxxZlzkYc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">10.69</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_909_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z65Y5bhD4Bb4" title="Range of exercise price - ending">0.73</span> &#8212; $<span id="xdx_90B_ecustom--RangeOfExercisePriceOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zl74jsOcklha" title="Range of exercise price - ending">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfjVOPoa6mBi" title="Weighted Average Remaining Life (Years) - outstanding">1.25</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziITM2nIy0Bc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">119,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9I7XEbBX41" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">10.69</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zGpi0HjkqS9e" title="Range of exercise price, exercisable">0.73</span> &#8212; $<span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z68Cyzk7jgb" title="Range of exercise price, exercisable">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zxMf8XuvRAxg" title="Weighted Average Remaining Life (Years) Exercisable">1.25</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zUyd0KSTciX2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1752">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfeqZe9NdTp5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1754">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zNklYsKDniK7" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1756">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -10pt; width: 36%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zhT8uY9khi6g" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">179,046</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3EkFTjq7eo4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">15.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90A_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zM8mOXJfgBG7" title="Range of exercise price - beginning">11.10</span> &#8212; $<span id="xdx_90D_ecustom--RangeOfExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zqDFez1h6oFb" title="Range of exercise price - beginning">25.40</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zncdrQjLZiHj" title="Weighted Average Remaining Life (Years) - outstanding">2.64</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Granted to advisor and its designees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4mYEWAlcD9d" style="text-align: right" title="Number of shares, warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1768">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zn7zpQy6lX8c" style="text-align: right" title="Weighted average exercise price per share warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1770">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGk8OwJR8lgk" style="text-align: right" title="Number of Shares, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1772">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7Cl3FRLOAx3" style="text-align: right" title="Weighted average exercise price per share warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1774">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zOHYQClIytwc" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1776">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGp4H3CPLHmb" style="text-align: right" title="Weighted average exercise price per share warrants expired"><span style="-sec-ix-hidden: xdx2ixbrl1778">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zQFsnR4DvQ05" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1780">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zVGeXTuAvgMa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1782">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdmXJDFfiAc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">179,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zk2SAluuWPo2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">9.12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z21SEWJvbacf" title="Range of exercise price - ending">1.32</span> &#8212; $<span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zi4vL1vjSsel" title="Range of exercise price - ending">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zS1GFYyy2eTk" title="Weighted Average Remaining Life (Years) - outstanding">1.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7kgmnZyJDL3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">179,046</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zzbLVt5DRJgf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">9.12</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z66oet1uEKP5" title="Range of exercise price, exercisable">1.32</span>- $<span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zLYXiXmkFyui" title="Range of exercise price, exercisable">25.40</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zavWyHEIYK5l" title="Weighted Average Remaining Life (Years) Exercisable">1.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zO9vfILQfrI2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMbWmp31gAJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1806">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1kvtOKXwtP4" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1808">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember', window );">Non Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_SummaryOfWarrantActivityTableTextBlock', window );">SCHEDULE OF WARRANT ACTIVITY</a></td>
<td class="text"><p id="xdx_893_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zBR5N0UoTtm" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zWaJcYtP6cid" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211;Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zBrhwrtA08f5" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning">547,003</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z16lgZwUetj" style="width: 12%; text-align: right" title="Weighted Average exercise price, warrants outstanding beginning">19.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90F_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6GP6w0701Se" title="Range of exercise price">1.32</span> - $<span id="xdx_90C_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zrjLOhUdlhJ1" title="Range of exercise price">20.00</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6gEOFOhuxa1" title="Weighted average remaining life (Years) exercisable">0.33</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Legacy Ritter warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z753JNxyM1al" style="text-align: right" title="Number of shares legal ritter warrants"><span style="-sec-ix-hidden: xdx2ixbrl1898">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSJEhpZPXz7k" style="text-align: right" title="Weighted Average exercise price, legal ritter warrants"><span style="-sec-ix-hidden: xdx2ixbrl1900">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Reclassification of Alpha Warrant from warrant liabilities to equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zXLV6IWbAiWf" style="text-align: right" title="Number of shares, warrants reclassification of Alpha warrant from warrant liabilities to equity">2,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zcoxUHSQUkW1" style="text-align: right" title="Weighted Average exercise price, reclassification of Alpha warrant from warrant liabilities to equity">0.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6JkInoHrxci" title="Range of exercise price, reclassification of Alpha warrant from warrant liabilities to equity">0.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zXc9CV8ffE54" style="text-align: right" title="Number of Shares, Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1908">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfE1qxUbr91" style="text-align: right" title="Weighted average exercise price, warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1910">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zyu7TMkrjFw" style="text-align: right" title="Number of Shares, Warrants Expired">(539,953</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSctCIyTwZT9" style="text-align: right" title="Weighted average exercise price, warrants expired">20.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMLIYRkHsNGk" title="Range of exercise price, expired">20.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z255AwZBtLR" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1918">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zc54vnC1hR5b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1920">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zNDjU6eYyCmc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending">2,507,050</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwuIMebw57Nf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average exercise price, warrants outstanding ending balance">0.73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zn3TozeyExo7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">2,507,050</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zphXwBoGbAQa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">0.73</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zQg5veEAr0a1" title="Range of exercise price, exercisable">0.73</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z0XUjsjeZ0H3" title="Weighted average remaining life (Years) exercisable">4.47</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGEjBufrUuo3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1934">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuZLFbaOM9a6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1936">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted&#8211; Average Exercise
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Range of</p>
                                                                                                    <p style="margin-top: 0; margin-bottom: 0">Exercise</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted&#8211; Average Remaining</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Life (Years)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zO7Cg7lGZ0T9" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning">554,914</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zg0hga9tUFDj" style="width: 12%; text-align: right" title="Weighted average exercise price, warrants outstanding beginning">20.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUg4iabg9xKe" title="Range of exercise price">11.10</span>&#8212; <span id="xdx_90E_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zT1SmbA6nB61" title="Range of exercise price">37.78</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zoksFYh7JX2g" title="Weighted average remaining life (Years) exercisable">1.32</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Legacy Ritter warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z3DaDuZucKPb" style="text-align: right" title="Number of shares legal ritter warrants"><span style="-sec-ix-hidden: xdx2ixbrl1948">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zO6BRIKiu9Yi" style="text-align: right" title="Weighted average exercise price, legal ritter warrants"><span style="-sec-ix-hidden: xdx2ixbrl1950">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJHb6Nismj6g" style="text-align: right" title="Number of shares, warrants granted">331,464</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zLMahoHMM1Ag" style="text-align: right" title="Weighted average exercise price, warrants granted">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--RangeOfExercisePriceExercisableGranted_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZn1SgKiH9h8" title="Range of exercise price, granted">0.01</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgFA4ipoXUD2" style="text-align: right" title="Number of Shares, Warrants Exercised">(331,464</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zjS2TWnu8HI3" style="text-align: right" title="Weighted average exercise price, warrants exercised">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_ecustom--RangeOfExercisePriceExercised_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfUq2hkkhWSh" title="Range of exercise price, exercised">0.01</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTUse044gCFk" style="text-align: right" title="Number of Shares, Warrants Expired">(7,911</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zpLxlMN7pXK6" style="text-align: right" title="Weighted average exercise price, warrants expired">37.78</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_ecustom--RangeOfExercisePriceExercisableExpired_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSPSLF3Ce2dg" title="Range of exercise price, expired">37.78</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJXpTgZPuKHk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1970">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zh0txminHaOl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1972">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_ecustom--RangeOfExercisePriceForfeited_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z8tIuIDKsdY8" title="Range of exercise price, forfeited">0</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdXwh1vfSNjd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending">547,003</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgxS2qW5u3X5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants outstanding ending balance">19.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zbnws0F622Z" title="Range of exercise price">1.32</span> - <span id="xdx_906_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJe2u5fV8yJ6" title="Range of exercise price">20.00</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zL8m6zhtMyU9" title="Weighted average remaining life (Years) exercisable">0.33</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuBf0CI8zkRj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">547,003</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwGx9fu8t437" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">19.76</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zrfdrjj9x2b" title="Range of exercise price, exercisable">1.32</span> - <span id="xdx_908_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zHgslEXoYM7h" title="Range of exercise price - Exercisable">20.00</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZvOqXPsGhT7" title="Weighted average remaining life (Years) exercisable">0.33</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxV5nkyftnZi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1996">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zPfNZv7sMpv3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1998">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfReservedSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Reserved Shares [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfReservedSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SummaryOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Warrant Activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SummaryOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235497670768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_znNnnEo4tKLd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents domestic and foreign components of consolidated loss before income taxes from continuing operations for the
periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span id="xdx_8BC_zLVxJoxV0zt9" style="display: none">SCHEDULE
OF DOMESTIC AND FOREIGN COMPONENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zroRJrFub7S4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">2023</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_zTWpwWAqnQoi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zi07Z33bFCFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(12,479,803</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(13,887,914</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zLt9DRSh7xpk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2031">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2032">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zQ14WvxvlJa4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss before provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(12,479,803</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,887,914</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zCwKsoCY7LYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the statutory income tax rates and the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zJSrkVjWc5O4" style="display: none">SCHEDULE
OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_z8vka4fOhIJg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20220101__20221231_z3Q4fMFAj0x6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zuGzWVPbb409" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Statutory federal income tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_zfIwNUKyYcia" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.76</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.50</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_maABC_zePFyfdYh9qb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-0.64</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-2.09</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_maABC_zvOKfgEE5Ia7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NOL expiration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-5.26</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-19.88</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_zbjEnCHJzTn4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.92</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.71</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_maABC_z1D7Vrub6YEc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maABC_zWBv6eerD4l5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_pid_dp_uPure_maABC_zhe4RJi20f5e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.35</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_pid_dp_uPure_maABC_z3jsT0z4L993" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax impact of convertible debenture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-5.46</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.37</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_pid_dp_uPure_maABC_zKHOwMPbHVz3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax impact of divestiture</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-229.26</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.01</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationTrueUp_pid_dp_uPure_maABC_z7WhUdWrI7Sa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>True-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-10.65</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.24</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_zCt7BzuD2EFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">222.28</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-17.91</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_mtABC_z59jjaWlBCb2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income taxes provision (benefit)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.04</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-0.05</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF PROVISION FOR INCOME TAXES</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zHUvtkkhZDhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense for the year ended December 31, 2023 and 2022 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zZUShjraxBOk" style="display: none">SCHEDULE
OF PROVISION FOR INCOME TAXES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_zVKL8yGFKLvd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_zuiJFykVdqQe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBz1MC_zmZ4dcINcYNd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">U.S. Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(10,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2081">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBz1MC_zV7QvzcEmUPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">U.S. State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBz1MC_zE9wn5sLbkSg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total current provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzCKf_zz2EpiDIeaM3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">U.S. Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,128,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(236,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzCKf_zDJeFJdwOUX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">U.S. State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,697,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,252,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzCKf_maITEBzWbu_z1ABCzTJbD76" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total deferred benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,825,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,488,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzWbu_zU5dkRo9vuZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in valuation allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,825,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,488,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3d_mtITEBzWbu_zPlvv7UdRbOc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Total provision (benefit) for income taxes</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,000</td><td style="text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zU271WlknDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of deferred tax assets and liabilities are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zRjLOzKUlSAh" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zo0eKliPjx44" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20221231_zUhsCaslYAy2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTATDzYdX_zXgzvBZDbCC2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,644,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">32,587,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTATDzYdX_zhEvn7CTUbf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,970,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,857,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DefferdTaxAssetsAccruedExpenses_iI_maDTATDzYdX_zbl8ZIJmlpmi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,020,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTATDzYdX_zz9WMcVBhkIh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Patent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2115">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2116">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTATDzYdX_zLOm9WndY0v1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,004,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,069,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentExpenses_iI_maDTATDzYdX_zR0akY1zAry" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,102,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,196,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTATDzYdX_zSinl3k6I6s6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2124">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">280,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iTI_mtDTATDzYdX_maDTAGzJfc_z9gjg4N7CKhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total deferred income tax assets</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,788,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">46,009,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzOxa_zGB9JwhXUJRk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2130">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_maDITLzOxa_zuj0yBDZZ4yh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Right-of-use asset</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2133">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(382,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzOxa_msDTAGzJfc_zonkDxVfkkZ4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total deferred income tax liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2136">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(395,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJfc_maDTALNzbeu_zxiB9qCTVw0e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net deferred income tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,788,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,614,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzbeu_zeGtvy75BvAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,788,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45,614,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNTI_di_mtDTALNzbeu_zdG5p2mx3xAe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax asset, net of allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2145">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2146">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235498434368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">These warrants were subsequently exercised on September 13, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses on construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember', window );">Pre-funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock</a></td>
<td class="nump">331,464<span></span>
</td>
<td class="nump">331,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="nump">381,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">NanoSynex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interests acquired</a></td>
<td class="nump">52.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">NanoSynex Ltd [Member] | Series A-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period shares acquisitions</a></td>
<td class="nump">2,232,861<span></span>
</td>
<td class="nump">2,232,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">NanoSynex Ltd [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, value, acquisitions</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235508652496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND GOING CONCERN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 3,165,985<span></span>
</td>
<td class="nump">$ 401,803<span></span>
</td>
<td class="nump">$ 3,165,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="nump">103,385,172<span></span>
</td>
<td class="nump">116,802,384<span></span>
</td>
<td class="nump">103,385,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,304,263<span></span>
</td>
<td class="nump">$ 13,247,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235414474384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 566,011<span></span>
</td>
<td class="nump">$ 1,329,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">25,053<span></span>
</td>
<td class="nump">37,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableInvestmentSale', window );">Receivable from sale of Qualigen, Inc.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PreapaidResearchAndDevelopmentExpenses', window );">Prepaid research and development expenses</a></td>
<td class="nump">173,900<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 764,964<span></span>
</td>
<td class="nump">$ 1,366,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PreapaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preapaid research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PreapaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableInvestmentSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable from sale of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableInvestmentSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235497708800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OTHER NON CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Funds held in escrow</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_LongtermResearchAndDevelopmentDeposits', window );">Long-term research and development deposits</a></td>
<td class="nump">416,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other non-current assets</a></td>
<td class="nump">$ 866,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_LongtermResearchAndDevelopmentDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term research and development deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_LongtermResearchAndDevelopmentDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235498042368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,287,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Non-current assets of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,236,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_TotalAssetsOfDiscontinuedOperations', window );">Total assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,524,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,441,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Non-current liabilities of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,708,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_TotalLiabilitiesOfdiscontinuedOperations', window );">Total liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,149,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">(Loss) from discontinued operations</a></td>
<td class="num">(683,008)<span></span>
</td>
<td class="num">(7,140,181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Gain (loss) on disposal of discontinued operations</a></td>
<td class="num">(602,232)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">LOSS FROM DISCONTINUED OPERATIONS</a></td>
<td class="num">(1,285,240)<span></span>
</td>
<td class="num">(7,140,181)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,448,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Non-current assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,876,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_TotalAssetsOfDiscontinuedOperations', window );">Total assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,299,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Non-current liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_TotalLiabilitiesOfdiscontinuedOperations', window );">Total liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">(Loss) from discontinued operations</a></td>
<td class="num">(171,701)<span></span>
</td>
<td class="num">(2,142,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Gain (loss) on disposal of discontinued operations</a></td>
<td class="nump">3,876,778<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">LOSS FROM DISCONTINUED OPERATIONS</a></td>
<td class="nump">3,705,077<span></span>
</td>
<td class="num">(2,142,763)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=QLGN_NanosynexMember', window );">NanoSynex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,838,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Non-current assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,360,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_TotalAssetsOfDiscontinuedOperations', window );">Total assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,199,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,141,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Non-current liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_TotalLiabilitiesOfdiscontinuedOperations', window );">Total liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,499,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">(Loss) from discontinued operations</a></td>
<td class="num">(511,307)<span></span>
</td>
<td class="num">(4,997,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Gain (loss) on disposal of discontinued operations</a></td>
<td class="num">(4,479,010)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">LOSS FROM DISCONTINUED OPERATIONS</a></td>
<td class="num">$ (4,990,317)<span></span>
</td>
<td class="num">$ (4,997,418)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_TotalAssetsOfDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_TotalAssetsOfDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_TotalLiabilitiesOfdiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total liabilities of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_TotalLiabilitiesOfdiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=QLGN_NanosynexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=QLGN_NanosynexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235413931552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,287,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total non-current assets of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,236,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_TotalAssetsOfDiscontinuedOperations', window );">Total assets of discontinued operations of Qualigen, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,524,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,441,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Total non-current liabilities of discontinued operations</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,708,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_TotalLiabilitiesOfdiscontinuedOperations', window );">Total liabilities of discontinued operations of Qualigen, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,149,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL</a></td>
<td class="num">(683,008)<span></span>
</td>
<td class="num">(7,140,181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived', window );">Fair value of consideration received</a></td>
<td class="nump">5,489,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment', window );">Working capital adjustment</a></td>
<td class="nump">235,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets', window );">Total assets of discontinued operations of NanoSynex</a></td>
<td class="num">(4,225,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities', window );">Total liabilities of discontinued operations of NanoSynex</a></td>
<td class="nump">3,005,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses', window );">Transaction expenses</a></td>
<td class="num">(627,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of Qualigen, Inc.</a></td>
<td class="nump">3,876,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">(BENEFIT) PROVISION FOR INCOME TAXES</a></td>
<td class="nump">602,232<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">LOSS FROM DISCONTINUED OPERATIONS</a></td>
<td class="num">(1,285,240)<span></span>
</td>
<td class="num">(7,140,181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Loss attributable to noncontrolling interest</a></td>
<td class="num">(343,038)<span></span>
</td>
<td class="num">(2,394,100)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_NanosynexMember', window );">NanoSynex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,621,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,838,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total non-current assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,360,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,141,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Total non-current liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">869,064<span></span>
</td>
<td class="nump">1,105,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses', window );">Total expenses</a></td>
<td class="nump">869,064<span></span>
</td>
<td class="nump">5,269,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">NET LOSS ATTRIBUTABLE TO STOCKHOLDERS</a></td>
<td class="num">(4,647,279)<span></span>
</td>
<td class="num">(2,603,318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets', window );">Total assets of discontinued operations of NanoSynex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,199,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities', window );">Total liabilities of discontinued operations of NanoSynex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,499,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued vacation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability', window );">R&amp;D grant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty', window );">Short term debt-related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment', window );">Goodwill and fixed asset impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,164,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax', window );">Loss on disposal of discontinued operations</a></td>
<td class="nump">4,479,010<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">(BENEFIT) PROVISION FOR INCOME TAXES</a></td>
<td class="num">(357,757)<span></span>
</td>
<td class="num">(271,622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">LOSS FROM DISCONTINUED OPERATIONS</a></td>
<td class="num">(4,990,317)<span></span>
</td>
<td class="num">(4,997,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Loss attributable to noncontrolling interest</a></td>
<td class="num">(343,038)<span></span>
</td>
<td class="num">(2,394,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained', window );">Fair value of Nan-Synex interest retained</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated', window );">Net assets deconsolidated</a></td>
<td class="num">(2,768,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare', window );">Non-controlling interest share</a></td>
<td class="nump">1,235,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable', window );">Accumulated OCI attributable to NanoSynex</a></td>
<td class="nump">131,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt', window );">Forgiveness of debt</a></td>
<td class="num">(3,077,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation', window );">Loss from deconsolidation of NanoSynex</a></td>
<td class="num">(4,479,010)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember', window );">Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,246,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">512,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,586,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,448,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total non-current assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,876,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_TotalAssetsOfDiscontinuedOperations', window );">Total assets of discontinued operations of Qualigen, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation', window );">Accrued vacation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent', window );">Deferred revenue, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Operating lease liability, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,299,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Total non-current liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,301,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Total non-current liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_TotalLiabilitiesOfdiscontinuedOperations', window );">Total liabilities of discontinued operations of Qualigen, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales', window );">Net product sales</a></td>
<td class="nump">3,661,121<span></span>
</td>
<td class="nump">4,983,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="nump">3,661,121<span></span>
</td>
<td class="nump">4,983,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of product sales</a></td>
<td class="nump">2,551,114<span></span>
</td>
<td class="nump">4,302,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">610,559<span></span>
</td>
<td class="nump">561,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">206,819<span></span>
</td>
<td class="nump">1,245,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment', window );">Sales and marketing</a></td>
<td class="nump">405,626<span></span>
</td>
<td class="nump">950,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing', window );">Goodwill and fixed asset impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses', window );">Total expenses</a></td>
<td class="nump">3,774,118<span></span>
</td>
<td class="nump">7,135,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease', window );">Loss on disposal of equipment held for lease</a></td>
<td class="nump">63,302<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense', window );">Interest (income) expense, net</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(7,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense', window );">Other expense (income), net</a></td>
<td class="num">(4,898)<span></span>
</td>
<td class="num">(1,125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal', window );">Loss on fixed asset disposal</a></td>
<td class="nump">300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Total other expense (income), net</a></td>
<td class="nump">58,704<span></span>
</td>
<td class="num">(8,876)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL</a></td>
<td class="num">(171,701)<span></span>
</td>
<td class="num">(2,142,763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc.', window );">Gain on sale of Qualigen, Inc., net of tax</a></td>
<td class="nump">3,876,778<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">NET LOSS ATTRIBUTABLE TO STOCKHOLDERS</a></td>
<td class="nump">$ 3,705,077<span></span>
</td>
<td class="num">$ (2,142,763)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets of disposal group including discontinued restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued goodwill and fixed asset impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued loss on disposal of equipment held for lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued loss onfixed asset disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation accrued vacation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation accumulated oci attributable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation fair value of interest retained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation fair value of consideration received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation forgiveness of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation gain on sale of qualigenInc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation goodwill and fixed asset impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation interest income expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation loss from deconsolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation net assets deconsolidated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation net product sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation non controlling interest share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other income expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation property right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation research and development grant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation short term debt related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation total assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation total liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation transaction expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation working capital adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued sales and marketing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued total expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_TotalAssetsOfDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_TotalAssetsOfDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_TotalLiabilitiesOfdiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total liabilities of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_TotalLiabilitiesOfdiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_NanosynexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_NanosynexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235509127904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 20, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 401,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,165,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PurchasePrice', window );">Purchase price</a></td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss', window );">Gain upward upon final payment of transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregrate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">NanoSynex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">NanoSynex Ltd [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage of voting interests acquired</a></td>
<td class="nump">49.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">NanoSynex Ltd [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage of voting interests acquired</a></td>
<td class="nump">39.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | NanoSynex Ltd [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage of voting interests acquired</a></td>
<td class="nump">52.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | NanoSynex Ltd [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage of voting interests acquired</a></td>
<td class="nump">49.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_AmendmentAndSettlementAgreementMember', window );">Amendment and Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Aggregrate amount</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_AmendmentAndSettlementAgreementMember', window );">Amendment and Settlement Agreement [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodShareSurrender', window );">Number of shares surrender</a></td>
<td class="nump">281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_ChembioDiagnosticsMember', window );">Chembio diagnostics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_NanoSynexLtdMember', window );">NanoSynex Ltd [Member] | Amendment and Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregrate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_NanoSynexLtdMember', window );">NanoSynex Ltd [Member] | Amendment and Settlement Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregrate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation gain loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedDuringPeriodShareSurrender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period share surrender.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedDuringPeriodShareSurrender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_AmendmentAndSettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_AmendmentAndSettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_ChembioDiagnosticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_ChembioDiagnosticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_NanoSynexLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_NanoSynexLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235414408416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AccruedCompensation', window );">Board compensation</a></td>
<td class="nump">$ 129,499<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest (Convertible debt)</a></td>
<td class="nump">10,004<span></span>
</td>
<td class="nump">2,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AccruedLicenseFees', window );">License fees</a></td>
<td class="nump">32,975<span></span>
</td>
<td class="nump">150,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Payroll</a></td>
<td class="nump">1,215<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">121,775<span></span>
</td>
<td class="nump">136,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AccruedResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">104,402<span></span>
</td>
<td class="nump">329,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Vacation</a></td>
<td class="nump">151,286<span></span>
</td>
<td class="nump">165,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">8,850<span></span>
</td>
<td class="nump">9,698<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 560,006<span></span>
</td>
<td class="nump">$ 864,559<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccruedLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccruedLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235498482432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS ACTIVITY (Details) - Series C Warrants [Member] - Common Stock Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Beginning</a></td>
<td class="nump">3,849,571<span></span>
</td>
<td class="nump">248,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Beginning</a></td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePrice', window );">Range of Exercise Price, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1', window );">Weighted-Average Remaining Life (Years) Outstanding</a></td>
<td class="text">5 months 26 days<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Warrants Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Shares, Warrants Forfeited</a></td>
<td class="num">(2,751,976)<span></span>
</td>
<td class="num">(247,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Forfeited</a></td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="num">(1,097,595)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Expired</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExpired', window );">Range of Exercise Price, Expired</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Warrants Granted</a></td>
<td class="nump">455,623<span></span>
</td>
<td class="nump">3,849,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Granted</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceGranted', window );">Range of Exercise Price, Granted</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1', window );">Weighted-Average Remaining Life (Years) Outstanding</a></td>
<td class="text">5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Ending</a></td>
<td class="nump">455,623<span></span>
</td>
<td class="nump">3,849,571<span></span>
</td>
<td class="nump">248,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Ending</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePrice', window );">Range of Exercise Ending</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants Exercisable</a></td>
<td class="nump">455,623<span></span>
</td>
<td class="nump">1,349,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice', window );">Weighted Average Exercise Price Per Share Exercisable</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of Exercise Price, Exercisable</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Life (Years) Exercisable</a></td>
<td class="text">5 months 26 days<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePrice', window );">Range of Exercise Price, Beginning</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePrice', window );">Range of Exercise Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePrice', window );">Range of Exercise Price, Beginning</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePrice', window );">Range of Exercise Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceExercisableVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceExercisableVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments granted weighted averag remaining contractual term1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average common stock warrants reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235415487904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="nump">$ 3,622,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise', window );">Common Stock Warrant liabilities, Exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnToEquity', window );">Common Stock Warrant liabilities, Fair value of warrant liabilities to equity</a></td>
<td class="num">(1,626,694)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment', window );">Common Stock Warrant liabilities, Loss on debt extinguishment</a></td>
<td class="nump">94,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(2,035,469)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="nump">54,600<span></span>
</td>
<td class="nump">3,622,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise', window );">Common Stock Warrant liabilities, Exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnToEquity', window );">Common Stock Warrant liabilities, Fair value of warrant liabilities to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment', window );">Common Stock Warrant liabilities, Loss on debt extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise', window );">Common Stock Warrant liabilities, Exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnToEquity', window );">Common Stock Warrant liabilities, Fair value of warrant liabilities to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment', window );">Common Stock Warrant liabilities, Loss on debt extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="nump">3,622,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise', window );">Common Stock Warrant liabilities, Exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesOnToEquity', window );">Common Stock Warrant liabilities, Fair value of warrant liabilities to equity</a></td>
<td class="num">(1,626,694)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment', window );">Common Stock Warrant liabilities, Loss on debt extinguishment</a></td>
<td class="nump">94,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(2,035,469)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="nump">$ 54,600<span></span>
</td>
<td class="nump">$ 3,622,647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueAdjustmentOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueAdjustmentOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities loss on debt extinguishment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities on date of exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantLiabilitiesOnToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of  warrant liabilities on to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantLiabilitiesOnToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235498445040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">5.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">68.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Fair value assumptions, measurement input, term</a></td>
<td class="text">5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Fair value assumptions, measurement input, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Fair value assumptions, measurement input, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Fair value assumptions, measurement input, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235414242144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITIES (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 05, 2023</div></th>
<th class="th"><div>Jan. 12, 2023</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Warrants forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Warrants reissued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,665<span></span>
</td>
<td class="nump">309,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Alpha Capital [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease', window );">Conversion price</a></td>
<td class="nump">1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Alpha Capital [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease', window );">Conversion price</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member] | Alpha Capital [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">203,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.136<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 7.195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002,717<span></span>
</td>
<td class="nump">49,952<span></span>
</td>
<td class="nump">49,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member] | Alpha Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ConversionPricePercentage', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235412887744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on convertible debenture</a></td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Total convertible debt-related party</a></td>
<td class="nump">1,299,216<span></span>
</td>
<td class="nump">$ 60,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=QLGN_SeniorSecuredConvertibleDebtMember', window );">Senior Secured Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Senior convertible debenture</a></td>
<td class="nump">1,418,922<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on convertible debenture</a></td>
<td class="num">(119,706)<span></span>
</td>
<td class="num">(3,239,803)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Total convertible debt-related party</a></td>
<td class="nump">$ 1,299,216<span></span>
</td>
<td class="nump">$ 60,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=QLGN_SeniorSecuredConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=QLGN_SeniorSecuredConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235402959536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE DEBT- RELATED PARTY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 08, 2023</div></th>
<th class="th"><div>Dec. 05, 2023</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Sep. 01, 2023</div></th>
<th class="th"><div>May 26, 2023</div></th>
<th class="th"><div>Jan. 12, 2023</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 20, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PurchasePrice', window );">Purchase Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debenture accrues interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of Common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,362,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,362,128<span></span>
</td>
<td class="nump">4,210,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,035,469)<span></span>
</td>
<td class="num">$ (906,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debenture principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(625,653)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DebtRedemptionAmountInCash', window );">Redemption amount in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DebtRedemptionAmountInCommonStock', window );">Redemption amounts in common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Derivative fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">October payment in shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_OctoberPaymentMember', window );">October Payment [Member] | Common Stock [Member] | Alpha Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">October payment in shares</a></td>
<td class="nump">181,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of Common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,157,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Resale of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,958,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002,717<span></span>
</td>
<td class="nump">49,952<span></span>
</td>
<td class="nump">49,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember', window );">Senior Convertible Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities', window );">Redeemable debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PrincipalAmountPercentage', window );">Principal amount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DebentureBeneficialOwnershipBlockerPercentage', window );">Debenture beneficial ownership blocker percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,665<span></span>
</td>
<td class="nump">309,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debenture principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,111,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Debt conversion of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Weighted price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,315<span></span>
</td>
<td class="nump">$ 34,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1', window );">Warrant liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instrument fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Securities Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Securities Purchase Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ConversionPricePercentage', window );">Conversion price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Senior Convertible Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtInterestRateIncrease', window );">Senior convertible debenture rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,418,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,418,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PurchasePrice', window );">Purchase Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 22,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalOtherThirdPartiesMember', window );">Alpha Capital Other Third Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet', window );">Fair value of embedded derivative features</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Fees and costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DebentureBeneficialOwnershipBlockerPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debenture beneficial ownership blocker percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DebentureBeneficialOwnershipBlockerPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DebtRedemptionAmountInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt redemption amount in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DebtRedemptionAmountInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DebtRedemptionAmountInCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt redemption amount in common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DebtRedemptionAmountInCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PrincipalAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal amount percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PrincipalAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480463/815-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a),(b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtInterestRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in the stated interest rate on a short-term debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtInterestRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_OctoberPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_OctoberPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=QLGN_AlphaCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=QLGN_AlphaCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=QLGN_AlphaCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=QLGN_AlphaCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalOtherThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_AlphaCapitalOtherThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235414287568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss used for basic earnings per share</a></td>
<td class="num">$ (13,417,212)<span></span>
</td>
<td class="num">$ (18,640,543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding</a></td>
<td class="nump">5,072,709<span></span>
</td>
<td class="nump">3,840,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants', window );">Dilutive potential shares issuable from convertible debt, stock options and warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding</a></td>
<td class="nump">5,072,709<span></span>
</td>
<td class="nump">3,840,340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dilutive potential shares issuable from stock options and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235511258912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Apr. 05, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation paid</a></td>
<td class="nump">$ 96,558<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235413239824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND LICENSE AGREEMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">47 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,209,250<span></span>
</td>
<td class="nump">$ 4,486,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ReimbursementOfPatent', window );">Reimbursement of patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_LicenseCost', window );">License costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member] | University of Louisville Research Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_MasterLaboratoryServicesAgreementMember', window );">Master Laboratory Services Agreement [Member] | MLM Medical Labs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember', window );">Sponsored Research and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_LicenseCost', window );">License costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember', window );">Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ReimbursementOfResearchExpenses', window );">Reimbursement of research expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,000<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AgreementTermPaymentDescription', window );">Agreement term payment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates.
Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is
responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront
license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered
net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative
$250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30%
to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement,
40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth
year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution
and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement
of certain regulatory and commercial milestones.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RegulatoryMarketingApprovalExpenses', window );">Marketing approval expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember', window );">Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember', window );">Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ReimbursementOfResearchExpenses', window );">Reimbursement of research expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 805,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AgreementTermPaymentDescription', window );">Agreement term payment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization
of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative
$250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income
received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third
or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter),
(iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred
prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RegulatoryMarketingApprovalExpenses', window );">Marketing approval expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PatentCosts', window );">Patent costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Licensed Product Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_CumulativeSales', window );">Cumulative sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RegulatoryMarketingApprovalExpensesOne', window );">Regulatory marketing approval, expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShortfallPayments', window );">Shortfall payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShortfallPayments', window );">Shortfall payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementsAndLicenseMember', window );">Sponsored Research Agreements And License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_LicenseCost', window );">License costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 743,000<span></span>
</td>
<td class="nump">$ 758,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_UpfrontPaymentMember', window );">Upfront Payment [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ReimbursementOfPatent', window );">Reimbursement of patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_PhaseOneClinicalTrialMember', window );">Phase 1 Clinical Trial [Member] | License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_PhaseTwoClinicalTrialMember', window );">Phase 2 Clinical Trial [Member] | License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_PhaseThreeClinicalTrialMember', window );">Phase 3 Clinical Trial [Member] | License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AgreementTermPaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement term payment, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AgreementTermPaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_CumulativeSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_CumulativeSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_LicenseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_LicenseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PatentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PatentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RegulatoryMarketingApprovalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory marketing approval, expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RegulatoryMarketingApprovalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RegulatoryMarketingApprovalExpensesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory marketing approval expenses one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RegulatoryMarketingApprovalExpensesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ReimbursementOfPatent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of patent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ReimbursementOfPatent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ReimbursementOfResearchExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of research expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ReimbursementOfResearchExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShortfallPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shortfall payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShortfallPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_UniversityOfLouisvilleResearchFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_UniversityOfLouisvilleResearchFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_MasterLaboratoryServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_MasterLaboratoryServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_MLMMedicalLabsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_MLMMedicalLabsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_LicensedProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_LicensedProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementsAndLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementsAndLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_UpfrontPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_UpfrontPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_PhaseOneClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_PhaseOneClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_PhaseTwoClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_PhaseTwoClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_PhaseThreeClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_PhaseThreeClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235497957552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF RESERVED SHARES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">5,781,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">755,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_ConversionOfConvertibleDebtMember', window );">Conversion Of Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">1,943,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">3,081,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_ConversionOfConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_ConversionOfConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235413917328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending</a></td>
<td class="text">1 year 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember', window );">Employees and Non-employee Service Provider [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, options outstanding, beginning</a></td>
<td class="nump">608,012<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">$ 35.02<span></span>
</td>
<td class="nump">$ 60.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending</a></td>
<td class="text">7 years 21 days<span></span>
</td>
<td class="text">8 years 1 month 2 days<span></span>
</td>
<td class="text">8 years 6 months 7 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares, options granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">134,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares, options expired</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(9,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options expired</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 932.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, options forfeited</a></td>
<td class="num">(209,088)<span></span>
</td>
<td class="num">(1,264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options forfeited</a></td>
<td class="nump">$ 34.71<span></span>
</td>
<td class="nump">$ 22.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Options Outstanding at Ending</a></td>
<td class="nump">398,924<span></span>
</td>
<td class="nump">608,012<span></span>
</td>
<td class="nump">484,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">$ 35.21<span></span>
</td>
<td class="nump">$ 35.02<span></span>
</td>
<td class="nump">$ 60.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of shares, options exercisable (vested)</a></td>
<td class="nump">320,918<span></span>
</td>
<td class="nump">288,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Range of exercise price, options exercisable (vested)</a></td>
<td class="nump">$ 41.97<span></span>
</td>
<td class="nump">$ 46.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)</a></td>
<td class="text">6 years 9 months 7 days<span></span>
</td>
<td class="text">7 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares, options non-exercisable (non-vested)</a></td>
<td class="nump">78,006<span></span>
</td>
<td class="nump">319,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, options non-exercisable (non-vested)</a></td>
<td class="nump">$ 7.36<span></span>
</td>
<td class="nump">$ 24.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested', window );">Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)</a></td>
<td class="text">8 years 4 months 9 days<span></span>
</td>
<td class="text">8 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Life (in Years), Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember', window );">Employees and Non-employee Service Provider [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">$ 5.14<span></span>
</td>
<td class="nump">$ 12.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Range of Exercise price, Options Forfeited</a></td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">5.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">12.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Range of exercise price, options exercisable (vested)</a></td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">12.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Range of exercise price, options non-exercisable (non-vested)</a></td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">5.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember', window );">Employees and Non-employee Service Provider [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">51.30<span></span>
</td>
<td class="nump">14,657.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Range of Exercise price, Options Forfeited</a></td>
<td class="nump">51.30<span></span>
</td>
<td class="nump">49.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">51.30<span></span>
</td>
<td class="nump">51.30<span></span>
</td>
<td class="nump">$ 14,657.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Range of exercise price, options exercisable (vested)</a></td>
<td class="nump">51.30<span></span>
</td>
<td class="nump">51.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Range of exercise price, options non-exercisable (non-vested)</a></td>
<td class="nump">$ 32.90<span></span>
</td>
<td class="nump">10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,657.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award option expired weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award option granted weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, options non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Remaining Contractual Life (in Years), Options Granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted- average remaining contractual life (in years), options non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235497795568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock-price volatility</a></td>
<td class="nump">103.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected average term of options (in years)</a></td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.58%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 5.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 10.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235511533696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 1,098,533<span></span>
</td>
<td class="nump">$ 5,484,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">939,228<span></span>
</td>
<td class="nump">4,649,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 159,305<span></span>
</td>
<td class="nump">$ 834,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235414572256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANT ACTIVITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_NonCompensatoryWarrantActivityMember', window );">Non Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Beginning</a></td>
<td class="nump">547,003<span></span>
</td>
<td class="nump">554,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Beginning</a></td>
<td class="nump">$ 19.76<span></span>
</td>
<td class="nump">$ 20.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1', window );">Weighted average remaining life (Years) exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 29 days<span></span>
</td>
<td class="text">1 year 3 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares, warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Warrants Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">331,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, warrants exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="num">(539,953)<span></span>
</td>
<td class="num">(7,911)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, warrants expired</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 37.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Shares, Warrants Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, warrants forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Ending</a></td>
<td class="nump">2,507,050<span></span>
</td>
<td class="nump">547,003<span></span>
</td>
<td class="nump">554,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Ending</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 19.76<span></span>
</td>
<td class="nump">$ 20.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants Exercisable</a></td>
<td class="nump">2,507,050<span></span>
</td>
<td class="nump">547,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 19.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of exercise price - Exercisable</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1', window );">Weighted average remaining life (Years) exercisable</a></td>
<td class="text">4 years 5 months 19 days<span></span>
</td>
<td class="text">3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants', window );">Number of shares legal ritter warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice', window );">Weighted average exercise price, legal ritter warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity', window );">Number of shares, warrants reclassification of Alpha warrant from warrant liabilities to equity</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice', window );">Weighted Average exercise price, reclassification of Alpha warrant from warrant liabilities to equity</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity', window );">Range of exercise price, reclassification of Alpha warrant from warrant liabilities to equity</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Warrants Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(331,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice', window );">Range of exercise price, expired</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber', window );">Number of Shares, Warrants Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableGranted', window );">Range of exercise price, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercised', window );">Range of exercise price, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableExpired', window );">Range of exercise price, expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceForfeited', window );">Range of exercise price, forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Non Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOutstanding', window );">Range of exercise price</a></td>
<td class="nump">1.32<span></span>
</td>
<td class="nump">11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOutstanding', window );">Range of exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.32<span></span>
</td>
<td class="nump">11.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of exercise price - Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Non Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOutstanding', window );">Range of exercise price</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">37.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOutstanding', window );">Range of exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00<span></span>
</td>
<td class="nump">$ 37.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of exercise price - Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Beginning</a></td>
<td class="nump">179,046<span></span>
</td>
<td class="nump">179,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Beginning</a></td>
<td class="nump">$ 9.12<span></span>
</td>
<td class="nump">$ 15.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1', window );">Weighted average remaining life (Years) exercisable</a></td>
<td class="text">1 year 3 months<span></span>
</td>
<td class="text">1 year 8 months 23 days<span></span>
</td>
<td class="text">2 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares, warrants granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, warrants granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Warrants Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, warrants exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="num">(60,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, warrants expired</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExpired', window );">Range of exercise price, expired</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Shares, Warrants Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, warrants forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Ending</a></td>
<td class="nump">119,046<span></span>
</td>
<td class="nump">179,046<span></span>
</td>
<td class="nump">179,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Ending</a></td>
<td class="nump">$ 10.69<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
<td class="nump">$ 15.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants Exercisable</a></td>
<td class="nump">119,046<span></span>
</td>
<td class="nump">179,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 10.69<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1', window );">Weighted average remaining life (Years) exercisable</a></td>
<td class="text">1 year 3 months<span></span>
</td>
<td class="text">1 year 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber', window );">Number of shares, warrants non-exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise', window );">Weighted Average Exercise Price Per Share Non-Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceNonexercisableNonvested', window );">Range of Exercise Price, Non-Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Warrants Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOutstanding', window );">Range of exercise price</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOutstanding', window );">Range of exercise price</a></td>
<td class="nump">0.73<span></span>
</td>
<td class="nump">1.32<span></span>
</td>
<td class="nump">11.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of exercise price - Exercisable</a></td>
<td class="nump">0.73<span></span>
</td>
<td class="nump">1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOutstanding', window );">Range of exercise price</a></td>
<td class="nump">25.40<span></span>
</td>
<td class="nump">25.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOutstanding', window );">Range of exercise price</a></td>
<td class="nump">25.40<span></span>
</td>
<td class="nump">25.40<span></span>
</td>
<td class="nump">$ 25.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of exercise price - Exercisable</a></td>
<td class="nump">$ 25.40<span></span>
</td>
<td class="nump">$ 25.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceExercisableExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price exercisable expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceExercisableExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceExercisableGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price exercisable granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceExercisableGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceExercisableVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceExercisableVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceNonexercisableNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceNonexercisableNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range Of Exercise Price Outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price reclassification of  alpha warrant from warrant liabilities to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares, warrants non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average vested non exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments expired in range of exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average common stock warrants reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments legal ritter warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments legal ritter warrants weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments non exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments reclassification of alpha warrant from warrant liabilities to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments eeclassification of alpha warrant from warrant liabilities to equity weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_NonCompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_NonCompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235410126048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 05, 2023</div></th>
<th class="th"><div>May 26, 2023</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Nov. 29, 2021</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Plan shares available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,781,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,098,533<span></span>
</td>
<td class="nump">$ 4,765,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Cost is expected to be recognized over a weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,035,469)<span></span>
</td>
<td class="num">(906,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098,533<span></span>
</td>
<td class="nump">5,484,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanosynexMember', window );">NanoSynex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 891<span></span>
</td>
<td class="nump">$ 2,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ModifiedToExercisePrice', window );">Modified to exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="nump">$ 90,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Alpha Capital [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease', window );">Conversion price</a></td>
<td class="nump">0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Alpha Capital [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease', window );">Conversion price</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">939,228<span></span>
</td>
<td class="nump">4,649,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="nump">67,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,620<span></span>
</td>
<td class="nump">67,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_StockholdersEquityReverseStockSplitPricePerShare', window );">Reverse stock split, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_WarrantsExtendedDateDescription', window );">Warrants extended date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">June
3, 2023 to September 14, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="nump">$ 7,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expired date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 14,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to nonvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,945<span></span>
</td>
<td class="nump">$ 67,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Plan shares available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option granted exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | 2020 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Plan shares available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,778<span></span>
</td>
<td class="nump">147,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,924<span></span>
</td>
<td class="nump">608,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_CompensatoryWarrantsMember', window );">Compensatory Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Issuance or sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember', window );">Noncompensatory Equity Classified Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,068<span></span>
</td>
<td class="nump">27,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.50<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_WarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants to purchase, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember', window );">Noncompensatory Equity Classified Warrants [Member] | Alpha Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember', window );">Noncompensatory Equity Classified Warrants [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember', window );">Noncompensatory Equity Classified Warrants [Member] | Warrant [Member] | Alpha Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ModifiedToExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modified to exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ModifiedToExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockholdersEquityReverseStockSplitPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity reverse stock split price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockholdersEquityReverseStockSplitPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WarrantsExtendedDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants extended date, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WarrantsExtendedDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanosynexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=QLGN_NanosynexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=QLGN_TwoThousandTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=QLGN_TwoThousandTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_CompensatoryWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_CompensatoryWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235509480416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 20, 2023</div></th>
<th class="th"><div>Jan. 12, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PurchasePrice', window );">Purchase Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember', window );">Pre-funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,464<span></span>
</td>
<td class="nump">331,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember', window );">NanoSynex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Number of common stock acquired shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Stock [Member] | NanoSynex Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Number of common stock acquired shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,232,861<span></span>
</td>
<td class="nump">2,232,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Senior Convertible Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtInterestRateIncrease', window );">Senior convertible debenture rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Principal amount</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,418,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_PurchasePrice', window );">Purchase Price</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtInterestRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in the stated interest rate on a short-term debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtInterestRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235509708864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (12,479,803)<span></span>
</td>
<td class="num">$ (13,887,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (12,479,803)<span></span>
</td>
<td class="num">$ (13,887,914)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235530989440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="nump">1.76%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion', window );">Non-deductible expenses</a></td>
<td class="num">(0.64%)<span></span>
</td>
<td class="num">(2.09%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration', window );">NOL expiration</a></td>
<td class="num">(5.26%)<span></span>
</td>
<td class="num">(19.88%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credit</a></td>
<td class="nump">2.92%<span></span>
</td>
<td class="nump">3.71%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Goodwill impairment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant', window );">Change in fair value of warrant liability</a></td>
<td class="nump">3.35%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture', window );">Tax impact of convertible debenture</a></td>
<td class="num">(5.46%)<span></span>
</td>
<td class="nump">1.37%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture', window );">Tax impact of divestiture</a></td>
<td class="num">(229.26%)<span></span>
</td>
<td class="nump">4.01%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_EffectiveIncomeTaxRateReconciliationTrueUp', window );">True-up</a></td>
<td class="num">(10.65%)<span></span>
</td>
<td class="nump">2.24%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">222.28%<span></span>
</td>
<td class="num">(17.91%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income taxes provision (benefit)</a></td>
<td class="nump">0.04%<span></span>
</td>
<td class="num">(0.05%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation fair value of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation non operating loss expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation tax impact of convertible debenture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation tax impact of divestiture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_EffectiveIncomeTaxRateReconciliationTrueUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate true-up.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_EffectiveIncomeTaxRateReconciliationTrueUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depletion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235509713920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF PROVISION FOR INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="num">$ (10,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">U.S. State</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="nump">23,128,000<span></span>
</td>
<td class="num">(236,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">U.S. State</a></td>
<td class="nump">4,697,000<span></span>
</td>
<td class="num">(2,252,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred benefit</a></td>
<td class="nump">27,825,000<span></span>
</td>
<td class="num">(2,488,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="num">(27,825,000)<span></span>
</td>
<td class="nump">2,488,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision (benefit) for income taxes</a></td>
<td class="num">$ (4,793)<span></span>
</td>
<td class="nump">$ 6,548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235418135104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 8,644,000<span></span>
</td>
<td class="nump">$ 32,587,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">4,970,000<span></span>
</td>
<td class="nump">7,857,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DefferdTaxAssetsAccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">68,000<span></span>
</td>
<td class="nump">1,020,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Patent</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">3,004,000<span></span>
</td>
<td class="nump">3,069,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">1,102,000<span></span>
</td>
<td class="nump">1,196,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">280,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Total deferred income tax assets</a></td>
<td class="nump">17,788,000<span></span>
</td>
<td class="nump">46,009,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use asset</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(382,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(395,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Net deferred income tax assets</a></td>
<td class="nump">17,788,000<span></span>
</td>
<td class="nump">45,614,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(17,788,000)<span></span>
</td>
<td class="num">(45,614,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax asset, net of allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DefferdTaxAssetsAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defferd tax assets accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DefferdTaxAssetsAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235414931280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">U.S. federal operating loss carryforwards</a></td>
<td class="nump">$ 15,942,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State operating loss carryforwards</a></td>
<td class="nump">$ 78,693,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit carryforward, limitations on use</a></td>
<td class="text">The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite
life for state tax purposes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">3,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">$ 1,410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140235412601664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 26, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 12, 2023</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,111,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Securities Purchase Agreement [Member] | Subsequent Event [Member] | 2024 Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares</a></td>
<td class="nump">900,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Purchase of shares increase decrease</a></td>
<td class="nump">1,800,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Securities Purchase Agreement [Member] | Subsequent Event [Member] | 2024 Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 0.6111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Principal amount increase decrease</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember', window );">Alpha Capital [Member] | Securities Purchase Agreement [Member] | 2024 Debenture And Warrant [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Cash purchase price</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_ReimbursementExpenses', window );">Reimbursement expenses</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity', window );">Additional cash proceeds</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional proceeds from issuance or sale of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ReimbursementExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ReimbursementExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_TwentyTwentyFourWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_TwentyTwentyFourWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=QLGN_TwentyTwentyFourDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=QLGN_TwentyTwentyFourDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=QLGN_TwentyTwentyFourDebentureAndWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=QLGN_TwentyTwentyFourDebentureAndWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M/^! UP[T4 =O[>"U0%>9M;!NF&;3BUH^H-I80S1ST8Y-ZPUH1&G*>*=K^%:
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M +Z?2Y YZQOS$F/STFKZ'U!+ P04    " !FKX58 'C&$(L"   I!P  &
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M4HJD^+GE+.29,H#_'X60+P^J@_JJ?/PO4$L#!!0    ( &:OA5@=TB/O'PD
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MS>E\#,3[4<N!Q]HO]ES;5N>YYH O6?T%!!3K(W>0.M6%<IB>=SC,=B^I8J/
M=GFV374&CS4_QU[(IDM-_-4RKZ[.@*)%H&@Q*%H"BI9"H0V9]VHUZ1G]%7CY
MF-G=!1(+'FN-P<)5)18H=Q$44#PI[@3*77K.W9 6O2*+KU%D&<FK3+)@73;/
M&1G=6E69/915*4HY Y,EBK3KWK6\@-)D\5AN1#[V_86ZU@S*8P0%%$\-/8'R
MF$[P."1(K\]BLSY[R2I#,]0EN1_KB<A>A)XS6J@.I;Q" <530T\TA@N\4 2*
M5 >'["!T3N@JN!=7L5E<_8$'<F;D2_(\UF!QZ*DG8:4Q"^5D66EP(ZBP8HT_
MF</ 5U>+:.P<F1E'S:$&S@WM4^M_<:]+8K,NN2+Y\9VE;N9:E+QY,%_6S0H1
MNB.LW:._@T.M&(4"6F&=A.F@<*%JG5 >XZD>$ZTA=CQ775N:ZB']P#GU9@GN
MI5!LED)-RW_-0R_))A#0"@HHPF,U5Y[11E%!JK ]W331F3JNO'I#-:%:S,"W
ML7?J"NZE1VR6'G^D"$,N:%R"HJU T2)0M!@4+0%%2[%.Z5RXP8G%YK@7.K%9
MZ#SQ!,O1$FN\$M1UL*]*V!HSA%S?\SQ5@%B9@[ND$HQ]WB#DA_)(0E<M!1K;
M9NV^YXUNXT#AI5-<#E\J[&5"QRP3GGD*IDVD,U:Q/,>7E7#T7B'H:D]0M @4
M+09%2T#14BBT \/FKUZ$;_[TPJ\9>RQK;E5D+>'M-X%D*3O\-8/#AJ"[]MWX
M!RH$W;9?-R0K"&L,Y/XUI>)EHWG=_O@W)>[_!U!+ P04    " !FKX58)&=:
MGB,)  #$+   &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;*V::W/B.!:&
M_XJ*G=J:J9HTUL47L@E5-$EVJ$H3*J1[/CNV"-H&F[%$+OOKY\@F-MBRN S]
MH0-&DL^K(QT].M+56YK]E'/.%7I?+A)YW9DKM;KL=F4TY\M0?DE7/(%?9FFV
M#!5\S5ZZ<I7Q,,XK+1==XCA>=QF*I-._RI]-LOY5NE8+D?!)AN1ZN0RSCZ]\
MD;Y==W#G\\&C>)DK_:#;OUJ%+WS*U??5)(-OW;*56"QY(D6:H(S/KCL#?#ED
M/5TA+_%#\#>Y]1EI*<]I^E-_&<77'4=;Q!<\4KJ)$/Z\\B%?+'1+8,=?FT8[
MY3MUQ>W/GZW?Y>)!S',H^3!=_"EB-;_N!!T4\UFX7JC'].T/OA'DZO:B="'S
M_]';IJS30=%:JG2YJ0P6+$52_ W?-QVQ50%[+17(I@*I5V M%>BF LV%%I;E
MLFY"%?:OLO0-9;HTM*8_Y'V3UP8U(M%NG*H,?A503_6':2+3A8A#Q6,T5? '
M?*0D2F=H&,HYN@,_2W2!OD]OT*^__';55?!27;4;;5[PM7@!:7D!)NA;FJBY
M1+=)S./=!KI@;6DR^33Y*[&V>,.C+XCBWQ%Q"#48-#R\.K&80\L>I'E[M*T'
M!],_T-W]PY]3=/?X\ T]3&X?!T^C\7_18/@T^C%Z&MU.3=U6M,K,K>K9>RE7
M8<2O.S ])<]>>:?_[W]AS_F/2?*9&MOI %9V +.UWA]#L%FD4II$%C7=O*:.
M**_]"TQ]SR&N<]5]W59@*$FP0YG':%ERQSRW-,^UFG</IJ%9EBY1+&0$0U$D
M:QCK$ BS4$<2^3M*0 $,>!6^FS04S7L[&DC@$E:78"CH8^;@ )L5>*4"[T %
M&_-%\K)EO\EFSV0S\UT'UXTVE:1!CS&/F*WV2ZM]Z[P8Q/^#\%5$$Y5"R ?C
M(['@^5BQR-&%M4,B'7[6$EPEDL^?H6 >]X427%Z:A/OGG%5G:FRG^X*R^P*K
MTV\X-!J)L%CLDAB%RS13XO_Y Y/RH.%(QGINS=O-0IA@SS5[NE>:VK.:.E5I
M]/-"+Z8QN'0)A"%;K>PU#7!Z@4MIS=!F.>9[+O$]LZG8J=8[QVKL<!XF+UR/
MJ5DH,O0:+M9<3_ZW,,O"!"*9")_%(A]@QL7.:<X7XE"7>;V: E/)GN-1UM+;
M>&O)QOOC 8R*UW2Q3A3 EYY(KSS+T0JD%-^4>(;)%O-G9=2!#8[P?1+X=1E6
M6\R3 %G&/R:53&*5.8BBC*N-ICQV@UJM^R!]I*D/?.0U@K;=B!/T5=R K:MR
MZ48M ?%W'=W60LYUQ#0JH@U%'G$]MSYS[&\]05#% =@. J4@(5>I#!?:;S/Q
M#E$AE)(K\WQB#54$^ZPQ"JUO/D%410_8C@]WQBBQ3&,Q$U$1G6$SA599.N-2
MST#0K0T044L :5*"WV/U.&THY?G4=UI"1T42V+/#:A[]9&U)S;V3+S);T<^X
MO&(KJ1R[OIZKM=W.J  %6Q?P_B3CJU#$,/?TDL6+'DC5G&>V >L;%@"/^0S7
M76@HB(D'BUV+$RLRP'8T@,"H0Z%$J_ CA"!H--.PTGN TX34S6P6O&"4L;:A
M5D$!ME.!#M\:M V]&ZVSC!^PUC8AX((0'SN-KC849#YAK 6\244+Q$X+XT-
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M;N7OT70PO9U;VRV$,:&9/*-X74RN$!KV9F7+@AY?]C+B6N,6&W*_4>'>]]C
MI*RB98Y73?N4MO0-L(.@H28[0FN5+5SEDDPCLYH '](5VU8<_WAZ,;9MYE\1
M'9[M@OFY95O,R'%9"HHT+G@AO]4.T<#K00#HR:HSO/^8(#P0E8<6C.5_-.6Z
M:>MVM8LO$?/3;&_ZBH(,V>)C-+80Z[XP_34\W-3JIR'RX")>+6Z0F.-:[YAO
M\\-3-T.\:^DU0M@K;SEA)%>DQ330TMA>'1.& W:[-.R!7@*VD=,D%I.["" ]
MD;PV=31(<0[1#]#L#7!N ;W6QB%D[^0Z'976Y3JK6&<+UMEK2QK#F &:2W*$
M5B;EW6?SOZ[,)V2Z.G"ZWHF*15LX6O%(LXO;-5M]7;/)X!7>X!W\?5/WB@UI
M\58,Z7DTI$[%0*6XB_'@U!T;*T)"$&#9(]\T_RG4'YMU<=(>>8-)I%GQ?0:<
M/G%!FS:$%2JWC;32>F"4UU[Y&1+.&@MP2\LKK8G85<@S9DY@?DQ=(=2-U]D1
MBVC>OSRZ(Y=%437O>Q(,QZ7*Z*[!+E'$"?A4>M1HLB>DJ'@4L07+V(<<9,TC
MD%'>*I445C$NO]*TKF)$JGB_$U[ F2DEJ@J9Q=F>U\-*]TD$@.,OT[4Q%2 &
M>A(ZP=.09X8U+#QH3G'L5)@>D(2W:0,0X&9D2/XNF,MV0>9_'.<$0=#CG5B;
M:X@9$3Y2,9S6('9?V<H4&1(:MN J =VA'[HI+4$4,V5)Q6!LV!: H(5)LJP4
M5*\65=M #TG-2F,J6<K09$\VIO=211!(42* B^S9?PTF.4D[X15!@0V'EF\Y
MHF"/,[!"Q3L"!=RPV<JX-D2X;%![]TVA'6^_CB,@T<I1Q-.2&&Z=L-!B2$7#
M( MX\$V,#_='![, 34KB)>3F<2<1#;6\[26OI&DBI/F(LT0%W3%?2$>).^(C
M-H2X1D8B+:$S@,9ALX7KQ!UMN[1G;'- ^H;D*JR^X40IIJEHSKK="E18M6T%
MG9J%5$AQ@V".# Y0GZD8.A*-4=3]D'P*W1S(/5[!#P?4GQ$MK@QA%&E -5<?
M),-97&)X=4F[L@?X>4<64!*RC_;E=\3M,;X[.B"M.S@Z5"%7RH0JQR-A_1#@
M5[-N(QBRAZ:4D(!0_ ,J)YK PE!Z0S_UPVG.G))\_IDGHQ5U%):'M%0!FS&0
MX+0SM]!/EJ/3(1Z^98G">I8.PXADG6($%06V9X4%2ZUK!X:3%8&NH'J-P7P]
M9TJ"^P#]I79K;,O:FH'CX!LDPG!OM66KF(>>I%1UG8U$!D=^%60 ]!THPV.O
M459H?\ 9]Z#$EVD3YXD9\6F\0_L\K"LDKU('D[&'7:(IS<!:# LRD"WOV/C>
M(I] $ED]OWWCLFDRU'\1H?H<]UR=@KM(@651$P%@HH-YL[:K->&<VI(KR9VE
MBZJ47+=M:*,3?S:HD#"B7JIGAX3K=^+^83PX(]0VAKR2[CZ3^UB2(CC)TK.D
M"S@MHAMSS$>$@?2>R<?R$FR7S1FT9 70T[ _'\VS&=B\R'2<,6H23B.-7NCF
ML\!N"3F#_PA))$'/6JPSN*+^1-C6[SP+&<W'M%J6%.R1F6,'RF.]-A626X16
M&+03^"1M85]SFA4E[K\^.S]] &+\3:Y;N7EQON1 =S^YDE=J8;KK:2B,_5K#
M>7%%@11?>:S&6N5=5%@$Z!7PSI--R!"G3;3$BAF#K4LR]*0\ZC>:@?C^DBAD
M1E^2V]&,1W!IYE6 M;&4[+CUE2P>YK7MR A\,-N!8%'IW^&586=ACPV\2%%)
M0%/$^21SOQOU9V(X(U\?6X&5<_7[VM9C*%>10@/\2# 4M0'*P/7 I9<E6 W0
M)+H '\L> 4SVSIH>#[ T68FQ9-9F B23-D?MC<8NVP(SP:%TO<$.:5J&&R*,
MF-4(8[)5+A8($6KF$5+TG)!B"<(RL_ISAHM<*3)+&]TT,"T=K[NN)5-,JTA1
MAA^%'JG(S.W\SJ%+OI[CC!]7M$Q7;,7(O&5H:.K+8H X#4@DD)VK<WK>=@SR
MB+5O*.H^>$-&LR*PSW HMPQ 2!Q:; EN-FR#;'R=C0MX7&.,FL?PD.IZ+3F%
M#L4UDBR9O<A7EC,O.LMKEK8KAPU<;\D7*H!_XTV#C+DA!F60FE@!88"K&4T^
MS<KL&F/O0!*Z;V)(\64K,&4IL!Y)#>=SA:(P2XI9'=+U;&.)G&8<^G@<[\<3
M2L6SI#L3ZB910BK[$+T;HT6=?'A3V64H+/A,32$.G=C0MI_'D5<&9^DG8<Q]
MD).H.QNZ4"_<&>3$)0%U(\KCD03;T>ZXE#I"\2'&E^]#[%OX&H-C*PY9]S'%
M%G/D M,;R8U10 .#N2"XY=-@#L$$X#(D0-Y\O.%CX,+IW"LR$#'.,UB6I.J]
M62K7UBRSR+PR%,G3_8,-63"$0:1*G_,;0-XKS6D60*V6_"];\[;461[4^7U)
MXS(Y)!22=,O9M9%/*!#*HFKC*]U[RS;5N&Q#;Z!LXQF9$4^<(C]KZUU>.Q@7
M!.][IRL5%!\L]FTQ3CQ.LBX/ .TEW."HYBR%&RC^F:TD'6.AE@.^N\,4=?_\
MXL-W>K-]?O9@$@[XD.GV5TL*HY@+MN$J3.4K@="N/NMX(.=48BAY8:XN-.P2
MV2LWL5QQ2GCE?:,#CC4F:\W8\E JRSP0:R,5I)<=3&Z>F%B:/%JL28<D*\M5
M>,XU%MG*Z] UX;6/ 4 ^VP.)XW#9$XS=%#+M-I;O1!^K#:%"3D2BNA3G\1J2
MA^-%A-4<X41MG*N77OW M04*G+SHD0/($VY16\O\\2%X*U$6GR_UJ1'"LF[P
MA<[4'):2#]#AIJ*]Y]3+EOZ+;BP4FU^?7+X,P5V!RL_'=DO@Y>GA]S"S7$?E
MB3K#BNKV)Y+9CX0 >,0$R0IZ)9>@A&O@$];O\;3%C70MV>B5;1K.PC<^>@DQ
MR8@Y8C)$<9*#BV1,:YR<!\'U;N31Z$W8]4*<@(XIKNE,*/T2EU<6)G,Z%R.6
M?8*-LW55FLL['!&Y5LE;%M%;$@(E,!,3Z#>\J=R/\AIEE<0A<*$1!7=)JB9'
MZKTTO%]RSCX7B30,2J72AB6\-1VJ]K5W?"EX)N%'L7#YT4<RY('(QE@2,D6'
MKY!,C5!U29%QVSE&BUFV!P7$!,6"-RXDT3CFN<"_A/\9TXXR02$^%/9SJ56*
M'*/D1TPTD)TO3=@:*2.=N?H G<&P&W)W(U5R,<4DDAM3]JT*"JMJ.H!O",@P
M9@-J=L/B#V82HO(K]KE*,E5^GRQ93I7Q(@O14T9%):!%AZPVED8XFQ$AY^LY
M#CPZ1FR*CMHH[&PW%+(;WK"A9A,[XYBGLEPE+$VX&/=#Q!;!(C>^<8RM2S;T
M0;#OR7)[D^R19_ \<_6+9W3\H\AJ2_M!GVCM2/#1[8PEQ9KG 9C$*E$)&23$
MGWMT8E8PI;%:SC8_6?<X_[YR2K:LM934"<.;)1(7G$E<#C5IS-*3(<EZVMBT
MWZ!^"]KUK)""FAAY9*B9 JE!&J,:X2:R.7\GCD@!W?Z:1=#]VV(,!.0]T#2R
M52/:9K?((%5A*$3DQ;%OZ00!W*2$;/3-O>I@:>(;Q63,+/7QM?EG+)!)D&20
M9@G49#KG+0/,/A> M'=O?NA"I)%X-A*4KG?.NEN*64@'_YMZ/#M^](S+N6>T
ME:\8OQ0)&YQ3=-\-*0GXNR19U9O,WN0(I6J-J!-I&5F0,")G"<(XM,BUJ5:\
M)WT.D2Y%'S+S#F &9;K1#$2ARF<W;LGR,0<* M)%RNUHHP2%GWJ6<&QH,Y5D
M8MQ-(8F,*GBT@ 8Q8L@0)79T^0I%]5O.=11+PXD@G[_G!-J2FUL0TE6<$$XO
M2K]6QJN]I*N8EQM;!.WVE%B2)-,(T"2?N:QW(RC![$HZZVU"#^O3F0.^R,]-
M"IH"FQBL9UM^L@%"T:;8@X0GG9N3P.QFO]8<R43C^RK\3('1?J-]A8NS(M\)
M4E2S'IH:];+6Y>>#RQ)Y>>=K"P<P[YA0<!(G%'%*Q!R<ZJYN"7UL0F,G*8RL
M>4+(2&=0MD8XQ[UL395USV;>#=SQ.A[Z"%+Q=?_(N6:33>8UW=!8M\XS,2)^
ME]>NE"B4U%-G8GL.?-:)58#3- U[F_WE[?NQ&OK#P3Y;P=TLN/WT .VI."H
M!UB<F46O#B@(%K]]0=AO1T'Q:R#JWYBK;R49(RL9F9RP2]U4^3;Y*W"0J??S
MEO[%"(,TC=49<T!7NWS(-?U&R+Q#.H=&LHY,&5(=61=QZ"N56@SB?]MS\X
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M0XC< &G)V7=1)-]BE\5QIKFR9-/"67JA>:XNVBU%6IT:T+W)1P_IYA7%@^W
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MI=F(6I9"MJVS'Q5:C/1&?"EFDU-(76NN@3*BD+Z.Q9'<Q$77=!H[2^X]5:C
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M'&_ ]\IB,O0O[&"XF5[]#U!+ P04    " !FKX58WHH2"F0#  "=!P  &
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MOQKT')#U8U K6I1V &^$IG%NQ3V]GRB- ?W?"N+0*"9 ^R*/OP)02P,$%
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M:XW].%D^&)G;#X(+:8Q,[7#-&59@6H#S2XEUIGJ@ YHOQ&?_ %!+ P04
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M,?4Z_@"[OK%JZ3Z&3I2U:N$NYX+#"5J ]U.E[/J&-FB^CE_^'U!+ P04
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M4&G.LSF#;X7&)IE9Q?BZXP%\.R.^;(TO"-38HL(PGC'Q%"78\" HWY,8Z2+
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MT._(JR]%NE"_]ANG19'.U>5,<)1-&H#GTS0MJB^T0/WSSU?_!5!+ P04
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MM;!&'"V419ATZ<G=:0SXF+>-GZ=/@@*\*(0;/Z] R$YAW%7-E<Q12R'WSAS
MBE,PW8,U#FQD3S[E%3Q+*IQCO44-C/G30T];(G&K&RZ/((QI*=DJR*JFY"%P
M21VD81K'81S'9,6]E83C9!)^8@SBJU]2^,8UE;(&LH%Z=0Q'ZFQ%X5OYIY6=
M AV$+3T+5YU3BZ!VWJ<IH;2MQA-"%]CZ/6^->CINJVEU7I(^ 0NO>^Z>\8)+
MM3Y*?(5EJUU=.Z)H#NN24\'E6U:VUXBDMA8*/]>LT:("]NG<]'C^HQ6:@EC(
M4A9.;A)(K_O!T6T=WXRI=!PG<.[T1R=B5:/>>TDV-*A6VDZWAM5!];-.[/X+
M[WX97[G>"[J[%>XHE;J]#D!W,MPY5C5>^K;*DI!ZLZ0_%VH70/L[14>W=UR!
MX5\X_Q=02P,$%     @ 9J^%6%> I*A5"P  11T  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C N>&ULM5E;4^,X%G[WKU!E>J>ZJT)(G(0D33=50$(/6SU
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M'/A30:3SPN#<C.0^+"7"H44X<X+/V*KX=T($+D"H0F40&AH:A%BMUB)Q@<\
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M/,.">M]1)^(^LK]V;G"*"2'7&H'+S*D[7GW'-=&RA&K(W:1:)(Z0FV)=;]G
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M-3X0)G_0#E.^=QUG&2>;QI"!((3P"T%X8,.X_2\FWU9U66]NPDM _+C:^[:
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M&F%KC6JTQ$%T%23^5/2%V .+K3M=56CK&MIW67+S!'81DT:! E\IP.[>B.;
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M<P/5^#4B_LJC1*1[+\[HU"10S>8</[@=7;P Y@M//H1V(^#FZ[?]*PK#2N_
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M?.T/^.[%%K6A7\OH)@PYAZG)4,'1,?P:+K51],_\/I6 BCXZ36_[J*=+EN#
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MD23_B)H/LG@M/US>Q5D6K^3CDC-X0RS _"*.LW(@-JB^9%_\%U!+ P04
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M%USI@5&:J9[0*$R /E]RKG:.N:">^>%O4$L#!!0    ( &:OA5B-9M L80,
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MY<#J69#BG*PR->6;UUCKZ1B^A&>R_(=-;>M8D*RDXGD-UA'DE%5/\KW.PQ9
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M[63.V*WN7&1#R]&",,=4:@:B7AL<8YYK(B7C9\-IM5-JX&[[GOV#\:Z\S(G
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MR'6 ^KY@3-YW=.UI?S6B/U!+ P04    " !FKX58)>6B-),"  #%!@  &0
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MH_VJD,9/V39> I9L%_%\-Z<X6VP5#K,-LI/S5_#2R3?\RIA\_W'JQ4]^E("
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MS^V.3#?%4X=WJ91I7&RN&55WU/D)ZOUEFLKGG3Q!]?#M]#]02P,$%     @
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M[FIHRL*':%@?G^TE0Q]^,,IE6]PK'!4SV(F!W+BM$1,MZ+NJ,TY@"SIZ#^-
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M/'X_)3X1_CIZ8^/9%\)WH\,5HPO&PP'R^Z7OB]U)Z"!]2VCT/U!+ P04
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M!)NP;$T6GJRXH&Y464;@VE[XC=^C1&Q5@-:1"BBJ@/8K5(Y4,*,*0>:,,++
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MS;C(;M#O/Z2I>CG)VLG+?Q\8_0]02P,$%     @ 9J^%6*>L=2F,!P  (E0
M !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULO9Q?<ZI&&,:_RH[M=-J9
M5F$1U#1QQB/_MG-RFDE.>RXZO2"Z4:8"%M8D9Z8?OH $!'$/M$^;BRBX[^]=
M]'%WW6?9ZY<H_B/9<B[(:[ +DYO!5HC]U6B4K+8\\))AM.=A^LI3% >>2 _C
MS2C9Q]Q;YT'!;D05Q1@%GA\.YM?YN;MX?AT=Q,X/^5U,DD,0>/'G=WP7O=P,
MU,';B7M_LQ79B='\>N]M^ ,7O^SOXO1H5%+6?L##Q(]"$O.GF\%"O6):'I"7
M^-7G+\G)<Y)=RF,4_9$=L/7-0,EJQ'=\)3*$ESX\\R7?[3)26H\_"^B@S)D%
MGCY_H]OYQ:<7\^@E?!GM/OEKL;T93 =DS9^\PT[<1R\N+RY(SWBK:)?D_\E+
M4589D-4A$5%0!*<U"/SP^.B]%F_$28 ZOA! BP#:-4 K K2N >,B8-P,T"X$
MZ$6 WC6#4008S8#)A8!)$3#IFF%:!$R[!LR*@%DNA^/GEW_XIB>\^74<O9 X
M*YW2LB>Y@O+H]#/WPTSL#R).7_73.#'_M+B_7WSX2-ZSQ3OVGGUDU@/YUN3"
M\W<)^>#%L9>)\3OR _F:C$BR]6*>7(]$FCF+'ZV*+,XQ"[V0126W42BV";'"
M-5_7XT=IC<MJT[=JOZ-2H,E70Z+HWQ.J4*VE/DMY^$]>."0JO1AN=LA.C^&T
M)=R2A]]ZGPDU+D;;\NC%/DZ3ZQ?#G0YUU]2+E^[*PW]>"6DXZYY=D>A *^6K
MY;SQ)?EF"@T%X:\\7OD))_O87_&6>KV3<K(NY2K9>RM^,TC[C(3'SWPP_^8K
MU5!^;%,7$F8B81829B-A#A+F(F'L")OFL&QP\#P?*\/)]>BY19CC4ICC+L),
M2#H>>>*^:+9Z1U%*&7U%B8292)AUA!DG;S =3PRJEV_Q46[(G X2YB)A# 2K
MR5(O9:EWDV7,_20YM*M2BNBK2B3,1,(L_4R5VMB8SHR&*I$Y'23,1<(8"%93
MI5&JTI"J<K';;SVR]/:^\';DMUL>//+X]S9I2CE]I8F$F4B8A8392)B#A+E(
M& /!:@*>E *>@(:A4DY? 2-AYN1L%)0.@K1Z8V@A,]I(F(.$N4@8 \%JPIR6
MPIQVZ^\O]_920%]%3L_ZU.E8G=!&GVHB<UI(F(V$.>?OAJ;,#*,Q[G6[%6.@
MJM5T-"MU-)/JZ-9[]8-#4/;-Y"_2WFFG+SSPU2'VA<\3<G>(5ULO;0\7FYCS
M@*=-I*QWE]:AKQ21,!,)LY P&PESD# 7"6,@6$W\JE)-DBJ@_KT G7:CZK#Y
M55[*T_45)Y1F06DVE.9 :2Z4QE"TND1/YO%5J4274?C,X]R#NBS.(V)6$Z=&
MF^*4)NHM3B3-@M)L*,V!TEPHC:%H=7'22IQ4/GSPP_]A^""O1-_Q Y1F0FD6
ME&9#:0Z4YD)I#$6K?PTJLTI%N54%Z+2E/O\UOI2GZRU1J!$%I=E0F@.EN5 :
M0]'J$JUL*U7N6W4:1HP[3!4MY8EZBQ-J2$%I-I3F0&DNE,90M+HX*_-*E;M7
M#SS.A@5+4DYK28<#4!\+2C.A- M*LZ$T!TISH32&HM7E7+E>JMSV*E7LA6L2
M9ZOR$A(=1"+28S_<$,'CH%784!<,2C.A- M*LZ$TYPL?KDZ"XY(W:I"U][EM
MT9P+K1!#T>IJKBPP5>Z!76Z<_Z-?>U K#4HSH30+2K.A- =*<Z$TAJ+5OQ"5
M]:;^:^]-/;=^J*(9^MF4'-*6,J$T"TJSH30'2G.A-(:BU=59&7JJW-$KU7DR
MXFB5*-24@]),*,V"TFPHS2EHIPW%6-<-VOC1[4*S,A2MOL2_<MUH)]<M>9LO
M\QYWK?,1<DQ?B4)I)I1F06DVE.84M"]*%)J5H6AUB5:N&Y6[;M)!;W/11*MV
MD3;/$DHSH30+2K.A- =*<Z$TAJ+5%5Y9=U1NW77W+.2@WE*&VF\%355/6B=]
MJ&J-A6E644X_*=9<#UX4F9P4F0S566.)AP.MOPNE,12M+JG*!J-R&TS>:#:L
MXE:E06_F@M),*,V"TFPHS8'27"B-H6AUA5<N&I6[:#T:3:0_LX323'KN\YTO
M%[**4A-YRVH7Q20MJP.MO0NE,12M+JC*^:)(YTL.ZRTJJ/,%I5E0F@VE.5":
M"Z4Q%*TNY\KYHIV<KR[M(]3K@M),*,V"TFPHS2EH7QCSNM"D#$6K:[3RLVBG
M>[IDT_=R0F]Q0BVH@G8Z':,J"IVHDV;_?5YP/)LU+0B[M9BF3IM].-0/@M(8
MBE875.4'4;D?] \,TE;106_8@M),*,V"TFPHS8'27"B-H6AUG5?.$NWD+'7I
MW*'>$I1F%C3YC3P6-*<-I3E0F@NE,12MOFE0Y2QI'9VERWV[G-!7FU":J9U;
M+517LK^&/*%I;2C-@=)<*(VA:'5Y5JZ2UN]>+K)/6U(>"F_3OK45U$."TLR"
MEJUJ/VE'FUO_6-"D-I3F0&DNE,90M*-01R?[" 8\WN2;4"9D%1U"<=R;KSQ;
M;G2YR+=W;)QWU"OWN%UEA3GNGGGKQ1L_3,B./Z5(93C1!\>EKV\'(MKGNQ4^
M1D)$0?YTR[TUC[,"Z>M/423>#K($Y;:@\[\!4$L#!!0    ( &:OA5CZ4)<(
M\ (   H*   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;+56:V_:,!3]
M*U8V3:TTFA<$TD&D-:$J4E_BT7V8]L&$"UAUXLPVT/[[V0F-2$D1FQ@?B!_W
M')_C^-ZXNV'\62P!)'I):"IZQE+*[-(T1;R$!(L+ED&J9N:,)UBJ+E^8(N.
M9SDHH:9C69Z98)(:03<?>^1!EZTD)2D\<B1628+YZQ50MND9MO$V,"2+I=0#
M9M#-\ )&("?9(U<]LV29D01205B*.,Q[QG?[,O1U?![P1& C=MI(.YDR]JP[
M@UG/L+0@H!!+S8#58PTA4*J)E(S?6TZC7%(#=]MO[->Y=^5EB@6$C/X@,[GL
M&1T#S6".5U0.V>8&MGY:FB]F5.3_:%/$>DT#Q2LA6;(%*P4)28LG?MGNPP[
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MZBJ0-Y?JL@9<!ZCY.6/RK:/O ^7U+_@#4$L#!!0    ( &:OA5AA[$&-4A<
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M1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K6$TL0 ;8HZFKRHTVTWOJ6
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M?+F\F[K\>HCV5U!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K6$TL0
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M-1?5/%3S42U M1#5(E2+42VA-#$5FZK/2%[UD1S:+':'->^5N@RTD1^[1"M
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MQS.6]WCB(E].\W6U^YXN5MOV$SURHG,:DIJ.:@:JF:AFH9I=:X<W?.[WV\Z
MH].ZJ.:U? AUH$YNM:,;7OGHM,&ETX;HM!&JQ:B64)J88DT!IWHI3;'7RWCB
M<UU$.= YPTA-1S4#U4Q4LU#-KC4APWJM&49.ZZ*:AVH^J@6H%J):A&HQJB64
M)J9A4[P9RXLW05KN;AWT4YF=V[U%*S6HIJ.:@6HFJEFH9O_BWX2>3:\53?N;
MHFB]W6GKEN.":(L&U3Q4\U$M0+40U2)4BU$MH30Q))L6S5C^M)U+;F A)SKG
M)-J<034#U4Q4LU#-KC7Y'9(==$X7U;R63W!:^??1.8.+Y@S1.2-4BU$MH30Q
MO)H&R[C+ W&B\CDKE*_/>3%3XK38WS-2>I$-VFA!-1W5#%0S4<U"-1O5'%1S
M4<U#-1_5 E0+42U"M1C5$DH3X[2IO8S9!]V,T>8+JNFH9J":B6H6JMFHYJ":
MBVH>JOFH%J!:B&H1JL6HEE":&*!-0V8L;\CL4W.6;Z9G3R&CG1A4TU'-0#43
MU2Q4LU'-0347U3Q4\U$MJ+73DV#'^^9H*0;58E1+*$W(PDE3BIG(2S'FVV.[
M#_K3RCQ/'_)Y7OYL2T>YV#4=44U'-0/53%2S4,U&-0?57%3S4,U'M:#6A!M]
M3-KB$9TV0K48U1)*$^.Q*;1,Y ^\$>-Q=Y!R-LMFRBPK\F]IF7_+E,=L=_ZZ
M_68\<KQS4J+U%E0S4,U$-0O5;%1S4,U%-:_6#K?5CG+(1R<,:FUT?L(0G3!"
MM1C5$DH3@T]K@D]>1#&S;*.DRYDR76W*C;).\UEKPJ'5$U334<U -1/5+%2S
M4<U!-1?5/%3S42VH->&R[=9-0;1[@FHQJB64]I*(-YOG+"OUM$SOWB^RXBF[
MS^;SC;(_)K@[]W+P7:7('JO$5-]]U*YN3K[OJ>]\M>7[@?HNW'__IN'OWJ_3
MIRQ(BZ=\N5'FV6,U5>]Z=VU1D3\]OWU1KM8?KJK\?UB5Y6JQ?_F<I=5&Y^X-
MU=\_KE;EZQ>[";ZOBC_V'^?NWU!+ P04    " !FKX582/D3'S4#  "8"
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M9KM,+\3A#AL]/8.7B$Q53S@TOHX%R4YID3?!Q"#G1?UF7YL\G 2X_3<"O";
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M2@77E)? <PH*S:G*F5![">C7=*NT-/?_^Y+Y3N3C91'[)B:J(3G$GFEZ!?(
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M7$!\/V,LV[R1"9X8_Y:OSN7_ %!+ P04    " !FKX58;(CL <H"   G"@
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MOD(/8]G) 5,;Y/<5I>)EHIJ+NC<,_@!02P,$%     @ 9J^%6'*K8)"=!P
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M35WH(FN(V43QU#:A!5>ZI=GA6G]$H# ']/Z2<_4X,03Y9TGW)U!+ P04
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M">COJS0M]A_* @XGRE_]"U!+ P04    " !FKX589P*.=YX9  !BM@$ &0
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MS0#E(_;.)[0BC6H&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%E&:F&-:DV/:,\X
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MSKXD1;V^Q6WYR/=3!F5[=^#5^\D_C/>+4OZ\7KYO'>AW9;N_0')_O.T!!^*
M2O> +[H'K-:[?IEV_""K]X_^N3P+*7;[U\0?_BQ_[ #J1_Q".(#SKMDU^EOK
MH9J/:@&JA:@649KXWZZF-3^5K]'^L?J=^?E]^>NX5#[$W_=+PKRKUF6X3JJ/
M7YWR<A_Y$+W_DX9VY5'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)*$X-+:X+K
M.5=EGZ*%>E334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(DH3(ZRIW4_EM?N3
MUF:0&[V3":W<HYJ!:B:J6:AFHYHS/5Z]OIP=5_^T+D-V;#@>=6SHH<?GHUJ
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MM99HDD40G0/X6D"I@KRKN"5.Q#L(ZZB!/R(2D(:%T/CGS8F#3J-T:B/':US
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M6$X&1,XF,$^1EFO33#MM9#6AWV%[ME[7[+W)2X'KRGX N?H26W^'_EM9\QL
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M&Q#Z +7_+DWE\XI^^:)Z_V?Q'U!+ P04    " !FKX58@=W!154#  "R%0
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M[\&=]U&P?D\%F__2CIX 4$L#!!0    ( &:OA5B7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 9J^%6/HR;]-F!0
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MBWJW/ZEWF3X/N5Q[OM9X_9^D>CJ?FZ^7ORR_=LYNP@7G!+\3/?X%4$L#!!0
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M4$L! A0#%     @ 9J^%6+R*U3_O    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 9J^%6)E<G",0!@  G"<
M !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " !FKX58RB82X_,'  !V-   &               @($."   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 9J^%6#-L@ HC!@  P!H
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M965T-BYX;6Q02P$"% ,4    " !FKX582KR!/! ?  !96   &
M    @(%X,P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M9J^%6 .S#-AH!@  I0X  !@              ("!OE(  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( &:OA5C>BA(*9 ,  )T'   8
M          " @5Q9  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " !FKX58/O!G)ZL"  #@!0  &0              @('V7   >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( &:OA5AM-]QGX0P  -XD
M   9              " @=A?  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ 9J^%6* ID&ZA P  T <  !D              ("!\&P
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !FKX58'[80
MW,H(   M%@  &0              @('(<   >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( &:OA5C@M#=,S@D  "D7   9
M  " @<EY  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M9J^%6,E76Q?) P  W @  !D              ("!SH,  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " !FKX58W_ FC[$#  ##!P  &0
M            @('.AP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( &:OA5@EO7%A(0H  .(>   9              " @;:+  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 9J^%6.K40@/A#0
M"BH  !D              ("!#I8  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " !FKX58F5_)XBT#   7!P  &0              @($F
MI   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( &:OA5A7
M@*2H50L  $4=   9              " @8JG  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ 9J^%6* 1PE,' P  ? 8  !D
M     ("!%K,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M" !FKX58JU 5BOH@  !J9@  &0              @(%4M@  >&PO=V]R:W-H
M965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( &:OA5C;_Y$!' ,  . &   9
M              " @877  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L!
M A0#%     @ 9J^%6&*#_)2H @  S04  !D              ("!V-H  'AL
M+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !FKX582RC@4[@)
M  #5'@  &0              @(&WW0  >&PO=V]R:W-H965T<R]S:&5E=#(U
M+GAM;%!+ 0(4 Q0    ( &:OA5C:Z6W<1 ,    '   9              "
M@:;G  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 9J^%
M6,;F!HKU!0  >1   !D              ("!(>L  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " !FKX580 8O]+T"  #_!0  &0
M        @(%-\0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( &:OA5B-9M L80,  %0'   9              " @4'T  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 9J^%6%*'$ 29"   A!\
M !D              ("!V?<  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " !FKX58P(5GLU$&  "9$   &0              @(&I  $
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( &:OA5A@1E D
M> 4  /,C   9              " @3$' 0!X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ 9J^%6&UH(LI3 P  $@H  !D
M ("!X P! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !F
MKX586>TT,0\#  !V"   &0              @(%J$ $ >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( &:OA5@EY:(TDP(  ,4&   9
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M970S.2YX;6Q02P$"% ,4    " !FKX58\+Y8&:4%   Q)   &0
M    @($ ,P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M &:OA5B1-YNJ&P4  +4B   9              " @=PX 0!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ 9J^%6&?:VH2F!0  2C   !D
M             ("!+CX! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " !FKX58IZQU*8P'   B5   &0              @($+1 $ >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( &:OA5CZ4)<(\ (
M  H*   9              " @<Y+ 0!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ 9J^%6&'L08U2%P  >Z,! !D              ("!
M]4X! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !FKX58
M2/D3'S4#  "8"   &0              @(%^9@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( &:OA5AJ"OPB'@(  #$$   9
M      " @>II 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ 9J^%6.4Z[MA-#P  2K8  !D              ("!/VP! 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !FKX58;(CL <H"   G"@
M&0              @('#>P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( &:OA5ARJV"0G0<  -TT   9              " @<1^ 0!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 9J^%6$@KA_T6
M P  H@@  !D              ("!F(8! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    " !FKX58DF3UVLL"  #E!P  &0
M@('EB0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( &:O
MA5A.^$G': H  %U>   9              " @>>, 0!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ 9J^%6&<"CG>>&0  8K8! !D
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M=#4X+GAM;%!+ 0(4 Q0    ( &:OA5ATO:0UWP,  -T.   9
M  " @;;" 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @
M9J^%6#>\#-.V P  K@X  !D              ("!S,8! 'AL+W=O<FMS:&5E
M=',O<VAE970V,"YX;6Q02P$"% ,4    " !FKX58S81^LN<%   +-   &0
M            @(&YR@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4
M Q0    ( &:OA5B!W<%%50,  +(5   -              "  =?0 0!X;"]S
M='EL97,N>&UL4$L! A0#%     @ 9J^%6)>*NQS     $P(   L
M     ( !5]0! %]R96QS+RYR96QS4$L! A0#%     @ 9J^%6/HR;]-F!0
MRR@   \              ( !0-4! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( &:OA5CU29+, 0(  %XD   :              "  =/: 0!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &:OA5C63,"2X $  .,C
M   3              "  0S= 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0  !% $4 VA(  !W? 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>278</ContextCount>
  <ElementCount>462</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - LIQUIDITY AND GOING CONCERN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/LiquidityAndGoingConcern</Role>
      <ShortName>LIQUIDITY AND GOING CONCERN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - OTHER NON-CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/OtherNon-currentAssets</Role>
      <ShortName>OTHER NON-CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - DISCONTINUED OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/DiscontinuedOperations</Role>
      <ShortName>DISCONTINUED OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - WARRANT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/WarrantLiabilities</Role>
      <ShortName>WARRANT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedParty</Role>
      <ShortName>CONVERTIBLE DEBT- RELATED PARTY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/EarningsLossPerShare</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - RESEARCH AND LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ResearchAndLicenseAgreements</Role>
      <ShortName>RESEARCH AND LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - OTHER NON-CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/OtherNon-currentAssetsTables</Role>
      <ShortName>OTHER NON-CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/OtherNon-currentAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - DISCONTINUED OPERATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>DISCONTINUED OPERATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/DiscontinuedOperations</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - WARRANT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/WarrantLiabilitiesTables</Role>
      <ShortName>WARRANT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/WarrantLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyTables</Role>
      <ShortName>CONVERTIBLE DEBT- RELATED PARTY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedParty</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/EarningsLossPerShareTables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/EarningsLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/LiquidityAndGoingConcernDetailsNarrative</Role>
      <ShortName>LIQUIDITY AND GOING CONCERN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/LiquidityAndGoingConcern</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - SCHEDULE OF OTHER NON CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails</Role>
      <ShortName>SCHEDULE OF OTHER NON CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - SCHEDULE OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails</Role>
      <ShortName>SCHEDULE OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails</Role>
      <ShortName>ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative</Role>
      <ShortName>DISCONTINUED OPERATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/DiscontinuedOperationsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - WARRANT LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative</Role>
      <ShortName>WARRANT LIABILITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/WarrantLiabilitiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails</Role>
      <ShortName>SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative</Role>
      <ShortName>CONVERTIBLE DEBT- RELATED PARTY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails</Role>
      <ShortName>SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative</Role>
      <ShortName>RESEARCH AND LICENSE AGREEMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/ResearchAndLicenseAgreements</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails</Role>
      <ShortName>SCHEDULE OF RESERVED SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails</Role>
      <ShortName>SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails</Role>
      <ShortName>SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANT ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/StockholdersEquityTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfDomesticAndForeignComponentsDetails</Role>
      <ShortName>SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigendiagnostics.com/role/SubsequentEvents</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>qlgn-20231231.xsd</File>
    <File>qlgn-20231231_cal.xml</File>
    <File>qlgn-20231231_def.xml</File>
    <File>qlgn-20231231_lab.xml</File>
    <File>qlgn-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>logo_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="846">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "QLGN",
   "nsuri": "http://qualigendiagnostics.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "qlgn-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "qlgn-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "qlgn-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "qlgn-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "qlgn-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 321,
   "keyCustom": 141,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 27,
   "memberCustom": 36,
   "hidden": {
    "total": 185,
    "http://qualigendiagnostics.com/20231231": 85,
    "http://xbrl.sec.gov/dei/2023": 3,
    "http://fasb.org/us-gaap/2023": 97
   },
   "contextCount": 278,
   "entityCount": 1,
   "segmentCount": 72,
   "elementCount": 645,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 846,
    "http://xbrl.sec.gov/dei/2023": 39
   },
   "report": {
    "R1": {
     "role": "http://qualigendiagnostics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://qualigendiagnostics.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://qualigendiagnostics.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://qualigendiagnostics.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates",
     "longName": "00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://qualigendiagnostics.com/role/LiquidityAndGoingConcern",
     "longName": "00000008 - Disclosure - LIQUIDITY AND GOING CONCERN",
     "shortName": "LIQUIDITY AND GOING CONCERN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "longName": "00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://qualigendiagnostics.com/role/OtherNon-currentAssets",
     "longName": "00000010 - Disclosure - OTHER NON-CURRENT ASSETS",
     "shortName": "OTHER NON-CURRENT ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://qualigendiagnostics.com/role/DiscontinuedOperations",
     "longName": "00000011 - Disclosure - DISCONTINUED OPERATIONS",
     "shortName": "DISCONTINUED OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "longName": "00000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://qualigendiagnostics.com/role/WarrantLiabilities",
     "longName": "00000013 - Disclosure - WARRANT LIABILITIES",
     "shortName": "WARRANT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "QLGN:WarrantLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "QLGN:WarrantLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedParty",
     "longName": "00000014 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY",
     "shortName": "CONVERTIBLE DEBT- RELATED PARTY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://qualigendiagnostics.com/role/EarningsLossPerShare",
     "longName": "00000015 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://qualigendiagnostics.com/role/CommitmentsAndContingencies",
     "longName": "00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreements",
     "longName": "00000017 - Disclosure - RESEARCH AND LICENSE AGREEMENTS",
     "shortName": "RESEARCH AND LICENSE AGREEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "QLGN:ResearchAndLicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "QLGN:ResearchAndLicenseAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://qualigendiagnostics.com/role/StockholdersEquity",
     "longName": "00000018 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://qualigendiagnostics.com/role/RelatedPartyTransactions",
     "longName": "00000019 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://qualigendiagnostics.com/role/IncomeTaxes",
     "longName": "00000020 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://qualigendiagnostics.com/role/SubsequentEvents",
     "longName": "00000021 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies",
     "longName": "00000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "QLGN:OrganizationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "QLGN:OrganizationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "00000023 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://qualigendiagnostics.com/role/OtherNon-currentAssetsTables",
     "longName": "00000024 - Disclosure - OTHER NON-CURRENT ASSETS (Tables)",
     "shortName": "OTHER NON-CURRENT ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://qualigendiagnostics.com/role/DiscontinuedOperationsTables",
     "longName": "00000025 - Disclosure - DISCONTINUED OPERATIONS (Tables)",
     "shortName": "DISCONTINUED OPERATIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "00000026 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://qualigendiagnostics.com/role/WarrantLiabilitiesTables",
     "longName": "00000027 - Disclosure - WARRANT LIABILITIES (Tables)",
     "shortName": "WARRANT LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyTables",
     "longName": "00000028 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY (Tables)",
     "shortName": "CONVERTIBLE DEBT- RELATED PARTY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://qualigendiagnostics.com/role/EarningsLossPerShareTables",
     "longName": "00000029 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://qualigendiagnostics.com/role/StockholdersEquityTables",
     "longName": "00000030 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "QLGN:ScheduleOfReservedSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "QLGN:ScheduleOfReservedSharesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://qualigendiagnostics.com/role/IncomeTaxesTables",
     "longName": "00000031 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
     "longName": "00000032 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2020-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-05-242022-05-26",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "QLGN:OrganizationPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://qualigendiagnostics.com/role/LiquidityAndGoingConcernDetailsNarrative",
     "longName": "00000033 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)",
     "shortName": "LIQUIDITY AND GOING CONCERN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "00000034 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "shortName": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails",
     "longName": "00000035 - Disclosure - SCHEDULE OF OTHER NON CURRENT ASSETS (Details)",
     "shortName": "SCHEDULE OF OTHER NON CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:EscrowDeposit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "QLGN:LongtermResearchAndDevelopmentDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails",
     "longName": "00000036 - Disclosure - SCHEDULE OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS (Details)",
     "shortName": "SCHEDULE OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_srt_ParentCompanyMember",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
     "longName": "00000037 - Disclosure - ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS (Details)",
     "shortName": "ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "QLGN:DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
     "longName": "00000038 - Disclosure - DISCONTINUED OPERATIONS (Details Narrative)",
     "shortName": "DISCONTINUED OPERATIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012023-12-31",
      "name": "QLGN:DisposalGroupIncludingDiscontinuedOperationGainLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "00000039 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "shortName": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "QLGN:AccruedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "QLGN:AccruedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
     "longName": "00000040 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "shortName": "SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember",
      "name": "QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails",
     "longName": "00000041 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "QLGN:FairValueAdjustmentOfWarrant",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "QLGN:FairValueOfWarrantLiabilitiesOnToEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
     "longName": "00000042 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)",
     "shortName": "SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative",
     "longName": "00000043 - Disclosure - WARRANT LIABILITIES (Details Narrative)",
     "shortName": "WARRANT LIABILITIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2020-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-05-232022-05-26",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails",
     "longName": "00000044 - Disclosure - SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)",
     "shortName": "SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_SeniorSecuredConvertibleDebtMember",
      "name": "us-gaap:SecuredDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
     "longName": "00000045 - Disclosure - CONVERTIBLE DEBT- RELATED PARTY (Details Narrative)",
     "shortName": "CONVERTIBLE DEBT- RELATED PARTY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2023-07-20",
      "name": "QLGN:PurchasePrice",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtConversionConvertedInstrumentAmount1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails",
     "longName": "00000046 - Disclosure - SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)",
     "shortName": "SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://qualigendiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000047 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2022-04-052022-04-05",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-04-052022-04-05",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
     "longName": "00000048 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)",
     "shortName": "RESEARCH AND LICENSE AGREEMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-01-31_custom_LicenseAgreementMember",
      "name": "QLGN:ReimbursementOfPatent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "QLGN:ResearchAndLicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails",
     "longName": "00000049 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)",
     "shortName": "SCHEDULE OF RESERVED SHARES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_ConversionOfConvertibleDebtMember",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfReservedSharesTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "00000050 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
     "longName": "00000051 - Disclosure - SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)",
     "shortName": "SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
     "longName": "00000052 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)",
     "shortName": "SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
     "longName": "00000053 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)",
     "shortName": "SCHEDULE OF WARRANT ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:SummaryOfWarrantActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember",
      "name": "QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "QLGN:SummaryOfWarrantActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
     "longName": "00000054 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "00000055 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2023-07-20",
      "name": "QLGN:PurchasePrice",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfDomesticAndForeignComponentsDetails",
     "longName": "00000056 - Disclosure - SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)",
     "shortName": "SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails",
     "longName": "00000057 - Disclosure - SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)",
     "shortName": "SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
     "longName": "00000058 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)",
     "shortName": "SCHEDULE OF PROVISION FOR INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "00000059 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative",
     "longName": "00000060 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000061 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourWarrantMember_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r656"
     ]
    },
    "QLGN_AccretionOfDiscountOnConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "AccretionOfDiscountOnConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of discount on convertible debt",
        "documentation": "Accretion of discount on convertible debt.",
        "label": "AccretionOfDiscountOnConvertibleDebt"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_AccruedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "AccruedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board compensation",
        "documentation": "Accrued compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "QLGN_AccruedLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "AccruedLicenseFees",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License fees",
        "documentation": "Accrued license fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedPayrollTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payroll",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "QLGN_AccruedResearchAndDevelopmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "documentation": "Research and development.",
        "label": "AccruedResearchAndDevelopmentCurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vacation",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r73"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r133",
      "r204",
      "r500",
      "r525",
      "r526"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r21",
      "r51",
      "r438",
      "r441",
      "r460",
      "r521",
      "r522",
      "r700",
      "r701",
      "r702",
      "r710",
      "r711",
      "r712"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r656",
      "r785"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r540",
      "r710",
      "r711",
      "r712",
      "r764",
      "r786"
     ]
    },
    "QLGN_AdditionalProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "AdditionalProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional cash proceeds",
        "documentation": "Additional proceeds from issuance or sale of equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant modification for professional services",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile loss from continuing operations to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_AgreementTermPaymentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "AgreementTermPaymentDescription",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement term payment, description",
        "documentation": "Agreement term payment, description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "terseLabel": "Compensation cost",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r395"
     ]
    },
    "QLGN_AlphaCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "AlphaCapitalMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alpha Capital [Member]",
        "documentation": "Alpha Capital [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_AlphaCapitalOtherThirdPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "AlphaCapitalOtherThirdPartiesMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alpha Capital Other Third Parties [Member]",
        "documentation": "Alpha Capital Other Third Parties [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_AmendmentAndSettlementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "AmendmentAndSettlementAgreementMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment and Settlement Agreement [Member]",
        "documentation": "Amendment And Settlement Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r94",
      "r141",
      "r330"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment losses on construction-in-progress",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r66"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r200",
      "r227",
      "r260",
      "r273",
      "r277",
      "r285",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r431",
      "r435",
      "r450",
      "r496",
      "r577",
      "r656",
      "r669",
      "r722",
      "r723",
      "r771"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r205",
      "r227",
      "r285",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r431",
      "r435",
      "r450",
      "r656",
      "r722",
      "r723",
      "r771"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/BalanceSheets",
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets of discontinued operations",
        "verboseLabel": "Total current assets of discontinued operations",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r102",
      "r116",
      "r150",
      "r151",
      "r195",
      "r196"
     ]
    },
    "QLGN_AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "documentation": "Assets of disposal group including discontinued restricted cash."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r683",
      "r684"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r683",
      "r684"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r683",
      "r684"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r651",
      "r652"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r85",
      "r428",
      "r651",
      "r652"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voting interests acquired",
        "verboseLabel": "Business acquisition, percentage of voting interests acquired",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r498",
      "r551",
      "r571",
      "r656",
      "r669",
      "r694"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and restricted cash from continuing operations - beginning of period",
        "periodEndLabel": "Cash from continuing operations - end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r143",
      "r224"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and restricted cash from discontinued operations - beginning of period",
        "negatedPeriodEndLabel": "Less: cash and restricted cash from discontinued operations - end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r143",
      "r224"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r143"
     ]
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash used in financing activities - discontinued operations",
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash provided by (used in) investing activities - discontinued operations",
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r143"
     ]
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net cash provided by (used in) operating activities - discontinued operations",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r143"
     ]
    },
    "QLGN_ChangeInFairValueOfWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ChangeInFairValueOfWarrantLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of warrant liabilities",
        "documentation": "Change in fair value of warrant liabilities.",
        "label": "ChangeInFairValueOfWarrantLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ChembioDiagnosticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ChembioDiagnosticsMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chembio diagnostics [Member]",
        "documentation": "Chembio diagnostics [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r201",
      "r202",
      "r203",
      "r227",
      "r247",
      "r248",
      "r251",
      "r253",
      "r258",
      "r259",
      "r285",
      "r299",
      "r301",
      "r302",
      "r303",
      "r306",
      "r307",
      "r335",
      "r336",
      "r338",
      "r341",
      "r347",
      "r450",
      "r529",
      "r530",
      "r531",
      "r532",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r563",
      "r586",
      "r606",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r691",
      "r706",
      "r713"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercise price",
        "verboseLabel": "Warrant exercise price",
        "terseLabel": "Exercise price of warrant",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase common stock",
        "verboseLabel": "Purchase of warrants",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants issued",
        "label": "Warrant to purchase shares",
        "terseLabel": "Purchase of warrants",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of outstanding warrants to purchase, shares",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Note 10)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r98",
      "r497",
      "r562"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r293",
      "r294",
      "r627",
      "r718"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "verboseLabel": "Plan shares available",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r710",
      "r711",
      "r764",
      "r784",
      "r786"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r563"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheetsParenthetical",
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Shares of Common stock, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r127",
      "r563",
      "r583",
      "r786",
      "r788"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value; 225,000,000 shares authorized; 5,362,128 and 4,210,737 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r499",
      "r656"
     ]
    },
    "QLGN_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants [Member]",
        "documentation": "Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "QLGN_CompensatoryWarrantActivityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "CompensatoryWarrantActivityMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensatory Warrant Activity [Member]",
        "documentation": "Compensatory Warrant Activity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_CompensatoryWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "CompensatoryWarrantsMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensatory Warrants [Member]",
        "documentation": "Compensatory Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to Qualigen Therapeutics, Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r207",
      "r209",
      "r216",
      "r491",
      "r512"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss attributable to noncontrolling interest from discontinued operations",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r88",
      "r92",
      "r207",
      "r209",
      "r215",
      "r490",
      "r511"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r169",
      "r207",
      "r209",
      "r214",
      "r489",
      "r510"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r230",
      "r431",
      "r432",
      "r435",
      "r436",
      "r467",
      "r629",
      "r721",
      "r724",
      "r725"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails"
     ],
     "auth_ref": [
      "r230",
      "r431",
      "r432",
      "r435",
      "r436",
      "r467",
      "r629",
      "r721",
      "r724",
      "r725"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r634"
     ]
    },
    "QLGN_ConversionOfConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ConversionOfConvertibleDebtMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of Convertible Debt [Member]",
        "documentation": "`Conversion Of Convertible Debt [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ConversionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ConversionPricePercentage",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price percentage",
        "documentation": "Conversion price percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets",
      "http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible debt - related party",
        "verboseLabel": "Total convertible debt-related party",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r175",
      "r780"
     ]
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt conversion of convertible debt",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r309",
      "r310",
      "r320",
      "r321",
      "r322",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_CumulativeSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "CumulativeSales",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative sales",
        "documentation": "Cumulative sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r709",
      "r760"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current provision",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r415",
      "r421",
      "r709"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r709",
      "r760"
     ]
    },
    "QLGN_DebentureBeneficialOwnershipBlockerPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DebentureBeneficialOwnershipBlockerPercentage",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debenture beneficial ownership blocker percentage",
        "documentation": "Debenture beneficial ownership blocker percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt conversion of convertible debt",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONVERTIBLE DEBT- RELATED PARTY",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r225",
      "r308",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r324",
      "r331",
      "r332",
      "r333"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r122",
      "r123",
      "r173",
      "r175",
      "r230",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r459",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r707"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion price",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r311"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPriceDecrease",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "Per share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r348"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion rate",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregrate amount",
        "verboseLabel": "Debenture principal balance",
        "terseLabel": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r309",
      "r459",
      "r642",
      "r643"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument fair value",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r449",
      "r642",
      "r643"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount increase decrease",
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debenture accrues interest rate",
        "verboseLabel": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r310"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r641",
      "r766"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r230",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r459",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r707"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Discount on convertible debenture",
        "verboseLabel": "Debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r96",
      "r727"
     ]
    },
    "QLGN_DebtRedemptionAmountInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DebtRedemptionAmountInCash",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption amount in cash",
        "documentation": "Debt redemption amount in cash."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DebtRedemptionAmountInCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DebtRedemptionAmountInCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption amounts in common stock",
        "documentation": "Debt redemption amount in common stock."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DeconsolidationOfDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DeconsolidationOfDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deconsolidation of discontinued operations",
        "documentation": "Deconsolidation of discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r759",
      "r760"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r167",
      "r189",
      "r420",
      "r421",
      "r709"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred income tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r174",
      "r409"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r759",
      "r760"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred income tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r758"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred tax asset, net of allowance",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r758"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. federal operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r758"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r758"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DeferredTaxAssetsResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DeferredTaxAssetsResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r758"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpense",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax assets",
        "label": "Deferred Tax Assets, Tax Deferred Expense",
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r758"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r758"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r758"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use asset",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r758"
     ]
    },
    "QLGN_DefferdTaxAssetsAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DefferdTaxAssetsAccruedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsTaxDeferredExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Defferd tax assets accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r263"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFairValueOfDerivativeNet",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative fair value of warrants",
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments and Warrant Liabilities",
        "documentation": "Derivative Financial Instruments and Warrant Liabilities [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on change in fair value of warrant liabilities",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "QLGN_DilutivePotentialSharesIssuableFromStockOptionsAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DilutivePotentialSharesIssuableFromStockOptionsAndWarrants",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive potential shares issuable from convertible debt, stock options and warrants",
        "documentation": "Dilutive potential shares issuable from stock options and warrants."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisclosureResearchAndLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisclosureResearchAndLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisclosureWarrantLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisclosureWarrantLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss from discontinued operations, net of tax",
        "verboseLabel": "(Loss) from discontinued operations",
        "terseLabel": "INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL",
        "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r105",
      "r107"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss from discontinued operations, net of tax",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r113",
      "r136",
      "r781"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on disposal of discontinued operations",
        "documentation": "Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r118"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share, basic - discontinued operations",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share, diluted - discontinued operations",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0,
       "order": 2.0
      },
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of discontinued operations, net of tax",
        "negatedTerseLabel": "Gain (loss) on disposal of discontinued operations",
        "verboseLabel": "(BENEFIT) PROVISION FOR INCOME TAXES",
        "label": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation",
        "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r107",
      "r118",
      "r762"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS ATTRIBUTABLE TO STOCKHOLDERS",
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations",
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r37"
     ]
    },
    "QLGN_DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and marketing",
        "documentation": "Disposal group including discontinued goodwill and fixed asset impairment."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on disposal of equipment held for lease",
        "documentation": "Disposal group including discontinued loss on disposal of equipment held for lease."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on fixed asset disposal",
        "documentation": "Disposal group including discontinued loss onfixed asset disposal."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net",
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r102",
      "r116",
      "r151"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other current liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r102",
      "r116",
      "r150",
      "r151"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r102",
      "r116",
      "r150",
      "r151"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued vacation",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current",
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r102",
      "r116",
      "r150",
      "r151"
     ]
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationAccruedVacation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedVacation",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued vacation",
        "documentation": "Disposal group including discontinued operation accrued vacation."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated OCI attributable to NanoSynex",
        "documentation": "Disposal group including discontinued operation accumulated oci attributable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/BalanceSheets",
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets of discontinued operations",
        "verboseLabel": "Total non-current assets of discontinued operations",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r7",
      "r102",
      "r116",
      "r151",
      "r195",
      "r196"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r102",
      "r116",
      "r151"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of product sales",
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r196"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue, current portion",
        "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r102",
      "r116",
      "r150",
      "r151"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liability",
        "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r102",
      "r116",
      "r151"
     ]
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of Nan-Synex interest retained",
        "documentation": "Disposal group including discontinued operation fair value of interest retained."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of consideration received",
        "documentation": "Disposal group including discontinued operation fair value of consideration received."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgiveness of debt",
        "documentation": "Disposal group including discontinued operation forgiveness of debt."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain upward upon final payment of transaction cost",
        "documentation": "Disposal group including discontinued operation gain loss."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc.": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc.",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on sale of Qualigen, Inc., net of tax",
        "documentation": "Disposal group including discontinued operation gain on sale of qualigenInc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill and fixed asset impairment",
        "documentation": "Disposal group including discontinued operation goodwill and fixed asset impairment.",
        "label": "Disposal group including discontinued operation goodwill and fixed asset impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill, Current",
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r102",
      "r116",
      "r150",
      "r151"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r7",
      "r102",
      "r116",
      "r151"
     ]
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest (income) expense, net",
        "documentation": "Disposal group including discontinued operation interest income expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, net",
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r102",
      "r116",
      "r150",
      "r151"
     ]
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss from deconsolidation of NanoSynex",
        "documentation": "Disposal group including discontinued operation loss from deconsolidation."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net assets deconsolidated",
        "documentation": "Disposal group including discontinued operation net assets deconsolidated."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationNetProductSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNetProductSales",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net product sales",
        "documentation": "Disposal group including discontinued operation net product sales."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interest share",
        "documentation": "Disposal group including discontinued operation non controlling interest share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total other expense (income), net",
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, current portion",
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r102",
      "r116",
      "r150",
      "r151"
     ]
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expense (income), net",
        "documentation": "Amount of other income expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent",
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r7",
      "r102",
      "r116",
      "r151"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total non-current liabilities of discontinued operations",
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r7",
      "r102",
      "r116",
      "r151"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other current assets",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r102",
      "r116",
      "r150",
      "r151"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, net",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r7",
      "r102",
      "r116",
      "r151"
     ]
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "documentation": "Disposal group including discontinued operation property right of use assets."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "documentation": "Disposal group including discontinued operation research and development.",
        "label": "Disposal group including discontinued operation research and development"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D grant liability",
        "documentation": "Disposal group including discontinued operation research and development grant liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total revenues",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r196"
     ]
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short term debt-related party",
        "documentation": "Disposal group including discontinued operation short term debt related party."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationTotalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationTotalAssets",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets of discontinued operations of NanoSynex",
        "documentation": "Disposal group including discontinued operation total assets."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationTotalLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationTotalLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities of discontinued operations of NanoSynex",
        "documentation": "Disposal group including discontinued operation total liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationTransactionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationTransactionExpenses",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction expenses",
        "documentation": "Disposal group including discontinued operation transaction expenses."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital adjustment",
        "documentation": "Disposal group including discontinued operation working capital adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedSalesAndMarketing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedSalesAndMarketing",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and fixed asset impairment",
        "documentation": "Disposal group including discontinued sales and marketing."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_DisposalGroupIncludingDiscontinuedTotalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedTotalExpenses",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total expenses",
        "documentation": "Disposal group including discontinued total expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "DISCONTINUED OPERATIONS",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r149"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r683",
      "r684"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r683",
      "r684",
      "r686"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/EarningsLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EARNINGS (LOSS) PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r254",
      "r255",
      "r256"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes provision (benefit)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory federal income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r403",
      "r423"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r761"
     ]
    },
    "QLGN_EffectiveIncomeTaxRateReconciliationFairValueOfWarrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationFairValueOfWarrant",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liability",
        "documentation": "Effective income tax rate reconciliation fair value of warrant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign rate differential",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r761"
     ]
    },
    "QLGN_EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration": {
     "xbrltype": "percentItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOL expiration",
        "documentation": "Effective income tax rate reconciliation non operating loss expiration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible expenses",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depletion."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r761"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill impairment",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r761"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State taxes, net of federal tax benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r761"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r761"
     ]
    },
    "QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture": {
     "xbrltype": "percentItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax impact of convertible debenture",
        "documentation": "Effective income tax rate reconciliation tax impact of convertible debenture."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture": {
     "xbrltype": "percentItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax impact of divestiture",
        "documentation": "Effective income tax rate reconciliation tax impact of divestiture."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_EffectiveIncomeTaxRateReconciliationTrueUp": {
     "xbrltype": "percentItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationTrueUp",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReconciliationsOfStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "True-up",
        "documentation": "Effective income tax rate true-up."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of embedded derivative features",
        "documentation": "Net fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost related to nonvested",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_EmployeesAndNonemployeeServiceProviderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "EmployeesAndNonemployeeServiceProviderMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees and Non-employee Service Provider [Member]",
        "documentation": "Employees and Non-employee Service Provider [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsTables",
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsTables",
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityTables",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r193",
      "r211",
      "r212",
      "r213",
      "r231",
      "r232",
      "r233",
      "r235",
      "r240",
      "r242",
      "r257",
      "r286",
      "r287",
      "r350",
      "r392",
      "r393",
      "r394",
      "r416",
      "r417",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r460",
      "r521",
      "r522",
      "r523",
      "r540",
      "r606"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "auth_ref": [
      "r282",
      "r283",
      "r284"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r93",
      "r283"
     ]
    },
    "us-gaap_EscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EscrowDeposit",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Funds held in escrow",
        "verboseLabel": "Escrow deposit",
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r628"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtinguishmentOfDebtAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Debt [Axis]",
        "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtTypeDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of debt extinguished."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "QLGN_FairValueAdjustmentOfWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "FairValueAdjustmentOfWarrant",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value for warrant liabilities",
        "periodEndLabel": "Fair value for warrant liabilities",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "FairValueAdjustmentOfWarrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liabilities",
        "verboseLabel": "Fair value of warrant liability",
        "terseLabel": "Fair value adjustment of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r446",
      "r471",
      "r472",
      "r473",
      "r642",
      "r643",
      "r648",
      "r649",
      "r650"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r354",
      "r359",
      "r446",
      "r471",
      "r648",
      "r649",
      "r650"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r354",
      "r359",
      "r446",
      "r472",
      "r642",
      "r643",
      "r648",
      "r649",
      "r650"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r446",
      "r473",
      "r642",
      "r643",
      "r648",
      "r649",
      "r650"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r471",
      "r472",
      "r473",
      "r642",
      "r643",
      "r648",
      "r649",
      "r650"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r34"
     ]
    },
    "QLGN_FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrant liabilities, Loss on debt extinguishment",
        "documentation": "Fair value of warrant liabilities loss on debt extinguishment."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "FairValueOfWarrantLiabilitiesOnDateOfExercise",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails",
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant liabilities on date of exercise",
        "verboseLabel": "Common Stock Warrant liabilities, Exercises",
        "documentation": "Fair value of warrant liabilities on date of exercise."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_FairValueOfWarrantLiabilitiesOnToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "FairValueOfWarrantLiabilitiesOnToEquity",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrant liabilities, Fair value of warrant liabilities to equity",
        "documentation": "Fair value of  warrant liabilities on to equity."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_FairValueOfWarrantModificationForBusinessAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "FairValueOfWarrantModificationForBusinessAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant modification for business acquisition",
        "documentation": "Fair value of warrant modification for business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_FairValueOfWarrantModificationForProfessionalServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "FairValueOfWarrantModificationForProfessionalServices",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of warrant modification for professional services",
        "documentation": "Fair value of warrant modification for professional services.",
        "label": "FairValueOfWarrantModificationForProfessionalServices"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_FairValueOfWarrantModificationsForBusinessAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "FairValueOfWarrantModificationsForBusinessAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant modifications for business acquisition",
        "documentation": "Fair value of warrant modifications for business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant modifications pursuant to Securities Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_FairValueOfWarrantReclassifiedFromLiabilitiesToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "FairValueOfWarrantReclassifiedFromLiabilitiesToEquity",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant reclassified from liabilities to equity",
        "documentation": "Fair value of warrant reclassified from liabilities to equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "QLGN_FractionalSharePaymentsRelatedToReverseStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "FractionalSharePaymentsRelatedToReverseStockSplit",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fractional share payments related to the reverse stock split",
        "documentation": "Fractional share payments related to the reverse stock split.",
        "label": "FractionalSharePaymentsRelatedToReverseStockSplit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfInvestments",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on sale of Qualigen, Inc.",
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on fixed asset disposal",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of other assets."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows",
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on debt extinguishment",
        "label": "Extinguishment loss",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r68",
      "r69"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r588"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "QLGN_GlobalEconomicConditionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "GlobalEconomicConditionsPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Global Economic Conditions",
        "documentation": "Global Economic Conditions [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r65"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill impairment charges",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r288",
      "r289",
      "r290",
      "r640"
     ]
    },
    "us-gaap_HedgingLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HedgingLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities",
        "documentation": "Carrying amount as of the balance sheet date of the liability arising from a financial instrument or a contract used to mitigate a specified risk (hedge), and which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r683",
      "r684"
     ]
    },
    "QLGN_ImpactOfCovid19PandemicPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ImpactOfCovid19PandemicPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impact of COVID-19 Pandemic",
        "documentation": "Impact Of Covid19 Pandemic [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r153"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDomesticAndForeignComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r422"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDomesticAndForeignComponentsDetails",
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES",
        "label": "Loss before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r135",
      "r179",
      "r260",
      "r272",
      "r276",
      "r278",
      "r493",
      "r505",
      "r636"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDomesticAndForeignComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r422"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows",
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS FROM CONTINUING OPERATIONS",
        "totalLabel": "Loss from continuing operations",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r227",
      "r234",
      "r260",
      "r272",
      "r276",
      "r278",
      "r285",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r445",
      "r450",
      "r505",
      "r636",
      "r722"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share, basic - continuing operations",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r178",
      "r180",
      "r217",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r247",
      "r251",
      "r252",
      "r445",
      "r492",
      "r782"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share, diluted - continuing operations",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r217",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r247",
      "r251",
      "r252",
      "r253",
      "r445",
      "r492",
      "r782"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM DISCONTINUED OPERATIONS",
        "label": "LOSS FROM DISCONTINUED OPERATIONS",
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r118",
      "r196",
      "r425",
      "r506"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DISCONTINUED OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r591"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r591"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r398",
      "r404",
      "r406",
      "r413",
      "r418",
      "r424",
      "r426",
      "r427",
      "r534"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      },
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(BENEFIT) PROVISION FOR INCOME TAXES",
        "totalLabel": "Total provision (benefit) for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r190",
      "r241",
      "r242",
      "r264",
      "r402",
      "r419",
      "r513"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r400",
      "r401",
      "r406",
      "r407",
      "r412",
      "r414",
      "r528"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_InducedConversionOfConvertibleDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InducedConversionOfConvertibleDebtExpense",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on voluntary conversion of convertible debt",
        "documentation": "Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense, net",
        "label": "Interest Income (Expense), Net",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r222",
      "r223"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest (Convertible debt)",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAndOtherNoncurrentAssetsTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OtherNon-currentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER NON-CURRENT ASSETS",
        "documentation": "The entire disclosure for investments and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsTables",
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r227",
      "r285",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r432",
      "r435",
      "r436",
      "r450",
      "r561",
      "r635",
      "r669",
      "r722",
      "r771",
      "r772"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities &amp; Stockholders\u2019 Equity (Deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r177",
      "r503",
      "r656",
      "r708",
      "r715",
      "r767"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r198",
      "r227",
      "r285",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r432",
      "r435",
      "r436",
      "r450",
      "r656",
      "r722",
      "r771",
      "r772"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/BalanceSheets",
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities of discontinued operations",
        "verboseLabel": "Total current liabilities of discontinued operations",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r102",
      "r116",
      "r150",
      "r151",
      "r195",
      "r196"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/BalanceSheets",
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities of discontinued operations",
        "verboseLabel": "Total non-current liabilities of discontinued operations",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r7",
      "r102",
      "r116",
      "r151",
      "r195",
      "r196"
     ]
    },
    "QLGN_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_LicenseAndSponsoredResearchAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "LicenseAndSponsoredResearchAgreementsMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Sponsored Research Agreements [Member]",
        "documentation": "License and Sponsored Research Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_LicenseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "LicenseCost",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License costs",
        "documentation": "License costs."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_LicensedProductSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "LicensedProductSalesMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensed Product Sales [Member]",
        "documentation": "Licensed Product Sales [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation paid",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_LongtermResearchAndDevelopmentDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "LongtermResearchAndDevelopmentDeposits",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term research and development deposits",
        "documentation": "Long-term research and development deposits"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_LossOnVoluntaryConversionOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "LossOnVoluntaryConversionOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on voluntary conversion of convertible debt",
        "documentation": "Loss on voluntary conversion of convertible debt.",
        "label": "LossOnVoluntaryConversionOfConvertibleDebt"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_MLMMedicalLabsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "MLMMedicalLabsMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MLM Medical Labs [Member]",
        "documentation": "MLM Medical Labs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_MasterLaboratoryServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "MasterLaboratoryServicesAgreementMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Laboratory Services Agreement [Member]",
        "documentation": "Master Laboratory Services Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r361",
      "r475",
      "r520",
      "r553",
      "r554",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r630",
      "r631",
      "r638",
      "r646",
      "r653",
      "r658",
      "r726",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "MilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone payment",
        "documentation": "Milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r361",
      "r475",
      "r520",
      "r553",
      "r554",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r630",
      "r631",
      "r638",
      "r646",
      "r653",
      "r658",
      "r726",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r176",
      "r227",
      "r285",
      "r299",
      "r301",
      "r302",
      "r303",
      "r306",
      "r307",
      "r450",
      "r502",
      "r565"
     ]
    },
    "QLGN_ModifiedToExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ModifiedToExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modified to exercise price",
        "documentation": "Modified to exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_NanoSynexLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "NanoSynexLtdMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NanoSynex Ltd [Member]",
        "documentation": "Nano Synex Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_NanosynexMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "NanosynexMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsTables",
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NanoSynex [Member]",
        "documentation": "Nano Synex [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in)/provided by financing activities - continuing operations",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net Cash Provided by (Used in) Operating Activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities - continuing operations",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to Qualigen Therapeutics, Inc.",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r145",
      "r181",
      "r196",
      "r206",
      "r208",
      "r213",
      "r227",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r249",
      "r260",
      "r272",
      "r276",
      "r278",
      "r285",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r445",
      "r450",
      "r509",
      "r585",
      "r604",
      "r605",
      "r636",
      "r667",
      "r722"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss attributable to non-controlling interest from discontinued operations",
        "verboseLabel": "Loss attributable to noncontrolling interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r170",
      "r206",
      "r208",
      "r241",
      "r242",
      "r508",
      "r702"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss used for basic earnings per share",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r236",
      "r237",
      "r238",
      "r239",
      "r244",
      "r245",
      "r250",
      "r253",
      "r260",
      "r272",
      "r276",
      "r278",
      "r636"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_NonCompensatoryWarrantActivityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "NonCompensatoryWarrantActivityMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Compensatory Warrant Activity [Member]",
        "documentation": "Non Compensatory Warrant Activity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NONCASH FINANCING AND INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_NoncompensatoryEquityClassifiedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "NoncompensatoryEquityClassifiedWarrantsMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncompensatory Equity Classified Warrants [Member]",
        "documentation": "Noncompensatory Equity Classified Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling interest adjustments relating to Stock-based compensation and other",
        "documentation": "Noncontrolling interest adjustments relating to stockbased compensation and other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r350",
      "r710",
      "r711",
      "r712",
      "r786"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total other expense (income), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER EXPENSE (INCOME), NET"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_OctoberPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "OctoberPaymentMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October Payment [Member]",
        "documentation": "October Payment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM OPERATIONS",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r272",
      "r276",
      "r278",
      "r636"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r146",
      "r147",
      "r168"
     ]
    },
    "QLGN_OrganizationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "OrganizationPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization",
        "documentation": "Organization Policy [TextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r199",
      "r495",
      "r669"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r20",
      "r169"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment from discontinued operations",
        "verboseLabel": "Foreign currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss, net of tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r716"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]"
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsTables",
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_PatentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "PatentCosts",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent costs",
        "documentation": "Patent costs."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Costs",
        "documentation": "Patent Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees and costs paid",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "QLGN_PhaseOneClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "PhaseOneClinicalTrialMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 1 Clinical Trial [Member]",
        "documentation": "Phase 1 Clinical Trial [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_PhaseThreeClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "PhaseThreeClinicalTrialMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 3 Clinical Trial [Member]",
        "documentation": "Phase 3 Clinical Trial [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_PhaseTwoClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "PhaseTwoClinicalTrialMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase 2 Clinical Trial [Member]",
        "documentation": "Phase 2 Clinical Trial [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "QLGN_PreapaidResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "PreapaidResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid research and development expenses",
        "documentation": "Preapaid research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r563",
      "r583",
      "r786",
      "r788"
     ]
    },
    "QLGN_PrefundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "PrefundedWarrantMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded Warrant [Member]",
        "documentation": "Pre-funded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets",
      "http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r639",
      "r716"
     ]
    },
    "QLGN_PrincipalAmountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "PrincipalAmountPercentage",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount percentage",
        "documentation": "Principal amount percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/LiquidityAndGoingConcernDetailsNarrative",
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "verboseLabel": "Proceeds from convertible debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "QLGN_ProceedsFromIssuanceOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ProceedsFromIssuanceOfConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of convertible debt",
        "documentation": "Proceeds from issuance of convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance or sale of equity",
        "verboseLabel": "Cash purchase price",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r529"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from warrant exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r279",
      "r476",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r632",
      "r647",
      "r657",
      "r692",
      "r719",
      "r720",
      "r729",
      "r783"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "auth_ref": [
      "r279",
      "r476",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r632",
      "r647",
      "r657",
      "r692",
      "r719",
      "r720",
      "r729",
      "r783"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows",
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r206",
      "r208",
      "r220",
      "r227",
      "r234",
      "r241",
      "r242",
      "r260",
      "r272",
      "r276",
      "r278",
      "r285",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r430",
      "r433",
      "r434",
      "r445",
      "r450",
      "r493",
      "r507",
      "r539",
      "r585",
      "r604",
      "r605",
      "r636",
      "r654",
      "r655",
      "r668",
      "r702",
      "r722"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r494",
      "r504",
      "r656"
     ]
    },
    "QLGN_PurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "PurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price",
        "verboseLabel": "Purchase Price",
        "documentation": "Purchase price."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r353",
      "r361",
      "r386",
      "r387",
      "r388",
      "r474",
      "r475",
      "r520",
      "r553",
      "r554",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r630",
      "r631",
      "r638",
      "r646",
      "r653",
      "r658",
      "r661",
      "r717",
      "r726",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r353",
      "r361",
      "r386",
      "r387",
      "r388",
      "r474",
      "r475",
      "r520",
      "r553",
      "r554",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r630",
      "r631",
      "r638",
      "r646",
      "r653",
      "r658",
      "r661",
      "r717",
      "r726",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "QLGN_RangeOfExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RangeOfExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Range of Exercise Price, Beginning",
        "periodEndLabel": "Range of Exercise Ending",
        "documentation": "Range of exercise price.",
        "label": "RangeOfExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_RangeOfExercisePriceExercisableExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RangeOfExercisePriceExercisableExpired",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Range of exercise price, expired",
        "documentation": "Range of exercise price exercisable expired.",
        "label": "RangeOfExercisePriceExercisableExpired"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_RangeOfExercisePriceExercisableGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RangeOfExercisePriceExercisableGranted",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise price, granted",
        "documentation": "Range of exercise price exercisable granted."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_RangeOfExercisePriceExercisableVested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RangeOfExercisePriceExercisableVested",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Range of Exercise Price, Exercisable",
        "label": "Range of exercise price - Exercisable",
        "documentation": "Range of exercise price, exercisable (vested)."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_RangeOfExercisePriceExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RangeOfExercisePriceExercised",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise price, exercised",
        "documentation": "Range of exercise price exercised."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_RangeOfExercisePriceExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RangeOfExercisePriceExpired",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price, Expired",
        "verboseLabel": "Range of exercise price, expired",
        "documentation": "Range of exercise price expired."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_RangeOfExercisePriceForfeited": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RangeOfExercisePriceForfeited",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise price, forfeited",
        "documentation": "Range of exercise price forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_RangeOfExercisePriceGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RangeOfExercisePriceGranted",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price, Granted",
        "documentation": "Range of exercise price granted."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_RangeOfExercisePriceNonexercisableNonvested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RangeOfExercisePriceNonexercisableNonvested",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price, Non-Exercisable",
        "documentation": "Range of exercise price, non-exercisable (non-vested)."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_RangeOfExercisePriceOutstanding": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RangeOfExercisePriceOutstanding",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Range of exercise price",
        "periodEndLabel": "Range of exercise price",
        "documentation": "Range Of Exercise Price Outstanding.",
        "label": "RangeOfExercisePriceOutstanding"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise price, reclassification of Alpha warrant from warrant liabilities to equity",
        "documentation": "Range of exercise price reclassification of  alpha warrant from warrant liabilities to equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivableInvestmentSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableInvestmentSale",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable from sale of Qualigen, Inc.",
        "documentation": "Amount of receivable from sale of investment."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r613",
      "r669"
     ]
    },
    "QLGN_RedemptionOfConvertibleDebtIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RedemptionOfConvertibleDebtIntoCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption of convertible debt into common stock"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_RegulatoryMarketingApprovalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RegulatoryMarketingApprovalExpenses",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing approval expenses",
        "documentation": "Regulatory marketing approval, expenses."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_RegulatoryMarketingApprovalExpensesOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "RegulatoryMarketingApprovalExpensesOne",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory marketing approval, expenses",
        "documentation": "Regulatory marketing approval expenses one."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ReimbursementExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ReimbursementExpenses",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement expenses",
        "documentation": "Reimbursement expenses."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ReimbursementOfPatent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ReimbursementOfPatent",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement of patent",
        "documentation": "Reimbursement of patent."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ReimbursementOfResearchExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ReimbursementOfResearchExpenses",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement of research expenses",
        "documentation": "Reimbursement of research expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r464",
      "r465",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r582",
      "r584",
      "r614"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r464",
      "r465",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r582",
      "r584",
      "r614",
      "r770"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r535",
      "r536",
      "r537",
      "r589",
      "r590",
      "r591",
      "r610",
      "r612"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable debt",
        "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on convertible notes payable",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r397",
      "r779"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "QLGN_ResearchAndLicenseAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ResearchAndLicenseAgreementsTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RESEARCH AND LICENSE AGREEMENTS",
        "documentation": "Research And License Agreements [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets",
      "http://qualigendiagnostics.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r159",
      "r501",
      "r524",
      "r526",
      "r533",
      "r564",
      "r656"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r231",
      "r232",
      "r233",
      "r235",
      "r240",
      "r242",
      "r286",
      "r287",
      "r392",
      "r393",
      "r394",
      "r416",
      "r417",
      "r437",
      "r439",
      "r440",
      "r442",
      "r444",
      "r521",
      "r523",
      "r540",
      "r786"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r271",
      "r274",
      "r275",
      "r279",
      "r280",
      "r281",
      "r351",
      "r352",
      "r476"
     ]
    },
    "QLGN_ReverseStockSplitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ReverseStockSplitPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split",
        "documentation": "Reverse Stock Split [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Resale of common stock shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/EarningsLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES",
        "documentation": "Schedule Of Assumptions Of Warrant Liabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROVISION FOR INCOME TAXES",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]",
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r161"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r33",
      "r36",
      "r102",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r117",
      "r119",
      "r120",
      "r152"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284"
     ]
    },
    "QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES",
        "documentation": "Schedule Of Fair Value Hierarchy For Warrant Liabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DOMESTIC AND FOREIGN COMPONENTS",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OtherNon-currentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OTHER NON CURRENT ASSETS",
        "documentation": "Tabular disclosure of noncurrent assets."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "QLGN_ScheduleOfReservedSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ScheduleOfReservedSharesTableTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESERVED SHARES",
        "documentation": "Schedule Of Reserved Shares [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r77"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Short-Term Debt [Table]",
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANTS ACTIVITY",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_SecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior convertible debenture",
        "verboseLabel": "Principal amount",
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r175",
      "r780"
     ]
    },
    "QLGN_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r280",
      "r637"
     ]
    },
    "QLGN_SeniorConvertibleDebentureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "SeniorConvertibleDebentureMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Convertible Debenture [Member]",
        "documentation": "Senior Convertible Debenture [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_SeniorSecuredConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "SeniorSecuredConvertibleDebtMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Secured Convertible Debt [Member]",
        "documentation": "Senior Secured Convertible Debt [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_SeriesAOnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "SeriesAOnePreferredStockMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A-1 Preferred Stock [Member]",
        "documentation": "Series A-1 Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r697",
      "r728"
     ]
    },
    "QLGN_SeriesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "SeriesCWarrantsMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Warrants [Member]",
        "documentation": "Series C Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Compensation cost",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected stock-price volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ]
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, warrants non-exercisable",
        "documentation": "Number of shares, warrants non-exercisable (non-vested)."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Shares, Warrants Exercisable",
        "label": "Warrants exercisable",
        "verboseLabel": "Number of Shares, Warrants Exercisable",
        "documentation": "The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Per Share Non-Exercisable",
        "documentation": "Weighted average exercise price per share non-exercisable (non-vested)."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Per Share Exercisable",
        "label": "Weighted average exercise price, exercisable",
        "documentation": "Weighted average exercise price per share exercisable (vested)."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average exercise price, exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercisable weighted average vested non exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Warrants Exercised",
        "label": "Number of Shares, Warrants Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Per Share Warrants Exercised",
        "verboseLabel": "Weighted average exercise price, warrants exercised",
        "documentation": "Weighted average exercise price per share warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Warrants Expired",
        "negatedLabel": "Number of Shares, Warrants Expired",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Per Share Warrants Expired",
        "verboseLabel": "Weighted average exercise price, warrants expired",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise price, expired",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments expired in range of exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Per Share Warrants Forfeited",
        "verboseLabel": "Weighted average exercise price, warrants forfeited",
        "documentation": "Weighted average exercise price per share warrants forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Warrants Forfeited",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Warrants Granted",
        "verboseLabel": "Number of shares, warrants granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-Average Remaining Life (Years) Outstanding",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments granted weighted averag remaining contractual term1.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Per Share Warrants Granted",
        "verboseLabel": "Weighted average exercise price, warrants granted",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average common stock warrants reverse recapitalization."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares legal ritter warrants",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments legal ritter warrants."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, legal ritter warrants",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments legal ritter warrants weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Warrants Exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments non exercisable number."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Remaining Life (Years) Outstanding",
        "verboseLabel": "Weighted average remaining life (Years) exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-Average Remaining Life (Years) Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Warrants Outstanding Beginning",
        "periodEndLabel": "Number of Shares, Warrants Outstanding Ending",
        "label": "Warrants outstanding",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25"
     ]
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining life (Years) exercisable",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Per Share Warrants Outstanding Beginning",
        "periodEndLabel": "Weighted Average Exercise Price Per Share Warrants Outstanding Ending",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, warrants reclassification of Alpha warrant from warrant liabilities to equity",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments reclassification of alpha warrant from warrant liabilities to equity."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average exercise price, reclassification of Alpha warrant from warrant liabilities to equity",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments eeclassification of alpha warrant from warrant liabilities to equity weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Range of Exercise price, Options Outstanding",
        "documentation": "Share based compensation arrangement by share based payment award option expired weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise price, Options Outstanding",
        "documentation": "Share based compensation arrangement by share based payment award option granted weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, options expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise price, Options Forfeited",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, options forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, options granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, options outstanding, beginning",
        "periodEndLabel": "Number of Shares, Options Outstanding at Ending",
        "label": "Options outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Range of Exercise price, Options Outstanding",
        "periodEndLabel": "Range of Exercise price, Options Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368"
     ]
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, options non-exercisable (non-vested)",
        "documentation": "Weighted average exercise price, options non-exercisable (non-vested)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, options exercisable (vested)",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise price, options exercisable (vested)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, options expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, options forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, options granted",
        "verboseLabel": "Stock option granted exercise price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected average term of options (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- Average Remaining Contractual Life (in Years), Options Granted",
        "documentation": "Weighted- Average Remaining Contractual Life (in Years), Options Granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, options non-exercisable (non-vested)",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants forfeited",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of exercise price, options non-exercisable (non-vested)",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending",
        "verboseLabel": "Cost is expected to be recognized over a weighted average period",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtInterestRateIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtInterestRateIncrease",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior convertible debenture rate",
        "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfSeniorSecuredConvertibleDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_ShortfallPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "ShortfallPayments",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shortfall payments",
        "documentation": "Shortfall payments."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "QLGN_SponsoredResearchAgreementAndLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "SponsoredResearchAgreementAndLicenseMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsored Research and License Agreement [Member]",
        "documentation": "Sponsored Research and License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_SponsoredResearchAgreementsAndLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "SponsoredResearchAgreementsAndLicenseMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsored Research Agreements And License [Member]",
        "documentation": "Sponsored Research Agreements And License [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r201",
      "r202",
      "r203",
      "r227",
      "r247",
      "r248",
      "r251",
      "r253",
      "r258",
      "r259",
      "r285",
      "r299",
      "r301",
      "r302",
      "r303",
      "r306",
      "r307",
      "r335",
      "r336",
      "r338",
      "r341",
      "r347",
      "r450",
      "r529",
      "r530",
      "r531",
      "r532",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r563",
      "r586",
      "r606",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r691",
      "r706",
      "r713"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsTables",
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityTables",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r48",
      "r193",
      "r211",
      "r212",
      "r213",
      "r231",
      "r232",
      "r233",
      "r235",
      "r240",
      "r242",
      "r257",
      "r286",
      "r287",
      "r350",
      "r392",
      "r393",
      "r394",
      "r416",
      "r417",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r460",
      "r521",
      "r522",
      "r523",
      "r540",
      "r606"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsTables",
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r257",
      "r476",
      "r527",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r563",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r587",
      "r588",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r606",
      "r662"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsTables",
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionUsedInBlack-scholesOption-pricingMethodDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r257",
      "r476",
      "r527",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r563",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r587",
      "r588",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r606",
      "r662"
     ]
    },
    "QLGN_StockIssuedDuringPeriodShareSurrender": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "StockIssuedDuringPeriodShareSurrender",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares surrender",
        "documentation": "Stock issued during period share surrender."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during period shares acquisitions",
        "verboseLabel": "Number of common stock acquired shares",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127",
      "r159"
     ]
    },
    "QLGN_StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock and prefunded warrants issued for business acquisition, shares",
        "documentation": "Stock issued during period shares common stock and prefunded warrants issued for business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary conversion of convertible debt into common stock, shares",
        "verboseLabel": "October payment in shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r47",
      "r71",
      "r159",
      "r325"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued",
        "verboseLabel": "Number of shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r126",
      "r127",
      "r159",
      "r529",
      "r606",
      "r621"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued upon exercise of warrants, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease",
     "presentation": [
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of shares increase decrease",
        "documentation": "The increase (decrease) during the period in the number of shares issued."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r786",
      "r787"
     ]
    },
    "QLGN_StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemptions of convertible debt into common stock, shares",
        "documentation": "Redemptions of convertible debt into common stock, shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of rounded shares as a result of the reverse stock split, shares",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r126",
      "r127",
      "r159",
      "r372"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "presentation": [
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants reissued",
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r127",
      "r159"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during period, value, acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r48",
      "r159"
     ]
    },
    "QLGN_StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock and prefunded warrants issued for business acquisition",
        "documentation": "Stock issued during period value common stock and prefunded warrants issued for business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Voluntary conversion of convertible debt into common stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r48",
      "r159"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued upon exercise of warrants",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemptions of convertible debt into common stock",
        "documentation": "Redemptions of convertible debt into common stock, value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregrate amount",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "QLGN_StockIssuedDuringPeriodValuesReverseStockSplits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "StockIssuedDuringPeriodValuesReverseStockSplits",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of rounded shares as a result of the reverse stock split",
        "documentation": "Stock issued during period values reverse stock splits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Qualigen Therapeutics, Inc. stockholders\u2019 equity (deficit)",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r130",
      "r131",
      "r148",
      "r565",
      "r583",
      "r607",
      "r608",
      "r656",
      "r669",
      "r708",
      "r715",
      "r767",
      "r786"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Qualigen Therapeutics, Inc. stockholders\u2019 equity (deficit):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets",
      "http://qualigendiagnostics.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity (deficit)",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r90",
      "r193",
      "r194",
      "r212",
      "r231",
      "r232",
      "r233",
      "r235",
      "r240",
      "r286",
      "r287",
      "r350",
      "r392",
      "r393",
      "r394",
      "r416",
      "r417",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r452",
      "r453",
      "r457",
      "r460",
      "r522",
      "r523",
      "r538",
      "r565",
      "r583",
      "r607",
      "r608",
      "r625",
      "r668",
      "r708",
      "r715",
      "r767",
      "r786"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity (deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r226",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r350",
      "r443",
      "r609",
      "r611",
      "r626"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "QLGN_StockholdersEquityReverseStockSplitPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "StockholdersEquityReverseStockSplitPricePerShare",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split, price per share",
        "documentation": "Stockholders equity reverse stock split price per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r469"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r469"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r469"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r469"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r469"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r470"
     ]
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/LiquidityAndGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY AND GOING CONCERN",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "QLGN_SummaryOfWarrantActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "SummaryOfWarrantActivityTableTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANT ACTIVITY",
        "documentation": "Summary Of Warrant Activity [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credit carryforward, limitations on use",
        "documentation": "Description of the limitation related to use of the tax credit carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r769"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "auth_ref": []
    },
    "QLGN_TotalAssetsOfDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "TotalAssetsOfDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets of discontinued operations",
        "verboseLabel": "Total assets of discontinued operations of Qualigen, Inc.",
        "documentation": "Total assets of discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_TotalLiabilitiesOfdiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "TotalLiabilitiesOfdiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/AssetsAndLiabilitiesClassifiedInDiscontinuedOperationsDetails",
      "http://qualigendiagnostics.com/role/ScheduleOfBalanceSheetsAndIncomeStatementClassifiedInDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total liabilities of discontinued operations",
        "verboseLabel": "Total liabilities of discontinued operations of Qualigen, Inc.",
        "documentation": "Total liabilities of discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_TransfersOfInventoryFromEquipmentHeldForLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "TransfersOfInventoryFromEquipmentHeldForLease",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net transfers to equipment held for lease from inventory",
        "documentation": "Transfers of inventory from equipment held for lease."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_TwentyTwentyFourDebentureAndWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "TwentyTwentyFourDebentureAndWarrantMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Debenture And Warrant [Member]",
        "documentation": "2024 Debenture And Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_TwentyTwentyFourDebentureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "TwentyTwentyFourDebentureMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Debenture [Member]",
        "documentation": "2024 Debenture [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_TwentyTwentyFourWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "TwentyTwentyFourWarrantMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Warrant [Member]",
        "documentation": "2024 Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_TwoThousandTwentyStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "TwoThousandTwentyStockIncentivePlanMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2020 Stock Incentive Plan [Member]",
        "documentation": "2020 Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative",
      "http://qualigendiagnostics.com/role/DiscontinuedOperationsDetailsNarrative",
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigendiagnostics.com/role/SubsequentEventsDetailsNarrative",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "QLGN_UniversityOfLouisvilleResearchFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "UniversityOfLouisvilleResearchFoundationMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "University of Louisville Research Foundation [Member]",
        "documentation": "University of Louisville Research Foundation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r405"
     ]
    },
    "QLGN_UpfrontLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "UpfrontLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront license fee",
        "documentation": "Upfront license fee."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_UpfrontPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "UpfrontPaymentMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Payment [Member]",
        "documentation": "Upfront Payment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://qualigendiagnostics.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r185",
      "r186",
      "r187",
      "r188"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "VoluntaryConversionOfConvertibleDebtIntoCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Voluntary conversion of convertible debt into common stock",
        "documentation": "Voluntary conversion of convertible debt into common stock.",
        "label": "VoluntaryConversionOfConvertibleDebtIntoCommonStock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1",
     "crdr": "credit",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability to equity",
        "documentation": "Amount of increase (decrease) in equity for down round feature triggered for warrant classified as equity."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r349"
     ]
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion price",
        "label": "Warrant, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://qualigendiagnostics.com/role/ConvertibleDebt-RelatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion price",
        "label": "Warrant, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "QLGN_WarrantLiabilitiesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "WarrantLiabilitiesRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://qualigendiagnostics.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://qualigendiagnostics.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities - related party",
        "documentation": "Warrant liabilities related party."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_WarrantLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "WarrantLiabilitiesTextBlock",
     "presentation": [
      "http://qualigendiagnostics.com/role/WarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANT LIABILITIES",
        "documentation": "Warrant Liabilities [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfReservedSharesDetails",
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r660",
      "r663",
      "r664",
      "r665",
      "r666"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants expired date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value assumptions, measurement input, percentages",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigendiagnostics.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value assumptions, measurement input, term",
        "verboseLabel": "Warrants and rights outstanding term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "QLGN_WarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "WarrantsExercised",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "QLGN_WarrantsExtendedDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "WarrantsExtendedDateDescription",
     "presentation": [
      "http://qualigendiagnostics.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants extended date description",
        "documentation": "Warrants extended date, description."
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r631",
      "r773",
      "r775",
      "r778"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails",
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average number of shares outstanding, diluted",
        "verboseLabel": "Diluted weighted-average common shares outstanding",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r253"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfDilutiveSecuritiesExcludedFromDilutedNetLossPerShareDetails",
      "http://qualigendiagnostics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average number of shares outstanding, basic",
        "verboseLabel": "Basic weighted-average common shares outstanding",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r253"
     ]
    },
    "QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested": {
     "xbrltype": "durationItemType",
     "nsuri": "http://qualigendiagnostics.com/20231231",
     "localname": "WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested",
     "presentation": [
      "http://qualigendiagnostics.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)",
        "documentation": "Weighted- average remaining contractual life (in years), options non-exercisable (non-vested)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://qualigendiagnostics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-11"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480463/815-10-45-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(4)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "c(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a),(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "40",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481194/470-20-40-16"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481244/470-50-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-3"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-40/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001493152-24-013400-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-013400-xbrl.zip
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ME. 1^%!$8B[!(]&YETX%RZR,B+*H0)?WN8QAF79+:#DX7(8BBZ MH(05#ZH
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M*,, DP4]A59**;I$)BC*,C"#P['0.Z5%CH_85D-8.!HQK!64$S3&HN]0_/Q
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M2 V/ILA*L66_H1\TB[A5NB1E% &B>QK:3Q)N+6-?4)8C!?$JWH\X]!Q;)(?
M52"W#&H_^(MYNR?P.:BW#QD'PSB:SF3H]B*/]CGZ?8Y^ESFH)4JNC)@OXD Q
MF)#&_:^0,W#S/"!;I+]GC-YAT,1,(21\I@EUP6*G?A-YE,P;?6YWSJ>I_=;E
M!E5!(WC0L(6H^ Q;E"0CG_G"^H%:E :Z=3&A ?.;+ 'W ;L[,^4"=.-[&/L0
M;A_"_0 9])8LF2*.-2SR%7!LYA0/\(A[-S GG(H/1[B<*C%E&)-(.LY?GM2Y
M2&))*M2<849WHKPRHJMT5E*+*;&5N/'XD0)AUS]SV/S=SU*FK,J2==GR/)DR
M JIENAHJ(6AJ %!Q=. ^9-LF(># /T=@G-5_WJH3I9KG*^99A9S63]^N3J8M
MP-TJVLMYXXOP\G$L].5(T/".G!R? 5RWR>.K+-6!M]OM0;-[43,U#WS#)SW-
M6O=BP\J]$U/P!5W].5-MF[!N:,*^/,.^!:J5>>+Q+";+?J)\(U@!MV(G9PIG
ML4=RO= )_3R=<SCP6\QPZ=[-H\US:2MYAI^J56B0B:A!!J"HS@']APPB/D1]
M3OJIRW(T2(\:2ZK5PI#M[O\V-IC:>TW^!Z^M4?_E.O5CJJ%,PN.SDF!-.MQG
M^*4#;G"K3T648+%[8C%I[G^U^DES]Z.58HB:-3!88;L5B]?0Y-ZL7_?#>==>
M#3_R]U_]XW\.\']02P,$%     @ ::^%6#]6%>>>!0  XR0   H   !E>#,R
M+3$N:'1M[5IM;]I($/YNR?]A#JE5(IFWI*E:H$B\."TZ&CAP3]>/BSW&VQK;
M7:]+Z*^_6;\ @5Q/J6@:*J(D8'9GYIF99[VS@UOOK/?#MJZUWIF=/KV"^FE9
M VMHMEO5[)5&J_EPJSOJ?X2I]7%HOBFY82 ;4*]%$BR^P!AN< F3<,$"(_O
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M"*?O :-%'C769:E((A0*YM!IE%0Q2SF>S3/J0S>XASQ[,M+12$32(+L?P,/
M>HW 69"A9\$Z_%)C!;PW#H>76;=C*IS'S8TLU3T(#%56(!X+0"*Q5)*O>:%*
M8E%1EL+6KA3+8XM7*^C&\A.@%EX;*W@$,$Q+,/1U ;P,?@.)61)(# ; ERJ
MR<@"L0=TN=8&9+XBJ:9!8LC&:=H6)R5"B# !IXU9'H>@]%4-,'Q/PAOV24I<
M6=+#N 2D/<@VE!/=#DO/0$P!218(CP9')W$/))<Y2,"(0.8E MS&<66 /LN#
M/1"('WS>3TA$-@;>U^W \T@,*PHNRRSZ)-[)XI-J2!'^NBD6]P&<&<R/9:R:
M^]OO"Y35"8'1URGM/5@M?B<' UB[BKL=_!QT#-#@3"M3UBI3#K-K9%7=SK%3
MYTPK6.Z18"$N0*QUD98/UD-1(+O!TX9:/C"C>4.EA]S1G=]9L:19/2_B6MD.
M.!1PC7D6U:-/8@4'7=/ 1>81Z-\E@@3SP2L"I998.CSO=%&O:89<R&Y+$>[*
M0*=%JP(X#HJ:#$4=&DY)-E6 J,D(Q<6438H2,$VHPY^UR#)5_W=8HT.J8_ !
M6K;%&S)^T"IB<Q_U:">Q_6(1/;1:"YF5MTBO!<0"R6' L$H!@7D!(W4.?+*V
M;.Q4X9>!X>30N@%P@9PIBRQ)5$'J/9B>U_!=/3]B',A5#,D0E<&$_<K %C!H
M+VD  [FP(0H68E"E3':4EJAR$&+=:^%#,"1-EA*"K4T)PL:AA&W'+1#4 *S%
M1K?CYW2FI$5)R_37RO0OO$&_BP:HWV,7M7'>"H'U@G^2LO;(?A2KC-;V / E
MJU>2?@PG/Y<%^I;$8G):$3 @_L]:?2\0 A,-ZAEZ&_(RF;J9X:<>]ZO"T RD
M/\(Q'BA-_BID+  (R 5D)R<I.HN1_8<VQL*W@@FD8"")(9QACM6+&%19:[&4
MHT*Q@RDAK7N@3223;F>J)%A1>@S<7,,2$_1:P;S>THG1TY8YL^:_Q%P:!W84
MS@$V RCZ)6G5P IU%J-!)YU'R[#PD<**3.L2FQ4'O!:!2]DDP:N)]X:+&@"3
MSR:\*'0K+D8'36% *"H@1FYWBPR@%!9(?+  AH_+<)\A'4N1*&E*D0*AQ!BV
MXLA8=9XP@E24(!^2)'PAFW9S:@J(9ACG]\/6 9B4<=/R;.R !?3?T)M@*X"Z
M B(;CEZ*\!I5D(Q#4-)Y;6,7'H*G4#;A2%1HEXS$U1(-424(=EKH)K6H8:$%
MXU>M9I?V![R=7J^3AC>VVQD1[A*T"@'_B31D ]:^R6V!S!@P,"5*C!'?M3>S
MMCY),8/ME5N]91'>F&1I5OH33/Y0-L)(D\.%@ST(^D-<P3R ?]*AYJ=R*U_R
M-1TBDZ.YZTQJG%H5!?YF3!9I\E 0U(VCU>T$9ZM5 ]8$/BBWP+E8L;5Q#+_5
M0D47U(5EZH'7QL5827+%+'/S-UU9 ?NSBF^WX\>"M*C4,EMG57P =]\-,8+
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MQ0M26D@3ANV"1$?):0/DD30C_ P#/^5TM8H9A/S0*=)[L%AZZ$3N-X@<9%0
M08=H;X,-G5!\S1I$:#B1QJ*^J"+2F.!I5%DF-HIF9 *?4 K-0(41.V BH$;Y
MO%=*>Z"-LM5GXXZL#O-H=\*"M]^^Y\,?&'K9B& G1*B9)Z1;@?J'&;.-,\VD
M$I92/BQJ;6D85J7U[^3LI,_^T!/>DK F8=PD849IR'@Z25SC<3:<Q)4G6( #
M<KNBG,155'X$=+OOG&-# =V:*:(Q%H=A>"!J:$Q!;&<VD\<5'SQ_]G*_#M2
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MO<4JOBU\1YA;M^):>029DW-LHF4(:\ZDQ5,X5N-^T.?8MK'D[HFQPM+E4IF
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M!'!N4,:(U?:XB2=V?M0NCHUC?>4S0F;#;*2S^<Q8!_\B5QMJE @3_=+7]94
M#6748I+O$2 #%K\);A6:3Q.DFQB0LWMHF:>R5Q*L8E7!'+W0,,;.WIIY,QO)
M,R\A_"-!D)9A-##T%C13V.PZ?.M,1X?<%[@OI:>X%3E=U6S0%*Y>D ?6>D+:
M+MKK!I^9^B48*H6]D:MEY/> D5/6CJ'H.95E!UJEK2CGFUVR6[+SS/:.*CT;
M(5;AWC;#YBAZ,<BJU+VI2FT.%3$<<@)> R;<E5Z+LJK)]*U?4-\NU 1Z++_H
M<35VH.6H!I;4(008"M6YHXY=E8!"BD,GT^ 2!-*]9RZRF;G AA3WC%)<R6(N
M&YAHJ.?P)+9/=CZ&NN[58#\=VT)SD=.Q96)K96*_H$Q/R5%S*B<M&ULW&PO-
M-U0*X !;;0;_S/KP:CY6PJMHQ-V&1$?75;^^36MIMQ+M:JJP [*_Q;"T'LDC
ME:#FHKBI?-#Z/AIEU#AK0 $#;PT'_4Z\GF7S<><-6\=:;;B8E9[?P68WL8[:
MAG!KYPF7582</2M:^_0^\0.O!;AKU?"<AZJ%KXR%88N2-;@<4A?6SHNT+#2^
M'3\S/7M50D;W1=5WX^%MA:[XO=MQIHEM@B-IYO:XKKG=+27*=#MON)O019VO
MVI[?-:=1=#M1ED]G.^/Y*QY=G,.F^X+R[ ]YGG$#@L7]I2:J;[0-M%%_=G\Q
M"NV%)5<H8#@EK?P%"3CY&U3:=YYM_=H>XO4=XG^^>7_1[5R>_'*V?_7AXE@<
M?!17;X_%X?MWY_MG'RWU+N'OWXXOCH_$\?\?'WZX.OGM^/)?[>%>'_B'-I+M
M!?1^]"G-)G 8A\Q['^BZ'CA93GJ<<T"V$=_?WK->:N*[GDC6)7\";-BFD?7)
M:].?LJ^Y+N[M<9NH0>#:MC86NZ?K.A*7W.!<01O2>)\S^UMZOE<WNGG +B)!
MS=D*=6W,.(LYFVTNGLI%>#8MA%]3YX&<V'[DUZIVZF,NKO7J($1]54Z4O?LC
MO&0Y=-HO\VHC#%R00TB37%-I+Z29>;[1P98K>O(B&Q;P'':=KN<,ZWSF'L0:
M;NIV[GO?^BP/;H+KDCQZLV$'OSJ6J&P?-S'4[>C91I^-*[7)5]^XSIK%M.OV
MBC<^TRV;[J*KQHW233!ZM>/0-4=P2[(MH^;7Q%5(5&I)J8[<686_]XW,XAE9
MWP/:-*_S*ZGPTJ=@-OUVG(Q4P7ZT5W<'_5M@7SP-7T57=E$0)Y*Y+FT_+<:Y
MZW)*:DZ3$?IF>,&-L4P4ZGO/.8O2WO)64@<9OC2VQMX#[OQ1%QV%14:S14C?
M6AS.A4)+:Y6>4-'.799:4@G0?U'-_O-?[Q+E!].ZA<+5T1V ]_SYG<(WLR7N
M!,0?[SV$SU_>*8@8Q&Z0V580WXN-?9<+_><9Z C_NA-:W-,M\J<$Z]%NURM=
M)NU^?71@U?O5EYD_'.OO&XK,?]H5[RD1T[P2IW@-<EMS?ON:\T=0%?[TX/W1
M1]SL3]]>O3M]_1]02P,$%     @ ::^%6 HH'- \0 , RN4D  P   !F;W)M
M,3 M:RYH=&WLO6ESV\B2*/J=OP*C.>>.'2'*7+3:?72#UN)6MRVI);F7>?'"
M42**)-H@0&.1Q/[U-S.K"@L)4MP)@C5QIDV16+*R<J]<?OJ_+UW;>.*>;[G.
M?_ZGNE?Y'X,[3=>TG/9__J=Q?W9U]3__][3T4R> R^!2Q__/3B<(>N_?O7M^
M?MY[KN^Y7OM=]>3DY-T+7K,C+GK_DGE=K5*IOOOSR^?[9H=W6=ER_( Y31[=
M9%O.]]'/QU^C2Q\]VTI=BM^HE]3?#3T:?C7C&Y(7'[X3/Z8N#3(O/1"7!NI2
MRW?W:]6C<7"(*Z(;7D9=6T68887\SX]WG^/+@^SKXTO?!1YS_);K=5D 6XA/
M.BA7:N7:8>(A99\W4P^"O_?:[M.KSSDNUZOJ.4.;DUXI_OS(_ CC)A] MWHG
M_ !WU.KJ0H^W1C[V\!W\JBX, V_DA2?OX-?H0K_<9JP77=QB_B-=*'](O1Z^
M\UR;^YE7TR^IR\W *P?]'O>S08&?W^'/>$^M7*DG\-=T0R?P^ME(D3^F7N5[
MP3!0\&7JHM\^?[J.KOH1,MMJ<\>T6-MQ_<!J^GM-MTLW5.%_.\C)G)FG)0/_
M[Z? "FQ^^M,[\6_IIRX/F('/*O,?H?7TGYTSUPFX$Y0?8$D[1E/\]9^=@+\$
M[XC=W\%=[\0C?_JO<MFXM+AMOC?N>?#!N&9=_MYX,5\^&%?G].%;Y>CPVY_G
M?WY#.JM6_ET[_[X'7QOE\H2WU\Z^?;V'VSXU&K?P#ZYK\IOKE]\06]]&8.F;
MPM+D3]QOT$V5:J4ZP]T')]\X, .L _[7Z ) \/_!I<W:WUK,]OD43VHDGG3N
M-D-ZD.4WF7W+/<LU+^$[_]OE7U,\\B#QR L'**1_!@_UF'WEF/SE5][_5@%I
MOG]8.:K4)G_LX4?8P/-OU6]2,(KGPU=3/*+V[;[#/.Y_JWTC-2">X=-W4SSF
M'"&YE8^J#P$TU[-/OMV&'O^VGWQ(#[Z9;I4_6L&WRC<0;!(*^%L\X-$U^X8?
M]&W^GYT6,.5[HUKI!<:#U04HK_FS<>=VF;,KOMB%EWA6"WG?M)[4;:;E]VS6
M?V\XKL/Q-^OE/?(Q]T XT!^6:7(')07^!5== U5Y5E-(@9?@#L7VI>=VD?#+
ME2K\+W#I<[5&4L\RX7?6#"KX?_L[A@.KA/=RZWV*UG=.B=A_>I=ZRZ+>>Y!\
M[TC.V#F]_&M) !PF <CDHYW3F)%& W'IP1-!,<NG24WVON'[//!O6N>PG:[/
M[$^>&_:NG*8=H@4'WR+0EA-R\Z;'/5+M9Z'G 00[J?4TX!F#:P ZK%E(P+"*
MVHX1.I:X%I@#M(__WK%L4 5>R%$+O ;HK><" $'_UF9.T'#,"U P/=R,:SXE
M*,?S@G(3=+@G$'?M.LTQZ*B-@.%H;G1,L5\303H*6T?[LT**JO+]'\P#LS#X
M;+%'R[8"B_MWW&8!-V\9[.54D)P<S(NS!!3+)GA0Z.N"=K:-KE:.Y@7XS.UV
MK0!9T@?^/"/ P$IJP@*F@J1:7S4D(]BT6IV9^"/QV@2-$1+%D]0 R'H>[W#'
MMYXX[*/;Y9]=WP<9=M-Z8"]3X6E_;NB^6([K@4*Y@G>"?3(=P1S,O4V@P,(F
MQ_V1\8.;EO@<6(\V/^>/P<5+#U#%=[)49TVHSC';=SPW27]BEN/C!@$/.A<O
M2$:AY7>0LH G < 9(3NI+ (R!.S&N6<VOVDE=-*L,,V]GP0#B!]7B"*G+0A\
MODT\.5R JAR6DL!L%ZT6;\(^QFR(0"E)2S)W^+[95D$1G/E6<1^XS>]7O@_
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M3.39G][!FD]+I=)//<,/^C:HB180_GNC6ND%Q@/(#-^XYL_&G=MESJ[X8M?
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M&+LM5+6ES-0@_^B7T,&^B[L&$MHN\0!KMX&+T%+K4DFCK/$>+=R;5!D.(+K
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M";7:VCEADS7"60&9(OG<L=.3T]QSL'-ZU@<G4]8!]%,<HQE'JQ"C5D!F2?/
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M6>^J3@Z/3I:RK)6N ]09P0V>OXUY/Z#)0#TV4:WZ(69T6FCZ@7U DJO)>E8
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MRMS+/N_0BETK]A0J0!B76+OM8;<9'"$6H!AJDFO? W(GY3&D&8'J_G6PMV\
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MZ1LR.[\!^D0^'E3'?>AC_J\E*X0>Y.P?8C/B'RS>D G^G"P0,;J03*L6%4
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M[8NI:M'7'=<VJ?I=O!TG$/+=K">75+1?6?ZX.-H3;/UFXX@@[.P3!GZ 5?M
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MN2N2.!Q?O4 >J<KXF93B>\8-A;)1I*1)HO3_V'O3YK:Q+$WX.WX%HB9KPIZ
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M>YQ5G2]7[><[JK^_/GET>GZ,1/#H&#=U=OJE2YU_S-[-!)'KNPXICB2^Z-"
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MAK=\K(G!E%WHFA7?D&P=U9<C/S;(-4H<5#"F4)E]6 1$^]D-_6YW@(XF<("
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MCJFLVB PRT#AZXKG6#I<1?J5A5-LR##E1$W3:' MPS5V*<*]0 T TABBPX*
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M0?P@!M$8(\$;'J1J HP3G]T;/CO2;4Q$>\RW?1S* :G28LM+AX$>1#)\7%
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MCGZ%6JN&E$0XK4RA+<;,+5.MX'\$CH?4V7);.+ZC/VZJ!LY&A18SGZA?:55
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MXL4;'1",R^(RE;7BSG<N,71Q=.X61N^/ 9E*6S?AWCRBUJ0]2I;PFZII3UI
M:7)0?5&AZ>^DVTSL<F_8Y4BW,1'M,=_V$<KX=%55C?1]QZIH=0V3') )5CJS
M&'>S4*1_O(P-9!#]8S+3[RLW'.DV)J(]YML^#A&._Y6:$]2C"!9QO.C,!"M&
MXR#AW.F1SL^)UN\-K1_I-B:B/>;;/@X!W;.Q'>@VI'.CB>B&LZ@0+S^Q>"(&
M"M#.IIIH_][0_I%N8R+:8[[MXQ#852K(L*FV=G6C95JL$\>7$.@,Y.5 - 7I
M#_AYA6H$5G/)WS)P>"3-YQ;L#R$35>9Z$NCWAS>.=!L3T1[S;1^'0&]T0=:S
M+6%A_$"8WP:U5&9W-T%P!)-9-U4.X<TCP"V\Z::N &V,@35:T/C#J8'5G-3$
MI;(XQJI4Q98'TRP"_&2[B$RU:N*C>\-'1[J-B6B/^;:/0_@K4[^2"DJBKUZ4
M<O+Q$8$&.4OZ-F&M5R5L^1#Y%?V=J$;GN0[*C)T :.]5:=^&*D91-0Q!JC->
M"GD!%L4%P%^:'EZK.I?QA:18:(6:\7N;%3V>L7HSA.^K^#*O"GZ3*)[O?WR3
M6+1[^:.=;>B+*ZWN6LOR>6X;0DGXOM6&:5TUS0GR!,I.S' @Q?WC,K# DPRX
M-S+@2+<Q$>TQW_9Q**XPL=NT%N5W% O2#;.UNLM.P<V;IM/&BR$=0TZ.0Q';
M\X1Q-KG30;0'-&/R\31CLOP]9TP^GF9,3C,F?RF+3C,$OBBT_6F&P.':&&0K
MF-)?QL>0 4_UN-<G5@2F*<UU7&K\2=7LM *#E+S;R<*^-Q;VD6YC(MICONWC
M$-D_=;7#F..VNU5>9R?HRMARK6]-<KNJZ7&8M+71-49O\J0JU2HV6R3ZUTM1
M8;H?S]F2(*1" 03*B-<8RU6;B01U14^C+V1YDQ;<*.(R64#((P>RJ\T#. IY
ME4OSMHM:"G#'/NPE^MW$BO>%%8]T&Q/1'O-M'X?^L";_'KU!QGU:B<+0<U77
M,G72(*C*/[QTI[_1LO\MI6UN-('-0BTK(N+2CK<,QC*;&0C(CTERCC[NY[:"
M+_<36*1/9*IKJAIN,(<_4FHIXECDF&$)*%8ZP[9K=; QF1YM?T"JD9P8#B-(
M\8> 455FTF3A,%J-=L-X2]EET^'EP7DQ]LEF4\E,:_&>@KG =AIM,"KV8 *K
MT]!VO^T#&1/[LXYDE*LJ&D MT#\0:[5S1O,1"XKLMQY[6GQCH=>.UF28TP(E
M6]K.2V$3F^\5QF("E[+62-7:)+!=$2L_3<4OP!?O9,3TCU69$RO@:W^I5"US
M4_UCN.#*B8=9_ Z?!"* .9+L2TRMXE\ILY]&S-3( 397+A,>3F5=6(/7Y^8!
M-0%XHF 8]4C* U9OFE9UIA!SYL3('KF#5?2R+M9JY;<V&VM2+\9> [/9)^CE
M;X"]"V6F*PZS>7<^CWS7:HY654%WT)4(=S=:EW;.M\GT0'J9(N4FSUSC2!(>
M23@E7-']EGJ1MX*\9["S5WZD+X_7[N-B)Y$-%]%BO9"G;0V*$51&]Y;SF]!'
MKE+W">=%?GG#XBQ^53K0[=XR]EV<XE*^ LA40FA<W-U7!D9[*(Q/V^>>F,'F
MZPTY.#:%AI)!6<$LNL"/Y96[ ]%QN_,UG?%(YJ[W L>A"U:8^J,KR B'F1-M
M*$O1,M697#>X8\)V",PMNB+NCSH>BHUI<OG!JZ0[4#]_GO_GG_/_?+6(#'0/
MMZIIJWT0ZLT!\P991:\7)" .$2OI<;-80&9R.5<TF=G> W"(Q(XMU/F&+2<?
M4?:\'#G(?%&*P6QN/)EGBY-.(EK.Z?9H[??K(@^<?@_'I!JQ^8D8VQR:!P5P
M5N/<C'19.O-03=&1;)81P\!:ZDKW NR:3D%&,#.G1"J$2?06C*9CR_$SQT8\
MR]GBK&AC%#3:+D UOG@]-*U"[6B\&5,N(A@ML)/X,%:*]+'=Z=CVW-8XZ7/%
MW,<X,+[/R2V65O/WUR>/3L]Q9F]4>?+VXIUH6/>5JU5E'N*<QX@NPVW<GNAP
M*:SNR%;1RI[A"!SDR";_Y__XYOSLZV_=-@9'DY/[QA_0OR*6/5=<!BHB3E_F
MJ7936<6;(U)(Q5S@HR,*%LLJ%LC*X#+]L5R2R<74 +./-;2U$,U'KJ('LV'M
M[R;%/ FVFPFVG[HZ(O/0CW\W'+)'RCC"W,=LPJ#BBG!8@_:<TW,4/<9; +OF
MK9H3KX.1@A%HPV>KHJV6&KP_T??!T_>=&9X7XKI&H>OJXXG&TZWSY@.43E.E
M.4<YW!!LKN2WCJNOZ#?&(Y.PL1L1*-!N(%-"7T8#F)"S":9$;.TVSC9 6>7(
M!&Y#_.3 UKQ(TAZZJ#8"E\:] <916Z]UG1J/;Y$7K)H!M"9#JC)RB>>Z2"12
M.L*!4:F7XD;S1%@IE&L,7J9TL_GXJML7XD7E=K*/#W+;!Z)&WC*Y-9&UHKCW
MO17[;8\!G!I-<:F!^!JO\N6*OT_6;YKJC=3G,;H)-!,_B;ZL"G8F4<X\X&\/
M?X*8#B+K]$LZHY0,MW^47%XDCPQ_QSPK3?6A+9X.M!A'\<'Z23^L&(=AQ;"/
MT\0^.7;*WS,Q.JC-,.Y(UG#3B^O?7^J:&.TFC/8C&4:(EB91ONC3+#S'H4+K
M]M']F -4BULR8!Y;]Z\#!DMLV)-[HB-OOG%8UNJKO*?(&/4?5EVIZKJZ0KZL
MD:S@?%-M7,37I1# ,7N7[]3Y8+&<;"A09VAE!10H_NUADG@1@8CAF+5BB^#$
MQK$W9$%P0!Z3'WW0=%05RZ&8Y1NS.+*W8L<4L'J>Q3_+L7%>9JY[S>/K*H.C
MCRMMVB[;LMQLB! @GV ;Y!S<=M&QP?7-XA]A7 SZ$".^/ E3%-P-6%VA\YRV
M; IKM$(Y3M.B]+M%>)ZL "8#8$>AR5T#8ILN@F/7;.'T;H)?X()H8Q;,+.JY
MS>,I7#X63+KDX*!FY4$V"IE8C0WW6W\AF)=I%RP!_T5>KTV((].!8#Y8Z3I)
MTKN4I*_:*&\ '=]P]$C$7 /)!K(:Z^H%OQ2T/Y*^,6,XU&R6L$"A'<$JN-SQ
M6H?MO@&!9U( 1QQ!&RI-TW CDJ]Q8;?A(KBV AR#UUX1+S;$?BH+K'@(@G%+
MOBA*$H::%_7/KL[Q7^R?K$EPD?F&[9CNWSY*D43P6((R0@6QNA$>N:[=3OGX
M$#P0P*)<9"+_EE;/T5-.G?%H6YP !'PKD'7T.(@10"1%]GE7M&"1DRB-$#MM
M"G%],8Q^9R& ]RL=A:8'R-IK[/S?SE[?D/FP5JGNN$R.OR>1V[Y99>8R<WC,
M\;G/4^^4!9EQ1B,Y*+$0P*"[(88$:MZ5T)+BSR4XT**6:'*_#W+;!Z++0/!.
M[_2B1[TNG$0"1/Q?&WJ66O)_-D2B9/_!-D,ERP>M-_QWU@%MWLCWR6:LA-K)
MXB5QG'!]2<WO,+5J292A4B.?=X8M0B5BI#@_S*M$S@2AL*%I#$^:")U713S=
MQ=?#Y2A;60L+XTORV";QOXB<4D>UR*48F(R&:HS%?3$^J1QJH'9OQ/B3#OI5
M#=!/I@;HW[4!^LG4 #TU0%_+HF(6V>.XEX;$)XW&GW6$UB/1(SGQIHEYN$I"
MU.#A<\[6YW4FU16Z"2M$)2*GG2Y&* =?43M5@::L4'JKPCJ+"#69JDY7-N8]
M?-@L?K6PI1R]=6056Y\-Z:9&"EH!")6J&AVVG8W)V;KS#J9"U[(/B,+.07%B
MU,-_VE?1:M^YUKJ-/?PX^:.T:&T*M$)3G+3NLE;KQO8 !Z58@;(E^P"1<83R
M49PH_J+]B2^/V;&SG:\[F<L'N>T#,9>)U6'=99H+WLOVTRQM<E@W9>TP=+-K
M9\YBLM==O:VMH^=2,FO4]NMN>W5;'!2!F<O*&@S!B^;X+O,VVC-]FTE_7QRO
MXN(+F]J2HHS(-.V/L2J'K3DF3/(OIT>OM+IDJ+DR_D>U^,'4>NV>C!U 0,_N
M572YD8Y6IMHG1O3$YV]_DF4VFZIL*D3'5:HRO<[3V$I&<BJ<'VTCSJ."\D)J
M2W:S[LG((LS+D^CZ-R?^6;ZB'4T\M.@_22$@SE;9$CP4#*A>'0S=D"W'\U0V
MN&5Z6&1\(TG4MV'?+<XGQ(9%A]$L_FMUA2P'[XVI9%"N:*B#6Y,4YS=L&T=>
M!Z[2C!@.AM=*(W.21*8JD8X Y^)*[<@;$F@'CN]IA9:FG:82CUL^TBC!56Q>
MR]@J=MY=H9>(6(8A%- $UR/A')&R*#-59[T Z_?/&<TP;/9BKY"KA(N<7VV*
M[1R=B9,YU*3T/S@]IOA+KNIPVCG0A>9$#$[CY Y."NC&\9I:(_U05O&R4S5)
M!6U3$*41W"R+=MN-1B3.& 57-H]ZI46ZL4 @\5ZA8<=VS"#6&$D0I2'B3CUZ
M2R]\ZJ,H@B[*)JL$^:TI63C3,&/[U(.?[IBIUMCLV8Q18#.J#,=C5[+;+\59
M7/QX;X=GV%TJJV5T F[J%+%A8 F27K-;)*)0ETMR!,7$E30ZVF-$96M>HRM_
MO,ZTY8B1Z:<+S-QK3E=^&.WIQ.-SY?K(4?@^;@=SW_8*4DI,?,K>=V1@2T4E
M<R;<S.0PO@9];*QRVZ@ADEP:6/OO[TI.M!MM874.T4?9+)@\I3?//(W5LA N
MXPPN\IT2(=Z12;]'UEVPK2,&3\($^B;).TG>&V9]%]%UKK/K?+NAX[S'[S4-
M(6+W#WR#GB$4?:)CU-2#L!D=](ON,?#$'TYLA77@7J-HA#_D\/N(P]Q$3J3M
M"8ZSY;[[TGUOHR?I!6>5^4O]DPUR<;I7Q30Q\L$S\IT%Z'X,4UG1('7KVZ@:
MXSQ_%"_2!Y4L3;/*DT+,2T6J4-IG;"4FG%W+Z=9-Z5DOIIK3)]:TK7H=89JA
M:VPKEO;% [U+&L8=23HU%3]K)XN-6$+>..\FVHEDV%":U)6@RLT6<WAN9N<^
MZ/<@C4PO%X-O[]9L?W[P939?@]HZCM[ABP9*V-;2!;7TB2T>,PI=Y;L6TMB^
MK7"9 GT'N>T#T?:]F/XX;^V)Z8^P^8 7=IE;HC)AK$FX/8F"PBC\:-'Q\X(B
MTO UN?.>]G'>_K!W7QKL;"NZ2VD0&VD0?59I<._989(,OZ"ANY=.TD#(+_)F
MQ?RGEK4.@P AUE7 KK7T=U@EC4IM=5E)S3J\<;(HOB.*#MJ[=UX7W?A5R2YK
MCZX(2"HY3 I?*\T=;T&L]#_NGCYF^S"7!S1R(O#,$S[X(<,!3OC@$UC@^#Z<
M;\* LY)]"477H@?LEXC[)D(.%I4=0Z*:IJOQUPDM\]Z@91[I-B:B/>;;/@ZI
M[1$'[?RH(5#XCA$,"%/T ]G^:<[7-'6W,:T[04]05P;%(7CP'*B!R!\A"NU>
M'=BK!F]6DTE??L S4YM@["TD7(=MO :LH3)=XW16Z,-^B9S@XV\>P>%%NP<*
MS%2-Z'A<Z!9UN1._WA=^/=)M3$1[S+=]'$H&F&58MVO801]"NMH5[)PSL5$2
M"U<7**-OX2I,U']?J/](MS$1[3'?]I&*[!X$4DT&-9GVI;Y2;OS!=7*;DT1<
M5R=Y*,[>-ZU, "+;ORHO=<E9*$2)ND,<@'#C*/;9^>SK)]S@-N5][C+O8VJ]
M.,VYQ\+@*BV!:[5EE -DLP$J!Y>-J%00:M;X_@<-#UGF(3?2V;_IZG2E@.R!
M0'_$'?[<HZ!,/P87=H7+ \K("1B,4YYY"X=9U37PXH-T$>K0369[3W;6U[F[
M)7$UZ96.]B>3AUL?0RQP>6.#?Q^FT +&[Y>N]++=TFL6RH0IB3LQ\\V8^:+<
M1J; F^,[=CZ%23* FBSQZH^Y5%[Y\HM^_"K$]QR#4AB.'W(5%S^#92.PK)$-
MA<5W#AFU)T]JG=%FT K$H2J9EQ<W&@&R6 KQ^7OSKO@@DL94KIN_[R!E3RSS
MJX (GDY !+\K$,'3"8A@ B*8@ A^.Q!!SZ9JM/Y@!D"T/$:)[;SVI,B)<QO;
M;$ D380N:9/KZI9OA(L5ECDF46^PE!(4S-Y7NPUC0FZJ%MV94_?]@6[[=K4Q
MD;&MN.U5F#)5!Q& @)2'M%S5OX%N)YMH(LB;B5W,P"CR#YH[DX:TQP7=H70=
MVO4R!H!Q005>(<]X$4-P090UJ9*[QH#XR469^+Z$SM#"TOM^Y+[/WYKG)%S3
M54D+7V[]L]C]6,"O" $&[! ;K!;=FJ1 S"31NMK4/+&HM]%93$<0!T- ) NC
MB.D6#$QQJ:.^,Z\&9V*ZB]&VFL1J7<'1LEW)Y9*VW&TJ:0I3P!]MQ*,RHPZ#
MI9B9.TW0D&Q+]X%$IQ,&1>"Z6B,%7$F!>1JV6 $S>7!I0/,9_SAX*S"C.R=-
M1@9$3D)E$BHW;C258%Y@M;G>_MT8'C[J&6P^MF9$DP0$87LQ]0J4!Z#@)<B^
MQI!7(7,W)LHQD>" F['#H83+=(;9PMH.JOIDH\50R0XEQU*7FH>"<A\'IHDR
MOCKWW$:#;3N1$1O9T%N;';^E++R&2 +74]IO*;5]_MC$HBO-E% 2-D0:8D;3
M)X !,.V_X5(FIIZ8^N8!Q\!>W?&\K(DK4RCS(@1:4G%#"MYP)D)]U1KC%1P2
M#AK-K1T\-(/=$()\N6J#\7<L$QBC/U4;!#+-N.8XRVNRO(LIEG[XI'TW<8:W
M: >*WO:+,%^1JF*,*4 <O*E1A]EN)S_^OFS[AC-]^R-*3?Y0@.7RDO\1-(]B
M]*A@X[0&N\SB3$"(J0U[.^-@Z#5ZYA@#+25*=/8]/S *'I@W!KO#OA3HZ76E
MLF1H47F@L,&HS\2E?]C\V0DP!'CP#5E7Y.SQ\G@Z*WPUX9\ ;2RPB/:"70R0
MI[TM8QH3#7HV_4'QL)5I1O&!;OM C!.$,8(DNR$I8V(W88! P X'=&HXRE+H
M!L@8F*3]0!QP'L5S"6K$:8B=DCT<;P6/7*B"L31-^&]NL/0@/P0Z7I7ML/X_
M9-(-L53'@#4.NZ8G9\S0\(%\,<"*_RCA*$7OVD$!1 H_J19D#(//Q4QJ'2E(
MA:K)K;.S5N@&N*X$@@M5=;NJ,HY!= T#Z1N]&IQ#$DQ7 8Q;&4Q'N?9(>G.'
M9:KS8,_L*_)0*0MDV=8JP_2\M-8&AM+<KL%]M) EKNW"+0.B5)%;%,+[V!LT
MI2E N"395_<"2@M8J3LK,U4F]I<6> X.&RY7)Y'%++*7FGA"!!(;/385J9F'
MQLG&&"<W%_$>GC/P,1,+N>9ZLNF"V?KF29EF8*>-IEVR3*8;0G;NRD]R[@,9
M((K7/UO&A?",IM(5\P'/\&S-!Y.A/HGYFXEY/P%0)#O3NNFJY;AH)?@AUD<-
MBMJ(^!PHI! ^1DFA,DTQ+P4C;-BS%(P0N)P!>JQ$437]A%W>)%KD,E%$X,HK
M$CJ=FZ\C\L" O)J6+H%+<,8BHR,NM(W/\B_8(,/D3\#+^K"W53LVIA1P_BQZ
M;R&1$X,Z:1YEA\@/%^*V.M=NV2BOXT0KBQT!K46=4*D%US=O^#'.9Y]C4A@$
M$[GY#*8;]03W1,@33]^T*I5,"AX=A>%P@C]B^]V)@N<(#C'KVG',B2-O#CFA
MQ5$(GUMHLG9EQ0 '?1U77:VTC'>C3_@W6>\YT5R;:8]DH=!)968BKV$(UI)H
ME31SV=H5O8M^+6&G 0!M_:F7F1F28E0ZW!_\HHF8P4//"9+ *.)0)MBP\!C(
M.B+3(C&@_EF@X80Q-WM<(&"B'0F=;8S1>$V6BVTEP-.0DR+H9#)057+06<1O
MS^2,Q>2<F']B_E^JT$D?\X35G:9E0ZZD8PMR-+KE"OS2=.N-3*@U$1 [,!5V
M*BO[G!/4X"OB@%6^2224DL3,VS!'O8UM[-"$-9AC&YN$L7S+^,]"]/M4ZIQ'
M").E7BY%@XI7U=7FY_*S"L$:=L)V68?![Q6'<&;Q.TY:V0?**WQ0W<(76__4
M["DO V,B3@N5KS$X$\N6\<.886Q$'#MJ&'ZLBX&H2R*>1ER)T$,%K\*XL]#8
MEXG  T^Z(<HT@DPL%=@#RV$^#7\:"R8%HP?+O@<9A=.5XZRK74HNV&S@"0_Q
MZH;/VSU<]B'[)VPJCU'6Q:TY!BY<.AW"H@-NXN'M,F:M(/4WK9TY41I([82G
MP=G0'@M].'2DX-@6S9L0/ZOJM?S<7^DQ"=*;U_$,)9<15Z!"4_A_G3/@"=^*
M/!$;QGXQXZY[D;*19IM> "R)1\6(C:OLMX+BZZP@#D=<P]H G8ORGFCH&SO8
M$/2$LPWIFUMW#O(Q^S\FKXX0$*PV]#V@VK,+*A?66B$:M^B*7E3*;"<*PS![
MYA78K1H#S\#NNV\+EO_(FT>#,V+[#8(_T=AK;:C=3DC)Z[1;RQ5<IP;)VC6I
M@H$4)_VL:U1TA9?#*/Z!&.=3+:N2&&8!%Q?/$"=S=.&CY^7&R$MUL&W98L<:
MDS(-9GEU55ZC3^S"$7 ,#SH\5#[I3ZB1"[]K!E,=[&'/E6,+6'WD%\W5(WF*
M[N7&%G6Q+\3[TYE?!(\WFJ,ECIE[/L?L:%;EKU_(U!\0/J!>,NGM$ZU-OT\E
MW&EHG6T#IN[(V3A7I<NC<V!6[(1DUP]B1I$[Y/$,I8D\"!E)PT[CPRJFGMM$
M.RJIA:O'22UR;(D^(#J^,+1):Q-?)"[45=/!S(,*7P9FF5T65*X$D'L#.;8;
MS8?+YZ$SJ=%38J;Y^R)6*M.M8-2'/A%O9Y&;7-=>+K$^)#IW>W:5DWT[,=I:
M!T)@A$\BRR?O5QC*H3VR)OMW06HB]OYK>&NAM MB1*3&BL()/RMH EM*+55>
M-JU?712RMR$K3N2YU&<0ZNTC'#$B.?'*P9HV!]2B]?74HO6[MFA]/;5H32U:
M4XO6;RR$P;QU;LLW+G:H=ZQ*,:9E7OII6_TD>\^0=RGG<MC$<B]O8')X;T*,
MW^=P\H+R;QAX",/846QCW5-);PA);_3094XKQ#C)/KA%LI?&K8%$YI 4EWLO
M6$I5]<=-SD-*>58IL!E75=UR21/**H8_4KVI"'0@8E5+S7PIT2(I2/%PZL-2
M-&,Y<S)49K U!IK&IDA[J1'_C;R)"U,*4<K8/%*.3?MPUZ&YSBDSWF04E,99
MYXQ>ZXW;8(H$)J\%ICN?6="UHCZ$=0=.XF 0X%I,_=WF. -@$)G1,G/<[D+7
MI.M=:40XM2*<8H%9HC*"4W4E#Y"%(VGC'%K5#*W)AS0H1Y:4$-V@:L@%_][X
M<D$S4M0U=E0@HBR--"?5>=6!E(##J>NJL46"7!1=Y\2+6!5(<E[3N@[5:)[B
M@8=6TOS=>E-46ZWC'[F(BU[RQG8HQR_RHI,@U;NV(I?A#9/??ROB%Q/(!PO\
MQ$S.#XZ#!R-(\Q?CSDW*^;YL^Y-6(>+/)L0\++[<+;>L-2L'P$1I0Z<FM%;%
M1*X8/Y;8+W$&I2)#$5:D'Y>Y(9JNRE)/_?:'N>T#L1+-M/L5*>MBVQ]Z_V.>
MKI0N2"[F=<[3<(E(GZ]RO8B_^\AU7.2;_,2IVIJI\/E*Y36O3?Y5YTAV0DC^
M4+7_EM__-R3I&U+QG-(T7Z1'1B])DY=<FVP>V:MLE>H5%%(YL'&MUO%*-=+A
MA.ZI#=L.9(A@V*:9WP4;I.'42!)?5@69P:A:SE"@!E9L7.MOEC?6S;+EKW\'
M+RTUO?M5F<[H&VI95G1W:7/B"_Z[.>TDQT,YP'GV+8S# =83EX.T5Y4Q"QU'
M3\;*Q*4W3U[VNT;(:M9.@?C^^:"0^#HU8=B]^9#ST&;71<^CGP/=(0D>DZXG
MKDPBZPDDO:DL Z3$7DY?WM(,7L+8!$&1I773S+(%4(T7/J+2(E/"(?IT1B:<
MRU]X] ,7E7=5K?;8F"F77)U6(U-AY(YWW%QK=,(SI36#.O(\/"[++FP5"D,P
MTO=7$'3UUE:6$+40]=1;YRQFU6[N#GNWJ01<AS8?EXU4SM)EU1!+W.835QO4
M_W>EZW5&M?J<AQ%$_<\839%$.F0R_,+49'DN2D&2*PJ?Z?$.IT$P(/?9#R,$
M02%%:-O*W:D\Y,7O5+=$P?5)](#O#YMS<WK<%?8K9;B@7K+<TLZT4S43MD#M
M;\2B7T7C27=N/Z^KJ]WB>S]0@J?6.]&-DF:(:B6]5?=>/!VXI#X81*Y:S[N\
MR'9&4PX":K!?I@CN86[[0+3^BXXCA;_*B(60'QBPMOT4)3ND'5ZJIGU#KZ:;
M^/KQM[YVPO7:A89LY W9!9YA+^XS48<SD7LOV'M0L^C"EKY>,5:"@4EEK&4.
M#H:,&"" L*%"HGY558T>'ZS=,S7X4$+@L@<!%)&)U#[D.]-IW>4]/<CZW'OS
M,,F@9S%QU[3'(%"<DGRH"V=*\,<<&QY!G4W\7\.I2'U!$Y%");>LD<@X[79.
MNQ"[A<&CN0!-7B.1]*9OS25QHPK-S7"HPK'V'9%:6^=S#I,]9&..A2!7'5E)
MF&/2NI5]$?T+93I,@F(=(OR<^*4;$\P;9,VV(0UL&Z<E7MX@SGW2ZRU4J<&
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M:E8>>ILL4P:QX]]KGL*@8XQXW11J:NFX1WQQI-N8B/:8;_LXA+GOR\<0/>P
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MVQB] Y,3!!9Z%U7=<SYZSL:5CB"0A"R*W &6N0C:0F3^L!DWY+,4@2M:K5'
M<RW$J;/[9X4>=(#W+DNM3/ZCUX0G8:NK%7'?%6B&=:&AH*%K)B*A5"1P1>:K
MIG5Z._2+C9X$OPFZAWS3"K1MQ!4USJFU+G&Q=5JU,\XD#)R:;2?[D/L;3SIH
MNCZ0["E1.;1)48E)B$Q U4%VEO%S6C )W3(70UW5(UZ8-,&.$7FHSJ[R(EOD
M8C43%ZV(>#]H:]U>2LV9PDLCUD8BV^DA"_X(:K-O<LWB[SZVL%?L[V*,_6M#
M@WB7Z41IR_L*I^YVC#D4I9D22V>M&;XVT=ZX*GO<FXS7@2=[R\9=+? L?K7
MA-;!6A,ZUBLZ#+H(J%;GVO F3949%#O.2M0O65ZU]*5!4=8*?3BF>5GLY$;4
MHK@XN7<"6;2=0+1MO?%&'J#8X#:2$P6QH5K4.;_<AW/,:=)">M9IZW2KZ\>H
M:K9:;:XX53S3,5\;TU5;:SKT'GIAOP4GA$.S5DK4.>Q//#&++\2:Z8O0O@T=
M"%P1K23+^=81Y2.6T>,A2./R\T7 &-N5MFP[D1=6*'-?AVI.3#GD6XOO$3U&
MQNOD8(L8I: 4&TWR>201?*:2 VT=Q(AP:;PLD4X(B%4.4!N^ D_K,D566-<B
MR'-X93!]S7?IWT3/DKBM?\E[!CDQW]QAY9X(-1%/UA!9:RTO9D?/+=G'@V?1
M@1LF$X?<T5%\9YDAVB'2)$BS<%%4Q1D3Y^F.D&\BDW)<BLCK%QLAH-_G4A4\
M^#4KZ AA"%7"[F;^R:[[0;*;[]IE%Q=R!$LA'^4[HN0C#L5:;SB%3(@\&_4:
M*7=R<.ROU,I6C:=ZK/S#O"8C_[J?D^>DG&]/]NN"R03)82I=\@8Q]C!$+$]$
M!R8M(^Y*^8P%D1ME;R<+)?WH3C^ZCW"IRQ?)CUT&R=1PO?ONN3>*PF$69+A6
MMN6%(XB\6S,**2T4;D1B,4%S# PB><&DJG]-6?CYZ506_GN6A9^?3F7A4UGX
M9"O<N)4-EB=\,#CU89$QUT5($[-H3CCN+X&R>'9Z\C=7W<S=UYI6F^UTAITE
M^T+XJB,=:56KATU'![269C!ENJJS&[TH?H!OH,"<Q"G_@=_ ?SC[]J&8%70Z
M1-&L2B5,OLB1Q?-QBBOB>K8[S.Z'YM-^$W^0+& 1C>6G[%'@&YF&Y8671SYM
M9*JM@8J3VO@[5YID7(.*9&')T7UXX=R:;N.;0=@_YX0%'S1Y+(R))@?]C]F[
M6?S]Q<4;I&Y@<@SW:9K!M6E#\YUX)LEL*FOC2U)/RJ7OQN[3'SF;0-+&+85,
M^'CGS9SA;JOJ0ZRBLN.KY'R:)"S9PFCUQIS 2LJ%QYRN,$K6\]>"C&IPH#@\
MJ03#=Y#!L4_#.<! \W?#>QL _/,_6P1LD'>RQRO7)AD9ASGC;U[J&CVE<$&]
M.V<RJO*F#6D3+XX8]W3?,SC7@]U^M!145N5)K6W[9- <V9B?"GEZPCG88J$[
M-]8._2A>_1*)&O]:B7H^E*CG XD:#21JIM&VPH4]4CP\QO:AW/VD)"'WSF!O
M:%VB.H[S\J:D(8M\N?"H_.(S\0S4HGJ&%QJ(ZK"#%@A,DJ\/@ISK.1VDBSLO
MJRJ[0H4>21J5URS+LTXXSC;D\,IMA62X/%$+0#0A\2,\['YT(5KV+3/X[,L@
M0\LY7\):/R,6V2VPXJ/KK)<=%M._S7JQ@\\\ZT12W%SJPE;H&P4IU"TU4L[B
M:?2RUDME*W.RKLU=OWEEDRBM0UKCG %XW!872U.\U>3T;Q_9?16$2][[TNWO
M=:F1_7ENX[!F-ZB?,@5W+D3K(US0J5XZF*J/0]6)D_Z[G9)9KFK-XD'A78N@
MW.]GCKH?[;-+HRM=%">Z@7.>-ROPP*ZA&G]N0S4*#=5#98S)6+PKS<=A?:Z2
M+3D*UBLW';7]M)VYMLKUI38%OI],W^U76DSF+M,1N,2>&0<U0B98OEME-)'W
MP9/WY\XQ,]!FOEQQ#L5BV!GOAV1PL3".CP3 WIT\0N(D9S1ZB588VP[ /.@;
MWA1;:TM-!60'N>U;MR[(\>-PHZ.@,?+:0U7.MT#NSOH,82=]MP'A?G7VY#0Y
M/>7_$VO<INE<=I.S?YE."R4U4'K?*[U,!CI$MZ13BP4.ZWP6_]6"3AK8S2!6
M,%?H+NCMJ<-D9)55F]8#2= R$J,H/N;K;AT D07)1<D=R]P(VZ:?-_TE&RPN
MZ[D@=EGJ$RDZM47+8O,LBDJUL_@OVL%41N$G>!*7.JW1-M/&#_1L.4OBK\YG
MSP!07G <8 3_[.'H1EQ^5A;?2)A@N'AWWA$@QF2+7YW-3L,72CR%2[/> V%N
MP:TXUUR=AYKF]I2\[5K6OEPF5J/L"['7@@E)7"03P[#'L>:)'8WDD\F,7&SY
M&*5C%+]*U29O57&HBO.>BK3;4))!(19*E&QO!'M+&3%ALQOE)B9\K9I,_6NG
MGT6A:<#\9 Q 9M*<A[CMNW U0':A./HE9)=8\D--:M^;%_(;02YZQV6_ 7E>
M@72C(O\ Q\$4.)<<Z;H,"YMYR,7>NB&NVY&6+ XA V6Z!Y+!N@(907+M5\J8
MH;U'7*UT&0&<^BIO5KP%^E5UJ()X\F#NZ"A^*J,+HL."#!0;1+[B-+(F>H45
M6E:M[^@N-& .?$_<#X;H_]ZAA\&!EK]P.>Q IEM4<[8@5)L,P%LY3\2M81#X
M)ODQGOG@)3)Z+B+"(PEM+LZC4\!L WE0C^$7IN2^+Q/8IHK,8NW&WI))&C\Y
M?W+Z('WXX.RA]#:.'8GDH(A=;6RCS^I.>=6N:G",[^7;=A'/Q7@"QBQ96;/X
MIY+^<QN?VXO"@Y^;\)PX#?B+K[SH.0,L4NC(4=#/I4YH19:=B+%M7EK)2QXG
MD8$JAKTK.38$[#EQ-SQO^:F#[7-2MG]XO0MG"&23VPCS@#A++)/;Y*> RR2N
M=L35Z^I2W*I]$LMP9)B7_DN>Q6]8V[ZPL#!$\$3\J;:):A%J8&_#".^8(X7W
MX@?F09[2\9N(^6=K)97E11%O<^,]L@5"U(QOS?,L0)3,N48Y8'_2Y)+$GNN"
M/%7X=Z<#G,A'I^RKD>?+!H7KULG45AJ!0I]NS9 S7@ZL\Y(]3[^,0"[N$8M(
MHOE#&8JDOKB,1%P^(8Y7#Q^</[2/%Y&@L]!CY^&/)JRK1E9&LF&X__!&?S0_
M\#?[UF_%%Q] O/1E^3=G+(X>/7QP\= 6FIN)3BH><UJN?9. ]/%42NY_]]1E
M3Y+53:2"YJD]5QCC"@]5X$W"[990+Z^15"P>;F)C+$)IY+3RT-#8S]71FZY&
MQ)!CW.8K\I&T[.TR4M\6<6+,L%?&(:4R;Z5%T]D.GB7.OB&>4(4N,TSH85%&
M3(-T8R$FSZG!U^?TT5+ML?FN9=59_,+7X.RL(AD],T'VC*2.+O"M+/R63?W.
MM95P!K +F[Y><KX?V4FR1UG(C4;7WN@:<5<66HPKD@)$9DR!>%F+<[]&%,5!
MR5)X/U U\;)6[N@FF?7)UHVSJ77C=VW=.)M:-Z;6C<FLN''UH6NF[^EI3HCM
M#:!<;_?.MSW%W#< +$P+,*98_</PKS"%:*#G)STR$:FW?1U=<GF==#U8T&<R
M=/+6Y+,_X47/=7L%ZQ/)7IAC/0.2PV#&? ,Z)!E$E^3TL9@W2/'1;S$R#_0R
M)QJ^[>#4V5B4EJ'LK@]5?2=#W@+O[P?^4C].99R*T?A39.)/#)5G?,,=Q\8W
M;#?FCR9XP2'[!U^=)4\?GR9/GIP_-$7H[_2F->4,+NZF&M\KGX^^*/J[&W7Z
M=J<W\.^N0L4/1#4^H52XC[TS;T5OV2C7'BZU3L[(1B,S1^^WQ;Y,#<9HO@ !
ML#E"WK[!HQ\'<PBN41@&&[L4LU9$REO@[)*3]]7Y[(DK^QB+B;T;>8XAJ[$@
M&5QM;D<HN*22/4' '*$LD\-PC_SKI."#&_W8+=V-Z]%!?O7$5!;1GDK-()(8
M?6XP+ 40"*?K1_D*\43KBB?)I'PC>0.,).YW )5<5;$AE@*' )A;'7Y)=GK^
MK9G,Y_?2,)T2IW@BW<=C2>AFQUFEQ4""5RV9'_L1,A1+>C80&!"C^"]58JI@
M_,2'*2R&A2$0)DRR@S8Z1>Z(T9!ZE_?<$_$;^LR%F%D)^E+8A@3;IS33S>X_
M-KHS/"H&RAICX\'JP((H"$*A5B]KON0^4%4*ZJ4=RB)%9SM!'I]'S!B&>7'M
MY7 <M1=FK\BF-<@=_C@F#7Q0V[X[*[+IYNN\Y9A</"1?']<D AUAWFO,OQ&!
MWWCA$+R$"_4LDP0)5G#QS7!QVZ'$ 7-)-/7&[!7=F+T>Y#,]2^+=H.M#IZ8_
MP7DD/ P5]KX-.8I,V9Y3S>V(=%H8$/%D*)R-RD)(]402YVAZ%8>J%(0:<[Z?
M5.N)S:]+E9D5U*4$V5TR>L=D"JI-X4#,-6NU %+'%0%9M>^K@FS7JW(#7*VQ
MMC*8@:ZH7&TV^G K)J?,]P%UTCC+\1,%&=<7P"5VP+"/$C'D8DC.VI2CH2HN
M4FY$6JUE\(V=NW"3HI#>F^==:VNW/1\"ZZ"K56FY4:0YK#KS8EI$&9%$[1JS
M+%4@7[Y33L.9&>92FYV! $I0 3V7,3]2=<(VK4FU6/P^;7)JM-K,6."[<R<-
M&-_.1$JQ;(#[M>%,#J?S ^UQ?2*>(;GE(F1H#\,V?.)\609&8Z<\B9))E/2.
MX@?.+S+16BN(%6BOA-4BKG(5*_GK';AU*UXOR-= 3@8UJ;5"'ZFI^!?\&6UG
M8LAW6T:YA=]DQIM8,-IHK6LX\W:FPZ&2[#TESSO"AN=WYMG__D.I_N_IZ>,_
MV/+^5ZU>1V=_F<7_*-'=7""6]JY5BP6,*BOR[F$S )V9):.#W?WM2KK751N9
M"1DD90Y5JDR*\)8ZD_H"Y<E H#R?Q<\Q5<:.9)FXZ$N@F%M.\: 55$8\2F4G
M?!7IBTPLW,Y6P) 9MZ!42YFT9D .9)J#1,)#6G-CVY3I:E#9)4S];!:_KDH_
MC<Y"[/ PB;:6<GP.*JM""E'+_H._E>)HLN(X5K0X(4OOI-=UZY;05(L6(X]F
M\<\!X [R]AV/6+&#V.2] OVQ5((VV-^,1%W,SQQ20ZO-M,^&?)]"F0D3V!ZM
MJ;!@?^0K<;!;DEA!VS!/;S!!\);^V\Y6B/Q\"';#>BLA S.WS;\\SH';'B1R
M1*9H97"J>8Q9W@IX(>\_JPRDF%_-X-%RE7Q.]GJ+;>0&TF"BN&)$1H61KW/N
M\^>F,';<[0\,ML1#LJ\/53U-@N5V^OZ9E*H234O]J9),\M5PB%>/&,U<%B8M
M#Q#)?AS/,2&V6RJ>.E)L.:AJN@O-:."\;I"FPZ2/5$=S>L&<W+]+,_?3/7&B
MT(/:]NU2Z,NJCD(D>I&^C8<PY$8*,[/G^=N?7.K1C11U(T@#E<2A\.#+U54Y
M%.%.W09C3.\?)7X)SMUM6N]/^];[^2Q^4U<,9J8G]_]@=W_;[G^I9Q%RLS)K
MVIIZ%LD\F!D2C.PB2^_\]/%Y_!R%3?$+79"-NE1%$C]7==',59:$(]O0&,O-
M+D:7EFKMS'7TVN99KNIMQ!W22TT[>%6F;&$V%2G@P9_I&=QU:R>,A!TU967A
MLG,3<[5I6=F<S#JEOY$-G_7+5;!&E)Y%@AT(EP'I%+/G;?Q@,-ZVORJ78N@:
M_5!2-BBM7''UU[J"E< .33XHDNF9W)#@/$6,;&13\7*9UYA=/S..R$2QAVYO
MW*9X_[HOWA_-XA_(V2P@Y-':1*1^(%+^+"]O0C<G9Y^3;";1/RKZIY/X-<UJ
MYU.SVN_:K'8^-:M-S6I?O/B^3>7_35_Y/YZAM%G'[]1"HW2Q-YSD  YL,@$.
M4O%-R=\OQ;\077N+$N;LU$F8-Q=OWT>O7ATPU]PW:K@#A?.LKW">S&R3%T(L
M;PUXKK1,<23DN=1Z2BU]0M^0N2A!XPT] %7U$K1^U30=_>F- 6ODS*6IPW_G
MJLJ_+%WV]-E,C,Y)G=UBZ<$X6M@H]$Q0;3S:N(C/F^UZ7A6V ^WO/WS_VA4%
MY'!1N OD*7>!G$[Z\YY+S/P__RHMA1/8\B%N^];'P9(.(X&2KN+S)P$&2&V0
M6<^_^=J@SFO,#S#=J#*\$R-*1V&\9?SH(E^BQL&UW]9Z47"'%: ?=,F-:R3-
MJBM4BJ_R#58B0%WQ2DM10UEAPJ D8R;!=?"T^[D%ES>RH@N978\<&&R[5W8T
MQC]8*1JC#!DL7392YX!>SDGF'>2V;Y>%WFD=O5%U&[]Z]2J)X2C$9^?6>'IG
MRU5^LF()$NZYKKD_[R]>;,GG!IC&E6KAG]=X$=8L8[P;7X,3\0A#AO^00<P&
M+2(-Z1=( P=;+S,)P5L3@F\95R-ZIPIQ0-$\X_2SEY"3I#O$;=]VY#1:=#7W
M! 9%ISR2B-M*V<;JSVZG#R$1)SES\*3TN>6,BW)%8U$N,];+AL2@]RX6&-+
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M:;ZP9$L&);+DD60(_/I=5=TMM6SY?$ &[77O9PC84G=U]57GJ@<7>* #!LK
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MZ#'6,B@#GM_YGA7>>J8:/R^K*E8>"-R,VG6(/5 ZAJ/L,Q;"*WT.#-^AL5/
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MZHZELE8H%*1'*I,41Z;?1QJ/%"H+Z??\^1[3A$C]/K+:0$+ [AP",\_U:X5
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M7@&7]]:V N[' %# 9APL'.IX]\,.A>AV8GHXX)3C6%@UPDJ$N!MN3[FB$A^
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MC >-50A;^%#+L7NPD- :CX= .3#X<!&"45"/ &W$]A 7#9>EZXK2M11(L[H
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M(/=GB!K^P'(91KB>WZ,2,_1<XQV/_ '4U2Y4120@0BC3!CGI*UR)]\BDZ3H
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M13DI_#OU?$D79N$G/\#^-D D(*;I!7SY?#JDPCB4S<-DOD@[I5F./2T<EE5
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MI\(?>^H9 ?J=Q>?9)R!=5/?P-A$,*S&8P:1DSPIO/5/Z-D<#Y,.TP88)D$\
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M0^21<U)'SDEYK4L-'673*#F>@<^RB:;74$\5.IM2*GWZV*31-N,1&G%?&2/
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MWW.JH ?NB))*<T&_Q<"SVKCVB/SN1DPRI_M(2Y_?61W!L)['II;&,UL5/@1
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MD,RN@.AK5$#J>^JA/"#R.)H+>2G-A029<(FC:.C?F&-S9(1&!@DG3O3)!(V
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MU >5 ?LSW(!AP:OF ZSQ#$.T):BPP0FP3T+0\>TV U=&B3WE:B;Q97I4R@"
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MF'-0;$IT3D\[A$ Q/8NIQ(:#5"?M\P&H]B"#K5 1QSA;C5^6RYR>][>>&-[
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M'\0&-PU K!@=-&X-]P%U5=<+X0&&;ZD8/X=UW/B&H_8-G\5M;JW 0EXGY<#
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M_??^UW^KS\X9P.A !-SA-^+-RV":Y[NSE;L&TC,4Q?6H'/^RS^Z_/[[W<\]
M?"Q)FKTLT2HX))>MV[^S*6""(Z5+U7JS7SCY5/Z9B\=IYYXR<VN#7#IKPXN9
MZT)6>6QKNY$;N(+KOG/S*)Y9.1,65J.]4&SMN9S.-J]]4I1_35<\TD[F4T>6
M\FE$H:S-Z%W3=Y:B 6T=[VSSVE\(WV_&E[?2F[&JO;/Z]">(B.27/^MKW_CE
M_W.KR;7-:W\9.'_EA>M5;58*?ZO:M2B;?7$;3Y0)S[5E5E*<#2FX*FK(6?"\
M4B$K6\P%_0M#_US0OYBCS@5]CO#/!.'S*,!6G--R%5E9.9.)-5=;=R;;O/;G
MP4\3JY>V[DRV>>U/RT]/H)=DMMAG<R287LZS=6R\S6M_<5<P*W; JO;#REA2
M<HORBY5?K&<8.GZ*K4TO]-@Z]MSFM3\/,V2.Q-"M.Z%M7ON+ ^ZGJ#/8I'XT
MM9)@ZUATF]>>@_=L:?SK\]A'I1>EX]2)U)94W!6'4=B.%QM <WG]^//Q[N9+
MW_WZ\<%92\-UT7=._V.%=#PP' .;HAJA>F1UJ%A-+14U%3M1CSEMOHZ5+F/"
M)1K:_1^IC4[7"T31;."Z/*=D=/HO<$'?-E,Y;M9RPHD-M\X_E,IV^Z+MO?\9
M#1+F!ZCQL<&OANA5&Z)78B3T*GP-$]N@3YF>NQ^<=>.6YV+KUR,[3S9#KR\W
M#1BN6+&@U4II0X0F\?N3<-X+N'*O)^_YB1EX)>)A%5Q?FW6&],BDM[*N%8MI
MHTIR;L^Y_:FX?6(CO2'.GV-RW/!TRX)6T>M:(76T;L[^.?L_&?O/VM5MZ"K,
M,<)OQG&?^2UX<;=@RNRB#5Z#]"YD0SQ?77[V4:&DE>H5K5A+&W[TA#=@G$,E
M9_[G+P+D]EE#'#_'),HDH]<TO531:H5&MM@\!_H7SNN3>F,-\?X<TSF'0%ZK
ME I:O9XK.3GO9X#WA]BZL2A;U[5:M:I5&MFW8%-GUU:'8RVM(!A8YM' 1U+#
MLSV39MX=>NX=G 7LZZS+?@YMH/REU8%/AK857#]6O_\Z^?"C97[_L,)1WFLD
MT5?/&;BAX3\@E_#-X;"B3KP]6HUIM4,<G^C!7] %".\>;02T27QXPOA*<SJ[
M,#_^='Y9:R3F_I^C1KWU7_U#IQQ%8F8X[S%G/1*\>6)@7)CHDR84Q_.)9W5Y
M-Y8+]-3+1:VF5V?%S4US_;.^T5GEX]EDS6K9N+YPY*:>.G [Y]XGY-[,,-T<
M 93ZX@$4K5@$$"VG*9\Y_VTU>LH/V@VLSJ[]>_?6-DT+7@:ZF&[_;OL.\$X%
M%UG7BWJ\RAR 7A(#5',&>)X,D!E1-MX37E_8$XZ22]<J]5R!>J[L.RM^U7/\
M>IX,\#3X%7HQ@@V!U<(^WHR#5:IC]^ :R!6$7F^R7_?",JU>'_<2)(A]9+7#
MEAMZDNU\_7A[?O=O[?=M0?]<6V!D^RIS[6=_ZWJ. M_\ZIU$O(4=Q_/N:)7K
MGPY,V:!S.H:MWJV[V&X%</8E/WEYZNUC7M!YKM]:'>:U\.);_Z)K?@R+D<-\
M/'NOGJ"L_&YE=7>,;])%T.>3]Z>3_>ASG,I*79%PLDMYU$N%AE:M5L9+J='"
MPRQ?\!P9-T.X<7"VK9=X7L5FQ5&QA<,)I4E5(/G5S:]N?G67O+IS!&4:"P=E
M]$I9*Q0FQ+7SJYQ?Y:V[RC.Z\QKCXU$YV^=L_VS9?GP4+F?[G.VWCNVSIKB-
M#T$V%@Y!HIY6*N9Z6GYSG]/-G55@C0^[YFR?L_W6L?V3"JSQ,>?&PC'GYR2=
M4@/4<JNN??/G( @Q<A5<>6.<--2'X?KQIN!UOCO?JI??RUM1971LV+YZA\R&
M,;1[P_<--U1[GFEW8<FX3UH,,(G:][VN%02T=36P_#N[,S)T),]*6?;%29F7
MYQAM\VG.J.V4"J4\R>QY,L#$)+.9Q<K:P@BEPL)AA)K6*$\(Y>=\N]5\.RMP
MY>4=+YP!\O*.9\H 3R*YQOI12X4EFAKE@NKYLNFL.)67<3Q3!E@_3HUUGY4*
M"[O/,@Q*J=ZP4IPPCAXC\DZ>=;\Q=]&%U7&,(+"[MF4BZ4YLHVT[5 ISY;%<
M[^O'QXM+[T?QPX4W,-<RWF#C/C)?VC7SD<'652?>NQIZJD6[S^]\[B3+3W-)
M$5XLYB+\>3+ ^.#80K)F?=ZRHKYXB695KVK51CF;,C]GXHVA6.[J?^$,4,X9
MX'DRP-.*L?&NL^+"4Q]RJ?7<>796T,K=_,^4 38(6N/]:,4E^C1E&J%2?6FU
M.3/+J'S^P C^'WMOVIRVLBX*?^=7Z+KV?FNM*ME;B'EEG51AC!T2&QR#DSA?
M*!DU(%M(1!(>^/5O/]VM$0F$F(WN/>>L&%"K^^EG'I$,'1.09DKP(Y+UUZ+)
M@7?@9C(5"[5I5A9-(<37I0\TLF)W.OS:;)3DBOQ#.(SNU^1XIX]P:NCAX!P[
MI?_4E9;>YJKBO)**\X^) "M'P]8@;#;G?Q.%Y'J"4"GSA5QN/_6$%/.WQ?K$
M-(IPY @@I@CP,1'@ &5?M--.3-RF*15U*:+O':+'GN"7$Q-7)%1XL5)*D3Y%
M^IT@?;1W4UPA_I(52GPY%WMXWYYY-Z-FDU_J!L)[K$T,+/YZ[QU#PK=!#E;5
M9/*72B['O=8FLEK]CO2VQ'3%[O2RTK-^W[WFZC^2^#QWFW)((<3U&(@XRX4*
MV8;D@"9E-*E'-+W-5:W"4FH5[A4"S!7W.Y4K&W1O)AY>+6*#+U3W39'WH+G7
MQZ&"7F\RFN#W(CEJVZ$4D7SN-=:=2WNJ-Z>$L2VQGA-2L?XQ$>##<,9H%W N
M[K2-6;^!4.%+Q=07EB+_GB-_?+=P+G'I3:[,YX0T&)+2PC[10K2W.)<\\)<O
M\\*^ZKRAON*:6U5^@3"P3%U59 +X5O]",0%\BC;!)L,8&>1CLSM]R]>JS\JW
M6N59.HA$UL#!H()<]AR-[$1WSI=RA]29F][FJE9?VI7LR!$@+5?ZF CPUYQZ
MI9@:Q'8<E[DE*II,#"J,SC/J7"[+ERO9/5#G_DZQ>#=L+&U:]C$18/ML;(Z7
M<8D02\JI4D3=,*+&]PCFER@&BD)<7LP5^'Q^'[R#*>H>%.I&._#R2X1M(O$R
M5RSQN=P^5+7[\7)ARN>MH?<5ZUHWS>ZT]I0;7#8[TH]^DEDHB_,OQY(L8R9Q
M2M?XA\N>%<;6IJ;'$& TD44VH>+S15Q%Z*8V2E!!L#SJAHP,9P/G*@8MW09'
M<#Y\5-)6"'[76YOG#=P^-LT%U:'AT39ALULTBFN^Y>.V>DLQ+\6\]6)>/L6\
M%/-V@GEQ0R\IYJ68MXH=9V=XN/;&DHZ&.V1)BH;DNF1H^.;-4!=#<0V^,3Z?
M+?&8(.+:<MNGC*#K(26*8R6*:#=Q?AT!K9044E(X%%)8PA&]1-E6!&E@6Y$7
M<N64+E*ZV"NZF./E7D?8D"\5!5XLQ$Y9W37>AWF_<_EN#X D9(5LMPO_RN+_
M\7C$28>)H:YB7#!ID]R&UE,G<)!ENADH]>ZT+7\Q>^\#493+Z\M]#0)57#,)
MGTNJI/40)UG<!>H1_LGELCS9!H KYEVO>UL).0O9!B?K$WQ7NW"DVWA7*9][
M<0QZFYBMB65:D@9@ W09*W(H:G8]J"E9"++;*5Y";I.N01.5ZIMB>GZ'OQBQ
M5BE4 ':G%^?38?&/=M?J2"><I5AP6G;3/&>2[9SL"2#G,\(9T/GY8=5L]4.T
M@QF(^+EC(2YW;#0O/6R1[N7D<X'/%44^*R96",3]\J;L/>VN&3C_648CV!M"
M6(N<6@OU)"Y\Q&JT6$QL7J94DU+-'E/-$IU$"LD'E67S?+%0X O%V.-)4S)*
MR6A]$:1"TJAYBG8IVBWM!MDB^XX3<"HLT?PTRJN2+?)E0>1SY=C9@]NGI+CN
MQ)2(4B**&: J+-%E-8)TL,DMY/A"(7;CE)1P4L)9C](3MV U57I2M(N!=FQ7
MR=;; WX?8.VKYQ[L'6N/"BW]C\#L<R;S[]B[Z#]<5L#(LP /1I(Q4+132Q__
MPPFP7?:!?0CO9[![_,GLD<)"1Z\T=+0.!(5SS!#V& Y,3L[UD*HRX),+A;_Q
MKWKVWTL#A=$B/HDJC4V\ _M?G[A71;:&L(KPWQ,[L#<WK!:[!B4J*D< \8J
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M*T%^GJ3)W-@^+]F$G9EGI^YA9.$>V;DYR3WX,3$4-^LROQ"A:'Y>+(RB/XW
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M$CZ?+_.52B6IYSE!26.*%2MC!14*W8!,""#%$H6MP435,F8@Y4+BDH84*7:
M%(';3QR**O)BN<27\YMG"7%S'6)$0+=3Q;;XAULLJ3OXS2SLE; $?01S\+"*
ME:4JEIYK^E6L?.=YVGN^1%<7VZG=B0S1-F=SY594K0XO#!_JB%[NJM>@/B6.
M<F))6<+\,D:9]-$5_^WDNF/I14O4Q@<E8ZXH8(5Y0VD:Z6TO=]N!:RTG3E7
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MBR)?R&U$A:PD%?042/\_>V^ZG#B3M W_YRCT=,Q\T1V!/4CL=]]?1P &&R]
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M6:WT;W-WQ3!M)@G,"P@0J[0;U._;RG7SO-Y"FK]5\S<M(+C(VQ'\-Y<<9@Y
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MMFM*AP8('3O310_<)\RL/DF@G'[8Q/^_ W2\A@0+OQP# S_B9BOHF#DXZA1
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M4OD-0W@M#"$R:_!DPMB&- W52:O09812/PQ\>IAYW]J*J!%_H%'U5A5K(4\
M$0I2 >/! EDF72[FWY<(!2&<N^P$0*;TU#WY3)K.1L6(VPEJHFT3:0DH->FS
M;[RRS2@5[\>*LER+^6D,1NF7]M:#ZDEO @00E""]L%[GG6;H=R8G(4GH+C)Q
M.,]I)K<;\R1<\^J&P,C2B%<4] )V"LIAF]#,&[GBW;Q\6[H-@T4=QO985W<X
M ^3D#W>2^14S&OTWC@"+3A??FT&*0$@784.$C,,WSA;2C(_*UA#B5MSP[MRG
M?&R-GOJ#*O.P&EVL1TE&3[O&X1S,;]E*L0 B%P2-RC.*RJ5SF=TX>D<E<M%H
MZ2YUL;C3Y72.CDI+KYC*:>3NV"%.RFP3M+<)>\DQT_/S?!B/<$M=NO[R8]"X
M#D($D)\@X#B>D0!R;$J%]R4_(0CH+C1QN-8%?P.8(@H-KDC9O#;?)CSWXW'Q
M?B7<_I[D$T;0^O8++^\H*GNCE,9NY[;M1^!?;.D8<LNE="F?T(")K_/;H37H
M&"*%<KI0CA&2;*<J:6S:7S<MTF\^SE1#@;P6E/*:+DYZS61"2P^H&5O]A6/N
M=1R%-I2UT :OR;/8QN?TLN/&R/%E0R,IM-!CPO(%N 39[7WX+I#WI\@^SWFY
M*[  <9=SD%4NG<_'"#_EIKA\EV-+558J-&=\\6ZRKQK! Y5C'W-]7AQ[QJ8Y
MQ6KZV5KMZ.P*_+V Y?$BU12':9P8,8$77GD9+I?Y&7H&&4!$BB19Q6L&$?5=
MX7FJ):D\E2<US?1/RMH]D3*!PWZ<?BKDDV0[ ) 2*GRS9D/^L++,BJJU(MBC
MEM^2P-ORI<>UT&-?%ROUOM7A]J4=#EV77S1XV%F7?_:X?FDO.FJ[(K<X]MNO
M/Y5NM_)5?/]I%6Y33#$9Y)S;@*4$10'U^$JD2@%UNV1E05HHE" N>21S,BE.
M'\C2,X]^U@&CY@MY""/10-G"&]%2:M1<YD<\\DS *4 ""3!43IPK-C67A26+
MM"_R\8<8A8KZ#@\$-F8R/XUG:8*NX-_3/W^<4GWTJ8T_$PN@+ 8*!I-3IROD
MZZL$R JM.TTMYNC5T,D#U?*D?#XE\RBF06N7>:2J!!4=QIIT]5D N,ARNX*J
M\G(:/1/M5AP#C!8B@)5<!B&&TFPFB=K.M3I]C<QI*-/_CUU R[8.I=J4A:9:
M;5=MN0M^8?V-EX>"PG>0^N6-/RK:7Q4:IX $#9N%]#R:K1@ZQI?VY!XLR]X!
M26A9TQ^K]T$^75?'RU*9KTP8HP]2^PPB UD1.FFTI%U^:ZA-;8M!])9$UY4[
M;(W?/%^SU;"[O!T,BJ%\^U4\I<MN%WM8::20DT"P.]+ ?4^(QX$;6 Y$&NA^
M2E5P]_9&=P81P$U&GK  [R;S,U80@5<1W\W@ 4ZVL59;Z%^NB!PA7WNA*BKB
M>_2 /OH^< BG/FSGD/K+0E!7P*HHWH:'^>&2-:]R"E.[H"NTDTN(PL"1#:*
MN2"\HV_;W(H IUTNY3-%^QD#4-0_W$(&+#L[,S 99P/4+L)]^Y4YS94W/"+M
M[#%:WE:%Q/&P6<"Y JX8\(:#NSH9@E0((P']">D.90%RA3X#3#%>"!P+@)A(
M<59Z-2I7RF!:PL\E.G^2RZ21I< NKIB"+PC0_JMH_<@L"K"07F-!2R$'=CCA
M522GTE+ 'P"]9:I)Y!U/%RK&*E%@"4,>[:>-WHH$>THQ>=(RY&#55^L6D1+%
M2H C_=$;VBT3IW9C,CDF__BHR.K)21?T,.%1_.\;]DV8+68:8\;&W[.S?+X^
MJ\R$HL'?]0-I/^8DDSM!^T?;?;3OUK\^9/Q>T4?6APXC ;R]P1SEO3$'TJ7Q
M,\??UO*6J_VEZRQS7,QAVVT YO";'?)FCL*I:]W[#M[ /I:3.6P=I>"V-+&3
MJLWAQ?-WR5N1[XO_I-A8(8LQ(#2FB,$?&@B3?H<5!K_?"L9A-S6E"6I7T2BP
M_<#];<0+>!R=<-9RU@%.UF_EJ/UD]5/-E3T0Q\FY0LI/)45ANL$QS"")++!1
MN6%7%%/8;5*H'2:E$:_6R#.%O9J4[*+QIZ1,6[APX_!:(W^"]A_)I$1WL<-I
M#3>+4MD;;R1B45['-U<W?VXOQ]GGX^*-D!8EZ_?"VYLW\J=TUNV:*(Q)8:*8
ME+QA4C!7Q&!27FCI5<B>J^PHMQD\$<69K#W)&_8$GW2 <PWG1EKL23GO5FWF
MWYZ@J!JB9&4Q5;4LBZ(;#D0%);TU7L;KP!&4M4>P J\8XZ.LKLR/=-@5_*J"
M;!37GI.)C1).BO'ZOQN2/.(%]&\4(2):(1[ &_5DGO7OU7GUJ;9>T^VGS9,?
MZ4_;>?C[V88_[G$P2#A74F<0)E=,%QCO*,/N+Q@$PU&R\^#S?H6^+_.LLI!7
M^$-=GG":]QFVA5NE^U>:9<7GS3.4^1CDUW5!H4XCFON7S172I;*W$G9Z;Q:?
MSTA[@<OGXOC]<7?\V#$KB![N7S96$T\S#+-7]^]Z>)7]4_I;G=,N2E\GP#ZM
M/,V<(!)$\0"ST3W D%;>S04L[8T_$G$!Y3HM2G_X\=GO\='Q1T@O,!?="Z1/
ML][^0C GL!+!"23<8/X4@Q/(=UZNFHW27%+R!W$"\?%:#CK L49S NET)L.D
MBZ[CQ'W[@9_K[O8SWE=7#":8KM(IR=6E(!?,3PO1-DG)O-30[V'/^ $2T86,
M#4=E.I^PEC*@DE%"846L 'QCXP]='B.%ISJLK*Y^N%ZA&P]F]:26[7;8J8RJ
MNXR5X8KS0R3:N.@/48+GJBNG_G8Q6]'5$[%T?5!+,#V&$Y8"MV"G]J_B#=?(
M%;J1R3B3GN5JLUC[7=RX/K82Q%_:-")IMEJV;0I/_^/F#AVJ,&*XD\YGO"!C
ML*QK9'+4$V"V+/Y4[#4'UC(*PHK:GHP2BA3<6#I,I?9DVQ<0!RN;_E4A ?_J
M@(Q:+]1'9UFF<Y\1/%)N0!M-EO?O=\7"G>'"/[O_5?",QJGO_ LB-8BUDU<L
M\-Y$J<(=-*8#<E$ W8P=\Y@7N/GCHK/0YJXDX&:%9H]^D65>,^)9L6T.*S*W
MHC'(W-C,UKY/3Q+$X)KYYH5 L9K6Q'+"6-@"C@D:WCWYX;^Z,ADZZ;1AAJ'6
M"CZHU67!K"6MP@OO(Z4KHAF[@NH)76=QU&!%/H%M_^M$0I9:DN'G.3+-N,X*
M;+**7 N*S BE+A<BK[L,)5NQSA#9>D@W0*D&*5I!"R=.!TRC4H:R,$!&7Q W
M-219Z\@V[ R/<'RU:%!<G0&%:.@)^H8LA<XG,O$J\-)7.DDV5;PYC2HU8*?8
MK5$F/)Z;Y59@Q-CS+WEKU9'NLV!X0;PPJ%D2J0H2+0[7XK6D4XHFCI3,CP%M
M#WW"-+141[/?J<I8YK%$ILFG,7F +(@(YN/8&2G%4U\E]#)%E1=X[B1XB\.)
MFQN%/$I>UE)%&R^EC)=2A!ZF2ZB#W%+?V1_XZZ7_HB>( F(.AU>G<2 9BKGA
M4\)9C=@E^AHBK<9IP!G?!S_TY8+%Q?K')(9^NKX?JO&Z02=T& O(?_F3GMT5
M-^"]-@UZ6RC@4$5HJ9!KY*UUA)F\/D4ADP^M/TW5#2.!VR-+<MJIMO5CUJEI
M'+)-A6]/TJW5QL-X)EY=+_F<I[K>9<2#$LUCC@(-J5CS)V\%;>KU72382-+9
M=7L^V3P+9>995"FU->_V"?C.E@M;EZ]G'?IR1->4TD?E.^N&'7P7O:@L<UIT
MPWQQ\MUWB]F>2XJ"E?EH@;6A67.[45!)++M3?_X@!:H6E>L:$QE:W5W=QEV^
M?=1,;U>VE7QE\)!5NL]%X;A*Q/>C;:-7RVV-JJS:=I/M<I^)[>RZ=M)IEEOS
MAEQZV;@A^3!LMT791@_F]ZAL->K]<#BZ*;1"B>*GPDP0L:^LQV#6Y^HUZ\Z'
MD6?I 8.UQ!Y4^)+XT5 80D(N'M_"47J]/0&, 1*F+,\D34+L<"C)4/L_7=D#
M)1D=$%S%:R]YW8SB8/=F')C63(M9Y/]U4_'A]UQ14HZ2)$<ZU2A/2E/29F@>
MN3#B4P=^4[5SPW!76>:-_Z@.^!97)'H!AL_ 3[>O*>_ZB\+G8D.[;])0^&6Q
M/OTKWG,?E0V]79-"]/R#3]?$3YW'3@\YW-7J\?!C3 5'_>;;[.Y>_;ML#\(6
MH"1Q/1LCV_HO:2E$*VEA,METP;NPF7(I:-DT^(3D:<V3@&L19/&W=<[AMU=W
MEP%7G67 +4DDE;^$;TR=8VV#)<?HTF/^<20@-_Q;_)N?+"IWA4T)L'0N.^?2
MX88"X]GQGX(6B0( SB<XA34]J34Z];?V>@-P0-$5/I#"5U5\PN+@!YU@3QHK
M6N7)EMOJ?3#T$=$Q8H=D/I\N,&ZNB[LIT"V"T;I"EIBRV $K9 )D$RPBX''E
MF_U*,N"IN?P;OG#_]>__G9Q0#8&?<O]0'7;,_T1/ MB#(7I"KO23NH-4S3\4
M0YV<:#" 2'_ZAR%UD*: \9@"#?GT-[K3#?;)>_ C.CHWN#T//&(R8= Q*=1*
M-YUB/RDP%/]0%9D=",.?5 LI"D+5E@3TRY6LW_J?_C7XDXGQIP/\_?L_1&@7
MDJ-PYOF$U&O\0\WQB5D9\MU0V$9-)]"A&Q&LI .:$K)96'EOTIQT$C!N,+E"
MR7NH-:[.F$A3Q $*L450Z.N,/KPF6F=<)UH'?.;CFBY-F=S5JE=0/_R0^/Z$
M3YDCJ8F<*HL96A[ZD(+SFV %EY".1S&-@85#6;!PC%XR'6$,0'8H4CVT8>_>
MY2SKVN/ZLM4]^WV^NGF"RDPWN&/[+&L-LJ]'56K]YEVS__ UKCK0>&/?<W9]
MSHK^207 1S?F D._7]R#@6UE:+H2BGU2\,<Y@P1F,Y,((.Y9U,>[7U/+VG3G
MIN;\]NL/?AC/Z>TS%0)+AO4+%?-_ BQ+O^ _]#IP$A\6\<4\+M3!%RTHRDWD
ME"*>7*(<%'%M7UP50"4EJ9$BGF-71P ]M)JZ%D8\]?T!L"Y_Q,=7?MV+</-%
M-$\R6T".9%]2V:DMFV; O3M;)I*?;6]<'90:>[_!Z9EW!X",J]^NQX,7'/@6
M@+BN^/D;$!GGU:NSB_Q3[<8LIB:;P##3V.%*FXE2RU:I*H^X%Z3FF_-TF/^&
M&+EQL+L$Q@?VK?Y'3TK:,R7%<+?S!@A,NI0KI_-%>N<(D"#R$)^@_<=%QBJ)
M7L]93E(W*YH]L960OB/!6TI/0K:I9@?5B7D%IVU-]]XIHSD6[X[J(*G$E$M4
M().ZD?)YAGN3T>B=%,C\[IZ>>Q@1W?I@+W[8J"^SW+GC&*$]>J?BYJN@K/AT
MD\]U*NI-9FJ(I!X:.40Q;1&V;6+D1K7D&'Q7T5@QCC:*+;6+)YL5BF<?G(/L
ME;%GM;N)\N>V67QBWC,'>5>_%I.%-WC'NG,+'$.RMM12Z&$WJT946T/, H1>
ML%,8M$ ;\RD80^*8(Y2XM5H2I&>%R[4LTF2X2">&DV3LD[*&SU;/:.L$#!/6
M$>Y"X_,U?(W)*):^[<_K"LXI*!0Y]1K)$5I6HZ0C=LQ+)M>&Y)Y-UYA<+,.S
MS4"GE&PRP5CVH] B<"W".[".ZY'TN_-2KO7'BN GCV#L\IO;"=A4JO9WD*$3
MX>UD(G <CSZ##H,1W@;RE,Z4,G!<):3#?GKP9J)SU4W6.-M'B2K/-44".K@U
M$GX?7M7Z+O]V/7GA"Q?%<90P.%Y^8@[*3]X;,!;U?E>3;"[:S0X82-LQ"WO"
M;0':LA=6;/,CEV5&;E\QN7FY6LWYL0'&P6R3V>][3QI;"._1[:4[BGZ&I@5,
M2I4"1>@*HA329*XHA\4\G2X7=P_]WN3X'S$+2C91JVAPT4>RBI5*IW,A]<:O
M,S:*5?0E8?M- @<ZK@/(7QSY#1])X?=DLH]K-7N+'N>"'+O/D$LZ=D2+)G/4
MWXVFN[\:SB9U97H[\A<WXF,Y+H_!0O8#:*Q@(*.>'@.=SI2+Z;SKN,E]>PSU
MA.-HS$,?R5\8S+GBA*E>C<:1+I-]2->^FQA]']7^):^<& 3D45AG%_C\;3=Y
MVE&]%XGIU2\NN]7;4>4WM_NF3I>+H/=TACSMG37CJ&WPON@]$@X]X@24HT#3
MS<,\A],S/<RM3]AZE[F[MM>5=AZV-Y.LBZKM^KVHB;OY966X+%7DW-2/>ZKM
M+D#9]3&421JKWKN:B@:HX T$X*MJVJ_F25HB#WJIA,]>^4B^,/VW6'^0^[V5
MR$7QA1,4Y:2\9?]G>0!13PQ*]?W+>B0.VQS8OLU+?V?FMR?<"-/QU3+7]%&1
MJ4ML4"_]<.8O.I3D-@R_=R8:[HYIG+*1+(*8QD9!:_".7 )OK^EIXXGI-XN;
MUO0DW@J\V&7-3P4>G<DD78$7C#% IG-^:^Y"B72"-RCZ.ABB&_RW V9W[8P)
MIVWPURA.6@RF?+ XN++WGL'Z>['*5^)-7UK57L6S0=">P3K1!M'.[$C["./W
M$.A,-(S4L $R$\TSB%U6O;L.\\?1=?AN1+?9?OBS9%Y>+Z5I7%V'"8KT,78B
M)B'ET=NR0L7&QR[FT3C*X?QG=S6BO1L9IN_7KQ?\;>5/H[0E**[;_>Y(K65)
M\'RRHW7>&^L'#WX#"T#CB!O2<)_+^PB()5D1?@NO%W]A.M6'#(B/O24M0GSL
M2^SW>T.LJ1(+(8Y$^>RYK<F*O/]N3'&Q_V>Y>FB-NU=/ ;K>,++^>_*70V')
MQ^$ET-%P=#Y^_)LLZHZG=N;O> 7]X[UZT-WGEPF@."Q[V1!1\ >0XMVGN3<)
M3VR>\?L6\5A=_\JNTDV#,0@G@"B_ S'NC>[/NFKMN3YF_=1P[IQJLZ6.TT&@
MO4E'8IFAKRAY9YHHX8L$]&=/A?SNKXW7 SXG/0PO1J/@4;*;I!Y=E$P7]A@E
MA^.5_47*VI25U)'/A;""*W\-6TYLUH@VS'MS6 (,Z>:%I38J_&TXP;9:'SZR
M.9UQ<RQ):@-&^$!C23XXI^UA>Q]W (K;S"\7='6OMP2HOHOS71&'J'BE2/<P
M7,6-!GZ(&_O4E8]R\$'&!D0\]T 370Y-WX,1<_L@AJ"V@$R>&SCG,Z2, 0V#
M7WL;TH#_$WTKYI"0][=V;8@(67C"*N^+[0=DV$T*AMV\/U[YXO,O/@^IWAW:
M/88#M4S-B>V9]@$X 7CE,!-OW!(DGD7OSMB5=FXLR1$XA0..P#ERF.G!G=)_
MJ0B%:M-7C_=''(%#)W!U$:ZYS0 PS)72=&$W.,KQ#,!)MKLLQ "<(Q>[X:Q<
M;[TQ;]G+IZ\!.#NOWA.04"8Z?E'QE,D<O8CZ9(5@C=3O2- J]=&=>M5E;A@?
MU^0Q#R5)@FVC5XQXL.U'&T%2/N**;_T>FS9DASY&V9EE'LZ>9GSIZ7FS4BSF
M:F_:N,>.26A\W6,SN2.O]F9.,YFO"23[;$WVFD!RY&8N.\GW>H5LOE6(;P+)
M(;!DC67M8TB1316$:\G2C6H^>PQ@\\E&8>%&L!RYX"P[EY=LL36\'//)CV Y
M1,5S! #99 4N.OZ/KP#L8/"<NSYXY(OY.+-J$L[^NLVJ.7*E5^^>SU[>2K>"
MI7;\X\VJ251]90/EC[;,JLD5TP7F&'#GD^VF"C>IYLCEJ-GGF"?ASVMM6?J:
M5+-7Z4LL#?9N[?51+>9=SZE)>+:=VYR:(]=S?R_NG]AZCN6K3$QS:GQ.HZ2S
MN2.9;IIL.CG,5)8CYYEE=EVH%@I<;10QL(Z/EPI'.]GT$ZO[SS!6(F&+XL2U
M/G+-,*#GPZ?B;?;OW_+G'"N1K&L<K?0HFR[ERNE\<;=O?.2(VCOL>>;8!DL<
MN="^GEWD+K+C^43)?0V6.)HX.!?'%#8?$UO?HZS':,G?!Q7BGR$0(QF.$7>=
M.1(,C[V-R-V*NW[D!FC,]H2,>CTZ9[DOW'6SQC )HQ(-=UWW(.D/!TNU+^\Q
M!/+ZD0OO;36S>OI[>9NGV2_D]5 E\$G(>71\K5#.X[&+>32.<I0AG_E'7C]N
M&7Y49%7; _D*_O>-( JSQ4R7\YK ]8?WLZ?5FMX3.GLL<@%[>;1MQ2$IT?':
MMTT4IDXH)]O0'YQMV#<KVTA*=URL/5?OJ^7WQS;6K3C8)GJ)&WU:<*L-^0(P
MW#FF_=B*^6TP_\<ML^M,OK2HC7X/GUKCI!L_8D^/^6K\R"<^]RYBXT?V] OE
M?Y^)E\+A4/Z/7!=T;\3?U\7?-]=/_!?*?P)16#Y:MH5.9S]\MJ5TG#C_1RZX
MHY?[2>&"DPK-,#F7#R#'(7'^DY#Q.#(MKO'C^Q;Q6'W_0DB<_R,7X_R\-KIF
ME697S!T#SG\2TI%L=N6]"<D>PN2]82-$Q/D_<M$<-.XSXMOXYNUFD#3._X'"
MY'U.PPN+\T_[QTB("^??^;:Y(5NE"OVXOKN^R=T.UD_USC0$;/>18Y;KI,'(
MY7[G4ZB2.:'B&\4K0W8.1<7R@K<S7,&1EQE.>&XQ19:JP0KR'3M=\!<"X@=Y
M.%DU)%GCZ6N!'0A3045RT(<CZJ,U5*>(Y[_93J:<LVB]: ]^7+-=?OQT_G!Q
M4<GOZXB/:0#"'%E=$%]]W %ZUPI7V11_*M0(D91: DVIB4Y4/,Y 0%]PPSJG
MIB:AJ1G/*@L9A2BL:GV2)*98&*&PD&58QH!5!(5B%7""G&4]V>,<BV P8A6I
MB%&I66K>%W(7<S.\X@1E/F71"2&10M_JU2[J9[?7=:K=H!J59I>ZJUS?UJF+
M9KU;Z=8N'JA&NTO]J72[E5:?NFY6JLWK9K]9[^F;3W06P[L<61 1KGUW9T1R
M6/01E_Y[(;FT120"*9\ N' 0Z.!8%_6UK7>UK? S+3ZO9KAAY6=>/9AF.#IZ
M]-"_A!%Z@'@XHKQ; ?R@V_K2*\&7CE.*>(K9EV[1:=)&T=(7.;Y4[9=..@S#
M-3GT WS_2P8-E310>'GI5I+S>6ER*TJ'I\J78OI$BJFB*/SFQ,?/*X%-<;[X
MHL?1T.,3ZJ*#S'RUWH.$:+I^QY-0OU_S2WY*T3_VONW/1F+FB\1)DSC[1>+$
M2(S!'7QN>>.1^^R!,,<D?OM59:>L..0]KJLW4"B2']%F%#U4.*@D@$J<]D@S
M0GBVTSPSS^ *K*Q1@95U5& 9SZBN-FLHL""0.JK-+Q!O!G^$UDNIGIE>/B/3
MK[>2V0'8,&__H7K@==-(^IYTYA,AL,#L0@@\]#@O\SB+1WB<C($6U:"+DE20
M+C.#0Q[G3O#0XSG.\A$>9]:8+O/0Z[]V_S3GY5$2Q^E=I[R-%%O+D[5]/6[9
MEJ/RS&\1,I2U(!O!XY^LQ<B ?%)@F'0A5SSZJ8 VQ*'H?+>^_7M7&UV,E?,L
M]SX8Q''X?ANU]WOX,6)F&>.XC, R)EQD-_XQ3L!20-D6SUC5TG*P5^_B]RJK
MEIZ*G>=AWF#/70&XT4QAX=,(MJB8.1(@:S<W\%@.S/ ?!N>]W\^=\ZN&.CW8
M@>WT!?=T8&='?&"&AS"3F;M>L3L6'[('.[!C@8K/Q'E@ZR?Y]TVWTF&RG<+!
M*!L1.#W92'OSW1;/ \7;NN,A\T/H%1)& L]1(UF:V<K.58GB<7/*P>QC7R+=
M,7NUC-D_E\/ZZNH\<SX*P%WN!'8E9RS\5SH2R:X>Y6$:5K/]-)P5A.73Y&Q\
MO(=9.A9'J'24AVE8U.KH[[U4K66F,V[_A^DQS,T><FTGEBL8=M9H8\R&#=1+
M?O$R,FYCUW"H1J-0K9 NE'-','6M$ \7KA_4IQ97G\U?+YX_'+O8NP=MS. 7
M6"%19D@ VWKS7=>2HE"(M!P_4"GT5T$<+P1E AF/F%G2+;/L=GBP(N3#HO74
M;<O9JP-S_?9VML@QYYVWIP!\OX68L=BXPTX:"AX['O(H#?>%NWNXK]^\W/QE
M)D=TE,?B>^;?P5$:SLNY,'I]75>N<X&L4=BC#&E\O"B5E.=2]CNL8R.W7,ZE
M:3K,@/E$.+&1!">N;]Z*M>KZNG=V];$XQMMY*0?P9!/@AX,,;=M<TCDKB'"$
MPPD&-4+_&.UR2GW5?\0X6,7_:,@:WD13W,I%CW-NS]45A4XEUY>EN^<+$T.J
MYI_>$:<U^;2TY9WYVR.?O^/?K3XN-C$<L/J(JY>>;Y\+JR/FDIVN]?OFDL:Q
M<HGAVRU>[L>SIV:GW"WLGTVV91I\T2LQYRY4"8%'3H))9[+Y=*Y0CF\PF[^:
MU/=H-->E_M_^]=O]W^KE^(,QI*?OR&0"Q!('9+?]37W;7F.;W;61P\R.VEYQ
M5=^KCUAAWLIGYR^]FV4^3 E7%&#*G58?;3ZHU3\V5$]O?J@<%3\8SF"WW%D7
M%@.Q>#T]0GX('"N\'W[('A4_&&[?4^VE5UC)V7ICO$=^B+'R,ZQKQV0"E ;;
M#6L^ERYD@D_2?C^\ZKMJW9U7UY7J5>OY9GG.<<5WS50.A@D0"^R/839P;+?"
MV%8>U_3+_*[87IT5E\./CG'J!G&Y+]C00^VY/^%E/O6*_H<2)4I%+*Z,>!F[
MSR-!1,ZTP$Z1.PW(!!220VM1P(!77WE>I(:LRH\E>86X#2E/C/:$$6$!29KB
M18[G-CWQT\]%Y4_*62DCX@9^<"LL>461V@" PB'YSV*%C^'$H4Z3%Y9ZC28
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M?L^P:"J29HQ2BC3#P0\65[(OHH\LX)UN]_8.@;%$3+!E#.F-J(&$1_N*9W*
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M8/G!YF)% D8@^@H)Z!*$/.8(?1 $"?6B:G0*>C%Y3C_:,<NBU:W7E$L<:FU
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MP@K0FA9+6D]1[6.T\ZSU)+7)^U+EN6(2IKY5,VX6,*#N>UCAJ#;=L&@UAE;
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MG1P7^Z3T*#QZTMPGI;>I5?2'T[<]R==\>[X4JL)084H'^HXI!4CA,:2LPZ0
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M%K&L!NDE1&/D/:XG>0<U_N--UO,DH\6"RI4\;L:"]];M] X%-5Y8G6@3,.S
M767,EEZ=D?5:H=[G2Q^5\+TJJ?/>3>>LFX3%'>YB$F;1Z,&A\DEA_YDTC=A0
MG+:U(<\=I(.&933H!=NB.>F>YI7LQ(&JQ&SV56-..^>%X$[R1J9/2V?ZGG':
ML9]"PK$?EZ%S:VF+[TZ\]@A/>S[!'^7%VU?-9=K<@7C#1'4*,<PD)4^\P=4.
MJF<MJM,R#<T 'C>,8K0%%,(PB<E"QP9II1F6N?A\>SH]?>U52_%%9;I!^#,C
MT9F"$9U!9FF<UPB'T!52J;GY&V%U_<FEB(.V/QCOKHAM6=WS]M!\O[R@=Q&T
M^2=0H[_#PO?E?.'[#*B" WQ?*K2\5WO^OG""!^S _=NOR6XV)EIGH2-/?*&Y
MNM)H_PNQ#A.**^UOUI"P D+I?%ML24V@NKXT=KBYW!K<7-@[S_Y&/<#EOM]&
MTX&2.PA65Z+P78<%-RWMK[;#EL4E8+,(7T9XS%E/!+XLX>D4)DI'"J !#^W;
MMU..&W#-R8^ +R/B2KH5HN7%BY5BGJCXY]RR U^V8\2:%'B!OW]NXF3OHKER
M&53\T^#+XF.4Z-GI$GY2=DL59(%5XH$O"S4+?!^9*U!V^8P[7SP6KI^*KR[9
MY3UOHH_ 3WZ9Y&+T3#)!GA0]DW'>;00[1MW;&=G:\\KW[POB\1ZO3*Y"##C\
M*63KG4,N1L\A$\5\B2J?4#\!R2S.XHTH<QL(@^F(Q.8V- OEZ]E=%Y?C*-_?
M&LF,,%+#D8RA0*GA8C8&-U1.*/* 9&;Q>DZ313)+P:NY+HQF DY.'^K#F)#,
M$E56]D-R'; ;$\*@C?VB>?-$H9@OEJJ^+DI*R$+$CJ';4J!JB7VC6@_XS:B\
M7DL4"W1;LF@(P0\U-0Z([J93)P$&J^X(U<AI3=5C:]O0]$Y&&".0GSTK$[.J
M\K2X&I=C=5CB:+8(<)S)L82?ITVEU*_OI-;BSZ)6NWO-/\FOKQ6Z6?X:':@U
MC(--Q>!@XR&<ZXR(]HJ#62+X4.[7FPFT[Q5=O;H0"JL.M=Z&MW4QM;;?C,%\
M4Y2];CKE6X4RNQH4WSL+#>K)@]'&F0'W!Z--@9M.7^<E 6]]W8I!< T#@)(F
MC%GH<FAI.0I4-%>YFB^4MW&4?^^2A)-"WTV!LJ_(&[+P7,'/6J-DT'>3=93C
M &1*@@FB>\O5 GE2IO;%7XYOS(&FD3+"'X'\Y7I]^K&\:\A4Y2US'DB X]R=
MOUR*P5_>E-YS@>$[_5F$:G>5A_<WQ=?'V:G $P="#>,JEW:0B]Z19#_@N^\K
MOGL*UN+7E5A^KU^5/[M!QJM_+WSW!,S$TG8HG89(R9.E\%!U>X/N'@HQ-RET
M]Q28ZOYB^7@UO5(*E>(!W3U5-ZVT7:S"JM9)\B1.'OPN\+@N^=2,H5]GQ'=L
M-WK+\\Y[EUF$,,GW&/TZ';\RCF*%4.CN<4:\]YR^[2YG>77?I/#;VE-E>J#O
MN-S1<O2X2;'JWC-S0'?_8>CN9$:&H>T W3T%V[ZP/!L5^GSU[-W-8>YK#O-W
M1W>/S6 O;Q>',QL%*WD@F_=^DJUW%VXHGSE^M-T4..I=:LBUAV*E77+QE@_H
M[O&RVW;Q*0>Z.[[_#)?&Z.@= V5GQ!\FOY1W8E%^N!VXP"SM>;-D@AYO.7HD
M:SNDL&^O< )YN>_GO6OFXJ;?YK]?9WJ2?FP,<9H#^-=>PKNG8"G6;D]Q^GVD
M="KKI6WIP;NG60A=(3+2)8P'K8<^P+LG$4$I[AC>/3&6?I0F3(]:5$2V&*@.
M^]M!3*<19*E$"[*0E4J^C(?/B69-&7L'6>),9L:'CIL8T\VE97]5%#N3KP.Z
M^T[",)7H89ABZ:1P",,$"<-D$_IZM_W@HX^'^^&%(%^XY'"_.?1U@C&;2O28
MS99SV>(,VNPMC=LC. WR;/! TD^?4_) X_%%>"J'",\!WMT&[YY"X$>HROSM
MHOGT?D;$U_N^+;Q[FO&?:NSQGSCAW<LG5&;#0C\5WGTMZ9@<O'MB[$[0\\NO
M&[(U.0TRP4[X"?#NL;F>U6BQH )1S1?PRMX[GON'[YX8MW6DL]'%2B:4^P.\
M>R:B0]7HT2&R>%+Q'Z"?=29-(SJT-H@_=8CLG4:".I>7[&NS53VM\#\"(CO!
MZ$]U5Q4[:T/YOSL)VP,]E_<4^=#$E9Y('4@X6G"G&CVX$VJ X ]40"Y%HHFB
MO*<0G1D^7K/*\K/<'L88G>E&A'E/,4I3PHE$8=[3";)88-Z=WS8WZ+52:[ZL
MQBM%8I_EZ]O:> M,Y7U$F=;/ZT<@:P^FK,3F/FD9H^=S203* J@D?KEN=S1\
MDTXO<X$22D@.%0PY5%#ED/$H4HV#Y5Q3\<;O=4;M+\31F\HENL01Q=Y#ESMO
M79T; L?ZM4 >R%O6%[BV@!8,65+09(GVDA?/-3H$1-"@RS$P8>01#3=4LBM8
MH%E/"$_;$-PT#[=("\PVH$V6>UK3%U'NZ6S0H*K+^TGUE$_EHM:%?MB+"NIZ
M;[HHZL3;B-<O"IBF(^=!R)C$\C0,NRQ$6Z>G930(MIBR&-1 &"LPX)/.YL]"
M#I+ 6DMH'KQ:AK$.[@.P\@DVF'(R^DZ,0T,?410$?NV0!9\<B1,!" 0&$X$&
MPVCLTQD.FJ-6:KB))-WI*-7(3G&S:K9&\S-Q?C=X+%E(,=H!!+%#--FQ$$WI
M$=2J*&>B]I?PKOU%A"B?6+&VO[]ZU&V!G[1GEYF+"8$DG4FB++\PXI8V@XL.
M*M^41]>MTW>V9":3T,?6T&'<?+,TMAE>Y;ILLW:.%Z^>SA8B%VF7\)&V+"LL
MTU D( _4Y:K.O>5;93T<SL1Z5\\4=U^<36Z?ZJS'+O1XCLL^&K'L(Y;+4,J/
M[?)SJ\2-"@'VD2*\%J*[D#:NG\E47==GP&SZ%"5&9@7_C&(VMN]M.?ILGW!1
MYS%N/S0=QWNY1&$/=K?]W5'1=M<57>S\+7ZAF1(N_\G)-JGQ"3QS79!CP!DP
MI C&H//S]0[@0_"<#C;;M]]S(F7P#58>21RBQMBTOOFW:YX6ND!"V(/1@T]Q
M,!45&3@N@T^PD*4J-H01^!FXL_ A7>]2]\/;09?]:M*TA]YES V$\-Z""$X]
MOAQXN0Y9Y.[M1;PD%,W+V9-@*(P 2$,]$N#_0OD+A!O#JM$%L%D<@\N$KC'#
M+H ;R G@$\,E^O.I"+X"NOX-#CC*"U$"-#A4%M@GQ_/0>_[%_<8X 7UT!%8&
M/PE?I>_?)M&P7[7?ACP#SC?XH!Z/!PPAYF%C+GS1 I Z?!'Z**H!4T93[1UY
MN$P:$/U?&'KU5.3!3O*8(&(\*\O@>?!6 OX9/ =?-J8Y*0>X](U=8!\PRP:]
M>;6J#!/5A3/TPOR^?Z'0_'7J6.@2$\$G)6.]SB_$[5^(N7]ASOT+80SG%^=R
MD"AO"7SXA0(.?HE9SW*[!6@[SMD6<.+E[P-B,CB)AJ3F03B(%F " Z.#D9!)
M08*X &IMQ,)@"]C$,=1F.37<<E!:.2BQP.GP"L/^^>__'1]C+8[EF7^P:WK"
M_@O>]*ZP@-'^P2CJ7PQED/_!2.SX6,N#,MQ'\"%ZCJ,I(9V"<D38B.5Y+=?T
M?T?X$?HW6.5(_[?].\#Y\/1<!DO1?_H7T[&D 9&ZJ2[O@E]P=6X)+8^Y]E#F
ML)+MZXYLYZ:?V+\85%7_8#6)'G*C?S&HA=13[8KP_"C*^M3?^F/P3V8634^A
M_?<W.&B7(Y=8^NUXR +Q"]X]1S=F)<B].6';:3I3B6Z'8#TZ>*;JL5E(.35N
M/AB5L>0&H1OBVZ62X9A@=5;#)\OV]./SS3=:EHGPQ/8.?,3HC.#FXJK&@..H
M@KJ@)\B*6,NHJ*8=,D.0N;)FIZBFC%K\KQH=_!)\7VZ[99 83'"OI4HS!Z2^
M511U5:W3DS).U'E7ZC:.RNX7[!\&>D >(*,/5RZ<5$M>C' P2[_]GO_C_L":
MS!PRJ=$$N'>%6RPQ1-TR((P_/^L\?B(-P$ *%'S0]5<6' _^)*O>+/2=CONC
MJ0B\;UW$0HD*U=!,9%@>1@Q4?8:<9MG-9\XCIQ^&9EB5MD8\+<O<F -RVJ@4
M@3X_> .2HR>Y2W:)7JM6D(!/*S--%W("LJO_^5DWY$:5ICME=9^<[E7H<[%Y
M5YY>V)&C>S7X^UV<LO4&UM#+Q4](BA,2/'*7BNM,++):*E=C6J4+<<>L:?2F
M-+1&5)\-3%AL"?UG&)A3HW!&R9+Q 1@%A2+ *&-:L1*,H*I"2I=<4_!O@855
M37.:,Y^6D?1!?Q2QD2))P'3#YD LR6@5X(5S>HFBGN836NA2>S/J3BG_"ZO*
M9C-14$.3)[9"Y?5V[ATQ1#8Y()NK2ISBUY=Z()0T5[6_LA&)F&,UI_4A\C0T
MRA9+4T8Z)9,A,\T/JRDNB?L OQT#-Q-)-#TD,>7 -TB0F,PG.&CBC;&Y,N2Y
M$;]4I:-$,YJ51@OP Y_<8LJY2T=.8,#!2# /HN6V=,D,/%X9=I[(FOA&KY.0
M^0)^X?:NH2)S BNK(EJK5-4J<^V5^\"BI'G]+6:Q*RO-#@)Z[U=U$-"9NY(?
M+*!O.?GM>"RQ+%HD!]-O, TL 4%D"F9)_Y#] U 8H])UW;2\.^F?8 .)I64%
M2$QD <.,.#L> PGF7AL '6AH^ +QJ<Q% :W"_AI!7&@B&CBN"T529?I!8&:>
M#PX"\T HWT]@VBQ:3<(X?7SX:TQBYT!2PC0+DDJ:H6>8D:HQK(I/+<H(TV:.
MUB9+5]F)FXV,5F&Q>[7<FQK3--)%\*42APH@&)&54<W.7&V<!B8H%+2B@ Q7
ML!P@TZ$@AM&^T12N DA[)&91L9=MAT-V1"NHT DM@\9040JJ]AJ/N1''J@E"
M&JU<0G44>9L)K;]:7I?;L/0(FLMJ8E#F9G->C:W.V,44G*.V?*-$J=^LGZ!5
M#%P_#LYFI/ >7Z6%7'0W0LM<0CUUO!!1#SO"G! 8M;;+[+C">-@-KWU>RVNZ
M*QR]6?M'QG2WZ[ECY1$]A_5!$IRK8<L/%M9*+T=3EE'@A 3WA*:U-OU>C\#7
MS #\ -[. *SJE <?/+)UT%=MLWIC_:*7U=GY+4$-Z\SEJ/C=6_-A/@8RN\0!
MQAG3:ADA)XQ$:2Y*J(M6<\'M^1DU(0.M2%58Z"+!4G1@9T C6ZYWWZJ25\8T
M<0Q$-ZJ'H6%_+L^+G_*/3KO8"BHJI]3+JM9L+#NKKT^IP!DTR7#RG*?!EP%&
M!HOIU\^;C;M.,]=K8;5^_^[J>M#N=;&[?K.!M;O8::=6OSP&'^IUFGVLA_YX
M?'W;KK>[9]A5<W#>:WAE?0(4T06_EF#E=LZLC_O,4O]YI.N@RMLA,(-%PK/Y
MOR-J\T0^3PAEM8H22;'T*5DOX4PCRS_\TQ*E'.1Q-)D%8D(Y2H?^^WOH2/6'
M&E0;\-*UM:DU4O!9G@E%!W[/KY,&&8(TUM[M3BU0]\:RVMAVF\ .R30&%6NR
MI43^Y8Y?Y<P$HD")\^BTEY!_;3P;78RY?I/[G>B/E!S/V.9=Q<&>PM^TQ]RC
M[5?M=1SF.-@U>+UMJCV-@6X6TTV_MX9V;;? 9D%U@,S\1;E6)-:U('!UTY<H
M\*X>X 2CN,^#!(Z"7E$R):Y!-QVLV,]ALH<:D:H-:CDF+=5]\(2/_N G^/JP
MNK\2 Z7;P+WNR2R=;#?Q;%"2WQ%S^BW/A_]BF<&PB13OC<,.R(&CZSNE]URZ
MOK\EUCG0_1J/-MU!^MQGW_)6_!=JUJDW_Q%X(0GV\]>IZU1YZYZ4^*D<Z+?D
M#0"T<9$KO)$6N)"V=A^06+7YN_YL&FCZ<?VJPA4']<&<JIBC8]WI((_-U&=3
MY=@-1Q"P1G[ST.(2&6KBZP9&/J'<0 $0/?YEC"Y.I&<H+=*Q3QU>3!I"^9D8
M%>^);TTZGL."2X50;17>I%,X*9<]26<7II@>N$?!?'%L! +AF%HT\>SW02FD
M@DJ^R8;9C$&UZGR4\.N&5.G7^'4CS?^"MYHP''"N7V$]W9#8 <%AE-7-XX.3
ML;/^J UGR! ^<(L?MZSA#V]$?_$Q:HK$7>OJDB8O/IS-K<';_/Q13GSLBD)T
M#).-8 C':[;$&D1ZN#.T:_>;V<W;HL?S(Z&:]!EN4+ QP(GZ3^-?G_^]>0!X
M_64E"_V;UIGP+A+3[YYE3"/_7*AZYY^M"@&.JVV)TKH):&G!K?&\.$*?MJ:4
MG6^13Y>PYVR+-'6*ZP&2;#PZXY7;SU'GVP^:MW87POG#:+2.M:;'-BT:UIL(
M,HMJ2"Q]@MP",\K.!93+0'GP_@+\!]T&-'9Z<V#\:"-\#BEKEY3UZ<NJ?G,_
M>+N]KBV)2I"4=?^\=ML\/JW!='6]=W7=[/9K*('=?(0_-S.<G+;M:KW6,+E<
M]58Y2OV2BE7RQ6W(]P-[-KN]N:^7[\>1<MVN*4"OL\E>HM/]R)HO;H[2^66_
M7+J\>5I5HY4'A#TR,IXC0];+_N;=2^F=>4LK7_(N;8CM/G94_I)LV<.WEA)[
MRO@JH1DBSC:^1[,\6<;=[&RJ)M3+U'B@+0 ;BS6,I8YFMSKF[9RQ K"?^)K
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M7CUEB@%]VTWM@0:XMP:R\5'KNO5R8V3\XC4Y6'RNGJ]<XO3&TA'P+&.N)>
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MD[1W,^ 3J6D+AXJ0$L,%JFN[JLQZCQ?CR>F92Y(D14B$L.3N5]!6VJX\V\8
MQ GA6</D7='F4]_H@9"Q.WJP5[:]-UKLBIB6Q)9O:5L&Z<&[IJT4O5;XAT%D
M%+/:TD88K$(D9JL((T:Z>>T\<^>OR;>T$48)6GBE'Z@$K53*8DL;>5(J'B R
M'-\6PIUNI0N1D8:+4)P]-1]J_*A195*&R"AE94)[IB RTKASH;R:WRQ+_&/%
M90K+3B RRH?A['L]6S0-B(Q:VA 9:;#BV5NE]WEQ6^&#@?S&"I%1]BW.34D
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M-U,]+-?X%1)6H@]#(TX*;GSD4T?H,U;#9;9^5FH(N>)'A_AX[<LLOV]TX%U
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MM@"+,[:"!EQOX6#G@CK86#0'NZ<YV"7+^+O@Q>L+AQEKE5/TA :+!QM.=HH
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MM*NUUQD3^,U'RLWJP@7&85'+ON<FY:5#>@+Q-N<U?D;!N5[>+ZJ'>PKMOEN
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M/TS,/=_[<?+PI?OCQS_S%.8_22Z-MO$T=68S;(MI:?*)H;(U!\.L5; :FLY
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MUPI\QG5ISI2$SNU+?[B6K "B0ADT'H#'K-;,/D"J!_K6F4>R(>#,D8+XMU+
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M3B+1^%KE;\?A=().BY*WU&-3I(L,O*:WM_[TN&XA]$;SXI_O'RI[-W92Y)W
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MXTI]N<'Q5??6D+\5AB+@E)5"N_B+6S[MY%U@]=F]'_Q(Z9)< W.\&#\E)XN
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MJ"PZ4J]YVACYHL*X@W6%W(<B*0.OGQQ MGGK6ZXH\R-4'O@1XZ.[Q;>5-P=
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M771XZ]%.R:2^770ZD5WB6K$''QFXEA?*X*31=0)LN(7&+HY&@:5)PN'<O'8
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MEGNT+/N,4B4M&@8(@ +(>E19\6+P8-/E<6:,\4%FC'&UK!>Q:+ELRQM3W#Q
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MC\Z0SH>:8Y\&D0'8!)3@6]6:V8?/]4(-9 6+E9!,OE.5E*^-AC+PRG!T&DV
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M<H$-;* ![W0=[@Q$W0(_%3#X;!LY$)C4E-8LI#5R!K"P&4%'"ACU82GZ'*J
M]0/TDZ(XP>I,6%U?<&N5KO&!0-UOQ5'/#]!I8USW (]"U/S+YE=F]JP[,@Q9
M0(XF3ZO;!WS8;S9+^Y6:&=)+1:-321@Z81B3M(B5SJ*PB,=B0?*W^;1KOI1!
M:)O(<QMAP1TYHACY3HS1YJ(S/?JZ)+X=@A8 R@_\V05;5U7=RS_;#NH\&$"%
M+U,H5DR7A6_0.5*+EH'-FIB2SY?@ZI 4[6, (#U!UIWEN):,DO'2>^X4&PV<
MWY\=S22V;[N*;$97D?_YOX=[^X=OUKV455#Y+-5F&CO(=1[@O\"P'>LX7+NF
M#D&A:H!QW;H*I:0LJ2X!1'(S]RI0Y,E=9QWI\P(BUS:9;9& ^X1=</N&F!8Y
MU3CCP5'/,^UC7#,&\:4WN3+;YR[R?G*=[=/>'X'5N=Y0/WLI_$_!0S+]0@J$
M+Z=NU*I3X731RH;9W(,PB /0&L(9N[_PC@["8P*:%\@X]"6 *H"!)J?#\L1;
M5&T[45BFQ/?TKTU18+J_+3!=:('I_K; ='D%IK/1R5;-W:JYFR2B2(6\1V50
MI3BH# =AF+895AG-L@^21?96A]SJD%L"S1!H$* [-D"'; <]-R[^A+UL'KC_
MB!< 4.84Q;)LITM^T(A3M+GCDXNH+:.72+[,[[Y^,UN;2\_>$N>6.+?$F2;.
MK/0<:]A11U$JC5#M+[E7A6PP[E[F"\W69%3$;D$A)7<5D'G8Y5^(K <]KBNC
M\.3(RN19T'<+>J5M8->EEQ@S04PR6C;H6TX8\9 ^CYK<I'!-N?_%DY1W N8_
MQ@GT9E_X#U$@ >@C'B@JKNA0/HV#Z:(6X:@Q>JFR>3'Z,[0SBN]07UD> N*!
M?.QY&P4QXP$*-'$' 8NRX3\1PR ZHYKM/G8,IDPG<FK:3,O1"4V/84$<I5B!
M5+3OG%!%0V@#*5#FHHTO*8282;![2>=J)=AP*K/*+V7A&?4:RI.():.//#6%
M*TD8"M3=_#)H5^#D+U&)"W!L9)ZR@[ 3E8P!"S!CB:)K0AS@QO@C(JD]NQF5
MYBWQDF,YB@*^@F@+S?/-&()#JS%"PHG=R*+.TD0[-ALP@C<U$\"L-HQ7\+[7
M\F/XIB:Y5 7=0X?)GL?GV G:VY5?3?('>=-G922.D7H.9>89H,(P;$7.6QB@
M*"Q1JV^L:;IE1+B4YH8BB'38+AQ2[T.+$@T3SXOW(QHOTQ.I3Y7H/+#%7WAY
M(OR?L:/:>(OT*-7[70E DU<0BMRGXE[QDM$4MW5_WVI=OB8(]GG5+,#B\$#N
M00:<QX5NN2U<"-1!'&#X5D5\]+B,HS(YT@VL7Q#%OT3!SG.J+OAE%?&K 2);
M% I:X"@YXJZ)"2"A)(DW^6;F!6IGZB%#XJ&&YV,U")[HB)P!TW?A14HR),1'
M[Z.4K41! /H?(-H5X>6(0% >TAP2"1UWK%[1$RF&*8T"6W7CV2C1,(Y"'(=
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MW&*]C"G_G_)D9AU^2S* -P7K%DK^FS\M89)J\>KMWZ3]I0.;XH#J-7JA<+I
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MR/8UX$9^L(C_/O+5WGF;N!2D)(SP;3%) @='H-?$-:TPC/O\ 5XZI/V"#XV
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MRKU3)J"!WTC2P2!VG;XZI)N]?[$\9B)\T%YD->*?O_U^=!ZRG;LXN&ND5N0
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MT,["51T(66(*L,K"YFT]U\<./6ANR,9%*<1"+.1[K@1$ZHPC[Z^#$15&QY3
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MZ.2BG,?9\4X!G@>@.,+D_.(J3BA4)=M044AE/.+?9-,D6;Y(%(XLD_3W!</
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M34"ZK"S<HKP> M):3(J>5!&0UGRM$?]TH51/JHA_9>-?-3?*9GUKK%%-@33
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MT+HO24:Q[$BB(X74.>5.<M?>.:6[?:U32F(?8E74QCWLPU^< -/Q!B)@KHA
M[[%!X(^FX@TCGWWA@?,7.PK"(;=GFKQ;Z[7ORB,3C])88CUF7PF82GU0JB"N
MU =E P&*9F>Y[?CD5H:>$Z0G5>2*T1RG$?]TH51/JHA_9>-?-3?*K2HBJ"G4
MMAJ-@U;35%"[W5X%:\\'(=XXT9!]/?[ WL2AXXDP9!^<D8/H>MJ+8E)C>(HA
M)"]*V5F(E<JVQH6^?O8U]YOF\O;NE=KAM\L2)"BLW5HC_NE"J9Y4$?_*QK]J
M;I0(A2L<F:(;ZIW*R[-6\C"?.D$8L;<"VW,.V&\\<+@,2(S\!5EY=P%BE5*7
M!!42'"8X3'"XO"RLN.ZF'#W]YD1/J@@-:[[4B'^Z4*HG5<2_LO&OFALE6E1;
MTS!=6\>PV83/]^F/ M0 F6_8.;Q;! '@W,LA#P0[C^&5? H@+RL(^XE[_N7$
M$]_9A\BN3X=H'Q):7@M:IA0\0LM/BI8)+/]("EZ3?,>5H(K0LN9KC?BG"Z5Z
M4D7\*QO_JKE1(EIN;HN8E $M6RNAY?M"XR-W/.3LF(^=B+OLR OA/Q$A9$+(
M6G&/$/):]#EQ;P,(.2M14Z@ D]5UR<<X7G9!\M/?]O;8J2-<^P4[YU?B)9#R
M5RR\/I#0/7S)?N-N#!\MMK>7,,EVKM.G)=56>GX4^:,7[(W+^]^866\#UT+?
M=>RTT$QV14?N4'DAF&+AE]G",-/OF*_H,E/Y97XCS,VB!<;.],2Y8B#OR.;_
MMLH'#5FZI<"WE&,OV9?)&-Y_%/">TW_)/O&14%S]Y"/_NH?%N_;3V_"G?%[3
M:7VU#XQ>P/) \&][/3'P WCV6,Y8PF0858DX/,7-5%AO8T*1=<A3*9$KR#Z5
M'9HB=]UEAZRU]+DJ076)!79[L1316FWXXI/D>VW1]P..(9HO6.R!K+F.)]9F
M[+<[G>8]7&,?>8@UB7(C'Y21-/ _CX4B$DQZ-/*_B/[0\UW_"@69G0+AL-PP
MX#1WC,WV>&!?AO",L8A!^,-"S<MI5UK>S&'"K,X"G+!U$CFW2:V5ZC6U4RPY
M3ZGD43FD=8M*'CV>N'948"NYZDI/%;GJ- ?]Q#]=*-63*N)?V?A7S8T2T7][
M+46'RR GF_#5/2[.;UKFP7U"8&_#Y&@*LI/1V/4G0K#+R.]_R]U_YR[WU@S'
MRR AY+W3BWODO=,&2F\I]\RDQP2AYM)31:A9\\5&_-.%4CVI(OZ5C7_5W"@1
M-7<(-9<'-3>MMG4/U'PT$IXMW>*??,#)6%()?>-@!382G P &GZ&ETN@C/[P
M6Y VX6A]_-?;R3R"T02CGQI&6^1\K@95!*,U7VS$/UTHU9,JXE_9^%?-C1)A
M]'HZWI9!3BH%HU?**)V&T68!1M_N=R8X37!::^81G%Z+[B?N$9PF:Y+@M.:+
MC?BG"Z5Z4D7\*QO_JKE1HDFU-19I!=!TI]FXCU/Z4O3CP(FPHO%\D:8TF_JM
MZ(M13P3,,E5*=8WU5+6F5;.T%U9U(LA-D)L@=\E92![L'^*>19"[*E01Y-9\
ML1'_=*%43ZJ(?V7C7S4W2H3<A]LB)I6"W"LYL ^> ^6>XP?LV/>D$&(=PK>B
M!PLF#N!3+ J(VY*(N\T<CPWX-=SD#PA-$YK6D7F$ILF!36BZ=+.B)U6$IC5?
M;,0_72C5DRKB7]GX5\V-$DRJ9F-;Q*12:+JY"IJ^$%=.&"ERV(5S-8S"VQS8
M%CFP-=-#!+D)<C\QY-Z:MG($N?68%3VI(LBM^6(C_NE"J9Y4$?_*QK]J;I1H
M4IF4@OT#F'L-4+K9,-OF02N!TBL%@W\0$?;OBGSVT>D/N7 9._>=P!%!"J3?
M<2_FP82938FCX=]  !&R?5??'XV%%_+(APO@=N]*A%O9HW=1YT&8@_?8=U#'
M892>N0443!S>D/B"1B?NZF1,M%7?K6;US8GMDA3"W=HM->*?+I3J217QKVS\
MJ^9&B5::1;A;)]R]4D1XCKN/1A/V)O =.W#ZWPAT/XT_D!S2Y)!^4@$$+4[L
M(UQ,9B'A8JV7&O%/%TKUI(KX5S;^57.C1(NJ2;A8)UR\4FQWCHN_\,#YBQT%
MX9#;!(L)%I.SN2(<7J^.)_81:J:%1JA9ZZ5&_-.%4CVI(OZ5C7_5W"C1HFIM
MBYB4/7&ZV6BU&N;A@]M1F^S&B88)@D;$?6MA\-FTZK9"X.H9E"I-J=(:,H\\
MT^O8$:C6]X^D2G<)8U>"*L+8FJ\UXI\NE.I)%?&O;/RKYD:)&+N]+6)2?HQM
MM3N-SH,P-M80NQ11Y"K\/(NDW\7NA)F'11C]B7O^Y<03WVOL0V13?VH"T 2@
MR\Y" M _0BF@YPX!Z$I010!:\[5&_-.%4CVI(OZ5C7_5W"@10'<HM+L\"/J@
MU6G?JS_UF"?%O7/,C&#Z9^&)@+OL0K@"?=,ICO8$8.@I=W0QI9I0]%K6W-ZO
MQ#V"T02C2\F] ]#,!*,K017!:,W7&O%/%TKUI(KX5S;^57.C-%O;8U&5'43#
MIX;9D6[HUFH@^MBW!?:-?A.'0$488N-I.^XK('T2#9U^2,"8W,N$BTO.PFW2
MXAM)@3Y$7-RH_G:_768AX6+MUAKQ3Q=*]:2*^%<V_E5SH[3,NOF/;1&3318.
M$]\M,P&KKR_C7NC8#@\PN1A@:304+&WC[$54IDL/2O6DBOA'_-LN_E5S8]TN
M.2$$6H*%1OPC_A'_RLN_:FZ45I,0Z \AT'N[9@&J-E.H>NQ[(48<H_.4?Q,!
MO,UU)^SK98U]^'!>8P[</Q;P#UP32 @K F&S<=QSG3[C_;X?>Q$6I!XXP8A\
MK%I1JB=5Q#_BWW;QKYK[]G;)"0'<$BPTXA_QC_A77OY5<Z.TMBAH+=\FQ_=_
M4-:#!B[-_O]X'MR_7\;_;33,9Z_/_1L PH"(CZ+(#SPQ83N.UW=C&X"O#R\%
M2G@4!X*-^978G0*]XX2/Y1E]3GGEA9.V .(?\8_X=[<) O_RGBM>&\;"#FGI
M;>-E%R0__6UOCYTZPK5?L'/8*EX"'7_%PNO#^P] M?_&W1@^6FQO+^&0[5RG
M3^OY@2V"O9X/>]#H!7OC\OXW9M;;P++0=QT[W3"R*SI2G4NZ@5.N.^8V=@K\
MU[/&,_DWC+&?_CW]CK[ONGP< BGIIY?LQK&C(;*I\7S1KI$;: O,KNE9<\5
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MX-H"WU*.O61?)F-X_U$ VK'_DGWB(Z&X^LE'_AV8Q;OVT]OPI]QX3BWG5_O
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M_/EK\.?!S9EU^NOHE],!GWSZ^>>NV?O3^OK^X-_'5Q>7'__3B$].QL/PM\'
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MJ>^:6>_,;S[,K%FSU[T_G7.?M:^S]SG[NK)R4V8I*X ;CW7U=0%4EW:3ZB8
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M=+_<C91P2#-&K_<GC-IF1#?SL^[W1=VRQ+N?@I[C#[0_P]H]RB_GV$$>Y5
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MOR=5?*<GQV5]OWPY\2:RS_1/=[*3/M^N;<]Z]L;V>\:(DE/R+WI_")(9\C4
M)^T2HI#UB]NB3IW[1NL@QYBLA2[=K2A!>H4S>#1LI9BLB3Y\PYS:4.36*9S/
M0=\T?O\A:*WM8$!\D4K'YLF3;0F+9.&?PH?_*I[^]U JG/B:H,.Q>8KEDQSZ
M[Z]LK#D*J79]>]*<($F5GXJ"EI!@FTNAF09LX$X!NTI6K\XXQR/U&F%RS%*]
MG+%@PWU]T07!P1_[M+X%]%"N70J 5QU6@H/HQ2W95E U?[($>=.#U9/# .#[
M44LU>1IY ?>K31?T)0J*@'79/1_/EF<=EWN\/C1/^[=M)00!Y4>%>Z$?09!L
M;J[OLXL&'JKR?MJ;DJSQ],[*-]/*X7]@3#CH1#=4<$+>EK[7PB:B/O#;Y_W7
M7_2V02=E6"SIXUTB$)6+>)TO5._6KO%5?]/=6+N%(-BUN\ZRXC<2)BO<7%4^
M>9X38;@W$9Y8DW"9%@U->2M<SZJ= T-KB]D,$=QBPNV=XV'A.+"W5Y]1)GBO
ML^'L$Y0MV*47WQ33\-/0Y>&D^/B9FL4R\U1=5@!X4F@%[;$[>NU2PANT1Q3M
M['A7N]H\:9.[JSFI9#M WK]J"7X@:5:XT*[]_I;$\2_277% Y@_X3R.<!%V_
M!S!QF;/:WU-HU:L>SMR+[4<I#AF\6N?UV>5VKXD(LG#I*UA HHSZF.]&2"W9
M>C.Z^5W)0);$LS\J^UI?I4]-6K0<X?2O4.YTXYVN*6UQO-3B=4?$;.\$"@#+
MUT@!_*[<0^"D-/(*G-',2V!?T9:$((*.V=KQU<Z_2 6P];9P, 7P;:J)' <I
M@371=?/#WT!HO*]^I+;;4[U39-*0J&OSX'/B#1:36-0GO9\FTG$2+289>IME
M^Q1 M0W.>RT[\DQMCL;B_7POBW!^)'L3^",GP1X2;4>HH-O6(L=W?L!Y$R*(
M)FB'K+)M;[%L^,)?3M$J#5:"I68# "\]^UG!!;&D^L7]W^469A,FFI<D.#H?
M-BB)1I+B$-B/\%$X@ (8(*W""(S6E_3W%(X KQ2?&X6A;;NRV0!"GEHB_W3(
M.0[VA=.M "^ [3*77,D#3!)Z=TG0F<PI@"1HS&5&#-4Y->O0B)XEX2C&FC?E
M<D;U_JG.C,V$*T4G\!$*X!HN=:N++#&NL*#I5;_07+-FM^:CQQRS[Y/6C_ .
M]UDY4$*QQ 9X7W='7^ #2[RF3V1>L>@*K:RDO0)AVM82NNR#5HQ2:]HUJKJ'
MKQK,+M.2_BRJ7-@;P1W5^'+8#'V_8^ZYVVV38G'.&.Y'N.J53S*]\Z+=B]:0
MOX  XIBFINMLH+,*C:4I) E!1P8'SZQXE8B.QC4\I&WO5>@O>-7I7(\[' @%
M^L0<073A1 Y"'P7PS^P2R]CPYO)9MQM-R-E<'KGA7?EC\DZ]CZS'TB*!@(0J
MC6L*X(Q,,%PM_N]#/6-UK073Q 4Y]0+% =?79U!IO3(\=D0MS'0'RK9A3K,B
M3'HL3666-Y$1Q\32W8I(1M1;IFJJ.>B2Q2>[:N.:NDIM9+(\6<\8"SX0:L7:
M1UHE3=>G#GVGJP_D;8'>L*Z[%,#Z*\PH*?A2LG^9>0V=%[I6T 6N=TE:"QZR
MW36I*7F)Q(WK_ 02]I6)H 4*8"4;=JP<O$5N_^>R./>6$)[PN49(RM*U!,O?
M7RPQ7J^KL)A3I5?Y#@)X3-;Y6H?+\$_SQ2FMD>A:M,M^Q1>B&B:H=YNH@>&;
M*S":7#M^Z66Q\=FJQI<A7DJ/24[E4"?B4JA>)^ N:?,#T#*19Y@"Z+/<4.AK
MGU8RZ5(WL;7KWA!2X:CL7SFF5X]FC@"A,[%D7")ZQB#F\63&0M_\<P8VF8,K
M/U\EJ4J\"P >78G8>YR>.WUGZ-TJIUO1OA$N:+DK#4_E< FCWYLLU0SG)_^"
MU='U1+@8C;<;*8_)P*>*FU*/S#X^E%"^\^15D<8@YSH4=%G5><%(LV_!\D!&
MMQS1'J:(4M2+5M!A$</]LP$L/(/HO";MC:)[?;=AE'77='>^I.M7-C=S9NH0
MG8[Q['5:%[X 8.^PBT4&SLGO=$:7%$\&X'*0!ZKVF>Z-&4S7JA4211^>2IWI
MD1ENE745DW]^LUH0^^EA;]+-DZW276/&1 + A2]#""&/X-OGN\,?3QM.%Q1K
ME\BWV1\ %P30SLZ',8W!XCL.@Q0 [>U+:>L%(S#-P;8-K7>_BH;E;.\H_70Z
MQB/)X&K$WE?8MC8BT!]\<<6- C@[ I*C0>B<_Z,A*8P@$_J3P=3%Y5U$*T4!
M9& N&^(LEPR)YPP? OD 0YO +V3X(*0HQTL9G69MC!NN!??<N]S:_()C7QL8
M*>80=LH*J>2\,*( :$XO \N8N!0WP$LN^SF)9/6U-]RQFTAE=Y2F"0R&H8+B
M#_UEV';>[N8\7]M,,A[*_U6E8B%4E+-=7N,$]SM91L&([.*F3>TY>S\TA9M:
MZARM_4E.DE(LAXD<-Y9?VQQ+POX!IJ0O\LSTO/<5\]FLJ?#BWHN^(('.WB?]
ML<A1<1#*#0(K0X&P+CFBY5<[/9GD\(=.A=;K7$T37<UY^.0\"?PZ"=0#<T?$
MM\IT@Y.;R-QHHB^R=&[>-NO^@/V?C_HOG':-2FFA Y;K,P>X$IA;=9 P;WV#
M,!FGT""5D==PK_JQ_.IAT;?+1+F4@_D5>A9=+W6]+@-)WOEZB=55DWM: GS$
MH7\)Q4 EILW&9-9E;,'UK#=& >]I-8T;1B_W:&KA+ALTS0GZJ)=9>\\.;;X/
MY9C:<A)I-.+UD,P[NWG=2>3LA_"LY2^^)B+[UIIF@?^8K>L\M(Q'F7UA]VEA
M0;B**=YR]X!#MW[MBTE/]Y.M39?(RV1<RIH;"C\'<OOX\G-7*P7(&,?, ],U
MTEN$S.;4.:0+'*G)BF/\K/AIM5(8FQBI%)K2Q>SCVT,8G@V5^,&YPV'VN+BD
MY6D)0QBM5H23=X7UL$<039#%Q*U4JQ=/!W9U&=X&WYP\M7B![(/Q(E9R0\43
MO;T4P #WRM6V1/W \2/.XOI%6'//G9@%9ISER'S9OY%KQ'6E+NA.G,G377%5
MD# VZA2(^3=PSG:/)ZH"XST3[\LVZ6+!*[D(]H:V6/)"VWBXBG=!7CL%X)H)
MW']]? V?[A"%42-?:_,KPUG^58\6G7?/&?]U5+'+5[ST*&#AN,I5CL-E-V+O
M""^!G6B^HR%?[702M@K>9\> NQ#L[2"X.W .^&PB0,*K[+CF7+'O91Z3K\=I
M?)*4N)*&=;6J3VDU^P8X#?R-+DY3TKW)YBA!QBBVX6>\W)/T7J'Q( VK,MIK
M&H\Q!Q 5P\MT+>"^E.X^K>=+C8(Q^59>I"^JON(12H[)(:D4?E5PX704U68+
MJCWQ/@A#L_0!^35Y<"[:Z*-9\I^R19&ZB*\0Z5?"\Z]\1A6.9^)@*_D(SGH8
MQW9.'!*KE.X"\_816_CUJ4*JSBFU^2K"<+N$[WO2]VO&R1N_NILOFR/P6KL,
MYDV/KRM4:D)X4IIEF)\T]X_W43_)C +0O*CI3AK!3O$K1/!>3&" Y&O9*&G-
M0VLB*PID:-*;83)A]NM^^7[;#ZEETZ8=AV>7_98: S\0@A"%WX?=3U,CF"Q[
MS_"?X"WWI#E;X?)^Z@J*T,!PM<OR?;YW/B-KM.;--N_6&!D]G6/RL?09:7S_
M"GS2"YX'=I.AV0$SDQ5Q!3TV M)7L\KT.9Z*I-K7;MP2R9S,T"=Z8.,10K"7
M%2;>\Q[(ERDMT!F>T>9$*I*.Q^/B,NF_01,IRG?-PA!$MB.R'HL !3"3#,0+
M0E];;L&(;/M G$&[;UA$$@N):68[SLEVS>4)$.=Z<4F4(DG)X=R8<;< 8T1/
MOOBSD8KGD8EIWHJ:U"1?EA9X:O@EEZ!9PU46+K;NR!3CDI;!PEW^-QTU>G-?
M06-G=A4X92LEMA-4[^6VZ6THIOU[6>$&*^Q>'YX.W]=/S@N944WV*EIF?0\N
MB1!&>Y"O]:P6T"_9[N8K3R)601VO$^PU.62M*UF.7#;?1KS2T()_E_B:Y39@
MW-.M.ILT/\^O%EQ]@'IT,U%;C\.=T_C!#\!UP)5V2VPW[B$\W NGOL2'WII#
MU*<6>0>0L\3?Y][(6,2?."SK.!: 6A7?F65]O/#QO QI"]? ^>ON\FR;^50:
MWN4?K5/XQ)^[?P[D%QZ)(#\*2*2D?F2@JC0S'RG*7S<MXX/16_;!&O7VL]80
MJ1".EPT4 #/,)2):4$7:]L!2R-;[>B\F]</MSLG"=\]7#I/R.'5>A,L2Q*!(
MR U-)J)C/4;F-:P.5N=4G\-%D!XY7^RA3K9</#7^JWCSL(]>RGU HC IYL%_
M_8OKUQ%.TB7Z4+X@F4\O,5"V;EI^(^87]0:;MA'OF=0/,B?>R<$30UB!IF-.
M5DFC"0&*!(7N M7^"TMISWL"]P21CFHQ-A/9(C6_W'OFM8JAAN'TN)80-!@5
MF(7Z^4AS1K!SNZ8ZR&DD"A= 5WO(4@Z?@%"1%R ,G;?<59]\?%9EUU6Y:U+%
M:O7'>J!&!-S]1)%\$X50T@1!?UW>>F06=U.MZF#H[F:?+>MN3KBG0GU1+:VN
M%E8]Z0W6NR$?/$^]2B:$9/*UJRRS,P6<<<XIZQ9NJN,#Q V/@;5+HAC1A%A_
MT+"3Z;NN9Z[YS\>EN*5:J#_S:GC$C"'<9 #!,18-$R\#0L3:6][J","<WX4C
M/XO @2FASW\C??CU[GB(>'99\M+M@GJ@]#O3% "Z$7KG?7T:Z^[8Q5^]FI!,
M7/ :NL;&)R8YKU4PH,Q$X19/@\O&R6$HDBC6JD<4 Z+?D,K(XI 7!)<Y+/#,
MFCK0)[78!!?4GZ.7! ]X8ZBX-5J@WZ(8].8;/%N"%S2PA88S8J83X'N(^F.M
MU3\>A"OG!&J?=D744[-'+7\+J2@3*YVPS^HZ)\Y@B8WXK#$$(@T2D'/R<U;\
M5<Q=NI=30^_,5.#5Z<D^[%F0%VLE\XA"50D*P)TEP<]P0Z_*4/CHF&RK\OI/
MGI-:A$<Y9J;/B)FHE-IM"+VHFL9]:UI@'("XTJ _4P#!EH/+M,3G^8+CJ_%[
MR-^N%IA=$_56]7G+O,-.-Y&0W.!%\)T9.'E<=C<(JH2SDI=OS#3V6,CTQDY*
M7WVLE[(26%VB+5O^90*RYWVBLH/:?1)347)*A, OA*I78(E+?+@TSAX<S#3U
MK'J 7:>^.'VKU#SR)E]V'YBU76.EPU1OHB%%Z\Z1@EMX[J,Y_:4YZ@Q5IO3!
M,[@@*=_S\(@LAMLSQ_!&]_2]??>]P* ^9BCNF9UG%JR=G[H 4T.'$LM&05+R
M93%>U84XGX9/<GVP[_X_^UMO1.18?;+?T $'OU_;=C>G)^AQG>JF<1L;FSX^
M]B0+0:;+IN>Q+2ZKU5SGYI.BQW=>HMRV,FD.='C%J>>;E^F)H6APJH)K_3#(
M1E^FE*:/:4Q=UPX6](H?P; N0WRY?(,"<+8/,L^R@PCRH1B;A][^5+UEN;:8
M3%;X&2Z/LT4M\^FAMRRG$;6G?UBT'GE[0OMX">;]-SPMO7I*=?YV[=-I:5/X
MXM=KYI=47)-CA"&RV&/*^H_H@ZEM^70;R@>]RWDL?)@"CQ\%LCT 2VAT54Z#
M.=65*H*%3OI^+R&PG#EMAJ_0K5G7SCM-[N,M(\-=IY8?DHJ$UH,SP SQOY\9
M-1DX8[-@2^#!)CJZ3H_?9[PBN!B"/"Y^QF"*N_?\Q,K.EG_ LSU*_3-[Y >>
ME2C#L:1D8!C,%EJ,9%=Y4NQ_[NV\<X)8">6JQ8!Z\"P)\@>!^-.>4G<V'<'V
M)5O! TFJJX"!$1UCS'*_$4.X0F=3/>;J9ZS?HNZ+9'K!KJ>O]*7H!69&R"*X
MN)+P1S@/-*$KYT9S*X8C:%HS(OMMU^<;W^Y"A*/ZPKP/9%V8EJG;G26C1#[Y
M8V<)5#XGUQ.J91R+)/KMK:;%S&^IF'K\5; :F/JF"\Q)5, P3./7'G:$E;^,
MO%^GC3D8&,50Y=.Y3Z+AR?5I?*X&56Y*$->)CY_4-TUB)!YY=<;R#:+C\A27
M&4_7.%B[AXN_>+[FR-RXW@R_C3,MV@W=VB^J=)M_<CIYJ+GX-NIM[T7U<5KY
M -$#[,)K7ZWP:&'AR5W)/?_E/]XG&@S@^8>K^ZW'.Y(H^OG [ 'K6*-UWOLI
MA7:>XNH!-6E("+NZ&GII9&G-89+V<[/CM_[7X_J2@H&%T4] ?9W<X78XOR(<
M78^F4/N$C8;7G\+&S,>>RH/J03<CGPM[P]7VG+"IAM>!-X(MG[9A1+=BSQ:,
M0;.[;L]=&I_J,OSL8LS+F9E%SDO4CY/;$;^Z'%WV[75$E@I Q$NE?K9,%[R@
M@\&FMI;&A39-.R<[3]XP3S#_1U=+*"L+\Q!U%-?)O-V(;WJC -Q?8$SLJ_>]
M,!1[?O/MO<_YD3.2! 4<T@R3$-N@-/FY'N16KD_#%Y=2VY1T\>K:!S$ZD<S,
MI78_,H,;OSX:\H ^>8O@I<FI#]XM/JT25#-;=S%S;S$VYW;Z@FDB<MQ?A22<
M@A)/#1;@K.YM+'/[7QHR%%X<M,P"BC3"\ S$?HQWXE&[!RK%%C*YJ%_N'F1B
M_\2R=,OQD5"/,J>V&G_%ASN!V7)*SH_LT]9IPPI^',W.()=Y&@RL[_HOI#$'
MO_SF=F:H+1=;YL,F9(W06FH3YC&Q5"Y1F7:SPCN1K\6M5%RJE:NXIK[[_1;2
MCP_5#%X\2ZYZ;)"^>RT B&:'>%G011)9BHE*:&CV:O7UY?WY%Y_HXT5VC7Q_
MA=6*9$08>L_0; R+C3[)"[E=R&&LH_7YO_<!6-S#*_0#&AX:X2K%R%=-C"5S
MTMV?NHV]HJ+.1N[;R#^E,M;QH&'3%WF%%,@0:).*M,)G+I441MXFW &Z$O0R
M@05-WKGU7LC24-1KSV=-;GP23BG%:GF%E_,*3$W&'O!>]IZTG9!1K&<^;"\:
M%F>3,7ZM.&4]7BGX0M>9IFQBO+3PTVS5:XN1/UY\*UH\G^*GW]U<TONBX6/@
M[<%<#+6[@60*&9F=E!C];59OPFOO3[!:S>!LC'OV-@-3]0^(?4:XT]T*]<C)
M+(5+WCCRZST E@,O<:5D.M,I3/RCCXNW^H?^'4<+Y=-!3NF&8BZ?D$ TDB9D
M9."_UILTY7R_\<@_%^11UA(_L@1*U"0.LE4V349EF@Y[<_Z2YABKJKW7(UPN
M!?T\^<Z$Z@W?'<=[23>8:*F30QUSO3V9BQV5;S]RHKLE_+3HF%.:@ZF\U3!I
MB;_+Q>ONJ&T4VT7!^?1]DS_6"\O:SUJBU5ZGB:D\E2/KEA9&6;-V>7-6@3AD
MBV4ENHO=.?5^,R01#.NGA%F7;'J"^#YUB2<KT\W0F.=(\'[R6/TC-F0LW9GM
M0A-3U.>5I(>B=1W3 5PF]O_W_X<<1IG['P!02P,$%     @ ::^%6!&9\/X!
M&0  $#,! !$   !Q;&=N+3(P,C,Q,C,Q+GAS9.U=6W/;.+)^/U7G/_#X5)TS
M6UN*8V>2F622W9(EVF&M)&I(.9G,RQ9-0A8V%*$!25_VUV\#O(@4;R EV["'
M>4A91./2^!J-1J,!?/S[W=I5;A#U,?$^'9V\>GVD(,\F#O:N/QU=FH.A.=*T
M(^7O?_OO_U+@W\?_&0R4<XQ<YX,R)O9 \Y;D%V5FK=$'Y0)YB%H!H;\H7RPW
M9%_(.781549DO7%1@" AJNF#\O;5Z:FE# 8"Y7Y!GD/HI:&EY:Z"8.-_.#Z^
MO;U]Y9$;ZY;0[_XKFZS%"C0#*PC]M+37=Z_C?V+9I]BWT\SOWTTW_D]W!O[M
M&GD_AV/+N_6_6J/IUZOY^W^__?WG-?J^NOEZ]O/5K^MW]/XV]/7-[\Y(^VMX
M]>WK]^7K853E1]]>H;6E !B>_^F(\1>S=_OF%:'7QZ>O7Y\<_S:=F)SN*"+\
M<.=B[WL9^<G[]^^/>6I"6J"\NZ)N4O2;8Y9\9?DH+1E2<0T]]OS \NP<O1.D
M&;+$;X^CQ!PI+B5]%Y'BA-1!.W0^LE]=DYMC2 #ZTS<)8>@/KBUKDQ(O+?^*
M%QHGY(A]&A0)X>,NT2"XWR"_E#1*RF5P KJ3(==KD'S,DEF>T\'K-X,W)TG.
M7R<7LS33'Z'E8A E!UO7'O$#;'/!YE6=G+),R$5KY 7GA*[':&F%+G##<RTQ
M<HZ4P*+7*&"2ZF\L&XD7G$B^Y7D$!@B,TO@+^[;98!@!Z0?XQ"3F R4N6@!7
M"OL#1FAC;8SN>$1 X1PIV/ET%/V9*3<IV4%+[&'>BGAPGB@#-A1#QCS\R7-^
M/-XE+I84^LC1O;_QOS<4^9"=<S>!#W'^F*0^KVVY=NAVRKIM7UW.^'O2IP?J
M[#/+90/57"$4^%&GYS\)=?XI]#A3FRCM?<\G+G;@BZ/$Y2E1@3TF[3"96Q38
M7R$@L=P2@/+I0FB]$4=+^2%7_E]Z]!K12WO6UY?ZAID\T Q_Z#G,S*%HA3P?
MWZ )\>/AUH)>"-T?Z]#=5J:0I;*M3K$\1\E5J+ :>[A;P3U:6=XU\C7/#(C]
M?45<!^Q9]8\0!_=%K.N(A8!^*PYT7)>"/25;V_\K47T]S.U@MOS5N4MN2P;P
M-DD(PG<M((22%5YTCU8C6CJ]MCS\;]YNT*1FN%Y;]%Y?FOC: T/8MKQ@:-LD
M] )8R,ZAQVV,F,I5H9PU]'J,[/[%"$G!3\QTA56C2_R0(OBA&Q?#F?;[<*'I
M,V4X&ROFY70Z-+XI^KEB:A<S[5P;#6<+93@:Z9>SA3:[4.;Z1!MIJLG)57.A
M38<+U>Q%I5%4)AA4H -*$'"[(( CC$$;42^2@,I4(6!_W@5VHOUZJ8VUQ3<.
MTX7.D!OILY%JS'JH&J&:4[2QL*/>;<!$X0--!\.4CD+*3-2A[Z=+&"%*(0C?
M[T(X-]3Y4(,Q]MM<G9GQ@-,7GU5#&5T:ALJ&I6FJBW[L":AI!LJ,> .["&%%
MF@AH)Z\+"I7C,]-G@QZCEABQ?B1L@@NANG2]$&%4D2:$T<DN1F/-!%4(D]FE
M"@-JKAI\^NLA:H8(;! *"%1HNPFVKK +34NL&G%R(2!/=X$$J\1@&-9HR(DV
M/-,FVD+K310!?+]:E%HE0)9\%T+LS2YB7X>&,>QA:>VG]FX0#?"5B\;H*A@8
MR&7KMKE%D^5^+8405#_N0@4J\HMJ++2SB:J,U;/%0#'4"9CZ8V4^-!;?>M@:
M85,MZH$A[S/_UAQ1<V51%,%5FB($T]M=F-2A,0/CWE1^F.BF^1<%IC/%_#PT
MU!X@@7&U7N. .SZX%Y2OKI%GIWJOCD (KG?%436=:HLI3$W1;!49(A?J;-2K
M0A'(#.#8HO8*X)A@FYD5PVN*(N=5A%DMA1!H!2^)H9HPS$:?.6(3;<2,#65X
M8:@J![*'3<"I6>6F[N21/BGX.\R%/OK'9WTR5@WS__[WY].3GWY1U%\OM7ZB
M$AI46VMA 8:>;]F9M5=EJA!2!;=&SHI0%F .FL-1OP 30TKSX$^TL.Z2&2K[
M002/TX+'0IO!G*0JB^%O_00DHLG"*Q_]$0+7ZLUVTBE\%<*BX)DP+\],T%IL
MX:I^Z:>6Q]F!2;X=:"<F+4Y(! H^C8/MR"@_)"WI8RD.X_%?6+"\;N'WC^F%
MY*#@*1'V_BL_1/7T*'?=!LCB6DLAA&3!D5*U)= #M^_>0!:X6@HAX JNE8I]
M@AZW!]@PR$+9-I,0N@5/3+O-@Q[T?781LNA6I@K!6/#-E.PH]%@=9FLABYH
MG1!^!<=-PS9#C^5^^PU9#&O2A; KN'(J]QYZU/9QC68QJTP50>Q-P=E3[2;M
M(>ODA<MB5?PL!%+!"Y3UR/6P/*(G:(P""[O^C%DH ;Y!!_((%8H5$HN'] S%
M+5+2)O7BU3U^MUQJA*F%A*'@'JJ)[^WA[38/VRODA"[2ER*^O;B+XTFZ4U8A
MX O>)'/T61U?@K$,H[Z%CS"NM!>$-H*0. -%D*^E%8*ZX'_*0ITZ$7MD#X%L
M[F KC-+(=$O/08U<R_?Y.7;-*W<L5DC!P<H5DIB"3RLK,6?#R1#F UB0J6H<
M;!0;EN8"K  6N:*,)B!%8#>H+*W:W]F+F+C#DX]['GN4^K=:2M-^10@)3L&+
M%BN3*+YIZTCKY>-Q-C+*34A!6B'$"WZW)C![X[';S"*\>5$Q@[3.+P1_P767
MG2G:[H3TP[V#7,3;'O[0AC$%R\(*^*O(1%#^L>CNRZ <;Y0 NJ.%]H5[_'H@
M.P!Y;F'*[]SZC$$E4WMU?TYH<5.K M^6N85@+X:196 _'VJ&\F4XN525SQIH
M>6/T^9MRKAOE&V>]1'11^;X?KC=\<DX'L("B%\LE) $%7V%.O9OFY70>S>Y;
M/=#C?K#=[7+K38!."%N1,W2]U;;G$#:1APDUD0U=[.SL=5>,7Y$L0@#7NOA,
M=::!LC95L,34<6&WO!^Y!XIU*!_#K7((@5UP\C7&/_0C>Z^1/<9NR'J-#U2N
MAM4[VPT=Y)Q3LN:IR)FA(!L443'B]RE*2#AJ_7EC;7()AKL:Z8)([:N_C2:7
M8Y"5<T.?1A3P8Z;"Y*";9C8>HU<3AS@56J4EQ#,(R4'!/5=[:K17$0<_25J.
M<ZL<0D 7O'(-)TU[J/><#1B$] 8Y7#=7K<S*B80 K?6S,7"-+Z"@N4[N5UT=
M3746$:?SA7.#+ZV&4@3,M[7N-!Y)I^CS*!JG=ZD=QH%RZ;,=KC/7LK\/?'L%
M9'X$X&!#L0W3ZA0%*^(TNE1:EB,D#K5NMJV31;DTH^VRL\EP](\!$.D3&.R1
MI SFAC9BL3I3=?%9'_?RTDT%,,4\8,\$\*N+82;FS,1[)E7:0"B3D"34NMNX
M<A^<#4V^7)^R+94H9"_>7NDQWV?_1&S[I).Z+SC:2G9/>DU_F!#W<@-;@$X(
MR:)'K2;LO;>H#WAC2-7"29!:"-V""ZWZ1I$>W7V]9V2-6"(L><\)1?C:8W,G
M\3)+WH*73""+$,[UWC!]RN+91WRA?*X;JG8QX].M/LLME'NXVRV/;>+9V,56
MO"_)7Z@*"+U/S[88,)(KU\VM<@L)0<$5EE]0LY!W;:(-T]U-%MMXN="-;YE3
M-(H!ZJ&7B(ZQ\.0&LY?28"QGSC=5AK_74@LA7KS:*Q?QKG_13&9-LQ"&_$&I
M'M\N"AXM$:7( 9S*XDZK=+Q8+B&\:UUF8_5<-=C&)QO&%4&J/?"=3BZ6FVIU
M!")POJN]7ZRWQ[H-UYW;Q2I63TU40O@UWTGVIP>1_<?\2 9:*OQMRP_L0<5/
M1SYFKXL>Q=]6%"T_'?WA7GN#Y&G#?P+;K^[6;D+":JAYVY)CO]M3<<5)$1:U
M"Z44WMZ$0LB&Q3$@_SAI?%) @ .6?9ZI1F'U@,X_/B#GKG75EG/(@MP'9'G"
MRG\(7D% V_*Z(],/Q/%H6\M#\ VCJRW?^0'Y0&R/TTJ*7'\\SC\I"K]WGQW]
M"(P3&BA>X2G3NN=HHX=T)\3F1=5D8;\&2;X!^S0X.1V\.7EUYSO;EK9IQ+8;
MVC4BR=>A$16/XI;5[U>1LS^X,(E66O&X;FVEI7F.D1OXR9?.3>"/[N[?!EY,
MJT8TO^];U9RFG/RWWTD(^(4(]+Z-(&2S)#^ZH;%]1%D,B(0^ H&]J]RUV@Y2
M4*R\4@3B)Y>YN<=>:_[GS/*(>>^ANTG@3-'ZBCUGS!KXZ:@T!;LNNTWDTU%
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M',"9%9?NC0%0?:G>(6KC+?=M,TG+_7:I+;IR;Y5#6KY%YN>*#NB65=J>J)_
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MYP B\!,LB(GLD$:O=,=W.O) =90- #]061*<D_EX[-LKM+;@S_\ 4$L#!!0
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M6!JCE6N[%-?-TU?V0I4;2WY!J 1?F;U]/#$/0B+E. [=^VV,\XS+ ,<3$&2
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ML?K)KBT3A8U/#BHA]Q;_XXNVDE3D%@A_R\A<H%40HLQ% F!%0@M$[_I6^&J
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MYX;@SQY*%X;##>;K7ZS=):[>LJU()RHB(CB5 "=ORET4GY2KA[BNO?0"]BY
MI0M')1CWCRF_I6W>WHRN1Y/137HE>Q>@<HFJ^PMND]+MN\#;^K$5OE).4E3
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MRL*D&6HUW[V9A0^6GQ9!XT>!, ;AZVQEN@\^*1_PXW0#B%30>ZZ=O!ZDPSB
M5H:_W&FV'[2!AIV,%T3;$,%?9HNKX=3XO^'2F$VUX72LF;<W-\/%;]KL4C.-
MJZEQ:8R&TZ4V'(UFM].E,;W2YK.),3)TDS37S:5Q,USJ9C\']R8NZ(SCQJ_
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M<'-C+&] XY-)D,SQ*WTZZDV-,@\X35R;5'\]A"@Y;E[-1<F[+W03D!A=$Q;
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M(;9_KY=!6"[UI?):/CJ1X?5R:"RTN^'D5M>N#7V!3PK]IEW.%M4%P;+$,(Q
M]Q])SF4/-"_[I:K&7#+"-&]OYDGZY0UYF4S7<D?/,GW'<_91A0R3B7PW"$UD
M Y5.H>:;BB.U--'4IP8HK:F/;A?ZN%0"WC>(M%IV/CA+-0_,JG;YT(Y=;XL_
M3, EJIO<WH"<)",.OT7.%,794G@JY-2]T;$QN07SK">@)_JM_SJ:W(Y!)I>+
MV4W2 OXRU6$6S$PS6SK?MS[4'D;E4X=2\IQZ.%6>,M .K/)Q6LJ6,PZPJJ#X
MF.OP"3E$H^G>B)H:QZPN[D!CB9)*]+?DK,>,.%R><.HC-9PB)S^TV3PY12 ]
MI'J+)9*+82X\R_YC$-EK:!8E/ \>0Q=?%7.#XG7@4#FG!E=OT85V:R;[61>3
MX>CO V@TFP# B5 &\X4QPB<);O3E]6PL$7:LOX/[XM.-Z6X050[4*(NH\^!B
M:!+7?(/W?9(S)>D>D#R.TVB+2\E+$5;%FD&>?I=.9W&9VX_EJ(IR3DN>5ZD^
MA<_'8BF4JC^5KX(S&0<;?.N7#2X4UGJPU/;Q7 S\C NMYI,>+<UN\&FL$?&B
ML+[3C:LIF8NS:<Z+2O"==@"!D)<\ AQAWV/%VS@(7_=E./C*+RKGI>@H[U3Q
M 2U8 0WWRSQ</'>[G"U^RQSJTQ:@$[)WFY-:$M"Z'.]B=[F+C"&IY+B2PKPB
M#.-+!+;,\JK5091]P<%E;XZ+ZT&Q^KD]$:N4LN5ABQ3FXO4'4.!57(#23&7J
M1Y6]6=^+KK"$>FQ*,@VPW]K:)$6SCV_3!^@/TQ3&T+++#7I1%R[Q=K^3RDGJ
M_M):G)@":MW:XE@\ZJ&#RBYF:*X ;7!_G.8"?C@*D5-]<D=@7F3'D5T>T8LA
M* M.J=<.FMHR8_-HN2'.:B8/<[?O,<I?D%VU(<UQU G[V(Q(NIK/+VM=Z(BW
MV5W+.TR)V*/+KB3I18%XA:Q&\%%^&OR H*-J,-FU*-T'&_4B5 -B^"$V8/B$
M4'Y7&/1Q&U8E,G@Y9X[,!_ZG(P:?4[C*:<+8)2\[M*< N0$YLU?O_SV KY"E
M(GB'6W3[> B^Z0"<>*J8CA1E]3@CNQ%YF<3PQPCB#%CN0*/D "5V3 E.GA<\
MTZ_L:OU#G&ISY)G)!K)7OI25O%T3)=%L)ME*W0,K7YV>N[EO=F>8>,<=EW;F
M;[*4N^.55AGON4S7?!?(1RO:?32L?I*>1$NH2O=5Q-FI[RA[1XH/I^*3=WSB
M4,G<IR3G]CO$<61UE[UG= B:?*)1"=.=:Q V,LR.<OE)YU5CMEC]9=L<3MR*
M]W0(24=%/:W>;!5%EV\4V9;H,(Q%)*42TL*@*CM'F^%V1%"5EQ'%E<9N!3+<
MX!O8ZS$4'TGVY!0#MZFD5+T#*5.265Q;YB]&HJ[+J 7_8_U27^ #2[@ L>8^
M),D+M!+O\(?=SU*U8/LB:F>YSG9/6JYD862%X>LJ")^MT*'L[@H-(MM4"R!9
M8[8%9*62"2^1;_CS,+!1%%7?*B" -W,DV2:\1= YI=9]\ATH ](RUCA_:5E-
MQIW92W9E7@.HN/@Z@@EY%03.L^MYY';=&(($O(W'NCQ;;!3997<M3D0.:2F-
M=IGS[&DSX"J-,R-R'NVB>!QM!(':02%'@Z_)+M9K47M:E'XOICY/?:,'(H1'
MD5UKU]P5-)&6TL8"8@X(-N/7N8?/:?H./MPH&J51QI!=%-?BQ&9*2D6<]RF&
MBL?=.1+RN5[2-39##<5'-XIPF@ZMRJ*3AG.]8A\F4!7U/<_4!%D1K**'N&[Q
M(?^L.Z\V5 ZARJKS8-0I E(4W31$#X-(:.F2M%=EME;S(1Y9BF$E/3?"PRU5
MI54ZVU+B+D/P%(F$3\6.RFEI-6?,970.;96MB4@988NE@3W.O&8("I7X*;&G
M5*[FHU]>\GWI9J7*XKW^KRO9WD?HZQ8O)I^X[_;ZOGQ9TNV%J?]RB]]\T._H
MMWFED.'_X N*X"?_#U!+ P04    " !IKX58WF!@&SQ(  !_*04 %0   '%L
M9VXM,C R,S$R,S%?9&5F+GAM;.U]6W/C.++F^T;L?]#61)SH?G!7N>[5,[TG
M9(FNTAE9\DAR=?>^*&@1MCA%D6Y>7/;\^@5(2J(D)BX4"( J]L.,70; S/P2
M2""1R/S'?S^MO,XC"B,W\'][<?[+JQ<=Y"\"Q_7O?WMQ,SWK3GN#P8M.%-N^
M8WN!CWY[X0<O_OO__N__U<'__>/_G)UU+EWD.;]V^L'B;.#?!7_OC.P5^K7S
M&?DHM.,@_'OGJ^TEY%^"2]=#8:<7K!X\%"/\A^S#OW;>_?+ZM=TY.^,8]ROR
MG2"\F0PVXR[C^"'Z]>7+[]^__^('C_;W(/P6_;((5GP#3F,[3J+-:*^>7N7_
M9=W_X;G^MU_)_]S:$>I@>?G1KT^1^]L+\MW\L]_?_!*$]R]?OWIU_O*/J^%T
ML40K^\SUB=P6Z,6Z%QFEK-_YIT^?7J9_73<]:/ET&WKK;[QYN29G,S+^JQ-O
M.A0;OWN9_;'8U*4,72 Z<G^-4DZ&P<*.4PUA4M0!6Y#?SM;-SL@_G9V_/GMS
M_LM3Y+Q8XY0*.PP\-$%W'?+_&.C-5_]*;,^]Q_B[]KT?1+&[2&%^2=J][ 58
MC3'1Z0C+$-W]]N(O[][''WK]YOQU]IF_[32*GQ^P.D<NT<87G9?'DW!A>T1R
MTR5"<<0BI;1QO21=VR'RXR7"36Q/B+[2GM*))3,1K?"'HO'=^(&L'ECGHJ[O
MD!4C1$OD1^XC&@814[CB(]7*3&]I^_<H&OC3.%A\6P:>@Q<^ZZ_$C9]%..$8
MIEXV[&AYZ07?A<1_T$DZB>/PWO;=_Z088XBGR6IEA\_CNZE[[[MW6&/]N+M8
M!(D?8ZMV'7CNPD5$%RP\S@H3RF1'V@>DLSYT,?H.QA]_[7. O]X+\)P-?19'
MK'[2";T.T8/M.M;3 YYZJ7#&>#D)>TE(%I9N%'&LF")CR%<R\JE1X)\M1$BF
M]Y).9-^-%@'1P@0YVV6/122]EW0B\50)\9< &(>N?>MZ;NRRIZ7P0-)9^=T.
M0UN(9KB'=.+PE,:;G=B]]5 ?W<9G$^3AM<C!IIQM=7CZ2B?8LD,?+T41,<O7
M*)PN\::#12BM3PT27:W<.+5KZ58B7>_Q<8D#=XZNTLF=H C9X6*)/SAT%V2.
M=.]#E-EE%KT\?6O8:XCOCI1MA(I38(;G<&0ON%975C_IA [P^7V%9O836RM+
MFLH'-;F-T%\)5ASKD4?SH/;F;1O7_U;[]G'_0UIV9S,;&P,I>[3=D13MU/C(
MY^FK:-?&1S!/7WT[.#X>*@ZG8#?'1S^KG]*='1_)_",HV>7Q$<WNJ6!'PD<J
MJU^=1I^/0K"#>7:VCV+;]:(1F6:Q^\@\$]3V067N&U&.1<>1/T\62^0D'AK?
M\6P <K*8D^B806MD<;U).(XGGE%J9&+'O8\%FJT'&\=MS[.C"$\6A/]0OL<0
M9ECV%^5O:U((TA/OQI)+DX.4P15M/467'[%1:E1J[IVDL/)6';E&9O-M9]1=
M8.GBM5^8)\8 -9)^:;MA>MW^Q<7:$BZ6SY=!>+B-%N:HVKAU*F04):N'=#IL
MY'V4&@J-I^"$)+I4\(]0(RI3Y+M!.$7XD(^<O:.0,"0"@RD]"(HB4V6L&C'J
MNUY"/I4*-E44ZVGA)0YR+L-@E?X5.2,4%P^#PMA)^(C*2P9Q2(6'4GH)(<I/
ME;%J5%%"3OB(G%0MQ-=R:O<Z5S_BFQBG1J3RUH$]AA*C>A.1K?.%9R^^G46+
M)6X6942=/83X5._?7Z%X&3A'F-EJ7Z@3/:(M9R2$+HUEPI,@W6WG&U-Q($6&
MJW\S>^Q>5IDR'OCW1-<R_A&4W62*+\=BX]2Y6PA6B/P16P:\XT?NO4^T.? +
MED%@5\ _6*W6!9^I%WB3;.?;_31..0["YXWK=H+%7\'L5!FW5H]A\.B2,' L
M[()7NH*3D&><.I40W:$0'P+P9\N\/>)Z*#1>G5<*HBL#1]?:XPR$%V3._C3"
M\>9T37M9XR(!0)C\.EJ?Q,>_2^E:XB'"17*+SAQW1>*6 _]%)_]043B;45P_
M?HF;OLS;O"P=H'ZZ-Q\[<X*5[0H2?=A; <7IE\Y6:'5+'@D(D;O;M7Y:;<\3
MHS#M4#]=?A!W14E;]U&JD^C.3KRXLE*NN^_2C/_9]5UB5X?XUQVZT5.,%R[D
MK"DG U9XV!*[,>F7OU Z[YR1YTP).0'C'_.6"F@J?[RR0]MK3-#F<B<ESH\"
MSW7(EK&3]^^L!U!-<OE[EAWZW_#3W_EI9[R?E?!3X8G+#G]O:?QM!^\$=YWM
M\!W;=SH['^AD7U#,,,]+F!UNW_%SFX_=<?U.<?3_LA^"Z.^=_",YNVN&O6"Q
MPZ5''LP%X>$R%:W7ESL[NDT7F20ZN[?MAY=D,_(2>7&T_I=T>Y(N6_D_S#=T
M8JFB ?YQ ZUGWR(O_>P\;US6]J5>JM,X$PZ*\W;[U&Z5JANNZ<Y79D[SEYF#
M7\E=)59#RTN_ADT*NB<_K"F["X,54Y2YV (J!T798D)>=((0:])O+\Y?;6GQ
M@@@YO[V(PZ2$9<4 9;J]/>QVGUP>#2OO)A6^TCTL"ZY=% "H:#R7(*<+HSTR
M^_FF&,(&:"X5D\,M.@L0JJP#'@8@7%Z_:C(P\_,2\F5AL]ZI'KOX'0M>RB2$
MWQMM^)$[LB#;1ESEIS<(NX.F<^FP[1XC 4CH<R-@TVS<ZM9UG%1DMG=MN\[
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MC805!2@8I>-ZS,!Q=+7S0:?<P5FBUZM^Q*67L%2@N[#S^FY!Y='X@\\>@S
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M_!BWFI(J<IB0)2:]CQZ1%SP0ICEAY.BLJR)C%11YV3'/L=[UTG&14^[HR%F
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MH744^%7/K3Q=Y^>:;LEJ70*"*D* -US-B^/&7.=/P5,?P<"/XC!)I:JBO*O
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M-5PCVP^B9Q\]T5^C[+::O]5T-<8_+0(&\9!\WTJ^!1.8/N0US/BN\'B&;J.
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M.1@T[D:]E.:ANW+CW&_IW]!B>+BZ-P]:?K:,NU:_\<--UD?,Q@7RL:!IU^5
MA^:!1F.$X[Y;U_U(<ANAOQ(2B/E8N EA^%7/#_S&-Q=3ZU\WUFC6L;[N7'QH
M=Z[N<<CA485[:#K-[-+#RA16VMH8ARD+COVC#(7W-G>8Y!<.-%FW&<3:#&(G
M#:.1+M0V@UB;0:S.XQ<>>WQ7*.%(O[H#FAMML.BD&W<@+I;3[/K.*/#M[;\4
M,_FR/-G" ^FYVZ/C$AS'DGDW?KK@-=*XU:\"BI/0K*,EUT]9NO<A2BECI$EA
M]-.4XJSJ= L$63-N#2Z-B:5;1DJ7)EA')L<&>1A+:>7,OE7>28_E8\N< R-S
M8UMDPV2R!9,(I5*+-?N.N7K._O<R2,)-7DJ\W/.\<.?NK\F"\4R9H"([QJV+
M^\L]_A0CT0K4H0D6B\&M04\+2RAE+8.4+II2K3"DS<3&7#LE$QZ3;90D" V-
MP]RCEQGF5]9<DY%BSQ8J-&R+I&WE:VY] GX[)%*E0-MKY[9*@9&FIZU2P,^<
M]B-1M8.0W@A_D2(%/"R ]U?Z#CTGEF-2X !4+=.DMBP-;:9)0ZU0FVF2$SRM
M=JB*.V[79Z6IP@%WWDDV]:#LM9F?ZS!8(.1$EYAKDD#']A=H'$YM$CZ2,0Y/
M)'9?73'0@B&:G(Q Z$F>.!/DKFZ3,,JF_-,#7D50V4Z -"YM:[K4Z82#6S0S
M#CF7]@)U5^0%*>\A9]O#=&!XR ?-OQGP7-EQDKXNQ2:3%Z!BGT9"=," <5<[
M2O..-A%"%C^&NT:+N9O3[:ISC8^,^ _V/?<TI(W12$R9#!GG9C4BB6@SH*[.
MFW&.#6,3"3=8$P2YA'3B@RG+>Y:.OX^R_[\,PBS#Z@AQ;X-I8S0$:4&&(% _
M&IDS./MYGRF:!UIXL(; 7)4S".]/DI\B.4XJ+MNKY+Q)'_<(#&$Z:)7X 9T,
M!5ZA]^SYOY/_N<70XW_Y_U!+ P04    " !IKX58-#!JW]&;   H0PD %0
M '%L9VXM,C R,S$R,S%?;&%B+GAM;.R]>W/C.)(O^O^-N-\!M_?&1G>$W=U5
M?7;W],SN.2'+<K7NN"R/I*J9.1,;$[0(V=RF235)N>SY]!< 'R*)!P$^@%3-
MGMBSVV5E)C+!'Q()()'X]__]^ARB%YRD01S]QS?OOO_Q&X2C7>P'T>-_?/-I
M<SG;S)?+;U":>9'OA7&$_^.;*/[F?_^O__O_0N3__?O_<WF);@(<^K]#U_'N
M<AGMX]^C.^\9_PY]P!%.O"Q.?H\^>^&1_B6^"4*<H'G\? AQALD/><._0__R
M_?OW'KJ\U)#[&4=^G'Q:+RNY3UEV2'_WPP]?OGSY/HI?O"]Q\FOZ_2Y^UA.X
MR;SLF%;2?GS]L?A_.?N_AT'TZ^_H_WKP4HQ(?T7I[U[3X#^^H>T6S7[YZ?LX
M>?SA_8\_OOOASQ]O-[LG_.Q=!A'MMQW^IN2B4D1\[W[^^><?V*\E*4?Y^I"$
M91L__5"J4TDFOP8*^IHF:?"[E*EW&^^\C'WVSF:0E(+^Z[(DNZ1_NGSW_O*G
M=]^_IOXW9>>S'DSB$*_Q'C$S?Y>]'0B4TH BX9OB;T\)WHN5"9/D!\K_0X0?
MO0S[M*&?:4/O_I4V]$_%GV^]!QQ^@R@EP8?4KI\;L@JF'VPK>X^3(/8743^M
MV]R.U"=C)\D&&%#GMV["-LZ\L)?R=4[K:M_A?CU^XK/?T\3/XWX]7>.<1.V,
M5]FX>\7]&M(_WI+_:JB(7S,R@6&_5)**4'A@U@*;& K9E?1XUY ;4F\>)[SM
M=&9D,O=>^L $']/+1\\[D ;>__0##K.T_,LE_0OKA.(/?Z-S(W[&4;;X[1AD
M;W3F)C% E*6SUR MVV*&_L<WFCP_M VAW+.DM,9+=AU=4E#\L(O)A';(+L.\
M\W/V?1(_:ZM2]%^LR?"W\*%J)^]THHK$H 99@M/XF.RPT3>O6V72PX66SR'A
MHD$<CBX_;;[Y7SDI.M&BOU+J__SW'TXM.($8T>@YCC99O/OU(WY^P(G$: &=
M32A)U:S#AR," QF99FV8Y'2($:*_YJ3N,3+S_8"&JEYX[P7^,II[AX#,P$J\
M=/#8Q(Z6^G4<*1G 8$I'RS:^3CR(,I$E$BK8 *%MMSL^'T,:?JRR)YQ0GYG@
M)QREP0M>DM7Q,U8C3Y_?*@I-S6H@4I<9#CH-->:0NIHOT2S+DN#AF'D/(499
M3#";D+D3#E37./.""/L++XF"Z#%5XE)&;!.$:H7KB!-3@H&74KTVEDIB5%+#
M05".:"5NFB0VT2)2KHZ1^N]@D"%0JHT':&[DCGR*.,J(:43JXS+*,.D4-2C4
M+#9!HJ-\'30J>C @TE"R#:HF"RIYX*#LZI@2)YBFLQU9BZ8L#%1L(TBI;6*K
M0^4ZK"2D8!"EUJ\-II(:U<A'VC'X+7R,&#C>O<_/"?[IC[<?[OYVYT7QYBW"
MK[>9+_0\4BH;@.A0D0)!0N(< &J]."]2$B)""<=W5%M>\]!+T]6>;5#H;$+R
M]$XV(&5J"S<?V\3.(:2K(;>;1,E0O"_WDZ;T'QN<!#B=K2)\3\APDF!?OJFH
MQ6'-K^BI7OD8-;ESL.CKV(9+SH1FE^]0Q37R5J0$/+2Y(SV6^9.7))YD/:2D
MM 86M:H52,1D,,"AU(U;*R7X,J=&!3F@68D!]DK#X6AQ6)V9NE5OS$UR<N>8
MTM=1XG"N)G,W#82E>/?]8_SR@X^#'%SD/TZ8(O_XVRU^],)%E 79FR"V$5+8
MP(Q"-8H1P<_.,2'7J8T!1H5RLNE7."D-K=7+FP:)U;6-0+G&PJ;VN_,/K%!*
MOJ29=N)(DZPV:9!_G08W^<??YG&4QF'@TQ,)!C<:(/&C7$UJ P\ZRE)<J.B<
MXT-#.?[L^T2.2OI)TR0Z$)-O$].#*R]Z$SH-*94MG"A4+"$B( &!#KE>DNWZ
M@G3JM<C\B8@/XNO >R3>+0MVXE.]#EIK$T>7NM4,(B-T#@8=[3A?D9,C_T0/
M9UFR);)7^QE=+#VR[1K%1IF$UN921*EN?1$B)'0.'QWM^*DF)-QQXF7!"T8U
M'N1%?N/?+'<!94]>A)I,DX:J,]*VSVR(_ W.LC WZ#'![#_D#DF3T9IW,C*D
M<E5:7,Z!9ZPJE^)2\C+4G;A1Q0['IVV.#RG^[4B37E_(_Z*#3;7]+Z.VNL6B
M5KFQO2(F=0XQ/?VX;96*&C%R1.FAY!NW3%'OUHEI'8)(L4,G(H0*(/6N7!L^
M3I?M:SH52];IM=]L+;@X=<IE5O6#\V\NTH;[QAF)8FC8[(7H(_;28U+,-^Y6
MVQ^]U^#Y^"Q=9[=^M_7!A6J5'[WQ(X@/+]*H_?$+&K?C^F,0J3]W\W=KGUND
M5O6YZS_"^-P"C;C/G=-,O6^2'^;,BT-"Q::)A-#R<;]$T=8I?XO*^3?O5$UR
MQ#8O#V^GWB;I&/7;@*QQ5OMEY <O@7_T0LG,+J&SY064:I;>0$CD'"%=FK4!
MPFAICM")>N*]C?#PY*END$FI[.U:2%4\;5%P),Z_O%HO;O.!$HY^^4LZ-^R.
M"3O/N2>6/GDIUMC+TF"R.&=H&E";/SHX8.!%5TU^7BGY4,DXP;:5[(CF=)NV
M.]Q0$-L[I.E2^'1*(Z.$ 9<N]93WF2V%( :;43=>D+"Z0U=OU7_^$N"$=.W3
MVRU^P:+XQ)39YG:5F4'U_2L]3N<H[*5N&Y64(Z\WA2H>M@=_-_L,99^TLFH9
M'8Y9RDQZI]PM57(X :%<=2'R>')X<)/J*,?8!<J9+A!C0^\ ^K^:6>^-0?8>
M"LC>FX'L_1F ['U/D+V'#;*?C$'V$Q20_60&LI_. &0_]0393W! 5CO$8#IV
M'%#+R6W"JTOI.K9DM&" U:$@MRM=.W5B]*!.J=O&K(/TUQNRNBUO=:^]3%V$
MQD2 2\AU&Z8"H9P;+"P[5>X$Z@6B,A 5<KKE3\6XW5K_$PX>GS+LSU[(BN91
MC$X%G:VM=:6:Y=:ZD,@YI+HT:R.GI$4%,=S9\CX)=OAS''I9$ :9.-?=D->E
M4U.:H_)G0D;GN.NCK8878^SHQ \7GHO7 ][EU6C%"0,FC"Z!*3=$A4J>"RPD
MI:IJX+'D1909/ABOZ6DICGSC4% E  (XY8;I@)3G!@]6J<HFH"V%V(@$#=![
MC1^(L6F6'#LNHH@(;:)1KF@==3P5&'1)56NCB!*B$^7495FB($[F<41"T"QX
M"#%IG31*4*PZ>._BL7CNKJ=^[=A=S> <+B9:\H?NE W5^%#%Z';Q25]<\8\T
MZ2@O=/X19T^QOR1ZIMFI4GK]KQC3YU\DZ5_#Q-E:RHYA=+GB'2++.:9',J -
M]Q/S!7LKR%Y>&KOUMWT*$O_>2VB2BUZBFI3-2>9:AQ'"5#8)CW.$&2JJ3G;+
M[W0R9E1P3YVQM-IE,1%_[[VI<][$=-;@HU*SPHN(" 9 %)JU$5&0HH(63L"^
MQJQF.L7EVS;QHM3;T>*?Z=5;_1=%(&\BP&[I<5/#FN7(=;F=0[&WRGS9<D;&
M?-3;!:CSL<5K%D2/QR!]HJ-GM:=K&@4FY>0V$=BE=!UO,EHPZ.I0D'M_J$%.
M\_W9,A0(G)HK(?6E8 FMW<>(%.HV'R02$(*!D$H[07&F^IIS\A3O?*G+LLRQ
MKP,/;2[+>Q<Z)K1V+U0LSL%CIJ=D!Z/@;.]D  K#9E^\Q.]((FK16'U,2*1>
MX\&@.H%ST*BTXM9JE&;,8$?B83X=2)=&6>>23$QGS8NHU*S\AHC(^4?OTJS]
MX0O2T9=DDN]_&^QPI'41349I#0-J52L4B,E@X$"I&U<3-B>V=Z'LHY=F.+G-
MJWO%R=L&)R]$AU0#'-JLUM!B:$P%'TT^&'@R4Y:O@$&YT8D=E?P6,7?[\2/V
M:046HH9B@UE,9P]-"C5/T!$0 <&)7#,.%+<?44%+D3'YGO#F0 O>DC!XC5-,
M[Z!5T)M%?N$"%4L= VY[2QYCDTY+'VU6&, RUI=;"I4"4"F!74&T/O=]B@*R
M!DN#[&VUOXV/0?H2A/1I]URGF_@8^1[=MU1$R(82[,7.O4P[1=5&[#!@V4MG
M+A*OA-"-PI.8$U)/@FR%Z9$O'W&*V=.(W7I ;V 4%^5K\,* I+G"LO4 *Y/*
MN\V3E,G?*:)U+E81GA-2&B=LDT!5Q$9);N_%HFZE3\\6R6EA@*E;0:YZ/*M-
M\@Z5'(BQ6$'*]DML@A09N5VDJ)5N(D5,"P@I2@7%2'GO!"F$Q,BKR!DLHZ5#
M\19>)-20$*-648R9GZ;"3+]W2Y+8/^ZR55)L:DB2+,5DUEXN42A9/5TBH'$.
ME0[%^/?S&&E1XIU13WNN401+?M'PQ@M5Z8LJ:MOAL$+E=O0K('4.##W])+&M
MCTJ@,!9W>T_IL,TG 3N W2>I41K;3QPO#*"9*ZRQ 55;2<UJ>U%@3N59';G5
M0;H=I:"S^^RT1,WF<],M(N>XZM*,RREC*?THIX0#DGNBI.1NB9C$)C1$RM51
M4?\=#" $2G%A#OF7A4L:9#VW?8J/*8FFME^(GWIC6%V2;H_HJTQ4"_FL9<!L
M;<XR-JB:L;0YG<.HE[IM@!$L_%C4$:V8$$,=&,>S>#Z$\1O&NK.4@MYJ6G27
MVHV\:!FQ<Y3I:LB%04]>@B^O/!:#%ZE'M1?@+L:>W^0UC0\DV&+9"%I%C:74
M-JL:=ZA<+VLL(76.&SW]!(6-*P: A8T+C93NIT5CT^4(U:N[F0:!<XBHM.**
M/N4T<*! 9LOX&=,'GY@_NZ6-$'^FB(Z5'#9AHJ%Z'30*<C 0ZM:1OP5-.5#%
M@DH>*)=W/N ()UXXB_R9_QQ$09KE3Z32TBBR721#7IN@,S*G#C\M1C! --&V
M#<F"-W\LM\&-"G8X[F\>>FFZVA=N>96L:4T^A?-3T%N]8M:E=N.:F8P8#-JZ
M-.3"*TI/DX_*Z31.$..9=GM!$ ;.=@37LIJ(NDPN0W*Q :K(O,GA'$-&:NK$
MZ:CDG'I-=Q?3N;MJ/]\O9= .]@'VNY=YA@*LP:R7817DC+AAP*^/RFTHMF2@
M8OO\)&7\=:0<E[T\G1Z?312:^SL=)C"8Z^OU""MRZOGRB[TI6:6L]MJWMS68
M+$ZDF@;4)M(.#ABHTE537 " \J'5?KJ+VQ(\E9NZ]&R;@!N7>[QY0LU]$M/B
MFXD<6F;\UE#6QZP*<";,,+#70V/NS+D4D;_7%4>7I90JNZJ4 V<-6J5H1/XU
M?3@E/K"*>!K[(UJ<=JLX:9O2+-_4R>8<HN:Z\@6;:A>Y:KSP=D7R3<6M]SH[
M9D]Q$B@KBLF([6\%RQ3F=X';E&#0I51/LO=+J%%%#F7;]YIHEF;!;AX?HRQ1
MOQDAH;5:7UJE;J/$M(@0#'Q4VG&%I@O:-GZ@."%VI$&3%8GT\/\[)D'J!SN-
MW+X.+KN9?EHF-//^E"Q@D*:G)Y=-0;GRB\R4#]49IUXDY'E%^?^^(7U1U<8F
M5J@.Q$V9+2:'&1I42P[3Y'0.MU[J"I+#_D>M%#K-71[['-X4<SV0!@=?IJ@Z
M"RR9(,@R:HR]$Q2/9.:%SL#S:'N;2?-\4KS[_C%^^<''01Y(D?\XQ4_D'W^;
MQR\XF3W0<_==UC),\+L-@$C5HGC@?G3^^64:\1N?+W0OJ:2R_:&OXQU[)H86
M1!18T/S9UF<6*55^Y?IO(#ZR0"%^I923L+*3EC_PC#3LT\9O0N]1H'[K=UN?
M6*A6^8T;/X+XR"*-N,JB)0VB1*X^\S5.=TG <LI5=C3(K']T@9+<MZ_1P((
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MX=Y+LO:E7RT.&S Q4)T"18/<.53T==0 "[I$2<Y(9LIDY.+7O1(MXN@%)UE
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MD\P$74PV)UL] ^JSK9H#"@2-M)6Y.Y^Q>"&%X3YX)7&>Q_A<95'>U^I,%65
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MFAH 1[1MV[F[>&SX%P6,JV?%T/R6_+"\62ZNT?(.07VT]M2-[3<@BW=3&\]
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MP[*(E<@^ 9$U^$@5K)#"4<  A4PMX>O5E*[<EW"_UJ@_Y^XE^,HC$>8\?J9
M9.>C,YK \<CVT-*KMQ--82D[<FT\:-^:34>4;[6FS=C=TJC5,99PY^B?RB)N
MX!3RZ1D X[YD[*C>!JHW@A[>&H1%0XBUA/[*V@+P8'Q79\GZZC:(,'OT7O8]
M1A!LO834*!W!U9H:)!7. !O+%&'9^8[1U#&8:!.(M>%^1-7RM,LWMEA>&CUP
M3%ZP3^MV'EF- IK+&.UDTU8/.79K^/4T4_*4@IX0,*.AK^;"I^.=8_8T>5[C
M/4X2Z1BGVX++R ]> O](EQO%QB W\&F2[SU9L29D@9'DWH$]_T'GWFV0T99.
M8@@M^2LQ3]R\7FP'5W$W02/<_E!%HU"U!N-WSJ:K5/%SR2N?[K\0[=&IW0M4
M&2 * _),_Z85J#3C@L8.S!+:]$DFXZ$_$7/D2D&)TR?_VEWQO$T%[%Z$M=VQ
MS0NUMEH'X\&LF\Q?\+7H?6"M37JOX8JK6[5;.ODMGK'7BO)VSF(OH*N;1MD:
MD#5B=80?\EJXF9=DJI/,J8SL>C/AHKH#6+L-1B(!_!A$$82+82-V3.MZ7:.0
MY_2?1=WZF8Y:G2Z=:"RKFO[*1[B&Z=QQ)FV%#ON2."](>X$*Z6@%Z#(HZX>'
M[JYZ,.ZJ-7[V NK7RO0M$K70+/7WJH]F6Q/KOL!-5W-^P:X:8.)\=[;+GL>X
M1(4 5$E -1'H-MAC]&T0H;]@+TF_NZ@[#^1E: '(C0SPN!]8/81EE#]G,)%;
M;S=R3H& N(/&G.^;+< :LF.;I1^J/U)V" ]-]TX@$/;#%/'YF!J &IKC=ZW1
MN!VO^?,9U*/;+'V>JJS7@EO!^MDY@(X>6[P>@H3Q3#W-"EL"-:#[=]68$ZZ@
M&3L#].=\@$;XT2/(GG(A+3=1?P;&5,8Y#, NGR7H#!?3L+$:H(;N1)T\ZH1L
MJ,/7,ROW,[SWU'PVGJ&CVV[B9(\#]D[ZQ%.SL"50X[M_5XTY-0N:^=JF9KF)
M^E/S/I=Q#D.PRW4)NL/%Y&RL!JC!.U$GCSHY&^KP]4S._0SO/3F?D6_0[[A9
MY%N*XJ?5"937L-']$P4'Y@J=CS^QT O&)^<W.DX%,)8=)6'9/8#-DS06T:3A
MJ]Q(>?BZ*<)701Z&WE'J>2 +:J+0UXU"+=///U5H0&=]QBGM'S99X%U&*Y+3
M/Q6FTRL-D^;OZC=_3M&1::>..?!UV_YJ8AY#@TW.."H)Z-L7ULIW_P#CW<'"
M::A27Y=OL!TJ#-/H'\B/#%D\R8]+H#J9 1F9QETI2]24O2X/2<%SRE8>_\.,
MF<0\GG:PG!*D+ADOY;EP8(NOT8'=T:J8U)3F:XL3?61I:^?D6CJZ;$P_(6GJ
MJQGT:OOT%S!1'%TVX@OZAY&&J+1NX^A!&.F-_BL4*$I9K$OIW-;3@(>AD7._
M *H;>I\=3^E-X$SXK1YD*>W77G9Z&WYJGZ^AP%F&!=H=.TFDT-FZ<R?AS&3C
M+0L'887&(H<N4)816YV<>J*F9M4O(N<\KGQKD_T4W5+-VV,*=SZZIK)H].7T
MW=G%[!_RNUB6@W*M5L\EZC;HPK'":HTF80Q::W:Z3 -0C<P!L8#8>-T:(&Y4
ML#MF[7=N<P#;:Q_0:+9N].BS](=Q[A]/,R$O\AM8EB=DK5;/94(VZ,*Q)F2-
M)J&\/F;7W'_,]+QJE3Y+T^-S=9.3[?Q=TW*C./+79#4_=C*$?KMGD71CVHVC
MY-7H-NI\2K9M:7LHEZ3(+VC16X##,[Z<I.J/SS%]N#<,LC?;X[;=\MF/7'%7
M3CYVF\U^W:-7:*MT_*;T>9-+-@^CEXKSZQK'ZR#]]2;!>$DB?_(),]HO'\F:
MX?GX;./#*)L_VQ&MT:F3#6M%VU_GV.XVF(NU"<?EGK"@H.!!"6&Z0,\Y&XP1
MWF<_0>7[)LD\U6CP+,YUM3MNE'/<SM9@C=0I391.OF7B!AF@SW1=7)[3THVK
M-[9Q!6.8=MX@<76;0WVS L99B%0E[ODD&HKE6R+./_LL9'*Q+Y[&BD>H)9;J
M,MN$BYE!=2CI<4+9X>NE]20O%LH>HJ=>=;5O[!?6]OU$&Y:=+/:>GM=3_O3F
MO)H>TF,/!OIJYAU!.V.YBZ-B!_NW(UGC+J,T2X[T5_F]<]W;39 4@W]2,\6'
M&'Z8,Z96SH,.<%W1F;R<5.>X(3N[S0]NZ[<LSZV4B+P7BT/H4?=).ENS7#!$
M(T:Q8&OWE1LBC_)H528_(T_:KXB^>VW@H!107QC?_' ,Z@D'>-E!MIQGU9YE
M8$ZRM6QB9G?=KS^5(*N8OQ+?6=D#Q7T:*?3U>]!^W='?B6)'^)YTO%<%)JTY
MTJI%6PBU4/W;S%XCG]I9C/^L/"JS!HX_U5;G'\&;FG?&$%_J#->BS<W">*V-
MVX(6&")T--6^*.KPZTR [*J\,12_8Z00,)R!Z8[^OD>KAOZY'!T!*O]KI.\(
MAT=GY(*4A6.M-?JWG[YV5R(WV7P?P\%9@X5N:?G6O"B-JYT,/84 ;+G!Z@?C
MJ<_=Z9DB-JU4^BPN7Z'%!04;9LIJ3G[H\BOT1;5@0(I^*,?\Y@I^_='Z.-TS
M<1X K+RB>E225WPK*T,Z"(O:"IQSGE!WQ]J*KYNMPYB37)ALD&C1JD)VEL.Y
M%;15?5+& <[#2(%&7\F U^UZ-\L83IU_!)>@V0?2N;^LY5+5A6!A-+HG#H1I
MQ6JK:4;$(Z>F&Y0B-&)WFK*N6TC0@!<&S,T5[JY1<I\OI>U <()Q>HL?O7 =
M9!E.RITN2QY"V/(YST**KIQRMA$T"V.X6;6U*\)$(65%">.MHLVS'J?6"H&-
MJ-57-KY='QD;JO2/Y!>F*)E_YCYDC7>AEZ;!/M@Q8:O]+#P\>46/W9#!4_SG
M;> ]T$HO 4ZW<2[&TH<<IN(Y>Y<Q/LZ4KF:(?E^MWQFA4PRVQI)6:Y2(M5>2
M( K1ZA_AJ4V4Q0BS5O\QO!6 T&@Z]?]1O9SK8&LJW?_;._;KL,X-PW;X!MA_
MBK:FQ@[7QF_#Z3;EJ '3V W &-,36:6=, YXP$UY54+4[;:O:XAU..?00:M[
MK=P+$BD 8\ [LGK,&R2PQO0=+88E2=*>N./%39_S"%9UYI0#5]3N5SM>%<:.
MG^P.:[!VI4V?NL;RG&RJUCD/\KX?P>6]@K9.7WNR;L_^F.J"P<CKYIIUK5):
M!JGY%:?3-:[<%-W[$&7)*Q#3G9&NVD&E1A6C:1!F#"PH>#*#T1F@QQPTY;\=
MP(9"O559P&"05)P0@"0P1=<QE54(($VU1BH#6?2*=*ZNSNL:66-P"BM.<26:
M*FJX_JFMHC9H7%4C*&L>D5CS.8Y8T?FY=P@R+\S7B&N<XN0%^\2PFV-V3/ R
M38]>)*ZS;RP$SCVYX2:T/_4]^5>9C.B]>$$X1E@\N)3_/1&#$^*>F(FY;?*"
MZ]I<-HOW:YI0!V8'BW-_8J8GA[22*W^_ZZ)$7:SW@.:$GZKW6K9X [1F.[]]
M.%DCE@MDJ  QG6UM$)6OKD(%C?Z7!U ,0%/!]C>H$Z%=G&8NO\!#-^H>NE'7
MYUEUAVK "TA<=@*/SS1# 2O;ES]9E<7H@5[2W\6/4?!W\H>8B$8>^M+>*<PK
M1CF/?H:ZTV:U[@])G+9O3TW:TED\#]G=56-.WH)F@'O_,6P3/Q96/A@WT@;I
M\-%&M:+K).Q?'Q/B:')#\K"6_;@JG\D3[Z\.$61UK/0VM#$4C*7 07I?U=5
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M7&C#0JL;3,>&4NA9#1 =2[C=F#BZ/#&Q2[&$:ZIM5DTKBF R>J21'RM@Y F
M/HI$:YNVXYA>[>T.$^<<UN/9P %Z=9LG@GA=F61@O#OYXSS!?L"]8ME7"#2_
MS1MHZJ1/$NQ ]^<<NA%^I ??J@WQ7MJW04L(T(Y1G 5@11/-\OG@!0G-#J3#
M=%"<KB<>&LA-.F6,&*4MV[E/G\B@]ECY$,?^ER DJ]J*_BP&3;$9VJ"X#@AC
M0BP(O"&]V2T:VF#1[0S3@=(E]ZP&B:8QDEUWMM6#_!J]PZ"^2CZO<D3Z!H0B
M2:"">+FI1L$[+\8Y=H?KSN7_/K%2HD&$]J=[!J?+!=7C2E,]J*09O-&9:9>M
M]G.:_)BP.>L:/Y!!=13??AM%+"A0:W:"$<([9)X/W/4,$<7\ 6/+<V$J1N27
MG#!0?QW0C-]@)+ WI$'%N,#DOM"NB3I+1//ZJX'LG^A=PC<YXD^'WN87W+#@
MV3#)#(Z,]8S@5]>7@QOY\?)X.(LU7Q[?+*/KHK8Q(9J1I6V6TN@H/^(-P_A+
MO11YCW6"42O05H(]NLAT46C0A/,Q,JU=\OC[I61!7LD#=(2)<HZ,.E$LP/VX
M4!G6#7D1-W T*U3FRB+5$KUJ.6#?%H?XWSG'ZOR8T%V6(E^'&%AL:E[E"DKZ
MI9/+Z@4E/1,:]Y/4+&#PIZ<G=ROR^\WWJ."! K!&$HPAS+IX'8!-SQP!Y-2,
MT("GI:T0?HP3"O@J[VV".BF3 [AU&"# F83#;A4&>K-;=0:MI2NWCJ)2T2YG
M/<VISK%61K.%XS7#G"ZS3>R9&53'H!XGM"N"1EJ#GG.OJX>,1)FG1H#4$^$"
MEB;&B<"IPP\5H@:Z YZ=2VOZ(1,4&'O@#P+D.F=H/67%4[1?/HP&)6.=WUYJ
M[T"5.U.SY_C('?7W%V,3D7V-K$/45 :TW,:>^H^VRSCAYS5P-+(Q:[D46Y>+
MZ5)3[%P$>VGP;E9R&]R-E/"YER1O1&=6!:O#_VI)<#'Q&9@FF@0UV,'LB9CK
MS.7XT]M<)1,*"1<\B"XC]@9 RA[=)3W]1,+,:_R"P_A 4U9U^Z93C%.P:AJI
M1&R'#+BPU5.<+Z"=$R,O\DEH5Y$7^?]3W;PBVA/U3\K/=KODB/UBKFB[33T6
M:^D1FLI7.1$=],XA9:!D&SX%U6@7]<9W?&5^/AD-RR@CNM.<MOPGW9&E%.'4
MX6D8IW1V"G[GJ!R@-/=:!5E9 +B6P5E"_J/\6S'.YO4'IR*_")I3<<556E%5
MM]-&:<HIUD?L+.68&*$=N&-G/./$#Y;M:L33A0Y-F\3Q3D<H82;"9FC1Q[AZ
MJ&'"[QRH Y36CF3AQB8D8"?+QNSMGAB2$6/I0SA&RS&% *>^NM,PI0>6<CN'
M:V^5N4MQP2M]R9WQPL,E/TOTGU_ 10T]@P!8NZOZ"G<<XM1J<<%#XVUQWR[
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MI>Z^)F-VY1E5<[ZA0Z\P]93::>#;,NP;#8KMIP"CWP+K-"G2%?,%YX2SX@C
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ME,:QGXNN$KC1E4:!HF^&8ZD.A]"7:C]-H9BP-+V!.^92G(=DYQX$Q?X 7:$
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MS.61I\U^V1R\Y.[VP0I_(^R93W^_#X,GRY/J$4!/[-M2J"X!,T$3#(/#CLV
MI8I@IBN'Y:560/;JR_('8B^'. /,GB?B'Y(WR>R%&WM*\[,;;P<'NOYV)!S[
M+%4'DP66AY@>+E;6L\@8JC$8$#]]Z?[@)E)M5NFZQ4C#PC-S^I[P*M15M,..
M X"M&BZ!Z.N&'K)M0IPHDX9\RGO^^A!VPG-8JBX$ .T&GA32XSH[<_*VEHL6
M^ \60"ND@BH\*VGF\S00M#/^HX.VC*4<+W1%'[$\8FO+\XZ%C3B\KVB'_TH
MQ&8NA6:]D#_G.F,G\/#IF/=#F,7L)U$6,_9 ?O%Y-$SSDBW1$Y.E*:?EZ<@*
M[9#>FY[@J/\61?9<OKU/F'&%5HUP\6EI>U0;\ Y?1@*/@I+&JO$&&3"V&7+1
M^EI2?:T,X-0MI8#)"-^R$=RR$1B6C:"=@E=I]C[9<\&*INAWM%=XH<NG7J\+
MN;I,%O-," -  /W0;W*O]*X:S$)T%UR6-%.V @O-T&]VK[?Z*AF$#ELNQ_'
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MO<*+UO:9:;+ED"R%T@*Y@FD ^C!4#%_A_>:U6*Q?.!LH\&H*5![RG-AXS5F
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MF%&:[9E7DCWA#+!3$>$((  4,Z2PCH]5M.)TQ?$!OHF=/TA-TK0RW@S9@@1
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M1'$6;TG(I# D6RI]=#=(M=(DB"+)\4MM%#.L'=#A3(TP_*,;<+Z @YWZ2&;
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M?_B<NGX45QV45, Q^I8%Q!><R+HZCW;+G:$H&7W)H,:ICFC+TS,Y!81S?:#
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M,RTQ+FAT;5!+ 0(4 Q0    ( &FOA5@;OEQ-30@   5    *
M  "  7@%  !E>#,Q+3$N:'1M4$L! A0#%     @ ::^%6(K@W@%)"   (T
M  H              ( ![0T  &5X,S$M,BYH=&U02P$"% ,4    " !IKX58
M/U85YYX%  #C)   "@              @ %>%@  97@S,BTQ+FAT;5!+ 0(4
M Q0    ( &FOA5CV8JL+YA8  %"9   *              "  20<  !E>#DW
M+3$N:'1M4$L! A0#%     @ ::^%6 HH'- \0 , RN4D  P
M ( !,C,  &9O<FTQ,"UK+FAT;5!+ 0(4 Q0    ( &FOA5A%CVL6ISD  #4_
M   ,              "  9AS P!L;V=O7S P,2YJ<&=02P$"% ,4    " !I
MKX58$9GP_@$9   0,P$ $0              @ %IK0, <6QG;BTR,#(S,3(S
M,2YX<V102P$"% ,4    " !IKX58\7=Z#5T9  "O4P$ %0
M@ &9Q@, <6QG;BTR,#(S,3(S,5]C86PN>&UL4$L! A0#%     @ ::^%6-Y@
M8!L\2   ?RD% !4              ( !*> # '%L9VXM,C R,S$R,S%?9&5F
M+GAM;%!+ 0(4 Q0    ( &FOA5@T,&K?T9L  "A#"0 5              "
M 9@H! !Q;&=N+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"% ,4    " !IKX58^YHL
MCEEH  !9-P< %0              @ &<Q 0 <6QG;BTR,#(S,3(S,5]P<F4N
9>&UL4$L%!@     -  T #P,  "@M!0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:QLGN="http://qualigendiagnostics.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="qlgn-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-05-242022-05-26_custom_NanoSynexLtdMember_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="From2022-05-242022-05-26_custom_NanoSynexLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-26_custom_PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="From2022-05-242022-05-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="From2022-05-242022-05-26_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-26_custom_NanoSynexLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="From2022-12-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NanosynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_ParentCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_NanosynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_srt_ParentCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NanosynexMember983343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_ParentCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NanosynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_custom_ChembioDiagnosticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:ChembioDiagnosticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="AsOf2023-07-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="From2023-10-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-30_custom_AmendmentAndSettlementAgreementMember_custom_NanoSynexLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:AmendmentAndSettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_AmendmentAndSettlementAgreementMember_custom_NanoSynexLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:AmendmentAndSettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-07-202023-07-20_custom_AmendmentAndSettlementAgreementMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:AmendmentAndSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MaximumMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MinimumMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="From2023-07-202023-07-20_custom_AmendmentAndSettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:AmendmentAndSettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-20</startDate>
            <endDate>2023-07-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-20</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_NanosynexMember983937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NanosynexMember984015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesCWarrantsMember985078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-04-25_srt_MaximumMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="AsOf2022-04-25_srt_MinimumMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="From2022-04-232022-04-25_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-23</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-26_srt_MaximumMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="AsOf2022-05-26_srt_MinimumMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="From2022-05-232022-05-26_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-23</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="From2022-05-232022-05-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2022-05-23</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-22_srt_MaximumMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="AsOf2022-12-22_srt_MinimumMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="From2022-12-222022-12-22_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="From2022-12-222022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <context id="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="AsOf2022-12-30_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="From2023-09-012023-09-01_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-01</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AlphaCapitalOtherThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalOtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AlphaCapitalOtherThirdPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalOtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-092023-01-12_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-09</startDate>
            <endDate>2023-01-12</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-12_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-12</instant>
        </period>
    </context>
    <context id="From2023-10-012023-10-31_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="From2023-12-012023-12-31_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-31_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-10-032023-10-03_custom_OctoberPaymentMember_us-gaap_CommonStockMember_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:OctoberPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-03</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="From2023-12-082023-12-08_custom_OctoberPaymentMember_us-gaap_CommonStockMember_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:OctoberPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-08</startDate>
            <endDate>2023-12-08</endDate>
        </period>
    </context>
    <context id="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeniorSecuredConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorSecuredConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorSecuredConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-04-052022-04-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2022-04-05</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-31_custom_UpfrontPaymentMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-01-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-07-31_custom_MasterLaboratoryServicesAgreementMember_custom_MLMMedicalLabsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:MasterLaboratoryServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:MLMMedicalLabsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-07-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-07-31_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-07-31_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-07-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-07-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-07-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-07-31_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicensedProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-31_srt_MinimumMember_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="AsOf2020-07-31_srt_MaximumMember_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SponsoredResearchAgreementsAndLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementsAndLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SponsoredResearchAgreementsAndLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementsAndLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2018-06-012022-04-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012022-04-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012022-04-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012022-04-30_custom_PhaseOneClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012022-04-30_custom_PhaseTwoClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012022-04-30_custom_PhaseThreeClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012022-04-30_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicensedProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012022-04-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SponsoredResearchAgreementAndLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2020-06-012020-06-30_srt_MinimumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-11-012020-11-30_srt_MinimumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CompensatoryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CompensatoryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_custom_CompensatoryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-04-25_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="From2022-04-252022-04-25_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-25</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="From2022-04-252022-04-25_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-25</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-26_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="AsOf2022-05-26_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="AsOf2022-04-25_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="AsOf2022-05-26_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="AsOf2022-04-25_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="From2022-04-242022-05-26_us-gaap_AdditionalPaidInCapitalMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-24</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-22_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="AsOf2022-12-22_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="AsOf2022-12-22_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="From2022-12-222022-12-22_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-05_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="AsOf2023-12-05_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="AsOf2023-12-05_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-05</instant>
        </period>
    </context>
    <context id="From2023-12-052023-12-05_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-05</startDate>
            <endDate>2023-12-05</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-29</instant>
        </period>
    </context>
    <context id="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-29</instant>
        </period>
    </context>
    <context id="From2021-11-292021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-29</startDate>
            <endDate>2021-11-29</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-25_custom_NanosynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-25</instant>
        </period>
    </context>
    <context id="From2022-04-252022-04-25_custom_NanosynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-25</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-26_custom_NanosynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="From2023-05-262023-05-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2023-05-26</startDate>
            <endDate>2023-05-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-22_custom_NanosynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="From2022-12-222022-12-22_custom_NanosynexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanosynexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ConversionOfConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:ConversionOfConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember990578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:SeniorConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-22_custom_AlphaCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="From2022-04-292022-04-29_custom_NanoSynexLtdMember_custom_SeriesAOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-29</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="From2022-04-292022-04-29_custom_NanoSynexLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">QLGN:NanoSynexLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-29</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-29_custom_PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureAndWarrantMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">QLGN:TwentyTwentyFourDebentureAndWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-26</startDate>
            <endDate>2024-02-26</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:TwentyTwentyFourDebentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-26</instant>
        </period>
    </context>
    <context id="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">QLGN:TwentyTwentyFourDebentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-26</startDate>
            <endDate>2024-02-26</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourWarrantMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:TwentyTwentyFourWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-26</instant>
        </period>
    </context>
    <context id="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourWarrantMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:AlphaCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:TwentyTwentyFourWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-26</startDate>
            <endDate>2024-02-26</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="Fact000004">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-12-31" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="Fact000006">0001460702</dei:EntityCentralIndexKey>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0062"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0068"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0072"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0074"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:WarrantLiabilitiesRelatedParty
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0101"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0107"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0113"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0114"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0144"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterest
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0190"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0193"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:DeconsolidationOfDiscontinuedOperations
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:DeconsolidationOfDiscontinuedOperations
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:DeconsolidationOfDiscontinuedOperations
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0441"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:LossOnVoluntaryConversionOfConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:AccretionOfDiscountOnConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:ProceedsFromIssuanceOfConvertibleDebt
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FractionalSharePaymentsRelatedToReverseStockSplit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0575"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0584"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0593"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0594"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:TransfersOfInventoryFromEquipmentHeldForLease
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0603"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0605"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:RedemptionOfConvertibleDebtIntoCommonStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0609"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:VoluntaryConversionOfConvertibleDebtIntoCommonStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0612"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0614"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantModificationsForBusinessAcquisition
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0617"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ReceivableInvestmentSale
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0709"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ReceivableInvestmentSale
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0710"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:PreapaidResearchAndDevelopmentExpenses
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0713"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="From2022-01-012022-12-31_srt_ParentCompanyMember"
      id="xdx2ixbrl0766"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="From2022-01-012022-12-31_custom_NanosynexMember"
      id="xdx2ixbrl0767"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0768"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:DisposalGroupIncludingDiscontinuedSalesAndMarketing
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0845"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0852"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0854"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0861"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc.
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0870"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      id="xdx2ixbrl0952"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
      contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015"
      id="xdx2ixbrl0959"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      id="xdx2ixbrl0973"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1080"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1082"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1134"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="xdx2ixbrl1136"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1162"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1164"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1170"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1172"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1174"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1176"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesOnToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1178"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesOnToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1180"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1186"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1188"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1194"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1196"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1202"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1204"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:DilutivePotentialSharesIssuableFromStockOptionsAndWarrants
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1359"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:DilutivePotentialSharesIssuableFromStockOptionsAndWarrants
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1360"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="xdx2ixbrl1491"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="xdx2ixbrl1493"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="xdx2ixbrl1495"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="xdx2ixbrl1497"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1714"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1716"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1718"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1720"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1728"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1730"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber
      contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1752"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise
      contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1754"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:RangeOfExercisePriceNonexercisableNonvested
      contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1756"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1768"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1770"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1772"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1774"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1776"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1778"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1780"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1782"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1804"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1806"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:RangeOfExercisePriceNonexercisableNonvested
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1808"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants
      contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203"
      id="xdx2ixbrl1898"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203"
      id="xdx2ixbrl1900"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203"
      id="xdx2ixbrl1908"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203"
      id="xdx2ixbrl1910"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203"
      id="xdx2ixbrl1918"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203"
      id="xdx2ixbrl1920"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber
      contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1934"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice
      contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1936"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1948"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1950"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1970"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1972"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1996"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1998"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl2031"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl2032"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl2081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl2115"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl2116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl2124"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl2130"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl2133"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl2136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl2145"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl2146"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="Fact000013">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-01-01to2023-12-31" id="Fact000014">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000015">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000016">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-12-31" id="Fact000017">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-12-31" id="Fact000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-12-31" id="Fact000019">001-37428</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="Fact000020">Qualigen Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="Fact000021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="Fact000022">26-3474527</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="Fact000023">5857 Owens Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-12-31" id="Fact000024">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="Fact000025">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="Fact000026">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="Fact000027">92008</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="Fact000028">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="Fact000029">452-8111</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-12-31" id="Fact000030">Common     Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-12-31" id="Fact000031">QLGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-12-31" id="Fact000032">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-01-01to2023-12-31" id="Fact000033">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-01-01to2023-12-31" id="Fact000034">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-12-31" id="Fact000035">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-12-31" id="Fact000036">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="Fact000037">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="Fact000038">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="Fact000039">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-01-01to2023-12-31" id="Fact000040">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-01-01to2023-12-31" id="Fact000041">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-12-31" id="Fact000042">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000043"
      unitRef="USD">4570535</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-03-25"
      decimals="INF"
      id="Fact000044"
      unitRef="Shares">6307371</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000045">None.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="From2023-01-01to2023-12-31" id="Fact000046">23</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2023-01-01to2023-12-31" id="Fact000047">Baker Tilly US, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-01-01to2023-12-31" id="Fact000048">San Diego, California</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">401803</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">3165985</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">764964</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">1366704</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">6287849</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">1166767</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000066"
      unitRef="USD">10820538</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">26242</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">866481</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">8236711</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">2033248</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">19083491</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">2222983</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">619568</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">560006</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000090"
      unitRef="USD">864559</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:HedgingLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">54600</us-gaap:HedgingLiabilitiesCurrent>
    <us-gaap:HedgingLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000093"
      unitRef="USD">788100</us-gaap:HedgingLiabilitiesCurrent>
    <QLGN:WarrantLiabilitiesRelatedParty
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">2834547</QLGN:WarrantLiabilitiesRelatedParty>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000098"
      unitRef="USD">1299216</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">60197</us-gaap:ConvertibleDebt>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">3441198</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">4136805</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">8608169</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">1708732</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">4136805</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">10316901</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000125"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000127"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000129"
      unitRef="Shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000131"
      unitRef="Shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000133"
      unitRef="Shares">5362128</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000135"
      unitRef="Shares">5362128</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000137"
      unitRef="Shares">4210737</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">4210737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000122"
      unitRef="USD">43262</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">42110</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000141"
      unitRef="USD">114655565</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000142"
      unitRef="USD">110528050</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000145"
      unitRef="USD">50721</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000147"
      unitRef="USD">-116802384</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000148"
      unitRef="USD">-103385172</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">-2103557</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000151"
      unitRef="USD">7235709</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000154"
      unitRef="USD">1530881</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000156"
      unitRef="USD">-2103557</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000157"
      unitRef="USD">8766590</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000159"
      unitRef="USD">2033248</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000160"
      unitRef="USD">19083491</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">6095607</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">10274600</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000168"
      unitRef="USD">5209250</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000169"
      unitRef="USD">4486120</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">11304857</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000172"
      unitRef="USD">14760720</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">-11304857</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000175"
      unitRef="USD">-14760720</us-gaap:OperatingIncomeLoss>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">2035469</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000181"
      unitRef="USD">907203</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000183"
      unitRef="USD">-1524722</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000184"
      unitRef="USD">-34397</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InducedConversionOfConvertibleDebtExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000186"
      unitRef="USD">1077287</us-gaap:InducedConversionOfConvertibleDebtExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">-625653</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">-21747</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">38994</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">-1174946</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000199"
      unitRef="USD">872806</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">-12479803</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000202"
      unitRef="USD">-13887914</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">-4793</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000205"
      unitRef="USD">6548</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">-12475010</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000208"
      unitRef="USD">-13894462</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000213"
      unitRef="USD">-683008</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000214"
      unitRef="USD">-7140181</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">602232</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">-1285240</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">-7140181</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000222"
      unitRef="USD">-13760250</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">-21034643</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000225"
      unitRef="USD">-343038</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">-2394100</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000228"
      unitRef="USD">-13417212</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000229"
      unitRef="USD">-18640543</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000231"
      unitRef="USDPShares">-2.46</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000233"
      unitRef="USDPShares">-2.46</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000235"
      unitRef="USDPShares">-3.62</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000237"
      unitRef="USDPShares">-3.62</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000239"
      unitRef="USDPShares">-0.19</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000241"
      unitRef="USDPShares">-0.19</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000243"
      unitRef="USDPShares">-1.24</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000245"
      unitRef="USDPShares">-1.24</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000247"
      unitRef="Shares">5072709</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000249"
      unitRef="Shares">5072709</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000251"
      unitRef="Shares">3840340</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000253"
      unitRef="Shares">3840340</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">-13760250</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000259"
      unitRef="USD">-21034643</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000261"
      unitRef="USD">119473</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000262"
      unitRef="USD">50721</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000264"
      unitRef="USD">-13640777</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000265"
      unitRef="USD">-20983922</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000267"
      unitRef="USD">-304735</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000268"
      unitRef="USD">-2394100</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000270"
      unitRef="USD">-13336042</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000271"
      unitRef="USD">-18589822</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000281"
      unitRef="Shares">4210737</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000273"
      unitRef="USD">42110</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000274"
      unitRef="USD">110528050</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000275"
      unitRef="USD">50721</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000276"
      unitRef="USD">-103385172</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000277"
      unitRef="USD">7235709</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000278"
      unitRef="USD">1530881</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000279"
      unitRef="USD">8766590</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">841726</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000283"
      unitRef="USD">842</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000284"
      unitRef="USD">1111740</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000287"
      unitRef="USD">1112582</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000289"
      unitRef="USD">1112582</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <QLGN:StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000301"
      unitRef="Shares">309665</QLGN:StockIssuedDuringPeriodSharesRedemptionsOfConvertibleDebtIntoCommonStock>
    <QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000293"
      unitRef="USD">310</QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock>
    <QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000294"
      unitRef="USD">254006</QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock>
    <QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000297"
      unitRef="USD">254316</QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock>
    <QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000299"
      unitRef="USD">254316</QLGN:StockIssuedDuringPeriodValueRedemptionsOfConvertibleDebtIntoCommonStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000304"
      unitRef="USD">7945</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000307"
      unitRef="USD">7945</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000309"
      unitRef="USD">7945</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000312"
      unitRef="USD">1626694</QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity>
    <QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000315"
      unitRef="USD">1626694</QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity>
    <QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000317"
      unitRef="USD">1626694</QLGN:FairValueOfWarrantReclassifiedFromLiabilitiesToEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000320"
      unitRef="USD">1098533</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000323"
      unitRef="USD">1098533</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000324"
      unitRef="USD">9297</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000325"
      unitRef="USD">1107830</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">28597</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000329"
      unitRef="USD">81170</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000331"
      unitRef="USD">109767</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000332"
      unitRef="USD">38303</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000333"
      unitRef="USD">148070</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <QLGN:DeconsolidationOfDiscontinuedOperations
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000337"
      unitRef="USD">-131891</QLGN:DeconsolidationOfDiscontinuedOperations>
    <QLGN:DeconsolidationOfDiscontinuedOperations
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">-131891</QLGN:DeconsolidationOfDiscontinuedOperations>
    <QLGN:DeconsolidationOfDiscontinuedOperations
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000340"
      unitRef="USD">-1235443</QLGN:DeconsolidationOfDiscontinuedOperations>
    <QLGN:DeconsolidationOfDiscontinuedOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000341"
      unitRef="USD">-1367334</QLGN:DeconsolidationOfDiscontinuedOperations>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000346"
      unitRef="USD">-13417212</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000347"
      unitRef="USD">-13417212</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-012023-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000348"
      unitRef="USD">-343038</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000349"
      unitRef="USD">-13760250</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000359"
      unitRef="Shares">5362128</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000351"
      unitRef="USD">43262</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000352"
      unitRef="USD">114655565</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000354"
      unitRef="USD">-116802384</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">-2103557</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000357"
      unitRef="USD">-2103557</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000369"
      unitRef="Shares">3529018</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">35290</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000362"
      unitRef="USD">101274073</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000364"
      unitRef="USD">-84744629</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000365"
      unitRef="USD">16564734</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000367"
      unitRef="USD">16564734</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000379"
      unitRef="Shares">3529018</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">35290</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000372"
      unitRef="USD">101274073</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000374"
      unitRef="USD">-84744629</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000375"
      unitRef="USD">16564734</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000377"
      unitRef="USD">16564734</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000389"
      unitRef="Shares">332000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000381"
      unitRef="USD">3320</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000382"
      unitRef="USD">4711</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000385"
      unitRef="USD">8031</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000387"
      unitRef="USD">8031</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000392"
      unitRef="USD">5484044</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000395"
      unitRef="USD">5484044</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000397"
      unitRef="USD">5484044</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <QLGN:StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000407"
      unitRef="Shares">350000</QLGN:StockIssuedDuringPeriodSharesCommonStockAndPrefundedWarrantsIssuedSharesForBusinessAcquisition>
    <QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000399"
      unitRef="USD">3500</QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition>
    <QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000400"
      unitRef="USD">3740417</QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition>
    <QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000403"
      unitRef="USD">3743917</QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition>
    <QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000404"
      unitRef="USD">3882225</QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition>
    <QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000405"
      unitRef="USD">7626142</QLGN:StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrantsIssuedForBusinessAcquisition>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000410"
      unitRef="USD">-42756</QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000413"
      unitRef="USD">-42756</QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther>
    <QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000414"
      unitRef="USD">42756</QLGN:NoncontrollingInterestAdjustmentsRelatingToStockbasedCompensationAndOther>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000419"
      unitRef="USD">50721</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000421"
      unitRef="USD">50721</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000423"
      unitRef="USD">50721</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000426"
      unitRef="USD">67370</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000429"
      unitRef="USD">67370</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000431"
      unitRef="USD">67370</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000434"
      unitRef="USD">696</QLGN:FairValueOfWarrantModificationForBusinessAcquisition>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000437"
      unitRef="USD">696</QLGN:FairValueOfWarrantModificationForBusinessAcquisition>
    <QLGN:FairValueOfWarrantModificationForBusinessAcquisition
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000439"
      unitRef="USD">696</QLGN:FairValueOfWarrantModificationForBusinessAcquisition>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000449"
      unitRef="Shares">-281</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000442"
      unitRef="USD">-505</QLGN:StockIssuedDuringPeriodValuesReverseStockSplits>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000445"
      unitRef="USD">-505</QLGN:StockIssuedDuringPeriodValuesReverseStockSplits>
    <QLGN:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000447"
      unitRef="USD">-505</QLGN:StockIssuedDuringPeriodValuesReverseStockSplits>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000454"
      unitRef="USD">-18640543</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000455"
      unitRef="USD">-18640543</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000456"
      unitRef="USD">-2394100</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000457"
      unitRef="USD">-21034643</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000467"
      unitRef="Shares">4210737</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000459"
      unitRef="USD">42110</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000460"
      unitRef="USD">110528050</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000461"
      unitRef="USD">50721</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000462"
      unitRef="USD">-103385172</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000463"
      unitRef="USD">7235709</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000464"
      unitRef="USD">1530881</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000465"
      unitRef="USD">8766590</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000477"
      unitRef="Shares">4210737</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000469"
      unitRef="USD">42110</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000470"
      unitRef="USD">110528050</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000471"
      unitRef="USD">50721</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000472"
      unitRef="USD">-103385172</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000473"
      unitRef="USD">7235709</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="0"
      id="Fact000474"
      unitRef="USD">1530881</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000475"
      unitRef="USD">8766590</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000482"
      unitRef="USD">-13760250</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000483"
      unitRef="USD">-21034643</us-gaap:ProfitLoss>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000485"
      unitRef="USD">-1285240</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000486"
      unitRef="USD">-7140181</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000488"
      unitRef="USD">-12475010</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000489"
      unitRef="USD">-13894462</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000494"
      unitRef="USD">4495</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000495"
      unitRef="USD">12165</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000497"
      unitRef="USD">1098533</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000498"
      unitRef="USD">4765276</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000500"
      unitRef="USD">-2035469</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">-906345</us-gaap:FairValueAdjustmentOfWarrants>
    <QLGN:LossOnVoluntaryConversionOfConvertibleDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000503"
      unitRef="USD">-1077287</QLGN:LossOnVoluntaryConversionOfConvertibleDebt>
    <QLGN:AccretionOfDiscountOnConvertibleDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000506"
      unitRef="USD">-1469640</QLGN:AccretionOfDiscountOnConvertibleDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000509"
      unitRef="USD">-625653</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000512"
      unitRef="USD">-21747</us-gaap:GainLossOnDispositionOfAssets1>
    <QLGN:FairValueOfWarrantModificationForProfessionalServices
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000515"
      unitRef="USD">7945</QLGN:FairValueOfWarrantModificationForProfessionalServices>
    <QLGN:FairValueOfWarrantModificationForProfessionalServices
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000516"
      unitRef="USD">67370</QLGN:FairValueOfWarrantModificationForProfessionalServices>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000521"
      unitRef="USD">264741</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000522"
      unitRef="USD">126985</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000524"
      unitRef="USD">1603422</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000525"
      unitRef="USD">-43440</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000527"
      unitRef="USD">-227101</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000528"
      unitRef="USD">-472441</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000530"
      unitRef="USD">-9093599</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000531"
      unitRef="USD">-10598862</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000533"
      unitRef="USD">-1210664</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000534"
      unitRef="USD">-2648679</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">-10304263</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000537"
      unitRef="USD">-13247541</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000542"
      unitRef="USD">4215943</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000543"
      unitRef="USD">-183763</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000545"
      unitRef="USD">4215943</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000546"
      unitRef="USD">-183763</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000552"
      unitRef="USD">7173</us-gaap:ProceedsFromWarrantExercises>
    <QLGN:ProceedsFromIssuanceOfConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000555"
      unitRef="USD">2903847</QLGN:ProceedsFromIssuanceOfConvertibleDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000557"
      unitRef="USD">550000</us-gaap:RepaymentsOfNotesPayable>
    <QLGN:FractionalSharePaymentsRelatedToReverseStockSplit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000561"
      unitRef="USD">505</QLGN:FractionalSharePaymentsRelatedToReverseStockSplit>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000563"
      unitRef="USD">-550000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000564"
      unitRef="USD">2910515</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000569"
      unitRef="USD">-550000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000570"
      unitRef="USD">2910515</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000572"
      unitRef="USD">-6638320</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000573"
      unitRef="USD">-10520789</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000576"
      unitRef="USD">22639</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000578"
      unitRef="USD">3165985</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000579"
      unitRef="USD">9174383</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000581"
      unitRef="USD">3874138</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000582"
      unitRef="USD">8363890</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000585"
      unitRef="USD">3874138</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000587"
      unitRef="USD">401803</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000588"
      unitRef="USD">3165985</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000596"
      unitRef="USD">5571</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000597"
      unitRef="USD">5571</us-gaap:IncomeTaxesPaidNet>
    <QLGN:TransfersOfInventoryFromEquipmentHeldForLease
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000602"
      unitRef="USD">83281</QLGN:TransfersOfInventoryFromEquipmentHeldForLease>
    <QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000606"
      unitRef="USD">858</QLGN:FairValueOfWarrantLiabilitiesOnDateOfExercise>
    <QLGN:RedemptionOfConvertibleDebtIntoCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000608"
      unitRef="USD">254316</QLGN:RedemptionOfConvertibleDebtIntoCommonStock>
    <QLGN:VoluntaryConversionOfConvertibleDebtIntoCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000611"
      unitRef="USD">1112582</QLGN:VoluntaryConversionOfConvertibleDebtIntoCommonStock>
    <QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000615"
      unitRef="USD">9439</QLGN:FairValueOfWarrantModificationsPursuantToSecuritiesPurchaseAgreeement>
    <QLGN:FairValueOfWarrantModificationsForBusinessAcquisition
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000618"
      unitRef="USD">33543</QLGN:FairValueOfWarrantModificationsForBusinessAcquisition>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000620">&lt;p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zOnsX2Pu4gA7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2014; &lt;span id="xdx_825_zet8NYo4nIGd"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--OrganizationPolicyTextBlock_zoELRG00RZqb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zEHGaHZAHxR7"&gt;Organization&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ritter
Pharmaceuticals, Inc. (the Company&#x2019;s predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the
name Ritter Natural Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals,
Inc. On May 22, 2020, upon completing a &#x201c;reverse recapitalization&#x201d; transaction with Qualigen, Inc., Ritter Pharmaceuticals,
Inc. was renamed Qualigen Therapeutics, Inc. (the &#x201c;Company&#x201d;). Qualisys Diagnostics, Inc. was formed as a Minnesota corporation
in 1996, reincorporated to become a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc.
was a wholly-owned subsidiary of the Company. On July 20, 2023, the Company sold all of the issued and outstanding shares of common stock
of Qualigen, Inc. to Chembio Diagnostics, Inc. (&#x201c;Chembio&#x201d;), a wholly-owned subsidiary of Biosynex, S.A. (&#x201c;Biosynex&#x201d;).
Following the consummation of this transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio (see Note 5 &#x2013; Discontinued
Operations).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 26, 2022, the Company acquired &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zAZ4kjiHJfug" title="Stock issued during period shares acquisitions"&gt;2,232,861&lt;/span&gt; shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (&#x201c;NanoSynex&#x201d;) from Alpha
Capital Anstalt (&#x201c;Alpha&#x201d;), a related party, in exchange for &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zm10E5bR0Vk9" title="Stock issued during period shares acquisitions"&gt;350,000&lt;/span&gt; reverse split adjusted shares of the Company&#x2019;s
common stock and a prefunded warrant to purchase &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zgOebxpv9q2h" title="Warrants to purchase common stock"&gt;331,464&lt;/span&gt; reverse split adjusted shares of the Company&#x2019;s common stock at an exercise
price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_znQiAcdJ9vQk" title="Warrants exercise price"&gt;0.001&lt;/span&gt; per share. &lt;span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20220524__20220526_zZLCTUTXqaVa" title="Reverse stock split"&gt;These warrants were subsequently exercised on September 13, 2022.&lt;/span&gt; Concurrently with this transaction, the
Company also entered into a Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022,
with NanoSynex (the &#x201c;NanoSynex Funding Agreement&#x201d;), to, among other things, provide for the further funding of NanoSynex,
and purchased &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBH1w32dlfCa" title="Stock issued during period shares acquisitions"&gt;381,786&lt;/span&gt; shares of Series B preferred stock from NanoSynex for a total purchase price of $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zP9BLEKsOO75" title="Stock issued during period, value, acquisitions"&gt;600,000&lt;/span&gt;. The transactions resulted
in the Company acquiring a &lt;span id="xdx_905_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zmyx8kufwR2e" title="Voting interests acquired"&gt;52.8&lt;/span&gt;% interest in NanoSynex (the &#x201c;NanoSynex Acquisition&#x201d;). NanoSynex is a nanotechnology diagnostics
company domiciled in Israel. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex (the &#x201c;NanoSynex
Amendment&#x201d;), which amended the NanoSynex Funding Agreement, to, among other things, eliminate most of the Company obligation for
the further funding of NanoSynex. Pursuant to the terms of the NanoSynex Amendment, the Company lost its controlling interest in NanoSynex
(see Note 5 -Discontinued Operations).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNRMCvRcDep" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zONvBnmWnJ7c"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#x201c;U.S. GAAP&#x201d;), Regulation S-X and rules and regulations of the Securities and Exchange Commission
(&#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zf9hM2AKGiw7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zzRYl9MVKxT2"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements include the accounts of the Company and its former wholly-owned and majority owned subsidiaries.
All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance
is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional
currency of the Company and its subsidiaries is the U.S. dollar. For NanoSynex, the functional currency was the local currency, New Israeli
Shekels (NIS). As such, assets and liabilities for NanoSynex were translated into U.S. dollars with the effects of foreign currency translation
adjustments reflected as a component of accumulated other comprehensive loss within the Company&#x2019;s consolidated statements of
changes in stockholders&#x2019; equity (deficit).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of July 20, 2023, NanoSynex was deconsolidated from these financial statements as the transactions contemplated by the NanoSynex Amendment
resulted in a loss of control of a subsidiary that constitutes a business under ASC 810. The retained investment in NanoSynex is accounted
for prospectively as an equity method investment. See Note 5 &#x2013; Discontinued Operations for further information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zjBN6sDUY1X" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z6285TUmPecj"&gt;Discontinued
Operations&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 20, 2023, the Company completed the sale of Qualigen, Inc. to Chembio Diagnostics, Inc. The sale of Qualigen Inc. constituted a
significant disposition and as such, the Company concluded that the disposition of ownership in Qualigen, Inc. represented a strategic
shift that had a major effect on its operations and financial results. Therefore, Qualigen, Inc. is classified as discontinued operations
for all periods presented herein.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 20, 2023, the Company entered into the NanoSynex Amendment, which amended the Master Funding Agreement
for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the &#x201c;NanoSynex
Funding Agreement&#x201d;), a former majority owned subsidiary of the Company, to, among other things, forfeit 281,000 Series B Preferred
Shares of NanoSynex held by the Company, resulting in the deconsolidation of NanoSynex. The disposition represents a strategic shift
that will have a material effect on the Company&#x2019;s operations and financial results. Accordingly, the business of NanoSynex is classified
as discontinued operations for all periods presented herein.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 5 - Discontinued Operations for further information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--EquityMethodInvestmentsPolicy_z0yVc3zgdCml" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zXqLYuXa0E2e"&gt;Equity
Method Investments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
deconsolidation of NanoSynex on July 20, 2023, the Company accounts for its retained investment under the equity method of accounting
as it retained the ability to exercise significant influence over the operating and financial policies of the investee. Under the equity
method, the Company recognizes its proportionate share earnings or losses each reporting period with an adjustment to the carrying value
of the investment. As of December 31, 2023, the carrying value of the retained investment was zero, and therefore the Company has suspended
application of the equity method as the Company is not liable for the obligations of the investee nor otherwise committed to provide
financial support. Future equity method earnings, if any, will not be recognized until the amount exceeds the unrecognized net losses
in prior periods. See Note 5 &#x2013; Discontinued Operations for further information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--UseOfEstimates_z4xRxysj5w3b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zxiaUaiQGjf3"&gt;Accounting
Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant
liabilities, and stock-based compensation. Actual results could vary from the estimates that were used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--ReverseStockSplitPolicyTextBlock_zPyRls5G3Qw8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z8rDi0S5KRI1"&gt;Reverse
Stock Split&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 23, 2022, the Company effected a 1-for-10 reverse stock split of its outstanding shares of common stock (the &#x201c;Reverse
Stock Split&#x201d;). The Reverse Stock Split reduced the Company&#x2019;s shares of outstanding common stock, stock options, and warrants
to purchase shares of common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse Stock Split
were rounded down to the nearest whole share and cash in lieu of fractional shares was paid to stockholders. All share and per share
data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively
to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zptILlwsNoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zj906zf4TUrh"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains the majority of its cash in government money market mutual funds and in accounts at banking institutions in the U.S.
that are of high quality. Cash held in these accounts often exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits.
If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations.
In March 2023, Silicon Valley Bank and Signature Bank, and more recently in May 2023, First Republic Bank, were closed due to liquidity
concerns and taken over by the FDIC. While the Company did not have an account at any of these banks, in the event of failure of any
of the financial institutions where the Company maintains its cash and cash equivalents, there can be no assurance that the Company would
be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely
affect the Company&#x2019;s business and financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zES8EVAkVpFc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zzGtVIkWEHvd"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the years ended December 31, 2023 and 2022, &lt;span id="xdx_908_eus-gaap--AssetImpairmentCharges_do_c20230101__20231231_zGFJtvprpUYc" title="Impairment losses on construction-in-progress"&gt;&lt;span id="xdx_90E_eus-gaap--AssetImpairmentCharges_do_c20220101__20221231_zqrYIsRX9XLe" title="Impairment losses on construction-in-progress"&gt;no&lt;/span&gt;&lt;/span&gt; such impairment
losses have been recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zFy6sd4R3J5d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_z83nPQFph3kk"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company
has viewed its operations and managed its business as one segment operating primarily within the United States (and in Israel prior to
the NanoSynex deconsolidation).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zyju2okuavG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zVTC3o3ff6sc"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Except
for acquired in process research and development (IPR&amp;amp;D), the Company expenses research and development costs as incurred including
therapeutics license costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--PatentCostsPolicyTextBlock_zdZxPitk3Mlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zjug10Hktfve"&gt;Patent
Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated
statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--BusinessCombinationsPolicy_z8WGLPtyAmeg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zsBOFrfYlQH3"&gt;Business
Combinations&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for business combinations using the acquisition method pursuant to Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;)
ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company&#x2019;s
financial results beginning on the respective acquisition date, and that assets acquired and liabilities assumed are recognized at fair
value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted
cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of
capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value of
the intangible asset. Any excess of the fair value of consideration transferred (the &#x201c;purchase price&#x201d;) over the fair values
of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may
be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition
date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zOLyA9Skf2T" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zaNulaXka052"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired,
when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized but is reviewed
for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.
In testing for impairment, the fair value of the reporting unit is compared to the carrying value. If the net assets assigned to the
reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the difference is recorded. As a result of the
annual goodwill impairment analysis, the Company recognized a $&lt;span id="xdx_905_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zn8hkA3dRh52" title="Goodwill impairment charges"&gt;4,239,000&lt;/span&gt; non-cash goodwill and fixed asset impairment charge in the valuation
of its business acquisition of NanoSynex for the year ended December 30, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_zpO2iZ5rIuMh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zUTkdHfTIgE7"&gt;Derivative
Financial Instruments and Warrant Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument,
the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception
and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as
liabilities or as equity, is re-assessed at the end of each reporting period (See Note 7-Warrant Liabilities and Note 8- Convertible
Debt - Related Party).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zl9QOmVDa5hl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zQXgBNLNIxY7"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability
    to access at the measurement date;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-align: justify; text-indent: -24.5pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs
    in markets that are not considered to be active; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 - Inputs that are unobservable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-align: justify; text-indent: -24.5pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zcOOuCmQgig9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zElovFA8AgRk"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash,
accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates
fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zw3foD3WaGE1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zTi9ooXhuPug"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss consists of net income and foreign currency translation adjustments related to the discontinued operations of NanoSynex. Comprehensive
gains (losses) have been reflected in the statements of operations and comprehensive loss and as a separate component in the statements
of stockholders&#x2019; equity (deficit) for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z9jJfqsCkC8g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zlDItihaHpx6"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company&#x2019;s
stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zm8AiE3fJ4p2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zsEuTaq4sI06"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years. For more information, refer to Note 14 - Income Taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued Accounting Standards Update 2023-09, Improvements to Income Tax Disclosures, which requires more detailed
income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation
as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis,
with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early
adoption permitted. The Company is evaluating the disclosure requirements related to the new standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z1ONaR6BlLXl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zq5GXQbmj1Ka"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
functional currency for the Company is the U.S. dollar. The functional currency for the discontinued operations of NanoSynex was the
New Israeli Shekel (NIS). The financial statements of NanoSynex were translated into U.S. dollars using exchange rates in effect at each
period end for assets and liabilities; using exchange rates in effect during the period for results of operations; and using historical
exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of NanoSynex was reflected
as a separate component of other comprehensive income (loss) (see Note 5 - Discontinued Operations).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8LlnmXoZKt1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zpa55FKXxkR3"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected
to have a significant impact to the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--GlobalEconomicConditionsPolicyTextBlock_zRY1aEAurJui" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zgjKyfRNhO2a"&gt;Global
Economic Conditions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Ongoing
Wars in Ukraine and Israel&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor
any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the
conflict on the Company&#x2019;s business and financial results remains uncertain and will depend on the severity and duration of the
conflict and its impact on regional and global economic conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2023, Hamas conducted terrorist attacks in Israel resulting in ongoing war. There continue to be hostilities between Israel and
Hezbollah in Lebanon and Hamas in the Gaza Strip, both of which have resulted in rockets being fired into Israel, causing casualties
and disruption of economic activities. In early 2023, there were a number of changes proposed to the political system in Israel by the
current government which, if implemented as planned, could lead to large-scale protests and additional uncertainty, negatively impacting
the operating environment in Israel. Popular uprisings in various countries in the Middle East over the last few years have also affected
the political stability of those countries and have led to a decline in the regional security situation. Such instability may also lead
to deterioration in the political and trade relationships that exist between Israel and these countries. Any armed conflicts, terrorist
activities or political instability involving Israel or other countries in the region could adversely affect the Company&#x2019;s minority
interest in NanoSynex, its results of operations, financial condition, cash flows and prospects (see Note 5 &#x2013; Discontinued Operations).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inflation
and Global Economic Conditions&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary
pressures attributable to government stimulus and recovery programs, government deficit spending and supply chain issues. The Company
cannot provide assurance that it will be successful in fully offsetting increased costs resulting from inflationary pressure. In addition,
the global economy suffers from slowing growth and rising interest rates, and some economists believe that there may be a global recession
in the near future. If the global economy slows, the Company&#x2019;s business may be adversely affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--ImpactOfCovid19PandemicPolicyTextBlock_zO8s7ZYnbAN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zNp25EDTxFY1"&gt;Impact
of COVID-19 Pandemic&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company&#x2019;s business as well. During the height of
the pandemic, sales of diagnostic products decreased significantly and the Company&#x2019;s net loss increased significantly, as clinics
and small hospitals&#x2019; demand for Qualigen, Inc.&#x2019;s FastPack&#x2122; diagnostic test kits was reduced sharply, largely due to
deferral of patients&#x2019; non-emergency visits to physician offices. In July 2023 the Company sold Qualigen, Inc., its wholly-owned
subsidiary, to Chembio (see Note 5 - Discontinued Operations).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#x2019;s
consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85D_z5DxZVh5ii58" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <QLGN:OrganizationPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000622">&lt;p id="xdx_84C_ecustom--OrganizationPolicyTextBlock_zoELRG00RZqb" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zEHGaHZAHxR7"&gt;Organization&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ritter
Pharmaceuticals, Inc. (the Company&#x2019;s predecessor) was formed as a Nevada limited liability company on March 29, 2004 under the
name Ritter Natural Sciences, LLC. In September 2008, this company converted into a Delaware corporation under the name Ritter Pharmaceuticals,
Inc. On May 22, 2020, upon completing a &#x201c;reverse recapitalization&#x201d; transaction with Qualigen, Inc., Ritter Pharmaceuticals,
Inc. was renamed Qualigen Therapeutics, Inc. (the &#x201c;Company&#x201d;). Qualisys Diagnostics, Inc. was formed as a Minnesota corporation
in 1996, reincorporated to become a Delaware corporation in 1999, and then changed its name to Qualigen, Inc. in 2000. Qualigen, Inc.
was a wholly-owned subsidiary of the Company. On July 20, 2023, the Company sold all of the issued and outstanding shares of common stock
of Qualigen, Inc. to Chembio Diagnostics, Inc. (&#x201c;Chembio&#x201d;), a wholly-owned subsidiary of Biosynex, S.A. (&#x201c;Biosynex&#x201d;).
Following the consummation of this transaction, Qualigen, Inc. became a wholly-owned subsidiary of Chembio (see Note 5 &#x2013; Discontinued
Operations).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 26, 2022, the Company acquired &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zAZ4kjiHJfug" title="Stock issued during period shares acquisitions"&gt;2,232,861&lt;/span&gt; shares of Series A-1 Preferred Stock of NanoSynex, Ltd. (&#x201c;NanoSynex&#x201d;) from Alpha
Capital Anstalt (&#x201c;Alpha&#x201d;), a related party, in exchange for &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zm10E5bR0Vk9" title="Stock issued during period shares acquisitions"&gt;350,000&lt;/span&gt; reverse split adjusted shares of the Company&#x2019;s
common stock and a prefunded warrant to purchase &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zgOebxpv9q2h" title="Warrants to purchase common stock"&gt;331,464&lt;/span&gt; reverse split adjusted shares of the Company&#x2019;s common stock at an exercise
price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_znQiAcdJ9vQk" title="Warrants exercise price"&gt;0.001&lt;/span&gt; per share. &lt;span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20220524__20220526_zZLCTUTXqaVa" title="Reverse stock split"&gt;These warrants were subsequently exercised on September 13, 2022.&lt;/span&gt; Concurrently with this transaction, the
Company also entered into a Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022,
with NanoSynex (the &#x201c;NanoSynex Funding Agreement&#x201d;), to, among other things, provide for the further funding of NanoSynex,
and purchased &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220524__20220526__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBH1w32dlfCa" title="Stock issued during period shares acquisitions"&gt;381,786&lt;/span&gt; shares of Series B preferred stock from NanoSynex for a total purchase price of $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_pp0p0_c20220524__20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zP9BLEKsOO75" title="Stock issued during period, value, acquisitions"&gt;600,000&lt;/span&gt;. The transactions resulted
in the Company acquiring a &lt;span id="xdx_905_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zmyx8kufwR2e" title="Voting interests acquired"&gt;52.8&lt;/span&gt;% interest in NanoSynex (the &#x201c;NanoSynex Acquisition&#x201d;). NanoSynex is a nanotechnology diagnostics
company domiciled in Israel. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex (the &#x201c;NanoSynex
Amendment&#x201d;), which amended the NanoSynex Funding Agreement, to, among other things, eliminate most of the Company obligation for
the further funding of NanoSynex. Pursuant to the terms of the NanoSynex Amendment, the Company lost its controlling interest in NanoSynex
(see Note 5 -Discontinued Operations).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:OrganizationPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact000624"
      unitRef="Shares">2232861</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember"
      decimals="INF"
      id="Fact000626"
      unitRef="Shares">350000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-05-26_custom_PrefundedWarrantMember"
      decimals="INF"
      id="Fact000628"
      unitRef="Shares">331464</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_custom_PrefundedWarrantMember"
      decimals="INF"
      id="Fact000630"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2022-05-242022-05-26" id="Fact000632">These warrants were subsequently exercised on September 13, 2022.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-05-242022-05-26_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000634"
      unitRef="Shares">381786</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2022-05-242022-05-26_custom_NanoSynexLtdMember_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact000636"
      unitRef="USD">600000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="AsOf2022-05-26_custom_NanoSynexLtdMember"
      decimals="INF"
      id="Fact000638"
      unitRef="Pure">0.528</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000640">&lt;p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNRMCvRcDep" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zONvBnmWnJ7c"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted
in the United States of America (&#x201c;U.S. GAAP&#x201d;), Regulation S-X and rules and regulations of the Securities and Exchange Commission
(&#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000642">&lt;p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_zf9hM2AKGiw7" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zzRYl9MVKxT2"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements include the accounts of the Company and its former wholly-owned and majority owned subsidiaries.
All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance
is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional
currency of the Company and its subsidiaries is the U.S. dollar. For NanoSynex, the functional currency was the local currency, New Israeli
Shekels (NIS). As such, assets and liabilities for NanoSynex were translated into U.S. dollars with the effects of foreign currency translation
adjustments reflected as a component of accumulated other comprehensive loss within the Company&#x2019;s consolidated statements of
changes in stockholders&#x2019; equity (deficit).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of July 20, 2023, NanoSynex was deconsolidated from these financial statements as the transactions contemplated by the NanoSynex Amendment
resulted in a loss of control of a subsidiary that constitutes a business under ASC 810. The retained investment in NanoSynex is accounted
for prospectively as an equity method investment. See Note 5 &#x2013; Discontinued Operations for further information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000644">&lt;p id="xdx_84F_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zjBN6sDUY1X" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z6285TUmPecj"&gt;Discontinued
Operations&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 20, 2023, the Company completed the sale of Qualigen, Inc. to Chembio Diagnostics, Inc. The sale of Qualigen Inc. constituted a
significant disposition and as such, the Company concluded that the disposition of ownership in Qualigen, Inc. represented a strategic
shift that had a major effect on its operations and financial results. Therefore, Qualigen, Inc. is classified as discontinued operations
for all periods presented herein.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 20, 2023, the Company entered into the NanoSynex Amendment, which amended the Master Funding Agreement
for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the &#x201c;NanoSynex
Funding Agreement&#x201d;), a former majority owned subsidiary of the Company, to, among other things, forfeit 281,000 Series B Preferred
Shares of NanoSynex held by the Company, resulting in the deconsolidation of NanoSynex. The disposition represents a strategic shift
that will have a material effect on the Company&#x2019;s operations and financial results. Accordingly, the business of NanoSynex is classified
as discontinued operations for all periods presented herein.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 5 - Discontinued Operations for further information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000646">&lt;p id="xdx_846_eus-gaap--EquityMethodInvestmentsPolicy_z0yVc3zgdCml" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zXqLYuXa0E2e"&gt;Equity
Method Investments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
deconsolidation of NanoSynex on July 20, 2023, the Company accounts for its retained investment under the equity method of accounting
as it retained the ability to exercise significant influence over the operating and financial policies of the investee. Under the equity
method, the Company recognizes its proportionate share earnings or losses each reporting period with an adjustment to the carrying value
of the investment. As of December 31, 2023, the carrying value of the retained investment was zero, and therefore the Company has suspended
application of the equity method as the Company is not liable for the obligations of the investee nor otherwise committed to provide
financial support. Future equity method earnings, if any, will not be recognized until the amount exceeds the unrecognized net losses
in prior periods. See Note 5 &#x2013; Discontinued Operations for further information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-12-31" id="Fact000648">&lt;p id="xdx_846_eus-gaap--UseOfEstimates_z4xRxysj5w3b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zxiaUaiQGjf3"&gt;Accounting
Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
uses estimates and assumptions in preparing its consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues
and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant
liabilities, and stock-based compensation. Actual results could vary from the estimates that were used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <QLGN:ReverseStockSplitPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000650">&lt;p id="xdx_844_ecustom--ReverseStockSplitPolicyTextBlock_zPyRls5G3Qw8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_z8rDi0S5KRI1"&gt;Reverse
Stock Split&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 23, 2022, the Company effected a 1-for-10 reverse stock split of its outstanding shares of common stock (the &#x201c;Reverse
Stock Split&#x201d;). The Reverse Stock Split reduced the Company&#x2019;s shares of outstanding common stock, stock options, and warrants
to purchase shares of common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse Stock Split
were rounded down to the nearest whole share and cash in lieu of fractional shares was paid to stockholders. All share and per share
data for all periods presented in the accompanying financial statements and the related disclosures have been adjusted retrospectively
to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:ReverseStockSplitPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000652">&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zptILlwsNoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zj906zf4TUrh"&gt;Cash&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains the majority of its cash in government money market mutual funds and in accounts at banking institutions in the U.S.
that are of high quality. Cash held in these accounts often exceed the Federal Deposit Insurance Corporation (FDIC) insurance limits.
If such banking institutions were to fail, the Company could lose all or a portion of amounts held in excess of such insurance limitations.
In March 2023, Silicon Valley Bank and Signature Bank, and more recently in May 2023, First Republic Bank, were closed due to liquidity
concerns and taken over by the FDIC. While the Company did not have an account at any of these banks, in the event of failure of any
of the financial institutions where the Company maintains its cash and cash equivalents, there can be no assurance that the Company would
be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely
affect the Company&#x2019;s business and financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000654">&lt;p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zES8EVAkVpFc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zzGtVIkWEHvd"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the years ended December 31, 2023 and 2022, &lt;span id="xdx_908_eus-gaap--AssetImpairmentCharges_do_c20230101__20231231_zGFJtvprpUYc" title="Impairment losses on construction-in-progress"&gt;&lt;span id="xdx_90E_eus-gaap--AssetImpairmentCharges_do_c20220101__20221231_zqrYIsRX9XLe" title="Impairment losses on construction-in-progress"&gt;no&lt;/span&gt;&lt;/span&gt; such impairment
losses have been recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000656"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000658"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000660">&lt;p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zFy6sd4R3J5d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_z83nPQFph3kk"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company
has viewed its operations and managed its business as one segment operating primarily within the United States (and in Israel prior to
the NanoSynex deconsolidation).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-12-31" id="Fact000662">&lt;p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zyju2okuavG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zVTC3o3ff6sc"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Except
for acquired in process research and development (IPR&amp;amp;D), the Company expenses research and development costs as incurred including
therapeutics license costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <QLGN:PatentCostsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000664">&lt;p id="xdx_840_ecustom--PatentCostsPolicyTextBlock_zdZxPitk3Mlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zjug10Hktfve"&gt;Patent
Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated
statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:PatentCostsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000666">&lt;p id="xdx_841_eus-gaap--BusinessCombinationsPolicy_z8WGLPtyAmeg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zsBOFrfYlQH3"&gt;Business
Combinations&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for business combinations using the acquisition method pursuant to Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;)
ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company&#x2019;s
financial results beginning on the respective acquisition date, and that assets acquired and liabilities assumed are recognized at fair
value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted
cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of
capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value of
the intangible asset. Any excess of the fair value of consideration transferred (the &#x201c;purchase price&#x201d;) over the fair values
of the net assets acquired is recognized as goodwill. The fair value of assets acquired and liabilities assumed in certain cases may
be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition
date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000668">&lt;p id="xdx_847_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zOLyA9Skf2T" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zaNulaXka052"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired,
when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized but is reviewed
for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.
In testing for impairment, the fair value of the reporting unit is compared to the carrying value. If the net assets assigned to the
reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the difference is recorded. As a result of the
annual goodwill impairment analysis, the Company recognized a $&lt;span id="xdx_905_eus-gaap--GoodwillImpairmentLoss_c20220101__20221231_zn8hkA3dRh52" title="Goodwill impairment charges"&gt;4,239,000&lt;/span&gt; non-cash goodwill and fixed asset impairment charge in the valuation
of its business acquisition of NanoSynex for the year ended December 30, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000670"
      unitRef="USD">4239000</us-gaap:GoodwillImpairmentLoss>
    <QLGN:DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000672">&lt;p id="xdx_841_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock_zpO2iZ5rIuMh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zUTkdHfTIgE7"&gt;Derivative
Financial Instruments and Warrant Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the consolidated statements of operations and comprehensive loss. Depending on the features of the derivative financial instrument,
the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception
and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as
liabilities or as equity, is re-assessed at the end of each reporting period (See Note 7-Warrant Liabilities and Note 8- Convertible
Debt - Related Party).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000674">&lt;p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zl9QOmVDa5hl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zQXgBNLNIxY7"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability
    to access at the measurement date;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-align: justify; text-indent: -24.5pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs
    in markets that are not considered to be active; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 - Inputs that are unobservable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 48.95pt; text-align: justify; text-indent: -24.5pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000676">&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zcOOuCmQgig9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zElovFA8AgRk"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash,
accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates
fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000678">&lt;p id="xdx_841_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zw3foD3WaGE1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zTi9ooXhuPug"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss consists of net income and foreign currency translation adjustments related to the discontinued operations of NanoSynex. Comprehensive
gains (losses) have been reflected in the statements of operations and comprehensive loss and as a separate component in the statements
of stockholders&#x2019; equity (deficit) for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000680">&lt;p id="xdx_842_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z9jJfqsCkC8g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zlDItihaHpx6"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company&#x2019;s
stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000682">&lt;p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zm8AiE3fJ4p2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zsEuTaq4sI06"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years. For more information, refer to Note 14 - Income Taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued Accounting Standards Update 2023-09, Improvements to Income Tax Disclosures, which requires more detailed
income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation
as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis,
with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early
adoption permitted. The Company is evaluating the disclosure requirements related to the new standard.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000684">&lt;p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z1ONaR6BlLXl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zq5GXQbmj1Ka"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
functional currency for the Company is the U.S. dollar. The functional currency for the discontinued operations of NanoSynex was the
New Israeli Shekel (NIS). The financial statements of NanoSynex were translated into U.S. dollars using exchange rates in effect at each
period end for assets and liabilities; using exchange rates in effect during the period for results of operations; and using historical
exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of NanoSynex was reflected
as a separate component of other comprehensive income (loss) (see Note 5 - Discontinued Operations).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000686">&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8LlnmXoZKt1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zpa55FKXxkR3"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected
to have a significant impact to the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <QLGN:GlobalEconomicConditionsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000688">&lt;p id="xdx_84A_ecustom--GlobalEconomicConditionsPolicyTextBlock_zRY1aEAurJui" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zgjKyfRNhO2a"&gt;Global
Economic Conditions&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Ongoing
Wars in Ukraine and Israel&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor
any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the
conflict on the Company&#x2019;s business and financial results remains uncertain and will depend on the severity and duration of the
conflict and its impact on regional and global economic conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2023, Hamas conducted terrorist attacks in Israel resulting in ongoing war. There continue to be hostilities between Israel and
Hezbollah in Lebanon and Hamas in the Gaza Strip, both of which have resulted in rockets being fired into Israel, causing casualties
and disruption of economic activities. In early 2023, there were a number of changes proposed to the political system in Israel by the
current government which, if implemented as planned, could lead to large-scale protests and additional uncertainty, negatively impacting
the operating environment in Israel. Popular uprisings in various countries in the Middle East over the last few years have also affected
the political stability of those countries and have led to a decline in the regional security situation. Such instability may also lead
to deterioration in the political and trade relationships that exist between Israel and these countries. Any armed conflicts, terrorist
activities or political instability involving Israel or other countries in the region could adversely affect the Company&#x2019;s minority
interest in NanoSynex, its results of operations, financial condition, cash flows and prospects (see Note 5 &#x2013; Discontinued Operations).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inflation
and Global Economic Conditions&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary
pressures attributable to government stimulus and recovery programs, government deficit spending and supply chain issues. The Company
cannot provide assurance that it will be successful in fully offsetting increased costs resulting from inflationary pressure. In addition,
the global economy suffers from slowing growth and rising interest rates, and some economists believe that there may be a global recession
in the near future. If the global economy slows, the Company&#x2019;s business may be adversely affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:GlobalEconomicConditionsPolicyTextBlock>
    <QLGN:ImpactOfCovid19PandemicPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000690">&lt;p id="xdx_845_ecustom--ImpactOfCovid19PandemicPolicyTextBlock_zO8s7ZYnbAN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zNp25EDTxFY1"&gt;Impact
of COVID-19 Pandemic&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company&#x2019;s business as well. During the height of
the pandemic, sales of diagnostic products decreased significantly and the Company&#x2019;s net loss increased significantly, as clinics
and small hospitals&#x2019; demand for Qualigen, Inc.&#x2019;s FastPack&#x2122; diagnostic test kits was reduced sharply, largely due to
deferral of patients&#x2019; non-emergency visits to physician offices. In July 2023 the Company sold Qualigen, Inc., its wholly-owned
subsidiary, to Chembio (see Note 5 - Discontinued Operations).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#x2019;s
consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

</QLGN:ImpactOfCovid19PandemicPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000692">&lt;p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zMMAGQLjfmwl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 &#x2014; &lt;span&gt;&lt;span id="xdx_82B_zwlfTzVoH959"&gt;LIQUIDITY AND GOING CONCERN&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December&#160;31, 2023, the Company had approximately $&lt;span id="xdx_909_eus-gaap--Cash_iI_pn5n6_c20231231_zpZpvhGTITN7"&gt;0.4&lt;/span&gt;&lt;/span&gt;
&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million in cash and an accumulated deficit of $&lt;span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20231231_zvkb6ozWL58j"&gt;116.8
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million. For the years ended December&#160;31,
2023 and 2022, the Company used cash of $&lt;span id="xdx_90F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20231231_zw5hB5OETJle"&gt;10.3&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and $&lt;span id="xdx_90F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20221231_zA6QNfYcaBV9"&gt;13.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, respectively, in operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s cash balances as of the date that these financial statements were issued along with the proceeds from the above sale
to Chembio, without additional financing, are expected to fund operations only into the second quarter of 2024. The Company expects to
continue to have net losses and negative cash flow from operations, which will challenge its liquidity. These factors raise substantial
doubt about the Company&#x2019;s ability to continue as a going concern for the one-year period following the date that these financial
statements were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
is no assurance that profitable operations will ever be achieved, or, if achieved, could be sustained on a continuing basis. In order
to fully execute its business plan, the Company will require significant additional financing for planned research and development activities,
capital expenditures, clinical testing for QN-302 and preclinical development of Pan-RAS, as well as commercialization activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historically,
the Company&#x2019;s principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds from
the issuance of debt. In December 2022 the Company raised $&lt;span id="xdx_900_eus-gaap--ProceedsFromConvertibleDebt_pn5n6_c20221201__20221231_z4aqTijq0Q68"&gt;3.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million from the sale of an 8% Senior Convertible
Debenture (the &#x201c;Debenture&#x201d;) to  Alpha (see Note 8 - Convertible Debt - Related Party). There can be no assurance that further
financing can be obtained on favorable terms, or at all. If the Company is unable to obtain funding, the Company could be required to
delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which
could adversely affect the Company&#x2019;s business prospects.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements
do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be
required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ
from those reflected in the accompanying financial statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000693"
      unitRef="USD">400000</us-gaap:Cash>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact000694"
      unitRef="USD">-116800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="-5"
      id="Fact000695"
      unitRef="USD">-10300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="-5"
      id="Fact000696"
      unitRef="USD">-13200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-12-012022-12-31"
      decimals="-5"
      id="Fact000697"
      unitRef="USD">3000000.0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000699">&lt;p id="xdx_800_eus-gaap--OtherAssetsDisclosureTextBlock_zARgnBgCCkp3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2014; &lt;span&gt;&lt;span id="xdx_82F_zyOZAHr3dore"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zFL6RiaYR2Ij" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets consisted of the following at December 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B3_zaBxxvAYKOaj"&gt;SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_zyipDHfi1Ki6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zz8Puu6B85T1" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzdSM_zDgnhzRorW98" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;566,011&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,329,034&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzdSM_zkttQ2OFjpO5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ReceivableInvestmentSale_iI_pp0p0_maPEAOAzdSM_zxVQHhn3sGF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Receivable from sale of Qualigen, Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0709"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PreapaidResearchAndDevelopmentExpenses_iI_pp0p0_maPEAOAzdSM_zlWYao4idRH2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Prepaid research and development expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;173,900&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0713"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzdSM_zXh1u3ZJH5Y8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses and
    other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;764,964&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,366,704&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_z6jr4cMUTI11" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses attributable to Qualigen, Inc. and NanoSynex were deemed disposed of as discontinued operations (see Note 5 - Discontinued Operations).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000701">&lt;p id="xdx_89C_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zFL6RiaYR2Ij" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses and other current assets consisted of the following at December 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B3_zaBxxvAYKOaj"&gt;SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_zyipDHfi1Ki6" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zz8Puu6B85T1" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzdSM_zDgnhzRorW98" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;566,011&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,329,034&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzdSM_zkttQ2OFjpO5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,670&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ReceivableInvestmentSale_iI_pp0p0_maPEAOAzdSM_zxVQHhn3sGF6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Receivable from sale of Qualigen, Inc.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0709"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PreapaidResearchAndDevelopmentExpenses_iI_pp0p0_maPEAOAzdSM_zlWYao4idRH2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Prepaid research and development expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;173,900&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0713"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzdSM_zXh1u3ZJH5Y8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses and
    other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;764,964&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,366,704&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000703"
      unitRef="USD">566011</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000704"
      unitRef="USD">1329034</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000706"
      unitRef="USD">25053</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000707"
      unitRef="USD">37670</us-gaap:OtherPrepaidExpenseCurrent>
    <QLGN:PreapaidResearchAndDevelopmentExpenses
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000712"
      unitRef="USD">173900</QLGN:PreapaidResearchAndDevelopmentExpenses>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000715"
      unitRef="USD">764964</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000716"
      unitRef="USD">1366704</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000718">&lt;p id="xdx_809_eus-gaap--InvestmentsAndOtherNoncurrentAssetsTextBlock_zug4PAji38r6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2014; &lt;span id="xdx_82A_zcYjvQ5vXOzg"&gt;OTHER NON-CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfOtherAssetsNoncurrentTextBlock_zMaDE9peYpFc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
non-current assets consisted of the following at December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8BF_z89w6uHf1Bx7" style="display: none"&gt;SCHEDULE
OF OTHER NON CURRENT ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zaZrvYydfiJd" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EscrowDeposit_iI_maOAzAWm_zzszp4MmBlLa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Funds held in escrow&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;450,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LongtermResearchAndDevelopmentDeposits_iI_maOAzAWm_zi3qvIX2HLSi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Long-term research and development deposits&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;416,481&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAssets_iI_mtOAzAWm_zgiA0JZTUTSk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;866,481&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_za5c34Gu05ef" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000720">&lt;p id="xdx_891_eus-gaap--ScheduleOfOtherAssetsNoncurrentTextBlock_zMaDE9peYpFc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
non-current assets consisted of the following at December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8BF_z89w6uHf1Bx7" style="display: none"&gt;SCHEDULE
OF OTHER NON CURRENT ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zaZrvYydfiJd" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--EscrowDeposit_iI_maOAzAWm_zzszp4MmBlLa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Funds held in escrow&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;450,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LongtermResearchAndDevelopmentDeposits_iI_maOAzAWm_zi3qvIX2HLSi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Long-term research and development deposits&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;416,481&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAssets_iI_mtOAzAWm_zgiA0JZTUTSk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;866,481&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000722"
      unitRef="USD">450000</us-gaap:EscrowDeposit>
    <QLGN:LongtermResearchAndDevelopmentDeposits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000724"
      unitRef="USD">416481</QLGN:LongtermResearchAndDevelopmentDeposits>
    <us-gaap:OtherAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000726"
      unitRef="USD">866481</us-gaap:OtherAssets>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000728">&lt;p id="xdx_804_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zGj9beVj43T" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2014; &lt;span id="xdx_82C_zn99i7KT0Hc2"&gt;DISCONTINUED OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p id="xdx_89D_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_z5Dt0YsaFggi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
summary of assets and liabilities classified in discontinued operations as of December 31, 2022 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BE_zM2GFwfBcb99" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zodx01DSNDs4" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Qualigen, Inc.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zkWbORC60jCl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_z50z0zVBbJah" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzI2M_maTAODOzy7K_zXkOI4AdQZJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 46%; text-align: left"&gt;Current assets of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;4,448,999&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;1,838,850&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;6,287,849&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_i01I_maCzo3N_maTAODOzy7K_z4TkzckFeGD8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Non-current assets of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,876,270&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,360,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,236,711&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--TotalAssetsOfDiscontinuedOperations_iI_zaOJz7puWoR" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total assets of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,325,269&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,199,291&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,524,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzCJ5_maTLOOzkOU_zEbnWh5YAST6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities of discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,299,948&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,141,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,441,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_i02I_maCzIDe_maTLOOzkOU_zwwt8URcENPa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Non-current liabilities of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,350,975&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;357,757&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,708,732&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--TotalLiabilitiesOfdiscontinuedOperations_iI_zCPvA2wOO6bh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,650,923&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,499,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,149,930&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
summary of gain (loss) from discontinued operations, net of tax, as of December 31, 2023 and 2022 are as follows:&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zgyRHLYRdNHk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zYirOfUwnfHi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231_zZOHikC3k2A7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_z7KOK0KzexEg" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zriQLS8NBlK6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zBmCU5FMeNv5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Qualigen, Inc.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Qualigen, Inc.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_maCzBjD_zXK0Entbw48b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: left"&gt;(Loss) from discontinued operations&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(171,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(511,307&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(683,008&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(2,142,763&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(4,997,418&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(7,140,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_iN_di_msCzBjD_zEyxLvK7bhpl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Gain (loss) on disposal of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,876,778&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,479,010&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(602,232&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0766"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0767"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_mtCzBjD_maCzhiC_zjo8O9g2rzk2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total gain (loss) from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,705,077&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,990,317&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,285,240&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,142,763&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,997,418&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(7,140,181&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_zHZhx5d7gqAe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Sale
of Qualigen, Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 20, 2023, the Company completed the sale of Qualigen, Inc., its formerly wholly-owned subsidiary, to Chembio Diagnostics, Inc.
for net cash consideration of $&lt;span id="xdx_909_eus-gaap--Cash_iI_pn5n6_c20230720__dei--LegalEntityAxis__custom--ChembioDiagnosticsMember_zvbvfYJRY5d7" title="Cash"&gt;5.4&lt;/span&gt; million, of which $&lt;span id="xdx_90A_ecustom--PurchasePrice_iI_pn5n6_c20230720_zQ1JqRdHxet8" title="Purchase price"&gt;4.9&lt;/span&gt; million was received during the year ended December 31, 2023, and $&lt;span id="xdx_906_eus-gaap--EscrowDeposit_iI_c20230720_z6ScgJ9i1cO6" title="Escrow deposit"&gt;450,000&lt;/span&gt;
is being held in escrow until January 20, 2025 to satisfy certain Company indemnification obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zRICwWBIIOpg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
assets and liabilities classified in discontinued operations for Qualigen, Inc. as of December 31, 2022 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span id="xdx_8BB_z8eP3ft272Ub" style="display: none"&gt;ASSETS
AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zOY75KWN9c0f" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_zGKYfYaxTuP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,246,482&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_zHdqUvOvAWj4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;512,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_iI_zHtJnaXnk68d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Inventory, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,586,297&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_zUgM1ml5g8S6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;104,132&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zIEHIrtrpUWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total current assets of discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,448,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets_iI_zHU6IGWDB8Y3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,422,538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_iI_zKbRdheWsea" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;289,696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_iI_zIDSZ58seAhc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Intangible assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145,702&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_iI_zMkyyWT4oEha" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,334&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_iI_zjRDEs67Ztx3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Total non-current assets of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,876,270&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--TotalAssetsOfDiscontinuedOperations_zEMDVnMkIPPd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;Total assets of discontinued operations of Qualigen, Inc.&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;6,325,269&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_zHmjfZc3mAO" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;236,470&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedVacation_iI_zFUrYTtBMubd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_iI_z9mMXvu4yod" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;518,766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_iI_zCPQARiRXiq9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred revenue, current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_iI_z4V9woU1rXdh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Operating lease liability, current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;240,645&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_z3PO2u2XYjzb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Total current liabilities of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,299,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_iI_zQQ6Ddu84EN4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liability, net of current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,301,919&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_iI_zonhoHs0imS" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Deferred revenue, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49,056&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_iI_zhBTeigkBoW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Total non-current liabilities of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,350,975&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--TotalLiabilitiesOfdiscontinuedOperations_zPfVDec32Sy2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;Total liabilities of discontinued operations of Qualigen, Inc.&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;2,650,923&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reclassified the following statement of operations items to discontinued operations for the years ended December 31, 2023 and
2022, respectively:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zHVOVMBBvRg2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zZgIAXsbIcn3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Years Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;REVENUES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedOperationNetProductSales_z80f30iqchab" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; width: 60%; text-align: left"&gt;Net product sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;3,661,121&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;4,983,556&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_z5vtcVatxqJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Total revenues&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,661,121&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,983,556&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;EXPENSES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_zO8Rbrocq78c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Cost of product sales&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,551,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,302,755&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_z70FNxYXKUU4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;610,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;561,047&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_zvOj8wb280n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,245,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment_zRBHa9jfx3Yf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Sales and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;405,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;950,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedSalesAndMarketing_z4yk1rxelthj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Goodwill and fixed asset impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0845"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedTotalExpenses_zFXxpOret2x8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"&gt;Total expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,774,118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,135,195&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;OTHER EXPENSE (INCOME), NET&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease_zMxym9pZFS8c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Loss on disposal of equipment held for lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63,302&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_ztT4uefCVgFh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest (income) expense, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0854"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,751&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_znvkUZyg6kO" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,898&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,125&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal_zCYNcNK7eRr8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Loss on fixed asset disposal&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0861"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_z5ZI3qdus78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"&gt;Total other expense (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,704&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,876&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_zoGT3t7RNRC8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(171,701&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,142,763&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc._zjz18nM1MRD1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Gain on sale of Qualigen, Inc., net of tax&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,876,778&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0870"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_zUCJBATU4V7f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;INCOME (LOSS) FROM DISCONTINUED OPERATIONS OF QUALIGEN, INC.&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,705,077&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,142,763&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with this transaction, the Company recorded a gain on the sale of Qualigen, Inc. in its consolidated financial statements
for the years ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gain on sale of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Qualigen, Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Fair value of consideration received&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived_c20230101__20231231_zopQLsek6o52" style="width: 16%; text-align: right" title="Fair value of consideration received"&gt;5,489,337&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Working capital adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment_c20230101__20231231_zgKCXMukPacc" style="text-align: right" title="Working capital adjustment"&gt;235,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total Assets of discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalAssets_iI_c20231231_z7F0kPUQmzjf" style="text-align: right" title="Total Assets of discontinued operations"&gt;(4,225,562&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total Liabilities of discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_iI_c20231231_zZB0sSvCh5Le" style="text-align: right" title="Total Liabilities of discontinued operations"&gt;3,005,407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Transaction expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationTransactionExpenses_c20230101__20231231_zoV99ipBQx9j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transaction expenses"&gt;(627,806&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Gain on sale of Qualigen, Inc.&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_c20230101__20231231_zQ7H97dMMNFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Gain on sale of Qualigen, Inc."&gt;3,876,778&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z7H3xYCom9q5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the fourth quarter of 2023, the gain was adjusted upward by $&lt;span id="xdx_908_ecustom--DisposalGroupIncludingDiscontinuedOperationGainLoss_c20231001__20231231_zVbCg4GPOMM6" title="Gain upward upon final payment of transaction cost"&gt;17,000&lt;/span&gt; upon final payment of transaction costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Amendment
and Settlement Agreement with NanoSynex Ltd.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 20, 2023, the Company entered into and effectuated the NanoSynex Amendment, pursuant to which the Company agreed to, in exchange
for eliminating all future NanoSynex Funding Agreement obligations for the Company to invest further cash in NanoSynex (except for obligations
to lend NanoSynex $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20231130__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__dei--LegalEntityAxis__custom--NanoSynexLtdMember_zR58KpzlTHml" title="Aggregrate amount"&gt;560,000&lt;/span&gt; on or before November 30, 2023, and $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__dei--LegalEntityAxis__custom--NanoSynexLtdMember_zE6Utrvvdq8h" title="Aggregrate amount"&gt;670,000&lt;/span&gt; on or before March 31, 2024), surrender &lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodShareSurrender_c20230720__20230720__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zjEXXTMviuec" title="Number of shares surrender"&gt;281,000&lt;/span&gt; Series B Preferred
Shares of NanoSynex held by the Company, resulting in the Company&#x2019;s ownership in NanoSynex being reduced from approximately &lt;span id="xdx_907_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20230720__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgZu0riom0j" title="Business acquisition, percentage of voting interests acquired"&gt;52.8&lt;/span&gt;%
to approximately &lt;span id="xdx_900_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20230720__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zGGlAYpWLnSa" title="Business acquisition, percentage of voting interests acquired"&gt;49.97&lt;/span&gt;% of the voting equity of NanoSynex; in addition, the Company agreed to surrender approximately $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationForfeited_pn5n6_c20230720__20230720__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember_z9l1kPmz4bug" title="Aggregrate amount"&gt;3.0&lt;/span&gt; million of
promissory notes which NanoSynex had issued to the Company under the NanoSynex Funding Agreement. On November 22, 2023, the Company further
agreed to eliminate the Company&#x2019;s obligations to lend NanoSynex $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20231130__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__dei--LegalEntityAxis__custom--NanoSynexLtdMember_zkqlYQSrKB5e" title="Aggregrate amount"&gt;560,000&lt;/span&gt; on or before November 30, 2023, and $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--AmendmentAndSettlementAgreementMember__dei--LegalEntityAxis__custom--NanoSynexLtdMember_zvbePe7rFk7i" title="Aggregrate amount"&gt;670,000&lt;/span&gt; on or before
March 31, 2024, by instead surrendering shares of Series A-1 Preferred Stock of NanoSynex in an amount that reduced the Company&#x2019;s
ownership in NanoSynex voting equity from approximately &lt;span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20230720__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__srt--RangeAxis__srt--MaximumMember_zSRQbpI7ma94" title="Business acquisition, percentage of voting interests acquired"&gt;49.97&lt;/span&gt;% to &lt;span id="xdx_907_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20230720__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__srt--RangeAxis__srt--MinimumMember_zcmgvLImb9o" title="Business acquisition, percentage of voting interests acquired"&gt;39.90&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
surrender of Series B Preferred Shares of NanoSynex was accounted for as a loss of control of a subsidiary that constitutes a business
under ASC 810. As a result, on July 20, 2023, the Company deconsolidated NanoSynex&#x2019;s related assets, liabilities, accumulated other
comprehensive income, and the noncontrolling interest. Subsequently, the retained investment in NanoSynex is accounted for as an equity
method investment. On the date of deconsolidation, the Company recognized its retained investment at fair value, which during the preparation
of these financial statements was determined to be de minimis based on various economic, industry, and other factors. As a result, the
Company has discontinued recognition of its proportionate share of equity method losses following the date of initial recognition. Future
equity method earnings, if any, will not be recognized until the amount exceeds the unrecognized net losses in prior periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
upon the magnitude of the disposition and because the Company is exiting certain research and development operations, the disposition
represents a strategic shift that will have a material effect on the Company&#x2019;s operations and financial results. Accordingly, the
business of NanoSynex is classified as discontinued operations for all periods presented herein.&lt;br/&gt;
&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hdei--LegalEntityAxis__custom--NanosynexMember_zql7Ocd1YQD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
assets and liabilities classified in discontinued operations for NanoSynex as of December 31, 2022 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8B8_zVjw2CrpUSug" style="display: none"&gt;ASSETS
AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231__dei--LegalEntityAxis__custom--NanosynexMember_ziAxeurFgqSb" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_hdei--LegalEntityAxis__custom--NanosynexMember_znAT1VGu4Enl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,621,967&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zN3N2jA1Xg8e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zS3OziL2bL64" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;190,384&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zudjy6jAUFJ8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total current assets of discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,838,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash_iI_hdei--LegalEntityAxis__custom--NanosynexMember_z8jgHUgNV9f3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,690&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zURxSXiS75G4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zatJLqdJ3iFb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,700,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zbN6DIJrYwDf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;625,602&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zeCqfvJF6T0h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Total non-current assets of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,360,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalAssets_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zjeoubzzdNKb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;Total assets of discontinued operations of NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,199,291&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zkJ2bH9V1TVi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zxpaYWoF1jK" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zlEFbYuQa6tg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;293,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zsDzep8kKing" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D grant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;780,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zedLNhd2fXGc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Short term debt-related party&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;950,722&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_z7XSBcqOkN72" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Total current liabilities of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,141,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zTYaf7L5SBr7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Deferred tax liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;357,757&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zTSesd573E2d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Total non-current liabilities of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;357,757&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zRjpF4OyIlf9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;Total liabilities of discontinued operations of NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,499,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reclassified the following statement of operations items to discontinued operations for the years ended December 31, 2023 and
2022, respectively:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20231231_zOTptJ3CuNPb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zx9oSOWhGWM3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;EXPENSES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_hdei--LegalEntityAxis__custom--NanosynexMember_zgccjshpdKPc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;869,064&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,105,040&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment_hdei--LegalEntityAxis__custom--NanosynexMember_zZERACgexWla" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Goodwill and fixed asset impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0952"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,164,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedTotalExpenses_hdei--LegalEntityAxis__custom--NanosynexMember_zmH5vnSWE61" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"&gt;Total expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;869,064&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,269,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zAk6YmXlslPj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Loss on disposal of discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,479,010&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0959"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_hdei--LegalEntityAxis__custom--NanosynexMember_zMk686AGWUY8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;(BENEFIT) PROVISION FOR INCOME TAXES&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(357,757&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(271,622&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zEcbOD2Rc3z4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;LOSS FROM DISCONTINUED OPERATIONS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,990,317&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,997,418&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_hdei--LegalEntityAxis__custom--NanosynexMember_zZ5uISHWCvCh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Loss attributable to noncontrolling interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(343,038&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,394,100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zbH1l6INY484" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;NET LOSS ATTRIBUTABLE TO STOCKHOLDERS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,647,279&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,603,318&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with this transaction, the Company recorded a loss on deconsolidation of NanoSynex in its consolidated financial statements
for the years ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"&gt;Loss on deconsolidation of NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value of NanoSynex interest retained&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_z5EXg1W5lC7f" style="text-align: right" title="Fair value of Nan-Synex interest retained"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Net assets deconsolidated&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zipg4Uspz2kf" style="width: 16%; text-align: right" title="Net assets deconsolidated"&gt;(2,768,403&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Non-controlling interest share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zycwxuIdu0u" style="text-align: right" title="Non-controlling interest share"&gt;1,235,443&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accumulated other comprehensive income attributable to NanoSynex&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_z3pfPwc5XUqe" style="text-align: right" title="Accumulated OCI attributable to NanoSynex"&gt;131,891&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forgiveness of debt&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zairUjzSigPa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forgiveness of debt"&gt;(3,077,941&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Loss from deconsolidation of NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zW9JtpnpW2f8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Loss from deconsolidation of NanoSynex"&gt;(4,479,010&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zKybyRV7sKGb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000730">&lt;p id="xdx_89D_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_z5Dt0YsaFggi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
summary of assets and liabilities classified in discontinued operations as of December 31, 2022 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BE_zM2GFwfBcb99" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF BALANCE SHEETS AND INCOME STATEMENT CLASSIFIED IN DISCONTINUED OPERATIONS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zodx01DSNDs4" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Qualigen, Inc.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zkWbORC60jCl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231_z50z0zVBbJah" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzI2M_maTAODOzy7K_zXkOI4AdQZJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 46%; text-align: left"&gt;Current assets of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;4,448,999&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;1,838,850&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;6,287,849&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_i01I_maCzo3N_maTAODOzy7K_z4TkzckFeGD8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Non-current assets of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,876,270&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,360,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,236,711&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--TotalAssetsOfDiscontinuedOperations_iI_zaOJz7puWoR" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total assets of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,325,269&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,199,291&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,524,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_maCzCJ5_maTLOOzkOU_zEbnWh5YAST6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities of discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,299,948&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,141,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,441,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_i02I_maCzIDe_maTLOOzkOU_zwwt8URcENPa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Non-current liabilities of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,350,975&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;357,757&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,708,732&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--TotalLiabilitiesOfdiscontinuedOperations_iI_zCPvA2wOO6bh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,650,923&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,499,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,149,930&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
summary of gain (loss) from discontinued operations, net of tax, as of December 31, 2023 and 2022 are as follows:&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_zgyRHLYRdNHk" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zYirOfUwnfHi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20230101__20231231_zZOHikC3k2A7" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231__srt--ConsolidatedEntitiesAxis__srt--ParentCompanyMember_z7KOK0KzexEg" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231__srt--ConsolidatedEntitiesAxis__custom--NanosynexMember_zriQLS8NBlK6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zBmCU5FMeNv5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Qualigen, Inc.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Qualigen, Inc.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_maCzBjD_zXK0Entbw48b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: left"&gt;(Loss) from discontinued operations&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(171,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(511,307&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(683,008&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(2,142,763&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(4,997,418&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(7,140,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_iN_di_msCzBjD_zEyxLvK7bhpl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Gain (loss) on disposal of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,876,778&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,479,010&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(602,232&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0766"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0767"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_mtCzBjD_maCzhiC_zjo8O9g2rzk2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total gain (loss) from discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,705,077&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,990,317&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,285,240&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,142,763&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,997,418&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(7,140,181&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31_srt_ParentCompanyMember"
      decimals="0"
      id="Fact000732"
      unitRef="USD">4448999</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000733"
      unitRef="USD">1838850</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000734"
      unitRef="USD">6287849</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="AsOf2022-12-31_srt_ParentCompanyMember"
      decimals="0"
      id="Fact000736"
      unitRef="USD">1876270</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000737"
      unitRef="USD">6360441</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000738"
      unitRef="USD">8236711</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <QLGN:TotalAssetsOfDiscontinuedOperations
      contextRef="AsOf2022-12-31_srt_ParentCompanyMember"
      decimals="0"
      id="Fact000740"
      unitRef="USD">6325269</QLGN:TotalAssetsOfDiscontinuedOperations>
    <QLGN:TotalAssetsOfDiscontinuedOperations
      contextRef="AsOf2022-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000741"
      unitRef="USD">8199291</QLGN:TotalAssetsOfDiscontinuedOperations>
    <QLGN:TotalAssetsOfDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000742"
      unitRef="USD">14524560</QLGN:TotalAssetsOfDiscontinuedOperations>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31_srt_ParentCompanyMember"
      decimals="0"
      id="Fact000744"
      unitRef="USD">1299948</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000745"
      unitRef="USD">2141250</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000746"
      unitRef="USD">3441198</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="AsOf2022-12-31_srt_ParentCompanyMember"
      decimals="0"
      id="Fact000748"
      unitRef="USD">1350975</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000749"
      unitRef="USD">357757</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000750"
      unitRef="USD">1708732</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <QLGN:TotalLiabilitiesOfdiscontinuedOperations
      contextRef="AsOf2022-12-31_srt_ParentCompanyMember"
      decimals="0"
      id="Fact000752"
      unitRef="USD">2650923</QLGN:TotalLiabilitiesOfdiscontinuedOperations>
    <QLGN:TotalLiabilitiesOfdiscontinuedOperations
      contextRef="AsOf2022-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000753"
      unitRef="USD">2499007</QLGN:TotalLiabilitiesOfdiscontinuedOperations>
    <QLGN:TotalLiabilitiesOfdiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000754"
      unitRef="USD">5149930</QLGN:TotalLiabilitiesOfdiscontinuedOperations>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="From2023-01-012023-12-31_srt_ParentCompanyMember"
      decimals="0"
      id="Fact000756"
      unitRef="USD">-171701</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember983343"
      decimals="0"
      id="Fact000757"
      unitRef="USD">-511307</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000758"
      unitRef="USD">-683008</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="From2022-01-012022-12-31_srt_ParentCompanyMember"
      decimals="0"
      id="Fact000759"
      unitRef="USD">-2142763</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="From2022-01-012022-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000760"
      unitRef="USD">-4997418</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000761"
      unitRef="USD">-7140181</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="From2023-01-012023-12-31_srt_ParentCompanyMember"
      decimals="0"
      id="Fact000763"
      unitRef="USD">-3876778</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember983343"
      decimals="0"
      id="Fact000764"
      unitRef="USD">4479010</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000765"
      unitRef="USD">602232</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2023-01-012023-12-31_srt_ParentCompanyMember"
      decimals="0"
      id="Fact000770"
      unitRef="USD">3705077</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember983343"
      decimals="0"
      id="Fact000771"
      unitRef="USD">-4990317</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000772"
      unitRef="USD">-1285240</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2022-01-012022-12-31_srt_ParentCompanyMember"
      decimals="0"
      id="Fact000773"
      unitRef="USD">-2142763</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2022-01-012022-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000774"
      unitRef="USD">-4997418</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000775"
      unitRef="USD">-7140181</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:Cash
      contextRef="AsOf2023-07-20_custom_ChembioDiagnosticsMember"
      decimals="-5"
      id="Fact000777"
      unitRef="USD">5400000</us-gaap:Cash>
    <QLGN:PurchasePrice
      contextRef="AsOf2023-07-20"
      decimals="-5"
      id="Fact000779"
      unitRef="USD">4900000</QLGN:PurchasePrice>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2023-07-20"
      decimals="0"
      id="Fact000781"
      unitRef="USD">450000</us-gaap:EscrowDeposit>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      id="Fact000783">&lt;p id="xdx_895_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zRICwWBIIOpg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
assets and liabilities classified in discontinued operations for Qualigen, Inc. as of December 31, 2022 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span id="xdx_8BB_z8eP3ft272Ub" style="display: none"&gt;ASSETS
AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zOY75KWN9c0f" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_zGKYfYaxTuP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,246,482&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_zHdqUvOvAWj4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;512,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_iI_zHtJnaXnk68d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Inventory, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,586,297&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_zUgM1ml5g8S6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;104,132&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_zIEHIrtrpUWh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total current assets of discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,448,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets_iI_zHU6IGWDB8Y3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,422,538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_iI_zKbRdheWsea" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;289,696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_iI_zIDSZ58seAhc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Intangible assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145,702&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_iI_zMkyyWT4oEha" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,334&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_iI_zjRDEs67Ztx3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Total non-current assets of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,876,270&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--TotalAssetsOfDiscontinuedOperations_zEMDVnMkIPPd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;Total assets of discontinued operations of Qualigen, Inc.&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;6,325,269&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_zHmjfZc3mAO" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;236,470&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DisposalGroupIncludingDiscontinuedOperationAccruedVacation_iI_zFUrYTtBMubd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187,906&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_iI_z9mMXvu4yod" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;518,766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_iI_zCPQARiRXiq9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred revenue, current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116,161&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_iI_z4V9woU1rXdh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Operating lease liability, current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;240,645&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_z3PO2u2XYjzb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Total current liabilities of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,299,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_iI_zQQ6Ddu84EN4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liability, net of current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,301,919&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_iI_zonhoHs0imS" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Deferred revenue, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;49,056&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_iI_zhBTeigkBoW2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Total non-current liabilities of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,350,975&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--TotalLiabilitiesOfdiscontinuedOperations_zPfVDec32Sy2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;Total liabilities of discontinued operations of Qualigen, Inc.&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;2,650,923&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reclassified the following statement of operations items to discontinued operations for the years ended December 31, 2023 and
2022, respectively:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zHVOVMBBvRg2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--ParentMember_zZgIAXsbIcn3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Years Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;REVENUES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedOperationNetProductSales_z80f30iqchab" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; width: 60%; text-align: left"&gt;Net product sales&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;3,661,121&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;4,983,556&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_z5vtcVatxqJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Total revenues&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,661,121&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,983,556&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;EXPENSES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_zO8Rbrocq78c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Cost of product sales&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,551,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,302,755&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_z70FNxYXKUU4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;610,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;561,047&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_zvOj8wb280n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,245,973&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment_zRBHa9jfx3Yf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Sales and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;405,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;950,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedSalesAndMarketing_z4yk1rxelthj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Goodwill and fixed asset impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0845"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedTotalExpenses_zFXxpOret2x8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"&gt;Total expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,774,118&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,135,195&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;OTHER EXPENSE (INCOME), NET&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease_zMxym9pZFS8c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Loss on disposal of equipment held for lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;63,302&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0852"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense_ztT4uefCVgFh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest (income) expense, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0854"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,751&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_znvkUZyg6kO" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other expense (income), net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,898&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,125&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal_zCYNcNK7eRr8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Loss on fixed asset disposal&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0861"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_z5ZI3qdus78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"&gt;Total other expense (income), net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,704&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,876&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_zoGT3t7RNRC8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;INCOME (LOSS) FROM DISCONTINUED OPERATIONS BEFORE DISPOSAL&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(171,701&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,142,763&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc._zjz18nM1MRD1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Gain on sale of Qualigen, Inc., net of tax&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,876,778&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0870"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_zUCJBATU4V7f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;INCOME (LOSS) FROM DISCONTINUED OPERATIONS OF QUALIGEN, INC.&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,705,077&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,142,763&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with this transaction, the Company recorded a gain on the sale of Qualigen, Inc. in its consolidated financial statements
for the years ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gain on sale of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Qualigen, Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Fair value of consideration received&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived_c20230101__20231231_zopQLsek6o52" style="width: 16%; text-align: right" title="Fair value of consideration received"&gt;5,489,337&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Working capital adjustment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment_c20230101__20231231_zgKCXMukPacc" style="text-align: right" title="Working capital adjustment"&gt;235,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total Assets of discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalAssets_iI_c20231231_z7F0kPUQmzjf" style="text-align: right" title="Total Assets of discontinued operations"&gt;(4,225,562&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total Liabilities of discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_iI_c20231231_zZB0sSvCh5Le" style="text-align: right" title="Total Liabilities of discontinued operations"&gt;3,005,407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Transaction expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationTransactionExpenses_c20230101__20231231_zoV99ipBQx9j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transaction expenses"&gt;(627,806&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Gain on sale of Qualigen, Inc.&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--GainLossOnSaleOfInvestments_c20230101__20231231_zQ7H97dMMNFh" style="border-bottom: Black 2.5pt double; text-align: right" title="Gain on sale of Qualigen, Inc."&gt;3,876,778&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000785"
      unitRef="USD">2246482</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000787"
      unitRef="USD">512088</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000789"
      unitRef="USD">1586297</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000791"
      unitRef="USD">104132</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000793"
      unitRef="USD">4448999</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000795"
      unitRef="USD">1422538</QLGN:DisposalGroupIncludingDiscontinuedOperationPropertyRightofuseAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000797"
      unitRef="USD">289696</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000799"
      unitRef="USD">145702</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000801"
      unitRef="USD">18334</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000803"
      unitRef="USD">1876270</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <QLGN:TotalAssetsOfDiscontinuedOperations
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000805"
      unitRef="USD">6325269</QLGN:TotalAssetsOfDiscontinuedOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000807"
      unitRef="USD">236470</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationAccruedVacation
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000809"
      unitRef="USD">187906</QLGN:DisposalGroupIncludingDiscontinuedOperationAccruedVacation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000811"
      unitRef="USD">518766</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000813"
      unitRef="USD">116161</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000815"
      unitRef="USD">240645</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000817"
      unitRef="USD">1299948</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000819"
      unitRef="USD">1301919</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000821"
      unitRef="USD">49056</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000823"
      unitRef="USD">1350975</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <QLGN:TotalLiabilitiesOfdiscontinuedOperations
      contextRef="AsOf2022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000825"
      unitRef="USD">2650923</QLGN:TotalLiabilitiesOfdiscontinuedOperations>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationNetProductSales
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000827"
      unitRef="USD">3661121</QLGN:DisposalGroupIncludingDiscontinuedOperationNetProductSales>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationNetProductSales
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000828"
      unitRef="USD">4983556</QLGN:DisposalGroupIncludingDiscontinuedOperationNetProductSales>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000830"
      unitRef="USD">3661121</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000831"
      unitRef="USD">4983556</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000833"
      unitRef="USD">2551114</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000834"
      unitRef="USD">4302755</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000836"
      unitRef="USD">610559</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000837"
      unitRef="USD">561047</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000839"
      unitRef="USD">206819</QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000840"
      unitRef="USD">1245973</QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment>
    <QLGN:DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000842"
      unitRef="USD">405626</QLGN:DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment>
    <QLGN:DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000843"
      unitRef="USD">950420</QLGN:DisposalGroupIncludingDiscontinuedGoodwillAndFixedAssetImpairment>
    <QLGN:DisposalGroupIncludingDiscontinuedSalesAndMarketing
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000846"
      unitRef="USD">75000</QLGN:DisposalGroupIncludingDiscontinuedSalesAndMarketing>
    <QLGN:DisposalGroupIncludingDiscontinuedTotalExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000848"
      unitRef="USD">3774118</QLGN:DisposalGroupIncludingDiscontinuedTotalExpenses>
    <QLGN:DisposalGroupIncludingDiscontinuedTotalExpenses
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000849"
      unitRef="USD">7135195</QLGN:DisposalGroupIncludingDiscontinuedTotalExpenses>
    <QLGN:DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000851"
      unitRef="USD">63302</QLGN:DisposalGroupIncludingDiscontinuedLossOnDisposalOfEquipmentHeldForLease>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000855"
      unitRef="USD">-7751</QLGN:DisposalGroupIncludingDiscontinuedOperationInterestIncomeExpense>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000857"
      unitRef="USD">-4898</QLGN:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000858"
      unitRef="USD">-1125</QLGN:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense>
    <QLGN:DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000860"
      unitRef="USD">300</QLGN:DisposalGroupIncludingDiscontinuedLossOnfixedAssetDisposal>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000863"
      unitRef="USD">58704</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000864"
      unitRef="USD">-8876</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000866"
      unitRef="USD">-171701</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000867"
      unitRef="USD">-2142763</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc.
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000869"
      unitRef="USD">3876778</QLGN:DisposalGroupIncludingDiscontinuedOperationGainOnSaleOfQualigenInc.>
    <QLGN:DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000872"
      unitRef="USD">3705077</QLGN:DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <QLGN:DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_ParentMember"
      decimals="0"
      id="Fact000873"
      unitRef="USD">-2142763</QLGN:DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000875"
      unitRef="USD">5489337</QLGN:DisposalGroupIncludingDiscontinuedOperationFairvalueOfConsiderationReceived>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000877"
      unitRef="USD">235402</QLGN:DisposalGroupIncludingDiscontinuedOperationWorkingCapitalAdjustment>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationTotalAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000879"
      unitRef="USD">-4225562</QLGN:DisposalGroupIncludingDiscontinuedOperationTotalAssets>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationTotalLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000881"
      unitRef="USD">3005407</QLGN:DisposalGroupIncludingDiscontinuedOperationTotalLiabilities>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationTransactionExpenses
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000883"
      unitRef="USD">-627806</QLGN:DisposalGroupIncludingDiscontinuedOperationTransactionExpenses>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000885"
      unitRef="USD">3876778</us-gaap:GainLossOnSaleOfInvestments>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationGainLoss
      contextRef="From2023-10-012023-12-31"
      decimals="0"
      id="Fact000887"
      unitRef="USD">17000</QLGN:DisposalGroupIncludingDiscontinuedOperationGainLoss>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-11-30_custom_AmendmentAndSettlementAgreementMember_custom_NanoSynexLtdMember"
      decimals="0"
      id="Fact000889"
      unitRef="USD">560000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_AmendmentAndSettlementAgreementMember_custom_NanoSynexLtdMember"
      decimals="0"
      id="Fact000891"
      unitRef="USD">670000</us-gaap:DebtInstrumentFaceAmount>
    <QLGN:StockIssuedDuringPeriodShareSurrender
      contextRef="From2023-07-202023-07-20_custom_AmendmentAndSettlementAgreementMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000893"
      unitRef="Shares">281000</QLGN:StockIssuedDuringPeriodShareSurrender>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MaximumMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000895"
      unitRef="Pure">0.528</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MinimumMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000897"
      unitRef="Pure">0.4997</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="From2023-07-202023-07-20_custom_AmendmentAndSettlementAgreementMember"
      decimals="-5"
      id="Fact000899"
      unitRef="USD">3000000.0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-11-30_custom_AmendmentAndSettlementAgreementMember_custom_NanoSynexLtdMember"
      decimals="0"
      id="Fact000901"
      unitRef="USD">560000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-03-31_us-gaap_SubsequentEventMember_custom_AmendmentAndSettlementAgreementMember_custom_NanoSynexLtdMember"
      decimals="0"
      id="Fact000903"
      unitRef="USD">670000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000905"
      unitRef="Pure">0.4997</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="AsOf2023-07-20_custom_NanoSynexLtdMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000907"
      unitRef="Pure">0.3990</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      id="Fact000909">&lt;p id="xdx_89E_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_hdei--LegalEntityAxis__custom--NanosynexMember_zql7Ocd1YQD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
assets and liabilities classified in discontinued operations for NanoSynex as of December 31, 2022 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8B8_zVjw2CrpUSug" style="display: none"&gt;ASSETS
AND LIABILITIES CLASSIFIED IN DISCONTINUED OPERATIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231__dei--LegalEntityAxis__custom--NanosynexMember_ziAxeurFgqSb" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_hdei--LegalEntityAxis__custom--NanosynexMember_znAT1VGu4Enl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,621,967&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zN3N2jA1Xg8e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zS3OziL2bL64" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;190,384&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zudjy6jAUFJ8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total current assets of discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,838,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash_iI_hdei--LegalEntityAxis__custom--NanosynexMember_z8jgHUgNV9f3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,690&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zURxSXiS75G4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zatJLqdJ3iFb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,700,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zbN6DIJrYwDf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;625,602&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zeCqfvJF6T0h" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Total non-current assets of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,360,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalAssets_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zjeoubzzdNKb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;Total assets of discontinued operations of NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,199,291&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zkJ2bH9V1TVi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zxpaYWoF1jK" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zlEFbYuQa6tg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;293,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zsDzep8kKing" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D grant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;780,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zedLNhd2fXGc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Short term debt-related party&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;950,722&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iI_hdei--LegalEntityAxis__custom--NanosynexMember_z7XSBcqOkN72" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Total current liabilities of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,141,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zTYaf7L5SBr7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Deferred tax liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;357,757&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zTSesd573E2d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Total non-current liabilities of discontinued operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;357,757&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DisposalGroupIncludingDiscontinuedOperationTotalLiabilities_iI_hdei--LegalEntityAxis__custom--NanosynexMember_zRjpF4OyIlf9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;Total liabilities of discontinued operations of NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,499,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reclassified the following statement of operations items to discontinued operations for the years ended December 31, 2023 and
2022, respectively:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20231231_zOTptJ3CuNPb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20221231_zx9oSOWhGWM3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;EXPENSES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_hdei--LegalEntityAxis__custom--NanosynexMember_zgccjshpdKPc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;869,064&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,105,040&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment_hdei--LegalEntityAxis__custom--NanosynexMember_zZERACgexWla" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Goodwill and fixed asset impairment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0952"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,164,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedTotalExpenses_hdei--LegalEntityAxis__custom--NanosynexMember_zmH5vnSWE61" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"&gt;Total expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;869,064&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,269,040&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zAk6YmXlslPj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Loss on disposal of discontinued operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,479,010&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0959"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_hdei--LegalEntityAxis__custom--NanosynexMember_zMk686AGWUY8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;(BENEFIT) PROVISION FOR INCOME TAXES&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(357,757&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(271,622&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zEcbOD2Rc3z4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;LOSS FROM DISCONTINUED OPERATIONS&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,990,317&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,997,418&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_hdei--LegalEntityAxis__custom--NanosynexMember_zZ5uISHWCvCh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Loss attributable to noncontrolling interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(343,038&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,394,100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax_hdei--LegalEntityAxis__custom--NanosynexMember_zbH1l6INY484" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;NET LOSS ATTRIBUTABLE TO STOCKHOLDERS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,647,279&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,603,318&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with this transaction, the Company recorded a loss on deconsolidation of NanoSynex in its consolidated financial statements
for the years ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"&gt;Loss on deconsolidation of NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value of NanoSynex interest retained&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--DisposalGroupIncludingDiscontinuedOperationFairValueOfInterestRetained_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_z5EXg1W5lC7f" style="text-align: right" title="Fair value of Nan-Synex interest retained"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0973"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Net assets deconsolidated&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zipg4Uspz2kf" style="width: 16%; text-align: right" title="Net assets deconsolidated"&gt;(2,768,403&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Non-controlling interest share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zycwxuIdu0u" style="text-align: right" title="Non-controlling interest share"&gt;1,235,443&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accumulated other comprehensive income attributable to NanoSynex&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_z3pfPwc5XUqe" style="text-align: right" title="Accumulated OCI attributable to NanoSynex"&gt;131,891&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forgiveness of debt&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zairUjzSigPa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forgiveness of debt"&gt;(3,077,941&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Loss from deconsolidation of NanoSynex&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation_c20230101__20231231__dei--LegalEntityAxis__custom--NanosynexMember_zW9JtpnpW2f8" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Loss from deconsolidation of NanoSynex"&gt;(4,479,010&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000911"
      unitRef="USD">1621967</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000913"
      unitRef="USD">26499</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000915"
      unitRef="USD">190384</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000917"
      unitRef="USD">1838850</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <QLGN:AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000919"
      unitRef="USD">5690</QLGN:AssetsOfDisposalGroupIncludingDiscontinuedRestrictedCash>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000921"
      unitRef="USD">29149</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000923"
      unitRef="USD">5700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000925"
      unitRef="USD">625602</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000927"
      unitRef="USD">6360441</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationTotalAssets
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000929"
      unitRef="USD">8199291</QLGN:DisposalGroupIncludingDiscontinuedOperationTotalAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000931"
      unitRef="USD">1273</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000933"
      unitRef="USD">115002</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000935"
      unitRef="USD">293571</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000937"
      unitRef="USD">780682</QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentGrantLiability>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000939"
      unitRef="USD">950722</QLGN:DisposalGroupIncludingDiscontinuedOperationShortTermDebtRelatedParty>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000941"
      unitRef="USD">2141250</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000943"
      unitRef="USD">357757</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000945"
      unitRef="USD">357757</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationTotalLiabilities
      contextRef="AsOf2022-12-31_custom_NanosynexMember983937"
      decimals="0"
      id="Fact000947"
      unitRef="USD">2499007</QLGN:DisposalGroupIncludingDiscontinuedOperationTotalLiabilities>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000949"
      unitRef="USD">869064</QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
      contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015"
      decimals="0"
      id="Fact000950"
      unitRef="USD">1105040</QLGN:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment
      contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015"
      decimals="0"
      id="Fact000953"
      unitRef="USD">4164000</QLGN:DisposalGroupIncludingDiscontinuedOperationGoodwillAndFixedAssetImpairment>
    <QLGN:DisposalGroupIncludingDiscontinuedTotalExpenses
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000955"
      unitRef="USD">869064</QLGN:DisposalGroupIncludingDiscontinuedTotalExpenses>
    <QLGN:DisposalGroupIncludingDiscontinuedTotalExpenses
      contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015"
      decimals="0"
      id="Fact000956"
      unitRef="USD">5269040</QLGN:DisposalGroupIncludingDiscontinuedTotalExpenses>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000958"
      unitRef="USD">4479010</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000961"
      unitRef="USD">-357757</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015"
      decimals="0"
      id="Fact000962"
      unitRef="USD">-271622</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000964"
      unitRef="USD">-4990317</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015"
      decimals="0"
      id="Fact000965"
      unitRef="USD">-4997418</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000967"
      unitRef="USD">-343038</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015"
      decimals="0"
      id="Fact000968"
      unitRef="USD">-2394100</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <QLGN:DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000970"
      unitRef="USD">-4647279</QLGN:DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <QLGN:DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="From2022-01-012022-12-31_custom_NanosynexMember984015"
      decimals="0"
      id="Fact000971"
      unitRef="USD">-2603318</QLGN:DiscontinuedOperationsGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000975"
      unitRef="USD">-2768403</QLGN:DisposalGroupIncludingDiscontinuedOperationNetAssetsDeconsolidated>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000977"
      unitRef="USD">1235443</QLGN:DisposalGroupIncludingDiscontinuedOperationNonControllingInterestShare>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000979"
      unitRef="USD">131891</QLGN:DisposalGroupIncludingDiscontinuedOperationAccumulatedOCIAttributable>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000981"
      unitRef="USD">-3077941</QLGN:DisposalGroupIncludingDiscontinuedOperationForgivenessOfDebt>
    <QLGN:DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation
      contextRef="From2023-01-012023-12-31_custom_NanosynexMember"
      decimals="0"
      id="Fact000983"
      unitRef="USD">-4479010</QLGN:DisposalGroupIncludingDiscontinuedOperationLossFromDeconsolidation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000985">&lt;p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z0ZCmVmVIgna" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &#x2014; &lt;span id="xdx_82B_zCP3sYxSfsya"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zFErq1PZDlN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consisted of the following at December 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8BA_zjGznIpol2O9" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_zHHxTMsGUIh" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231_zQSJfkKD45Cc" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccruedCompensation_iI_pp0p0_maALCzkYM_zpGjW49FxaAe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Board compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;129,499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--InterestPayableCurrent_iI_pp0p0_maALCzkYM_zDHR8SsSsiFg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest (Convertible debt)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzkYM_zcthN6R2i8Tc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;License fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCzkYM_z7Xgssvzn5lg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzkYM_zpF47Vp9U8U1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCzkYM_zDTbB2YyfHzf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329,412&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maALCzkYM_zxhaJd2lGG5g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165,040&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzkYM_zXgg7XyiUQh5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,850&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzkYM_zw6s9z17hSI1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued expenses and
    other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;560,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;864,559&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zoBao6Ime7Vh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
accrued liabilities attributable to Qualigen Inc, and NanoSynex were deemed disposed of as discontinued operations (see Note 5 &#x2013; Discontinued
Operations).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000987">&lt;p id="xdx_897_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zFErq1PZDlN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses and other current liabilities consisted of the following at December 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8BA_zjGznIpol2O9" style="display: none"&gt;SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_zHHxTMsGUIh" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231_zQSJfkKD45Cc" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AccruedCompensation_iI_pp0p0_maALCzkYM_zpGjW49FxaAe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Board compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;129,499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;70,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--InterestPayableCurrent_iI_pp0p0_maALCzkYM_zDHR8SsSsiFg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest (Convertible debt)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AccruedLicenseFees_iI_pp0p0_maALCzkYM_zcthN6R2i8Tc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;License fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCzkYM_z7Xgssvzn5lg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCzkYM_zpF47Vp9U8U1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,775&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;136,203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCzkYM_zDTbB2YyfHzf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329,412&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maALCzkYM_zxhaJd2lGG5g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165,040&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzkYM_zXgg7XyiUQh5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,850&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCzkYM_zw6s9z17hSI1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued expenses and
    other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;560,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;864,559&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <QLGN:AccruedCompensation
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000989"
      unitRef="USD">129499</QLGN:AccruedCompensation>
    <QLGN:AccruedCompensation
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000990"
      unitRef="USD">70000</QLGN:AccruedCompensation>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000992"
      unitRef="USD">10004</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000993"
      unitRef="USD">2829</us-gaap:InterestPayableCurrent>
    <QLGN:AccruedLicenseFees
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000995"
      unitRef="USD">32975</QLGN:AccruedLicenseFees>
    <QLGN:AccruedLicenseFees
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000996"
      unitRef="USD">150130</QLGN:AccruedLicenseFees>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000998"
      unitRef="USD">1215</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000999"
      unitRef="USD">1247</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001001"
      unitRef="USD">121775</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001002"
      unitRef="USD">136203</us-gaap:AccruedProfessionalFeesCurrent>
    <QLGN:AccruedResearchAndDevelopmentCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001004"
      unitRef="USD">104402</QLGN:AccruedResearchAndDevelopmentCurrent>
    <QLGN:AccruedResearchAndDevelopmentCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001005"
      unitRef="USD">329412</QLGN:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001007"
      unitRef="USD">151286</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001008"
      unitRef="USD">165040</us-gaap:AccruedVacationCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001010"
      unitRef="USD">8850</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001011"
      unitRef="USD">9698</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001013"
      unitRef="USD">560006</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001014"
      unitRef="USD">864559</us-gaap:AccruedLiabilitiesCurrent>
    <QLGN:WarrantLiabilitiesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001016">&lt;p id="xdx_807_ecustom--WarrantLiabilitiesTextBlock_ziSawuytXNPd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2013; &lt;span id="xdx_82D_zqOuPtOArNda"&gt;WARRANT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a
private placement (the &#x201c;Series C Warrants&#x201d;). The Series C Warrants were subsequently extended and, upon closing of the
reverse recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, at $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zjLBgv89eAh2" title="Warrant exercise price"&gt;7.195&lt;/span&gt;
per share, subject to adjustment. As of December 31, 2023, the Series C Warrants had a remaining term of &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zzetds2CH1A1" title="Warrants and rights outstanding term"&gt;0.49&lt;/span&gt;
years. The Series C Warrants were determined to be liability-classified pursuant to the guidance in ASC 480 and ASC 815-40, based on
the inclusion of a leveraged ratchet provision for subsequent dilutive issuances. On April 25, 2022, the Series C warrants were
repriced from $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zzmD55EmAmi7" title="Exercise price"&gt;7.195&lt;/span&gt;
per share exercise price to $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zZNvUdCZ1Ea2" title="Exercise price"&gt;6.00&lt;/span&gt;
per share exercise price with &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220423__20220425__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zbihTPaibQx6" title="Issuance of shares"&gt;49,318&lt;/span&gt;
additional ratchet Warrants issued. On May 26, 2022, the Series C warrants were repriced from $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z3uFW8slN005" title="Exercise price"&gt;6.00&lt;/span&gt;
per share exercise price to $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zwgMKMWUJg3k" title="Exercise price"&gt;5.136&lt;/span&gt;
per share exercise price with &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220523__20220526__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zq1owi3Gtaf4" title="Warrants issued"&gt;49,952&lt;/span&gt;
additional ratchet Warrants issued. As a result of these repricings, &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20220523__20220526_zQyGBjCzz1Oj" title="Warrants forfeited"&gt;247,625&lt;/span&gt;
warrants were forfeited and &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesTreasuryStockReissued_pid_c20220523__20220526_zOiUsRZom3nk" title="Warrants reissued"&gt;346,896&lt;/span&gt;
warrants were reissued. On December 22, 2022, the Series C Warrants were repriced again from $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zLcK3W8ZBp14" title="Warrants repriced"&gt;5.136&lt;/span&gt;
per share exercise price to $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zrE1noWegDQg" title="Warrants repriced"&gt;1.32&lt;/span&gt;
per share exercise price with &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20221222__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zePqKIF8pos5" title="Warrants issued"&gt;1,002,717&lt;/span&gt;
additional ratchet Warrants issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
on December 22, 2022, in conjunction with the issuance of the Debenture to Alpha (see Note 8 &#x2013; Convertible Debt &#x2013; Related
Party), the Company issued to Alpha a warrant to purchase &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zwDokrBI7CQ7" title="Warrant to purchase shares"&gt;2,500,000&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;Alpha Warrant&#x201d;).
The exercise price of the Alpha Warrant was $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zE6EfD32PX0i" title="Exercise price of warrant"&gt;1.65&lt;/span&gt; (equal to &lt;span id="xdx_90C_ecustom--ConversionPricePercentage_pid_dp_uPure_c20221222__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zT7a2w0nD7Of" title="Conversion price percentage"&gt;125&lt;/span&gt;% of the conversion price of the Debenture on the closing date). The Alpha
Warrant may be exercised by Alpha, in whole or in part, at any time before June 22, 2028, subject to certain terms and conditions described
in the Alpha Warrant. The fair value of this warrant was included in Warrant liabilities-related party on the Company&#x2019;s consolidated
balance sheet as of December 31, 2022. On December 5, 2023, the Company entered into an Amendment No. 1 with regard to Securities Purchase
Agreement, with Alpha. This Amendment amended two instruments which the Company issued under the Securities Purchase Agreement dated
December 21, 2022: (a) the 8% Senior Convertible Debenture dated December 22, 2022 in favor of Alpha, and (b) the Common Stock Purchase
Warrant dated December 22, 2022 in favor of Alpha. The Amendment reduced the conversion price of the Debenture from $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_ztFYgmnKLve4" title="Conversion price"&gt;1.32&lt;/span&gt; per share to
$&lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_z9LmP1Jf1Cs8" title="Conversion price"&gt;0.73&lt;/span&gt; per share (subject to possible future adjustment pursuant to the terms of the Debenture) and reduced the exercise price of the
Warrant from $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zA5AbY3sRk7i" title="Warrant exercise price"&gt;1.65&lt;/span&gt; per share to $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_zhPI9NpFr8qg" title="Warrant exercise price"&gt;0.73&lt;/span&gt; per share (subject to possible future adjustment pursuant to the terms of the Warrant). The Amendment
also eliminated certain adjustment provisions of the Warrant. The Company determined the event resulted in equity classification for
the Warrant and, accordingly, the Company remeasured the warrant liabilities to fair value, and reclassified.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the Alpha Warrant repricing, on December 5, 2023 the Series C Warrants were repriced again from $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zltPM2dK32xe" title="Conversion price"&gt;1.32&lt;/span&gt; per share exercise
price to $&lt;span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_zFsev7ElZnXd" title="Conversion price"&gt;0.73&lt;/span&gt; per share exercise price with &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zTIxmVXtZvOb" title="Warrants issued"&gt;203,652&lt;/span&gt; additional ratchet Series C Warrants issued, resulting in &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_z4cZ7Z5huAV6" title="Warrants outstanding"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_zz1hCFPExOz2" title="Warrants exercisable"&gt;455,623&lt;/span&gt;&lt;/span&gt; of these Series
C Warrants outstanding and exercisable as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z18l24KyS6ta" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity in liability classified warrants for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8BC_zJNRDQGyMj46" style="display: none"&gt;SCHEDULE OF WARRANTS ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013; Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013;Average&lt;/p&gt;
                                                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLGBKDH5jCM8" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;3,849,571&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvoji3It3bBh" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;1.53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;$&lt;span id="xdx_902_ecustom--RangeOfExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_z7jM54PAtM0l" title="Range of Exercise Price, Beginning"&gt;1.32&lt;/span&gt; - $&lt;span id="xdx_90D_ecustom--RangeOfExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zDCVhsWUI7j2" title="Range of Exercise Price, Beginning"&gt;1.65&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zt8ioksd4Nj2" title="Weighted - Average Remaining Life (Years) Outstanding"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfoQPq9CTgsi" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1080"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zV5xLhqe6H7g" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1082"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z2rOK24p9BB4" style="text-align: right" title="Number of Shares, Warrants Forfeited"&gt;(2,751,976&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAAPPHoSgwma" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;1.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAXKcmhEslUf" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;(1,097,595&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbpd7h2BKfgh" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;1.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceExpired_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSEHJRBUfAQd" title="Range of Exercise Price, Expired"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVpJAcv8Ar4l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"&gt;455,623&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1Z7EYrTSynd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;0.73&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--RangeOfExercisePriceGranted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSiMilgKv4Il" title="Range of Exercise Price, Granted"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zUL1lFj2TI7d" title="Weighted-Average Remaining Life (Years) Outstanding"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zKnMToyCwnDb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;455,623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zIOYWv2qwJol" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;0.73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--RangeOfExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1XzwHeUAWF8" title="Range of Exercise Ending"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zorsiQiwHZs1" title="Weighted-Average Remaining Life (Years) Outstanding"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7TWvyYNgRKj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;455,623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRkqheAxivS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;0.73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iE_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSfXDRtCkEga" title="Range of Exercise Price, Exercisable"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zzbe4oYcHff1" title="Weighted-Average Remaining Life (Years) Exercisable"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity in the Common Stock Warrants received in exchange for the Series C Warrants for the year ended
December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Common Stock Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Weighted&#x2013;
Average&lt;/b&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Range
of&lt;/b&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Weighted&#x2013;Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Total outstanding &#x2013;December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbVsTqAi6BIl" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;248,162&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcm9ENx2x3Jj" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;7.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--RangeOfExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAEfVtKR2M2a" title="Range of Exercise Price, Beginning"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zm0YDjme8jk3" title="Weighted-Average Remaining Life (Years) Outstanding"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z3h5SS635N6i" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;(536&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvPJJa7NcJge" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;7.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zERGmqx8Uiga" style="text-align: right" title="Number of Shares, Warrants Forfeited"&gt;(247,625&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zITd2jiWwCv8" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;7.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZHXjaE4aeB2" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1134"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zv3z6B66dCfe" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1136"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zb1pcj7U3ZZ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"&gt;3,849,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwDH4H3gphs4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;1.53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgaSi0tLfGad" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;3,849,571&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zUB0yjZJU51a" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;1.53&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--RangeOfExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zCidTcXmjyz1" title="Range of Exercise Ending"&gt;1.32&lt;/span&gt; - &lt;span id="xdx_901_ecustom--RangeOfExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zosRg7CkBXB9" title="Range of Exercise Ending"&gt;1.65&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z058uCfQcjNg" title="Weighted-Average Remaining Life (Years) Outstanding"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRMnQL7QMLje" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;1,349,571&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfqXh6Hdo6Ia" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;1.32&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5pCfLasIRn4" title="Range of Exercise Price, Exercisable"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbFX0nxgMxMb" title="Weighted-Average Remaining Life (Years) Exercisable"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A1_zVLM4UbzjEPl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_zaRegjGYHHA5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s fair value hierarchy for its Common Stock Warrant liabilities measured at fair value on
a recurring basis as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span id="xdx_8B1_zf8I8IX64Hpe" style="display: none"&gt;SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Quoted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Market&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Prices for&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Identical&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Observable&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Unobservable&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Common Stock Warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zk2S50r1wUo9" style="width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwF17oo6oJ0b" style="width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1164"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3YSTwRWIp9f" style="width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;3,622,647&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231_zUZVCfHgsG3d" style="width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;3,622,647&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercises&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQy3t8j7Pkc5" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1170"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbGSQkPGKFtl" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1172"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmr2VS7RgnY3" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1174"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231_zjrQMRAP23P6" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1176"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair value of warrant reclassified from liabilities to equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3WJcEyKG0Gf" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1178"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zOjcm6ivjhDg" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1180"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zBfZXoBC0lmd" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity"&gt;(1,626,694&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231_zYtjNdEmpwHk" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity"&gt;(1,626,694&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss on debt extinguishment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLxxDu42GPxj" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdVYXEMqMZ2h" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1188"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGifwwzAL4Hk" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment"&gt;94,116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231_zMx7CBzLSDK" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment"&gt;94,116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Gain on change in fair value of warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6PA4TroVkH4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1194"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEfdE8kUk6y" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1196"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuqXgmjIP9R6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities"&gt;(2,035,469&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231_z8TZTLxXZBJg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities"&gt;(2,035,469&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zA2x9DGqSMv5" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zR9Pz6ubn7Ll" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1204"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjCqS6yr3EFg" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;54,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231_zABKNkMvGdd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;54,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z1qpV7OyD7vc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers of financial assets or liabilities between category levels for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo
simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the
fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a
public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common
stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and
does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher
or lower fair value measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_z931rg3adps8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the assumptions used in, and the weighted average and the range of assumptions used in estimating the fair value of warrant
liabilities (weighted average calculated based on the number of outstanding warrants on each issuance) as of December 31, 2023 and December
31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8B9_z96BAMXS0VHi" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Actual&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 48%"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJCfIiEqdgMe" title="Risk-free interest rate"&gt;5.13&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zxlMDbpDQmzg" title="Risk-free interest rate"&gt;3.906&lt;/span&gt;% &#x2014; &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_za3tnsv0nytg" title="Risk-free interest rate"&gt;4.628&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_z0l4hoNa3Vl5" title="Fair value assumptions, measurement input, percentages"&gt;4.15&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (peer group)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zb3YVa1Xbt5i" title="Expected volatility"&gt;68.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zcvwFxKOAXf5" title="Expected volatility"&gt;88&lt;/span&gt;% &#x2014; &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z7fyT5FHPUg" title="Expected volatility"&gt;103&lt;/span&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxuFn49vKpAe" title="Expected volatility"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term of warrants (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zehqffzt9hZe" title="Term of warrants (in years)"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuG1mYphnsXg" title="Term of warrants (in years)"&gt;.90&lt;/span&gt; &#x2014; &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zbVrTNrWKuk8" title="Term of warrants (in years)"&gt;5.48&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6bowoNviRDa" title="Fair value assumptions, measurement input, term"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zUID2ZCOsYb1" title="Expected dividend yield"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJ5NamsSDabb" title="Expected dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zoGx3mIIsM7h" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A6_zwqn3b2J6boc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

</QLGN:WarrantLiabilitiesTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001018"
      unitRef="USDPShares">7.195</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember985078"
      id="Fact001020">P0Y5M26D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-25_srt_MaximumMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001022"
      unitRef="USDPShares">7.195</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-25_srt_MinimumMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001024"
      unitRef="USDPShares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-04-232022-04-25_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001026"
      unitRef="Shares">49318</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_srt_MaximumMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001028"
      unitRef="USDPShares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_srt_MinimumMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001030"
      unitRef="USDPShares">5.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-05-232022-05-26_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001032"
      unitRef="Shares">49952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2022-05-232022-05-26"
      decimals="INF"
      id="Fact001034"
      unitRef="Shares">247625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="From2022-05-232022-05-26"
      decimals="INF"
      id="Fact001036"
      unitRef="Shares">346896</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_srt_MaximumMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001038"
      unitRef="USDPShares">5.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_srt_MinimumMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001040"
      unitRef="USDPShares">1.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-12-222022-12-22_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001042"
      unitRef="Shares">1002717</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001044"
      unitRef="Shares">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001046"
      unitRef="USDPShares">1.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:ConversionPricePercentage
      contextRef="From2022-12-222022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001048"
      unitRef="Pure">1.25</QLGN:ConversionPricePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPriceDecrease
      contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001050"
      unitRef="USDPShares">1.32</us-gaap:DebtInstrumentConvertibleConversionPriceDecrease>
    <us-gaap:DebtInstrumentConvertibleConversionPriceDecrease
      contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001052"
      unitRef="USDPShares">0.73</us-gaap:DebtInstrumentConvertibleConversionPriceDecrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001054"
      unitRef="USDPShares">1.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001056"
      unitRef="USDPShares">0.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentConvertibleConversionPriceDecrease
      contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001058"
      unitRef="USDPShares">1.32</us-gaap:DebtInstrumentConvertibleConversionPriceDecrease>
    <us-gaap:DebtInstrumentConvertibleConversionPriceDecrease
      contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001060"
      unitRef="USDPShares">0.73</us-gaap:DebtInstrumentConvertibleConversionPriceDecrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001062"
      unitRef="Shares">203652</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001064"
      unitRef="Shares">455623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2023-12-31_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001066"
      unitRef="Shares">455623</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001068">&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z18l24KyS6ta" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity in liability classified warrants for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8BC_zJNRDQGyMj46" style="display: none"&gt;SCHEDULE OF WARRANTS ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013; Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013;Average&lt;/p&gt;
                                                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zLGBKDH5jCM8" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;3,849,571&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvoji3It3bBh" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;1.53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;$&lt;span id="xdx_902_ecustom--RangeOfExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_z7jM54PAtM0l" title="Range of Exercise Price, Beginning"&gt;1.32&lt;/span&gt; - $&lt;span id="xdx_90D_ecustom--RangeOfExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zDCVhsWUI7j2" title="Range of Exercise Price, Beginning"&gt;1.65&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zt8ioksd4Nj2" title="Weighted - Average Remaining Life (Years) Outstanding"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfoQPq9CTgsi" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1080"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zV5xLhqe6H7g" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1082"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z2rOK24p9BB4" style="text-align: right" title="Number of Shares, Warrants Forfeited"&gt;(2,751,976&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAAPPHoSgwma" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;1.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAXKcmhEslUf" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;(1,097,595&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbpd7h2BKfgh" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;1.32&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceExpired_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSEHJRBUfAQd" title="Range of Exercise Price, Expired"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zVpJAcv8Ar4l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"&gt;455,623&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1Z7EYrTSynd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;0.73&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--RangeOfExercisePriceGranted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSiMilgKv4Il" title="Range of Exercise Price, Granted"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zUL1lFj2TI7d" title="Weighted-Average Remaining Life (Years) Outstanding"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zKnMToyCwnDb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;455,623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zIOYWv2qwJol" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;0.73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--RangeOfExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z1XzwHeUAWF8" title="Range of Exercise Ending"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zorsiQiwHZs1" title="Weighted-Average Remaining Life (Years) Outstanding"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z7TWvyYNgRKj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;455,623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRkqheAxivS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;0.73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--RangeOfExercisePriceExercisableVested_iE_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zSfXDRtCkEga" title="Range of Exercise Price, Exercisable"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zzbe4oYcHff1" title="Weighted-Average Remaining Life (Years) Exercisable"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity in the Common Stock Warrants received in exchange for the Series C Warrants for the year ended
December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Common Stock Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Weighted&#x2013;
Average&lt;/b&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Range
of&lt;/b&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt;
                                                                                                         &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Weighted&#x2013;Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;Total outstanding &#x2013;December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbVsTqAi6BIl" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;248,162&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zcm9ENx2x3Jj" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;7.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--RangeOfExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zAEfVtKR2M2a" title="Range of Exercise Price, Beginning"&gt;7.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zm0YDjme8jk3" title="Weighted-Average Remaining Life (Years) Outstanding"&gt;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z3h5SS635N6i" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;(536&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zvPJJa7NcJge" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;7.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zERGmqx8Uiga" style="text-align: right" title="Number of Shares, Warrants Forfeited"&gt;(247,625&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zITd2jiWwCv8" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;7.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zZHXjaE4aeB2" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1134"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zv3z6B66dCfe" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1136"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zb1pcj7U3ZZ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"&gt;3,849,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zwDH4H3gphs4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;1.53&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zgaSi0tLfGad" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;3,849,571&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zUB0yjZJU51a" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;1.53&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--RangeOfExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MinimumMember_zCidTcXmjyz1" title="Range of Exercise Ending"&gt;1.32&lt;/span&gt; - &lt;span id="xdx_901_ecustom--RangeOfExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__srt--RangeAxis__srt--MaximumMember_zosRg7CkBXB9" title="Range of Exercise Ending"&gt;1.65&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_pid_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z058uCfQcjNg" title="Weighted-Average Remaining Life (Years) Outstanding"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zRMnQL7QMLje" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;1,349,571&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zfqXh6Hdo6Ia" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;1.32&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_iE_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_z5pCfLasIRn4" title="Range of Exercise Price, Exercisable"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember_zbFX0nxgMxMb" title="Weighted-Average Remaining Life (Years) Exercisable"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001070"
      unitRef="Shares">3849571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001072"
      unitRef="USDPShares">1.53</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePrice
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001074"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePrice>
    <QLGN:RangeOfExercisePrice
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001076"
      unitRef="USDPShares">1.65</QLGN:RangeOfExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="Fact001078">P3Y10M24D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001084"
      unitRef="Shares">-2751976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001086"
      unitRef="USDPShares">1.53</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001088"
      unitRef="Shares">-1097595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001090"
      unitRef="USDPShares">1.32</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceExpired
      contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001092"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePriceExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001094"
      unitRef="Shares">455623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001096"
      unitRef="USDPShares">0.73</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceGranted
      contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001098"
      unitRef="USDPShares">0.73</QLGN:RangeOfExercisePriceGranted>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="Fact001100">P0Y5M26D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAveragRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001102"
      unitRef="Shares">455623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001104"
      unitRef="USDPShares">0.73</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePrice
      contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001106"
      unitRef="USDPShares">0.73</QLGN:RangeOfExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="Fact001108">P0Y5M26D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001110"
      unitRef="Shares">455623</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001112"
      unitRef="USDPShares">0.73</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001114"
      unitRef="USDPShares">0.73</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="Fact001116">P0Y5M26D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001118"
      unitRef="Shares">248162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001120"
      unitRef="USDPShares">7.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePrice
      contextRef="AsOf2021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001122"
      unitRef="USDPShares">7.20</QLGN:RangeOfExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1
      contextRef="From2021-01-012021-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="Fact001124">P2Y</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001126"
      unitRef="Shares">536</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001128"
      unitRef="USDPShares">7.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001130"
      unitRef="Shares">-247625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001132"
      unitRef="USDPShares">7.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001138"
      unitRef="Shares">3849570</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001140"
      unitRef="USDPShares">1.53</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001142"
      unitRef="Shares">3849571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001144"
      unitRef="USDPShares">1.53</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePrice
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001146"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePrice>
    <QLGN:RangeOfExercisePrice
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001148"
      unitRef="USDPShares">1.65</QLGN:RangeOfExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="Fact001150">P3Y10M24D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001152"
      unitRef="Shares">1349571</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001154"
      unitRef="USDPShares">1.32</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      decimals="INF"
      id="Fact001156"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_custom_SeriesCWarrantsMember_custom_CommonStockWarrantsMember"
      id="Fact001158">P1Y</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1>
    <QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001160">&lt;p id="xdx_894_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_zaRegjGYHHA5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the Company&#x2019;s fair value hierarchy for its Common Stock Warrant liabilities measured at fair value on
a recurring basis as of December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span id="xdx_8B1_zf8I8IX64Hpe" style="display: none"&gt;SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Quoted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Market&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Prices for&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Identical&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Observable&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Unobservable&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Common Stock Warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Balance as of December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zk2S50r1wUo9" style="width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zwF17oo6oJ0b" style="width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1164"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3YSTwRWIp9f" style="width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;3,622,647&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueAdjustmentOfWarrant_iS_pp0p0_c20230101__20231231_zUZVCfHgsG3d" style="width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;3,622,647&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercises&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zQy3t8j7Pkc5" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1170"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbGSQkPGKFtl" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1172"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zmr2VS7RgnY3" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1174"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueOfWarrantLiabilitiesOnDateOfExercise_c20230101__20231231_zjrQMRAP23P6" style="text-align: right" title="Common Stock Warrant liabilities, Exercises"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1176"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair value of warrant reclassified from liabilities to equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z3WJcEyKG0Gf" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1178"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zOjcm6ivjhDg" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1180"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zBfZXoBC0lmd" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity"&gt;(1,626,694&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--FairValueOfWarrantLiabilitiesOnToEquity_c20230101__20231231_zYtjNdEmpwHk" style="text-align: right" title="Common Stock Warrant liabilities, Fair value of warrant liabilities to equity"&gt;(1,626,694&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss on debt extinguishment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zLxxDu42GPxj" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1186"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdVYXEMqMZ2h" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1188"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zGifwwzAL4Hk" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment"&gt;94,116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment_c20230101__20231231_zMx7CBzLSDK" style="text-align: right" title="Common Stock Warrant liabilities, Loss on debt extinguishment"&gt;94,116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Gain on change in fair value of warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6PA4TroVkH4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1194"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEfdE8kUk6y" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1196"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuqXgmjIP9R6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities"&gt;(2,035,469&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiabilities_pdp0_c20230101__20231231_z8TZTLxXZBJg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value of warrant liabilities"&gt;(2,035,469&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zA2x9DGqSMv5" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1202"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zR9Pz6ubn7Ll" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1204"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjCqS6yr3EFg" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;54,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_iE_c20230101__20231231_zABKNkMvGdd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;54,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001166"
      unitRef="USD">3622647</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001168"
      unitRef="USD">3622647</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:FairValueOfWarrantLiabilitiesOnToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001182"
      unitRef="USD">-1626694</QLGN:FairValueOfWarrantLiabilitiesOnToEquity>
    <QLGN:FairValueOfWarrantLiabilitiesOnToEquity
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001184"
      unitRef="USD">-1626694</QLGN:FairValueOfWarrantLiabilitiesOnToEquity>
    <QLGN:FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001190"
      unitRef="USD">94116</QLGN:FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment>
    <QLGN:FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001192"
      unitRef="USD">94116</QLGN:FairValueOfWarrantLiabilitiesLossOnDebtExtinguishment>
    <QLGN:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001198"
      unitRef="USD">-2035469</QLGN:ChangeInFairValueOfWarrantLiabilities>
    <QLGN:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001200"
      unitRef="USD">-2035469</QLGN:ChangeInFairValueOfWarrantLiabilities>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001206"
      unitRef="USD">54600</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001208"
      unitRef="USD">54600</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001210">&lt;p id="xdx_89C_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_z931rg3adps8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the assumptions used in, and the weighted average and the range of assumptions used in estimating the fair value of warrant
liabilities (weighted average calculated based on the number of outstanding warrants on each issuance) as of December 31, 2023 and December
31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8B9_z96BAMXS0VHi" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Actual&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 48%"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJCfIiEqdgMe" title="Risk-free interest rate"&gt;5.13&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zxlMDbpDQmzg" title="Risk-free interest rate"&gt;3.906&lt;/span&gt;% &#x2014; &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_za3tnsv0nytg" title="Risk-free interest rate"&gt;4.628&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--WeightedAverageMember_z0l4hoNa3Vl5" title="Fair value assumptions, measurement input, percentages"&gt;4.15&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (peer group)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zb3YVa1Xbt5i" title="Expected volatility"&gt;68.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zcvwFxKOAXf5" title="Expected volatility"&gt;88&lt;/span&gt;% &#x2014; &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z7fyT5FHPUg" title="Expected volatility"&gt;103&lt;/span&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxuFn49vKpAe" title="Expected volatility"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term of warrants (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zehqffzt9hZe" title="Term of warrants (in years)"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuG1mYphnsXg" title="Term of warrants (in years)"&gt;.90&lt;/span&gt; &#x2014; &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zbVrTNrWKuk8" title="Term of warrants (in years)"&gt;5.48&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__srt--RangeAxis__srt--WeightedAverageMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6bowoNviRDa" title="Fair value assumptions, measurement input, term"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zUID2ZCOsYb1" title="Expected dividend yield"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJ5NamsSDabb" title="Expected dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__srt--RangeAxis__srt--WeightedAverageMember_zoGx3mIIsM7h" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001212"
      unitRef="Pure">5.13</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001214"
      unitRef="Pure">3.906</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001216"
      unitRef="Pure">4.628</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_WeightedAverageMember"
      decimals="INF"
      id="Fact001218"
      unitRef="Pure">4.15</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001220"
      unitRef="Pure">68.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001222"
      unitRef="Pure">88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001224"
      unitRef="Pure">103</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001226"
      unitRef="Pure">98</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001228">P0Y5M26D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-12-31_srt_MinimumMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001230">P0Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-12-31_srt_MaximumMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001232">P5Y5M23D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-12-31_srt_WeightedAverageMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001234">P3Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001236"
      unitRef="Pure">0.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001238"
      unitRef="Pure">0.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_srt_WeightedAverageMember"
      decimals="INF"
      id="Fact001240"
      unitRef="Pure">0.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001242">&lt;p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_zXPNpobi84E2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &#x2014; &lt;span id="xdx_826_zU0mCH8rZLB8"&gt;CONVERTIBLE DEBT- RELATED PARTY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 22, 2022, the Company issued to Alpha an &lt;span id="xdx_908_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z8roDX7mhdwa" title="Senior convertible debenture rate"&gt;8&lt;/span&gt;%
Senior Convertible Debenture in the aggregate principal amount of $&lt;span id="xdx_909_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zJjwuj3Wkfmi" title="Principal amount"&gt;3,300,000&lt;/span&gt;
for a purchase price of $&lt;span id="xdx_90A_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zZxNtAGjOgdf" title="Purchase Price"&gt;3,000,000&lt;/span&gt;
(less expenses) pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture has a maturity date
of &lt;span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zXINtaF809T" title="Maturity date"&gt;December
22, 2025&lt;/span&gt; and was initially convertible, at any time, and from time to time, until the Debenture is no longer outstanding, at
Alpha&#x2019;s option, into shares of common stock of the Company (the &#x201c;Conversion Shares&#x201d;), at a price equal to $&lt;span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zEVFFvK7NUzb" title="Conversion price"&gt;1.32&lt;/span&gt;
per share, subject to adjustment as described in the Debenture (the &#x201c;Conversion Price&#x201d;) and other terms and conditions
described in the Debenture, including the necessary stockholder approvals, which the Company obtained at its 2023 annual meeting of
stockholders on July 13, 2023. As a part of the same transaction, on December 22, 2022, the Company issued to Alpha a
liability classified warrant (the &#x201c;Alpha Warrant&#x201d;) to purchase &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zUn6rDXZB204" title="Warrant to purchase shares"&gt;2,500,000&lt;/span&gt;
shares of the Company&#x2019;s common stock (see Note 7 - Warrant Liabilities). The exercise price of the Alpha Warrant was initially
$&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zaAHAlERsS7" title="Exercise price of warrant"&gt;1.65&lt;/span&gt;
(equal to &lt;span id="xdx_902_ecustom--ConversionPricePercentage_pid_dp_uPure_c20221222__20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zNe8JeCy6HU8" title="Conversion price percentage"&gt;125&lt;/span&gt;%
of the Conversion Price of the Debenture on the closing date) subject to adjustment as described in the Alpha Warrant. The Alpha
Warrant may be exercised by Alpha, in whole or in part, at any time before June 22, 2028, subject to certain terms and
conditions described in the Alpha Warrant, including the necessary stockholder approvals, which the Company obtained at its 2023
annual meeting of stockholders on July 13, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
proceeds from the transaction were used to advance the Company&#x2019;s QN-302 Investigative New Drug candidate towards clinical trials
and other working capital purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption
of the Debenture (each such date, a &#x201c;Monthly Redemption Date&#x201d;), the Company must redeem $&lt;span id="xdx_90B_eus-gaap--RepaymentsOfLongTermDebtAndCapitalSecurities_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_z7kI6s7A3oL8" title="Redeemable debt"&gt;110,000&lt;/span&gt; plus accrued but unpaid
interest, liquidated damages and any amounts then owing under the Debenture (the &#x201c;Monthly Redemption Amount&#x201d;). The Monthly
Redemption Amount must be paid in cash; provided that after the first two monthly redemptions, the Company may elect to pay all or a
portion of a Monthly Redemption Amount in shares of common stock of the Company, based on a Conversion Price equal to the lesser of (i)
the then Conversion Price of the Debenture and (ii) &lt;span id="xdx_902_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zYYn5O6h1BS1" title="Conversion rate"&gt;85&lt;/span&gt;% of the average of the VWAPs (as defined in the Debenture) for the five consecutive
trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. The Company may also redeem
some or all of the then outstanding principal amount of the Debenture at any time for cash in an amount equal to &lt;span id="xdx_901_ecustom--PrincipalAmountPercentage_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zVJpjKZNZtP9" title="Principal amount percentage"&gt;105&lt;/span&gt;% of the then outstanding
principal amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under
the Debenture. The Company&#x2019;s election to pay monthly redemptions in Conversion Shares or to effect an optional redemption is subject
to the satisfaction (or waiver) of the Equity Conditions (as defined in the Debenture), including the necessary stockholder approvals,
which the Company obtained at its 2023 annual meeting of stockholders on July 13, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Debenture accrues interest at the rate of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221222_zhA0tJv13IH4" title="Debenture accrues interest rate"&gt;8&lt;/span&gt;% per annum, which did not begin accruing until December 1, 2023. Interest may be paid in
cash or shares of common stock of the Company or a combination thereof at the option of the Company; provided that interest may only
be paid in shares if the Equity Conditions have been satisfied (or waived).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Both
the Debenture and the Alpha Warrant provide for adjustments to the Conversion Price and exercise price, respectively, in connection with
stock dividends and splits, subsequent equity sales and rights offerings, pro rata distributions, and certain fundamental transactions.
Both the Debenture and the Alpha Warrant include a beneficial ownership blocker of &lt;span id="xdx_907_ecustom--DebentureBeneficialOwnershipBlockerPercentage_pid_dp_uPure_c20221222__20221222__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zFs5ai4mfo8c" title="Debenture beneficial ownership blocker percentage"&gt;9.99&lt;/span&gt;%, which may only be waived by Alpha upon
61 days&#x2019; notice to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to resale registration rights granted by the Company to Alpha in such Securities Purchase Agreement, the Company filed a
resale registration statement on Form S-3 (File Number 333-269088) on December 30, 2022 registering the resale by Alpha of
up to &lt;span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_pid_c20221230__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlphaCapitalMember_zh0M8xs4Zapb" title="Shares of Common stock, issued"&gt;5,157,087&lt;/span&gt;
shares of common stock of the Company which could be issued to Alpha pursuant to the Debenture and the Alpha Warrant, which
registration statement was declared effective by the SEC on January 5, 2023 (the &#x201c;Original Registration Statement&#x201d;). The
Company later became ineligible to update the Original Registration Statement via incorporation by reference of its future SEC
periodic and current reports as a result of its failure to timely file its annual report on Form 10-K for the fiscal year ended
December 31, 2022. Therefore, the Company filed a Post-Effective Amendment No. 1 to Form S-3 on Form S-1 (No. 333-269088)(the
&#x201c;Post-Effective Amendment No. 1&#x201d;) on September 1, 2023 in order to maintain the registration of the resale by Alpha of up to &lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230901__20230901__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AlphaCapitalMember_zoC4W55AW0md" title="Resale of common stock shares"&gt;3,958,537&lt;/span&gt;
shares of common stock of the Company issuable under the Debenture and the Alpha Warrant., which Post-Effective Amendment No. 1 was
declared effective by the SEC on September 7, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluated the Debenture and the Alpha Warrant and determined that the Alpha Warrant is a freestanding financial instrument. Initially,
the Alpha Warrant is not considered indexed to the Company&#x2019;s own stock, because the settlement amount would not equal the difference
between the fair value of a fixed number of the Company&#x2019;s equity shares and a fixed strike price and all of the adjustment features
in Section 3(b) of the Alpha Warrant are not down round provisions, as defined in ASU 2017-11. Accordingly, the Alpha Warrant was classified
as a liability and recognized at fair value, with subsequent changes in fair value recognized in earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
proceeds from the Debenture were allocated to the initial fair value of the Alpha Warrant, with the residual balance allocated to the
initial carrying value of the Debenture. The Company has not elected the fair value option for the Debenture. The Debenture was recognized
as proceeds received after allocating the proceeds to the Alpha Warrant, and then allocating remaining proceeds to a suite of bifurcated
embedded derivative features (conversion option, contingent acceleration upon an Event of Default, and contingent interest upon an Event
of Default), with the resulting difference, if any, allocated to the loan host instrument. The suite of derivative features was measured
and determined to have no fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
original issue discount of $&lt;span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zEgEQc4q7Zr2" title="Debt discount"&gt;0.3&lt;/span&gt; million, the initial fair value of the Alpha Warrant of $&lt;span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zTnCdbaQyKk7" title="Fair value of warrants"&gt;2.8&lt;/span&gt; million, the initial fair value of the suite
of bifurcated embedded derivative features of $&lt;span id="xdx_90F_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet_iI_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_z98HP0how0Ea" title="Fair value of embedded derivative features"&gt;0&lt;/span&gt;, and the fees and costs paid to Alpha and other third parties of $&lt;span id="xdx_905_eus-gaap--PaymentsForFees_pn5n6_c20230101__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalOtherThirdPartiesMember_zrMTqvxAkYxj" title="Fees and costs paid"&gt;0.1&lt;/span&gt; million
comprised the debt discount upon issuance. The debt discount is amortized to interest expense over the expected term of the Debenture
using the effective interest method, in accordance with ASC 835-30. The debt host instrument of the Debenture will subsequently be measured
at amortized cost using the effective interest method to accrete interest over its term to bring the Debenture&#x2019;s initial carrying
value to the principal balance at maturity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Between
January 9 and 12, 2023, the Company issued &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230109__20230112__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zpKLUlhKdc6j" title="Number of shares issued"&gt;841,726&lt;/span&gt;
shares of common stock upon Alpha&#x2019;s partial conversion of the Debenture at $&lt;span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230112__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z6LXJUp5nUg6" title="Conversion price"&gt;1.32&lt;/span&gt;
per share for a total of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20230112__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zPqlWAgmu3gd" title="Debenture voluntarily converted"&gt;1,111,078&lt;/span&gt;
principal. Upon conversion, the Company recognized a loss on conversion of convertible debt of approximately $&lt;span id="xdx_90E_eus-gaap--ConvertibleDebtCurrent_iI_pn5n6_c20230112__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zqYlqHFJOLgd" title="Debt conversion of convertible debt"&gt;1.1&lt;/span&gt;
million, recorded to other expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October and December 2023, the Company issued &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231031__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zfO8ezg0jt32" title="Number of shares issued"&gt;&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231201__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zwZJmES49Kl5" title="Number of shares issued"&gt;309,665&lt;/span&gt;&lt;/span&gt;
shares of common stock to Alpha in lieu of cash for monthly redemption payments on the Debenture at a weighted average price
of $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20231031__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_znzRejM6O6m8" title="Weighted price per share"&gt;&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zbVsq0thiYN6" title="Weighted price per share"&gt;0.71&lt;/span&gt;&lt;/span&gt;
per share. Upon redemption for shares, the Company recognized a loss on partial debt extinguishment of $&lt;span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20231001__20231031__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zxaPPvA0wwcj" title="Losses on debt extinguishment"&gt;&lt;span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20231201__20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_znbCtZ507maa" title="Losses on debt extinguishment"&gt;34,315&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 22, 2023, the Company entered into a consent and waiver (the &#x201c;Waiver&#x201d;) with Alpha. Pursuant to the Waiver,
Alpha consented to the Company&#x2019;s election to pay all of the Monthly Redemption Amount for October 2023 in Conversion Shares
(the &#x201c;October Payment&#x201d;) and waived the requirement of satisfaction of the Equity Conditions in relation to the October and
December Payment. On October 3, 2023 the Company issued &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20231003__20231003__us-gaap--TypeOfArrangementAxis__custom--OctoberPaymentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlphaCapitalMember_zh1tCKtDFNv4" title="October payment in shares"&gt;128,595&lt;/span&gt; shares of common stock to Alpha in satisfaction of the October
Payment. On December 8, 2023 the Company issued &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20231208__20231208__us-gaap--TypeOfArrangementAxis__custom--OctoberPaymentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AlphaCapitalMember_z02IwALocw64" title="October payment in shares"&gt;181,070&lt;/span&gt; shares of common stock to Alpha in satisfaction of the December Payment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 5, 2023, the Company and Alpha executed Amendment No. 1 with regard to Securities Purchase Agreement (the &#x201c;SPA
Amendment&#x201d;), pursuant to which the Company and Alpha agreed to, among other things, reduce the Conversion Price of the
Debenture from $&lt;span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zErmCRdhg94b" title="Conversion price"&gt;1.32&lt;/span&gt;
per share to $&lt;span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_z71owejzYxXf" title="Conversion price"&gt;0.73&lt;/span&gt;
per share and reduce the exercise price of the Alpha Warrant from $&lt;span id="xdx_909_eus-gaap--WarrantExercisePriceIncrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zNQPdd9gHgLd" title="Conversion price"&gt;1.65&lt;/span&gt;
per share to $&lt;span id="xdx_907_eus-gaap--WarrantExercisePriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z5h5hVHuscji" title="Conversion price"&gt;0.73&lt;/span&gt;
per share, in each case subject to certain adjustments. In addition, the SPA Amendment revised certain provisions of the Alpha
Warrant to (i) limit the circumstances which would trigger a potential adjustment to the exercise price of the Alpha Warrant and
(ii) clarify the treatment of the Alpha Warrant upon a Fundamental Transaction. The purpose of these revisions was to remove the
terms that caused the Alpha Warrant to be liability-classified under U.S. GAAP. The Company performed an assessment and concluded
that all remaining adjustment features in the revised language meet the FASB&#x2019;s definition of a down-round feature. In
addition, the Alpha Warrant was determined to meet all of the additional requirements for equity classification. Accordingly, as of
December 5, 2023, the Company remeasured the Alpha Warrant to its fair value immediately prior to the modification and recognized
the change in fair value in earnings. The incremental fair value impact from the Alpha Warrant modification of $&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_pn4n6_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zsHzOVlBYjfk" title="Fair value of warrant liability"&gt;0.09&lt;/span&gt;
million was included in the Company&#x2019;s evaluation of the Debenture modification under ASC 470, discussed further below. The
Company then reclassified the Alpha Warrant liability to equity at its post-modification fair value of $&lt;span id="xdx_903_eus-gaap--WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1_pn5n6_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z28OGtBcetVc" title="Warrant liability to equity"&gt;1.6&lt;/span&gt;
million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASC 470-50, the Company determined that the modified terms of the Debenture were substantially different when
compared to the original terms that existed prior to the SPA Amendment, and thus the event was required to be accounted for as a
debt extinguishment. Accordingly, the Company derecognized the net carrying value of the original Debenture, and recorded the new
debt instrument at its fair value of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFairValue_iI_pn5n6_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zmEovKpEQWoc" title="Debt instrument fair value"&gt;1.4&lt;/span&gt;
million, and recorded a $&lt;span id="xdx_90A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zrGXj6XAxCP1" title="Loss on extinguishment"&gt;0.6&lt;/span&gt;
million loss on debt extinguishment. The difference between the remaining Debenture principal and its fair value on December 5, 2023
was recorded as a debt discount and will be amortized to interest expense over the expected term of the Debenture using the
effective interest method, in accordance with ASC 835-30.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company recognized a loss on voluntary conversion of convertible debt of
approximately $&lt;span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20230101__20231231_zlBLnd30p5Md" title="Debt conversion of convertible debt"&gt;1.1&lt;/span&gt;
million, recognized an extinguishment loss of $&lt;span id="xdx_90D_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn5n6_c20230101__20231231__us-gaap--ExtinguishmentOfDebtAxis__us-gaap--ConvertibleDebtMember_z4AhbSkaLfd6" title="Extinguishment loss"&gt;0.6&lt;/span&gt;
million upon October and December 2023 share redemptions and December 2023 modification of the Debenture, and recorded
accrued interest of approximately $&lt;span id="xdx_903_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn5n6_c20230101__20231231_zPBNjTr9bLu7" title="Accrued interest"&gt;1.5&lt;/span&gt;
million, in other expenses in the consolidated statements of operations. During the year ended December 31, 2023 the Company paid
Monthly Redemption Amounts of $&lt;span id="xdx_904_ecustom--DebtRedemptionAmountInCash_c20230101__20231231_z2HOt3us9Rel" title="Redemption amount in cash"&gt;550,000&lt;/span&gt;
in cash and $&lt;span id="xdx_907_ecustom--DebtRedemptionAmountInCommonStock_c20230101__20231231_zBrNhLXO6z77" title="Redemption amounts in common stock"&gt;220,000&lt;/span&gt;
in common stock, and as of December 31, 2023 the remaining Debenture principal balance was approximately $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20231231_zGKiB1S3yAn5" title="Debenture principal balance"&gt;1.4&lt;/span&gt;
million, the remaining discount was approximately $&lt;span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20231231_zQyEIsVwkAgf" title="Debt discount"&gt;0.1&lt;/span&gt;
million, and the fair value of the suite of bifurcated embedded derivative features was $&lt;span id="xdx_90E_eus-gaap--DerivativeFairValueOfDerivativeNet_iI_c20231231_zPo5ocEwE4Bj" title="Derivative fair value of warrants"&gt;0&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ConvertibleDebtTableTextBlock_zOeh0D24vQXj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
senior convertible debt comprises the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span id="xdx_8B8_zH4MDVn648ug" style="display: none"&gt;SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zB5SrNpsgSZ5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20221231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zJufdsid8uN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--SecuredDebt_iI_zL6i72Wp3Pah" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Senior convertible debenture&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,418,922&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_znbJgSde29C9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Discount on convertible debenture&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(119,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,239,803&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_zQZXTcRUnVne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total convertible debt-related party&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,299,216&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;60,197&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zWRyG2Pv5sQk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, there were no unwaived events of default or violation of any covenants under the Company&#x2019;s financing obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ShortTermDebtInterestRateIncrease
      contextRef="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      id="Fact001244"
      unitRef="Pure">0.08</us-gaap:ShortTermDebtInterestRateIncrease>
    <us-gaap:SecuredDebt
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="0"
      id="Fact001246"
      unitRef="USD">3300000</us-gaap:SecuredDebt>
    <QLGN:PurchasePrice
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="0"
      id="Fact001248"
      unitRef="USD">3000000</QLGN:PurchasePrice>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      id="Fact001250">2025-12-22</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      id="Fact001252"
      unitRef="USDPShares">1.32</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001254"
      unitRef="Shares">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001256"
      unitRef="USDPShares">1.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:ConversionPricePercentage
      contextRef="From2022-12-222022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001258"
      unitRef="Pure">1.25</QLGN:ConversionPricePercentage>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember"
      decimals="0"
      id="Fact001260"
      unitRef="USD">110000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      id="Fact001262"
      unitRef="Pure">0.85</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <QLGN:PrincipalAmountPercentage
      contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      id="Fact001264"
      unitRef="Pure">1.05</QLGN:PrincipalAmountPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-12-22"
      decimals="INF"
      id="Fact001266"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <QLGN:DebentureBeneficialOwnershipBlockerPercentage
      contextRef="From2022-12-222022-12-22_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      id="Fact001268"
      unitRef="Pure">0.0999</QLGN:DebentureBeneficialOwnershipBlockerPercentage>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-30_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001270"
      unitRef="Shares">5157087</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-09-012023-09-01_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001272"
      unitRef="Shares">3958537</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-01-012023-12-31_custom_AlphaCapitalOtherThirdPartiesMember"
      decimals="-5"
      id="Fact001274"
      unitRef="USD">300000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_custom_AlphaCapitalOtherThirdPartiesMember"
      decimals="-5"
      id="Fact001276"
      unitRef="USD">2800000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet
      contextRef="AsOf2023-12-31_custom_AlphaCapitalOtherThirdPartiesMember"
      decimals="0"
      id="Fact001278"
      unitRef="USD">0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet>
    <us-gaap:PaymentsForFees
      contextRef="From2023-01-012023-12-31_custom_AlphaCapitalOtherThirdPartiesMember"
      decimals="-5"
      id="Fact001280"
      unitRef="USD">100000</us-gaap:PaymentsForFees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-092023-01-12_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001282"
      unitRef="Shares">841726</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-01-12_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001284"
      unitRef="USDPShares">1.32</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-01-12_custom_AlphaCapitalMember"
      decimals="0"
      id="Fact001286"
      unitRef="USD">1111078</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2023-01-12_custom_AlphaCapitalMember"
      decimals="-5"
      id="Fact001288"
      unitRef="USD">1100000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-012023-10-31_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001290"
      unitRef="Shares">309665</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-12-012023-12-31_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001292"
      unitRef="Shares">309665</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-10-31_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001294"
      unitRef="USDPShares">0.71</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-12-31_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001296"
      unitRef="USDPShares">0.71</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-10-012023-10-31_custom_AlphaCapitalMember"
      decimals="0"
      id="Fact001298"
      unitRef="USD">34315</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-12-012023-12-31_custom_AlphaCapitalMember"
      decimals="0"
      id="Fact001300"
      unitRef="USD">34315</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-10-032023-10-03_custom_OctoberPaymentMember_us-gaap_CommonStockMember_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001302"
      unitRef="Shares">128595</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-12-082023-12-08_custom_OctoberPaymentMember_us-gaap_CommonStockMember_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001304"
      unitRef="Shares">181070</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001306"
      unitRef="USDPShares">1.32</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001308"
      unitRef="USDPShares">0.73</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001310"
      unitRef="USDPShares">1.65</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001312"
      unitRef="USDPShares">0.73</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-4"
      id="Fact001314"
      unitRef="USD">90000.00</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
      contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact001316"
      unitRef="USD">1600000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact001318"
      unitRef="USD">1400000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact001320"
      unitRef="USD">600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="From2023-01-01to2023-12-31"
      decimals="-5"
      id="Fact001322"
      unitRef="USD">1100000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtMember"
      decimals="-5"
      id="Fact001324"
      unitRef="USD">600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="-5"
      id="Fact001326"
      unitRef="USD">1500000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <QLGN:DebtRedemptionAmountInCash
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001328"
      unitRef="USD">550000</QLGN:DebtRedemptionAmountInCash>
    <QLGN:DebtRedemptionAmountInCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001330"
      unitRef="USD">220000</QLGN:DebtRedemptionAmountInCommonStock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001332"
      unitRef="USD">1400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-12-31"
      decimals="-5"
      id="Fact001334"
      unitRef="USD">100000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001336"
      unitRef="USD">0</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001338">&lt;p id="xdx_893_eus-gaap--ConvertibleDebtTableTextBlock_zOeh0D24vQXj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
senior convertible debt comprises the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span id="xdx_8B8_zH4MDVn648ug" style="display: none"&gt;SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zB5SrNpsgSZ5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20221231__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertibleDebtMember_zJufdsid8uN4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--SecuredDebt_iI_zL6i72Wp3Pah" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Senior convertible debenture&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,418,922&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;3,300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_znbJgSde29C9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Discount on convertible debenture&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(119,706&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,239,803&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ConvertibleDebt_iI_zQZXTcRUnVne" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total convertible debt-related party&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,299,216&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;60,197&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:SecuredDebt
      contextRef="AsOf2023-12-31_custom_SeniorSecuredConvertibleDebtMember"
      decimals="0"
      id="Fact001340"
      unitRef="USD">1418922</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt
      contextRef="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember"
      decimals="0"
      id="Fact001341"
      unitRef="USD">3300000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-12-31_custom_SeniorSecuredConvertibleDebtMember"
      decimals="0"
      id="Fact001343"
      unitRef="USD">119706</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember"
      decimals="0"
      id="Fact001344"
      unitRef="USD">3239803</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2023-12-31_custom_SeniorSecuredConvertibleDebtMember"
      decimals="0"
      id="Fact001346"
      unitRef="USD">1299216</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2022-12-31_custom_SeniorSecuredConvertibleDebtMember"
      decimals="0"
      id="Fact001347"
      unitRef="USD">60197</us-gaap:ConvertibleDebt>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001349">&lt;p id="xdx_805_eus-gaap--EarningsPerShareTextBlock_zJPsDjOau3O6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2014; &lt;span id="xdx_827_zPGQQYysyT1e"&gt;EARNINGS (LOSS) PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share (&#x201c;EPS&#x201d;) is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted
EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during
the period. Potentially dilutive common shares consist of shares issuable from convertible debt, stock options and warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z3OXkzOiCRvi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following potentially dilutive securities have been excluded from diluted net loss per share as of December 31, 2023 and 2022 because
their effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span id="xdx_8B7_zlzE769K8vK4" style="display: none"&gt;SCHEDULE
OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zSIovIChNxfh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_zQLGPWwKm7yg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Years Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zJiUFN0xyJHh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 60%; text-align: left"&gt;Net loss used for basic earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;(13,417,212&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;(18,640,543&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zIibE0Bcgfv9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Basic weighted-average common shares outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,072,709&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,840,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_zE5ERx10oJ9a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Dilutive potential shares issuable from convertible debt, stock options and warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1359"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1360"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zhTDRiIz5Ita" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Diluted weighted-average common shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,072,709&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,840,340&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zMzxpJE7OSu" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001351">&lt;p id="xdx_89E_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z3OXkzOiCRvi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following potentially dilutive securities have been excluded from diluted net loss per share as of December 31, 2023 and 2022 because
their effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span id="xdx_8B7_zlzE769K8vK4" style="display: none"&gt;SCHEDULE
OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zSIovIChNxfh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_zQLGPWwKm7yg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For the Years Ended&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zJiUFN0xyJHh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 60%; text-align: left"&gt;Net loss used for basic earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;(13,417,212&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"&gt;(18,640,543&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zIibE0Bcgfv9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Basic weighted-average common shares outstanding&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,072,709&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,840,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--DilutivePotentialSharesIssuableFromStockOptionsAndWarrants_zE5ERx10oJ9a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Dilutive potential shares issuable from convertible debt, stock options and warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1359"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1360"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zhTDRiIz5Ita" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Diluted weighted-average common shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,072,709&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,840,340&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001353"
      unitRef="USD">-13417212</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001354"
      unitRef="USD">-18640543</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001356"
      unitRef="Shares">5072709</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001357"
      unitRef="Shares">3840340</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001362"
      unitRef="Shares">5072709</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001363"
      unitRef="Shares">3840340</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001365">&lt;p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z3eveFH7U4Je" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 &#x2014; &lt;span id="xdx_82E_zK0KLzZoSfxb"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Litigation
and Other Legal Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 9, 2021, the Company was named as a defendant in an action brought by Mediant Communications Inc. (&#x201c;Mediant&#x201d;) in
the U.S. District Court for the Southern District of New York. The complaint alleged that Qualigen entered into an implied contract with
Mediant, whereby Qualigen retained Mediant to distribute proxy materials and subsequently conduct shareholder vote tabulations. The Company
filed a Motion to Dismiss with the District Court and on March 14, 2022 a hearing was held during which the presiding judge ruled in
favor of the Motion to Dismiss. The Company and Mediant settled the litigation on April 5, 2022 in the amount of $&lt;span id="xdx_90E_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pdp0_c20220405__20220405_zzjcwTUTcAV" title="Litigation paid"&gt;96,558&lt;/span&gt;, at which time
the amount was paid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2022-04-052022-04-05"
      decimals="0"
      id="Fact001367"
      unitRef="USD">96558</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <QLGN:ResearchAndLicenseAgreementsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001369">&lt;p id="xdx_80A_ecustom--ResearchAndLicenseAgreementsTextBlock_z5Spl7nwPGt5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 &#x2014; &lt;span id="xdx_82E_zKvwRiE4sicb"&gt;RESEARCH AND LICENSE AGREEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;UCL
Business Limited&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2022, the Company entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a
genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London,
including lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for
University College London.) The program&#x2019;s lead compound is now being developed at the Company under the name QN-302 as a candidate
for treatment for pancreatic ductal adenocarcinoma, which represents the vast majority of pancreatic cancers. The License Agreement required
a $&lt;span id="xdx_900_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--AwardTypeAxis__custom--UpfrontPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zPhiPwBij0sa" title="Reimbursement of patent"&gt;150,000&lt;/span&gt; upfront payment, reimbursement of past patent prosecution expenses (approximately $&lt;span id="xdx_900_ecustom--ReimbursementOfPatent_c20220101__20220131__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_z6J1jIG6szR2" title="Reimbursement of patent"&gt;160,000&lt;/span&gt;), and (if and when applicable)
tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments and a percentage of any non-royalty
sublicensing consideration paid to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022 there were license costs of approximately $&lt;span id="xdx_90B_ecustom--LicenseCost_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zSJnVgnPmzR4" title="License cost"&gt;128,000&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zhJsnrAaVqSi" title="License cost"&gt;338,000&lt;/span&gt;, respectively, related to
this agreement which are included in research and development expenses in the consolidated statements of operations and other comprehensive
loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;QN-302
Phase 1 Study&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2023, the Company entered into a Master Clinical Research Services Agreement with Translational Drug Development, LLC (&#x201c;TD2&#x201d;)
whereby TD2 agreed to perform certain clinical research and development services for the Company including but not limited to trial management,
side identification and selection, site monitoring/management, medical monitoring, project management, data collection, statistical programming
or analysis, quality assurance auditing, scientific and medical communications, regulatory affairs consulting and submissions, strategic
consulting, and/or other related services. From time to time, the Company intends to enter into statements of work with TD2 for the performance
of specific services under this Master Clinical Research Services Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2023, the Company entered into a Master Laboratory Services Agreement with MLM Medical Labs, LLC (&#x201c;MLM&#x201d;) whereby MLM
agreed to perform certain clinical research and development services for the Company including but not limited to laboratory, supply,
testing, validation, data management, and storage services. From time to time, the Company intends to enter into work orders with MLM
for the performance of specific services under this Master Laboratory Services Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2023, the Company entered into a Master Services Agreement with Clinigen Clinical Supplies Management, Inc. (&#x201c;Clinigen&#x201d;)
whereby Clinigen agreed to provide certain pharmaceutical products and/or services. From time to time, the Company intends to enter into
statements of work with Clinigen for the performance of specific services under this Master Services Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2023, pursuant to the above agreements, the Company entered into work orders and statements of work for clinical trial services
for the conduct of the QN-302 Phase 1 study. The project timeline started in July 2023 and is expected to continue until approximately
July 2026. The total amount to be paid under these work orders and statements of work is currently expected to be approximately $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20230701__20230731__us-gaap--TypeOfArrangementAxis__custom--MasterLaboratoryServicesAgreementMember__dei--LegalEntityAxis__custom--MLMMedicalLabsMember_z72LbVTys471" title="Research and Development Expense"&gt;7.6&lt;/span&gt;
million over the term of the QN-302 Phase 1 study, subject to available funding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;University
of Louisville Research Foundation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with University of Louisville
Research Foundation, Inc. (&#x201c;ULRF&#x201d;) for development of several small-molecule RAS interaction inhibitor drug candidates. Under
the terms of this agreement, the Company agreed to reimburse ULRF for sponsored research expenses of initially up to $&lt;span id="xdx_90A_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z9ihjn2cNfO4"&gt;693,000&lt;/span&gt; for this
program. This agreement was amended in February 2021, March 2022 and August 2023, with the current term of this agreement set to expire
in December 2023 and the aggregate amount that the Company would reimburse ULRF for sponsored research expenses increased to approximately
$&lt;span id="xdx_904_ecustom--ReimbursementOfResearchExpenses_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zxzcpDsU38Oj" title="Research expenses"&gt;2.9&lt;/span&gt; million. &lt;span id="xdx_901_ecustom--AgreementTermPaymentDescription_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zmY422FEK0rl" title="Agreement term payment, description"&gt;In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates.
Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is
responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront
license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered
net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative
$250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30%
to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement,
40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth
year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution
and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $&lt;span id="xdx_908_ecustom--MilestonePayment_pp0p0_c20200701__20200731__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z1QYrpKnNfFl" title="Milestone payment"&gt;50,000&lt;/span&gt; to $&lt;span id="xdx_906_ecustom--MilestonePayment_pp0p0_c20200701__20200731__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z6v8GZqfH8Ih" title="Milestone payment"&gt;5,000,000&lt;/span&gt; upon the achievement
of certain regulatory and commercial milestones.&lt;/span&gt; Milestone payments for the first therapeutic indication would be $&lt;span id="xdx_901_ecustom--MilestonePayment_pp0p0_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_zu95KF0L3qSc" title="Milestone payment"&gt;50,000&lt;/span&gt; for first dosing
in a Phase 1 clinical trial, $&lt;span id="xdx_90C_ecustom--MilestonePayment_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zki8k56pknbj"&gt;100,000&lt;/span&gt; for first dosing in a Phase 2 clinical trial, $&lt;span id="xdx_900_ecustom--MilestonePayment_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zM5uSQcQwsEl" title="Milestone payment"&gt;150,000&lt;/span&gt; for first dosing in a Phase 3 clinical trial,
$&lt;span id="xdx_905_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zGFYrI2V68Z8" title="Marketing approval expenses"&gt;300,000&lt;/span&gt; for regulatory marketing approval and $&lt;span id="xdx_90A_ecustom--CumulativeSales_pp0p0_c20200701__20200731__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zKSMxhSwBF5a" title="Cumulative sales"&gt;5,000,000&lt;/span&gt; upon achieving a cumulative $&lt;span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zQVumjShMKX4" title="Revenue"&gt;500,000,000&lt;/span&gt; of Licensed Product sales. The Company
also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income
for any year is less than the applicable annual minimum (ranging from $&lt;span id="xdx_90A_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200731__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zbWgwfbBkx0j" title="Upfront license fee"&gt;20,000&lt;/span&gt; to $&lt;span id="xdx_90D_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200731__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zY838exDZYJi" title="Upfront license fee"&gt;100,000&lt;/span&gt;) for such year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Sponsored
research expenses related to these RAS agreements for the years ended December 31, 2023 and December 31, 2022 were approximately $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember_zYYDVW9x8cz9" title="Research and development expenses"&gt;743,000&lt;/span&gt;
and $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember_zsIRTn6j87hh" title="Research and development expenses"&gt;758,000&lt;/span&gt;, respectively, and are recorded in research and development expenses in the Consolidated Statements of Operations. License
costs related to these agreements for the years ended December 31, 2023 and December 31, 2022 were approximately $&lt;span id="xdx_901_ecustom--LicenseCost_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember_zeOno0P3mY36" title="License costs"&gt;133,000&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementsAndLicenseMember_zAeEG0xHV4If" title="License costs"&gt;40,000&lt;/span&gt;,
respectively, and are included in research and development expenses in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Between
June 2018 and April 2022, the Company entered into license and sponsored research agreements with ULRF for QN-247, a novel aptamer-based
compound that has shown promise as an anticancer drug. Under the agreements, the Company took over development, regulatory approval and
commercialization of the compound from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return,
ULRF received a $&lt;span id="xdx_90D_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_ziXZGPOYq6L4" title="Proceeds from convertible debt"&gt;50,000&lt;/span&gt; convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#x2019;s
common stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to approximately $&lt;span id="xdx_900_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zWsGO7qjqMdc" title="Reimbursement of research expenses"&gt;805,000&lt;/span&gt; and prior patent
costs of up to $&lt;span id="xdx_90D_ecustom--PatentCosts_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zR5SyuN5SDIl" title="Patent costs"&gt;200,000&lt;/span&gt;. &lt;span id="xdx_90C_ecustom--AgreementTermPaymentDescription_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z02gdTuCaJe9" title="Agreement term payment, description"&gt;In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization
of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative
$250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income
received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third
or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter),
(iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred
prior to June 2018, and (iv) payments ranging from $&lt;span id="xdx_903_ecustom--MilestonePayment_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zPdeQJply0Q1" title="Milestone payment"&gt;100,000&lt;/span&gt; to $&lt;span id="xdx_90B_ecustom--MilestonePayment_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zoqDS22p7z97" title="Milestone payment"&gt;5,000,000&lt;/span&gt; upon the achievement of certain regulatory and commercial milestones.&lt;/span&gt;
Milestone payments for the first therapeutic indication would be $&lt;span id="xdx_90A_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z3pIMe0TMwJ3" title="Milestone payment"&gt;100,000&lt;/span&gt; for first dosing in a Phase 1 clinical trial, $&lt;span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zUZtPwpffupa" title="Milestone payment"&gt;200,000&lt;/span&gt; for
first dosing in a Phase 2 clinical trial, $&lt;span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20180601__20220430__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zMaz19EJUYxg" title="Milestone payment"&gt;350,000&lt;/span&gt; for first dosing in a Phase 3 clinical trial, $&lt;span id="xdx_900_ecustom--RegulatoryMarketingApprovalExpenses_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zfN7wuwOKwrd" title="Marketing approval expenses"&gt;500,000&lt;/span&gt; for regulatory marketing approval
and $&lt;span id="xdx_90F_ecustom--CumulativeSales_pp0p0_c20180601__20220430__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zxlmofmtKRPk" title="Cumulative sales"&gt;5,000,000&lt;/span&gt; upon achieving a cumulative $&lt;span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20180601__20220430__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z3hlTwNjuUsb" title="Revenue"&gt;500,000,000&lt;/span&gt; of Licensed Product sales. The Company also agreed to pay another $&lt;span id="xdx_900_ecustom--RegulatoryMarketingApprovalExpensesOne_pp0p0_c20180601__20220430__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zmVCw5mhYaJc" title="Regulatory marketing approval, expenses"&gt;500,000&lt;/span&gt; milestone
payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The Company must
also pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for
any year is less than the applicable annual minimum (ranging from $&lt;span id="xdx_908_ecustom--ShortfallPayments_pp0p0_c20180601__20220430__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zOISJkAzMvy1" title="Shortfall payments"&gt;10,000&lt;/span&gt; to $&lt;span id="xdx_905_ecustom--ShortfallPayments_c20180601__20220430__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zkaSrkWUhRE7" title="Shortfall payments"&gt;50,000&lt;/span&gt;) for such year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
sponsored research agreement for QN-247 expired in August 2022. The sponsored research expenses related to these QN-247 agreements for
the years ended December 31, 2023 and December 31, 2022 were $&lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_z4lt68itSEqi"&gt;0&lt;/span&gt; and approximately $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zaeeugH71kw"&gt;164,000&lt;/span&gt;, respectively, and these amounts are recorded
in research and development expenses in the consolidated statements of operations and other comprehensive loss. License costs related
to these agreements were approximately $&lt;span id="xdx_907_ecustom--LicenseCost_pp0p0_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zzGECV6B2eeg"&gt;23,000&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--LicenseCost_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zLULny5Wi9qa"&gt;94,000&lt;/span&gt; for the years ended December 31, 2023 and December 31, 2022, respectively,
and are included in research and development expenses in the consolidated statements of operations and other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;br/&gt;
In June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as
a treatment for COVID-19. Under the agreement, the Company took over development, regulatory approval and commercialization of the compound
(for such use) from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received
approximately $&lt;span id="xdx_904_ecustom--UpfrontLicenseFee_iI_pp0p0_c20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zs6wIUOQmRSa" title="Upfront license fee"&gt;24,000&lt;/span&gt; for an upfront license fee and reimbursement of prior patent costs. In addition, the Company was required to enter
into a separate sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) for at least $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200601__20200630__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zwcC8dBKeIhh" title="Research and development expense"&gt;250,000&lt;/span&gt;. In November 2020,
the Company executed a sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) supporting up to approximately
$&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20201101__20201130__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zfrwx4kHwiF4" title="Research and development expense"&gt;430,000&lt;/span&gt; in research which satisfied this requirement. This sponsored research agreement expired in November 2021 and the exclusive license
agreement was terminated on October 31, 2022. There were no sponsored research expenses or license costs related to these QN-165 agreements
for the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:ResearchAndLicenseAgreementsTextBlock>
    <QLGN:ReimbursementOfPatent
      contextRef="From2022-01-012022-01-31_custom_UpfrontPaymentMember_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact001371"
      unitRef="USD">150000</QLGN:ReimbursementOfPatent>
    <QLGN:ReimbursementOfPatent
      contextRef="From2022-01-012022-01-31_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact001373"
      unitRef="USD">160000</QLGN:ReimbursementOfPatent>
    <QLGN:LicenseCost
      contextRef="From2023-01-012023-12-31_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact001375"
      unitRef="USD">128000</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2022-01-012022-12-31_custom_LicenseAgreementMember"
      decimals="0"
      id="Fact001377"
      unitRef="USD">338000</QLGN:LicenseCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-07-31_custom_MasterLaboratoryServicesAgreementMember_custom_MLMMedicalLabsMember"
      decimals="-5"
      id="Fact001379"
      unitRef="USD">7600000</us-gaap:ResearchAndDevelopmentExpense>
    <QLGN:ReimbursementOfResearchExpenses
      contextRef="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001380"
      unitRef="USD">693000</QLGN:ReimbursementOfResearchExpenses>
    <QLGN:ReimbursementOfResearchExpenses
      contextRef="From2023-01-012023-12-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="-5"
      id="Fact001382"
      unitRef="USD">2900000</QLGN:ReimbursementOfResearchExpenses>
    <QLGN:AgreementTermPaymentDescription
      contextRef="From2020-07-012020-07-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      id="Fact001384">In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates.
Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is
responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront
license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered
net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative
$250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30%
to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement,
40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth
year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution
and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement
of certain regulatory and commercial milestones.</QLGN:AgreementTermPaymentDescription>
    <QLGN:MilestonePayment
      contextRef="From2020-07-012020-07-31_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001386"
      unitRef="USD">50000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2020-07-012020-07-31_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001388"
      unitRef="USD">5000000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2020-07-012020-07-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember"
      decimals="0"
      id="Fact001390"
      unitRef="USD">50000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2020-07-012020-07-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember"
      decimals="0"
      id="Fact001391"
      unitRef="USD">100000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2020-07-012020-07-31_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember"
      decimals="0"
      id="Fact001393"
      unitRef="USD">150000</QLGN:MilestonePayment>
    <QLGN:RegulatoryMarketingApprovalExpenses
      contextRef="From2020-07-012020-07-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001395"
      unitRef="USD">300000</QLGN:RegulatoryMarketingApprovalExpenses>
    <QLGN:CumulativeSales
      contextRef="From2020-07-012020-07-31_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001397"
      unitRef="USD">5000000</QLGN:CumulativeSales>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2020-07-012020-07-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001399"
      unitRef="USD">500000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <QLGN:UpfrontLicenseFee
      contextRef="AsOf2020-07-31_srt_MinimumMember_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001401"
      unitRef="USD">20000</QLGN:UpfrontLicenseFee>
    <QLGN:UpfrontLicenseFee
      contextRef="AsOf2020-07-31_srt_MaximumMember_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001403"
      unitRef="USD">100000</QLGN:UpfrontLicenseFee>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_SponsoredResearchAgreementsAndLicenseMember"
      decimals="0"
      id="Fact001405"
      unitRef="USD">743000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementsAndLicenseMember"
      decimals="0"
      id="Fact001407"
      unitRef="USD">758000</us-gaap:ResearchAndDevelopmentExpense>
    <QLGN:LicenseCost
      contextRef="From2023-01-012023-12-31_custom_SponsoredResearchAgreementsAndLicenseMember"
      decimals="0"
      id="Fact001409"
      unitRef="USD">133000</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementsAndLicenseMember"
      decimals="0"
      id="Fact001411"
      unitRef="USD">40000</QLGN:LicenseCost>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2018-06-012022-04-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001413"
      unitRef="USD">50000</us-gaap:ProceedsFromConvertibleDebt>
    <QLGN:ReimbursementOfResearchExpenses
      contextRef="From2018-06-012022-04-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001415"
      unitRef="USD">805000</QLGN:ReimbursementOfResearchExpenses>
    <QLGN:PatentCosts
      contextRef="From2018-06-012022-04-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001417"
      unitRef="USD">200000</QLGN:PatentCosts>
    <QLGN:AgreementTermPaymentDescription
      contextRef="From2018-06-012022-04-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      id="Fact001419">In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization
of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative
$250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income
received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third
or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter),
(iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred
prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones.</QLGN:AgreementTermPaymentDescription>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012022-04-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001421"
      unitRef="USD">100000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012022-04-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001423"
      unitRef="USD">5000000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012022-04-30_custom_PhaseOneClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001425"
      unitRef="USD">100000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012022-04-30_custom_PhaseTwoClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001427"
      unitRef="USD">200000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012022-04-30_custom_PhaseThreeClinicalTrialMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001429"
      unitRef="USD">350000</QLGN:MilestonePayment>
    <QLGN:RegulatoryMarketingApprovalExpenses
      contextRef="From2018-06-012022-04-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001431"
      unitRef="USD">500000</QLGN:RegulatoryMarketingApprovalExpenses>
    <QLGN:CumulativeSales
      contextRef="From2018-06-012022-04-30_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001433"
      unitRef="USD">5000000</QLGN:CumulativeSales>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2018-06-012022-04-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001435"
      unitRef="USD">500000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <QLGN:RegulatoryMarketingApprovalExpensesOne
      contextRef="From2018-06-012022-04-30_custom_LicensedProductSalesMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001437"
      unitRef="USD">500000</QLGN:RegulatoryMarketingApprovalExpensesOne>
    <QLGN:ShortfallPayments
      contextRef="From2018-06-012022-04-30_srt_MinimumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001439"
      unitRef="USD">10000</QLGN:ShortfallPayments>
    <QLGN:ShortfallPayments
      contextRef="From2018-06-012022-04-30_srt_MaximumMember_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001441"
      unitRef="USD">50000</QLGN:ShortfallPayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      id="Fact001442"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      id="Fact001443"
      unitRef="USD">164000</us-gaap:ResearchAndDevelopmentExpense>
    <QLGN:LicenseCost
      contextRef="From2023-01-012023-12-31_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      id="Fact001444"
      unitRef="USD">23000</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2022-01-012022-12-31_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      id="Fact001445"
      unitRef="USD">94000</QLGN:LicenseCost>
    <QLGN:UpfrontLicenseFee
      contextRef="AsOf2020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001447"
      unitRef="USD">24000</QLGN:UpfrontLicenseFee>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-06-012020-06-30_srt_MinimumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001449"
      unitRef="USD">250000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-11-012020-11-30_srt_MinimumMember_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      id="Fact001451"
      unitRef="USD">430000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001453">&lt;p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z3CfDa6rNHjg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12 &#x2014; &lt;span id="xdx_82B_zJQMTosbNfn2"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, and 2022 the Company had two classes of capital stock: common stock and preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holders
of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject
to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive
dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, any
remaining assets will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of any
preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive,
subscription or conversion rights and there are no redemption or sinking fund provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023, the Company has reserved &lt;span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20231231_zwCKHUUeVtdj" title="Common stock reserved for future issuance"&gt;5,781,161&lt;/span&gt; shares of authorized but unissued common stock for possible future issuance as
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--ScheduleOfReservedSharesTableTextBlock_zwTy7UYVbLH4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_z6DIgiLX7U56" style="display: none"&gt;SCHEDULE
OF RESERVED SHARES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20231231_zHoQ9JF85b0f" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5WBLsQhG06k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Exercise of issued and future grants of stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;755,715&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__custom--ConversionOfConvertibleDebtMember_zNUiJ3e0hid5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Conversion of convertible debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,943,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zr39N6ecJFsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of stock warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,081,717&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zjAWdC7CbToj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,781,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zMTDeIMRyP9d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023 and December 31, 2022, there were &lt;span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_zQHj2ADN0JKc" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zU3ojb1dnOL9" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; shares of preferred stock outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock
Options and Equity Classified Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes all compensatory stock-based payments as compensation expense over the service period, which is generally the vesting
period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2020, the Company adopted the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;) which provides for the grant of incentive
or non-statutory common stock options, restricted stock, stock bonus awards, stock appreciation rights, restricted stock units and performance
awards to qualified employees, officers, directors, consultants and other service providers. At December 31, 2023 and December 31, 2022
there were &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z2PHP0fjlCIa" title="Options outstanding"&gt;398,924&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z9WFEV0vLDZ7" title="Options outstanding"&gt;608,012&lt;/span&gt; outstanding stock options, respectively, under the 2020 Plan and there were &lt;span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zuHsQg5DiD0j" title="Plan shares available"&gt;356,778&lt;/span&gt; and &lt;span id="xdx_908_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zpNtBMtkpoHb" title="Plan shares available"&gt;147,690&lt;/span&gt; Plan shares
available, respectively, for future grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zs8yiFww238k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December
31, 2023, and changes during the twelve months then ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zFOnad0Z0GNb" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&#x2013;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&#x2013;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkIsHDFTE0Oi" style="width: 14%; text-align: right" title="Number of shares, options outstanding, beginning"&gt;608,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ziTkSGk7A1vf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"&gt;35.02&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z1A2GvKClF0g" title="Range of Exercise price, Options Outstanding"&gt;5.14&lt;/span&gt; - $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_z09sF6T2A68f" title="Range of Exercise price, Options Outstanding"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zsPcTXYTQkFk" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"&gt;8.09&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zYz3AeE2OExk" style="text-align: right" title="Number of shares, options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1491"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zIRryovNL914" style="text-align: right" title="Weighted average exercise price, options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1493"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zZU1qmiE3F8" style="text-align: right" title="Number of shares, options expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1495"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ziujHsfwWzMa" style="text-align: right" title="Weighted average exercise price, options expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1497"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zzTGWHF4F2Tk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options forfeited"&gt;(209,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zpmO8ELPhGq9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited"&gt;34.71&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zbWJhn9PPoIj" title="Range of Exercise price, Options Forfeited"&gt;5.14&lt;/span&gt; - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zEkZKn9nbud6" title="Range of Exercise price, Options Forfeited"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zN2jD7JuHcYa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options Outstanding at Ending"&gt;398,924&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBrjiTdDhbO2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending"&gt;35.21&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zvj28x2nVpl" title="Range of Exercise price, Options Outstanding"&gt;5.14&lt;/span&gt; &#x2014; $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zvf5zIhj1efd" title="Range of Exercise price, Options Outstanding"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkBJbEz2epD5" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"&gt;7.06&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Exercisable (vested)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zpG7XaKkSemc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)"&gt;320,918&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zaeMd4Xni5We" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of exercise price, options exercisable (vested)"&gt;41.97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zpVEguyqgJAa" title="Range of exercise price, options exercisable (vested)"&gt;5.14&lt;/span&gt; &#x2014; $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zkGjM8ZYcPug" title="Range of exercise price, options exercisable (vested)"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zKKIJUisZMfh" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"&gt;6.77&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Non-Exercisable (non-vested)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjNvfdbF1y98" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)"&gt;78,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zG2CA3CSl6v8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)"&gt;7.36&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z91mmxAdBLH3" title="Range of exercise price, options non-exercisable (non-vested)"&gt;5.14&lt;/span&gt; - $&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zIpg0XstkxAf" title="Range of exercise price, options non-exercisable (non-vested)"&gt;32.90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zJwkYBBjO96" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"&gt;8.36&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that were outstanding at December 31, 2022, and changes during the twelve months then ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013;Average&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013;Average&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zWIRkBiiTiEg" style="width: 14%; text-align: right" title="Number of shares, options outstanding, beginning"&gt;484,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zlVZE02OJEza" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"&gt;60.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;$&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zGiHtX3PY4j3" title="Range of Exercise price, Options Outstanding"&gt;12.40&lt;/span&gt; &#x2014; $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zVqt1XV08gM6" title="Range of Exercise price, Options Outstanding"&gt;14,657.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkE37PmUN0sh" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"&gt;8.52&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zP3cmn02hWCb" style="text-align: right" title="Number of shares, options granted"&gt;134,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zrek5FW0Qc76" style="text-align: right" title="Weighted average exercise price, options granted"&gt;5.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zm71m9uYtMf7" title="Range of Exercise price, Options Outstanding"&gt;5.14&lt;/span&gt; &#x2014; &lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zlYsjj8aE7xc" title="Range of Exercise price, Options Outstanding"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zza9MJn3zL58" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBjp6n0FxRok" style="text-align: right" title="Number of shares, options expired"&gt;(9,379&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zM2Q23Z80GFc" style="text-align: right" title="Weighted average exercise price, options expired"&gt;932.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zCChvyUDs58k" title="Range of Exercise price, Options Outstanding"&gt;57.50&lt;/span&gt; - &lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zbVQ4jXmBnl1" title="Range of Exercise price, Options Outstanding"&gt;14,657.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zxMo7qCM7wNc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options forfeited"&gt;(1,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zVJyXMhMu384" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited"&gt;22.64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zIDOyHLqNdt1" title="Range of Exercise price, Options Forfeited"&gt;5.14&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_z7zVE50RAY8h" title="Range of Exercise price, Options Forfeited"&gt;49.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z3yGc3Sl9Gqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options Outstanding at Ending"&gt;608,012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zqrDsAW48I64" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending"&gt;35.02&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z2xuq1t7WRTg" title="Range of Exercise price, Options Outstanding"&gt;5.14&lt;/span&gt; &#x2014; $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zqHOPdJQSIl3" title="Range of Exercise price, Options Outstanding"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zARB0aqcuL8c" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"&gt;8.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Exercisable (vested)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zXrgdO5t8oe4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)"&gt;288,704&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zprySz4oLgx" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of exercise price, options exercisable (vested)"&gt;46.32&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zmcvWVbJnsJh" title="Range of exercise price, options exercisable (vested)"&gt;12.40&lt;/span&gt; &#x2014; $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zD2GTW2aYwh2" title="Range of exercise price, options exercisable (vested)"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zn9slRtEYqG1" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"&gt;7.59&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Non-Exercisable (non-vested)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z1apKxQ2FgBb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)"&gt;319,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zLrGcJzs1uV" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)"&gt;24.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zLKKejEF9B8l" title="Range of exercise price, options non-exercisable (non-vested)"&gt;5.14&lt;/span&gt; &#x2014; $&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zKV52WE0uOo5" title="Range of exercise price, options non-exercisable (non-vested)"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zbXPeuyw7Ib1" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AE_zfzureZsPRAf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
was approximately $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zooOWNiHFMH" title="Compensation cost"&gt;1.1&lt;/span&gt; million and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGTD59yVg9Bl" title="Compensation cost"&gt;5.4&lt;/span&gt; million of compensation costs related to outstanding options for the year ended December 31, 2023
and December 31, 2022, respectively. This cost is expected to be recognized over a weighted average period of &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zEFcpGopUTX6" title="Cost is expected to be recognized over a weighted average period"&gt;1.09&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7Q7cPFBqe6b" title="Stock options granted"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAH04MYGtoi" title="Stock options granted"&gt;&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZ5iV4mgRYCe" title="Stock options exercised"&gt;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zu7XI7ZF6ic3" title="Stock options exercised"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
stock options were granted or exercised during the year ended December 31, 2023 or 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_z5VbRTNexEaa" title="Stock options description"&gt;The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.&lt;/span&gt; The options awarded under the 2020 Plan will vest as determined by the Board of Directors but will not exceed a 10-year
period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9mA0gyIhvwk" title="Stock options granted"&gt;no&lt;/span&gt; options granted during the year ended December 31, 2023. The weighted average grant date fair value per share of the shares underlying
options granted during the year ended December 31, 2022 was $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZz9Cag701Cl" title="Stock option granted exercise price"&gt;3.96&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
Value of Equity Awards&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes the Black-Scholes option pricing model to value awards under the 2020 Plan, and for equity classified compensatory warrants.
Key valuation assumptions include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    dividend yield.&lt;/i&gt; The expected dividend is assumed to be zero, as the Company has never paid dividends and has no current plans
    to pay any dividends on the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    stock-price volatility.&lt;/i&gt; The Company&#x2019;s expected volatility is derived from the average historical volatilities of publicly
    traded companies within the Company&#x2019;s industry that the Company considers to be comparable to the Company&#x2019;s business
    over a period approximately equal to the expected term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Risk-free
    interest rate.&lt;/i&gt; The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon
    U.S. Treasury notes with maturities approximately equal to the expected term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Expected
    term.&lt;/i&gt; The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&#x2019;s
    historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of
    a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the SEC.
    The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zGHR15bCdKc4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zAEDyLzxwr3i" style="display: none"&gt;SCHEDULE
OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
the Years Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zQSr5rVaOadd" style="width: 16%; text-align: right" title="Expected dividend yield"&gt;0.00%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected stock-price volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zcPUuOZ6PVR1" style="text-align: right" title="Expected stock-price volatility"&gt;103%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zCM8i4TCTp58" title="Risk-free interest rate, minimum"&gt;1.58&lt;/span&gt;% &#x2014; &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_ztgDn7Z1c4V1" title="Risk-free interest rate, minimum"&gt;3.77&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected average term of options (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zLv60PDr8SAl" title="Expected average term of options (in years)"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MinimumMember_z41UFMKa2Jvk" title="Stock price"&gt;5.14&lt;/span&gt; - &lt;span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MaximumMember_zQmQktOllcn9" title="Stock price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8AC_zsnSQFGnqo1h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_z4fcGluRwcLf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense and classified it in the Consolidated Statements of Operations as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zCQVTkRPAy18" style="display: none"&gt;SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_zWeGmRQVC7Vf" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231_zHKS76KQYz95" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zzLhM2YRzOl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;939,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,649,649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrifLxBJYHPe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;159,305&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;834,395&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zpHZ3aJEeIDd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,098,533&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,484,044&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zdZbf09O8MU9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Equity
Classified Compensatory Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zVMGPmt8I3ig" title="Issuance or sale of equity"&gt;4.0&lt;/span&gt; million equity capital raise as part of the May 2020 reverse recapitalization transaction, the Company issued
common stock warrants to an advisor and its designees for the purchase of &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zleuOGXOvu4k" title="Warrants issued"&gt;81,143&lt;/span&gt; reverse split adjusted shares of the Company&#x2019;s
common stock at a reverse split adjusted exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zJ8Dch6Fh1c6" title="Exercise price"&gt;11.10&lt;/span&gt; per share. The issuance cost of these warrants was charged to additional
paid-in capital, and did not result in expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier (originally exercisable to
purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock) for the purchase of &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20171231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_zFhqKb3CUDy8" title="Purchase of warrants"&gt;66,802&lt;/span&gt; reverse
split adjusted shares of Company common stock at a weighted average exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20171231__us-gaap--AwardTypeAxis__custom--CompensatoryWarrantsMember_ze31QcTqJ2p2" title="Exercise price of warrants"&gt;23.40&lt;/span&gt; per share. These are to be differentiated
from the Series C Warrants described in Note 7- Warrant Liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 25, 2022, &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyOAFc5gq2g2" title="Purchase of warrants"&gt;60,000&lt;/span&gt;
warrants were repriced from $&lt;span id="xdx_906_ecustom--StockholdersEquityReverseStockSplitPricePerShare_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZHAB7WEFjef" title="Reverse stock split, price per share"&gt;13.20&lt;/span&gt;
per share exercise price to a reverse split adjusted exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zy2ncQaMYXuf" title="Class of warrant or right, exercise"&gt;6.00&lt;/span&gt;
per share exercise price and extended from &lt;span id="xdx_905_ecustom--WarrantsExtendedDateDescription_c20220425__20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZ4P2TtwzZMk" title="Warrants extended date description"&gt;June
3, 2023 to September 14, 2023&lt;/span&gt;. The increase in fair value of $&lt;span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20220425__20220425__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLO5vzQCCQ0g" title="Fair value of warrants"&gt;67,370&lt;/span&gt;
for the modification of these warrants was charged to general and administrative expenses in the Company&#x2019;s consolidated
statements of operations and comprehensive loss. These warrants expired on &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsGUBQ9bxlH5" title="Warrants expired date"&gt;September 14, 2023&lt;/span&gt;. On April 25, 2022 and May 26, 2022 an
additional &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrPmMJgYvLL7" title="Purchase of warrants"&gt;&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z88LO3jDDlcl" title="Purchase of warrants"&gt;67,620&lt;/span&gt;&lt;/span&gt;
reverse split adjusted warrants were repriced from reverse split adjusted $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zNhQJ7inRFig" title="Exercise price"&gt;&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z7d2IK97cXQ6" title="Exercise price"&gt;11.10&lt;/span&gt;&lt;/span&gt;
per share exercise price to $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zjSVTpw5APqc" title="Exercise price"&gt;&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5CupuhJkOU5" title="Exercise price"&gt;5.136&lt;/span&gt;&lt;/span&gt;
per share exercise price. The increase in fair value of $&lt;span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20220424__20220526__us-gaap--StatementEquityComponentsAxis__us-gaap--AdditionalPaidInCapitalMember__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zUgUb2bQVW01" title="Fiar value of warrants"&gt;31,010&lt;/span&gt;
for the modification of these warrants was charged to additional paid-in capital and did not result in expense on the
Company&#x2019;s consolidated statements of operations and comprehensive loss. On December 22, 2022 &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaquUJUAi2E2" title="Warrants purchased"&gt;67,620&lt;/span&gt;
warrants were repriced from $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_ziu87vorlQ16" title="Exercise price"&gt;5.136&lt;/span&gt;
per share exercise price to $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zYcyNViqXhdh" title="Exercise price"&gt;1.32&lt;/span&gt;
per share exercise price. The increase in fair value of $&lt;span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20221222__20221222__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9xfLHm4udul" title="Fair value of warrants"&gt;8,548&lt;/span&gt;
for the modification of these warrants was charged to additional paid-in capital and did not result in expense on the
Company&#x2019;s consolidated statements of operations and comprehensive loss. On December 5, 2023, &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20231205__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSqSvUUOWNgk" title="Warrants purchased"&gt;67,620&lt;/span&gt;
warrants were repriced from $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zBCUPRV7uDCk" title="Exercise price"&gt;1.32&lt;/span&gt;
per share exercise price to $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zxzprKaDj7el" title="Exercise price"&gt;0.73&lt;/span&gt;
per share exercise price. The increase in fair value of $&lt;span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20231205__20231205__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6qC580aP7oa" title="Fair value of warrants"&gt;7,945&lt;/span&gt;
for the modification of these warrants was charged to general and administrative expenses in the Company&#x2019;s consolidated
statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
new compensatory warrants were issued during the year ended December 31, 2023 or 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6GUf15Mz9we" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zVoQ4hpIQza" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
                                                                                             &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013; Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013;Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zblP58bGJTgk" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;179,046&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zAphciBbsr2g" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;9.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zVWAipJ9nxTk" title="Range of exercise price - beginning"&gt;1.32&lt;/span&gt; &#x2014; $&lt;span id="xdx_90A_ecustom--RangeOfExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zcrVGzRoA0U" title="Range of exercise price - beginning"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zATa9y3tLSWk" title="Weighted Average Remaining Life (Years) - outstanding"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Granted to advisor and its designees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zABUY8DGxu79" style="text-align: right" title="Number of shares, warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1714"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zaV5yahtMok5" style="text-align: right" title="Weighted average exercise price per share warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1716"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_za5wV3NENpWk" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1718"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zyHYwqNDa7xl" style="text-align: right" title="Weighted average exercise price per share warrants exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1720"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsy6bu1YZI31" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;(60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z07igXGcGk5d" style="text-align: right" title="Weighted average exercise price per share warrants expired"&gt;6.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--RangeOfExercisePriceExpired_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zh3G3jVWMf69" title="Range of exercise price, expired"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1XLk7Se0jXc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1728"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zoiiH9doHS5g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1730"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztLDDtjzLI24" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;119,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zvcMxxZlzkYc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;10.69&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_909_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z65Y5bhD4Bb4" title="Range of exercise price - ending"&gt;0.73&lt;/span&gt; &#x2014; $&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zl74jsOcklha" title="Range of exercise price - ending"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfjVOPoa6mBi" title="Weighted Average Remaining Life (Years) - outstanding"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziITM2nIy0Bc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;119,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9I7XEbBX41" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;10.69&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zGpi0HjkqS9e" title="Range of exercise price, exercisable"&gt;0.73&lt;/span&gt; &#x2014; $&lt;span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z68Cyzk7jgb" title="Range of exercise price, exercisable"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zxMf8XuvRAxg" title="Weighted Average Remaining Life (Years) Exercisable"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zUyd0KSTciX2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1752"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfeqZe9NdTp5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1754"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zNklYsKDniK7" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1756"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013; Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013;Average Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: -10pt; width: 36%"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zhT8uY9khi6g" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;179,046&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3EkFTjq7eo4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;15.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90A_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zM8mOXJfgBG7" title="Range of exercise price - beginning"&gt;11.10&lt;/span&gt; &#x2014; $&lt;span id="xdx_90D_ecustom--RangeOfExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zqDFez1h6oFb" title="Range of exercise price - beginning"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zncdrQjLZiHj" title="Weighted Average Remaining Life (Years) - outstanding"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Granted to advisor and its designees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4mYEWAlcD9d" style="text-align: right" title="Number of shares, warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1768"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zn7zpQy6lX8c" style="text-align: right" title="Weighted average exercise price per share warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1770"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGk8OwJR8lgk" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1772"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7Cl3FRLOAx3" style="text-align: right" title="Weighted average exercise price per share warrants exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1774"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zOHYQClIytwc" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1776"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGp4H3CPLHmb" style="text-align: right" title="Weighted average exercise price per share warrants expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1778"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zQFsnR4DvQ05" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1780"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zVGeXTuAvgMa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1782"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdmXJDFfiAc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;179,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zk2SAluuWPo2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;9.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z21SEWJvbacf" title="Range of exercise price - ending"&gt;1.32&lt;/span&gt; &#x2014; $&lt;span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zi4vL1vjSsel" title="Range of exercise price - ending"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zS1GFYyy2eTk" title="Weighted Average Remaining Life (Years) - outstanding"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7kgmnZyJDL3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;179,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zzbLVt5DRJgf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;9.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z66oet1uEKP5" title="Range of exercise price, exercisable"&gt;1.32&lt;/span&gt;- $&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zLYXiXmkFyui" title="Range of exercise price, exercisable"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zavWyHEIYK5l" title="Weighted Average Remaining Life (Years) Exercisable"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zO9vfILQfrI2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1804"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMbWmp31gAJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1806"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1kvtOKXwtP4" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1808"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A7_zo38110xVQ08" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;There
was $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zrX8NulCZstd" title="Compensation cost"&gt;7,945&lt;/span&gt; in compensation costs related to outstanding warrants for the year ended December 31, 2023 and $&lt;span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqB81TWujB54" title="Compensation cost"&gt;67,370&lt;/span&gt; for the year
ended December 31, 2022. As of December 31, 2023 and December 31, 2022, there was &lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlf1IIJEmkXj" title="Unrecognized compensation cost related to nonvested"&gt;&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHmeMbRvRsYj" title="Unrecognized compensation cost related to nonvested"&gt;no&lt;/span&gt;&lt;/span&gt; unrecognized compensation cost related to nonvested
warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Noncompensatory
Equity Classified Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to Alpha (a related party) for the
purchase of &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zzQVYo7vfJJ9" title="Purchase of warrants"&gt;27,048&lt;/span&gt; reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zu4Tmmpb8Id5" title="Exercise price"&gt;11.10&lt;/span&gt; per share
(of which warrants for &lt;span id="xdx_903_ecustom--WarrantsExercised_pid_c20201201__20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zpbYVDRcGhId" title="Warrants exercised"&gt;20,000&lt;/span&gt; shares were subsequently exercised in December 2020). In July 2020 the Company issued noncompensatory equity
classified warrants to Alpha for the purchase of &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z2XOLcPgyFki" title="Warrants purchased"&gt;78,019&lt;/span&gt; reverse split adjusted shares of Company common stock at a reverse split
adjusted exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z5rA4ikxSTo" title="Exercise price"&gt;0.01&lt;/span&gt; per share (which were subsequently exercised in July 2020), and &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_ztz2ydT8N9rh" title="Class of warrants"&gt;192,068&lt;/span&gt; reverse split adjusted shares
of Company common stock at a reverse split adjusted exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200731__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zmUy60jbvmdg" title="Exercise price"&gt;52.50&lt;/span&gt; per share. In August 2020, the Company issued noncompensatory
equity classified warrants to Alpha for the purchase of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20200831__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmpm4YzLcY01" title="Purchase of warrants"&gt;128,783&lt;/span&gt; reverse split adjusted shares of Company common stock at a reverse
split adjusted exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200831__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZi8fPyl1nxh" title="Exercise price"&gt;60.00&lt;/span&gt; per share. In December 2020, the Company issued noncompensatory equity classified warrants to
Alpha for the purchase of &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zd8zgoN5ezU3" title="Purchase of warrants"&gt;100,000&lt;/span&gt; reverse split adjusted shares of Company common stock at a reverse split adjusted exercise
price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_zrCioPMb5uF9" title="Exercise price"&gt;0.10&lt;/span&gt; per share (which were exercised in February 2021) and &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20201231_zI2VMyaMLim1" title="Purchase of warrants"&gt;219,101&lt;/span&gt; reverse split adjusted shares of Company common stock at
a reverse split adjusted exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20201231_zuwzuPLSE4d3" title="Exercise price"&gt;40.70&lt;/span&gt; per share. In May 2022, the Company issued noncompensatory equity classified warrants
to Alpha for the purchase of &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zBrDNpvbQL8d" title="Purchase of shares"&gt;331,464&lt;/span&gt; reverse split adjusted shares of Company common stock at a reverse split adjusted exercise
price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zQEuAIMh7A1f" title="Class of warrant or right, exercise"&gt;0.01&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 29, 2021, with the exception of the warrants to purchase &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zvX0rMY85Rdk" title="Number of securities called by Each warrant or right"&gt;27,048&lt;/span&gt; reverse split adjusted shares of the Company&#x2019;s common
stock at a reverse split adjusted exercise price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhiB8i3YySk" title="Exercise price of warrants"&gt;11.10&lt;/span&gt; per share, the exercise prices of all outstanding warrants to purchase a total
of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zDKAPdIKLncb" title="Number of outstanding warrants to purchase, shares"&gt;539,951&lt;/span&gt; reverse split adjusted shares of the Company&#x2019;s common stock were modified to a reverse split adjusted exercise price
of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_z419J8Rk6vNj" title="Exercise price of warrants"&gt;20.00&lt;/span&gt; per share and each of their remaining terms extended by six months. The fair value of the modification cost of these warrant
modifications of approximately $&lt;span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20211129__20211129__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zmOqfUomSUl9" title="Fair value of warrants"&gt;2.3&lt;/span&gt; million was charged to additional paid-in capital and did not result in expense on the Company&#x2019;s
consolidated statements of operations and comprehensive loss. In May 2022, pre-funded warrants to purchase &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zd5iP2ijhVWf" title="Purchase of warrants"&gt;331,464&lt;/span&gt; reverse split adjusted
shares of the Company&#x2019;s common stock at a reverse split adjusted exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220531__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_zV8JVjwigXoj" title=" Exercise price of warrants or rights"&gt;0.01&lt;/span&gt; per share with no expiration date were
issued to Alpha. These warrants were subsequently exercised in 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with the NanoSynex Acquisition, on April 25, 2022 the exercise price of &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zt6anm1UdZ34" title="Purchase of warrants"&gt;7,048&lt;/span&gt;
reverse split adjusted outstanding warrants at $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_z1i8COC4aik7" title="Exercise price of warrants"&gt;11.10&lt;/span&gt;
was modified to a reverse split adjusted exercise price of $&lt;span id="xdx_90C_ecustom--ModifiedToExercisePrice_iI_pid_c20220425__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zByuF8VeXI44" title="Modified to exercise price"&gt;6.00&lt;/span&gt;.
The increase in fair value of $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20220425__20220425__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zP376pEeUFSl" title="Fair value of warrants"&gt;2,533&lt;/span&gt;,
using a Monte Carlo pricing model for the modification of these warrants, was charged to additional paid-in capital and did not
result in expense on the Company&#x2019;s consolidated statements of operations and comprehensive loss. On May 26, 2022, the reverse
split adjusted exercise price of these warrants was modified again to $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220526__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zq5hDeNKiAE5" title="Class of warrant or right, exercise"&gt;5.136&lt;/span&gt;,
and the increase in fair value of $&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20230526__20230526_zreq5GUJ0oLf" title="Fair value adjustment of warrants"&gt;696&lt;/span&gt;,
using a Monte Carlo pricing model for the modification of these warrants, was included in consideration transferred in the NanoSynex
Acquisition. On December 22, 2022 the exercise price of these warrants was modified again to $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_zNQhfNL33gFi" title="Class of warrant or right, exercise"&gt;1.32&lt;/span&gt;.
The increase in fair value of $&lt;span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20221222__20221222__us-gaap--BusinessAcquisitionAxis__custom--NanosynexMember_z3Co7zbBG5gj" title="Fair value adjustment of warrants"&gt;891&lt;/span&gt;,
using a Monte Carlo pricing model for the modification of those warrants, was charged to additional paid-in capital and did not
result in expense on the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 5, 2023, the Company entered into an Amendment No. 1 with regard to Securities Purchase Agreement, with Alpha. This
Amendment amended two instruments which the Company issued under the Securities Purchase Agreement dated December 21, 2022: (a) the 8%
Senior Convertible Debenture dated December 22, 2022 in favor of Alpha, and (b) the Common Stock Purchase Warrant dated December
22, 2022 in favor of Alpha. The Amendment reduced the Conversion Price of the Debenture from $&lt;span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zNQCYDt9tMC" title="Conversion price"&gt;1.32&lt;/span&gt; per share to $&lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPriceDecrease_pid_c20231205__20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_zB5dR6kulR44" title="Conversion price"&gt;0.73&lt;/span&gt;
per share (subject to possible future adjustment pursuant to the terms of the Debenture) and reduced the Exercise Price of the Alpha
Warrant from $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zB0NfVcoZzr1" title="Warrant exercise price"&gt;1.65&lt;/span&gt; per share to $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231205__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MinimumMember_zkui0DYHTHO5" title="Warrant exercise price"&gt;0.73&lt;/span&gt; per share (subject to possible future adjustment pursuant to the terms of the Alpha Warrant). The
Amendment revised certain provisions of the Warrant which resulted in reclassification of the Warrant from liabilities to equity. For
more details see Note 7 - Warrant Liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zBR5N0UoTtm" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zWaJcYtP6cid" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013;Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013; Average Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zBrhwrtA08f5" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;547,003&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z16lgZwUetj" style="width: 12%; text-align: right" title="Weighted Average exercise price, warrants outstanding beginning"&gt;19.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90F_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6GP6w0701Se" title="Range of exercise price"&gt;1.32&lt;/span&gt; - $&lt;span id="xdx_90C_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zrjLOhUdlhJ1" title="Range of exercise price"&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6gEOFOhuxa1" title="Weighted average remaining life (Years) exercisable"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Legacy Ritter warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z753JNxyM1al" style="text-align: right" title="Number of shares legal ritter warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1898"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSJEhpZPXz7k" style="text-align: right" title="Weighted Average exercise price, legal ritter warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1900"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Reclassification of Alpha Warrant from warrant liabilities to equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zXLV6IWbAiWf" style="text-align: right" title="Number of shares, warrants reclassification of Alpha warrant from warrant liabilities to equity"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zcoxUHSQUkW1" style="text-align: right" title="Weighted Average exercise price, reclassification of Alpha warrant from warrant liabilities to equity"&gt;0.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6JkInoHrxci" title="Range of exercise price, reclassification of Alpha warrant from warrant liabilities to equity"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zXc9CV8ffE54" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1908"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfE1qxUbr91" style="text-align: right" title="Weighted average exercise price, warrants exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1910"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zyu7TMkrjFw" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;(539,953&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSctCIyTwZT9" style="text-align: right" title="Weighted average exercise price, warrants expired"&gt;20.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMLIYRkHsNGk" title="Range of exercise price, expired"&gt;20.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z255AwZBtLR" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1918"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zc54vnC1hR5b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1920"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zNDjU6eYyCmc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending"&gt;2,507,050&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwuIMebw57Nf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average exercise price, warrants outstanding ending balance"&gt;0.73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zn3TozeyExo7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;2,507,050&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zphXwBoGbAQa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;0.73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zQg5veEAr0a1" title="Range of exercise price, exercisable"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z0XUjsjeZ0H3" title="Weighted average remaining life (Years) exercisable"&gt;4.47&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGEjBufrUuo3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1934"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuZLFbaOM9a6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1936"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013; Average Exercise
    Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013; Average Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zO7Cg7lGZ0T9" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;554,914&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zg0hga9tUFDj" style="width: 12%; text-align: right" title="Weighted average exercise price, warrants outstanding beginning"&gt;20.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUg4iabg9xKe" title="Range of exercise price"&gt;11.10&lt;/span&gt;&#x2014; &lt;span id="xdx_90E_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zT1SmbA6nB61" title="Range of exercise price"&gt;37.78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zoksFYh7JX2g" title="Weighted average remaining life (Years) exercisable"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Legacy Ritter warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z3DaDuZucKPb" style="text-align: right" title="Number of shares legal ritter warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1948"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zO6BRIKiu9Yi" style="text-align: right" title="Weighted average exercise price, legal ritter warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1950"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJHb6Nismj6g" style="text-align: right" title="Number of shares, warrants granted"&gt;331,464&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zLMahoHMM1Ag" style="text-align: right" title="Weighted average exercise price, warrants granted"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--RangeOfExercisePriceExercisableGranted_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZn1SgKiH9h8" title="Range of exercise price, granted"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgFA4ipoXUD2" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;(331,464&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zjS2TWnu8HI3" style="text-align: right" title="Weighted average exercise price, warrants exercised"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--RangeOfExercisePriceExercised_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfUq2hkkhWSh" title="Range of exercise price, exercised"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTUse044gCFk" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;(7,911&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zpLxlMN7pXK6" style="text-align: right" title="Weighted average exercise price, warrants expired"&gt;37.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--RangeOfExercisePriceExercisableExpired_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSPSLF3Ce2dg" title="Range of exercise price, expired"&gt;37.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJXpTgZPuKHk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1970"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zh0txminHaOl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1972"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_904_ecustom--RangeOfExercisePriceForfeited_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z8tIuIDKsdY8" title="Range of exercise price, forfeited"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdXwh1vfSNjd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending"&gt;547,003&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgxS2qW5u3X5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants outstanding ending balance"&gt;19.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zbnws0F622Z" title="Range of exercise price"&gt;1.32&lt;/span&gt; - &lt;span id="xdx_906_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJe2u5fV8yJ6" title="Range of exercise price"&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zL8m6zhtMyU9" title="Weighted average remaining life (Years) exercisable"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuBf0CI8zkRj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;547,003&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwGx9fu8t437" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;19.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zrfdrjj9x2b" title="Range of exercise price, exercisable"&gt;1.32&lt;/span&gt; - &lt;span id="xdx_908_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zHgslEXoYM7h" title="Range of exercise price - Exercisable"&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZvOqXPsGhT7" title="Weighted average remaining life (Years) exercisable"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxV5nkyftnZi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1996"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zPfNZv7sMpv3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1998"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zkPWLd4VQhp3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001455"
      unitRef="Shares">5781161</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <QLGN:ScheduleOfReservedSharesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001457">&lt;p id="xdx_89A_ecustom--ScheduleOfReservedSharesTableTextBlock_zwTy7UYVbLH4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_z6DIgiLX7U56" style="display: none"&gt;SCHEDULE
OF RESERVED SHARES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20231231_zHoQ9JF85b0f" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5WBLsQhG06k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Exercise of issued and future grants of stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;755,715&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__custom--ConversionOfConvertibleDebtMember_zNUiJ3e0hid5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Conversion of convertible debt&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,943,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zr39N6ecJFsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of stock warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,081,717&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_zjAWdC7CbToj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,781,161&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</QLGN:ScheduleOfReservedSharesTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001459"
      unitRef="Shares">755715</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31_custom_ConversionOfConvertibleDebtMember"
      decimals="INF"
      id="Fact001461"
      unitRef="Shares">1943729</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember990578"
      decimals="INF"
      id="Fact001463"
      unitRef="Shares">3081717</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001465"
      unitRef="Shares">5781161</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001467"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001469"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact001471"
      unitRef="Shares">398924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact001473"
      unitRef="Shares">608012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact001475"
      unitRef="Shares">356778</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      id="Fact001477"
      unitRef="Shares">147690</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001479">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zs8yiFww238k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following represents a summary of the options granted to employees and non-employee service providers that were outstanding at December
31, 2023, and changes during the twelve months then ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zFOnad0Z0GNb" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&#x2013;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&#x2013;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkIsHDFTE0Oi" style="width: 14%; text-align: right" title="Number of shares, options outstanding, beginning"&gt;608,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ziTkSGk7A1vf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"&gt;35.02&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z1A2GvKClF0g" title="Range of Exercise price, Options Outstanding"&gt;5.14&lt;/span&gt; - $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_z09sF6T2A68f" title="Range of Exercise price, Options Outstanding"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zsPcTXYTQkFk" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"&gt;8.09&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zYz3AeE2OExk" style="text-align: right" title="Number of shares, options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1491"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zIRryovNL914" style="text-align: right" title="Weighted average exercise price, options granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1493"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zZU1qmiE3F8" style="text-align: right" title="Number of shares, options expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1495"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_ziujHsfwWzMa" style="text-align: right" title="Weighted average exercise price, options expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1497"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zzTGWHF4F2Tk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options forfeited"&gt;(209,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zpmO8ELPhGq9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited"&gt;34.71&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zbWJhn9PPoIj" title="Range of Exercise price, Options Forfeited"&gt;5.14&lt;/span&gt; - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zEkZKn9nbud6" title="Range of Exercise price, Options Forfeited"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zN2jD7JuHcYa" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options Outstanding at Ending"&gt;398,924&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBrjiTdDhbO2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending"&gt;35.21&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zvj28x2nVpl" title="Range of Exercise price, Options Outstanding"&gt;5.14&lt;/span&gt; &#x2014; $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zvf5zIhj1efd" title="Range of Exercise price, Options Outstanding"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkBJbEz2epD5" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"&gt;7.06&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Exercisable (vested)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zpG7XaKkSemc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)"&gt;320,918&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zaeMd4Xni5We" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of exercise price, options exercisable (vested)"&gt;41.97&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zpVEguyqgJAa" title="Range of exercise price, options exercisable (vested)"&gt;5.14&lt;/span&gt; &#x2014; $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zkGjM8ZYcPug" title="Range of exercise price, options exercisable (vested)"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zKKIJUisZMfh" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"&gt;6.77&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Non-Exercisable (non-vested)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjNvfdbF1y98" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)"&gt;78,006&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zG2CA3CSl6v8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)"&gt;7.36&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z91mmxAdBLH3" title="Range of exercise price, options non-exercisable (non-vested)"&gt;5.14&lt;/span&gt; - $&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zIpg0XstkxAf" title="Range of exercise price, options non-exercisable (non-vested)"&gt;32.90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20230101__20231231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zJwkYBBjO96" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"&gt;8.36&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that were outstanding at December 31, 2022, and changes during the twelve months then ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013;Average&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Range
of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                               &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013;Average&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zWIRkBiiTiEg" style="width: 14%; text-align: right" title="Number of shares, options outstanding, beginning"&gt;484,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zlVZE02OJEza" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"&gt;60.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;$&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zGiHtX3PY4j3" title="Range of Exercise price, Options Outstanding"&gt;12.40&lt;/span&gt; &#x2014; $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zVqt1XV08gM6" title="Range of Exercise price, Options Outstanding"&gt;14,657.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zkE37PmUN0sh" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"&gt;8.52&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zP3cmn02hWCb" style="text-align: right" title="Number of shares, options granted"&gt;134,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zrek5FW0Qc76" style="text-align: right" title="Weighted average exercise price, options granted"&gt;5.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zm71m9uYtMf7" title="Range of Exercise price, Options Outstanding"&gt;5.14&lt;/span&gt; &#x2014; &lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zlYsjj8aE7xc" title="Range of Exercise price, Options Outstanding"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zza9MJn3zL58" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zBjp6n0FxRok" style="text-align: right" title="Number of shares, options expired"&gt;(9,379&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zM2Q23Z80GFc" style="text-align: right" title="Weighted average exercise price, options expired"&gt;932.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zCChvyUDs58k" title="Range of Exercise price, Options Outstanding"&gt;57.50&lt;/span&gt; - &lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zbVQ4jXmBnl1" title="Range of Exercise price, Options Outstanding"&gt;14,657.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zxMo7qCM7wNc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, options forfeited"&gt;(1,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zVJyXMhMu384" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, options forfeited"&gt;22.64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zIDOyHLqNdt1" title="Range of Exercise price, Options Forfeited"&gt;5.14&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_z7zVE50RAY8h" title="Range of Exercise price, Options Forfeited"&gt;49.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z3yGc3Sl9Gqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options Outstanding at Ending"&gt;608,012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zqrDsAW48I64" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending"&gt;35.02&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z2xuq1t7WRTg" title="Range of Exercise price, Options Outstanding"&gt;5.14&lt;/span&gt; &#x2014; $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zqHOPdJQSIl3" title="Range of Exercise price, Options Outstanding"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zARB0aqcuL8c" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"&gt;8.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Exercisable (vested)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zXrgdO5t8oe4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options exercisable (vested)"&gt;288,704&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zprySz4oLgx" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of exercise price, options exercisable (vested)"&gt;46.32&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zmcvWVbJnsJh" title="Range of exercise price, options exercisable (vested)"&gt;12.40&lt;/span&gt; &#x2014; $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zD2GTW2aYwh2" title="Range of exercise price, options exercisable (vested)"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zn9slRtEYqG1" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"&gt;7.59&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Non-Exercisable (non-vested)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z1apKxQ2FgBb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, options non-exercisable (non-vested)"&gt;319,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zLrGcJzs1uV" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, options non-exercisable (non-vested)"&gt;24.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;$&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zLKKejEF9B8l" title="Range of exercise price, options non-exercisable (non-vested)"&gt;5.14&lt;/span&gt; &#x2014; $&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zKV52WE0uOo5" title="Range of exercise price, options non-exercisable (non-vested)"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20220101__20221231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zbXPeuyw7Ib1" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001481"
      unitRef="Shares">608012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001483"
      unitRef="USDPShares">35.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001485"
      unitRef="USDPShares">5.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001487"
      unitRef="USDPShares">51.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="Fact001489">P8Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001499"
      unitRef="Shares">209088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001501"
      unitRef="USDPShares">34.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001503"
      unitRef="USDPShares">5.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001505"
      unitRef="USDPShares">51.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001507"
      unitRef="Shares">398924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001509"
      unitRef="USDPShares">35.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001511"
      unitRef="USDPShares">5.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001513"
      unitRef="USDPShares">51.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="Fact001515">P7Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001517"
      unitRef="Shares">320918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001519"
      unitRef="USDPShares">41.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001521"
      unitRef="USDPShares">5.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001523"
      unitRef="USDPShares">51.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="Fact001525">P6Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001527"
      unitRef="Shares">78006</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001529"
      unitRef="USDPShares">7.36</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001531"
      unitRef="USDPShares">5.14</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001533"
      unitRef="USDPShares">32.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested
      contextRef="From2023-01-012023-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="Fact001535">P8Y4M9D</QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001537"
      unitRef="Shares">484186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001539"
      unitRef="USDPShares">60.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001541"
      unitRef="USDPShares">12.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001543"
      unitRef="USDPShares">14657.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2021-01-012021-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="Fact001545">P8Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001547"
      unitRef="Shares">134469</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001549"
      unitRef="USDPShares">5.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001551"
      unitRef="USDPShares">5.14</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001553"
      unitRef="USDPShares">10.50</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice>
    <QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="Fact001555">P5Y11M26D</QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001557"
      unitRef="Shares">9379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001559"
      unitRef="USDPShares">932.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001561"
      unitRef="USDPShares">57.50</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001563"
      unitRef="USDPShares">14657.50</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001565"
      unitRef="Shares">1264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001567"
      unitRef="USDPShares">22.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001569"
      unitRef="USDPShares">5.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001571"
      unitRef="USDPShares">49.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001573"
      unitRef="Shares">608012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001575"
      unitRef="USDPShares">35.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001577"
      unitRef="USDPShares">5.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001579"
      unitRef="USDPShares">51.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="Fact001581">P8Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001583"
      unitRef="Shares">288704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001585"
      unitRef="USDPShares">46.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001587"
      unitRef="USDPShares">12.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001589"
      unitRef="USDPShares">51.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="Fact001591">P7Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001593"
      unitRef="Shares">319308</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      id="Fact001595"
      unitRef="USDPShares">24.80</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001597"
      unitRef="USDPShares">5.14</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001599"
      unitRef="USDPShares">10.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested
      contextRef="From2022-01-012022-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="Fact001601">P8Y7M2D</QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact001603"
      unitRef="USD">1100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="Fact001605"
      unitRef="USD">5400000</us-gaap:ShareBasedCompensation>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-01to2023-12-31" id="Fact001607">P1Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001609"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001611"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001613"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001615"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember_custom_TwoThousandTwentyStockIncentivePlanMember"
      id="Fact001617">The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001619"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001621"
      unitRef="USDPShares">3.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001623">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zGHR15bCdKc4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B5_zAEDyLzxwr3i" style="display: none"&gt;SCHEDULE
OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;For
the Years Ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zQSr5rVaOadd" style="width: 16%; text-align: right" title="Expected dividend yield"&gt;0.00%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected stock-price volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zcPUuOZ6PVR1" style="text-align: right" title="Expected stock-price volatility"&gt;103%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MinimumMember_zCM8i4TCTp58" title="Risk-free interest rate, minimum"&gt;1.58&lt;/span&gt;% &#x2014; &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__srt--RangeAxis__srt--MaximumMember_ztgDn7Z1c4V1" title="Risk-free interest rate, minimum"&gt;3.77&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected average term of options (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zLv60PDr8SAl" title="Expected average term of options (in years)"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MinimumMember_z41UFMKa2Jvk" title="Stock price"&gt;5.14&lt;/span&gt; - &lt;span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20221231__srt--RangeAxis__srt--MaximumMember_zQmQktOllcn9" title="Stock price"&gt;10.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001625"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001627"
      unitRef="Pure">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-01-012022-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001629"
      unitRef="Pure">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-01-012022-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001631"
      unitRef="Pure">0.0377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31" id="Fact001633">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001635"
      unitRef="USDPShares">5.14</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001637"
      unitRef="USDPShares">10.50</us-gaap:SharePrice>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001639">&lt;p id="xdx_898_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_z4fcGluRwcLf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recorded stock-based compensation expense and classified it in the Consolidated Statements of Operations as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zCQVTkRPAy18" style="display: none"&gt;SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230101__20231231_zWeGmRQVC7Vf" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220101__20221231_zHKS76KQYz95" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zzLhM2YRzOl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;939,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,649,649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrifLxBJYHPe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;159,305&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;834,395&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_zpHZ3aJEeIDd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,098,533&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,484,044&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001641"
      unitRef="USD">939228</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001642"
      unitRef="USD">4649649</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001644"
      unitRef="USD">159305</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001645"
      unitRef="USD">834395</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001647"
      unitRef="USD">1098533</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001648"
      unitRef="USD">5484044</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantsMember"
      decimals="-5"
      id="Fact001650"
      unitRef="USD">4000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-12-31_custom_CompensatoryWarrantsMember"
      decimals="INF"
      id="Fact001652"
      unitRef="Shares">81143</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_CompensatoryWarrantsMember"
      decimals="INF"
      id="Fact001654"
      unitRef="USDPShares">11.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2017-12-31_custom_CompensatoryWarrantsMember"
      decimals="INF"
      id="Fact001656"
      unitRef="Shares">66802</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2017-12-31_custom_CompensatoryWarrantsMember"
      decimals="INF"
      id="Fact001658"
      unitRef="USDPShares">23.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-04-25_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001660"
      unitRef="Shares">60000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <QLGN:StockholdersEquityReverseStockSplitPricePerShare
      contextRef="AsOf2022-04-25_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001662"
      unitRef="USDPShares">13.20</QLGN:StockholdersEquityReverseStockSplitPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-25_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001664"
      unitRef="USDPShares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:WarrantsExtendedDateDescription
      contextRef="From2022-04-252022-04-25_us-gaap_WarrantMember"
      id="Fact001666">June
3, 2023 to September 14, 2023</QLGN:WarrantsExtendedDateDescription>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-04-252022-04-25_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001668"
      unitRef="USD">67370</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2022-04-25_us-gaap_WarrantMember"
      id="Fact001670">2023-09-14</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-04-25_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001672"
      unitRef="Shares">67620</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-05-26_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001674"
      unitRef="Shares">67620</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001676"
      unitRef="USDPShares">11.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-25_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001678"
      unitRef="USDPShares">11.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001680"
      unitRef="USDPShares">5.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-25_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001682"
      unitRef="USDPShares">5.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-04-242022-05-26_us-gaap_AdditionalPaidInCapitalMember_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001684"
      unitRef="USD">31010</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-12-22_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001686"
      unitRef="Shares">67620</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001688"
      unitRef="USDPShares">5.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001690"
      unitRef="USDPShares">1.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-12-222022-12-22_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001692"
      unitRef="USD">8548</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-12-05_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001694"
      unitRef="Shares">67620</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-05_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001696"
      unitRef="USDPShares">1.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-05_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001698"
      unitRef="USDPShares">0.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-12-052023-12-05_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001700"
      unitRef="USD">7945</us-gaap:FairValueAdjustmentOfWarrants>
    <QLGN:SummaryOfWarrantActivityTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember"
      id="Fact001702">&lt;p id="xdx_898_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z6GUf15Mz9we" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zVoQ4hpIQza" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
                                                                                             &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013; Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013;Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zblP58bGJTgk" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;179,046&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zAphciBbsr2g" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;9.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zVWAipJ9nxTk" title="Range of exercise price - beginning"&gt;1.32&lt;/span&gt; &#x2014; $&lt;span id="xdx_90A_ecustom--RangeOfExercisePriceOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zcrVGzRoA0U" title="Range of exercise price - beginning"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zATa9y3tLSWk" title="Weighted Average Remaining Life (Years) - outstanding"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Granted to advisor and its designees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zABUY8DGxu79" style="text-align: right" title="Number of shares, warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1714"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zaV5yahtMok5" style="text-align: right" title="Weighted average exercise price per share warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1716"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_za5wV3NENpWk" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1718"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zyHYwqNDa7xl" style="text-align: right" title="Weighted average exercise price per share warrants exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1720"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zsy6bu1YZI31" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;(60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z07igXGcGk5d" style="text-align: right" title="Weighted average exercise price per share warrants expired"&gt;6.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--RangeOfExercisePriceExpired_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zh3G3jVWMf69" title="Range of exercise price, expired"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1XLk7Se0jXc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1728"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zoiiH9doHS5g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1730"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztLDDtjzLI24" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;119,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zvcMxxZlzkYc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;10.69&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_909_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z65Y5bhD4Bb4" title="Range of exercise price - ending"&gt;0.73&lt;/span&gt; &#x2014; $&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceOutstanding_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zl74jsOcklha" title="Range of exercise price - ending"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfjVOPoa6mBi" title="Weighted Average Remaining Life (Years) - outstanding"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziITM2nIy0Bc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;119,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9I7XEbBX41" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;10.69&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zGpi0HjkqS9e" title="Range of exercise price, exercisable"&gt;0.73&lt;/span&gt; &#x2014; $&lt;span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_z68Cyzk7jgb" title="Range of exercise price, exercisable"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zxMf8XuvRAxg" title="Weighted Average Remaining Life (Years) Exercisable"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zUyd0KSTciX2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1752"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfeqZe9NdTp5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1754"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zNklYsKDniK7" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1756"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the equity classified compensatory warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013; Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013;Average Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: -10pt; width: 36%"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zhT8uY9khi6g" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;179,046&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3EkFTjq7eo4" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;15.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90A_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zM8mOXJfgBG7" title="Range of exercise price - beginning"&gt;11.10&lt;/span&gt; &#x2014; $&lt;span id="xdx_90D_ecustom--RangeOfExercisePriceOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zqDFez1h6oFb" title="Range of exercise price - beginning"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zncdrQjLZiHj" title="Weighted Average Remaining Life (Years) - outstanding"&gt;2.64&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Granted to advisor and its designees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4mYEWAlcD9d" style="text-align: right" title="Number of shares, warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1768"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zn7zpQy6lX8c" style="text-align: right" title="Weighted average exercise price per share warrants granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1770"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGk8OwJR8lgk" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1772"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7Cl3FRLOAx3" style="text-align: right" title="Weighted average exercise price per share warrants exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1774"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zOHYQClIytwc" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1776"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zGp4H3CPLHmb" style="text-align: right" title="Weighted average exercise price per share warrants expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1778"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zQFsnR4DvQ05" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1780"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zVGeXTuAvgMa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price per share warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1782"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdmXJDFfiAc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;179,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zk2SAluuWPo2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;9.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_902_ecustom--RangeOfExercisePriceOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z21SEWJvbacf" title="Range of exercise price - ending"&gt;1.32&lt;/span&gt; &#x2014; $&lt;span id="xdx_907_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zi4vL1vjSsel" title="Range of exercise price - ending"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zS1GFYyy2eTk" title="Weighted Average Remaining Life (Years) - outstanding"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7kgmnZyJDL3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;179,046&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zzbLVt5DRJgf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;9.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_z66oet1uEKP5" title="Range of exercise price, exercisable"&gt;1.32&lt;/span&gt;- $&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zLYXiXmkFyui" title="Range of exercise price, exercisable"&gt;25.40&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zavWyHEIYK5l" title="Weighted Average Remaining Life (Years) Exercisable"&gt;1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zO9vfILQfrI2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1804"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMbWmp31gAJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1806"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--RangeOfExercisePriceNonexercisableNonvested_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1kvtOKXwtP4" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1808"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</QLGN:SummaryOfWarrantActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001704"
      unitRef="Shares">179046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001706"
      unitRef="USDPShares">9.12</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001708"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001710"
      unitRef="USDPShares">25.40</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="Fact001712">P1Y8M23D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001722"
      unitRef="Shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001724"
      unitRef="USDPShares">6.00</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceExpired
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001726"
      unitRef="USDPShares">6.00</QLGN:RangeOfExercisePriceExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001732"
      unitRef="Shares">119046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001734"
      unitRef="USDPShares">10.69</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001736"
      unitRef="USDPShares">0.73</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001738"
      unitRef="USDPShares">25.40</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember"
      id="Fact001740">P1Y3M</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001742"
      unitRef="Shares">119046</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001744"
      unitRef="USDPShares">10.69</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001746"
      unitRef="USDPShares">0.73</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2023-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001748"
      unitRef="USDPShares">25.40</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember"
      id="Fact001750">P1Y3M</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001758"
      unitRef="Shares">179046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001760"
      unitRef="USDPShares">15.20</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001762"
      unitRef="USDPShares">11.10</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2021-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001764"
      unitRef="USDPShares">25.40</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1
      contextRef="From2021-01-012021-12-31_custom_CompensatoryWarrantActivityMember"
      id="Fact001766">P2Y7M20D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001784"
      unitRef="Shares">179046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001786"
      unitRef="USDPShares">9.12</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001788"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001790"
      unitRef="USDPShares">25.40</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="Fact001792">P1Y8M23D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001794"
      unitRef="Shares">179046</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001796"
      unitRef="USDPShares">9.12</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001798"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2022-12-31_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001800"
      unitRef="USDPShares">25.40</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      id="Fact001802">P1Y8M23D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="0"
      id="Fact001810"
      unitRef="USD">7945</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="0"
      id="Fact001812"
      unitRef="USD">67370</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001814"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001816"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      id="Fact001818"
      unitRef="Shares">27048</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      id="Fact001820"
      unitRef="USDPShares">11.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:WarrantsExercised
      contextRef="From2020-12-012020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      id="Fact001822"
      unitRef="Shares">20000</QLGN:WarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001824"
      unitRef="Shares">78019</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001826"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      id="Fact001828"
      unitRef="Shares">192068</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      id="Fact001830"
      unitRef="USDPShares">52.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001832"
      unitRef="Shares">128783</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001834"
      unitRef="USDPShares">60.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001836"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact001838"
      unitRef="USDPShares">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact001840"
      unitRef="Shares">219101</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31"
      decimals="INF"
      id="Fact001842"
      unitRef="USDPShares">40.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      id="Fact001844"
      unitRef="Shares">331464</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      id="Fact001846"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      id="Fact001848"
      unitRef="Shares">27048</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001850"
      unitRef="USDPShares">11.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      id="Fact001852"
      unitRef="Shares">539951</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      id="Fact001854"
      unitRef="USDPShares">20.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-11-292021-11-29_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="-5"
      id="Fact001856"
      unitRef="USD">2300000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      id="Fact001858"
      unitRef="Shares">331464</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      id="Fact001860"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-04-25_custom_NanosynexMember"
      decimals="INF"
      id="Fact001862"
      unitRef="Shares">7048</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-25_custom_NanosynexMember"
      decimals="INF"
      id="Fact001864"
      unitRef="USDPShares">11.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:ModifiedToExercisePrice
      contextRef="AsOf2022-04-25_custom_NanosynexMember"
      decimals="INF"
      id="Fact001866"
      unitRef="USDPShares">6.00</QLGN:ModifiedToExercisePrice>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-04-252022-04-25_custom_NanosynexMember"
      decimals="0"
      id="Fact001868"
      unitRef="USD">2533</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-05-26_custom_NanosynexMember"
      decimals="INF"
      id="Fact001870"
      unitRef="USDPShares">5.136</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-05-262023-05-26"
      decimals="0"
      id="Fact001872"
      unitRef="USD">696</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_custom_NanosynexMember"
      decimals="INF"
      id="Fact001874"
      unitRef="USDPShares">1.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-12-222022-12-22_custom_NanosynexMember"
      decimals="0"
      id="Fact001876"
      unitRef="USD">891</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentConvertibleConversionPriceDecrease
      contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001878"
      unitRef="USDPShares">1.32</us-gaap:DebtInstrumentConvertibleConversionPriceDecrease>
    <us-gaap:DebtInstrumentConvertibleConversionPriceDecrease
      contextRef="From2023-12-052023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001880"
      unitRef="USDPShares">0.73</us-gaap:DebtInstrumentConvertibleConversionPriceDecrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001882"
      unitRef="USDPShares">1.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-05_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001884"
      unitRef="USDPShares">0.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:SummaryOfWarrantActivityTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="Fact001886">&lt;p id="xdx_893_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zBR5N0UoTtm" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zWaJcYtP6cid" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013;Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013; Average Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zBrhwrtA08f5" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;547,003&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z16lgZwUetj" style="width: 12%; text-align: right" title="Weighted Average exercise price, warrants outstanding beginning"&gt;19.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90F_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6GP6w0701Se" title="Range of exercise price"&gt;1.32&lt;/span&gt; - $&lt;span id="xdx_90C_ecustom--RangeOfExercisePriceOutstanding_iS_c20230101__20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zrjLOhUdlhJ1" title="Range of exercise price"&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6gEOFOhuxa1" title="Weighted average remaining life (Years) exercisable"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Legacy Ritter warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z753JNxyM1al" style="text-align: right" title="Number of shares legal ritter warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1898"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSJEhpZPXz7k" style="text-align: right" title="Weighted Average exercise price, legal ritter warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1900"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Reclassification of Alpha Warrant from warrant liabilities to equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zXLV6IWbAiWf" style="text-align: right" title="Number of shares, warrants reclassification of Alpha warrant from warrant liabilities to equity"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zcoxUHSQUkW1" style="text-align: right" title="Weighted Average exercise price, reclassification of Alpha warrant from warrant liabilities to equity"&gt;0.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z6JkInoHrxci" title="Range of exercise price, reclassification of Alpha warrant from warrant liabilities to equity"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zXc9CV8ffE54" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1908"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfE1qxUbr91" style="text-align: right" title="Weighted average exercise price, warrants exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1910"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zyu7TMkrjFw" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;(539,953&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSctCIyTwZT9" style="text-align: right" title="Weighted average exercise price, warrants expired"&gt;20.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zMLIYRkHsNGk" title="Range of exercise price, expired"&gt;20.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z255AwZBtLR" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1918"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zc54vnC1hR5b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1920"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zNDjU6eYyCmc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending"&gt;2,507,050&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwuIMebw57Nf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average exercise price, warrants outstanding ending balance"&gt;0.73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zn3TozeyExo7" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;2,507,050&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zphXwBoGbAQa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;0.73&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceExercisableVested_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zQg5veEAr0a1" title="Range of exercise price, exercisable"&gt;0.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z0XUjsjeZ0H3" title="Weighted average remaining life (Years) exercisable"&gt;4.47&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zGEjBufrUuo3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1934"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20231231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuZLFbaOM9a6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1936"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the noncompensatory equity classified warrant activity for the year ended December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Common Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted&#x2013; Average Exercise
    Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Range of&lt;/p&gt;
                                                                                                    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&#x2013; Average Remaining&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Total outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zO7Cg7lGZ0T9" style="width: 12%; text-align: right" title="Number of shares, warrants outstanding beginning"&gt;554,914&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zg0hga9tUFDj" style="width: 12%; text-align: right" title="Weighted average exercise price, warrants outstanding beginning"&gt;20.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zUg4iabg9xKe" title="Range of exercise price"&gt;11.10&lt;/span&gt;&#x2014; &lt;span id="xdx_90E_ecustom--RangeOfExercisePriceOutstanding_iS_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zT1SmbA6nB61" title="Range of exercise price"&gt;37.78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zoksFYh7JX2g" title="Weighted average remaining life (Years) exercisable"&gt;1.32&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Legacy Ritter warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z3DaDuZucKPb" style="text-align: right" title="Number of shares legal ritter warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1948"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrantsWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zO6BRIKiu9Yi" style="text-align: right" title="Weighted average exercise price, legal ritter warrants"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1950"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJHb6Nismj6g" style="text-align: right" title="Number of shares, warrants granted"&gt;331,464&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zLMahoHMM1Ag" style="text-align: right" title="Weighted average exercise price, warrants granted"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--RangeOfExercisePriceExercisableGranted_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZn1SgKiH9h8" title="Range of exercise price, granted"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgFA4ipoXUD2" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;(331,464&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zjS2TWnu8HI3" style="text-align: right" title="Weighted average exercise price, warrants exercised"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_ecustom--RangeOfExercisePriceExercised_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zfUq2hkkhWSh" title="Range of exercise price, exercised"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zTUse044gCFk" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;(7,911&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zpLxlMN7pXK6" style="text-align: right" title="Weighted average exercise price, warrants expired"&gt;37.78&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--RangeOfExercisePriceExercisableExpired_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zSPSLF3Ce2dg" title="Range of exercise price, expired"&gt;37.78&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJXpTgZPuKHk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1970"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zh0txminHaOl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, warrants forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1972"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_904_ecustom--RangeOfExercisePriceForfeited_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_z8tIuIDKsdY8" title="Range of exercise price, forfeited"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zdXwh1vfSNjd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, warrants outstanding ending"&gt;547,003&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zgxS2qW5u3X5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, warrants outstanding ending balance"&gt;19.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zbnws0F622Z" title="Range of exercise price"&gt;1.32&lt;/span&gt; - &lt;span id="xdx_906_ecustom--RangeOfExercisePriceOutstanding_iE_c20220101__20221231__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zJe2u5fV8yJ6" title="Range of exercise price"&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zL8m6zhtMyU9" title="Weighted average remaining life (Years) exercisable"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zuBf0CI8zkRj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;547,003&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zwGx9fu8t437" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;19.76&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_zrfdrjj9x2b" title="Range of exercise price, exercisable"&gt;1.32&lt;/span&gt; - &lt;span id="xdx_908_ecustom--RangeOfExercisePriceExercisableVested_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_zHgslEXoYM7h" title="Range of exercise price - Exercisable"&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zZvOqXPsGhT7" title="Weighted average remaining life (Years) exercisable"&gt;0.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zxV5nkyftnZi" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1996"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice_iI_c20221231__us-gaap--AwardTypeAxis__custom--NonCompensatoryWarrantActivityMember_zPfNZv7sMpv3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1998"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</QLGN:SummaryOfWarrantActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001888"
      unitRef="Shares">547003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001890"
      unitRef="USDPShares">19.76</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001892"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001894"
      unitRef="USDPShares">20.00</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="Fact001896">P0Y3M29D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity
      contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203"
      decimals="INF"
      id="Fact001902"
      unitRef="Shares">2500000</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203"
      decimals="INF"
      id="Fact001904"
      unitRef="USDPShares">0.73</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquityWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity
      contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001906"
      unitRef="USDPShares">0.73</QLGN:RangeOfExercisePriceReclassificationOfAlphaWarrantFromWarrantLiabilitiesToEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203"
      decimals="INF"
      id="Fact001912"
      unitRef="Shares">539953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203"
      decimals="INF"
      id="Fact001914"
      unitRef="USDPShares">20.00</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice
      contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001916"
      unitRef="USDPShares">20.00</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001922"
      unitRef="Shares">2507050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001924"
      unitRef="USDPShares">0.73</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001926"
      unitRef="Shares">2507050</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001928"
      unitRef="USDPShares">0.73</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2023-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001930"
      unitRef="USDPShares">0.73</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_custom_NonCompensatoryWarrantActivityMember992203"
      id="Fact001932">P4Y5M19D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001938"
      unitRef="Shares">554914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001940"
      unitRef="USDPShares">20.10</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2021-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001942"
      unitRef="USDPShares">11.10</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2021-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001944"
      unitRef="USDPShares">37.78</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1
      contextRef="From2021-01-012021-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="Fact001946">P1Y3M25D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001952"
      unitRef="Shares">331464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001954"
      unitRef="USDPShares">0.01</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableGranted
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001956"
      unitRef="USDPShares">0.01</QLGN:RangeOfExercisePriceExercisableGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001958"
      unitRef="Shares">331464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001960"
      unitRef="USDPShares">0.01</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceExercised
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001962"
      unitRef="USDPShares">0.01</QLGN:RangeOfExercisePriceExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001964"
      unitRef="Shares">7911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001966"
      unitRef="USDPShares">37.78</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableExpired
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001968"
      unitRef="USDPShares">37.78</QLGN:RangeOfExercisePriceExercisableExpired>
    <QLGN:RangeOfExercisePriceForfeited
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001974"
      unitRef="USDPShares">0</QLGN:RangeOfExercisePriceForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001976"
      unitRef="Shares">547003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001978"
      unitRef="USDPShares">19.76</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001980"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:RangeOfExercisePriceOutstanding
      contextRef="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001982"
      unitRef="USDPShares">20.00</QLGN:RangeOfExercisePriceOutstanding>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="Fact001984">P0Y3M29D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001986"
      unitRef="Shares">547003</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2022-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001988"
      unitRef="USDPShares">19.76</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2022-12-31_srt_MinimumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001990"
      unitRef="USDPShares">1.32</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="AsOf2022-12-31_srt_MaximumMember_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      id="Fact001992"
      unitRef="USDPShares">20.00</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1
      contextRef="From2022-01-012022-12-31_custom_NonCompensatoryWarrantActivityMember"
      id="Fact001994">P0Y3M29D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact002000">&lt;p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zsCa2udMVYug" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13 &#x2014; &lt;span id="xdx_823_zxb0Y46TjKI6"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Convertible
Debt&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
Note 8 &#x2013; Convertible Debt &#x2013; Related Party for additional information concerning convertible debt &#x2013; related party
transactions. On December 22, 2022, the Company issued to Alpha, an &lt;span id="xdx_900_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221222__20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zHrR5fn6Fovb" title="Senior convertible debenture rate"&gt;8&lt;/span&gt;%
Senior Convertible Debenture in the aggregate principal amount of $&lt;span id="xdx_905_eus-gaap--SecuredDebt_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_znva6CQlRlx4" title="Principal amount"&gt;3,300,000&lt;/span&gt;
for a purchase price of $&lt;span id="xdx_900_ecustom--PurchasePrice_iI_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zPMhZnl4aWr2" title="Purchase Price"&gt;3,000,000&lt;/span&gt;
pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. As of December 31, 2023 the Debenture had a
remaining principal balance of $&lt;span id="xdx_90B_eus-gaap--SecuredDebt_iI_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zcwEnj3Z8fC9" title="Principal amount"&gt;1,418,922&lt;/span&gt;,
and was convertible, at any time, and from time to time, at Alpha&#x2019;s option, into shares of common stock of the Company, at a
price equal to $&lt;span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20231231__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--DebtInstrumentAxis__custom--SeniorConvertibleDebentureMember_zdyXAhxZRHe8" title="Conversion price"&gt;0.73&lt;/span&gt;
per share, subject to adjustment as described in the Debenture and other terms and conditions described in the Debenture.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
on December 22, 2022, in conjunction with the issuance of the Debenture to Alpha, the Company issued to Alpha the Alpha
Warrant to purchase &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221222__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_z8sfarcko6C3" title="Warrant to purchase shares"&gt;2,500,000&lt;/span&gt; shares of the Company&#x2019;s common stock (the &#x201c;Alpha Warrant&#x201d;). As of December 31, 2023,
the exercise price of the Alpha Warrant was $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221222__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember_znlmZKGazR41" title="Exercise price of warrant"&gt;0.73&lt;/span&gt;. The Alpha Warrant may be exercised by Alpha, in whole or in part, at any time
before June 22, 2028, subject to certain terms and conditions described in the Alpha Warrant. The Alpha Warrant is included in equity
on the Company&#x2019;s consolidated balance sheets (see Note 12 &#x2013; Stockholders&#x2019; Equity).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;NanoSynex&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to a Share Purchase Agreement dated April 29, 2022, the Company acquired &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220429__20220429__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_z40TJa9X7eSj" title="Number of common stock acquired shares"&gt;2,232,861&lt;/span&gt; shares of NanoSynex Series A-1 Preferred Stock from
Alpha in exchange for &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20220429__20220429__us-gaap--BusinessAcquisitionAxis__custom--NanoSynexLtdMember_zPCdWz5fKSea" title="Number of common stock acquired shares"&gt;350,000&lt;/span&gt; reverse split adjusted shares of the Company&#x2019;s common stock and a prefunded warrant to purchase
&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220429__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zw0gIIuu5k42" title="Warrants to purchase common stock"&gt;331,464&lt;/span&gt; reverse split adjusted shares of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220429__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zBxwYZBeQzrc" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"&gt;0.001&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ShortTermDebtInterestRateIncrease
      contextRef="From2022-12-222022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      id="Fact002002"
      unitRef="Pure">0.08</us-gaap:ShortTermDebtInterestRateIncrease>
    <us-gaap:SecuredDebt
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="0"
      id="Fact002004"
      unitRef="USD">3300000</us-gaap:SecuredDebt>
    <QLGN:PurchasePrice
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="0"
      id="Fact002006"
      unitRef="USD">3000000</QLGN:PurchasePrice>
    <us-gaap:SecuredDebt
      contextRef="AsOf2023-12-31_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="0"
      id="Fact002008"
      unitRef="USD">1418922</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-12-31_custom_AlphaCapitalMember_custom_SeniorConvertibleDebentureMember"
      decimals="INF"
      id="Fact002010"
      unitRef="USDPShares">0.73</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-12-22_custom_SeriesCWarrantsMember_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact002012"
      unitRef="Shares">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-12-22_custom_AlphaCapitalMember"
      decimals="INF"
      id="Fact002014"
      unitRef="USDPShares">0.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-04-292022-04-29_custom_NanoSynexLtdMember_custom_SeriesAOnePreferredStockMember"
      decimals="INF"
      id="Fact002016"
      unitRef="Shares">2232861</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2022-04-292022-04-29_custom_NanoSynexLtdMember"
      decimals="INF"
      id="Fact002018"
      unitRef="Shares">350000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-04-29_custom_PrefundedWarrantMember"
      decimals="INF"
      id="Fact002020"
      unitRef="Shares">331464</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-04-29_custom_PrefundedWarrantMember"
      decimals="INF"
      id="Fact002022"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact002024">&lt;p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zbT1rnyeVcif" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
14 &#x2014; &lt;span id="xdx_82A_z8mcgtwwCItb"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_znNnnEo4tKLd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents domestic and foreign components of consolidated loss before income taxes from continuing operations for the
periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8BC_zLVxJoxV0zt9" style="display: none"&gt;SCHEDULE
OF DOMESTIC AND FOREIGN COMPONENTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zroRJrFub7S4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_zTWpwWAqnQoi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zi07Z33bFCFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(12,479,803&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(13,887,914&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zLt9DRSh7xpk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2031"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2032"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zQ14WvxvlJa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Loss before provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(12,479,803&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(13,887,914&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z918ZCezRllb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zCwKsoCY7LYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the statutory income tax rates and the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zJSrkVjWc5O4" style="display: none"&gt;SCHEDULE
OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_z8vka4fOhIJg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_z3Q4fMFAj0x6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zuGzWVPbb409" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Statutory federal income tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_zfIwNUKyYcia" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.76&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_maABC_zePFyfdYh9qb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.64&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-2.09&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_maABC_zvOKfgEE5Ia7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;NOL expiration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-5.26&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-19.88&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_zbjEnCHJzTn4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.92&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.71&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_maABC_z1D7Vrub6YEc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maABC_zWBv6eerD4l5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_pid_dp_uPure_maABC_zhe4RJi20f5e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_pid_dp_uPure_maABC_z3jsT0z4L993" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax impact of convertible debenture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-5.46&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.37&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_pid_dp_uPure_maABC_zKHOwMPbHVz3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax impact of divestiture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-229.26&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.01&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationTrueUp_pid_dp_uPure_maABC_z7WhUdWrI7Sa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;True-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-10.65&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.24&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_zCt7BzuD2EFa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;222.28&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-17.91&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_mtABC_z59jjaWlBCb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Income taxes provision (benefit)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0.05&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zlhfMWSfWB73" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zHUvtkkhZDhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense for the year ended December 31, 2023 and 2022 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zZUShjraxBOk" style="display: none"&gt;SCHEDULE
OF PROVISION FOR INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_zVKL8yGFKLvd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20221231_zuiJFykVdqQe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBz1MC_zmZ4dcINcYNd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;U.S. Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(10,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2081"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBz1MC_zV7QvzcEmUPh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;U.S. State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBz1MC_zE9wn5sLbkSg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total current provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred Benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzCKf_zz2EpiDIeaM3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;U.S. Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,128,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(236,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzCKf_zDJeFJdwOUX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;U.S. State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,697,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,252,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzCKf_maITEBzWbu_z1ABCzTJbD76" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total deferred benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,825,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,488,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzWbu_zU5dkRo9vuZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,825,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,488,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3d_mtITEBzWbu_zPlvv7UdRbOc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total provision (benefit) for income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A2_z51p20xX4ET4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zU271WlknDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zRjLOzKUlSAh" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_zo0eKliPjx44" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221231_zUhsCaslYAy2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTATDzYdX_zXgzvBZDbCC2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net operating loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,644,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;32,587,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTATDzYdX_zhEvn7CTUbf7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,970,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,857,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DefferdTaxAssetsAccruedExpenses_iI_maDTATDzYdX_zbl8ZIJmlpmi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,020,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTATDzYdX_zz9WMcVBhkIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Patent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2115"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2116"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTATDzYdX_zLOm9WndY0v1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,004,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,069,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentExpenses_iI_maDTATDzYdX_zR0akY1zAry" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,102,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,196,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTATDzYdX_zSinl3k6I6s6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2124"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;280,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iTI_mtDTATDzYdX_maDTAGzJfc_z9gjg4N7CKhh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total deferred income tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,788,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;46,009,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzOxa_zGB9JwhXUJRk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2130"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_maDITLzOxa_zuj0yBDZZ4yh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Right-of-use asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2133"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(382,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzOxa_msDTAGzJfc_zonkDxVfkkZ4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total deferred income tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2136"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(395,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJfc_maDTALNzbeu_zxiB9qCTVw0e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net deferred income tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,788,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,614,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzbeu_zeGtvy75BvAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,788,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(45,614,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNTI_di_mtDTALNzbeu_zdG5p2mx3xAe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax asset, net of allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2145"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2146"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zhMBM80kDSg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the available objective evidence, including the Company&#x2019;s history of cumulative losses, management believes it is likely that
the Company&#x2019;s U.S. federal and state net deferred tax assets will not be realizable. Accordingly, the Company provided for a full
valuation allowance against its U.S. federal and state net deferred tax assets at December 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to the full valuation allowance already in place on the Company&#x2019;s U.S. federal and state net deferred tax assets, the Company does
not anticipate significant changes in the Company&#x2019;s effective tax rate. However, there is no valuation allowance recorded against
the Company&#x2019;s foreign net operating loss deferred tax assets, as the Company&#x2019;s foreign IPR&amp;amp;D deferred tax liabilities
and foreign net operating loss deferred tax assets are both indefinite-lived and thus they may be netted to arrive at a net foreign deferred
tax liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Tax Cuts and Jobs Act resulted in significant changes to the treatment of research or experimental (&#x201c;R&amp;amp;E&#x201d;) expenditures
under Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&amp;amp;E expenditures
that are paid or incurred in connection with their trade or business which represent costs in the experimental or laboratory sense. Specifically,
costs for U.S. based R&amp;amp;E activities must be amortized over five years and costs for foreign R&amp;amp;E activities must be amortized
over 15 years; both using a midyear convention. The Company has incorporated the impact of this new tax legislation into its 2023 and
2022 consolidated financial statements, noting that the impact on the Company&#x2019;s consolidated financial statements was immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2023, the Company has U.S. federal and state net operating loss carryforwards of approximately $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_iI_c20231231_zY2Mbl5CiQo3" title="U.S. federal operating loss carryforwards"&gt;15,942,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20231231_zapUZGzk1bki" title="State operating loss carryforwards"&gt;78,693,000&lt;/span&gt;,
respectively, which are available to offset future taxable income. U.S. federal and state net operating loss carryovers began to expire
in 2020. As a result of the May 2020 reverse recapitalization, an ownership change has occurred. The Company has not completed an Internal
Revenue Code Section 382 analysis. As a result, there could be substantial limitations on the Company&#x2019;s ability to utilize its
pre-ownership change net operating loss and tax credit carryforwards. These substantial limitations may result in both a permanent loss
of certain tax benefits related to net operating loss carryforwards and federal research and development credits, and an annual utilization
limitation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also has research and development credit carryforwards for federal and state tax purposes of approximately $&lt;span id="xdx_902_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zIebNCmZ8608" title="Research and development credit carryforwards"&gt;3,560,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zrpFbfYHE9I1" title="Research and development credit carryforwards"&gt;1,410,000&lt;/span&gt;,
respectively. &lt;span id="xdx_902_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_c20230101__20231231_zQhT2ePyxmil" title="Tax credit carryforward, limitations on use"&gt;The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite
life for state tax purposes&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S.
income tax has not been recognized on the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries
that is indefinitely reinvested outside the United States. This amount becomes taxable upon a repatriation of assets from the subsidiary
or a sale or liquidation of the subsidiary. Determination of the amount of any unrecognized deferred income tax liability on this temporary
difference is not practicable because of the complexities of the hypothetical calculation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files income tax returns in the U.S. federal jurisdiction and in various states. The Company&#x2019;s U.S. federal income tax
returns remain subject to examination by the Internal Revenue Service. The Company&#x2019;s California income tax returns remain subject
to examination by the California Franchise Tax Board. Due to net operating losses, research and development credits and other tax credit
carryforwards that may be utilized in future years, all U.S. federal and state tax years are open to examination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Generally
accepted accounting principles clarify the accounting for uncertainty in income taxes recognized in the Company&#x2019;s financial statements
and prescribe thresholds for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax
return, and also provide guidance on de-recognition and measurement of a tax position taken or expected to be taken in a tax return.
The Company adopted these provisions effective April 1, 2009.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company did &lt;span id="xdx_909_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20231231_zBEjxnZLFxwd" title="Unrecognized tax benefits"&gt;&lt;span id="xdx_900_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20221231_zR5qIRXeS3n6" title="Unrecognized tax benefits"&gt;no&lt;/span&gt;&lt;/span&gt;t have any unrecognized tax benefits as of December 31, 2023 and December 31, 2022 and does not expect this to change significantly
over the next 12 months. In accordance with generally accepted accounting principles, the Company will recognize interest and penalties
accrued on any unrecognized tax benefits as a component of income tax expense. As of December 31, 2023, the Company has not accrued any
interest or penalties related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact002026">&lt;p id="xdx_89D_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_znNnnEo4tKLd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents domestic and foreign components of consolidated loss before income taxes from continuing operations for the
periods presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_8BC_zLVxJoxV0zt9" style="display: none"&gt;SCHEDULE
OF DOMESTIC AND FOREIGN COMPONENTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zroRJrFub7S4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_zTWpwWAqnQoi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_zi07Z33bFCFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(12,479,803&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(13,887,914&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_zLt9DRSh7xpk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2031"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2032"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zQ14WvxvlJa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Loss before provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(12,479,803&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(13,887,914&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact002028"
      unitRef="USD">-12479803</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002029"
      unitRef="USD">-13887914</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact002034"
      unitRef="USD">-12479803</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002035"
      unitRef="USD">-13887914</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact002037">&lt;p id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zCwKsoCY7LYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the statutory income tax rates and the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zJSrkVjWc5O4" style="display: none"&gt;SCHEDULE
OF RECONCILIATIONS OF STATUTORY INCOME TAX RATE&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_z8vka4fOhIJg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20220101__20221231_z3Q4fMFAj0x6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zuGzWVPbb409" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Statutory federal income tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_zfIwNUKyYcia" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal tax benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.76&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion_pid_dp_uPure_maABC_zePFyfdYh9qb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-0.64&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-2.09&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration_pid_dp_uPure_maABC_zvOKfgEE5Ia7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;NOL expiration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-5.26&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-19.88&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCredits_iN_pid_dpi_uPure_msABC_zbjEnCHJzTn4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.92&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.71&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_maABC_z1D7Vrub6YEc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maABC_zWBv6eerD4l5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationFairValueOfWarrant_pid_dp_uPure_maABC_zhe4RJi20f5e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture_pid_dp_uPure_maABC_z3jsT0z4L993" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax impact of convertible debenture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-5.46&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.37&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture_pid_dp_uPure_maABC_zKHOwMPbHVz3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax impact of divestiture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-229.26&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.01&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationTrueUp_pid_dp_uPure_maABC_z7WhUdWrI7Sa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;True-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-10.65&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.24&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_zCt7BzuD2EFa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;222.28&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-17.91&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_mtABC_z59jjaWlBCb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Income taxes provision (benefit)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-0.05&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact002039"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002040"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact002042"
      unitRef="Pure">0.0176</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002043"
      unitRef="Pure">0.0750</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact002045"
      unitRef="Pure">-0.0064</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002046"
      unitRef="Pure">-0.0209</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepletion>
    <QLGN:EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact002048"
      unitRef="Pure">-0.0526</QLGN:EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration>
    <QLGN:EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002049"
      unitRef="Pure">-0.1988</QLGN:EffectiveIncomeTaxRateReconciliationNonOperatingLossExpiration>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact002051"
      unitRef="Pure">-0.0292</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002052"
      unitRef="Pure">-0.0371</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact002054"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002055"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact002057"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002058"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <QLGN:EffectiveIncomeTaxRateReconciliationFairValueOfWarrant
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact002060"
      unitRef="Pure">0.0335</QLGN:EffectiveIncomeTaxRateReconciliationFairValueOfWarrant>
    <QLGN:EffectiveIncomeTaxRateReconciliationFairValueOfWarrant
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002061"
      unitRef="Pure">0.0000</QLGN:EffectiveIncomeTaxRateReconciliationFairValueOfWarrant>
    <QLGN:EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact002063"
      unitRef="Pure">-0.0546</QLGN:EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture>
    <QLGN:EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002064"
      unitRef="Pure">0.0137</QLGN:EffectiveIncomeTaxRateReconciliationTaxImpactOfConvertibleDebenture>
    <QLGN:EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact002066"
      unitRef="Pure">-2.2926</QLGN:EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture>
    <QLGN:EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002067"
      unitRef="Pure">0.0401</QLGN:EffectiveIncomeTaxRateReconciliationTaxImpactOfDivestiture>
    <QLGN:EffectiveIncomeTaxRateReconciliationTrueUp
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact002069"
      unitRef="Pure">-0.1065</QLGN:EffectiveIncomeTaxRateReconciliationTrueUp>
    <QLGN:EffectiveIncomeTaxRateReconciliationTrueUp
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002070"
      unitRef="Pure">0.0224</QLGN:EffectiveIncomeTaxRateReconciliationTrueUp>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact002072"
      unitRef="Pure">2.2228</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002073"
      unitRef="Pure">-0.1791</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact002075"
      unitRef="Pure">0.0004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact002076"
      unitRef="Pure">-0.0005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact002078">&lt;p id="xdx_891_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zHUvtkkhZDhj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
tax expense for the year ended December 31, 2023 and 2022 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zZUShjraxBOk" style="display: none"&gt;SCHEDULE
OF PROVISION FOR INCOME TAXES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_zVKL8yGFKLvd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20221231_zuiJFykVdqQe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_maCITEBz1MC_zmZ4dcINcYNd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;U.S. Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(10,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2081"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_maCITEBz1MC_zV7QvzcEmUPh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;U.S. State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_mtCITEBz1MC_zE9wn5sLbkSg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total current provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred Benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_maDITEBzCKf_zz2EpiDIeaM3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;U.S. Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,128,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(236,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_maDITEBzCKf_zDJeFJdwOUX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;U.S. State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,697,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,252,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_mtDITEBzCKf_maITEBzWbu_z1ABCzTJbD76" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total deferred benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,825,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,488,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_iN_di_msITEBzWbu_zU5dkRo9vuZ6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,825,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,488,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3d_mtITEBzWbu_zPlvv7UdRbOc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Total provision (benefit) for income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact002080"
      unitRef="USD">-10000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact002083"
      unitRef="USD">5000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002084"
      unitRef="USD">7000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact002086"
      unitRef="USD">-5000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002087"
      unitRef="USD">7000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact002089"
      unitRef="USD">23128000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002090"
      unitRef="USD">-236000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact002092"
      unitRef="USD">4697000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002093"
      unitRef="USD">-2252000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact002095"
      unitRef="USD">27825000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002096"
      unitRef="USD">-2488000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact002098"
      unitRef="USD">27825000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact002099"
      unitRef="USD">-2488000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="-3"
      id="Fact002101"
      unitRef="USD">-5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="-3"
      id="Fact002102"
      unitRef="USD">7000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact002104">&lt;p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zU271WlknDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
components of deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zRjLOzKUlSAh" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_zo0eKliPjx44" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20221231_zUhsCaslYAy2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTATDzYdX_zXgzvBZDbCC2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net operating loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,644,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;32,587,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTATDzYdX_zhEvn7CTUbf7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,970,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,857,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DefferdTaxAssetsAccruedExpenses_iI_maDTATDzYdX_zbl8ZIJmlpmi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,020,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTATDzYdX_zz9WMcVBhkIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Patent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2115"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2116"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTATDzYdX_zLOm9WndY0v1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Stock compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,004,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,069,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsResearchAndDevelopmentExpenses_iI_maDTATDzYdX_zR0akY1zAry" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Research and development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,102,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,196,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTATDzYdX_zSinl3k6I6s6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2124"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;280,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_iTI_mtDTATDzYdX_maDTAGzJfc_z9gjg4N7CKhh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total deferred income tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17,788,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;46,009,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_di_maDITLzOxa_zGB9JwhXUJRk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2130"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesLeasingArrangements_iNI_di_maDITLzOxa_zuj0yBDZZ4yh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Right-of-use asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2133"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(382,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLzOxa_msDTAGzJfc_zonkDxVfkkZ4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total deferred income tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2136"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(395,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzJfc_maDTALNzbeu_zxiB9qCTVw0e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net deferred income tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,788,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,614,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzbeu_zeGtvy75BvAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,788,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(45,614,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iNTI_di_mtDTALNzbeu_zdG5p2mx3xAe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax asset, net of allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2145"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2146"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002106"
      unitRef="USD">8644000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002107"
      unitRef="USD">32587000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002109"
      unitRef="USD">4970000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002110"
      unitRef="USD">7857000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <QLGN:DefferdTaxAssetsAccruedExpenses
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002112"
      unitRef="USD">68000</QLGN:DefferdTaxAssetsAccruedExpenses>
    <QLGN:DefferdTaxAssetsAccruedExpenses
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002113"
      unitRef="USD">1020000</QLGN:DefferdTaxAssetsAccruedExpenses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002118"
      unitRef="USD">3004000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002119"
      unitRef="USD">3069000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <QLGN:DeferredTaxAssetsResearchAndDevelopmentExpenses
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002121"
      unitRef="USD">1102000</QLGN:DeferredTaxAssetsResearchAndDevelopmentExpenses>
    <QLGN:DeferredTaxAssetsResearchAndDevelopmentExpenses
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002122"
      unitRef="USD">1196000</QLGN:DeferredTaxAssetsResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002125"
      unitRef="USD">280000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002127"
      unitRef="USD">17788000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002128"
      unitRef="USD">46009000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002131"
      unitRef="USD">13000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002134"
      unitRef="USD">382000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002137"
      unitRef="USD">395000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002139"
      unitRef="USD">17788000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002140"
      unitRef="USD">45614000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002142"
      unitRef="USD">17788000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002143"
      unitRef="USD">45614000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002148"
      unitRef="USD">15942000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002150"
      unitRef="USD">78693000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact002152"
      unitRef="USD">3560000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact002154"
      unitRef="USD">1410000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse contextRef="From2023-01-01to2023-12-31" id="Fact002156">The research and development credit carryforwards began to expire in 2020 for federal tax purposes and have an indefinite
life for state tax purposes</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002158"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002160"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact002162">&lt;p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zlao3mNfPhG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
15 &#x2014; &lt;span id="xdx_826_zrMWVJ9CLbw6"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 26, 2024, the Company entered into a Securities Purchase Agreement (&#x201c;Agreement&#x201d;) with Alpha. The transactions
contemplated by the Agreement closed on February 27, 2024, at which time the Company delivered to Alpha the 2024 Debenture and the
2024 Warrant, as described below, and Alpha paid the Company a cash purchase price of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourDebentureAndWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJ6vRphEqjz3" title="Cash purchase price"&gt;500,000&lt;/span&gt;
(less $&lt;span id="xdx_903_ecustom--ReimbursementExpenses_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourDebentureAndWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zNea2Tid9vP2" title="Reimbursement expenses"&gt;25,000&lt;/span&gt;
for expense reimbursement). Pursuant to the Agreement, the Company issued to Alpha an 8% Convertible Debenture (the &#x201c;2024
Debenture&#x201d;) in the principal amount of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zSGjOK5oxFO4" title="Principal amount"&gt;550,000&lt;/span&gt;.
The Debenture has a maturity date of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrj2kxG5AzJk" title="Maturity date"&gt;December
31, 2024&lt;/span&gt; and is convertible, at any time, and from time to time, at Alpha&#x2019;s option, into shares of common stock of the
Company, at $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zt0mDH2hYBt6" title="Conversion price"&gt;0.6111&lt;/span&gt;
per share, subject to adjustment as described in the 2024 Debenture (the &#x201c;Conversion Price&#x201d;). The Debenture accrues
interest on its outstanding principal balance at the rate of &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHp0piqUBawd" title="Interest rate"&gt;8&lt;/span&gt;%
per annum. The 2024 Debenture does not call for scheduled payments of principal or interest before the scheduled maturity date of
December 31, 2024. Pursuant to the terms of the Agreement, the Company also issued to Alpha a 5-year common stock purchase warrant
(the &#x201c;2024 Warrant&#x201d;) to purchase (at $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyFourWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvG5H1y2PZlb" title="Warrant exercise price"&gt;0.26&lt;/span&gt;
per share) &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyFourWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGkwqWb9Q8S6" title="Purchase of warrants for shares"&gt;900,016&lt;/span&gt;
shares of common stock of the Company. Under the Agreement, Alpha also has an option, exercisable until July 1, 2024, to
purchase from the Company up to an additional $&lt;span id="xdx_901_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyFourDebentureMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmGym4aSzN7j" title="Principal amount increase decrease"&gt;1,100,000&lt;/span&gt;
in principal amount of 2024 Debentures of like tenor, together with up to an additional &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyFourWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxOHAZj8cS3i" title="Purchase of shares increase decrease"&gt;1,800,032&lt;/span&gt;
2024 Warrants of like tenor, which would (if and when Alpha exercises such option) provide us up to an additional $&lt;span id="xdx_903_ecustom--AdditionalProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240226__20240226__srt--TitleOfIndividualAxis__custom--AlphaCapitalMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--TwentyTwentyFourDebentureAndWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z45OZjJ06Td8" title="Additional cash proceeds"&gt;1.0&lt;/span&gt;
million in cash proceeds (less expense reimbursement, and not including any possible cash proceeds from any future exercise of the
additional 2024 Warrants). We granted Alpha &#x201c;piggyback&#x201d; registration rights for the common shares underlying the
2024 Debenture and the 2024 Warrant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureAndWarrantMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact002164"
      unitRef="USD">500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <QLGN:ReimbursementExpenses
      contextRef="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureAndWarrantMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact002166"
      unitRef="USD">25000</QLGN:ReimbursementExpenses>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact002168"
      unitRef="USD">550000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember"
      id="Fact002170">2024-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002172"
      unitRef="USDPShares">0.6111</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002174"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourWarrantMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002176"
      unitRef="USDPShares">0.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourWarrantMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002178"
      unitRef="Shares">900016</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureMember_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact002180"
      unitRef="USD">1100000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourWarrantMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002182"
      unitRef="Shares">1800032</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <QLGN:AdditionalProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2024-02-262024-02-26_custom_AlphaCapitalMember_custom_SecuritiesPurchaseAgreementMember_custom_TwentyTwentyFourDebentureAndWarrantMember_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact002184"
      unitRef="USD">1000000.0</QLGN:AdditionalProceedsFromIssuanceOrSaleOfEquity>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
